Sector / Row / Position
Poster Number / Abstract Number
Abstract Title
Session Title
Poster Presenter
A / 1 / 1

Poster P0001

Abstract 12

Decreased risk of nosocomial transmission of hepatitis B virus and hepatitis C virus among hemodialysis patients from southern Bulgaria

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Radka KOMITOVA

A / 1 / 2

Poster P0002

Abstract 102

Re-engagement of formerly incarcerated people living with HIV lost to care

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Max BRITO

A / 1 / 3

Poster P0003

Abstract 798

Metabolic co-morbidities among people living with HIV (PLWH) in an urban specialist HIV clinic in the United Kingdom

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Irfaan MAAN

A / 1 / 4

Poster P0004

Abstract 1220

Impact of CRISPR-Cas gene cassettes on the packaging efficiency and transduction titer of lentiviral vectors

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Pascal Zion KROON

A / 1 / 5

Poster P0005

Abstract 1306

High levels of HIV-1 recombinants circulating in Portugal

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Vitor DUQUE

A / 1 / 6

Poster P0006

Abstract 1781

CRISPR-Cas therapy towards a cure for HIV/AIDS

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Elena HERRERA CARRILLO

A / 1 / 7

Poster P0007

Abstract 2139

We need to talk about ART: a survey of clinicians and people living with HIV

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Amy BELFIELD

A / 1 / 8

Poster P0008

Abstract 2261

Economic evaluation of post-exposure prophylaxis-in-pocket (PIP) compared to pre-exposure prophylaxis (PrEP) for individuals with a low frequency of high-risk HIV exposures: a matched control study

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Mia SAPIN

A / 1 / 9

Poster P0009

Abstract 2991

The influence of concurrent low-dose oral calcium carbonate supplementation on steady state pharmacokinetics of once daily oral raltegravir

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Luana Leticia TEIXEIRA NUNES PORTO

A / 1 / 10

Poster P0010

Abstract 3067

Perceived knowledge, attitudes, and practices of major non-communicable diseases and their risk factors among people living with HIV in Rwanda

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Vivianne UMUHIRE NIYONKURU

A / 1 / 11

Poster P0011

Abstract 3192

Whole genome sequencing approach to identify HIV-1 drug resistance in clinical samples

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Sofiane MOHAMED

A / 1 / 12

Poster P0012

Abstract 3558

Immune responses after mpox infection or vaccination in a cohort of HIV-PrEP users

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Aleksandra PETTKE

A / 1 / 13

Poster P0013

Abstract 4176

Extinction of all infectious HIV in cell culture by the CRISPR-cjCas9 system

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Yuanling BAO

A / 1 / 14

Poster P0014

Abstract 4307

Clinical impact of APOBEC mutations and prevalence in HIV antiretroviral resistance reports

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Lucia CHAVES BLANCO

A / 1 / 15

Poster P0015

Abstract 4309

Ten years of HIV admissions at a tertiary infectious diseases centre: increased mortality and length of stay

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Bethan ENGLAND

A / 1 / 16

Poster P0016

Abstract 4507

Update on transmitted resistances in treatment-naive patients in Spain (2022)

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Lucia CHAVES BLANCO

A / 1 / 17

Poster P0017

Abstract 4515

Effect of HIV treatment milestones on the HIV care continuum and AIDS diagnoses in CoRIS (2005-2022).

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Alejandro G GARCIA-RUIZ DE MORALES

A / 1 / 18

Poster P0018

Abstract 4528

Cabotegravir/rilpivirine long-acting for HIV treatment in a real-life setting: data from an Italian monocentric cohort

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Maddalena MATONE

A / 1 / 19

Poster P0019

Abstract 4545

Prevalence and risk factors of sarcopenia among people living with HIV

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Jasmin JÄGER

A / 1 / 20

Poster P0020

Abstract 4739

Quantification of HIV RNA in cerebrospinal fluid

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Sandro GRELLI

A / 1 / 21

Poster P0021

Abstract 5143

Altered gut microbiota composition in virologically suppressed HIV-infected individuals on antiretroviral therapy: implications for chronic inflammation and metabolic health

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Joo EUN-JEONG

A / 1 / 22

Poster P0022

Abstract 5411

NeuMoDx HIV viral load failure in a large group of Mayotte patients: viral diversity is still a challenge

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Benoit VISSEAUX

A / 1 / 23

Poster P0023

Abstract 5552

Familiarity of primary care physicians and infectious diseases specialists with PrEP and their willingness to prescribe it in the MENA region

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Jihane NAOUS

A / 1 / 24

Poster P0024

Abstract 6097

Gut innate immunity dysregulation and T cells activation go in parallel during HIV immunopathogenesis

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Luca MADDALONI

B / 1 / 1

Poster P0025

Abstract 6287

HIV-DNA minority mutations profile in long-term infected paediatric population

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Luna COLAGROSSI

B / 1 / 2

Poster P0026

Abstract 6543

Elimination of infectious HIV DNA by CRISPR–saCas9

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Zhenghao YU

B / 1 / 4

Poster P0028

Abstract 6743

Provision of care among migrants and refugees in a tertiary care center in Romania

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Irina IANACHE

B / 1 / 6

Poster P0030

Abstract 6879

Intersection of HIV, biological considerations and comorbidities in women living with HIV: impact of online independent medical education on physician knowledge and confidence

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Julia DUFFEY

B / 1 / 8

Poster P0032

Abstract 7493

A retrospective review of equivocal HIV serology results at a London (UK) teaching hospital

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Merennage Anusha Yasanthi FERNANDO

B / 1 / 9

Poster P0033

Abstract 7509

Endoscopic features of gastric cryptosporidiosis in patients with HIV

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Takashi SHINHA

B / 1 / 10

Poster P0034

Abstract 8141

High level of archived and circulating HIV-1 drug resistance mutations in adolescents with suppressed and unsuppressed viral loads in Cameroon

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Armando Blondel DJIYOU DJEUDA

B / 1 / 11

Poster P0035

Abstract 8307

The newly developed NeuMoDx HIV-1 quant assay compared to the established alinity m HIV-1 assay for routine viral load measurement

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Robert EHRET

B / 1 / 12

Poster P0036

Abstract 8510

HIV prevalence rates amongst migrant sex workers in Europe

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Denis ONYANGO

B / 1 / 13

Poster P0037

Abstract 8712

A framework to evaluate the effectiveness of models of care for people with HIV (PWH)

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Giovanni GUARALDI

B / 1 / 14

Poster P0038

Abstract 8914

Delayed HIV diagnoses in the West of Ireland

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Ellen WALSH

B / 1 / 15

Poster P0039

Abstract 387

Comparison of non-invasive methods and liver biopsy for detection of liver fibrosis associated with chronic hepatitis B

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Mine FILIZ

B / 1 / 16

Poster P0040

Abstract 389

Investigation of stanniocalcin-1 as a new biomarker in the detection of chronic hepatitis B associated liver fibrosis: a pilot study

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Mine FILIZ

B / 1 / 17

Poster P0041

Abstract 440

Distribution and relevance of hepatitis B genotypes in the general population of Slovakia

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Ivana HOCKICKOVA

B / 1 / 18

Poster P0042

Abstract 748

The characteristic of maternal HBV quasispecies is related to occult HBV infection of infants born to highly viremic mothers

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Yi LI

B / 1 / 19

Poster P0043

Abstract 1145

Repressed expression of human endogenous retroviruses HERV-K (HML-2) and HERV-9 in chronic hepatitis C patients with endogenous activation of the interferon system in the liver

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Konstantina KITSOU

B / 1 / 20

Poster P0044

Abstract 1248

New molecular assay for the detection and quantification of hepatitis B virus load in EDTA-plasma

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Irene CORTÉS PORTERO

B / 1 / 21

Poster P0045

Abstract 1853

Is HBV RNA a promising biomarker in chronic hepatitis B?

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Aikaterini SKEVA

B / 1 / 22

Poster P0046

Abstract 2301

In silico 3-D structural prediction and characterisation of hepatitis E virus RNA-dependant RNA-polymerase (RdRp) region for antiviral research

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Vikram THAKUR

B / 1 / 23

Poster P0047

Abstract 2542

On the road to Hepatitis C elimination, the need for screening beyond risk factors

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Manuel RODRÍGUEZ MARESCA

B / 1 / 24

Poster P0048

Abstract 2736

Hepatitis Delta virus variability in Italy

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Anna Rosa GARBUGLIA

A / 2 / 1

Poster P0049

Abstract 2783

Hepatitis B associated with severe COVID-19: a nationwide cohort study in Sweden

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Frida JAKOBSSON

A / 2 / 2

Poster P0050

Abstract 3070

Diagnostic performance of two chemiluminescence immunoassays for the detection and quantification of hepatitis B virus surface antigen (HBsAg): a comparative study

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Felipe PÉREZ-GARCÍA

A / 2 / 3

Poster P0051

Abstract 3208

Surveillance of the zoonotic rat hepatitis E virus in rodents in Spain

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Javier CABALLERO GÓMEZ

A / 2 / 4

Poster P0052

Abstract 3591

Evaluation of RT-qPCR for the diagnosis of active hepatitis D virus (HDV) through a single-step approach

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Helena GARCIA LOPEZ

A / 2 / 5

Poster P0053

Abstract 4512

Detection and quantification of hepatitis delta virus RNA by three different assays

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Marta ILLESCAS LÓPEZ

A / 2 / 6

Poster P0054

Abstract 4656

An innovative strategy to relink into care patients with active HCV infection.

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Federico GARCIA

A / 2 / 7

Poster P0055

Abstract 4899

Outbreak of acute hepatitis HCV in HIV-infected individuals

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Goretti REDONDO

A / 2 / 8

Poster P0056

Abstract 4989

Antibody coated liposomes for transmucosal vaccination

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Saurabh BHARGAVA

A / 2 / 9

Poster P0057

Abstract 5198

Limited uptake of hepatitis D virus testing in people living with hepatitis B virus infection in Australia

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Krispin HAJKOWICZ

A / 2 / 10

Poster P0058

Abstract 5405

Hepatitis B infection and immunity in Timor-Leste: a population-representative serological survey

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Joshua FRANCIS

A / 2 / 11

Poster P0059

Abstract 2418

Hepatitis C virus (HCV) screening in an emergency department (ED), an effective strategy to hepatitis C elimination

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Manuel RODRÍGUEZ MARESCA

A / 2 / 12

Poster P0060

Abstract 5784

Analytic validation of a lab-developed qPCR assay for fully-automated high-throughput detection of Rocahepevirus ratti (ratHEV)

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Marc LUETGEHETMANN

A / 2 / 13

Poster P0061

Abstract 5914

Predictive factors for progression of fibrosis in chronic HBV infection on the indeterminate phase

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Sana ROUIS

A / 2 / 14

Poster P0062

Abstract 6072

The newly developed NeuMoDx HBV Quant Assay compared to the established Alinity m HBV Assay in routine viral load measurement

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Robert EHRET

A / 2 / 15

Poster P0063

Abstract 6459

The newly developed NeuMoDx HCV Quant Assay compared to the established Alinity m HCV Assay in routine viral load measurement

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Robert EHRET

A / 2 / 16

Poster P0064

Abstract 6836

Prevalence of HDV infection in HBV positive patients from University Hospital in North Sardinia: updated data

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Lucia DENTI

A / 2 / 17

Poster P0065

Abstract 7288

Performance of a new fully automated platform for HIV, HBV and HCV viral load assessment

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Susana BANDARRA

A / 2 / 18

Poster P0066

Abstract 7438

Evaluation and usefulness of rapid molecular assay for hepatitis C virus RNA detection

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Livia MELO VILLAR

A / 2 / 19

Poster P0067

Abstract 7523

A large outbreak of hepatitis A in a northern community in Canada 2021-2022: public health interventions and immunisation in a remote context

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Yassen TCHOLAKOV

A / 2 / 20

Poster P0068

Abstract 7968

Evaluation of the virological profile of pregnant women infected with the hepatitis B virus treated at a referral center in Rio de Janeiro, Brazil

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Livia MELO VILLAR

A / 2 / 21

Poster P0069

Abstract 8207

Hepatitis E virus molecular surveillance in Hungary between 2018-2023 reveals infections with rare subtypes

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Agnes DENCS

A / 2 / 22

Poster P0070

Abstract 8330

Profile of patients diagnosed with active HCV infection in an emergency department in Almeria, Spain

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Manuel RODRÍGUEZ MARESCA

A / 2 / 23

Poster P0071

Abstract 8358

Opportunistic rescue of patients with HCV infection and lost in the healthcare system: results of the relink-C study in Almeria, Spain

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Manuel RODRÍGUEZ MARESCA

A / 2 / 24

Poster P0072

Abstract 8594

3Hdtect-Q real-time PCR kit for simultaneous detection and differentiation of HIV, HCV and HBV in human plasma, serum and whole blood samples

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Bahadur Singh GURJAR

A / 2 / 25

Poster P0073

Abstract 8911

Is it cost-effective to implement double reflex testing strategy to diagnose hepatitis D-superinfection? Reflections from Sweden representing a country with low prevalence of hepatitis B and D viruses

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

John WALLES

A / 2 / 26

Poster P0074

Abstract 77

Underdiagnosis of viral aetiologies in moderate-to-severe community-acquired pneumonia: an important clinical gap

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Ng DOROTHY HUI LIN

A / 2 / 27

Poster P0075

Abstract 137

Phylogenetic lineage dynamics of global parainfluenza virus type 3 post-COVID-19 pandemic

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Kuenyoul PARK

A / 2 / 28

Poster P0076

Abstract 287

Nanobody-based PROTAC strategy provides broad-spectrum antiviral activity against porcine arterivirus

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Fandan MENG

B / 2 / 1

Poster P0077

Abstract 400

Frequency of respiratory virus detection in the upper respiratory tract of hospitalised patients

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Charalampos ZARRAS

B / 2 / 2

Poster P0078

Abstract 429

Beyond influenza and SARS-CoV-2: advancing respiratory sentinel surveillance in Sweden

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Carmen ESPINOSA-GONGORA

B / 2 / 3

Poster P0079

Abstract 454

Prophylactic efficacy of CD388, a novel drug-Fc conjugate (DFC), in an influenza A/H3N2 human challenge model

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Roxana E. ROJAS

B / 2 / 4

Poster P0080

Abstract 504

Clinical performance evaluation of two commercial antigen test kits for diagnosis of SARS-CoV-2, influenza A and influenza B infection

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Jeonghyun CHANG

B / 2 / 5

Poster P0081

Abstract 670

Respiratory syncytial virus infections in recipients of bone marrow transplantations: a systematic review and meta-analysis

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Matteo RICCÒ

B / 2 / 6

Poster P0082

Abstract 673

Influenza virus, SARS-CoV-2, respiratory syncytial virus, rhinovirus, adenovirus, bocavirus, and other respiratory virus circulation during 2022–2023 season in Latvia: focus on codetections

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Oksana SAVICKA

B / 2 / 7

Poster P0083

Abstract 739

The resurgence of influenza activity and out-of-season epidemics of RSV during the Omicron waves in Beijing, China

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Yi LI

B / 2 / 8

Poster P0084

Abstract 802

Determination of RSV reinfection in a German population cohort between 2020 and 2023 using a newly established RSV antigen-derived 9-plex immunoassay (RSV MIA)

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Patrick MARSALL

B / 2 / 9

Poster P0085

Abstract 917

Risk of cardiovascular events after influenza: a population-based self-controlled case series study, Spain 2011-2018

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Cintia MUÑOZ-QUILES

B / 2 / 10

Poster P0086

Abstract 1082

Evaluation and comparison of three case definitions for influenza detection in the same setting and population in the Valencia region of Spain

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Ainara MIRA-IGLESIAS

B / 2 / 11

Poster P0087

Abstract 1115

Rapid intra-season waning of vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Alexander DOMNICH

B / 2 / 12

Poster P0088

Abstract 1246

Consumer preferences for features of influenza vaccines in the United Kingdom: results from a discrete-choice experiment study

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Darshan METHA

B / 2 / 13

Poster P0089

Abstract 1281

General population and healthcare professionals' level of knowledge of the burden and prevention of respiratory syncytial virus and other respiratory infections in France

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Joshua PUEL

B / 2 / 14

Poster P0090

Abstract 1338

A generic, saliva-based PCR test for the detection of RSV offers a low-burden approach for sustainable surveillance of RSV

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Anne WYLLIE

B / 2 / 15

Poster P0091

Abstract 1426

A nationwide retrospective cohort study to assess the relative vaccine effectiveness of high-dose compared to standard dose influenza vaccines in France during the 2021-2022 season: results of a complementary analysis of DRIVEN study

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Hélène BRICOUT

B / 2 / 16

Poster P0092

Abstract 1446

Comparison of efficacy and safety between baloxavir marboxil and oseltamivir in outpatients with uncomplicated influenza: a real-world study of more than 1,500 patients

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Yu LUO

B / 2 / 17

Poster P0093

Abstract 1458

Clinical characteristics, complications, and predictors of serious outcomes among adult outpatients with respiratory syncytial virus infection

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Suwei WANG

B / 2 / 18

Poster P0094

Abstract 1550

The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: a meta-analysis of evidence from randomized trials

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Kristoffer Grundtvig SKAARUP

B / 2 / 19

Poster P0095

Abstract 1581

Clinical assessment of a fully automated RT-PCR assay for the qualitative detection of parainfluenza virus 1,3 and 2/4 in human nasal/throat swabs under IVDR

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Jasmin KÖFFER

B / 2 / 20

Poster P0096

Abstract 1587

Evaluation of the clinical performance of a fully automated RT-PCR assay for the qualitative detection of RSV and hMPV in human nasal/throat swabs and bronchoalveolar lavage under IVDR

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Ulrich EIGNER

B / 2 / 21

Poster P0097

Abstract 1748

Higher waist circumference was associated with reduced cellular immune response to influenza vaccine: findings from the DYNAMIC cohort study of older adults in Singapore

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Sapna P. SADARANGANI

B / 2 / 22

Poster P0098

Abstract 1873

Relative effectiveness of an adjuvanted influenza vaccine vs non-adjuvanted influenza vaccines in high-risk older adults during the 2019-2020 U.S. influenza season

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Emanuele CIGLIA

B / 2 / 23

Poster P0099

Abstract 2054

A behaviour change techniques analysis, systematic review meta-analysis and meta-regression of communication-mediated interventions supporting influenza vaccination uptake in adults in primary care settings

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Bilal QURESHI

B / 2 / 24

Poster P0100

Abstract 2095

Cost-effectiveness of protective equipment stockpiles for reducing essential worker absenteeism in a pandemic: a modelling study

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Nadia X MONTAZERI

B / 2 / 25

Poster P0101

Abstract 2136

Increased 90 days mortality associated with RSV compared to influenza among adults in Denmark

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Thomas BENFIELD

B / 2 / 26

Poster P0102

Abstract 2285

Isolation of monoclonal antibodies against human parainfluenza virus type 3 strains

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Foong Ying WONG

To be defined

Poster P0102

Abstract 1948

Galectin-3 regulates viral pathogenesis and inflammation in H5N1 and H7N9 avian influenza virus infections

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Zih-Syuan YANG

B / 2 / 27

Poster P0103

Abstract 2395

Quantitative analysis of FluNet surveillance data: has B Yamagata really gone extinct?

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Laurent COUDEVILLE

B / 2 / 28

Poster P0104

Abstract 2679

Comparison of three commercial nucleic amplification tests for influenza A testing in a symptomatic patient population

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Salma KODSI

A / 3 / 1

Poster P0105

Abstract 2686

RSV circulation in the SARS-Cov-2 pandemic era in the north of Spain (Asturias)

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Marta Elena ALVAREZ-ARGÜELLES

A / 3 / 2

Poster P0106

Abstract 2687

Influenza A and B viral loads are higher in nasopharyngeal swabs compared to mid-turbinate swabs

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Steffen WILDUM

A / 3 / 3

Poster P0107

Abstract 2738

Estimating the health and economic burden of pneumococcal diseases attributable to V116 vs PCV20 serotypes among adults in Spain

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Muloongo SIMUZINGILI

A / 3 / 4

Poster P0108

Abstract 2818

Respiratory syncytial virus as single detection is associated with younger age and worse clinical outcomes

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Anna CREUS-COSTA

A / 3 / 5

Poster P0109

Abstract 2935

Next-generation mRNA-based seasonal influenza vaccines including additional A/H3N2 strains: Phase 1/2 trial findings in adults aged 50-75 years

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Denise HSU

A / 3 / 6

Poster P0110

Abstract 2979

Respiratory syncytial virus incidence trends during omicron COVID pandemic in older adults: a community-based prospective study

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Wendelyn BOSCH

A / 3 / 7

Poster P0111

Abstract 3036

The utility of multiplex real-time PCR screening for viral respiratory infections

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Reda AMRANI-SOUHLI

A / 3 / 9

Poster P0113

Abstract 3257

A comparative study of the incidence, risk factors and outcome of hospitalised adults with RSV vs influenza A infection

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Amos ADLER

A / 3 / 10

Poster P0114

Abstract 3286

Tracking seasonal influenza trends in South Tyrol during season 2022-2023

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Irene BIANCONI

A / 3 / 11

Poster P0115

Abstract 3288

Enterovirus landscape in Barcelona: A virological surveillance journey through the 2020-2023 seasons in the shadow of the COVID-19 pandemics

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Cristina ANDRÉS

A / 3 / 12

Poster P0116

Abstract 3398

Seasonal trends in sentinel surveillance: a seven-year retrospective analysis from the Aegean region, Turkiye (2016-2023)

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Özlem TÜRKMEN RECEN

A / 3 / 13

Poster P0117

Abstract 3415

Unraveling the genetic, antigenic, and antiviral landscape of influenza viruses circulating in Catalonia (Spain) during the 2022-2023 season

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Cristina ANDRÉS

A / 3 / 14

Poster P0118

Abstract 3500

Identification of granzymes as crucial regulators and potential targets of influenza-associated immunopathology and superinfections

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Marcela GARZÓN-TITUAÑA

A / 3 / 15

Poster P0119

Abstract 3656

Severe manifestations of parainfluenza type 4 infections in children

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Kenta KURUMA

A / 3 / 16

Poster P0120

Abstract 3703

Decoding severity: the GIHSN SevScale for hospitalised ARI cases

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Bronke BOUDEWIJNS

A / 3 / 17

Poster P0121

Abstract 3876

Assessing the cost-effectiveness and public health impact of the adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in Canadian older adults

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

George SYDNEY

A / 3 / 18

Poster P0122

Abstract 3877

Do pregnant women get the flu shot? A view over Greece

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Panagiota Georgia MALTEZOU

A / 3 / 19

Poster P0123

Abstract 3999

Mapping the trends of non-SARS-CoV-2 respiratory viruses: a 2016–2023 analysis in a Rome hospital microbiology laboratory

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Rosaria SANTANGELO

A / 3 / 20

Poster P0124

Abstract 4027

Digitally facilitated access to information on influenza complications and its prevention: a multicentric study

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Nagham Léa KHANAFER

A / 3 / 21

Poster P0125

Abstract 4058

Estimation of RSV-attributable mortality in adults in Italy between 2015 and 2019

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Giuseppe Pietro INNOCENTI

A / 3 / 22

Poster P0126

Abstract 4079

Modelling the health and economics benefits of a rapid vaccine intervention in an influenza pandemic in the United Kingdom

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Ray LONGSTAFF

A / 3 / 23

Poster P0127

Abstract 4116

Changes in influenzavirus-A/B and human respiratory syncytial virus seasonality and activity during the COVID-19 pandemic in Switzerland

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Karoline LEUZINGER

A / 3 / 24

Poster P0128

Abstract 4278

Estimated impact of delayed influenza vaccine strain selection on vaccine effectiveness: a descriptive and modeling study

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Ombeline JOLLIVET

A / 3 / 25

Poster P0129

Abstract 4529

Nosocomial acquisition, a zoom on respiratory viruses (NAZARE): A laboratory-based surveillance study to explore epidemiology and risk factors

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Quentin LE HINGRAT

A / 3 / 26

Poster P0130

Abstract 4580

Impact of community pharmacy vaccination services on vaccination coverage of immunocompromised patients against respiratory tract infections

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Daniel J.G. THIRION

A / 3 / 27

Poster P0131

Abstract 4673

Estimating the health and economic burden of pneumococcal diseases attributable to V116 vs PCV20 serotypes among adults in Switzerland

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Muloongo SIMUZINGILI

A / 3 / 28

Poster P0132

Abstract 4963

Molecular epidemiology of rhinovirus: genotypes detected during and after the COVID-19 pandemic

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

William Fernando CHAPARRO-PICO

B / 3 / 1

Poster P0133

Abstract 4971

Setting the bar for new generation influenza vaccine reactogenicity: expected clinical and cost tradeoffs compared to standard-of-care vaccines

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

José BARTELT-HOFER

B / 3 / 2

Poster P0134

Abstract 4979

Validation of a genome sequencing protocol for influenza B viruses

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Alexandra PRESBITERO

B / 3 / 3

Poster P0135

Abstract 4987

Diversification of the ON1 genotype of HVRS-A on the coast of Peru during 2009-2020

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Wilmer SILVA-CASO

B / 3 / 4

Poster P0136

Abstract 5225

The clinical and economic value of MF59-adjuvanted quadrivalent influenza vaccination in the elderly in Argentina

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Jose MONTES

B / 3 / 5

Poster P0137

Abstract 5516

Hospital and community epidemiology of SARS-CoV-2, influenza and RSV during 2022/2023 season in Auvergne-Rhône-Alpes, France: a comparative analysis

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Benoit VISSEAUX

B / 3 / 6

Poster P0138

Abstract 5600

Economic burden of respiratory syncytial virus (RSV) and unspecified lower respiratory tract infection (UBP) during RSV season in adults in Germany (2015-2018): a health claims analysis

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Caroline BEESE

B / 3 / 7

Poster P0139

Abstract 5723

Subtyping and whole-genome sequencing of influenza A/B viruses using pan-subtype primers, widely-used library prep reagents, and cloud-based data analysis

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Robert SCHLABERG

B / 3 / 8

Poster P0140

Abstract 5738

Impact of COVID-19 pandemic on influenza vaccination rates among healthcare personnel at a tertiary-care centre in Lebanon

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Eid AZAR

B / 3 / 9

Poster P0141

Abstract 5744

Molecular investigation of seasonal viral respiratory outbreaks

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Jack O'NEILL

B / 3 / 10

Poster P0142

Abstract 6186

Respiratory syncytial virus burden in older adults (≥ 60 years): a two-year Italian multicentre study in the late COVID-19 pandemic and early post-pandemic period

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Federica NOVAZZI

B / 3 / 11

Poster P0143

Abstract 6204

Serological investigation of RSV antibody responses in UK healthcare workers (SIREN study)

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Ashley OTTER

B / 3 / 12

Poster P0144

Abstract 6211

Co-circulation of influenza, SARS-CoV-2 and RSV (tripledemic) among severe acute respiratory infection cases in the Philippines, 2022-2023

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Vina Lea ARGUELLES

B / 3 / 13

Poster P0145

Abstract 6317

Self-collected saliva demonstrates utility for influenza surveillance by extraction-free PCR

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Janet WILLIAMSON

B / 3 / 14

Poster P0146

Abstract 6605

Overview of adenovirus respiratory infections: preliminary findings of a multicentre study in Italy, 2022-2023

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Federica GIARDINA

B / 3 / 15

Poster P0147

Abstract 6694

Modelling the impact on carbon emissions of using a high dose influenza vaccine instead of standard dose among 65 years and older adults in France

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Hélène BRICOUT

B / 3 / 16

Poster P0148

Abstract 6775

Comparison of burden of respiratory syncytial virus hospitalisation in paediatric population during two consecutive seasons 2021-2023

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Cristina VEINTIMILLA

B / 3 / 17

Poster P0149

Abstract 6790

Early assessment of viral respiratory epidemics for the 2023/2024 season based on community laboratory surveillance network in France

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Benoit VISSEAUX

B / 3 / 18

Poster P0150

Abstract 6798

A novel multiplex, quantitative immunoassay for anti-influenza IgG demonstrates individual variability in binding specificity targeting antigenically distinct haemagglutinin proteins

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Del DSOUZA

B / 3 / 19

Poster P0151

Abstract 6829

Influenza like-illness surveillance using a Belgian sentinel network of nursing homes: results of October 2022 onwards

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Karl MERTENS

B / 3 / 20

Poster P0152

Abstract 6840

Understanding antibody cross-reactivity between seasonal Influenza and H5N1 as a method to conduct H5N1-specific serosurveillance

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Ashley OTTER

B / 3 / 21

Poster P0153

Abstract 7117

Serological responses to a boosted tetravalent influenza vaccine regimen in multiple myeloma patients: evaluating the impact of daratumumab treatment.

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Simon GRESSENS

B / 3 / 22

Poster P0154

Abstract 7125

Changing pattern of respiratory virus detection among severe acute respiratory syndrome corona virus: two symptomatic patients in the central province of Sri Lanka

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Shiyamalee ARUNASALAM

B / 3 / 23

Poster P0155

Abstract 7133

Investigating innovative system methods for the diagnosis of respiratory viruses for rapid clinical diagnosis

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Gozde AKKUS KAYALI

B / 3 / 24

Poster P0156

Abstract 7444

Impact of hospitalisations due to respiratory syncytial virus in a highly complex public paediatric hospital in Brazil, between January 2021 and May 2023

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Marcelo OTSUKA

B / 3 / 25

Poster P0157

Abstract 7448

Tasmania's COVID mitigation strategies provide insights into respiratory syncytial virus evolution

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Christopher Thomas ATKINSON

B / 3 / 26

Poster P0158

Abstract 7470

Trends and severity of parainfluenza virus infections over the past decade

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Marta Elena ALVAREZ-ARGÜELLES

B / 3 / 27

Poster P0159

Abstract 7533

Further characterisation of vaccine efficacy in infants from a Phase 3 RCT of a bivalent prefusion F RSV vaccine administered during pregnancy

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Emma SHITTU

B / 3 / 28

Poster P0160

Abstract 7644

Impacts on respiratory viruses among hospitalised children with respiratory diseases after lifting COVID-19 restrictions

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Yo MURATA

A / 4 / 1

Poster P0161

Abstract 7675

Pre-immunisation landscape of human respiratory syncytial virus: genomic insights from Catalonia's SIVIC programme in the era of neutralising monoclonal antibody deployment

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Maria PIÑANA

A / 4 / 2

Poster P0162

Abstract 7986

Neutralising monoclonal antibodies raised against highly conserved influenza hemagglutinin, neuraminidase, and matrix epitopes may offer novel cocktail therapeutic strategies

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Clara J SEI

A / 4 / 3

Poster P0163

Abstract 8031

Oxford Nanopore Sequencing revolutionizes Influenza surveillance in resource-limited settings

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Debasis BISWAS

A / 4 / 4

Poster P0164

Abstract 8050

Impact of influenza-related hospitalisation in Spain: characteristics and risk factor of mortality during five influenza seasons (2016 to 2021)

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

José Manuel RAMOS

A / 4 / 5

Poster P0165

Abstract 8065

CD388, a drug-Fc conjugate, shows long half-life in early clinical studies

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Ruben FAELENS

A / 4 / 6

Poster P0166

Abstract 8066

Using nanopore amplicon sequencing data for rapid analysis of influenza type A

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Oscar ASPELIN

A / 4 / 7

Poster P0167

Abstract 8138

Verification of the Savanna respiratory viral panel-4 as a rapid screening tool for respiratory viral infections

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Marijke REYNDERS

A / 4 / 8

Poster P0168

Abstract 8316

What was the burden of winter pressures on the UK SIREN healthcare worker cohort winter 2022-23?

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Victoria HALL

A / 4 / 9

Poster P0169

Abstract 8605

Forecasting the epidemiological trends of pediatric acute respiratory infections at the community level using time series predictive models: an Italian scenario

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Costanza DI CHIARA

A / 4 / 10

Poster P0170

Abstract 8722

Evaluation of the performance of the Hologic Panther fusion 4 plex-assay

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Robert EHRET

A / 4 / 11

Poster P0171

Abstract 8879

RSV viral load and co-infection in a very large cohort of pediatric patients, which role in the disease severity?

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Rossana SCUTARI

A / 4 / 12

Poster P0172

Abstract 8884

Differences in influenza vaccination among healthcare workers: impact of work task, area of membership and gender

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Vincenzo PAOLOZZI

A / 4 / 14

Poster P0174

Abstract 1940

Age-sex patterns of human herpesvirus infection seroprevalences among hospitalised patients in Paris area, France, 2016 to 2022

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Olivier SUPPLISSON

A / 4 / 15

Poster P0175

Abstract 2191

Cytomegalovirus reactivation in critically ill mechanically ventilated patients

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Atul GARG

A / 4 / 16

Poster P0176

Abstract 3109

Validation of a herpes zoster conceptual model on quality of life in East Asia

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Cheryl NG

A / 4 / 17

Poster P0177

Abstract 3761

Clinical relevance of human herpesvirus-7 DNA detection in a tertiary care setting over a 13-year period

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Annika BARGETZI

A / 4 / 18

Poster P0178

Abstract 4248

Varicella-zoster virus circulating clades in a French tertiary referral centre, Paris, France, 2018-2023

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

David BOUTOLLEAU

A / 4 / 19

Poster P0179

Abstract 4480

Oedema volume on admission may predict poor outcome in HSV-encephalitis, varies in reliability across aetiologies and lower oedema volumes

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Youssef ALY

A / 4 / 20

Poster P0180

Abstract 4579

Potential relationship between cytomegalovirus and immunosenescence: evidence from observational studies

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

John DIAZ-DECARO

A / 4 / 21

Poster P0181

Abstract 4710

Incidence and risk factors for varicella-zoster virus central nervous system infections

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Tobias TYRBERG

A / 4 / 22

Poster P0182

Abstract 5679

The association between acyclovir-related neurotoxicity and its concentration

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Chia-Chi CHEN

A / 4 / 23

Poster P0183

Abstract 5789

Ganciclovir/valganciclovir therapy in congenital CMV infection: 24-year experience of a tertiary care children hospital in northern Italy

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Erica RICCI

A / 4 / 24

Poster P0184

Abstract 5946

CMV plasma reactivation predicts CMV organ disease in patients with moderate to severe ulcerative colitis needing hospitalisation

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Matteo RINALDI

A / 4 / 25

Poster P0185

Abstract 6356

Immune response to human herpes virus in SARS-CoV-2 mild infection

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Serena VITA

A / 4 / 26

Poster P0186

Abstract 6367

Review of laboratory testing and processing protocols for varicella zoster virus in a north London hospital

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Cavan James O'CONNOR

A / 4 / 27

Poster P0187

Abstract 6451

Trends in hospitalisations related to herpes zoster in Denmark from 1998 to 2021

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Mads Frederik EIBERG

A / 4 / 28

Poster P0188

Abstract 6548

CMV infection in pregnancy: a 5-years clinical experience of the regional reference center for infections in pregnancy in a low-birth Italian region

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Carolina SAFFIOTI

B / 4 / 1

Poster P0189

Abstract 6993

Management of CMV primary infection in pregnancy and neonatal outcome in the era of valacyclovir treatment: a monocentric prospective study

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Carolina SAFFIOTI

B / 4 / 2

Poster P0190

Abstract 7149

Comparison of two IVDR molecular diagnostic assays for the detection of HSV-1, HSV-2 and VZV in lesions and ulcers.

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Michelle LISTER

B / 4 / 3

Poster P0191

Abstract 7188

Cytomegalovirus infection in patients hospitalised in intensive care

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Zohra BENEZZINE

B / 4 / 4

Poster P0192

Abstract 7780

Herpetic gingivostomatitis caused by human herpesvirus type 7: a new entity?

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Agustin ESTEVEZ

B / 4 / 5

Poster P0193

Abstract 8040

The role of Epstein-Barr virus in children with post-acute sequelae of SARS-CoV-2 infection in Taiwan

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Yu-Lung HSU

B / 4 / 6

Poster P0194

Abstract 8688

Development and clinical validation of extraction-free loop-mediated isothermal amplification assays for rapid detection and subtyping of herpes simplex virus

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Monique ANDERSSON

B / 4 / 7

Poster P0195

Abstract 8862

Antigen-specific immunoassays improve the serological staging of cytomegalovirus infection

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

David SPRINGER

B / 4 / 8

Poster P0196

Abstract 193

sST2 is a potential biomarker for early prognostication of severe dengue

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Po Ying CHIA

B / 4 / 9

Poster P0197

Abstract 231

Steroid pulse therapy for severe fever with thrombocytopenia syndrome patients may not improve prognosis: retrospective analysis with overlap weighting using a national inpatient database

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Satoshi KUTSUNA

B / 4 / 10

Poster P0198

Abstract 301

Development of a clinical scoring system to make a presumptive diagnosis of Kyasanur Forest disease: a case-control study from South India

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Nitin GUPTA

B / 4 / 11

Poster P0199

Abstract 524

Autochtonous dengue outbreak in Lombardy region, Italy, 2023: results of a seroprevalence study

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Irene CASSANITI

B / 4 / 12

Poster P0200

Abstract 786

Effect of montelukast in preventing dengue with warning signs among patients with dengue: a multicentre, randomised, double-blind, placebo-controlled trial

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Nattapat NITINAI

B / 4 / 13

Poster P0201

Abstract 853

Exploratory analysis of the knowledge, attitudes and perceptions of healthcare workers about arboviruses in the context of surveillance in the Republic of Guinea

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Salifou Talassone BANGOURA

B / 4 / 14

Poster P0202

Abstract 878

NS1-based IgG FcγR Enzyme-Linked Immunosorbent Assays allow serological differential diagnosis of dengue and zika virus infections in both returning travellers and individuals from endemic regions

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Christina DESCHERMEIER

B / 4 / 15

Poster P0203

Abstract 905

NanoHarmony: unleashing silver's whisper in swift Zika detection

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Mayank GANGWAR

B / 4 / 16

Poster P0204

Abstract 912

Factors associated with mpox vaccination willingness and uptake among men who have sex with men

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Shui Shan LEE

B / 4 / 17

Poster P0205

Abstract 1119

Intensified surveillance for tick-borne encephalitis to identify possible places of infection in Bavaria, Germany, May–October 2023

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Jasmin METZ

B / 4 / 18

Poster P0206

Abstract 1124

Lassa virus: unravelling the within-host evolutionary dynamics of acute and persistent infections and the virulence evolution among hosts

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Liana KAFETZOPOULOU

B / 4 / 19

Poster P0207

Abstract 1216

Correlation between the cycle threshold values of medium- and small-segment severe fever with thrombocytopenia syndrome virus and viral load: prognostic implications

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Lee SEUNGHEE

B / 4 / 20

Poster P0208

Abstract 2152

Do infectious diseases specialists and neurologists manage patients with tick-borne encephalitis differently?

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Dasa STUPICA

B / 4 / 21

Poster P0209

Abstract 2253

A ‘living' rapid research needs appraisal platform for WHO priority diseases: henipavirus evidence-gaps

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Louise SIGFRID

B / 4 / 22

Poster P0210

Abstract 2340

Spatio-temporal distribution of Crimean-Congo hemorrhagic fever and the effect of climate factors and Eid ul Adha in Pakistan: a decade-long experience from tertiary care laboratory network

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Muhammad Abbas ABID

B / 4 / 23

Poster P0211

Abstract 2538

Laboratory results of mpox suspected cases tested by differential diagnostic panel during the mpox outbreak in Hungary in 2022/2023

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Dániel DÉRI

B / 4 / 24

Poster P0212

Abstract 2565

Exploring mpox genome variations amidst the 2022 outbreak

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Michela DEIANA

B / 4 / 25

Poster P0213

Abstract 2592

First detection of the zoonotic rat hepatitis E virus in pigs

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

María CASARES JIMÉNEZ

B / 4 / 26

Poster P0214

Abstract 2628

Clinical importance of Alongshan virus, a new tick-borne Flaviviridae virus: a retrospective serological and molecular study

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Florian TAGINI

B / 4 / 27

Poster P0215

Abstract 2718

Assessing the synergistic insecticidal activity of Syzygium aromaticum and Citrus aurantifolia leaf extract combination against Aedes vectors

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Malshi GALAPPATHTHI

B / 4 / 28

Poster P0216

Abstract 2739

Orthopoxvirus differential diagnosis by neutralising antibodies in mpox patients and vaccinated individuals

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Concetta CASTILLETTI

A / 5 / 1

Poster P0217

Abstract 2770

MCP-3 as a prognostic biomarker for severe fever with thrombocytopenia syndrome: a longitudinal cytokine profile Study

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Zishuai LIU

A / 5 / 2

Poster P0218

Abstract 2900

Prospective evaluation of serum cytokines and musculoskeletal ultrasound as surrogate markers for chronic post-chikungunya rheumatism

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Hugh WATSON

A / 5 / 3

Poster P0219

Abstract 2909

A question from an endemic area: which diseases are included in the differential diagnosis with CCHF?

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Esma ERYILMAZ-EREN

A / 5 / 4

Poster P0220

Abstract 3020

Increased likelihood of leukopenia, thrombocytopenia, and other characteristics in Crimean-Congo haemorrhagic fever patients: a systematic review and analysis of clinical factors that indicate infection

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Joseph ALBERTS

A / 5 / 5

Poster P0221

Abstract 3026

Dengue vaccine: a risk model to prioritise and maximize the impact of a dengue vaccination program in Peru

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Antonio QUISPE

A / 5 / 6

Poster P0222

Abstract 3034

Mayaro virus and chikungunya virus IgM and IgG testing in parallel improves diagnosis of acute mayaro virus infections

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Fabian LINDHORST

A / 5 / 7

Poster P0223

Abstract 3354

Epidemiology trends of infections and outbreaks of Crimean-Congo hemorrhagic fever worldwide, 2017-2023.

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Luca ZWEERS

A / 5 / 8

Poster P0224

Abstract 3385

Strengthening preparedness to arbovirus infections in Europe: a prospective, observational study in southeast Europe

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Xin Hui CHAN

A / 5 / 9

Poster P0225

Abstract 3479

Expression of galectin-3 ameliorates zika virus infection

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Jie-Yu HUANG

A / 5 / 10

Poster P0226

Abstract 4270

Assessing the endemicity of Japanese encephalitis in central India: a comprehensive study of human and animals in Madhya Pradesh

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Ram Kumar NEMA

A / 5 / 11

Poster P0227

Abstract 4563

A meta-analysis and mapping of global mpox infection among children and adolescents

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Tarun Kumar SUVVARI

A / 5 / 12

Poster P0228

Abstract 4854

Clinical presentation and viral shedding in patients with mpox in South Korea

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Min-Kyung KIM

A / 5 / 13

Poster P0229

Abstract 4900

Clinical-laboratory features and predictive factors for sequelae of tick-borne encephalitis virus infection: a retrospective observational study

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Nicole BARP

A / 5 / 14

Poster P0230

Abstract 4909

Tick of the iceberg: using a One Health approach to assess and respond to the threat of tick-borne encephalitis in England

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Berkin HACK

A / 5 / 15

Poster P0231

Abstract 5070

Relation of WNV seroprevalence with ABO and D blood groups among blood donors: implication for transfusion safety

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Rym AYARI

A / 5 / 16

Poster P0232

Abstract 5148

Clinical and microbiological study of bacterial or fungal co-infections in severe fever with thrombocytopenia syndrome

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Hiroyuki TANAKA

A / 5 / 18

Poster P0234

Abstract 5317

Enhancing clinical diagnosis of dengue: performance evaluation of NS1 antigen and IgG/IgM antibody tests

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Kyu Tae CHOI

A / 5 / 19

Poster P0235

Abstract 5335

Mpox in Colombia: an analysis of the 4,114 PCR confirmed cases in June 2022-November 2023

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Alfonso J. RODRIGUEZ-MORALES

A / 5 / 20

Poster P0236

Abstract 5686

Co-detection of RNA and DNA viruses in a single library prep and enrichment workflow

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Robert SCHLABERG

A / 5 / 21

Poster P0237

Abstract 5905

Results from a large-scale dengue diagnostic accuracy systematic review and meta-analysis: NS1 ELISA performs similarly to RT-PCR

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Ellen SUGRUE

A / 5 / 22

Poster P0238

Abstract 5977

TBE vaccination: insights from a KAB survey among Lyme borreliosis cases in Bavaria, Germany, 2019

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Stefanie BÖHM

A / 5 / 23

Poster P0239

Abstract 6027

Children hospitalised with Crimean-Congo haemorrhagic fever in Turkiye have different clinical and diagnostic features and lower mortality than adults, implying that diagnostic criteria and illness severity scoring systems need adaptation for use in children

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Ilkay BOZKURT

A / 5 / 24

Poster P0240

Abstract 6094

Elevated plasma level of IP-10 /CXCL10 is correlated with severity of human West Nile virus (WNV) infection

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Giada ROSSINI

A / 5 / 25

Poster P0241

Abstract 6205

Effect of severe fever with thrombocytopenia syndrome virus genotype on disease severity, viral load, and cytokines in South Korea

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Ji-Soo KWON

A / 5 / 26

Poster P0242

Abstract 6538

Clinical findings and IL-6 levels in patients with dengue

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Anandi GOEL

A / 5 / 27

Poster P0243

Abstract 6566

Arthropod-borned zoonosis in Cádiz, south of Spain: serological prevalence in a high-risk group

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Natalia MONTIEL QUEZEL-GUERRAZ

A / 5 / 28

Poster P0244

Abstract 6643

Development and validation of the PLNA score to predict cytokine storm in patients with acute phase of SFTS: a single-center cohort study

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Zishuai LIU

B / 5 / 1

Poster P0245

Abstract 6773

Hybrid capture-based next-generation sequencing: implementation for Lassa virus for the recovery of in-depth viral genomic data

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Ine BOONEN

B / 5 / 2

Poster P0246

Abstract 6809

Development of a multiplexed serological mpox assay for diagnostics, serosurveillance, and immunology studies

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Scott JONES

B / 5 / 3

Poster P0247

Abstract 6826

Genotypic diversity and molecular characterisation of DENV-2 in endemic areas of Peru during 2016-2021

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Wilmer SILVA-CASO

B / 5 / 4

Poster P0248

Abstract 6867

The clinical characteristics of human mpox disease before and after the 2022 outbreak: any difference? a metaanalysis study

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Parnian JAMSHIDI

B / 5 / 5

Poster P0249

Abstract 7432

Early identification of complex biomarker signatures predicting plasma leakage in dengue patients

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Samaneh MOALLEMI

B / 5 / 6

Poster P0250

Abstract 7758

Genetic characteristics of aigai virus: a recently reclassified orthonairovirus

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Anna PAPA-KONIDARI

B / 5 / 7

Poster P0251

Abstract 7981

Knowledge, risk perception and attitudes about mpox and the implementation of preventive measures in people belonging to the LGTBIQ+ community in Colombia

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Candida Rosa DIAZ BROCHERO

B / 5 / 8

Poster P0252

Abstract 8019

Adjuvanted unconjugated highly conserved multi-epitope influenza peptide vaccine induced broadly reactive antibodies to multiple influenza viruses in pigs

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Kellie Ann KROSCHER

B / 5 / 9

Poster P0253

Abstract 8120

Investigating the pathogenesis of Middle East respiratory syndrome coronavirus infection using a quantitative phosphoproteomics approach

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Jasper CHAN

B / 5 / 10

Poster P0254

Abstract 8327

Evaluation of viral load and neutralising antibody levels in Crimean-Congo hemorrhagic fever patients

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Mert Ahmet KUSKUCU

B / 5 / 11

Poster P0255

Abstract 8393

Nanopore sequencing of RdRp gene used as a genetic marker for characterization of coronaviruses in clinical samples

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Iris SARMIENTO GUÀRDIA

B / 5 / 12

Poster P0256

Abstract 8485

Mpox experience at a tertiary infectious diseases centre in a tropical country between 2022-2023

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Luís Arthur Brasil GADELHA FARIAS

B / 5 / 13

Poster P0257

Abstract 8500

Combining phylogeographic and niche modelling approaches to investigate the ecological drivers of TBEV at the Palearctic scale

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Maria Fernanda VINCENTI GONZALEZ

B / 5 / 14

Poster P0258

Abstract 8532

Chikungunya in Colombia, 2022: An analysis of the cases notified to the National Surveillance System in the midst of South American reemergence

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Alfonso J. RODRIGUEZ-MORALES

B / 5 / 15

Poster P0259

Abstract 8600

Dengue epidemics in Colombia, 2023: an analysis of the cases notified to the national surveillance system

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Alfonso J. RODRIGUEZ-MORALES

B / 5 / 16

Poster P0260

Abstract 8667

Minor clinical sequelae and absence of viral persistence: an 8-month follow-up study of former mpox patients

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Nicole BERENS-RIHA

B / 5 / 17

Poster P0261

Abstract 8776

Sero-catalytic and spatial modeling of dengue force-of-infection from age-stratified seroprevalence data in Timor-Leste

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Paul ARKELL

B / 5 / 18

Poster P0262

Abstract 31

Evaluation of clinical applicability for a novel ultrasensitive ELISA detection of dengue virus

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Po-Kai CHEN

B / 5 / 19

Poster P0263

Abstract 473

Performance analysis of a commercial meningitis/encephalitis panel compared to other microbiological tests and clinical diagnosis at discharge: a retrospective observational study of 1000 consecutive patients

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Gülsen ÖZKAYA SAHIN

B / 5 / 20

Poster P0264

Abstract 851

Consistent differences in analytical and clinical performance for detection of SARS-CoV-2, influenza A/B and RSV between point-of-care tests

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Christel Barker JENSEN

B / 5 / 21

Poster P0265

Abstract 925

Biomarkers and genotypes in patients with central nervous system infection caused by enterovirus

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Karolina ALSÉN

B / 5 / 22

Poster P0266

Abstract 1140

Concurrent assessment of three viral RNA pathogens in MK buffered solution using droplet digital PCR: performance comparison for diagnostic based detection

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Daniel BRAZEAU

B / 5 / 23

Poster P0267

Abstract 1226

Validation of a new molecular assay for the quantification of Epstein-Barr virus load in EDTA-plasma

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Irene CORTÉS PORTERO

B / 5 / 24

Poster P0268

Abstract 1239

A comparison of four molecular assays for the detection of mpox virus DNA

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Henar ALONSO

B / 5 / 25

Poster P0269

Abstract 1292

Comparison between conventional primary HPV cervical screening vs by vaginal self-sampling in France

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Benoît VISSEAUX

B / 5 / 26

Poster P0270

Abstract 1402

JC virus VP1 gene: a more accurate detection and quantification of viral DNA

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Alba GARCÍA-MURILLO

B / 5 / 27

Poster P0271

Abstract 1758

Performance evaluation test on rapid polymerase chain reaction test for mpox without nucleic acid extraction

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Kei YAMAMOTO

B / 5 / 28

Poster P0272

Abstract 2114

Verification of a new molecular point of care system for respiratory viruses for its use with two widely used transportation media

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Juergen BECKER

A / 6 / 1

Poster P0273

Abstract 2697

Enhancing pathogen detection in viral respiratory tract infections among individuals aged >55 years through expanded PCR panel testing

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Jelena FEENSTRA

A / 6 / 2

Poster P0274

Abstract 2801

Comparison of three assays for the detection of human papillomavirus and their correlation with cervical cytology

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Ben VANMASSENHOVE

A / 6 / 3

Poster P0275

Abstract 2874

Validation of a multiplex qRT-PCR assay for RSV, influenza A/B and SARS-CoV-2

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Alihan BULGURCU

A / 6 / 4

Poster P0276

Abstract 2910

Clinical performance evaluation of a real-time PCR-based test for the detection of high-risk HPV genotypes

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Jelena FEENSTRA

A / 6 / 5

Poster P0277

Abstract 3416

Establishing EBV load thresholds for predicting persisting EBV-DNAemia and associated disease

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Svenia SCHMID

A / 6 / 6

Poster P0278

Abstract 3883

Multicenter evaluation of the Standard M10 Influenza, RSV and SARS-CoV-2 assay in nasopharyngeal swabs in liquid Amies medium

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Dagmar OBBELS

A / 6 / 7

Poster P0279

Abstract 4059

Comparison of Allplex HPV28 and Anyplex II HPV28 Assays for the detection and genotyping of human papillomavirus

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Karoline LEUZINGER

A / 6 / 8

Poster P0280

Abstract 4090

Urine-based HPV-DNA screening for cervical cancer prevention in a rural health clinic in Eswatini

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Simone VILLA

A / 6 / 9

Poster P0281

Abstract 4550

A lateral flow test for rapid identification of paediatric viral infection based on host response mRNA transcripts

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Ruth REID

A / 6 / 10

Poster P0282

Abstract 5050

Performance evaluation of the comercial BK virus ASR on the NeuMoDx system

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Amorce LIMA

A / 6 / 11

Poster P0283

Abstract 5067

Clinical evaluation of an adenoviral species-typing model using PCR melt-curve data

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Benjamin GALVIN

A / 6 / 12

Poster P0284

Abstract 5626

Molecular epidemiology of measles virus from measles outbreak in the Philippines, 2023

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Leonibel REYES

A / 6 / 13

Poster P0285

Abstract 6050

New approaches in laboratory surveillance in the face of polio threat for public health, Romania 2023

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Teodora SOLOMON

A / 6 / 14

Poster P0286

Abstract 6208

Implementation of the allplex high risk HPV genotyping assay in a routine clinical lab

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Dagmar OBBELS

A / 6 / 15

Poster P0287

Abstract 6387

Utilising digitally characterised control material to improve comparability of molecular workflows for viral gastroenteritis

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Emily MCKLOUD

A / 6 / 16

Poster P0288

Abstract 7227

Validation of commercial real-time PCR kit for detection of mpox

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Marcus POND

A / 6 / 17

Poster P0289

Abstract 7562

Diagnostic performance of five real-time PCR assays for mpox virus detection

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Aida PEIRO-MESTRES

A / 6 / 18

Poster P0290

Abstract 7626

Urine and vaginal high-risk human papilloma virus (hrHPV) self-sampling among HIV-positive women in Guinea-Bissau is well-accepted: three in four women are HPV-positive

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Kia Lærke MADSEN

A / 6 / 19

Poster P0291

Abstract 7764

Evaluating and expanding measles serological assays: toward an improved diagnostic tool

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Rebecca STURM

A / 6 / 20

Poster P0292

Abstract 8259

Cerebrospinal fluid and plasma biomarkers in patients with central nervous system infections: a retrospective study

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Maria Antonella ZINGAROPOLI

A / 6 / 21

Poster P0293

Abstract 8271

Acute viral gastro-enteritis in infants and toddlers, from the big three to the big five?

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Jos VAN ACKER

A / 6 / 22

Poster P0294

Abstract 8498

Identification of adeno-associated virus type 2 viremia in a large cohort from Berlin, Germany

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Till D. BEST

A / 6 / 23

Poster P0295

Abstract 394

Viral and inflammatory markers in sudden death caused by myocarditis: a retrospective bicentric study

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Domitille CALLON

A / 6 / 24

Poster P0296

Abstract 1457

HPV genotypes distribution in urethral samples in French men

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Stéphanie HAIM-BOUKOBZA

A / 6 / 25

Poster P0297

Abstract 1554

Molecular epidemiology of Coxsackie A6 strains circulating in Hungary between 2020-2023

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Nóra DEÉZSI-MAGYAR

A / 6 / 26

Poster P0298

Abstract 1935

Epidemiological study of high-risk human papillomavirus before the advent of primary molecular screening in Occitania, France

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Matthieu BERNIER

A / 6 / 28

Poster P0300

Abstract 2594

Cutavirus prevalence in malignant and non-malignant tissues

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Irini Maria ASSIMAKOPOULOU

B / 6 / 1

Poster P0301

Abstract 3191

National diagnostics case series and One Health phylogenetic analysis of Murray valley encephalitis outbreak in Australia

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Howard-Jones ANNALEISE

B / 6 / 2

Poster P0302

Abstract 3593

Molecular epidemiology of human papillomavirus in a lower-middle-income and cervical cancer high-burden country

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Clara FAPPANI

B / 6 / 3

Poster P0303

Abstract 3641

Patterns of enterovirus infections in hospitalisations and outpatient visits in Denmark 2015-2022

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Caroline Klint JOHANNESEN

B / 6 / 4

Poster P0304

Abstract 3661

Detection of different viruses of clinical importance in bone marrow

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Marta Elena ALVAREZ-ARGÜELLES

B / 6 / 5

Poster P0305

Abstract 3832

Norovirus genotype distribution among children with acute gastroenteritis in South-East Austria

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Evelyn STELZL

B / 6 / 6

Poster P0306

Abstract 5554

First results of laboratory surveillance for enteroviruses in Italy (2022-2023)

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Laura PELLEGRINELLI

B / 6 / 7

Poster P0307

Abstract 5926

Comprehensive genotyping supports the epidemiological investigation of Austrian measles virus outbreaks in 2023

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Maria Joao CARDOSO

B / 6 / 8

Poster P0308

Abstract 6039

Rotavirus A epidemiology shifts due to pandemic: 14-year experience of Belgian National Reference Center in the COVID-19 context

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Mustafa KARATAS

B / 6 / 9

Poster P0309

Abstract 6083

Circulation of respiratory viruses in hospitalised children in the post-COVID-19 era

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Angeliki KASSOMENAKI

B / 6 / 10

Poster P0310

Abstract 6178

Negative conversion and recurrence rate of high risk human papillomavirus in cervical infection

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Kyutaeg LEE

B / 6 / 11

Poster P0311

Abstract 6323

Rotavirus clinical and genomic surveillance reveals predominance of equine-like G3 strains, antigenic mismatches with vaccines, NSP2-reassortants and multiple vaccine breakthrough cases, 2021-2023, Madrid, Spain

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Rocio SANCHEZ LEON

B / 6 / 12

Poster P0312

Abstract 6567

Male human papillomavirus genital infection: a focus on non-vaccine genotypes

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Michela BUTTÀ

B / 6 / 13

Poster P0313

Abstract 6889

Analysis of human papillomavirus 51 (HPV51) genetic variations detected in women with cervical dysplasia

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Marianna MARTINELLI

B / 6 / 14

Poster P0314

Abstract 7742

Evaluation of biomarkers associated with human papillomavirus 16 (HPV16) persistent infection

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Chiara GIUBBI

B / 6 / 15

Poster P0315

Abstract 8473

Understanding Measles Comeback

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Berksan SIMSEK

B / 6 / 16

Poster P0316

Abstract 8539

Establishing a 24/7 mpox outbreak helpline: an overlooked source of early epidemiological data?

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Sowsan ATABANI

B / 6 / 17

Poster P0317

Abstract 8553

Descriptive study of the distribution of human papillomavirus genotypes in a hospital in southern Spain

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Yolanda GARCÍA COLLADO

B / 6 / 18

Poster P0318

Abstract 8803

Echovirus 11 reported in emilia-romagna region during 2023

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Alessia CANTIANI

B / 6 / 19

Poster P0319

Abstract 8832

Contribution of rotavirus infections to child mortality in the Cchild health and mortality prevention (CHAMPS) network

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Inacio MANDOMANDO

B / 6 / 20

Poster P0320

Abstract 3861

Dengue virus infection elicits galectin-3 expression with inhibitory impact on dengue viral infectivity

27/04 12:00

1i. Basic and applied virology (incl in vitro and in vivo models, novel methods)

Sheng-Fan WANG

B / 6 / 21

Poster P0321

Abstract 4604

Detection of human polyomaviruses in oral samples supports the oral transmission route

27/04 12:00

1i. Basic and applied virology (incl in vitro and in vivo models, novel methods)

Maria DOLCI

B / 6 / 22

Poster P0322

Abstract 8213

Identification of viral inhibitors: evaluating Himalayan herbs as alternatives for dengue treatment

27/04 12:00

1i. Basic and applied virology (incl in vitro and in vivo models, novel methods)

Gaurav BADONI

B / 6 / 23

Poster P0323

Abstract 20

Recently published randomised controlled trials investigating treatments against COVID-19 displayed lower risk of bias: a systematic review and critical appraisal

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Kavina KUDHAIL

B / 6 / 24

Poster P0324

Abstract 116

Real-world safety and effectiveness of molnupiravir during the Omicron wave: a final report of a post-marketing surveillance in Japan

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Kimata MASAHIRO

B / 6 / 25

Poster P0325

Abstract 130

Drug interactions with nirmatrelvir/ritonavir in hospitalised patients: prevalence, severity and management strategies

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sohair SWAID

B / 6 / 26

Poster P0326

Abstract 161

Influence of cytokine levels on the effect of tocilizumab on mortality or ICU admission in COVID-19 pneumonia

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Guiomar HERNÁNDEZ-GARCÍA

B / 6 / 27

Poster P0327

Abstract 181

Long COVID looks like other post-viral syndromes 12 months after infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Matthew BROWN

B / 6 / 28

Poster P0328

Abstract 225

Cross-sectional surveillance study of long COVID in Toyonaka city, Osaka Prefecture, Japan

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Satoshi KUTSUNA

A / 7 / 1

Poster P0329

Abstract 239

The impact of the COVID-19 pandemic on adult vaccination, with emphasis on influenza and pneumococcal vaccination in India: a comprehensive report

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sureshkumar DORAIRAJAN

A / 7 / 2

Poster P0330

Abstract 350

Healthcare workers' attitude toward COVID-19 vaccination campaign in Armenia

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Goulia OHAN

A / 7 / 3

Poster P0331

Abstract 415

The predictors of COVID-19 immunogenicity elicited by vaccines against SARS-CoV-2 in bone marrow transplant recipients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Oguz Resat SIPAHI

A / 7 / 4

Poster P0332

Abstract 437

Improved SARS-CoV-2 molecular detection in European expert public health laboratories: results of the third external quality assessment, 2023

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Kamelia STANOEVA

A / 7 / 6

Poster P0334

Abstract 509

Normalisation of eosinophil count is predictive of reduced oxygen requirement during COVID-19 infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Benjamin DAVIDO

A / 7 / 7

Poster P0335

Abstract 511

Humoral anti-SARS-CoV-2 response in patients with different long COVID phenotypes

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Piotr RZYMSKI

A / 7 / 8

Poster P0336

Abstract 519

Influence of anti-spike protein antibody levels on tocilizumab efficacy in hospitalised patients with severe COVID-19 pneumonia: a post-hoc analysis of the COVACTA trial

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Pablo GUISADO-VASCO

A / 7 / 9

Poster P0337

Abstract 543

Unraveling the past: analysing the effects of COVID-19 on hematological malignancy patients - observations from 2020 to 2022

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Jon SALMANTON-GARCIA

A / 7 / 10

Poster P0338

Abstract 552

Circulating antibody titres predict infection and severity in COVID-19 close contacts

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Joanne BYRNE

A / 7 / 11

Poster P0339

Abstract 567

First serological study of MERS-CoV on dromedary camels from Algeria

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Mammar KHAMES

A / 7 / 12

Poster P0340

Abstract 573

Cost-effectiveness of oral nirmatrelvir/ritonavir in patients at high risk for progression to severe COVID-19 in the United States

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Tendai MUGWAGWA

A / 7 / 13

Poster P0341

Abstract 607

Enhancing respiratory disease diagnosis: a comparative analysis of multiplex point-of-care PCR and antigen testing for SARS-CoV-2, influenza, and respiratory syncytial virus in Germany

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Jordan CHASE

A / 7 / 15

Poster P0343

Abstract 693

Antibody responses against recently emerged SARS-CoV-2 variants: a population-based cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Annelies J. H. DE ROOIJ

A / 7 / 16

Poster P0344

Abstract 703

For COVID vaccination choices in Germany or the United Kingdom, efficacy ranks first followed by common side effects

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Matthew ROUSCULP

A / 7 / 17

Poster P0345

Abstract 706

Comparison of characteristics between patients who received COVID-19 non-mRNA and mRNA vaccines in Germany

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Lucie KUTIKOVA

A / 7 / 18

Poster P0346

Abstract 825

Systematic review and meta-regression analysis of clinical therapeutic responses and viral clearance in early symptomatic COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Shivani SINGH

A / 7 / 19

Poster P0347

Abstract 850

Prognostic of COVID-19 in ICU-admitted COPD patients: the impact of high-flow nasal cannulas and other factors

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Laia FERNÁNDEZ-BARAT

A / 7 / 20

Poster P0348

Abstract 859

Robust immune response to COVID-19 vaccination in Greenlanders: an observational study in an island population

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Mie MØLLER

A / 7 / 21

Poster P0349

Abstract 863

To die with or to die for COVID-19 infection during the Omicron era

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Marco BONGIOVANNI

A / 7 / 22

Poster P0350

Abstract 876

Recurrent ventilator-associated pneumonia in severe COVID-19 ARDS patients requiring ECMO support

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Charles-Edouard LUYT

A / 7 / 23

Poster P0351

Abstract 900

Protective effect of previous omicron BA.2 infection and fourth dose vaccination on SARS-CoV-2 XBB infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Nicole Ngai Yung TSANG

A / 7 / 24

Poster P0352

Abstract 913

External validations of prognostic COVID-19 scores: an innovative mass validation using the multi-center ORCHESTRA cohort

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Katharina APPEL

A / 7 / 25

Poster P0353

Abstract 949

Real-world evidence comparing the risk of Delta and Omicron infection outcomes by SARS-CoV-2 antibody levels

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Yue JIN

A / 7 / 26

Poster P0354

Abstract 950

Remdesivir reduces mortality in immunocompromised patients hospitalised for COVID-19 across the pandemic and endemic eras

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Essy MOZAFFARI

A / 7 / 27

Poster P0355

Abstract 977

Efficacy of tofacitinib as add-on therapy to remdesivir and corticosteroids in COVID-19 infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Tahsine MAHFOUZ

B / 7 / 1

Poster P0357

Abstract 1111

Proteomic and cellular characterisation of Omicron breakthrough infections and a third homologous or heterogenous boosting vaccination by a longitudinal cohort

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Yi ZHANG

B / 7 / 2

Poster P0358

Abstract 1232

Levels of inflammatory and cardiac biomarkers as a predictor factor for complications and outcomes in hospitalised COVID-19 patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Catia CILLONIZ

B / 7 / 3

Poster P0359

Abstract 1237

Changes in Pneumocystis jirovecii pneumonia (PCP) before and during COVID-19 pandemic

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Julen ARMENDARIZ GAYRAUD

B / 7 / 4

Poster P0360

Abstract 1251

SARS-CoV-2 breakthrough infections in healthcare workers of an Italian university hospital: an update three years after the start of the vaccination campaign

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Luigi DE MARIA

B / 7 / 5

Poster P0361

Abstract 1258

Cracking the SARS-CoV-2 Omicron variants: unveiling the sensitivity of rapid antigen tests and optimal sampling sites

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Piubelli CHIARA

B / 7 / 6

Poster P0362

Abstract 1290

Vaccination shapes within-host SARS-CoV-2 diversity of Omicron BA.2.2 breakthrough infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Yi ZHANG

B / 7 / 7

Poster P0363

Abstract 1323

In vitro neutralisation of VYD222 against Omicron sublineages

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Pamela HAWN

B / 7 / 8

Poster P0364

Abstract 1405

Clinical outcomes of COVID-19 vaccine breakthrough infections: a single-centre study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Claudine Dayle MARANAN

B / 7 / 9

Poster P0365

Abstract 1437

Descriptive analysis of self-reported HRQoL using EQ-5D-5L among symptomatic outpatients with COVID-19 in the US during an Omicron predominant period

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Ashley CHA-SILVA

B / 7 / 10

Poster P0366

Abstract 1447

Clinical presentation of COVID-19 among healthcare workers across the early COVID-19 pandemic, Peru

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Diana PONCE

B / 7 / 11

Poster P0367

Abstract 1460

Sentinel cohort safety of AZD5156/AZD3152 from the phase 1/3 SUPERNOVA trial for COVID-19 prevention in participants with immune impairment

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Taylor S. COHEN

B / 7 / 12

Poster P0368

Abstract 1467

Developing a model for decision-making around antibiotic prescribing for patients with COVID-19 pneumonia in acute NHS hospitals during the first wave of the COVID-19 pandemic: qualitative results from the procalcitonin evaluation of antibiotic use in COVID-19 hospitalised patients (PEACH Study)

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Joanne EUDEN

B / 7 / 13

Poster P0369

Abstract 1494

Descriptive epidemiology of adverse events following mRNA COVID-19 vaccination in Curacao

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Jonathan LAMBO

B / 7 / 14

Poster P0370

Abstract 1500

Assessing transmission of SARS-CoV-2 via the aerosol and contact routes using a direct human totransgenic K18-hACE2 mouse model

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

John CONLY

B / 7 / 15

Poster P0371

Abstract 1514

Antimicrobial resistance before, during, and after the COVID-19 pandemic, 120 U.S. Hospitals

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Yek CHRISTINA

B / 7 / 16

Poster P0372

Abstract 1548

Retrospective study of baseline co-medication potential DDI in COVID-19 hospitalised patients in Spain: the COCOS Study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Manuel COTARELO

B / 7 / 17

Poster P0373

Abstract 1572

The gut microbiota as an early predictor of COVID-19 severity

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Marco FABBRINI

B / 7 / 18

Poster P0374

Abstract 1625

Procalcitonin evaluation of antibiotic use in COVID-19 hospitalised patients: the PEACH study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Emma THOMAS-JONES

B / 7 / 19

Poster P0375

Abstract 1655

Effect of co-formulation on pharmacokinetics of AZD7442, a monoclonal antibody combination against COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Taylor S. COHEN

B / 7 / 20

Poster P0376

Abstract 1679

COVID-19 pandemic encourages childhood vaccination in Japan: findings from the VENUS study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Yusuke ASAI

B / 7 / 21

Poster P0377

Abstract 1705

Comparative biodistribution study of baculoviral and adenoviral vector based-vaccines against SARS-CoV-2

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Hee-Jung LEE

B / 7 / 22

Poster P0378

Abstract 1752

COVID-19 hospitalisations amongst immunocompromised individuals receiving 300 mg AZD7442 (tixagevimab/cilgavimab) pre-exposure prophylaxis: real-world effectiveness data from Israel's largest health maintenance organisation

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Samah HAYEK

B / 7 / 23

Poster P0379

Abstract 1789

Serum AZD7442 (tixagevimab-cilgavimab) concentrations and in vitro IC50 values predict SARS-CoV-2 neutralising antibody (nAb) titres

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Anastasia A. AKSYUK

B / 7 / 24

Poster P0380

Abstract 1793

COVIDRIVE: a European public-private partnership for generating real-world evidence on the effectiveness of COVID-19 vaccines

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Kaatje BOLLAERTS

B / 7 / 25

Poster P0381

Abstract 1796

High prevalence of immunocompromising conditions among patients with severe acute respiratory infection, including SARS-CoV-2: results from a multicentre, test-negative case-control study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Wilhelmine MEERAUS

B / 7 / 26

Poster P0382

Abstract 1800

Immunocompromise, cancer and other comorbidities in patients with severe acute respiratory infection testing positive versus negative for SARS-CoV-2: a post hoc analysis of COVIDRIVE data from May 2021 to May 2023

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Wilhelmine MEERAUS

B / 7 / 27

Poster P0383

Abstract 1801

Prospective study on clinical and biochemical parameters in post-COVID fatigue and myalgia

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sunit SIKDAR

B / 7 / 28

Poster P0384

Abstract 1864

Evaluation of a saliva home collection kit and temperature stability demonstrates the utility of home-collected saliva specimens for laboratory-based COVID-19 diagnostic testing

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Julie CARSTENS

A / 8 / 1

Poster P0385

Abstract 1883

Clinical outcomes and safety of remdesivir use in hospitalised COVID-19 patients with and without severe renal impairment

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Yi-Tsung LIN

A / 8 / 2

Poster P0386

Abstract 1903

Can a correlate of protection against SARS-CoV-2 infection be established in cancer patients: a statistical modeling perspective

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Yana DEBIE

A / 8 / 3

Poster P0387

Abstract 1967

Limited effectiveness of adding remdesivir to dexamethasone in COVID-19 pneumonia during the evolution of SARS-CoV-2: a comparative study using a clinical data warehouse

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Yeunji LEE

A / 8 / 4

Poster P0388

Abstract 1988

Adding hyponatraemia to “rule-of-six” prediction tool improves performance in identifying hospitalised patients with COVID-19 at risk of adverse clinical outcomes

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Meng Ying SIM

A / 8 / 5

Poster P0389

Abstract 2068

Persisting differences in the immunogenicity of the two COVID-19 primary vaccines series, modulated by booster mRNA vaccination and breakthrough infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Keon Young LEE

A / 8 / 6

Poster P0390

Abstract 2098

Immunogenicity of a single booster dose of Soberana Plus (FINLAY-FR-1A) vaccine in adults with different previous history of COVID-19 vaccination

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Igor STOMA

A / 8 / 7

Poster P0391

Abstract 2110

De-mystifying the double danger of COVID-19 and dengue co-infection in India

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sonam SINGLA

A / 8 / 8

Poster P0392

Abstract 2122

Integrated severe acute respiratory infection (SARI) sentinel surveillance of influenza, SARS-CoV-2 and RSV in Serbia

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Dragana DIMITRIJEVIC

A / 8 / 9

Poster P0393

Abstract 2172

Comparison of clinical characteristics and outcomes in candidemic patients with and without COVID-19: a multicentre, propensity score-matched analysis

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sung Un SHIN

A / 8 / 10

Poster P0394

Abstract 2180

SARS-CoV-2 Spike fusion peptide (FP) mutation P812S unique to the nasal compartment in a 101-day persistent infection shows infectivity reduction and context-dependent neutralisation evasion of vaccinee sera

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Tsz Kin Mark CHENG

A / 8 / 11

Poster P0395

Abstract 2184

The high expression of PD-1 defines a subpopulation of T follicular helper cell responding to COVID-19 vaccine in humans

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Jingxin GUO

A / 8 / 12

Poster P0396

Abstract 2189

Cell-free DNA as a promising non-invasive marker for predicting critical COVID-19 cases: a pilot study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Senulyte AUGUSTE

A / 8 / 13

Poster P0397

Abstract 2206

Usage of oral contraceptives among healthcare workers: impact on COVID-19 booster vaccine immunogenicity

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Manuel KRONE

A / 8 / 14

Poster P0398

Abstract 2254

Local and systemic reactogenicity after mRNA and protein-based COVID vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomised phase 2 trial (COV-BOOST)

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Seth TOBACK

A / 8 / 16

Poster P0400

Abstract 2316

Survival impact of comorbidities on the one-year mortality among hospitalised COVID-19 patients in a vaccinated Omicron-infected multicentre cohort

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Tsai MING-TAO

A / 8 / 17

Poster P0401

Abstract 2328

Bivalent Omicron BA1 vaccine booster increases the breadth and potency of memory-B and T cell response and protects against emerging SARS-CoV-2 variants

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Lok Bahadur SHRESTHA

A / 8 / 18

Poster P0402

Abstract 2344

Hospital-acquired COVID-19 at The Northern Hospital, 2021-2022, an outcome and costs analysis

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

George DREWETT

B / 8 / 1

Poster P0403

Abstract 2366

Increased MP/CP co-infection in COVID-19 positive kidney transplant recipients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Zhonghao WANG

B / 8 / 2

Poster P0404

Abstract 2380

Risk of severe COVID-19 in SARS-CoV-2 vaccinated individuals with hematologic malignancies: a nationwide cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sabine HAGGENBURG

B / 8 / 3

Poster P0405

Abstract 2472

Comercial Sars-CoV-2 test: performance evaluation on bronchoaspirates and broncholavages

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Elena NICOLINI

B / 8 / 4

Poster P0406

Abstract 2535

Risk factors for SARS-CoV-2 infection among healthcare workers in 168 hospitals: a multi-centre study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Wang MEIXIA

B / 8 / 5

Poster P0407

Abstract 2600

Longitudinal shifts in gut microbiota during mild COVID-19 are linked to post-acute COVID-19 syndrome (PACS)

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Marco FABBRINI

B / 8 / 6

Poster P0408

Abstract 2626

A Randomized, Double-Blinded, Cohort Clinical Trial on Evaluating the Safety and Immunogenicity of Sequential Immunization of Two Doses of Omicron Specific Inactivated COVID-19 Vaccines as Boosters in Adults

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Ruiqi ZHANG

B / 8 / 7

Poster P0409

Abstract 2688

Continued increased risk of COVID-19 hospitalisation and death in immunocompromised individuals despite receipt of ≥4 vaccine doses: updated 2023 results from INFORM, a retrospective health database study in England

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sabada DUBE

B / 8 / 8

Poster P0410

Abstract 2699

Comparison of COVID-19 vs non-COVID-19 patients without haematological malignancies treated for invasive pulmonary aspergillosis: a 5 years retrospective cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sara VOLPI

B / 8 / 9

Poster P0411

Abstract 2721

Pulmonary function in patients with dyspnea in the post-acute phase of COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Olha SHCHUDRO

B / 8 / 10

Poster P0412

Abstract 2723

Healthcare resource use and overall costs of COVID-19 during the Omicron-predominant period in immunocompromised individuals: results from INFORM, a retrospective health database study in England

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sabada DUBE

B / 8 / 11

Poster P0413

Abstract 2751

Tracking SARS-CoV-2 Omicron VOC and sub-variants in Odisha, India November 2021 to May 2023

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Ira PRAHARAJ

B / 8 / 12

Poster P0414

Abstract 2785

Prospects for reducing the risk of emergence of SARS-CoV-2 variants from infections in immunocompromised individuals: a modelling approach

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Lisa J WHITE

B / 8 / 13

Poster P0415

Abstract 2788

Optimising a novel treatment strategy for COVID-19-related ARDS: a randomised, placebo-controlled clinical trial on supplementary therapies

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Mehrdad MOSADEGH MARVASTI

B / 8 / 14

Poster P0416

Abstract 2805

Pooled analysis of randomised trials comparing the clinical efficacy of early treatments of COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Fulvia MAZZAFERRI

B / 8 / 15

Poster P0417

Abstract 2847

Duration of viral shedding in immunocompromised patients with SARS-CoV-2 infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Matthias VON ROTZ

B / 8 / 16

Poster P0418

Abstract 2856

Clinical characteristics and outcomes of hospitalised patients with SARS-CoV-2 infection in three different epidemic periods, Milan, Italy

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Martina ZACHEO

B / 8 / 17

Poster P0419

Abstract 2927

A Phase 1, concentration-QTc analysis shows bemnifosbuvir does not alter cardiac repolarisation

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Xiao-Jian ZHOU

B / 8 / 18

Poster P0420

Abstract 2928

Sotrovimab in severely ill COVID-19 immunocompromised patients: multicentre retrospective cohort

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Rubén LOBATO CANO

A / 9 / 1

Poster P0421

Abstract 2943

Pharmacokinetics, safety, and tolerability of ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2, in participants with hepatic impairment

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Takayuki KATSUBE

A / 9 / 2

Poster P0422

Abstract 2963

The mRNA-1273 COVID-19 vaccine induces CD4+ T cell responses among solid organ transplant recipients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Bethany GIRARD

A / 9 / 3

Poster P0423

Abstract 2980

Efficacy and safety of EDP-235 in non-hospitalised adults with mild or moderate COVID-19: results from the phase 2 SPRINT study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Scott ROTTINGHAUS

A / 9 / 4

Poster P0424

Abstract 3009

A decoy strategy of using plant-based virus-like-particles (VLPs) against SARS-CoV-2 Infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Hsin (Jady) LIANG

A / 9 / 5

Poster P0425

Abstract 3024

Bayesian analysis of a randomised trial comparing the clinical efficacy of early treatments of COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Fulvia MAZZAFERRI

A / 9 / 6

Poster P0426

Abstract 3071

Canadian healthcare and education workers' hesitance to receive original and bivalent COVID-19 vaccines

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Brenda L COLEMAN

A / 9 / 7

Poster P0427

Abstract 3075

Viral, immunologic, and laboratory evaluations in patients with and without post-acute sequelae of SARS-CoV-2 infection (PASC)

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sang Hyun RA

A / 9 / 8

Poster P0428

Abstract 3122

Fingerstick blood shows excellent correlation with plasma for SARS-CoV-2 antibody detection with a novel multiplex immunoassay

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Dylan GEORGE

A / 9 / 9

Poster P0429

Abstract 3207

Hamster model to evaluate post-COVID-19 condition treated with ensitrelvir: smell disorder

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Ryoichi TASHIMA

A / 9 / 10

Poster P0430

Abstract 3266

Bivalent COVID-19 vaccination enhances neutralising antibody responses against Omicron subvariants up to nine months, except for EG.5

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Hakjun HYUN

A / 9 / 11

Poster P0431

Abstract 3270

Detection and surveillance of SARS-CoV-2 genomic variants in Georgia

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Nino MITAISHVILI

A / 9 / 12

Poster P0432

Abstract 3295

SARS-CoV-2 vaccination is not associated with involuntary childlessness - results of a prospective multicentre cohort

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Tamara Kathrin DÖRR

A / 9 / 13

Poster P0433

Abstract 3313

Safety and immunogenicity of the investigational CV0501 mRNA COVID-19 vaccine administered to adults ≥18 years of age

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Nicolas VANHOUTTE

A / 9 / 14

Poster P0434

Abstract 3345

Post-acute symptoms of COVID-19 in healthcare workers: temporal course, impact on daily life, and therapeutic measures

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Tamara Kathrin DÖRR

A / 9 / 15

Poster P0435

Abstract 3350

Characteristics and outcomes of old and oldest-old hospitalised patients with COVID-19 during the late phase of the pandemic in central Taiwan

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Po-Ren HSUEH

A / 9 / 16

Poster P0436

Abstract 3358

Reduction of post-acute COVID-19 sequelae after SARS-CoV-2 wild-type infection in healthcare workers over a 30-month period

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Tamara Kathrin DÖRR

A / 9 / 17

Poster P0437

Abstract 3394

Long-term cardiovascular, cerebrovascular, and thrombotic complications after SARS-CoV-2 Omicron vs Delta infection: a retrospective cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Liang En Ian WEE

A / 9 / 18

Poster P0438

Abstract 3407

Wastewater monitoring as an early warning system for SARS-CoV-2 variants: a comparison of clinical and wastewater samples in Hesse, Germany, Sep 2021-Dec 2022

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Syamend SAEED

A / 9 / 19

Poster P0439

Abstract 3468

Rapid recovery from SARS-CoV-2 infection among immunocompromised children despite limited neutralising antibody response: a virologic and sero-immunologic analysis of a single-centre cohort

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Jin Yang BAEK

A / 9 / 20

Poster P0440

Abstract 3533

Long-term risk of death and cardiovascular events following COVID-19 vaccination or positive SARS-CoV-2 test amongst adult Singaporeans during Omicron

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

David Chien LYE

B / 9 / 1

Poster P0441

Abstract 3564

Development of a high-sensitivity fluorescence in situ hybridisation method for detecting SARS-CoV-2

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Agnieszka KRAWCZYK

B / 9 / 2

Poster P0442

Abstract 3625

Recent COVID-19 is associated with reduced cytokine response to LPS ex vivo and in vivo

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Anselm JORDA

B / 9 / 3

Poster P0443

Abstract 3628

Performance of a novel dual marker RT-qPCR-based whole-blood assay for the detection of SARS-CoV-2-reactive T cells

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Franziska Maria KANIS

B / 9 / 4

Poster P0444

Abstract 3672

Seroepidemiology of SARS-CoV-2 in a cohort of pregnant women in Kampala, Uganda

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Lauren HOOKHAM

B / 9 / 5

Poster P0445

Abstract 3704

Long-term neuropsychiatric sequelae of Delta versus Omicron SARS-CoV-2 infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Calvin J CHIEW

B / 9 / 6

Poster P0446

Abstract 3707

Evidence of exposure to the SARS-CoV-2 virus in UK healthcare workers who reported no known COVID-19 infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Yanie TAYIPTO

B / 9 / 7

Poster P0447

Abstract 3715

Live single-cycle SARS-CoV-2 vaccine elicits high protection and sterilising immunity

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

David HAUSER

B / 9 / 8

Poster P0448

Abstract 3732

Real-world performance of a single-use, analyser-free, molecular point-of-care test for COVID-19 used in the emergency department: results of a prospective trial (ED-POC)

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Mary E CHAPMAN

B / 9 / 9

Poster P0449

Abstract 3734

Investigating factors associated with the economic cost of healthcare worker COVID-19-related absenteeism

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Liam TOWNSEND

B / 9 / 10

Poster P0450

Abstract 3758

Development and characterisation of a novel SARS-CoV-2 macrodomain (Mac1) targeting inhibitor

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Susanne PFEFFERLE

B / 9 / 11

Poster P0451

Abstract 3900

Long-term trajectories of COVID-19 symptoms and their associations with quality of life: results from the 2-year-follow-up of the prospective Predi-COVID study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Aurélie FISCHER

B / 9 / 12

Poster P0452

Abstract 3941

Clinical trajectory of post COVID-19 condition during different SARS-CoV-2 variant periods

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Pontus HEDBERG

B / 9 / 13

Poster P0453

Abstract 3961

Surfaces environmental monitoring of SARS-CoV-2: loop mediated isothermal AMPlification (LAMP) and droplet digital PCR (ddPCR) in comparison with standard real time PCR (RT-PCR)

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Simona SPITERI

B / 9 / 14

Poster P0454

Abstract 4004

Impact of treatment of COVID-19 with sotrovimab on post-acute COVID-19 syndrome: an analysis of national COVID cohort collaborative (N3C) data

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Jennifer HAN

B / 9 / 15

Poster P0455

Abstract 4025

Quasi-species prevalence and evolution of mutations in SARS-CoV-2 variants in European COVID-19 cohorts

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Mathias SMET

B / 9 / 16

Poster P0456

Abstract 4118

A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalised patients during the first wave of COVID-19 (PEACH study)

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Jonathan SANDOE

B / 9 / 17

Poster P0457

Abstract 4122

A longitudinal description of the health-related quality of life among high-risk individuals with COVID-19: a Dutch multicentre observational cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Magda VERGOUWE

B / 9 / 18

Poster P0458

Abstract 4135

Early initiation of combined therapy in severely immunocompromised patients with COVID-19: A retrospective cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Salvatore ROTUNDO

B / 9 / 19

Poster P0459

Abstract 4172

Extended remdesivir use in haematological patients with malignancies and prolonged COVID-19 in omicron era: tolerance and outcomes

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Emmanuelle GRAS

B / 9 / 20

Poster P0460

Abstract 4177

Dual SARS-CoV-2 infections: genomics-based approach for detection of SARS-CoV-2 co-infections and diverse viral populations

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Bryan Stiven JIMÉNEZ ARAYA

A / 10 / 1

Poster P0461

Abstract 4285

Ultrasonological predictors of severity of dengue in a teaching hospital in South India

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Vishnu . V NAIR

A / 10 / 2

Poster P0462

Abstract 4335

COVID-19 and network medicine: utilising multi-omic approaches in response to future pandemics

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Bradley WARD

A / 10 / 3

Poster P0463

Abstract 4352

Persistent DNA methylation changes up to 7 months after SARS-CoV-2 infection: initial findings from population-based studies

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Pamela MATIAS GARCIA

A / 10 / 4

Poster P0464

Abstract 4384

Anti-RBD IgG titres after a primary vaccination course with BNT162b2 and after a third booster dose with a first-generation m-RNA vaccine in a cohort of people living with HIV

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Anna Maria AZZINI

A / 10 / 5

Poster P0465

Abstract 4475

Dynamics of Streptococcus pneumoniae non-PCV13 lineages in Spain during SARS-CoV-2 pandemic

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sara CALVO SILVERIA

A / 10 / 6

Poster P0466

Abstract 4493

Unraveling the role of casein kinase II in the SARS-CoV-2 lifecycle: implications for host-targeted antiviral development

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Dennis Salomon LOPEZ MOLINA

A / 10 / 7

Poster P0467

Abstract 4510

Clinical manifestations of SARS-CoV-2 infection in Omicron subvariants

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Jayanthi SHASTRI

A / 10 / 8

Poster P0468

Abstract 4511

Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Javier Tomás SOLERA RALLO

A / 10 / 9

Poster P0469

Abstract 4541

Surveillance of invasive pulmonary aspergillosis in COVID and non-COVID patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Simona KARABELA

A / 10 / 10

Poster P0470

Abstract 4557

SARS-CoV-2 infection and re-infection by Delta and Omicron variants in a population with low vaccine coverage

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Rhys WENLOCK

A / 10 / 11

Poster P0471

Abstract 4562

Pre-exposure prophylaxis for COVID-19 with tixagevimab/cilgavimab in kidney transplant recipients in the Kraken variant (XBB.1.5) era: a single-centre experience

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Biagio PINCHERA

A / 10 / 12

Poster P0472

Abstract 4573

Molecular epidemiology of Pneumocystis jirovecii in patients with and without COVID-19, based on real time PCR assay

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Faezeh ROUHI

A / 10 / 13

Poster P0473

Abstract 4599

Effect of tixagevimab-cilgavimab on viral shedding kinetics in immunocompromised patients with breakthrough COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Jaijun HAN

A / 10 / 14

Poster P0474

Abstract 4632

Impact of multiple-dose remdesivir, a COVID-19 antiviral, on CYP3A4 activity: a clinical drug-drug interaction (DDI) study with midazolam

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Abdul Naveed SHAIK

A / 10 / 15

Poster P0475

Abstract 4703

A cost and resource utilisation study of COVID-19 patients treated in German tertiary care hospitals

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Shimita SIKDAR

A / 10 / 16

Poster P0476

Abstract 4727

Divergent SARS-CoV-2-induced immunity signals in the upper and lower respiratory tract in severe COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Bryan Stiven JIMÉNEZ ARAYA

A / 10 / 17

Poster P0477

Abstract 4831

Pharmacokinetics, safety, and tolerability of single-dose obeldesivir in healthy Japanese and Caucasian participants

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Chi-Chi PENG

A / 10 / 18

Poster P0478

Abstract 4860

Prevalence of and factors associated with long COVID among diverse healthcare workers in the United Kingdom: a cross-sectional analysis of a nationwide study (UK-REACH)

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Amani AL-ORAIBI

A / 10 / 19

Poster P0479

Abstract 4861

Characteristics and outcomes of hospitalised patients across five waves of the COVID-19 pandemic

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Khetam HUSSEIN

A / 10 / 20

Poster P0480

Abstract 4880

SARS-CoV-2 point-of-care antibody testing: a cross sectional study in healthy people and individuals at high-risk for severe COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Ioannis GRIGOROPOULOS

B / 10 / 1

Poster P0481

Abstract 4882

Use of antibiotics in patients hospitalised for COVID-19: no beneficial effect on clinical outcome or course of disease

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Anette FRIEDRICHS

B / 10 / 2

Poster P0482

Abstract 4897

Increasing antimicrobial resistance rates in relation to antibiotic misuse and overuse during COVID-19 pandemic

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Omar LOAY

B / 10 / 3

Poster P0483

Abstract 4925

Long-term impairment of working ability in subjects under 60 years of age hospitalised for COVID-19 at 2 years of follow-up: a cross-sectional study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Luisa FRALLONARDO

B / 10 / 4

Poster P0484

Abstract 4929

Comparison of a novel concentration method for SARS-CoV-2 wastewater monitoring

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Tom KORITNIK

B / 10 / 6

Poster P0486

Abstract 5015

Bacterial co-infection and secondary infection in SARS-CoV-2 (COVID-19) adult patients in a national tertiary infectious disease hospital

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Maria Yvez Erika UGALE

B / 10 / 7

Poster P0487

Abstract 5058

Surveillance and detection of SARS-CoV-2 in four national university campuses, the UniCoV Project: apps, antigens, saliva, wastewater, and participation

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

John MAC SHARRY

B / 10 / 8

Poster P0488

Abstract 5082

Brief cognitive assessment for long COVID-19 sequelae and its significance

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Seo DA-YOUNG

B / 10 / 9

Poster P0489

Abstract 5088

Dual antiviral therapy can be effective for treatment of protracted SARS-CoV-2 infection in immunocompromised hosts

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Jessica LITTLE

B / 10 / 10

Poster P0490

Abstract 5107

Sub-populations of critically ill COVID-19 patients exist with distinct antibody responses to SARS-CoV-2

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

David BRETT-MAJOR

B / 10 / 11

Poster P0491

Abstract 5113

Missed opportunities of early SARS-CoV-2 therapy among hospitalized patients: a retrospective observational cohort study, Milan, Italy

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Andrea RABBIONE

B / 10 / 13

Poster P0493

Abstract 5135

Safety and tolerability of tocilizumab for COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Meriam DEEB

B / 10 / 14

Poster P0494

Abstract 5159

Safety and tolerability of baricitinib for COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Meriam DEEB

B / 10 / 15

Poster P0495

Abstract 5179

Epidemiology of bacterial co-infections in COVID-19 associated pulmonary aspergillosis patients in a tertiary-care teaching hospital in Mexico City.

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Benjamin VALENTE ACOSTA

B / 10 / 16

Poster P0496

Abstract 5194

Evaluation of the digital lightcycler in monitoring SARS-CoV-2 RNA in sewage

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Tung-Yuan LEE

B / 10 / 17

Poster P0497

Abstract 5259

Impact of COVID-19 infection in quality of life of hospitalised patients with autoimmune conditions: experience from a single-center in Greece

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Amalia PAPANIKOLOPOULOU

B / 10 / 18

Poster P0498

Abstract 5274

Safety of tocilizumab and baricitinib for treatment of COVID-19 in hospitalised patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Meriam DEEB

B / 10 / 19

Poster P0499

Abstract 5319

Reinfection of SARS-CoV-2 variants in immunocompromised patients with prolonged or relapsed viral shedding

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Ji Yeun KIM

B / 10 / 20

Poster P0500

Abstract 5324

Associations of COVID-19 control measures, the incidence of pneumonia and various respiratory pathogens in Finland, 2020-2023

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Hanna M. NOHYNEK

A / 11 / 1

Poster P0501

Abstract 5388

Clinical characteristics and factors associated with in-hospital post-surgical mortality in COVID-19 patients at a tertiary care center in Karachi, Pakistan

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Nosheen NASIR

A / 11 / 2

Poster P0502

Abstract 5389

Changes in antibiotic consumption due to COVID-19 pandemic in tertiary-care hospitals in Costa Rica: a five year interrupted time series study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Cristina FERNANDEZ-BARRANTES

A / 11 / 3

Poster P0503

Abstract 5409

T-cell mediated response and post-COVID-19 syndrome

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Elda RIGHI

A / 11 / 4

Poster P0504

Abstract 5412

Antibiotic use in outpatients with COVID-19 diagnosed with point of care tests in an integrated healthcare network in Utah, USA

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Rj WILLIAMS

A / 11 / 5

Poster P0505

Abstract 5420

Evaluation of humoral immune responses against SARS-CoV-2 variants after receiving booster doses

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Yu-Cheng CHENG

A / 11 / 6

Poster P0506

Abstract 5474

Adding a SARS-CoV-2 RT-PCR on a faecal sample to a RT-PCR on a nasopharyngeal sample augments diagnostic sensitivity

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Nathalie VAN DER MOEREN

A / 11 / 7

Poster P0507

Abstract 5531

COVID-19 and influenza- role of haematological parameters in assesing the disease severity

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Aida-Isabela ADAMESCU

A / 11 / 8

Poster P0508

Abstract 5590

Is early empiric antibiotherapy in patients hospitalised in ward settings with COVID-19 pneumonia beneficial?

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Aude KOPP-DEROUET

A / 11 / 9

Poster P0509

Abstract 5691

Proteomic insights into the impact of COVID-19 on peripheral blood mononuclear cells in kidney transplant recipients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Giuseppe G. F. LEITE

A / 11 / 10

Poster P0510

Abstract 5757

Increased risk of invasive aspergillosis in immunocompromised patients with persistent SARS-CoV-2 viral shedding > eight weeks, a retrospective case-control study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Cléa MELENOTTE

A / 11 / 11

Poster P0511

Abstract 5803

The association of platelet-to-lymphocyte ratio with COVID-19 and acute ischemic stroke in admitted adult patients in Zamboanga City Medical Center

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Abdusattar ABDURAUP

A / 11 / 12

Poster P0512

Abstract 5826

Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in patients with multiple sclerosis on disease modifying therapies

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Alessandra AIELLO

A / 11 / 13

Poster P0513

Abstract 5953

Increased risk of SARS-CoV-2 infection in professional settings, shops, shared transport, and leisure activities in a case-control study in France, 2020-2022

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Simon GALMICHE

A / 11 / 14

Poster P0514

Abstract 5959

Comparing the disease burden of COVID-19 in-patients with and without high risk factors for severe outcomes: a retrospective study using routine hospital data

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Nicole BIHRER

A / 11 / 15

Poster P0515

Abstract 5961

Genomic detection of SARS-CoV-2 reinfections in the SIREN cohort study: has the 90-day interval endured?

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Dominic SPARKES

A / 11 / 16

Poster P0516

Abstract 5995

Longitudinal anti-SARS-CoV-2 antibody responses reveal cross-reactive boosting following vaccination

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Dylan GEORGE

A / 11 / 17

Poster P0517

Abstract 5997

Prevalence and impact of persistent symptoms following SARS-CoV-2 infections in UK healthcare workers in the SIREN cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sarah FOULKES

A / 11 / 18

Poster P0518

Abstract 6020

Concomitant vaccination uptake of the COVID-19 booster and influenza vaccine in the United States during the 2021/22 and 2022/23 seasons

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Aung Pone MYINT

B / 11 / 1

Poster P0519

Abstract 6046

Impact of age on SARS-CoV-2 transmission in French households: comparison of Alpha and Omicron variants

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sophie CHERVET

B / 11 / 2

Poster P0520

Abstract 6128

Tracking SARS-CoV-2 RNA in urban wastewater through diverse biomarkers

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Rosario MUSUMECI

B / 11 / 3

Poster P0521

Abstract 6168

Immunosupressive treatment and CD4/CD8 T-cell exhaustion impact SARS-CoV-2-specific adaptive responses after vaccination in solid organ transplant

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Laura DONADEU

B / 11 / 4

Poster P0522

Abstract 6212

Genomic characterization of SARS-CoV-2 outbreak during international scientific workshop: evidence of cross-border transmission

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

María Paula VARGAS DURÁN

B / 11 / 5

Poster P0523

Abstract 6216

Different effect of anti-s monoclonal antibodies on immunity depending on SARS-CoV-2 vaccination status

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Luca MADDALONI

B / 11 / 6

Poster P0524

Abstract 6224

Enhanced SARS-CoV-2 surveillance in Slovenia through wastewater analysis: a comprehensive community-level approach

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Tea JANKO

B / 11 / 7

Poster P0525

Abstract 6245

Safety of a self-amplifying mRNA COVID-19 vaccine, ARCT-154

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Igor SMOLENOV

B / 11 / 8

Poster P0526

Abstract 6295

Treatment strategies to avoid residents' isolation in nursing home: modelling analysis

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Hind ZAARAOUI

B / 11 / 9

Poster P0527

Abstract 6303

The impact Of COVID-19 on healthcare utilization associated with antibiotic resistance among inpatients at a tertiary hospital in Vietnam

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Nga NGUYEN TQ.

B / 11 / 10

Poster P0528

Abstract 6348

Nasopharyngeal microbial dysbiosis in COVID-19 patients revealed by 16S metagenomics

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Filippos KARDARAS

B / 11 / 11

Poster P0529

Abstract 6352

IgG anti SARS-CoV-2 spike levels and vaccination on a cohort of hospital healthcare workers

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Miriam LATORRE-MILLÁN

B / 11 / 12

Poster P0530

Abstract 6370

Multi-tissue immune analysis of severe COVID-19 patients indicates differential adaptive immune response enrichment in secondarylymphoid tissues

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Eduardo SOARES

B / 11 / 13

Poster P0531

Abstract 6374

SARS-CoV-2 infection accompanied by gastrointestinal symptoms elicits antibodies with significantly higher avidity as compared to infections without gastrointestinal symptoms

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Wegene BORENA

B / 11 / 14

Poster P0532

Abstract 6408

A polymersome COVID-19 booster is safe and immunogenic in pre-vaccinated healthy volunteers and confers exceptional thermostability

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Katherine SCHULTHEIS

B / 11 / 15

Poster P0533

Abstract 6443

Ceftazidime-avibactam in the treatment of bacterial superinfection in COVID-19 patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Tu HA THI CAM

B / 11 / 16

Poster P0534

Abstract 6508

Infection of macrophages by SARS-CoV-2: implications for viral spreading and immune response

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Lucia SIGNORINI

B / 11 / 17

Poster P0535

Abstract 6520

Machine learning models based on exhaled volatile organic compounds combined with serum cytokine profile for severity prediction in COVID-19 and other respiratory infections

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Patricia ESTEBAN SÁNCHEZ

B / 11 / 18

Poster P0536

Abstract 6581

COVID-19 mRNA vaccines may also boost immunity to seasonal coronaviruses and influenza

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Vennila GOPAL

A / 12 / 1

Poster P0537

Abstract 6584

Is there still room for COVID-19 pre-exposure prophylaxis? A real-world case-control effectiveness study in high-risk patients with hematologic malignancies during the emerging Omicron surge

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Emilia TRUCILLO

A / 12 / 2

Poster P0538

Abstract 6604

Safety and immunogenicity of SARS-CoV-2 mRNA-based vaccines in a cohort of lung transplant recipients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sara Colonia UCEDA RENTERIA

A / 12 / 3

Poster P0539

Abstract 6647

Long COVID among people living with HIV (PLWH): a real-life study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Melania DEGLI ANTONI

A / 12 / 4

Poster P0540

Abstract 6654

Diffuse transcriptional upregulation of human endogenous retroviruses in the bronchoalveolar lavage fluid of patients with severe COVID-19 pneumonia

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Konstantina KITSOU

A / 12 / 5

Poster P0541

Abstract 6657

Impact of COVID-19 on the incidence of nosocomial pneumonia in two intensive care units

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Nagham Léa KHANAFER

A / 12 / 6

Poster P0542

Abstract 6671

Complicating bacterial pulmonary infections in critical COVID-19 pneumonia

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Miroslava HTOUTOU SEDLAKOVA

A / 12 / 7

Poster P0543

Abstract 6688

Prediction of transmission inhibition based on the antiviral effect of ensitrelvir and simulation of its impact on epidemics

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Shogo MIYAZAWA

A / 12 / 8

Poster P0544

Abstract 6699

Evolutionary timeline of SARS-CoV-2

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Rishika KAUSHAL

A / 12 / 9

Poster P0545

Abstract 6739

Cross-neutralising activity and durability of antibody responses against BA.4/5 and XBB 1.5 variant after BA.4/5 bivalent vaccination according to the previous SARS-CoV-2 infection: a three-month prospective cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Hye Hee CHA

A / 12 / 10

Poster P0546

Abstract 6801

Adaptive immunity-derived epitope profiles as indicators of COVID-19 severity

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

A / 12 / 11

Poster P0547

Abstract 6805

Impact of the COVID-19 pandemic on the resistance of bacterial agents isolated from the lower respiratory tract in ICU patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Miroslava HTOUTOU SEDLAKOVA

A / 12 / 12

Poster P0548

Abstract 6819

Comparative analysis of symptom profile and risk of death associated with infection by SARS-CoV-2 and its variants in Hong Kong

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Wan In WEI

A / 12 / 13

Poster P0549

Abstract 6846

Immunogenicity of SARS-CoV-2 mRNA-based vaccines in a cohort of lung and liver transplant recipients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sara Colonia UCEDA RENTERIA

A / 12 / 14

Poster P0550

Abstract 6851

Driving selection of target populations to design RCT assessing therapies for the prevention and treatment of the post-COVID-19 syndrome

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Evelina TACCONELLI

A / 12 / 15

Poster P0551

Abstract 6859

Estimating the effect of vaccination and previous infection on Ct values as a proxy of viral load

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Stijn ANDEWEG

A / 12 / 16

Poster P0552

Abstract 6911

Neurosensorial cluster of the post-COVID 19 syndrome: prospective psychophysical assessment of smell and taste impairment and impact on quality of life

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Elisa GENTILOTTI

A / 12 / 17

Poster P0553

Abstract 6913

Comparative effectiveness of the mRNA-1273 and BNT162b2 COVID-19 vaccines among older adults: a systematic literature review and meta-analysis using the GRADE framework

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Ekkehard BECK

A / 12 / 18

Poster P0554

Abstract 6916

Safety and immunogenicity of SARS-CoV-2 mRNA-based vaccines in a cohort of liver transplant recipients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Giovanni GIACOMEL

A / 12 / 19

Poster P0555

Abstract 6933

Monitoring protection from SARS-CoV-2 infection and COVID-19 vaccination in the UK SIREN healthcare worker cohort 2020-2024: assessing the impact of vaccine boosters

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Peter Douglas KIRWAN

A / 12 / 20

Poster P0556

Abstract 6986

In-house software development reveals insights into 'closed system' diagnostics - a lesson from rapid development of high-throughput SARS-CoV-2 screening

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Michael KIDD

A / 12 / 21

Poster P0557

Abstract 7088

Bio-humoral characterisation of patients by clusters of post-COVID-19 syndrome at 18-month follow-up: the multicentre, prospective ORCHESTRA study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Elisa GENTILOTTI

A / 12 / 22

Poster P0558

Abstract 7202

Seroprevalence of Omicron BA.2 neutralising antibodies among residents in residential care homes for the elderly in Hong Kong, February – November 2022

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Wan In WEI

A / 12 / 23

Poster P0559

Abstract 7210

Effectiveness and safety of favipiravir versus standard of care in adult COVID-19 patients in a tertiary hospital setting: a retrospective cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Carla Nicole DAYAO

A / 12 / 24

Poster P0560

Abstract 7223

Impact of COVID-19 on home healthcare agencies and nursing homes in the United States

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Monika POGORZELSKA-MAZIARZ

A / 12 / 25

Poster P0561

Abstract 7313

Reduction of post COVID-19 condition during the Omicron wave: results from the EuCARE POSTCOVID Study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Andrea SANTORO

A / 12 / 26

Poster P0562

Abstract 7331

Increasing prevalence of comorbidities in patients hospitalised with COVID-19 across variant eras

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Mark BERRY

A / 12 / 27

Poster P0563

Abstract 7351

Rates of long COVID-related symptoms and diagnoses in patients hospitalised with COVID-19 increased across variant eras

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Mark BERRY

A / 12 / 28

Poster P0564

Abstract 7424

Risk factors for morbidity and mortality among adult patients with COVID-19 and pulmonary tuberculosis co-infection admitted at a national infectious disease referral hospital in Manila, Philippines

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Catherine Denise MENDOZA

B / 12 / 1

Poster P0565

Abstract 7480

Gut microbiota composition in COVID-19 patients during the Delta and Omicron variant predominance in Uzhhorod, Ukraine

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Pavlo PETAKH

B / 12 / 2

Poster P0566

Abstract 7482

Varicella zoster virus-induced neurological disease after COVID-19 vaccination: a multicentre observational cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Meital ELBAZ

B / 12 / 3

Poster P0567

Abstract 7528

Clinical prediction model for bacterial coinfection in hospitalised COVID-19 patients during four waves of the pandemic

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Meital ELBAZ

B / 12 / 4

Poster P0568

Abstract 7541

Expansion of the laboratory surveillance of respiratory viruses in the Philippines: a response to the COVID-19 pandemic

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Catherine DACASIN

B / 12 / 5

Poster P0569

Abstract 7566

Identification of new host-directed antiviral targets by proteome analysis of cysteamine anti-SARS-CoV-2 activity

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Tonino ALONZI

B / 12 / 6

Poster P0570

Abstract 7598

Evaluation of SARS-CoV-2 spike mutations in immunocompromised and immunocompetent patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Alessandra D'ABRAMO

B / 12 / 7

Poster P0571

Abstract 7599

Remdesivir 30-days-COVID-19-related mortality, length of hospitalization and time until negative swab test in severely immunocompromised patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Riccardo POL

B / 12 / 8

Poster P0572

Abstract 7606

Nirmatrelvir/ritonavir in the management of COVID-19: a retrospective study in a highly vaccinated population

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sofia JORDAO

B / 12 / 9

Poster P0573

Abstract 7633

Distinct variation pattern between consensus sequences and mutant spectra during the COVID-19 pandemic

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Brenda MARTÍNEZ GONZÁLEZ

B / 12 / 10

Poster P0574

Abstract 7640

Extinction of SARS-CoV-2 by synergistic lethal mutagenesis exerted by remdesivir and ribavirin

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Carlos GARCÍA-CRESPO

B / 12 / 11

Poster P0575

Abstract 7708

Independent online medical education significantly increases physician knowledge and confidence regarding real-world data for COVID-19 antiviral therapy in high-risk patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Julia DUFFEY

B / 12 / 12

Poster P0576

Abstract 7720

Antiviral use in mild to moderate SARS-CoV-2 infections during the Omicron wave in geriatric patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Virginie PRENDKI

B / 12 / 13

Poster P0577

Abstract 7753

Resurgence of SARS-CoV-2 viral load following antiviral therapy cessation in haematologic patients with COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Mariana CHUMBITA

B / 12 / 14

Poster P0578

Abstract 7815

Nasopharyngeal microbiome in COVID-19 infection.

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Jorge RODRÍGUEZ-GRANDE

B / 12 / 15

Poster P0579

Abstract 7833

Investigating the impact of vaccination and reinfection dynamics on the XBB variant of SARS-CoV-2 ???

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Priscila TRINDADE

B / 12 / 16

Poster P0580

Abstract 7838

Nirmatrelvir/ritonavir or remdesivir for COVID-19 in patients with B-cell malignancies and plasma cell dyscrasias

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Pantazis-Michael VOUTSINAS

B / 12 / 17

Poster P0581

Abstract 7870

Determinants of recorded SARS-CoV-2 vaccine uptake among ART-compliant people living with HIV

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Grazia ALESSIO

B / 12 / 18

Poster P0582

Abstract 7903

Discordant results in the Xpert® Xpress SARS-CoV-2/ Flu/RSV assay: The importance of an accurate assessment at curve analysis in PCR testing

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Cristina VEINTIMILLA

B / 12 / 19

Poster P0583

Abstract 7992

Type I interferon pathway-related hub genes as a potential therapeutic target for SARS-CoV-2 omicron variant-induced symptoms

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sun BAOQING

B / 12 / 20

Poster P0584

Abstract 8028

Multicomplex pharmacophore based virtual screening, docking, and molecular dynamics to discover novel inhibitors against main protease (Mpro) of coronaviruses

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Prerna RAJORIA

B / 12 / 21

Poster P0585

Abstract 8123

Monitoring anti-SARS-CoV-2 antibodies and variant-specific neutralization in healthy children by dried blood spots

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Matteo Domenico MARSIGLIA

B / 12 / 22

Poster P0586

Abstract 8140

Clinical epidemiology and biomarker identification in patients with novel coronavirus infection (severe/critical) secondary to bacterial infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Zhongyu HAN

B / 12 / 23

Poster P0587

Abstract 8161

Risk of SARS-CoV-2 infection and severe COVID-19 in haematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation during Omicron BA.5 dominated wave

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Giusy TISEO

B / 12 / 24

Poster P0588

Abstract 8174

Global rate of antibiotic use, co-infections, resistance and clinical outcomes in COVID-19 patients receiving antibiotics in 65 countries worldwide

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Daniele DONA'

B / 12 / 25

Poster P0589

Abstract 8185

Anion exchange woven fabric ensures a most efficient concentration of SARS-CoV-2 from wastewater

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Yuliya KALTUNOVA

B / 12 / 26

Poster P0590

Abstract 8246

Increased viral loads of Omicron EG.5.1 compared to co-circulating SARS-CoV-2 lineages

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Timo FROYEN

B / 12 / 27

Poster P0591

Abstract 8284

Broad immunity to SARS-CoV-2 mediated by a Vaccine Formulation Based on the receptor binding domain (RBD)-Nucleoprotein cocktail Co-Administered with an AddaVax adjuvant

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Amir GHAEMI

B / 12 / 28

Poster P0592

Abstract 8291

Surveillance of SARS-COV2 variants in wastewater of aircraft

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Elke WOLLANTS

A / 13 / 1

Poster P0593

Abstract 8432

Household transmission dynamics of SARS-CoV-2 in the north of the Netherlands: the COVID-HOME study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Maria Fernanda VINCENTI GONZALEZ

A / 13 / 2

Poster P0594

Abstract 8548

Evaluation of immune response to anti-SARS-CoV-2 vaccination in cancer patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Ombretta TURRIZIANI

A / 13 / 3

Poster P0595

Abstract 8619

COVID-19 does not increase the risk of invasive fungal infection in hematopoietic stem-cell transplanted patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Bruno RANDI

A / 13 / 4

Poster P0596

Abstract 8675

Coinfection of SARS-Cov-2 with other respiratory viruses in a large cohort study: the UnCoVER-Brazil project

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Felipe Santos De CARVALHO

A / 13 / 5

Poster P0597

Abstract 8696

Lessons for future pandemic preparedness: The SIREN experience

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Jasmin ISLAM

A / 13 / 6

Poster P0598

Abstract 8697

Promotion of SARS-CoV-2 vaccination in at-risk sectors: methods and impact of an intervention in jail health care

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Maxence ROUYER

A / 13 / 7

Poster P0599

Abstract 8807

Concomitant administration of seasonal influenza and COVID-19 mRNA

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Teresa AYDILLO

A / 13 / 8

Poster P0600

Abstract 8829

T cell receptor sequencing allows monitoring longitudinal T cell clonal responses and antigen-specificity to COVID-19 vaccination

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Isabel FERREIROS-VIDAL

A / 13 / 10

Poster P0602

Abstract 8913

The acquisition of SARS-CoV-2 immunity from sequential Spike exposures via infection or vaccination

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Marianne SHAWE-TAYLOR

A / 13 / 11

Poster P0603

Abstract 8916

Post-acute sequalae of COVID-19 three to twelve months after infection: Delta versus Omicron

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Siméon DE BRUIJN

A / 14 / 1

Poster P1924

Abstract 165

Urine collection practices analysis and the impact of boric acid tubes on quantitative urinary bacterial cultures in hospitalised patients

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Debby BEN-DAVID

A / 14 / 2

Poster P1925

Abstract 461

Pre-analytical delays in blood culture pathway do not always postpone actionable results

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Tim INGLIS

A / 14 / 3

Poster P1926

Abstract 610

GDH/toxin assay plus PCR vs PCR for the diagnosis and treatment of Clostridioides difficile infection

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Hossein SALIMNIA

A / 14 / 4

Poster P1927

Abstract 874

Urine culture reflex implemented to reduce inappropriate testing and treatment of UTIs

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Erika ORNER

A / 14 / 5

Poster P1928

Abstract 1107

Can IgM predict IgG avidity values for Toxoplasma and CMV?

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Laura VERDURME

A / 14 / 6

Poster P1929

Abstract 1304

Same-day reporting of blood cultures in gram-negative sepsis: achieving holy grail of microbiology sans MALDI-TOF

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Ayush GUPTA

A / 14 / 7

Poster P1930

Abstract 1359

Development of a cost-effective rapid detection of carbapenem-resistance Gram-negative bacteria laboratory workflow

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Kangjun SUN

A / 14 / 8

Poster P1931

Abstract 1408

Preliminary evaluation of a rapid lateral flow immunoassay for the detection of Candida albicans, Trichomonas vaginalis, or Gardneralla vaginalis antigen kit using clinical vaginal swab specimens

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Kangjun SUN

A / 14 / 9

Poster P1932

Abstract 1509

Evaluation of a novel chromogenic culture medium for the detection and enumeration of Pseudomonas aeruginosa

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Jose DEGROSSI

A / 14 / 10

Poster P1933

Abstract 1665

Evaluation of the analytical and clinical performance of a new diagnostic test for the detection of Campylobacter antigens in stool specimen

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Juergen BECKER

A / 14 / 11

Poster P1934

Abstract 2059

Performance comparison of a new GDH antigen chemiluminescent immunoassay for the diagnosis of Clostridioides difficile infection

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Ana LÓPEZ GONZÁLEZ-SALIDO

A / 14 / 12

Poster P1935

Abstract 2168

Blood volume is the key determinant of paediatric blood culture performance: results from a pre- and post-intervention study

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Sean Olann WHELAN

A / 14 / 13

Poster P1936

Abstract 2260

Impact of laboratory processing delays on microbiological diagnostics

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Valentina DE SARIO

A / 14 / 14

Poster P1937

Abstract 2273

Rates of Gram-positive blood culture contamination in El Paso Texas: a comparative assessment between nuclic acid diagnostic test & conventional method

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Nouf ALMAGHLOUTH

A / 14 / 15

Poster P1938

Abstract 2454

Blood cultures in resource-limited settings: extended stability testing in simulation experiments

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Liselotte HARDY

A / 14 / 17

Poster P1940

Abstract 2990

The impact of implementing a new blood culture system for coagulase-negative staphylococci contamination

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Hiroki KITAGAWA

A / 14 / 18

Poster P1941

Abstract 3156

Enhancing microbiology laboratory organisation: first WASPLab installation in Romania

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Bota MARCELA

A / 14 / 19

Poster P1942

Abstract 3338

Efficient ELISA tests for early diagnosis of plague

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Herve BOUTAL

A / 14 / 20

Poster P1943

Abstract 3375

Direct Gram staining replaced by a flow cytometer automate to save time

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Mathilde DUBUC

A / 14 / 21

Poster P1944

Abstract 3726

Evaluation of laser light scattering method for urine culture screening in outpatients

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Amina OBRADOVIC BALIHODZIC

A / 14 / 22

Poster P1945

Abstract 3733

Comparing optical microscopy with table-top scanning electron microscopy in a clinical bacteriology laboratory: a cost-effectiveness analysis

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Omar ZMERLI

A / 14 / 23

Poster P1946

Abstract 3860

Evaluation of a 16 hour incubation for urine culture using wasp/wasplab imaging analysis

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Mark GASKIN

A / 14 / 24

Poster P1947

Abstract 3887

Understanding routine laboratory practices for C. ulcerans and C. diphtheriae culture in primary clinical testing providers in the United Kingdom: a mixed-methods evaluation

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Charlotte ROBIN

A / 14 / 25

Poster P1948

Abstract 4260

Fast-track algorithm for the early detection of microorganisms in urine in patients with suspected sepsis

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Belén RODRÍGUEZ MÁRQUEZ

A / 14 / 26

Poster P1949

Abstract 4283

Changing the culture around blood cultures

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Amy READ

A / 14 / 27

Poster P1950

Abstract 4373

Evaluation of a new diagnostic system that identifies microorganisms from clinical samples

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Lisa SCHECHTER

A / 14 / 28

Poster P1951

Abstract 4643

Comparison of two culture strategies for the diagnostic of vulvovaginal candidiasis leading to reduction of the turnaround time and consumption of media

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Annette SKOVBY

B / 14 / 1

Poster P1952

Abstract 4729

Comparing enrichment broths and plates for detection of MRSA in screening samples

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Annette SKOVBY

B / 14 / 3

Poster P1954

Abstract 4933

Contribution of anaerobic culture in semen samples in medically assisted reproduction

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Joséphine VASSE

B / 14 / 4

Poster P1955

Abstract 5098

Performance of a novel chromogenic agar for primary isolation of pathogenic beta-hemolytic streptococci from throat swabs

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Abdulrahman ALMODAHKA

B / 14 / 5

Poster P1956

Abstract 5211

Retrospective analysis post-implementation of a novel lab-developed multiplex RT-PCR/MALDI-TOF MS syndromic test for infectious diarrhea

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Robert LIAO

B / 14 / 6

Poster P1957

Abstract 5753

The optimal storage conditions of faeces for detection of bacterial pathogens

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Vishal HIRA

B / 14 / 7

Poster P1958

Abstract 5828

Significance of Bristol value in the finding of gastrointestinal pathogens

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Marina VICENTE CIURANS

B / 14 / 8

Poster P1959

Abstract 6130

Legionella diagnosis: comparison between two urinary antigen commercial tests

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Valentina LEPERA

B / 14 / 9

Poster P1960

Abstract 6839

European evaluation of 16 assays for the detection of Legionella pneumophila antigen in urine samples from patients with pneumonia

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Sophie JARRAUD

B / 14 / 10

Poster P1961

Abstract 7192

Evaluation of an immunochromatographic test for the detection of Streptococcus pneumoniae in pleural fluids

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Souha MOKNI

B / 14 / 11

Poster P1962

Abstract 7483

Correlation between manual and automated treponemal assays in serum and spinal fluid samples

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Veselka Petrova DIMOVA-SVETOSLAVOVA

B / 14 / 12

Poster P1963

Abstract 7707

Are you choosing the right colony? Exploring phenotypic and genomic variability between colonies from clinical Enterococcus faecium and Enterococcus faecalis pure cultures

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Ana Raquel FREITAS

B / 14 / 13

Poster P1964

Abstract 7725

Detection of diphtheria toxin production by Elek test: interlaboratory proficiency testing among three laboratories in three different countries

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Anja BERGER

B / 14 / 14

Poster P1965

Abstract 7775

Improved performance in diagnosis of Lyme disease utilising a novel multiplexed modified two-tier test when compared with the standard two-tier test

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Thomas R. FRITSCHE

B / 14 / 15

Poster P1966

Abstract 7845

Evaluation of the influence of different blood volumes and inoculum size on the time to positivity detection in a system for continuous monitoring of blood cultures

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Maja BOGDAN

B / 14 / 16

Poster P1967

Abstract 8082

Production of monoclonal antibodies against quorum sensing molecule HQNO to diagnose P. aeruginosa infections

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Irene ROVIRA

B / 14 / 17

Poster P1968

Abstract 8341

Performance of a new lipid enriched blood agar to detect catheter colonization by Malassezia spp. and by other commonly associated microorganisms

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Pablo MARTÍN-RABADÁN

B / 14 / 18

Poster P1969

Abstract 8416

Infection-related stillbirths: a detailed examination of a nine-year multidisciplinary study

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Matteo PAVONI

B / 14 / 19

Poster P1970

Abstract 8689

Improving yield of peritoneal dialysis effluent cultures: an LMIC experience

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Anusha ROHIT

B / 14 / 20

Poster P1971

Abstract 8918

The first IVDR-certified Treponema pallidum haemagglutination assay was accurate and reliable to confirm and quantify T. pallidum antibodies in sexual health attendees and pregnant women

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Hafsa DUALE

B / 14 / 21

Poster P1972

Abstract 39

Evaluation of performance of early identification of urinary pathogens using combination of an automated picker and chromogenic medium at 12h incubation

27/04 12:00

4b. Laboratory management (incl automation, data management, QC/QA, regulatory aspects)

Corine FULCHIRON

B / 14 / 22

Poster P1973

Abstract 1079

External quality assurance (EQA) network in south and southeast Asia: experience and results from an international EQA program in One Health sector reference laboratories

27/04 12:00

4b. Laboratory management (incl automation, data management, QC/QA, regulatory aspects)

Tomislav KOSTYANEV

B / 14 / 23

Poster P1974

Abstract 1192

Inter and intra-lot variance precludes use of manufacturer's kit controls for quality monitoring

27/04 12:00

4b. Laboratory management (incl automation, data management, QC/QA, regulatory aspects)

Yuan Yi Constance CHEN

B / 14 / 24

Poster P1975

Abstract 2330

Impact and benefits of implementing the Nagoya protocol regulation in microbiological collection for research & development activities

27/04 12:00

4b. Laboratory management (incl automation, data management, QC/QA, regulatory aspects)

Caroline MIRANDE-MEUNIER

B / 14 / 25

Poster P1976

Abstract 2571

Preliminary performance assessment of automated individual blood volume measurement system for blood culture instrument

27/04 12:00

4b. Laboratory management (incl automation, data management, QC/QA, regulatory aspects)

Joshua HERR

B / 14 / 26

Poster P1977

Abstract 3930

Comparison of AI-assisted and manual interpretation of dics diffusion test from 12 antibiotics of Pseudomonas aeruginosa

27/04 12:00

4b. Laboratory management (incl automation, data management, QC/QA, regulatory aspects)

Hilmar WISPLINGHOFF

B / 14 / 27

Poster P1978

Abstract 4394

Use of a data analytic platform for the determination and tracking of blood culture contamination at an academic health care system.

27/04 12:00

4b. Laboratory management (incl automation, data management, QC/QA, regulatory aspects)

Heinz SALAZAR

B / 14 / 28

Poster P1979

Abstract 4904

Validation of an automated instrument for handling specimen preparation

27/04 12:00

4b. Laboratory management (incl automation, data management, QC/QA, regulatory aspects)

Michael CHAN

A / 15 / 1

Poster P1980

Abstract 4968

Environmental impact of urine analyses: comparison of manual, semi and fully automatised analytical workflow

27/04 12:00

4b. Laboratory management (incl automation, data management, QC/QA, regulatory aspects)

Olivier DAUWALDER

A / 15 / 2

Poster P1981

Abstract 5583

LEAN optimisation with two track integrated InoqulAs

27/04 12:00

4b. Laboratory management (incl automation, data management, QC/QA, regulatory aspects)

Mariska OKKEMA-VAN DER LEI

A / 15 / 3

Poster P1982

Abstract 5618

Human papillomavirus: external quality assessment, 2009-2023 a review

27/04 12:00

4b. Laboratory management (incl automation, data management, QC/QA, regulatory aspects)

Deane BYERS

A / 15 / 4

Poster P1983

Abstract 5711

Educational preanalytical cases support end-to-end EQA in bacteriology laboratories

27/04 12:00

4b. Laboratory management (incl automation, data management, QC/QA, regulatory aspects)

Kristel VIRTANEN

A / 15 / 5

Poster P1984

Abstract 5850

Can a fast call to the microbiology laboratory improve the diagnosis and management of patients with sepsis alert?

27/04 12:00

4b. Laboratory management (incl automation, data management, QC/QA, regulatory aspects)

Ana ÁLVAREZ-URÍA

A / 15 / 6

Poster P1985

Abstract 7476

Assessing E.coli antimicrobial resistance detection proficiency: insights from EQASIA matrix external quality assessment (EQA) in south and southeast Asia

27/04 12:00

4b. Laboratory management (incl automation, data management, QC/QA, regulatory aspects)

Hiba ALMIR

A / 15 / 7

Poster P1986

Abstract 774

Experimental study on factors associated with low identification rates of Streptococcus pneumoniae using commercial enrichment kit for direct MALDI-TOF MS identification

27/04 12:00

4c. MALTI-TOF and other proteomic methods

You-Keun KO

A / 15 / 8

Poster P1987

Abstract 897

Optimal commercial enrichment kit protocol for rapid bacterial pathogen identification from blood positive culture by matrix-assisted laser desorption ionization-time of flight mass spectrometry system

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Hyun-Seung LEE

A / 15 / 9

Poster P1988

Abstract 1063

The importance of using two complementary mass spectrometry databases in the resolution of complex pathogens

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Florencia ROCCA

A / 15 / 10

Poster P1989

Abstract 1162

Is the correct identification directly from blood culture bottles just a dream?

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Dilan KARADAG

A / 15 / 11

Poster P1990

Abstract 1517

Rapid classification of Staphylococcus lugdunensis sequence type 3 based on MALDI-TOF mass spectrometry

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Lee-Chung LIN

A / 15 / 12

Poster P1991

Abstract 1570

Evaluation of a rapid MALDI-TOF protocol for the detection of pathogenic microorganisms on positive blood cultures in an MDRO-endemic hospital environment

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Angeliki KASSOMENAKI

A / 15 / 13

Poster P1992

Abstract 1628

Performance and workflow comparison between two MALDI TOF MS systems in microbiology routine laboratory settings

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Ulrich EIGNER

A / 15 / 14

Poster P1993

Abstract 2274

Performance evaluation of Vitek MS PRIME compared to Vitek MS

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Sae Am SONG

A / 15 / 15

Poster P1994

Abstract 2543

MALDI-TOF MS database expansion for robust and improved diagnostics in microbiology

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Valérie CHALANSONNET

A / 15 / 16

Poster P1995

Abstract 2777

Detection of Escherichia coli O157:H7 using MALDI-TOF mass spectrometry

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Florencia ROCCA

A / 15 / 17

Poster P1996

Abstract 3123

Performance of the VITEK MS PRIME was equivalent to the VITEK MS in microbial identification with improved time to result

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Crystal WONG

A / 15 / 18

Poster P1997

Abstract 3921

Use of FT-IRS to detect in-patient diversity of vancomycin-resistant Enterococcus faecium

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Paul G HIGGINS

A / 15 / 19

Poster P1998

Abstract 3931

Legionella spp. identification by MALDI-TOF mass spectroscopy: improvement of technique and species relationship

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Luna GIROLAMINI

A / 15 / 20

Poster P1999

Abstract 4406

Evaluating MALDI-TOF for differentiation of Streptococcus pneumoniae from viridans group streptococci in blood cultures

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Eliza GIL

A / 15 / 21

Poster P2000

Abstract 4687

New insights on Serratia spp. taxonomy: are we doing our best?

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Blanca PÉREZ VISO

A / 15 / 22

Poster P2001

Abstract 4913

Bacterial identification by direct MALDI-TOF MS from blood culture bottles

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Santiago MUNILLA

A / 15 / 23

Poster P2002

Abstract 5770

Evaluation of fast direct MALDI-TOF identification of organisms from positive blood-culture bottles (BCB): the saponin method vs full extraction

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Dennis Schröder HANSEN

A / 15 / 24

Poster P2003

Abstract 5895

Determination of the globally most common Streptococcus agalactiae strain, ST1, using MALDI-TOF mass spectrometry

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Kwanchai ONRUANG

A / 15 / 25

Poster P2004

Abstract 6001

Evaluation of MALDI-TOF MS to identify Acinetobacter spp. circulating in a Danish tertiary hospital

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Lekovic SONJA

A / 15 / 26

Poster P2005

Abstract 6059

A simple protocol for rapid bacterial identification by MALDI-TOF MS directly from positive blood cultures

27/04 12:00

4c. MALTI-TOF and other proteomic methods

João SIMÕES MARRAZES

A / 15 / 27

Poster P2006

Abstract 6195

Application of Fourier transform infrared spectroscopy to discriminate B. anthracis from B. cereus sensu stricto

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Viviana MANZULLI

A / 15 / 28

Poster P2007

Abstract 7024

Assessing diagnostic methods: MOLDI TOF Direct vs. ePlex BCID panels in detecting bacteremia and fungemia from positive blood cultures in a tertiary level hospital

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Sofia NARVÁEZ MORALES

B / 15 / 1

Poster P2008

Abstract 7679

Evaluation of VITEK MS prime bacterial identification performance in conjunction with a fully automated slide preparation system in urine cultures

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Jana ROVIRA-PLUJÀ

B / 15 / 2

Poster P2009

Abstract 8268

Detection of cfiA gene in Bacteroides fragilis using MALDI-TOF

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Nurver ULGER TOPRAK

B / 15 / 3

Poster P2010

Abstract 8692

Comparison between direct MALDI-TOF MS method and a commercial multiplex PCR panel for rapid identification of bacteria directly from positive blood cultures

27/04 12:00

4c. MALTI-TOF and other proteomic methods

Ivana VELIMIROVIC

B / 15 / 4

Poster P2011

Abstract 41

Diagnostic accuracy of pooling samples for the detection of N. gonorrhoeae and C. trachomatis using a commercial CT/NG assay

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Amy SHANLEY

B / 15 / 5

Poster P2012

Abstract 530

Argentine multicentre study on the usefulness of multiplex PCR in the diagnosis of septic arthritis

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Rolando SOLOAGA

B / 15 / 6

Poster P2013

Abstract 640

High diagnostic accuracy of pooled samples analysed with a commercial PCR for detecting MRSA carriage

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Ditte BANG OTURAI

B / 15 / 7

Poster P2014

Abstract 785

Prospective evaluation of a commercial multiplex PCR system to identify microorganisms in explanted heart valves from suspected infective endocarditis cases

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Benjamin BERINSON

B / 15 / 8

Poster P2015

Abstract 839

Detection of Chlamydia trachomatis and Neisseria gonorrhoeae (and its resistance to ciprofloxacin): a molecular biology solution for rapid diagnosis and treatment

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Blanca DEHESA-GARCÍA

B / 15 / 9

Poster P2016

Abstract 854

A novel filarial-multiplexed probe-quantitative PCR for the advance in the diagnosis of co-infected human filariasis

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Raquel CAPOTE-MORALES

B / 15 / 10

Poster P2017

Abstract 862

Towards better treatment of bacterial endophthalmitis

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Tim SCHUURMAN

B / 15 / 11

Poster P2018

Abstract 879

Duplex Salmonella spp. qPCR for screening of poultry environmental samples

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Durda SLAVIC

B / 15 / 12

Poster P2019

Abstract 922

Molecular approaches to the rapid and accurate diagnosis of bone and joint infections

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Kiyofumi OHKUSU

B / 15 / 13

Poster P2020

Abstract 1027

Comparison of three multiplex PCR assays for Chlamydia trachomatis and Neisseria gonorrhoeae detection in symptomatic genital infections

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Ali ZEROUKI

B / 15 / 14

Poster P2021

Abstract 1105

Filmarray syndromic diagnostics strengthens clinical outcomes, biosecurity and response in eight small island states

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

John LEE

B / 15 / 15

Poster P2022

Abstract 1116

Prospective evaluation of the performance and clinical impact of a commercial PCR panel in patients with suspected joint infections

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Benjamin BERINSON

B / 15 / 16

Poster P2023

Abstract 1227

The relevance of SCCmec-orfX junction target in the accurate detection of methicillin-resistant Staphylococcus aureus: a comparative study of interpretation criteria in a real-time PCR kit

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Esther FRANCO

B / 15 / 17

Poster P2024

Abstract 1257

Would a rapid response be possible in developing countries for the diagnosis of hepatitis B and malaria using DBS samples?

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

María MARTÍNEZ-SANTOLARIA

B / 15 / 18

Poster P2025

Abstract 1259

Quick lysis reagent: a rapid alternative to automatic extraction

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

María MARTÍNEZ-SANTOLARIA

B / 15 / 19

Poster P2026

Abstract 1280

T2 magnetic resonance technology identifies 3.55 times more on-panel Candida species compared to conventional blood culture

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Oscar GUZMAN

B / 15 / 20

Poster P2027

Abstract 1302

Method validation: spike!

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Sabine TROMBERT-PAOLANTONI

B / 15 / 21

Poster P2028

Abstract 1367

Using protein microarrays to enhance lateral flow development for detecting multiplex beta-lactam and colistin resistance

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Sascha D. BRAUN

B / 15 / 22

Poster P2029

Abstract 1431

Reagent decontamination needed to develop microorganism's qPCR assays with a mammalian endogenous control

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

María GISTAS LOSCOS

B / 15 / 23

Poster P2030

Abstract 1432

qPCR Reagent decontamination needed for 16S rDNA qPCR and Sanger sequencing

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

María GISTAS LOSCOS

B / 15 / 24

Poster P2031

Abstract 1470

Detection of bacteria directly from synovial fluid using digital PCR: proof of concept

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Marthe CHARLES

B / 15 / 25

Poster P2032

Abstract 1560

Improved meningitis diagnostics of culture-negative CSF samples with molecular culture

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Lauren REMIJAS

B / 15 / 26

Poster P2033

Abstract 1565

Comparison of two automatic methods for the identification of pathogens isolated from clinical samples

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Stavroula BAKA

B / 15 / 27

Poster P2034

Abstract 1683

Causative microorganisms of sexually transmitted infections in a STI clinic during the year 2023

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Jorge-Alfredo PEREZ-GARCIA

B / 15 / 28

Poster P2035

Abstract 1756

Evaluation of a multiplex real time PCR assay for the diagnosis of vaginal candidiasis: a comparison with conventional laboratory culture methods

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Laura VANDERVORE

A / 16 / 1

Poster P2036

Abstract 1776

What have we learned from COVID-19 global health emergency?

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Laura PASTOR-BERNARD

A / 16 / 2

Poster P2037

Abstract 1784

Fast, multiplexed, and automated diagnosis of sexual transmitted infections (STIs) in different human specimens

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Laura PASTOR-BERNARD

A / 16 / 3

Poster P2038

Abstract 1817

Kitoma, extraction kit microbiome

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Laura PASTOR-BERNARD

A / 16 / 4

Poster P2039

Abstract 1856

Rapid PCR-based syndromic testing improved pathogen identification in lower respiratory tract infections

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Kerry FALCONER

A / 16 / 5

Poster P2040

Abstract 1909

Evaluation of a culture-independent gastrointestinal multiplex PCR panel for detection of gastrointestinal pathogens

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Erdal ÖZBEK

A / 16 / 6

Poster P2041

Abstract 2009

Evaluation of the Abbott Alinity m STI assay for the diagnosis of sexually transmitted diseases

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Mercedes PÉREZ RUIZ

A / 16 / 7

Poster P2042

Abstract 2039

Use of T2Bacteria panel in pediatric hematopoietic stem cell transplant patients: a single centre experience

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Lisa HISKEY

A / 16 / 8

Poster P2043

Abstract 2306

Clinical usefulness of the rapid bacterial identification panel at a tertiary hospital

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Woo KWANG-SOOK

A / 16 / 9

Poster P2044

Abstract 2551

Evaluation of molecular culture for pleural infection diagnosis

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Lauren REMIJAS

A / 16 / 10

Poster P2045

Abstract 2610

Non-classical pathogens involved in proctitis among frequent sex-group and chemsex participants

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Miguel PEREZ-POLANCO

A / 16 / 11

Poster P2046

Abstract 2617

Assessment of various transport media for compatibility with a novel molecular point-of-care system for respiratory viruses

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Juergen BECKER

A / 16 / 12

Poster P2047

Abstract 2749

BCID2 vs phenotypic culture: good, but not perfect, interim analysis from an Indian ICU

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Umang AGRAWAL

A / 16 / 13

Poster P2048

Abstract 2797

One script, many actors: multiplex-PCR meningitis/encephalitis syndromic panel acceptance level among pediatric and adult physicians

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Patricio FAVIER

A / 16 / 14

Poster P2049

Abstract 2841

NGS-based pathogen diagnostic in patients after allogeneic haematopoietic stem cell transplantation: a prospective single-centre study

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Sophie WEIL

A / 16 / 15

Poster P2050

Abstract 2845

GI pathogen detection using multiplexed PCR assay in kidney transplant recipients with diarrhea - before after study

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Alaa ATAMNA

A / 16 / 16

Poster P2051

Abstract 2854

Implementation of the first-of-its-kind high-throughput molecular testing platform for sexually transmitted infections into a national health service laboratory

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Anita JUSTICE

A / 16 / 17

Poster P2052

Abstract 3006

Misidentification of coagulase negative Staphylococcus species as Staphylococcus epidermidis by the blood culture identification panel 2 (BCID2)

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Stella ANTONARA

A / 16 / 18

Poster P2053

Abstract 3046

Etiologies of children digestives infections by syndromic molecular diagnosis

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Doria BENSERSA-NEDJAR

A / 16 / 19

Poster P2054

Abstract 3058

Diagnosis of community-acquired meningitis and meningo-encephalitis through syndromic PCR

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Doria BENSERSA-NEDJAR

A / 16 / 20

Poster P2055

Abstract 3173

A commercial molecular diagnostic test: clinical case series of the top six bloodstream infection and sepsis causing bacteria

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Lisa SIMMS

A / 16 / 21

Poster P2056

Abstract 3176

Value of a commercial multiplex PCR panel for the diagnosis of cholera in an outbreak setting in Hammanskraal, Tshwane, South Africa

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Mohamed SAID

A / 16 / 22

Poster P2057

Abstract 3179

Effects of a colloidal gold immunochromatographic assay for carbapenemase detection on the clinical outcomes of patients with bloodstream infection caused by carbapenem-resistant Enterobacterales

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Jiajie WANG

A / 16 / 23

Poster P2058

Abstract 3183

Evaluation of a commercial multiplex PCR assay as a routine screening method for the detection of stool pathogens

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Sarona LENGANA

A / 16 / 24

Poster P2059

Abstract 3243

Detects the main sexually transmitted pathogens plus Candida albicans and Gardnerella vaginalis by one-step real-time PCR

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Blanca DEHESA-GARCÍA

A / 16 / 25

Poster P2060

Abstract 3316

Evaluation of a commercial PCR-panel for detection of lower respiratory-tract infection pathogens compared to standard bacterial culture

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Julija GERM

A / 16 / 27

Poster P2062

Abstract 3389

Multiplex molecular testing reveals the burden of Vibrio cholerae infection in travellers

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Victoria K. OWEN

A / 16 / 28

Poster P2063

Abstract 3437

Development of a strain-specific PCR as a diagnostic tool for surveillance, detection, and monitoring of vancomycin-resistant Enterococcus faecium during outbreak

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Artur SABAT

B / 16 / 1

Poster P2064

Abstract 3522

Identification of bacterial pathogens in brain abscesses by metagenomic approach using nanopore 16S amplicon sequencing

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Yoonhyuk JANG

B / 16 / 2

Poster P2065

Abstract 3530

Microbiological culture vs molecular techniques: what is the best for the diagnosis of gastrointestinal infections?

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Mireia IGLESIAS ALGILAGA

B / 16 / 3

Poster P2066

Abstract 3633

Comparison of two diagnostic techniques for the detection of sexually transmitted infections

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Berta PINO CALM

B / 16 / 4

Poster P2067

Abstract 3833

High-throughput development of multiple qPCR and RT-qPCR diagnostic kits for comprehensive pathogen detection

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Ana ALVES CONCEIÇÃO

B / 16 / 5

Poster P2068

Abstract 4060

The role of Streptococcus pneumoniae polymerase chain reaction (PCR) in the diagnosis of pleural effusion due to pneumonia

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Laura Eva FRANCO FOBE

B / 16 / 6

Poster P2069

Abstract 4065

Optimising microbiological diagnosis and antimicrobial therapy of suspected osteoarticular infections using a syndromic molecular panel in paediatric patients

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Marilena AGOSTA

B / 16 / 7

Poster P2070

Abstract 4095

Comparison of the QIAstat-Dx and the BioFire for the detection of viral and bacterial respiratory tract pathogens

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Karoline LEUZINGER

B / 16 / 8

Poster P2071

Abstract 4143

Standardisation of a rapid tool for the detection of bacterial pneumonia in children.

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Arturo MARTÍNEZ TREJO

B / 16 / 9

Poster P2072

Abstract 4279

Culture-free rapid identification of bacterial strains in urinary tract infections (UTI) using RapidID, a novel multiplex, ribosomal RNA-based hybridization assay.

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Joseph M. BLONDEAU

B / 16 / 10

Poster P2073

Abstract 4613

Evaluation of a novel commercial RT-PCR assay for the detection of Helicobacter pylori and clarithromycin resistance

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Ursa KOLENC

B / 16 / 11

Poster P2074

Abstract 4684

Severe pneumonia monitoring: dynamics of culture and of multiplex PCR according to bacterial type

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Sarah TIMSIT

B / 16 / 12

Poster P2075

Abstract 4754

Evaluation of respiratory multiplex panel performance at a large teaching hospital in the United Kingdom

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Deepak PATHIYIL

B / 16 / 13

Poster P2076

Abstract 4766

Evaluation of four pneumococcal urinary antigen tests in patients with community-acquired pneumonia

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Rosa M PACHECO-GONZALEZ

B / 16 / 14

Poster P2077

Abstract 4793

Development and application of non-toxigenic Clostridioides difficile quantitative polymerase chain reaction assay

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Jinhee JO

B / 16 / 15

Poster P2078

Abstract 4813

The use of a syndromic panel in the diagnosis of septic arthritis

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Ana MARTÍN

B / 16 / 16

Poster P2079

Abstract 4837

Implementation of a multiplex RT-PCR for the rapid detection of pathogens in neonatal sepsis.

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Helena GIL CAMPESINO

B / 16 / 17

Poster P2080

Abstract 4844

Impact of rapid molecular diagnosis on the clinical-therapeutic management of severe pneumonia

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Alicia GALAR

B / 16 / 18

Poster P2081

Abstract 4874

Performance of new rapid multiplex real-time PCR kit detecting sexually transmitted pathogens

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Florence DOUCET POPULAIRE

B / 16 / 19

Poster P2082

Abstract 5031

Emergence of OXA-48-producing Klebsiella pneumoniae ST5994: a subclone of ST307 high-risk clone

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Jorge RODRÍGUEZ-GRANDE

B / 16 / 20

Poster P2083

Abstract 5044

Molecular diagnostic techniques are useful in ruling out native vertebral osteomyelitis: a systematic review and meta-analysis

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Omar MAHMOUD

B / 16 / 21

Poster P2084

Abstract 5117

Retrospective analysis of a multiplex vaginitis panel reveals diagnostic uncertainty in high cycle threshold positive specimens

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Lucas OSBORN

B / 16 / 22

Poster P2085

Abstract 5144

Evaluation of a custom NAAT gastrointestinal panel for syndromic testing of infectious diarrhea

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Yim GRACE

B / 16 / 23

Poster P2086

Abstract 5181

Detection of Helicobacter pylori and clarithromycin-resistance prediction by real-time PCR in paediatric stool specimens

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Molly BUTLER

B / 16 / 24

Poster P2087

Abstract 5236

Impact of multiplex polymerase chain reaction test in patients with meningitis or encephalitis

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Daisuke KITAGAWA

B / 16 / 25

Poster P2088

Abstract 5249

Quantitative PCR: a novel clinical tool for patients with bloodstream infections

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

David FARLOW

B / 16 / 26

Poster P2089

Abstract 5353

Impact on hospital length of stay and antimicrobial usage in aseptic meningitis patients dignosed by rapid multiplexed PCR assay at a pediatric hospital

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Lu JACKY

B / 16 / 27

Poster P2090

Abstract 5555

Development of a dipstick-based diagnostic assay for rapid detection of AMR genes in critical and high-priority bacterial pathogens

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Deepjyoti PAUL

B / 16 / 28

Poster P2091

Abstract 5608

Correlation of FilmArray pneumonia panel plus assay results with conventional diagnostic methods in determining the microbiological aetiology of nosocomial lower respiratory tract infections and antibiotic resistance profiles

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Tercan US

A / 17 / 1

Poster P2092

Abstract 5624

Evaluation of clinical performance and usability of a new automatic assay for gastrointestinal syndromic testing

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Jasmin KÖFFER

A / 17 / 2

Poster P2093

Abstract 5765

Implementation of molecular syndromic testing in routine laboratory diagnosis of infectious gastroenteritis

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Tjasa CERAR KISEK

A / 17 / 3

Poster P2094

Abstract 5825

Application of rapid molecular technology in precision medicine tackling Gram-negative bacteraemia

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Murnihayati HASSAN

A / 17 / 4

Poster P2095

Abstract 5900

Comparison of self-collected and physician-collected rectovaginal swabs for the detection of Group B Streptococcus colonisation in pregnancy using PCR from commercial enrichment broth swabs

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Samo JEVERICA

A / 17 / 5

Poster P2096

Abstract 5952

Assessing five methods that utilise host depletion methods to target bacterial DNA from synovial joint fluid.

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Hermione WEBSTER

A / 17 / 6

Poster P2097

Abstract 6063

Evaluation of four PCR Allplex gastrointestinal panel for the detection of bacterial, parasitical and viral pathogens in faeces.

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Pauline PITTI

A / 17 / 7

Poster P2098

Abstract 6173

Quantification of bacterial loads using interspace profiling (IS-Pro)

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Anne-Xander VAN DER STEL

A / 17 / 8

Poster P2099

Abstract 6175

Evaluation of a multiplex PCR panel for the diagnosis of community acquired meningitis/encephalitis and its integration in the laboratory diagnostic algorithm

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Max THOBURN

A / 17 / 9

Poster P2100

Abstract 6264

Added value of syndromic PCR panels for diagnosis in patients with ventilator-associated pneumonia with or without chronic respiratory diseases

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Davide CALABRETTA

A / 17 / 10

Poster P2101

Abstract 6280

Small amount of precious sample: can qPCR eye panel be helpful for rapid diagnosis of infections in keratitis patients?

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Bedia DINC

A / 17 / 11

Poster P2102

Abstract 6422

Syndromic point of care respiratory testing is clinically impactful and cost-effective compared to laboratory-based respiratory PCR

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Jonathan WILD

A / 17 / 12

Poster P2103

Abstract 6579

Evaluation of a multiplex PCR platform to enhance antimicrobial stewardship through rapid infection and antimicrobial resistance diagnostics in liver disease

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Veena RAMACHANDRAN

A / 17 / 13

Poster P2104

Abstract 6607

Detection by real-time PCR of Helicobacter pylori and clarithromycin resistance compared to histology on gastric biopsies

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Guillaume PITTIE

A / 17 / 14

Poster P2105

Abstract 6736

Evaluation of the multiplex PCR rapid testing for diagnosis of central nervous system infections

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Banu BAYRAKTAR

A / 17 / 15

Poster P2106

Abstract 6919

Effects of rapid detection of bloodstream infections using molecular method in developing country

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Eduardo CASTRO

A / 17 / 16

Poster P2107

Abstract 6996

Ten minutes from collection to final result: a novel nucleic acid detection technology

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Kyle GERBER

A / 17 / 17

Poster P2108

Abstract 6997

Molecular diagnostics for pathogen identification in joint infections

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Petra KMETIC

A / 17 / 18

Poster P2109

Abstract 7326

Engineered reverse transcriptases and Taq DNA Polymerases deliver robust yields in the presence of clinically relevant inhibitors ?????

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Julie WALKER

A / 17 / 19

Poster P2110

Abstract 7431

Evaluation of the microbiological performance of the FilmArray BCID2 in a developing country

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Eduardo CASTRO

A / 17 / 20

Poster P2111

Abstract 7530

16S ribosomal and ITS gene PCR in osteoarticular infections: is it useful for all types of samples?

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Manuel PINA SÁNCHEZ

A / 17 / 21

Poster P2112

Abstract 7560

Streptococcus pyogenes carriage detection with primary diagnostic and with qPCR-guided cultures in oropharyngeal and nasopharyngeal samples collected from children

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Rob MARIMAN

A / 17 / 22

Poster P2113

Abstract 7600

Analytical and clinical equivalence study of a syndromic panel for gastroenteritis on a alternative extraction platform

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Julie GREEN

A / 17 / 23

Poster P2114

Abstract 7736

Novel molecular assays for detection of the opportunistic pathogen Kalamiella piersonii.

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Louise O'CONNOR

A / 17 / 24

Poster P2115

Abstract 7792

Value of syndromic multiplex PCR in epidemiology of respiratory infections in lung transplant patients

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Noémie PEREZ MUNOZ

A / 17 / 25

Poster P2116

Abstract 8069

An optimised protocol for cost-efficient and rapid sequencing of bacterial 16S rDNA in clinical samples using nanopore

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Jozef DINGEMANS

A / 17 / 26

Poster P2117

Abstract 8136

Is 16S rRNA approach an option to improve molecular diagnosis in bacterial infections?

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Olivier DAUWALDER

A / 17 / 27

Poster P2118

Abstract 8698

Risk management of false positives with using multiplex PCR blood culture panels

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Sophie GREGG

A / 17 / 28

Poster P2119

Abstract 8745

Can PCR replace culture for diagnosing gastro-intestinal pathogens? Validation of Seegene's Allplex GI-EB panel.

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Astrid HOLDERBEKE

B / 17 / 1

Poster P2120

Abstract 8848

Prevalence of gastrointestinal pathogens detected by multiplex PCR in a third-level teaching hospital in Mexico City

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Lucia MARTINEZ-HERNANDEZ

B / 17 / 2

Poster P2121

Abstract 8896

Large diagnostic gap for hospitalized acute febrile illness admissions

27/04 12:00

4d. Molecular diagnostics (incl POCT and syndromic testing)

Kalpa KARIYAWASAM

B / 17 / 3

Poster P2122

Abstract 284

Evaluation and proof of concept study for timely antimicrobial resistant organisms tacking (TAROT)

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Kotaro AOKI

B / 17 / 4

Poster P2123

Abstract 926

Burden and serotype distribution of Streptococcus pneumoniae associated with pediatric invasive pneumococcal disease (IPD): a prospective surveillance study in Japan

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Katsunori YANAGIHARA

B / 17 / 5

Poster P2124

Abstract 970

MRSA nasal carriage in Taiwanese senior high school students and narrative comparison with local metadata

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Cheng Yu LEE

B / 17 / 6

Poster P2125

Abstract 1021

National FTIR surveillance allows for early detection of outbreak of high risk Klebsiella pneumoniae ST307 in several hospitals in the north of Israel

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Mor LURIE-WEINBERGER

B / 17 / 7

Poster P2126

Abstract 1370

A fast and economic protein-microarray based approach for serotyping of Salmonella enterica strains

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Sascha D. BRAUN

B / 17 / 8

Poster P2127

Abstract 1624

Machine learning-based typing of Clostridium botulinum by FT-IR spectroscopy: preliminary results

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Ilenia DRIGO

B / 17 / 9

Poster P2128

Abstract 2286

Investigation of multidrug resistant Acinetobacter baumannii using IR Biotyper, a Fourier transform infrared spectroscopy system

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Felipe TUON

B / 17 / 10

Poster P2129

Abstract 2768

Early identification of a nosocomial outbreak of vancomycin-resistant Enterococcus faecium by Fourier-transform infrared spectroscopy and performance comparison with PFGE and WGS

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Ignasi ROCA

B / 17 / 11

Poster P2130

Abstract 3227

Big data genomic analysis of multidrug-resistant Acinetobacter baumannii in indian clinical isolates carrying different types of CRISPR/Cas systems

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Aishwarya DAS

B / 17 / 12

Poster P2131

Abstract 3386

Complete genomic analysis of Korean ST72-spa t324 community-associated methicillin-resistant Staphylococcus aureus SCCmec type IVa isolates from blood cultures

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Jae-Seok KIM

B / 17 / 13

Poster P2132

Abstract 3989

Comparison between cultural method and isothermal loop mediated amplification (LAMP) in hospital environment monitoring

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Federica MARINO

B / 17 / 14

Poster P2133

Abstract 4061

Differentiation of Pseudomonas aeruginosa clinical outbreaks by Fourier transform infrared spectroscopy

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Paul G HIGGINS

B / 17 / 15

Poster P2134

Abstract 4137

Evaluating FT-IRS in outbreak detection of vancomycin-resistant Enterococcus faecium

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Paul G HIGGINS

B / 17 / 16

Poster P2135

Abstract 4286

Evaluation of FT-IR spectroscopy and machine learning for the discrimination of Escherichia coli and Shigella spp.

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Miriam CORDOVANA

B / 17 / 17

Poster P2136

Abstract 4409

Accelerating diagnosis by streamlining Klebsiella pneumoniae typing from blood culture bottles with Fourier transform infrared spectroscopy

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

B / 17 / 18

Poster P2137

Abstract 5347

Discrepancies between cultural and molecular methods for carbapenem-resistant Enterobacterales in active surveillance: an experience of a Italian large tertiary Hospital

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Selene Rebecca BONCOMPAGNI

B / 17 / 19

Poster P2138

Abstract 5586

Genomic surveillance of multidrug-resistant organisms based on long-read sequencing

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Antoni P.A. HENDRICKX

B / 17 / 20

Poster P2139

Abstract 5709

Successive Staphylococcus aureus isolates from cystic fibrosis patients: clonal lineages, resistance, virulence and detection of CC398 isolates

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Paula EGUIZÁBAL

B / 17 / 21

Poster P2140

Abstract 5788

Evaluation of a genotypic method for detection of ESBL and carbapenemase-producing-Gram-negative bacteria directly from rectal and pharyngeal swabs in a tertiary hospital

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

María Paula VARGAS DURÁN

B / 17 / 22

Poster P2141

Abstract 5835

Profiling the diversity of Scottish Staphylococcus pseudintermedius clinical isolates by development of a novel core genome multilocus typing scheme

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Imogen JOHNSTON-MENZIES

B / 17 / 23

Poster P2142

Abstract 6065

Application of Fourier transform infrared spectroscopy for a neonatal Kluyvera ascorbata clinical outbreak

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Miriam CORDOVANA

B / 17 / 24

Poster P2143

Abstract 6078

Exploring the Streptococcus genus composition in nasopharynx of adult patients with pneumococcal pneumonia: a marker gene study

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Miguel BLANCO FUERTES

B / 17 / 25

Poster P2144

Abstract 6206

Subtyping Legionella pneumophila using MLVA-8, MALDI-TOF MS and whole genome sequencing

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Lana MADAGI

B / 17 / 26

Poster P2145

Abstract 6238

Genomic surveillance of multidrug-resistant bacteria: first results of the SLOSEQ project

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Urska KRAMAR

B / 17 / 27

Poster P2146

Abstract 6514

Comparability and reproducibility of bacterial genotyping is affected by species- and isolate-dependent issues in long read assemblies: a multi-centre performance study

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Johanna DABERNIG-HEINZ

B / 17 / 28

Poster P2147

Abstract 6545

Specimen pooling for cost-sparing PCR-based surveillance of methicillin resistant Staphylococcus aureus (MRSA)

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Glenn PATRIQUIN

A / 18 / 1

Poster P2148

Abstract 6571

Community spread of Staphylococcus aureus ST398 in patients at risk of sexually transmitted infections

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Maxime DANJEAN

A / 18 / 2

Poster P2149

Abstract 6603

Genomics insights into the complexity of Staphylococcus epidermidis transmission in a neonatal intensive care units (NICU)

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Maria MIRAGAIA

A / 18 / 3

Poster P2150

Abstract 6761

Molecular characterisation of O157, O26 and O103 Shiga toxin-producing Escherichia coli (STEC) Slovenian isolates using whole genome sequencing

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Tjasa CERAR KISEK

A / 18 / 4

Poster P2151

Abstract 6841

Limitations of sequence typing for isolate inclusion in outbreak investigations

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Karolina JACKOWSKA

A / 18 / 5

Poster P2152

Abstract 7177

Fourier-transform infrared spectroscopy for low-cost and real-time vancomycin-resistant Enterococcus faecium outbreak investigation

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Asma ZOUARI SASSI

A / 18 / 6

Poster P2153

Abstract 7370

Evaluation of three high molecular weighted DNA extraction kits and in silico assemblers for circularization of Listeria monocytogenes genomes using third generation sequencing

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

François GRAVEY

A / 18 / 7

Poster P2154

Abstract 7643

Real-time outbreak investigation of OXA-48-producing Escherichia coli using Fourier-transform infrared spectroscopy

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Jalal TARABEIA

A / 18 / 8

Poster P2155

Abstract 8035

Rapid profiling of Helicobacter pylori carcinogenic toxin antibodies in serum via deep learning analysis of label-free SERS spectra

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Liang WANG

A / 18 / 9

Poster P2156

Abstract 8111

Molecular surveillance of group A streptococcal infections in the Netherlands: clonal sweep by the M1UK lineage

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Lidewij RUMKE

A / 18 / 10

Poster P2157

Abstract 8143

Six months of experience with day-to-day sequencing of Listeria monocytogenes for outbreak investigation in an entire Danish region and concordance between changing chemistries

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Laus KREMS VEJRUM

A / 18 / 11

Poster P2158

Abstract 8158

be.Prepared to increase integration of health data as a way of strengthening the surveillance of infectious diseases

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Heleen MASSET

A / 18 / 12

Poster P2159

Abstract 8300

City lights, microbial insights: unmasking the urban challenges of group A Streptococcus

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Rachel KETTLES

A / 18 / 13

Poster P2160

Abstract 8378

Exploring the potential of FT-IR spectroscopy and machine learning to discriminate between Enterococcus faecium and Enterococcus lactis

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Angela NOVAIS

A / 18 / 14

Poster P2161

Abstract 8707

Use of biotyper to distinguish Klebsiella pneumoniae sequence types 16 and 11: preliminary data

27/04 12:00

4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)

Patrícia BARTH

A / 18 / 15

Poster P2162

Abstract 790

Study of the resistome and virulome of H. pylori by NGS approach using DNA capture technology

27/04 12:00

4f. Whole genome sequencing (incl pathogen characterisation, diagnostics, excl typing)

Léo GILLET

A / 18 / 16

Poster P2163

Abstract 1067

Molecular characterisation of lugdunin inactivation mechanisms and their association with Staphylococcus lugdunensis genetic types

27/04 12:00

4f. Whole genome sequencing (incl pathogen characterisation, diagnostics, excl typing)

Jang-Jih LU

A / 18 / 17

Poster P2164

Abstract 1295

WGS-based characterisation of putative hypervirulent Klebsiella pneumoniae identified in a tertiary care hospital in Germany

27/04 12:00

4f. Whole genome sequencing (incl pathogen characterisation, diagnostics, excl typing)

Bernd NEUMANN

A / 18 / 18

Poster P2165

Abstract 3190

Streptococcus equi invasive isolates in Belgium between 2014 and 2022: characterisation and subspecies identification using MALDI-TOF MS and whole genome sequencing

27/04 12:00

4f. Whole genome sequencing (incl pathogen characterisation, diagnostics, excl typing)

Sien DE KOSTER

A / 18 / 19

Poster P2166

Abstract 3584

Automation of the library preparation for whole-genome sequencing of bacterial genomes using an open-source programming liquid-handler robot

27/04 12:00

4f. Whole genome sequencing (incl pathogen characterisation, diagnostics, excl typing)

Erin MEIJERS

A / 18 / 20

Poster P2167

Abstract 3620

Unravelling adaptation of Pseudomonas aeruginosa in cystic fibrosis patients: a longitudinal genomic analysis

27/04 12:00

4f. Whole genome sequencing (incl pathogen characterisation, diagnostics, excl typing)

Martina ROSSITTO

A / 18 / 22

Poster P2169

Abstract 3975

Hyper-transmissible Klebsiella pneumoniae carbapenemase (KPC): unravelling multi-species transmission within a single patient using whole genome sequencing

27/04 12:00

4f. Whole genome sequencing (incl pathogen characterisation, diagnostics, excl typing)

Xena LI

A / 18 / 23

Poster P2170

Abstract 4250

Comparing Illumina and Nanopore for bacterial whole genome sequencing in clinical microbiology

27/04 12:00

4f. Whole genome sequencing (incl pathogen characterisation, diagnostics, excl typing)

Srinithi PURUSHOTHAMAN

A / 18 / 24

Poster P2171

Abstract 4257

How whole genome sequencing shed new light on Staphylococcus hominis subsp. novobiosepticus

27/04 12:00

4f. Whole genome sequencing (incl pathogen characterisation, diagnostics, excl typing)

Kassandra WOLK

A / 18 / 25

Poster P2172

Abstract 4775

Occurrence of hypervirulent Klebsiella pneumoniae clones in Santander, Spain

27/04 12:00

4f. Whole genome sequencing (incl pathogen characterisation, diagnostics, excl typing)

Jorge RODRÍGUEZ-GRANDE

A / 18 / 26

Poster P2173

Abstract 5968

Prevalence and characteristics of plasmid-encoded serine protease EspP in clinical Shiga toxin-producing Escherichia coli strains from Sweden

27/04 12:00

4f. Whole genome sequencing (incl pathogen characterisation, diagnostics, excl typing)

Andreas MATUSSEK

A / 18 / 28

Poster P2175

Abstract 6470

Economic effects of next-generation-sequencing diagnostics: a budget impact analysis from the healthcare providers' perspective

27/04 12:00

4f. Whole genome sequencing (incl pathogen characterisation, diagnostics, excl typing)

Ann-Cathrine SIEFEN

B / 18 / 1

Poster P2176

Abstract 6585

Genotypic characterisation of Staphylococcus aureus isolates associated with invasive infections in children

27/04 12:00

4f. Whole genome sequencing (incl pathogen characterisation, diagnostics, excl typing)

Panagiota-Christina GEORGIOU

B / 18 / 2

Poster P2177

Abstract 6957

Comparative study of gDNA-extraction from clinically relevant species for third generation sequencing

27/04 12:00

4f. Whole genome sequencing (incl pathogen characterisation, diagnostics, excl typing)

Tobias PEDERSEN

B / 18 / 4

Poster P2179

Abstract 8617

Invasive and non-invasive Group A Streptococcus (GAS) identified in a paediatric cohort differ for emm type, virulence factors and mobilome

27/04 12:00

4f. Whole genome sequencing (incl pathogen characterisation, diagnostics, excl typing)

Valeria FOX

B / 18 / 5

Poster P2180

Abstract 221

Urinary tract infections and microbiome

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Ekaterina MALAEVA

B / 18 / 6

Poster P2181

Abstract 678

Gut microbiota and recompensation liver cirrhosis

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Ekaterina MALAEVA

B / 18 / 7

Poster P2182

Abstract 1613

Gut microbiota in preterm infants: changes associated with bacterial and fungal bloodstream infections

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Yubeen OH

B / 18 / 8

Poster P2183

Abstract 1778

The effects of probiotic Bifidobacterium breve Bif195 for diarrhoea-predominant irritable bowel syndrome

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Ida Marie Bruun GRØNBÆK

B / 18 / 9

Poster P2184

Abstract 1955

Gut microbiome dynamics in human melioidosis: a comprehensive analysis from early infection through recovery

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Chiranjay MUKHOPADHYAY

B / 18 / 10

Poster P2185

Abstract 2109

Comparative metagenomic study of vaginal microbiota in women infected with HPV 16/18 and other high-risk HPV subtypes: multi-kingdom microbiota approach

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Ji Young PARK

B / 18 / 11

Poster P2186

Abstract 2320

Antibiotic treatment delayed gut microbiome recovery in children with watery diarrhoea

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Hao CHUNG THE

B / 18 / 12

Poster P2187

Abstract 2413

Comparison of faecal sample collection methods in gut microbiome research

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Ida Marie Bruun GRØNBÆK

B / 18 / 13

Poster P2188

Abstract 2456

Nasopharyngeal microbiome composition in SARS-CoV-2 infected patients, with relation to COVID-19 clinical outcome

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Jean-Luc TISON

B / 18 / 14

Poster P2189

Abstract 2480

Structural variations in microbiome after prolonged cryopreservation of faecal samples

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Josip UJEVIC

B / 18 / 15

Poster P2190

Abstract 2606

Evaluating the correlation between the vaginal microbiome and clinical outcomes: is our data analysis accurate?

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Courtney POVEY

B / 18 / 16

Poster P2191

Abstract 2635

The urinary microbiome is highly diverse: shotgun metagenomics of urine samples from 1,000 individuals of the population-based SCAPIS cohort

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Tiscar GRAELLS

B / 18 / 17

Poster P2192

Abstract 2820

Whole-genome sequencing and 16s metabarcoding analysis provide new insights in the relationship between the composition of gut microbiota and colonization by Klebsiella pneumoniae.

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Roberto ROSATO

B / 18 / 18

Poster P2193

Abstract 2879

Faecal microbiota differences in patients with HIV, chronic hepatitis C and HIV/HCV coinfection

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Monta MADELANE

B / 18 / 19

Poster P2194

Abstract 3430

Higher total bacterial load in vagina is associated with endometrial hyperplasia

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Ekaterina VOROSHILINA

B / 18 / 20

Poster P2195

Abstract 4087

Dead or alive? Novel strategy for the differential analysis of the microbiome composition

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Clémence ROBERT

B / 18 / 21

Poster P2196

Abstract 4308

Comparing the lung microbiome across COPD GOLD stages

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Leticia BUENO FREIRE

B / 18 / 22

Poster P2197

Abstract 4328

The effect of recurrent urinary tract infections on the proteome

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Adrià CRUELLS GASCON

B / 18 / 23

Poster P2198

Abstract 4375

Vaginal and gut phageomes and microbiomes in recurrent urinary tract infection

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Adrià CRUELLS GASCON

B / 18 / 24

Poster P2199

Abstract 4403

The influence of age on the stability of the gut microbiota composition as a factor determining the faecal microbiota transplantation effectiveness in a rat model

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Agnieszka KRAWCZYK

B / 18 / 25

Poster P2200

Abstract 4572

The microbiome from diabetic foot ulcers: are there particular patterns to take care in clinical practice?

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Laura SOLDEVILA-BOIXADER

B / 18 / 26

Poster P2201

Abstract 5497

Quantitative detection of short-chain fatty acids in the fecal metabolome

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Gaute HOVDE BØ

B / 18 / 27

Poster P2202

Abstract 5530

Analyses of nasopharyngeal microbiota patterns associated to pneumococcal pneumonia in adults: a prospective double case-control study in COVID-19 pandemic period

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Beatriz DIETL

B / 18 / 28

Poster P2203

Abstract 5619

Nanopore-based 16S rRNA gene sequencing improves bacterial identification in clinical samples compared to Sanger-sequencing

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Karina GRAVGAARD THOMSEN

A / 19 / 1

Poster P2204

Abstract 6047

Refinement of the microbiome analysis for low-microbial biomass biospecimens

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Andreas MATUSSEK

A / 19 / 2

Poster P2205

Abstract 6074

Early development and dynamics of nasopharyngeal microbiota in infants during the COVID-19 pandemic: a 2-year prospective cohort study

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Aleix LLUANSÍ

A / 19 / 3

Poster P2206

Abstract 6788

Optimization of urinary microbiome analysis from 16S sequencing data

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Camille VILLENAVE

A / 19 / 4

Poster P2207

Abstract 7129

Next-generation sequencing improves diagnostic 16S rRNA amplicon-based microbiota analyses of clinical samples compared to Sanger sequencing

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Huma AFTAB

A / 19 / 5

Poster P2208

Abstract 7132

Gut microbiota and COVID19: descriptive and comparative analysis in hospitalised patients

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Maria Vittoria MAURO

A / 19 / 6

Poster P2209

Abstract 8431

Effect of prophylactic antibiotics in breast milk on the meconium microbiota and 6th month fecal microbiota of newborns born vaginally or by cesarean section

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Gulsum KAYA

A / 19 / 7

Poster P2210

Abstract 8934

Medication-induced osteonecrosis of the jaw: the role of oral microbiota and antibiotics

27/04 12:00

4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)

Jacopo MULA

A / 19 / 8

Poster P2211

Abstract 18

Characteristics of whole genome sequencing of multi-drug-resistant clinical Escherichia coli O99 H30 ST38 isolated from wound infection in intensive care unit

27/04 12:00

4h. Clinical metagenomics

Ali DASHTI

A / 19 / 10

Poster P2213

Abstract 1108

Thoughts and perspectives of metagenome sequencing as a diagnostic tool for infectious diseases: an interpretive phenomenological study

27/04 12:00

4h. Clinical metagenomics

Hannah TRIVETT

A / 19 / 11

Poster P2214

Abstract 1859

Clinical metagenomics by nanopore sequencing to improve the success rate of respiratory pathogen identification

27/04 12:00

4h. Clinical metagenomics

Amélia RODRIGUES

A / 19 / 12

Poster P2215

Abstract 2099

Development of a comprehensive genomics (NGS) based test for the detection of anti-microbial resistance and sepsis

27/04 12:00

4h. Clinical metagenomics

Suresh THAKUR

A / 19 / 13

Poster P2216

Abstract 2774

Rapid detection of pathogens directly from paediatric clinical specimens using an automated amplicon-based next generation sequencing pipeline

27/04 12:00

4h. Clinical metagenomics

Lucas OSBORN

A / 19 / 14

Poster P2217

Abstract 3136

Analytical and clinical evaluation of tNGS and mNGS performance on suspected pulmonary infections in HIV patients

27/04 12:00

4h. Clinical metagenomics

Ling ZHANG

A / 19 / 15

Poster P2218

Abstract 3723

Updated diagnostic performance of metagenomic next-generation sequencing in brain abscess

27/04 12:00

4h. Clinical metagenomics

Xinyun ZHANG

A / 19 / 16

Poster P2219

Abstract 3746

Rapid pan-metagenomics: improving pneumonia diagnosis and responding swiftly to mpox outbreak.

27/04 12:00

4h. Clinical metagenomics

Adela ALCOLEA MEDINA

A / 19 / 17

Poster P2220

Abstract 4265

16S targeted metagenomics in the diagnosis of bone and joint infections: it's not just magic!

27/04 12:00

4h. Clinical metagenomics

Olivier DAUWALDER

A / 19 / 18

Poster P2221

Abstract 4981

Plasma cell-free DNA metagenomic sequencing in paediatric cancer patients

27/04 12:00

4h. Clinical metagenomics

Sandra CASTEJON RAMIREZ

A / 19 / 19

Poster P2222

Abstract 5232

Prospective whole-genome sequencing in the era of precision infection prevention

27/04 12:00

4h. Clinical metagenomics

Rossana ROSA

A / 19 / 20

Poster P2223

Abstract 5359

Assessing the diagnostic performance of cell-free DNA sequencing in routine bloodstream infection diagnostics: a retrospective single centre study of the first 300 cases

27/04 12:00

4h. Clinical metagenomics

Marijo PARCINA

A / 19 / 21

Poster P2224

Abstract 5547

Pilot study and cost-effectiveness analysis of an ultra-rapid metagenomic sequencing test for pathogen detection in adult patients with sepsis

27/04 12:00

4h. Clinical metagenomics

Yuyao YIN

A / 19 / 22

Poster P2225

Abstract 5625

Pathogen detection by metagenomic next-generation sequencing in people living with HIV/AIDS.

27/04 12:00

4h. Clinical metagenomics

Daniel GRIMM

A / 19 / 23

Poster P2226

Abstract 5666

Diagnosing visceral leishmaniasis using the microbiome 16S/18S test

27/04 12:00

4h. Clinical metagenomics

Kaziwa RASOUL

A / 19 / 25

Poster P2228

Abstract 5879

Quality control (QC) metrics for hybrid capture-based NGS enrichment workflows

27/04 12:00

4h. Clinical metagenomics

Robert SCHLABERG

A / 19 / 26

Poster P2229

Abstract 5987

NGS enrichment panels as a surveillance tool to monitor the growing burden of drug-resistance pathogens and antimicrobial resistance genes

27/04 12:00

4h. Clinical metagenomics

Robert SCHLABERG

A / 19 / 27

Poster P2230

Abstract 6155

Metagenomic analysis of cell-free DNA from whole blood specimens of patients with suspected infections: performance and therapeutic impact in clinical routine

27/04 12:00

4h. Clinical metagenomics

Jürgen HELD

A / 19 / 28

Poster P2231

Abstract 6167

Evaluation of decentralised Salmonella serovar prediction by whole genome sequencing

27/04 12:00

4h. Clinical metagenomics

Kat STEINKE

B / 19 / 1

Poster P2232

Abstract 6786

Genetic diversity and virulence factors in Escherichia coli: a comparative study between neonatal sepsis, adults and environmental sources

27/04 12:00

4h. Clinical metagenomics

Lucia BARCELLINI

B / 19 / 2

Poster P2233

Abstract 7286

Impact of an in-house metagenomic test for diagnostic of tropical and neglected infectious diseases: three years of experience

27/04 12:00

4h. Clinical metagenomics

Andre DOI

B / 19 / 3

Poster P2234

Abstract 8660

Systematic review on surveillance systems integrating whole-genome sequencing and epidemiological information worldwide, 2012-2023

27/04 12:00

4h. Clinical metagenomics

Felix REICHERT

B / 19 / 4

Poster P2235

Abstract 293

Advancing Streptococcus pneumoniae capsular typing: MALDI-TOF mass spectrometry and machine learning algorithms

27/04 12:00

4i. Bioinformatics tools & pipelines

Jonathan ZINTGRAFF

B / 19 / 5

Poster P2236

Abstract 1415

Evaluation of a real-time plasmid transmission detection pipeline

27/04 12:00

4i. Bioinformatics tools & pipelines

Natalie SCHERFF

B / 19 / 6

Poster P2237

Abstract 1478

Using NCBI's pathogen detection system to determine the distribution of KPC-family carbapenemases in Klebsiella pneumoniae isolates from China and the U.S.

27/04 12:00

4i. Bioinformatics tools & pipelines

Michael FELDGARDEN

B / 19 / 7

Poster P2238

Abstract 1749

Reference guided clustering for the identification of bacteria using 16S long reads

27/04 12:00

4i. Bioinformatics tools & pipelines

Korneel DUMON

B / 19 / 8

Poster P2239

Abstract 1808

Costs of an infection risk scan in a hospital

27/04 12:00

4i. Bioinformatics tools & pipelines

Miranda VAN RIJEN

B / 19 / 9

Poster P2240

Abstract 2393

Design of a plasmid classification workflow for local bacterial population analysis

27/04 12:00

4i. Bioinformatics tools & pipelines

Markéta NYKRÝNOVÁ

B / 19 / 10

Poster P2241

Abstract 2604

Mega pipeline: an automated pipeline for easy microbial whole genome sequencing analysis

27/04 12:00

4i. Bioinformatics tools & pipelines

Marc FINIANOS

B / 19 / 11

Poster P2242

Abstract 4028

Batch effect correction in MALDI-TOF spectra for microorganism classification

27/04 12:00

4i. Bioinformatics tools & pipelines

Erica PADIAL FUILLERAT

B / 19 / 12

Poster P2243

Abstract 4852

Deciphering global patterns of antimicrobial resistance in key gram-negative pathogens using indirect predictors

27/04 12:00

4i. Bioinformatics tools & pipelines

Sneha KOTIAN

B / 19 / 13

Poster P2244

Abstract 5988

A comprehensive database for the direct identification of plasmid transfer genes

27/04 12:00

4i. Bioinformatics tools & pipelines

Csongor FREYTAG

B / 19 / 14

Poster P2245

Abstract 6860

Metagenomic sample composition explains variance in taxonomic classification performance

27/04 12:00

4i. Bioinformatics tools & pipelines

Iris GOLD RODAL

B / 19 / 15

Poster P2246

Abstract 1109

Raman spectroscopy-based characterisation of immunocyte responses to in vitro stimulation with pathogen-associated molecular patterns

27/04 12:00

4j. Other novel diagnostic technologies

Max NAUMANN

B / 19 / 16

Poster P2247

Abstract 1433

Breath biopsy reveals promising VOC biomarkers for early detection and monitoring of acute pulmonary exacerbations in people with cystic fibrosis

27/04 12:00

4j. Other novel diagnostic technologies

Hsuan CHOU

B / 19 / 17

Poster P2248

Abstract 2824

The association of host signature based on TRAIL, IP-10, and CRP with paediatric pneumonia

27/04 12:00

4j. Other novel diagnostic technologies

Sriram RAMGOPAL

B / 19 / 18

Poster P2249

Abstract 3196

New generation table-top scanning electron microscope: a robust tool in clinical microbiology for direct specimen examination

27/04 12:00

4j. Other novel diagnostic technologies

Omar ZMERLI

B / 19 / 19

Poster P2250

Abstract 3290

Evaluation of Sysmex fluorescence flow cytometry analyser in rapid diagnosis of urinary tract infections

27/04 12:00

4j. Other novel diagnostic technologies

Baran IRMAK

B / 19 / 20

Poster P2251

Abstract 3767

Quorum sensing molecular signatures to diagnose P. aeruginosa infections

27/04 12:00

4j. Other novel diagnostic technologies

Juan RAYA

B / 19 / 21

Poster P2252

Abstract 5166

Application of AI vision for the rapid automatic counting of microbial colonies on agar

27/04 12:00

4j. Other novel diagnostic technologies

Li XUE

B / 19 / 22

Poster P2253

Abstract 5247

Evaluation of early stage implementation results of a cellular host-response test in an emergency department setting

27/04 12:00

4j. Other novel diagnostic technologies

Hollis O'NEAL

B / 19 / 23

Poster P2254

Abstract 5413

The hydrogel-based gram staining method with no wastewater

27/04 12:00

4j. Other novel diagnostic technologies

Mijin KIM

B / 19 / 24

Poster P2255

Abstract 5422

Neonatal sepsis diagnosis: dual assay platforms utilising aptamer-labelled electrochemical and fluorescent chips

27/04 12:00

4j. Other novel diagnostic technologies

Chaitali SINGHAL

B / 19 / 25

Poster P2256

Abstract 6631

Identification of bacteria in mixed infections from urinary tract of patient's samples using Raman spectroscopy

27/04 12:00

4j. Other novel diagnostic technologies

María José GONZÁLEZ VÁZQUEZ

B / 19 / 26

Poster P2257

Abstract 7187

A rapid, sensitive, and specific detection of carbapenem-resistant Acinetobacter baumannii by CRISPR Cas-based detection system

27/04 12:00

4j. Other novel diagnostic technologies

Sreekanthreddy BASIREDDY

B / 19 / 27

Poster P2258

Abstract 7697

Detection of Helicobacter pylori infection in human gastric fluid through surface-enhanced Raman spectroscopy coupled with machine learning algorithms

27/04 12:00

4j. Other novel diagnostic technologies

Liang WANG

A / 20 / 1

Poster P3717

Abstract 310

Clinical profile and outcomes in patients with melioidois and uncontrolled diabetes mellitus (MeloDi): a retrospective cohort study from South India

27/04 12:00

10a. Host genetics: susceptibility to infection & primary immunodeficiency

Nitin GUPTA

A / 20 / 2

Poster P3718

Abstract 2954

Single nucleotide polymorphisms in Toll-like receptors and their association with susceptibility to recurrent vulvovaginal candidiasis

27/04 12:00

10a. Host genetics: susceptibility to infection & primary immunodeficiency

Maria MAVROULI

A / 20 / 3

Poster P3719

Abstract 6343

Polymorphism in BoLA DRB3 and BoLA A genes lead to increased susceptibility to foot-and-mouth disease virus in vaccinated cattle

27/04 12:00

10a. Host genetics: susceptibility to infection & primary immunodeficiency

Yash CHAUDHARY

A / 20 / 4

Poster P3720

Abstract 190

Solid organ transplantation in SARS-CoV-2 positive candidates: a survey among ESGICH members

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Andrea LOMBARDI

A / 20 / 5

Poster P3721

Abstract 448

From widespread to tailored antifungal prophylaxis in lymphoma patients treated with CD19 CAR T- cell therapy: less is better

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Giovanna MELICA

A / 20 / 6

Poster P3722

Abstract 722

Population dynamics and molecular epidemiology of Staphylococcus epidermidis ST2 from patients with haematological malignancies 1980-2022

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Raphael SIEBER

A / 20 / 7

Poster P3723

Abstract 742

Torque teno virus as an indicator of infectious complications in the first year after lung transplantation: first results from Croatia

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Ivana MAREKOVIC

A / 20 / 8

Poster P3724

Abstract 757

Impaired T and “memory-like” NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessation

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Chris David LAURUSCHKAT

A / 20 / 9

Poster P3725

Abstract 778

Risk factors for hepatitis B reactivation and effectiveness of hepatitis B vaccination after solid organ transplantation: a matched case-control study

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Yongseop LEE

A / 20 / 10

Poster P3726

Abstract 846

Metagenomic next-generation sequencing of plasma cell-free DNA in clinical practice: improving infection diagnosis and antimicrobial therapy in immunocompromised patients

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Guankun YIN

A / 20 / 11

Poster P3727

Abstract 1157

Incidence and risk factors of cytomegalovirus reactivation after autologous stem cell transplantation: a retrospective single-centre study

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Giuseppe GENTILE

A / 20 / 12

Poster P3728

Abstract 1181

Chimeric antigen receptor T cell post-infusion fever: infection profile, clinical parameters and biomarkers trends to assist antibiotic stewardship

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Olivier PEYRONY

A / 20 / 13

Poster P3729

Abstract 1299

A prospective analysis of cytomegalovirus-specific cell-mediated immunity (CMV-CMI) in a multicentre Phase 3 randomised placebo-controlled trial of letermovir prophylaxis in CMV-seropositive recipients (R+) of an allogeneic haematopoietic cell transplant (HCT)

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Genovefa PAPANICOLAOU

A / 20 / 14

Poster P3730

Abstract 1300

Prophylaxis against pneumocystis pneumonia and toxoplasmosis with low-dose trimethoprim-sulfamethoxazole (cotrimoxazole 20/100mg) in heart transplant patients

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Alexandre BLEIBTREU

A / 20 / 15

Poster P3731

Abstract 1383

Clinical characteristics and prognostic factors in patients with fever of unknown origin who developed secondary haemophagocytic lymphohistiocytosis

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Yuan GUANMIN

A / 20 / 16

Poster P3732

Abstract 1385

The value of 18F-FDG PET/CT in clinical etiological diagnosis of secondary hemophagocytic lymphohistiocytosis

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Yuan GUANMIN

A / 20 / 17

Poster P3733

Abstract 1413

Hyperammonemia syndrome in immunocompromised patients: a systematic review on patient populations, clinical manifestations and outcome

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Laura WALTI

A / 20 / 18

Poster P3734

Abstract 1502

Effectiveness of cefiderocol in immunosuppressed patients with serious Gram-negative bacterial infections in the PERSEUS study in Spain

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Sarda JESSICA

B / 20 / 1

Poster P3735

Abstract 1662

Follow-up, diagnosis, and outcomes of fever of unknown origin cases with an erythrocyte sedimentation rate of 100 mm/h or more: an international ID-IRI study

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Oguz Resat SIPAHI

B / 20 / 2

Poster P3736

Abstract 1680

Low pan-immune-inflammation value predicts Gram negative bacteremia-related 30-day mortality in solid organ transplant recipients

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Caglayan Merve AYAZ

B / 20 / 3

Poster P3737

Abstract 1688

Recurrent cytomegalovirus reactivations: frequency, viral dynamic and risk factors in allogeneic stem cell transplantation

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Sylvia DALCOLMO

B / 20 / 4

Poster P3738

Abstract 1695

Quantiferon-cytomegalovirus after allogeneic stem cell transplantation: prediction of CMV reactivation and clinically significant infection

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Sylvia DALCOLMO

B / 20 / 5

Poster P3739

Abstract 1704

The impact of pre-transplant cultures screening on the risk of infection after kidney transplantation

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Maristela P FREIRE

B / 20 / 6

Poster P3740

Abstract 1881

Risk factors associated with Clostridioides difficile infection in the first 100-days after allogeneic hematopoietic stem cell transplantation

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Cameron GMEHLIN

B / 20 / 7

Poster P3741

Abstract 1913

Does secondary prophylaxis prevent recurrent episodes of Clostridioides difficile in allogeneic transplant patients?

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Maria Alejandra MENDOZA

B / 20 / 8

Poster P3742

Abstract 1919

Norovirus in allogeneic hematopoietic stem cell transplant recipients: does nitazoxanide help?

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Maria Alejandra MENDOZA

B / 20 / 9

Poster P3743

Abstract 1953

Antibiotic resistance patterns in dialysis patients: a comprehensive epidemiological study on 1,174 strains in Occitania (France)

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Matthieu BERNIER

B / 20 / 10

Poster P3744

Abstract 2123

Kinetics and role of pancreatic stone protein as predictor of sepsis and bacteremia in children with haematological malignancies

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Tragiannidis ATHANASIOS

B / 20 / 11

Poster P3745

Abstract 2225

Clinical features, diagnostic, aetiology and outcome of hospitalised solid organ recipients with community-acquired pneumonia: a cohort analysis over ten years

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Oana JOEAN

B / 20 / 12

Poster P3746

Abstract 2240

Secondary infections and clinical outcomes after respiratory syncytial virus (RSV) infections in heart and lung transplant recipients

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Mitchell DUMAIS

B / 20 / 13

Poster P3747

Abstract 2297

Role of human cytomegalovirus (HCMV) reactivation in causing pneumonia in immunocompetent mechanically ventilated patients

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Chhavi GUPTA

B / 20 / 14

Poster P3748

Abstract 2312

Correlation of cytomegalovirus specific cell-mediated immunity (CMV CMI) with subclinical CMV DNAemia in allogeneic haematopoietic cell transplant recipients (HCT)

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Kodama RICH

B / 20 / 15

Poster P3749

Abstract 2401

High burden of non-serious infections during biological use for rheumatoid arthritis

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Barbara Janina Maria BERGMANS

B / 20 / 16

Poster P3750

Abstract 2406

Burden of herpes zoster in adults aged ≥18 years and patients with immunodeficiencies, autoimmune diseases, and chronic conditions in Taiwan: A population-based database study

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Jing CHEN

B / 20 / 17

Poster P3751

Abstract 2812

Discontinuation of fluoroquinolone prophylaxis for neutropenia after bone marrow transplantation in a setting with high prevalence of multidrug-resistant pathogens

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Valeria CASTELLI

B / 20 / 18

Poster P3752

Abstract 2813

Seven versus 14 days of antibiotic treatment for acute pyelonephritis (APN) in kidney transplant recipients: a cohort study (SHOUT study)

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Chiara FANELLI

A / 21 / 1

Poster P3753

Abstract 2839

Exploring the utility of unsupervised machine learning for bacteraemia forecasting in neutropenic fever patients with haematological malignancies: a pilot study

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Antonio GALLARDO-PIZARRO

A / 21 / 3

Poster P3755

Abstract 3084

Adult-onset immunodeficiency due to neutralizing anti-(IFN)-γ autoantibodies: a syndrome that extends beyond opportunistic intracellular infections

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Wan-Ting TSAI

A / 21 / 4

Poster P3756

Abstract 3090

Incidence and progression of granulomatous lesions following Bacillus Calmette-Guérin immunotherapy

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Maristela P FREIRE

A / 21 / 5

Poster P3757

Abstract 3242

Clinical characteristics, outcomes and causative organism distribution of respiratory infection of second lung transplantation

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Min HAN

A / 21 / 6

Poster P3758

Abstract 3360

Transplant-related risk factors for the development of retinitis due to cytomegalovirus in allogeneic stem cell transplant recipients: an international case-control study

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Romain GUENEAU

A / 21 / 7

Poster P3759

Abstract 3442

Epidemiology and clinical outcome of paediatric liver transplant recipients with multidrug-resistant gram-negative bacteria colonization: a 10-year observational study

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Andrea CONA

A / 21 / 8

Poster P3760

Abstract 3574

Changing seroprevalence of viral diseases among young adults in Izmir

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Oguzhan ACET

A / 21 / 10

Poster P3762

Abstract 3925

Risk of serious infections in patients treated with biological disease modifying anti-rheumatoid drugs (b-DMARDs) in Qatar

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Sreethish SASI

A / 21 / 11

Poster P3763

Abstract 4078

Toward improved monitoring the cellular immune response against cytomegalovirus in transplants recipients: comparative analysis of ELISA-QuantiFERON-CMV and CLIA-LIAISON-QuantiFERON-TB Gold Plus

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Maria ARNEDO MUÑOZ

A / 21 / 12

Poster P3764

Abstract 4130

Previous infection with resistant organisms may not predispose to surgical site infection following liver transplantation: a retrospective cohort study

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Sarah SHALHOUB

A / 21 / 13

Poster P3765

Abstract 4191

A robust SARS-CoV-2-specific T and B cell response is associated with early viral clearance in SARS-CoV-2 Omicron infected immunocompromised individuals

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Magda VERGOUWE

A / 21 / 14

Poster P3766

Abstract 4288

Pre-emptive management of Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disorders after paediatric kidney transplantation

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Maia DE LUCA

A / 21 / 15

Poster P3767

Abstract 4489

Uptake and yield of immunological investigation in patients with invasive infections with encapsulated bacteria: high yield and missed opportunities

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Maria Concepcion GIL MERINO

A / 21 / 16

Poster P3768

Abstract 4556

Secondary anti-viral prophylaxis in solid organ transplant recipients for the prevention of CMV relapse: a systematic review and meta-analysis

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

David MOYNAN

A / 21 / 17

Poster P3769

Abstract 4708

Strongyloides stercoralis westernblot for serologic screening of solid organ transplant candidates

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Alexander OBERLI

A / 21 / 18

Poster P3770

Abstract 4711

Infectious risk stratification expands the solid organ donors pool: activity of the Italian national transplant centre in 2022-2023

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Elena GRAZIANO

B / 21 / 1

Poster P3771

Abstract 4716

Herpes simplex virus prophylaxis in adult patients undergoing haematopoietic stem cell transplantation

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Atheer ALDAIREM

B / 21 / 2

Poster P3772

Abstract 4807

Pseudomonas aeruginosa bloodstream infections presenting with septic shock in neutropenic cancer patients

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Cristina ROYO-CEBRECOS

B / 21 / 3

Poster P3773

Abstract 4898

Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in hematologic patients: a randomised, multicentre, open-label, superiority clinical trial (BEATLE)

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Julia LAPORTE-AMARGOS

B / 21 / 4

Poster P3774

Abstract 4955

Tobramycin systemic absorption in lung transplant recipients treated with inhaled tobramycin: a cohort study

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Abiu SEMPERE

B / 21 / 5

Poster P3775

Abstract 4997

Real-world utilisation of maribavir for cytomegalovirus infection in transplant recipients

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Kassandra MARSH

B / 21 / 6

Poster P3776

Abstract 5025

Real-world single centre analysis of virological response to third-party CMV-specific T cell lymphocyte (CTL) for refractory CMV infection following allogeneic haematopoietic cell therapy (HCT)

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Michelle YONG

B / 21 / 7

Poster P3777

Abstract 5069

Infection risk in relapsed refractory multiple myeloma: The impact of BCMA-targeted bispecific antibody therapy

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Jessica LITTLE

B / 21 / 8

Poster P3778

Abstract 5147

Therapeutic drug monitoring of piperacillin in patients with neutropenic fever after allogeneic hematopoietic stem cell transplantation

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Güzin SURAT

B / 21 / 9

Poster P3779

Abstract 5344

Early viral suppression less likely among solid organ transplant recipients with drug-resistant cytomegalovirus infection

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Aaron HUNT

B / 21 / 10

Poster P3780

Abstract 5535

Pneumonia and bloodstream infections during intensive care unit stay after heart transplant

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Silvia RODA

B / 21 / 11

Poster P3781

Abstract 5681

Filmarray pneumonia panel plus vs standard culture in lung transplant recipients: preliminary results of the PNEUMOARRAY STUDY

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Giulia RENISI

B / 21 / 12

Poster P3782

Abstract 5755

Ribavirin treatment for respiratory syncytial virus infection in patients with haematologic malignancy and haematopoietic stem cell transplant: single center experience

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Alessandra RICCIARDI

B / 21 / 13

Poster P3783

Abstract 5878

Human herpesvirus 8 infection in solid organ transplant recipients: results of the implementation of a protocol for risk stratification and early treatment of HHV8-related disease

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Andrea CONA

B / 21 / 14

Poster P3784

Abstract 6042

Multiparameter mass spectrometry deciphers specific circulating natural killer T cell subsets protecting kidney transplant patients from CMV infection

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Laura DONADEU

B / 21 / 15

Poster P3785

Abstract 6109

Colonisation resistance to carbapenem-resistant Pseudomonas aeruginosa in acute myeloid leukemia patients in induction, consolidation, and relapse/refractory phases

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Xiaomeng FENG

B / 21 / 16

Poster P3786

Abstract 6552

Incidence of infections in patients with acute myeloid leukemia during remission induction chemotherapy: a monocentric retrospective analysis of 78 patients

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Sabine EHRLICH

B / 21 / 17

Poster P3787

Abstract 6639

Risk factors and clinical characteristics of CMV reactivation in allogeneic hematopoietic stem cell transplant recipients

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Siwar FRIGUI

B / 21 / 18

Poster P3788

Abstract 6677

Ceftazidime/avibactam for the treatment of bloodstream infection due to carbapenem-resistant Enterobacterales in onco-hematologic neutropenic patients: A real-life experience (TARZAN study)

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Enric SASTRE-ESCOLÀ

A / 22 / 1

Poster P3789

Abstract 6744

Going with the STREAM: a quality improvement intervention in solid organ transplantation

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Alessandro VISENTIN

A / 22 / 2

Poster P3790

Abstract 6950

High incidence of breakthrough viremia in lung transplant recipients despite valganciclovir prophylaxis: a retrospective analysis

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Ester MÁRQUEZ ALGABA

A / 22 / 3

Poster P3791

Abstract 7414

Efficacy of oral fosfomycin trometamol as empirical therapy for acute cystitis in kidney transplant recipients: an open-label randomised controlled trial

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Pongsathorn SAENKOTARA

A / 22 / 4

Poster P3792

Abstract 7612

Cytomegalovirus disease in children after allogeneic hematopoietic stem cell transplantation

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Siwar FRIGUI

A / 22 / 5

Poster P3793

Abstract 7709

Exploring the impact of a targeted antibiotic prophylaxis in orthotopic liver transplant recipients colonised by carbapenem-resistant Enterobacterales: a multicentre retrospective study

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Beatrice MIANI

A / 22 / 6

Poster P3794

Abstract 7859

Higher bacterial profile and antibiotic resistance pattern of sepsis among adult Human Immunodeficiency Virus (HIV) – infected patients assessing care in a Nigerian tertiary hospital

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Chukwudi UMENZEKWE

A / 22 / 7

Poster P3795

Abstract 7949

Hospitalisation status at the time of organ acceptance and its impact to bloodstream infections

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Jacques SIMKINS

A / 22 / 8

Poster P3796

Abstract 8130

Should the QuantiFERON-CMV cut-off point be modified in order to predict risk of CMV replication in solid organ transplant recipients? QuantiCor-CMV study

27/04 12:00

10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections)

Elisa RUIZ ARABÍ

A / 22 / 9

Poster P3797

Abstract 481

Driving uptake of missed routine vaccines in adult migrants to Europe: a prospective observational pilot study in primary care

27/04 12:00

10c. General vaccinology (incl.in vitro and in vivo studies, policy, social aspects)

Sally HARGREAVES

A / 22 / 10

Poster P3798

Abstract 860

Defining the role of primary care in hepatitis B elimination in the UK

27/04 12:00

10c. General vaccinology (incl.in vitro and in vivo studies, policy, social aspects)

Jessica CARTER

A / 22 / 11

Poster P3799

Abstract 1059

Lessons learned from national COVID-19 testing strategies in Germany: a qualitative study of key stakeholder perspectives

27/04 12:00

10c. General vaccinology (incl.in vitro and in vivo studies, policy, social aspects)

Katarzyna SKIPIOL

A / 22 / 12

Poster P3800

Abstract 1131

Vaccination coverage and barriers and facilitators to vaccine uptake amongst migrant populations in the Middle East and North Africa: a systematic review and qualitative study

27/04 12:00

10c. General vaccinology (incl.in vitro and in vivo studies, policy, social aspects)

Bouaddi OUMNIA

A / 22 / 14

Poster P3802

Abstract 1475

Impact of vaccine tolerability on shingles vaccine decision-making

27/04 12:00

10c. General vaccinology (incl.in vitro and in vivo studies, policy, social aspects)

Guy DE LA ROSA

A / 22 / 15

Poster P3803

Abstract 4200

Antibody response and decay following COVID-19 inactivated vaccine in adults and its influencing factors

27/04 12:00

10c. General vaccinology (incl.in vitro and in vivo studies, policy, social aspects)

Song JIEYU

A / 22 / 16

Poster P3804

Abstract 5467

Assessing vaccine recommendations and attitudes towards vaccination among people living with HIV

27/04 12:00

10c. General vaccinology (incl.in vitro and in vivo studies, policy, social aspects)

Oguzhan ACET

A / 22 / 17

Poster P3805

Abstract 6588

Barriers and facilitators for receiving mpox vaccines among men who have sex with men: a mixed-methods study

27/04 12:00

10c. General vaccinology (incl.in vitro and in vivo studies, policy, social aspects)

Tsz Ho KWAN

A / 22 / 18

Poster P3806

Abstract 6980

Older adult and physician preferences for respiratory syncytial virus vaccination in Germany and Italy: a discrete choice experiment

27/04 12:00

10c. General vaccinology (incl.in vitro and in vivo studies, policy, social aspects)

Alen MARIJAM

A / 22 / 19

Poster P3807

Abstract 6982

Myths and misinformation associated with vaccine incompleteness: a survey study

27/04 12:00

10c. General vaccinology (incl.in vitro and in vivo studies, policy, social aspects)

Lucas KALLÁS SILVA

A / 22 / 20

Poster P3808

Abstract 7581

What is the number of missed opportunities for pneumococcal vaccination among at-risk adults in France?

27/04 12:00

10c. General vaccinology (incl.in vitro and in vivo studies, policy, social aspects)

Elisabeth BOTELHO-NEVERS

A / 22 / 21

Poster P3809

Abstract 8512

Investigating vaccine coverage in Timor-Leste in a population-representative serological survey

27/04 12:00

10c. General vaccinology (incl.in vitro and in vivo studies, policy, social aspects)

Paul ARKELL

A / 22 / 22

Poster P3810

Abstract 8663

Maximizing LGBTQ+ vaccination adherence: counseling impact in the mpox epidemic

27/04 12:00

10c. General vaccinology (incl.in vitro and in vivo studies, policy, social aspects)

Francesca STELLA

A / 22 / 23

Poster P3811

Abstract 1198

Patient preferences towards herpes zoster vaccination among adults aged 50 to 64 years in Australia: findings from a discrete choice experiment

27/04 12:00

10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses and COVID-19)

Raunak PARIKH

A / 22 / 24

Poster P3812

Abstract 2983

Can receipt of the HPV vaccine increase recommendation for HPV vaccine?

27/04 12:00

10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses and COVID-19)

Ana Karina MASCARENHAS

A / 22 / 25

Poster P3813

Abstract 3643

Mice mucosal immunisation with vaccine vector Streptococcus gordonii expressing the RBD of SARS-CoV-2 spike protein elicits antigen-specific systemic immune response with persistent long-lived plasma cells

27/04 12:00

10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses and COVID-19)

Mariana TIRZIU

A / 22 / 26

Poster P3814

Abstract 4748

Measles vaccine RNA shedding in children after receiving measles, mumps and rubella vaccination

27/04 12:00

10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses and COVID-19)

Huanyu WANG

A / 22 / 27

Poster P3815

Abstract 4818

BNT162b2 vaccine is well tolerated and efficient in children with acute leukemia

27/04 12:00

10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses and COVID-19)

Fanny ALBY-LAURENT

A / 22 / 28

Poster P3816

Abstract 4994

Safety and immunogenicity of fractional doses of modified vaccinia Ankara-Bavarian nordic

27/04 12:00

10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses and COVID-19)

Sharon FREY

B / 22 / 1

Poster P3817

Abstract 5362

The willingness of physicians and nurses to receive mpox vaccine at a tertiary-care educational university hospital: a cross-sectional study

27/04 12:00

10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses and COVID-19)

Oguz Resat SIPAHI

B / 22 / 2

Poster P3818

Abstract 5774

Long-term immunity of yellow fever vaccination: a systematic review and meta-analysis

27/04 12:00

10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses and COVID-19)

Jenny Lea SCHNYDER

B / 22 / 3

Poster P3819

Abstract 5938

Knowledge and attitudes regarding human papillomavirus (HPV) infection and vaccine among university students: a cross-sectional study

27/04 12:00

10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses and COVID-19)

Christelle ELIAS

B / 22 / 4

Poster P3820

Abstract 6174

Assessment of retrospective measles serology based on routine vaccination and natural immunity status: is vaccination insufficient?

27/04 12:00

10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses and COVID-19)

Ali Gökhan AKÇAY

B / 22 / 5

Poster P3821

Abstract 6563

Cost-effectiveness of the herpes zoster vaccine in Korea

27/04 12:00

10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses and COVID-19)

Won Suk CHOI

B / 22 / 6

Poster P3822

Abstract 6690

Development of a high-throughput screening pipeline to identify candidate antivirals against mpox virus

27/04 12:00

10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses and COVID-19)

Winston CHIU

B / 22 / 7

Poster P3823

Abstract 7003

Subcutaneous versus intradermal routes of administration of MVA-BN vaccine

27/04 12:00

10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses and COVID-19)

Valentina MAZZOTTA

B / 22 / 8

Poster P3824

Abstract 7142

Assessment of post-vaccination specific T-cell responses to varicella zoster virus glycoprotein E in people with multiple sclerosis receiving disease-modifying therapies

27/04 12:00

10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses and COVID-19)

Marco IANNETTA

B / 22 / 9

Poster P3825

Abstract 7321

Development of bipolymer-based novel nanoparticles in microsphere system as vaccine adjuvant

27/04 12:00

10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses and COVID-19)

Varun BHARGAVA

B / 22 / 10

Poster P3826

Abstract 750

S. pneumoniae serotypes causing invasive pneumococcal disease after the introduction of the 13-valent pneumococcal conjugate vaccine in Navarra, Spain

27/04 12:00

10e. Antibacterial vaccines

Irati ARREGUI GARCIA

B / 22 / 11

Poster P3827

Abstract 892

Sequential versus simultaneous pneumococcal vaccination with the 13-valent conjugate vaccine (PCV13) and the 23-valent polysaccharide vaccine (PPSV23) in unvaccinated older adults: a randomised controlled trial on serotype-specific memory B-cell and humoral immune response

27/04 12:00

10e. Antibacterial vaccines

Christina BAHRS

B / 22 / 12

Poster P3828

Abstract 1095

A novel recombinant adenovirus-based vector vaccine for plague tested in a Phase 1b trial in Uganda, appears safe and immunogenic

27/04 12:00

10e. Antibacterial vaccines

Arabella S V STUART

B / 22 / 13

Poster P3829

Abstract 1582

Evaluation of antibody response before and after meningococcal vaccine and determination meningococcal carriage rates

27/04 12:00

10e. Antibacterial vaccines

Dilsah BASKOL ELIK

B / 22 / 14

Poster P3830

Abstract 2319

Exploring the pre- and post-functional immune response of 23-valent pneumococcal polysaccharide vaccine in Indian Adults

27/04 12:00

10e. Antibacterial vaccines

Sravani DHARMAVARAM

B / 22 / 15

Poster P3831

Abstract 2769

A bacterial vaccine composition against recurrent urinary tract infections stimulates the innate immune system

27/04 12:00

10e. Antibacterial vaccines

Roland NAU

B / 22 / 16

Poster P3832

Abstract 2784

Estimating the health and economic burden of pneumococcal diseases attributable to V116 Vs. PCV20 serotypes among adults in the Netherlands

27/04 12:00

10e. Antibacterial vaccines

Zinan YI

B / 22 / 17

Poster P3833

Abstract 2843

Estimating the health and economic burden of pneumococcal diseases attributable to V116 vs PCV20 serotypes among adults in Sweden

27/04 12:00

10e. Antibacterial vaccines

Zinan YI

B / 22 / 18

Poster P3834

Abstract 2949

Serotype distribution of invasive disease-causing Streptococcus pneumoniae after 13 years of systematic vaccination

27/04 12:00

10e. Antibacterial vaccines

Pedro Miguel JUIZ GONZÁLEZ

B / 22 / 19

Poster P3835

Abstract 3010

A multi-epitope protein composed of PcrV and OmpE virulence factors from Pseudomonas aeruginosa induces protective immunity against respiratory tract infection

27/04 12:00

10e. Antibacterial vaccines

Mohammadreza ASADIKARAM

B / 22 / 20

Poster P3836

Abstract 4457

Low pneumococcal vaccination coverage in France: would a vaccination in the 65+ would help identifying at-risk population?

27/04 12:00

10e. Antibacterial vaccines

Benjamin WYPLOSZ

B / 22 / 21

Poster P3837

Abstract 5358

Safety and immunogenicity of Vi-diphtheria toxoid typhoid conjugate vaccine among children below two years: a systematic review and meta-analysis

27/04 12:00

10e. Antibacterial vaccines

Alfonso J. RODRIGUEZ-MORALES

B / 22 / 22

Poster P3838

Abstract 5482

In vivo evaluation of a novel multiepitope vaccine against uropathogenic Escherichia coli

27/04 12:00

10e. Antibacterial vaccines

Maryam REZAEI

B / 22 / 23

Poster P3839

Abstract 5630

Using immunobioinformatic tools to design a multiepitope subunit vaccine against Klebsiella pneumoniae

27/04 12:00

10e. Antibacterial vaccines

Zeinab ABBASNEZHAD FARSANGI

B / 22 / 24

Poster P3840

Abstract 5671

Aetiology of acute otitis media in children: impact of vaccination and SARS-CoV-2 pandemic

27/04 12:00

10e. Antibacterial vaccines

Lucia FERNANDEZ DELGADO

B / 22 / 25

Poster P3841

Abstract 5749

Updating anti-pneumococcal vaccination coverages among adults in Catalonia before COVID19 pandemic era

27/04 12:00

10e. Antibacterial vaccines

Cinta DE DIEGO-CABANES

B / 22 / 26

Poster P3842

Abstract 5985

Deep intraclonal analysis for development of multivalent vaccines against drug resistant Klebsiella pneumoniae lineages

27/04 12:00

10e. Antibacterial vaccines

Ana TAJUELO MORENO-PALANCAS

B / 22 / 27

Poster P3843

Abstract 6847

Invasive pneumococcal disease in adults after the introduction of pneumococcal vaccination: a retrospective study in the metropolitan area of Zagreb, Croatia (2010–2022)

27/04 12:00

10e. Antibacterial vaccines

Karla DRAZENOVIC

B / 22 / 28

Poster P3844

Abstract 6927

One- or Two-dose of 13-valent conjugated pneumococcal vaccine (PCV13) for patients with multiple myeloma (MM)

27/04 12:00

10e. Antibacterial vaccines

Hsin-Yun SUN

A / 23 / 1

Poster P3845

Abstract 7068

Effect of introduction of MenACWY vaccination on circulating Neisseria meningitidis carriage strains in the Netherlands

27/04 12:00

10e. Antibacterial vaccines

Rob MARIMAN

A / 23 / 2

Poster P3846

Abstract 7215

Breakthrough rectal gonorrhoea after meningococcus B vaccination: microbiologic and clinical characteristics

27/04 12:00

10e. Antibacterial vaccines

Angelo Roberto RACCAGNI

A / 23 / 4

Poster P3848

Abstract 8236

Did you get your shot? A prospective study on recommended vaccination coverage in older adults in Greece

27/04 12:00

10e. Antibacterial vaccines

Evdoxia DOUMOULIAKA

A / 23 / 5

Poster P3849

Abstract 424

Highly-neutralising anti-PcrV antibodies as clinical candidates against Pseudomonas aeruginosa

27/04 12:00

10f. Other preventive modalities (incl new vaccine technologies, antibody-based treatments)

Jan RYBNIKER

A / 23 / 6

Poster P3850

Abstract 2075

Immune effects of membrane vesicle on elimination of pneumococcal colonisation in the nasopharynx

27/04 12:00

10f. Other preventive modalities (incl new vaccine technologies, antibody-based treatments)

Soichiro KIMURA

A / 23 / 7

Poster P3851

Abstract 3938

Repurposing daratumumab for patients with anti-interferon-gamma autoantibodies: a case series.

27/04 12:00

10f. Other preventive modalities (incl new vaccine technologies, antibody-based treatments)

Tsai MING-TAO

A / 23 / 8

Poster P3852

Abstract 4704

The safety and efficacy of guluronic acid (G2013) in ankylosin spondylitis: a randomised controlled parallel clinical trial

27/04 12:00

10f. Other preventive modalities (incl new vaccine technologies, antibody-based treatments)

Sepideh NAZERI

A / 23 / 9

Poster P3853

Abstract 5490

A novel physical inactivation method based on high hydrostatic pressure for the production of whole inactivated virus vaccines

27/04 12:00

10f. Other preventive modalities (incl new vaccine technologies, antibody-based treatments)

Martina BRANDOLINI

A / 23 / 10

Poster P3854

Abstract 6156

Development of a plasmidic DNA vaccine platform: from in silico design to in vivo testing

27/04 12:00

10f. Other preventive modalities (incl new vaccine technologies, antibody-based treatments)

Sonia PRIETO MARTIN GIL

A / 23 / 11

Poster P3855

Abstract 6489

Development of a novel chikungunya self-amplifying RNA vaccine platform

27/04 12:00

10f. Other preventive modalities (incl new vaccine technologies, antibody-based treatments)

Krunal POLRA

A / 23 / 12

Poster P3856

Abstract 7391

Murine monoclonal antibodies against secreted Staphylococcus aureus prothrombin-activating virulence factors induce macrophage opsonophagocytosis

27/04 12:00

10f. Other preventive modalities (incl new vaccine technologies, antibody-based treatments)

Ting WONG

A / 23 / 13

Poster P3857

Abstract 8250

Intravenous immunoglobulins (IVIG) inhibit Streptococcus pneumoniae-induced macrophage activation and death in vitro, but lack beneficial effects in a mouse meningitis model in vivo

27/04 12:00

10f. Other preventive modalities (incl new vaccine technologies, antibody-based treatments)

Susanne DYCKHOFF-SHEN

A / 23 / 14

Poster P3858

Abstract 8501

Opsonic IgG2a and IgG2b monoclonal antibodies targeting HSP16.3 and peptidoglycan cell wall components recognise and effectively bind to clinical strains of Mycobacterium tuberculosis

27/04 12:00

10f. Other preventive modalities (incl new vaccine technologies, antibody-based treatments)

Bong-Akee SHEY

A / 23 / 15

Poster P3859

Abstract 8809

In vitro models to assess auto-Abs neutralizing the protective effect of type I IFNs against WNV infection

27/04 12:00

10f. Other preventive modalities (incl new vaccine technologies, antibody-based treatments)

Alessandro FERRARI

A / 23 / 16

Poster P3860

Abstract 122

Different cytokines responses after treatment with benzathine penicillin in patients with syphilis primary infection or reinfection

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Hung-Chin TSAI

A / 23 / 17

Poster P3861

Abstract 157

Biological effect of cell-free DNA extracted from septic mice in vitro, in vivo and its mechanism

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Hyungdon LEE

A / 23 / 18

Poster P3862

Abstract 861

Host-pathogen interactions: Galleria mellonella-Candida albicans infection model to study the virulence and efficacy of antifungal drugs

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Margy Alejandra ESPARZA MORA

A / 23 / 19

Poster P3863

Abstract 1020

Distinct clinical characteristics and cerebrospinal fluid tissue-based assay staining pattern between infectious and autoimmune encephalitis: IMPROVE trial study (2022-01)

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Ke LIN

A / 23 / 20

Poster P3864

Abstract 1104

Evaluation of the local and the peripheral immune response in patients with cystic echinococcosis

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Linda PETRONE

A / 23 / 21

Poster P3865

Abstract 1129

The impact of interferon lambda polymorphisms on influenza vaccine responses in treated HIV

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Rachel MAC CANN

A / 23 / 22

Poster P3866

Abstract 1158

Pgm-1 contributed to macrophage function in murine pneumococcal meningitis

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Rutger KONING

A / 23 / 23

Poster P3867

Abstract 1206

AIM impact on immune checkpoints in Mycobacterium avium infection

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Chiaki KAJIWARA

A / 23 / 24

Poster P3868

Abstract 1445

Accuracy of a host response test for diagnosis of bacterial and viral infections and prediction of illness severity

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Oliver LIESENFELD

A / 23 / 25

Poster P3869

Abstract 1700

Decreased intracellular killing of Escherichia coli by blood phagocytes from Clostridioides difficile-infected patients

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Roland NAU

A / 23 / 27

Poster P3871

Abstract 1956

CRP velocity as a biomarker for bacterial virulence

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Tal LEVINSON

A / 23 / 28

Poster P3872

Abstract 2178

Influence of parasitic infections on clinical outcomes in patients with tuberculosis and their contacts

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Augstine YEBOAH

B / 23 / 1

Poster P3873

Abstract 2433

Investigation of baseline functional antibody immune response to 23 pneumococcal vaccine serotypes in Indian healthy Naïve adults

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Sravani DHARMAVARAM

B / 23 / 3

Poster P3875

Abstract 2867

Immune checkpoint inhibitor therapy restores neutrophil response against Candida albicans in patients with malignancy

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Anna APOSTOLOPOULOU

B / 23 / 4

Poster P3876

Abstract 2917

Study of the lung protective immunomodulation induced by Streptococcus mitis in pulmonary colonised mice

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Clément LEMAIGRE

B / 23 / 5

Poster P3877

Abstract 2944

Potential of a host-response diagnostic test for differentiating bacterial from viral infections to improve the lower respiratory tract infections care pathway in the NHS: a qualitative evaluation.

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Sara GRAZIADIO

B / 23 / 6

Poster P3878

Abstract 2974

Interferon-gamma responses to Chlamydia trachomatis vaccine candidate antigens and relation to infection outcomes in women

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

William GEISLER

B / 23 / 7

Poster P3879

Abstract 3141

Establishment of flow cytometry-based opsonophagocytosis assay: an efficient platform for assessing of functional antibodies against Streptococcus pneumoniae

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Sravani DHARMAVARAM

B / 23 / 8

Poster P3880

Abstract 3167

Estradiol and progesterone modulate expression of Toll-like receptors(TLRs) in peripheral blood cells infected by HIV-1 subtypes G and A

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Marina NOSIK

B / 23 / 9

Poster P3881

Abstract 3228

UL44 protein as a potential candidate for a vaccine against Cytomegalovirus

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Carmen SERRANO RÍSQUEZ

B / 23 / 10

Poster P3882

Abstract 3599

High mortality of Acinetobacter baumannii infection is attributed to macrophage-mediated induction of cytokine storm but preventable by naproxen

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Han WANG

B / 23 / 11

Poster P3883

Abstract 3808

Differential host immune response during malarial and bacterial acute febrile illness: circulating inflammatory markers and extracellular vesicles

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Natalia TIBERTI

B / 23 / 12

Poster P3884

Abstract 4151

Immunomodulatory activity of omadacycline in vitro and in a murine model of acute lung injury (ALI)

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Madeline SANDERS

B / 23 / 15

Poster P3887

Abstract 5386

Zebrafish as a model for Staphylococcus aureus infection treatment and immune response

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Cecilia VOLK

B / 23 / 16

Poster P3888

Abstract 5468

A potential biomarker in symptomatic West-Nile virus (WNV) infections: monocyte CD169 (mCD169) expression in peripheral blood

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Massimo CRAPIS

B / 23 / 17

Poster P3889

Abstract 5944

Cysteamine as a host-directed therapy for tuberculosis: first in vitro assessment of the immunomodulatory effects

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Saeid NAJAFI-FARD

B / 23 / 18

Poster P3890

Abstract 6318

The tricarboxylic acid cycle regulates fibroblast-driven tissue remodelling during Mycobacterium tuberculosis infection

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Ramla CUSMAN

B / 23 / 19

Poster P3891

Abstract 6393

Cytokine Patterns in 250 Patients with Alveolar Echinococcosis

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Lynn PETERS

B / 23 / 20

Poster P3892

Abstract 6984

Real-world Impact of MeMed BV, a rapid host response test for distinguishing bacterial and viral infections, in an urgent care network

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Shirley SHAPIRO BEN DAVID

B / 23 / 21

Poster P3893

Abstract 7116

Role of cmv-IL-10 in a HCMV-Aspergillus-Co-infection model

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Lydia BUSSEMER

B / 23 / 22

Poster P3894

Abstract 8390

Adverse events following immunization with fractional one-fifth and one-half doses of yellow fever vaccine compared to full dose in children 9–23 months old in Uganda — preliminary report

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Ellon TWINOMUHWEZI

B / 23 / 23

Poster P3895

Abstract 8684

SeptiCyte rapid, a new biomarker for the diagnosis of ventilator-associated pneumonia in polytrauma patients

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Lisa NEUTRE

B / 23 / 24

Poster P3896

Abstract 8737

Varicella zoster virus antibody titer is not a good marker of the clinical protection driven by chickenpox vaccine

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Lorena FORQUÉ RODRIGUEZZ

B / 23 / 25

Poster P3897

Abstract 8866

Implications of ageing on cancer immunotherapy treatment using mycobacteria

27/04 12:00

10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers)

Paula HERRERO-ABADÍA

A / 1 / 1

Poster P0604

Abstract 71

Tuberculosis severity predictive model using Mtb variants and serum biomarkers in a Colombian cohort of APTB patients

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Andres BAENA

A / 1 / 2

Poster P0605

Abstract 87

Cerebrospinal fluid adenosine deaminase levels are non-discriminatory for the diagnosis of tuberculous meningitis in moderate TB incidence Singapore

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Jinghao Nicholas NGIAM

A / 1 / 3

Poster P0606

Abstract 103

Phylogenomics of Mycobacterium avium complex from clinical respiratory samples

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Ka Lip CHEW

A / 1 / 4

Poster P0607

Abstract 164

Treatment success rate of nontuberculous mycobacteria was low in Arkhangelsk region of Russia in 2010-2020

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Platon ELISEEV

A / 1 / 5

Poster P0608

Abstract 167

An easy and rapid method for differentiating Mycobacterium ulcerans from M. marinum based on lipid spectra

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Komine TAKESHI

A / 1 / 6

Poster P0609

Abstract 304

Omadacycline alone and in combination as a treatment option for Mycobacterium avium infections

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Saskia Emily MUDDE

A / 1 / 7

Poster P0610

Abstract 605

Multicentre in vitro susceptibility of nontuberculous mycobacteria to apramycin and amikacin: comparing MIC distributions and tentative epidemiological cutoffs

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Nguyen MINH-VU

A / 1 / 8

Poster P0611

Abstract 609

Increased risk of all cause-mortality in active tuberculosis patients attributed to SARS-CoV-2 infection: time-dependent survival analysis in Chile

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Salvador VARGAS GARCIA

A / 1 / 9

Poster P0612

Abstract 663

Biofilm prevention concentration of clarithromycin against clinically relevant species of nontuberculous mycobacteria

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Abrar SENHAJI

A / 1 / 10

Poster P0613

Abstract 762

Transmission dynamics and genotypic diversity of Mycobacterium tuberculosis in Colombian persons deprived of liberty

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Ashley HEILMANN

A / 1 / 11

Poster P0614

Abstract 770

Mycobacterium abscessus infection in children: a six year study in Singapore

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Chia Yin CHONG

A / 1 / 12

Poster P0615

Abstract 788

Extrapulmonary nontuberculous mycobacteria infections: a ten-year review in a tertiary care hospital in Belgium

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Larranaga Lapique EVA

A / 1 / 13

Poster P0616

Abstract 1058

Video-observed therapy (VOT) vs directly observed therapy (DOT) for tuberculosis treatment: a systematic review on adherence, cost of treatment, time spent observing treatment and patient satisfaction

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Thiago NETTO

A / 1 / 14

Poster P0617

Abstract 1189

The discordant diagnostic dilemma: analysis of the anyplex II MTB/MDR and BACTEC MGIT 960 system to assess the susceptibility of Mycobacterium tuberculosis from clinical specimens

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Kanphai WONGJARIT

A / 1 / 15

Poster P0618

Abstract 1199

Risk of tuberculosis among recent arrived minor migrants: A nationwide cohort study

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Kristina Langholz KRISTENSEN

A / 1 / 17

Poster P0620

Abstract 1483

Occurrence of mutations associated with rifampicin and isoniazid resistant in Mycobacterium tuberculosis isolates from patients in Kaduna state Nigeria

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Kasimu MAMUDA

A / 1 / 19

Poster P0622

Abstract 1508

Doxycycline normalises vasculatures to enhance TB drug delivery in CNS-tuberculosis

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Fei Kean LOH

A / 1 / 20

Poster P0623

Abstract 1684

Effect of aminoglycoside-induced ototoxicity on NTM guideline-based therapy (NTM-AGOTO) (ESGMYC)

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Francis DROBNIEWSKI

A / 1 / 21

Poster P0624

Abstract 1851

Optimizing the preparation of non-tuberculous mycobacterial (NTM) isolates for MALDI-TOF (VITEK) MS identification and speciation

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Kruthi MALUR

A / 1 / 22

Poster P0625

Abstract 1968

Contezolid demonstrated equivalent efficacy to linezolid in tuberculosis treatment in an early bactericidal activity study

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Mengqiu GAO

A / 1 / 23

Poster P0626

Abstract 1970

Rifampicin resistant Mycobacterium tuberculosis complex strains with rpoB I491F mutation missed by GenoType MTBDRplus in Mozambique

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Stefan NIEMANN

A / 1 / 24

Poster P0627

Abstract 2041

Contribution of commercial test in the diagnosis of extra-pulmonary tuberculosis: first experience in Algeria

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Ali ZEROUKI

B / 1 / 1

Poster P0628

Abstract 2131

Bedaquiline and clofazimine synergy against Mycobacterium abscessus clinical strains

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Priya SOLANKI

B / 1 / 2

Poster P0629

Abstract 2255

Occupational latent tuberculosis infection among healthcare workers in Vietnam: prevalence and risk factors

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Van NGUYEN

B / 1 / 4

Poster P0631

Abstract 2509

A dose escalation study to evaluate the safety of aerosol BCG infection in previously BCG-vaccinated UK adults

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Timothy FREDSGAARD-JONES

B / 1 / 5

Poster P0632

Abstract 2692

Targeted pan-mycobacterial PCR increases diagnostic yield compared to 16S rRNA gene PCR and culture alone

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Laura ATKINSON

B / 1 / 6

Poster P0633

Abstract 2698

Clinical and genomic features of M. avium complex: a multi-national European study

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Nils WETZSTEIN

B / 1 / 7

Poster P0634

Abstract 2795

Occurrence of nontuberculous mycobacteria in households and urbanised environments

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Paulina WÓJTOWICZ

B / 1 / 8

Poster P0635

Abstract 2814

Evaluation of the NTM Elite agar for cultivation of nontuberculous mycobacteria from different types of environmental samples

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Paulina WÓJTOWICZ

B / 1 / 9

Poster P0636

Abstract 2825

Blood-based mRNA test for tuberculosis shows promising diagnostic accuracy

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Seda YERLIKAYA

B / 1 / 10

Poster P0637

Abstract 2830

C-terminal region of Rv1039c (PPE15) of Mycobacterium tuberculosis induces mitochondria mediated macrophage apoptosis

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

PRIYANKA

B / 1 / 12

Poster P0639

Abstract 2977

Evaluation of an automated molecular assay for the detection of Mycobacterium tuberculosis in cerebrospinal fluid (CSF)

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Marthe CHARLES

B / 1 / 13

Poster P0640

Abstract 3042

Detection of T-cell responses in tuberculosis patients using a new prototype interferon-gamma release assay

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Irene LATORRE

B / 1 / 14

Poster P0641

Abstract 3053

Development of a multiplex droplet digital PCR method for detection and monitoring of Mycobacterium tuberculosis and drug-resistant tuberculosis

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Yu Jeong CHOI

B / 1 / 15

Poster P0642

Abstract 3083

Modern Mycobacterium tuberculosis lineages are driving cross-border transmission of multidrug-resistant tuberculosis

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Pedro GOMES

B / 1 / 16

Poster P0643

Abstract 3087

Clinical characteristic and mortality of tuberculosis in adult people living with HIV/AIDS: a single centre retrospective cohort study in Thailand

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Hariwong CHAICHAROEN

B / 1 / 17

Poster P0644

Abstract 3105

Mycobacterium smegmatis: a case series and review of antimicrobial susceptibility patterns

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Patrick CROWLEY

B / 1 / 18

Poster P0645

Abstract 3195

The challenge of tuberculosis diagnosis in malnourished children: employing clinical scores in Tosamaganga Hospital, Tanzania

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Anna Hermine MARKOWICH

B / 1 / 19

Poster P0646

Abstract 3342

Solving the gap between molecular and genomic epidemiology in tuberculosis: inferring MIRU-VNTR patterns from genomic data

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Sergio BUENESTADO-SERRANO

B / 1 / 20

Poster P0647

Abstract 3374

In vitro evaluation of inhaled pentamidine for the treatment of pulmonary M. tuberculosis H37Rv

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Jelmer RAAIJMAKERS

B / 1 / 21

Poster P0648

Abstract 3456

Culture-free sequencing reveals high correlation in Mycobacterium tuberculosis genomic variability compared to culture

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Carla MARINER-LLICER

B / 1 / 22

Poster P0649

Abstract 3615

A recombinant adenylate cyclase toxoid expands HLA-E-restricted cytotoxic CD8+ T cells against Mycobacterium tuberculosis

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Giusto Davide BADAMI

B / 1 / 23

Poster P0650

Abstract 3646

Increasing problem of drug-resistant tuberculosis in Nepal

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Prabin SHRESTHA

B / 1 / 24

Poster P0651

Abstract 3665

Blood-based three-gene TB host response score is predictive of TB disease or 30-day mortality in hospitalised Ugandans with advanced HIV disease: a prospective cohort study

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Jayne ELLIS

A / 2 / 1

Poster P0652

Abstract 3682

In vitro susceptibility testing of BTZ-043 against Mycobacterium tuberculosis complex isolates to establish the epidemiological cut-off values and MIC distribution

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Ilaria IANNUCCI

A / 2 / 2

Poster P0653

Abstract 3788

Improved detection of mycobacteria in CF and tissue samples cultivated in mycobacterium growth indicator tube incubated at 30°C compared to conventional growth conditions of liquid and solid media

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Jan KEHRMANN

A / 2 / 3

Poster P0654

Abstract 3836

Increased risk of malignancy in patients with tuberculosis: a nationwide cohort study

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Jinnam KIM

A / 2 / 4

Poster P0655

Abstract 3990

Simplified strategy to update tuberculosis transmission situation in Madrid by rationalisating molecular and genomic sequential analysis

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Cristina RODRÍGUEZ

A / 2 / 6

Poster P0657

Abstract 4029

PanSpoTyping: fast and accurate in silico Mycobacterium spoligotyping with pangenome

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Cheng Yee TANG

A / 2 / 7

Poster P0658

Abstract 4035

Tuberculosis infection control in Nepal

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Prabin SHRESTHA

A / 2 / 8

Poster P0659

Abstract 4064

Genomic variations in Mycobacterium tuberculosis from pulmonary and extrapulmonary isolates: Insights into compartmentalization

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Gérard LINA

A / 2 / 9

Poster P0660

Abstract 4113

Tuberculosis-associated hemophagocytic lymphohistiocytosis: diagnostic challenges and determinants of outcome

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Lisa KURVER

A / 2 / 10

Poster P0661

Abstract 4182

Management of latent tuberculosis infections: national survey among French physicians

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Nathalie DOURNON

A / 2 / 11

Poster P0662

Abstract 4227

Mycobacterium chimaera: a respiratory pathogen to be considered

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Alicia ARNAIZ-NIEVA

A / 2 / 12

Poster P0663

Abstract 4236

Speciation of nontuberculosis Mycobacteria and implication for disease management in Sheffield

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Emily WARD-WILLIAMS

A / 2 / 13

Poster P0664

Abstract 4356

Diagnostic performance of a two new molecular assays for Mycobacterium tuberculosis complex and non-tuberculous mycobacteria detection from respiratory tract specimens

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Alba LLOP-ALGUERO

A / 2 / 14

Poster P0665

Abstract 4361

Deeplex Myc-TB: performance evaluation and integration in diagnostic workflow for tuberculosis

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Elena NICOLINI

A / 2 / 15

Poster P0666

Abstract 4525

Application of Fourier-transform infrared spectroscopy for differentiation of Mycobacteroides abscessus complex subspecies

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Norman MAUDER

A / 2 / 16

Poster P0667

Abstract 4535

TB-SEQ: a new strategy to complement tuberculosis contact tracing in Catalonia

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Elisa MARTRO

A / 2 / 17

Poster P0668

Abstract 4764

A global perspective: the gene expression profile of tuberculosis disease among people living with HIV

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Erwin John TAGUIAM

A / 2 / 18

Poster P0669

Abstract 4771

Integrative analysis of blood transcriptomes and machine learning models, unveiling potential biomarkers for discriminating high-risk tuberculosis infection

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Maryam OMRANI

A / 2 / 19

Poster P0670

Abstract 4842

Mycobacterium abscessus resistance to beta-lactams in cystic fibrosis outbreak strains

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Adrian ZELAZNY

A / 2 / 20

Poster P0671

Abstract 4870

Point-of-care ultrasound and urine lipoarabinomannan testing to identify disseminated tuberculosis among patients with HIV at a teaching hospital in Accra, Ghana

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Johanna ÅHSBERG

A / 2 / 21

Poster P0672

Abstract 4872

Completion rate and side effects of two regimens for the treatment of tuberculosis infection: a randomised controlled trial

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Alberto MATTEELLI

A / 2 / 22

Poster P0673

Abstract 4878

Effect of clarithromycin in the viability of Mycobacterium avium complex species biofilms

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Jaime ESTEBAN

A / 2 / 23

Poster P0674

Abstract 4932

Improved identification of Mycobacterium avium complex by MALDI-TOF coupled with machine learning

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Alexandra AUBRY

A / 2 / 24

Poster P0675

Abstract 5079

Increase in cases of nontuberculous mycobacterial lymphadenitis presenting to Children's Health Ireland: results of a 15-year retrospective case review

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Cilian ?MAOLDOMHNAIGH

A / 2 / 25

Poster P0676

Abstract 5109

Dynamic PET facilitated development of antibiotic regimens for tuberculous meningitis due to multidrug-resistant strains

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Sanjay JAIN

A / 2 / 26

Poster P0677

Abstract 5121

Low tuberculosis interferon-gamma release assay conversion rate among exposed healthcare workers

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Geehan SULEYMAN

A / 2 / 27

Poster P0678

Abstract 5157

Comparison of MIC results obtained with EUCAST BMD and MGIT for levofloxacin, moxifloxacin, D-cycloserine and linezolid

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Christopher MASSEY

A / 2 / 28

Poster P0679

Abstract 5277

Comparison study of mutations in a drug-resistant Mycobacterium tuberculosis isolates with rifampicin, fluoroquinolones, bedaquiline, delamanid, pretomanid and linezolid MICs in Korea using whole genome sequencing & 2023 WHO mutation catalogue

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Lee HEE JOO

B / 2 / 1

Poster P0680

Abstract 5345

Systematic evaluation of clarithromycin resistance-associated mutations in Mycobacterium abscessus species based on whole genome sequencing and drug susceptibility testing

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Mitsunori YOSHIDA

B / 2 / 2

Poster P0681

Abstract 5401

Point-of-care ultrasound in evaluation of people living with HIV with disseminated infection due to non-tuberculous mycobacteria: a multicentre case-series

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Francesco TACCARI

B / 2 / 3

Poster P0682

Abstract 5562

Biomarkers to differentiate between tuberculosis and conditions mimicking tuberculosis: a prospective diagnostic accuracy study

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Anne ØSTERGAARD AHRENS

B / 2 / 4

Poster P0683

Abstract 5591

Increasing nontuberculous mycobacteria recovery rate and regional difference of mycobacterial species over 11 years in a Korean tertiary care hospital

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Jae Hyeon PARK

B / 2 / 5

Poster P0684

Abstract 5604

When atypical does not mean uncommon. Mycobacterium fortuitum infection in breast surgery with prosthesis implant: case report and literature review

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Lucia BONATO

B / 2 / 6

Poster P0685

Abstract 5651

Improving tuberculosis diagnosis using a hidden Markov model-based decision model for multiple testing strategy

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Onya OPOTA

B / 2 / 7

Poster P0686

Abstract 5680

Culture-free whole genome sequencing of Mycobacterium tuberculosis using ligand-mediated bead enrichment method

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Shruthi VASANTHAIAH

B / 2 / 8

Poster P0687

Abstract 5687

Diagnostic performance of a WHO-recommended rapid diagnostic test in detecting rifampicin susceptibility in a low drug-resistant setting

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Tai-Hua CHAN

B / 2 / 9

Poster P0688

Abstract 5702

Modifications in chronic colonisation by nontuberculous mycobacteria after CFTR-modulator treatment in cystic fibrosis patients

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

María Paula VARGAS DURÁN

B / 2 / 10

Poster P0689

Abstract 5730

99mTechnetium labelled ethambutol scintigraphy with SPECT/CT in patients with abdominal tuberculosis: a pilot study

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Sunit SIKDAR

B / 2 / 11

Poster P0690

Abstract 5791

Reassessing ongoing risk of Mycobacterium chimaera infection following exposure to heater cooler units during cardiothoracic surgery in the UK

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Laura MAYNARD-SMITH

B / 2 / 13

Poster P0692

Abstract 5847

Evaluation of rapid molecular MTB/XDR assay in England: a low incidence drug resistant TB setting

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Elena FERRAN

B / 2 / 14

Poster P0693

Abstract 5852

The first evaluation of targeted nanopore-based sequencing for tuberculosis drug resistance detection

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Kiarash MOGHADDASI

B / 2 / 15

Poster P0694

Abstract 5863

Tuberculosis contact investigation: a 20 year experience from a third-level hospital in Girona

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Martin QUINTANA GRIJALVO

B / 2 / 16

Poster P0695

Abstract 6117

Burden of tuberculosis in migrant populations in the Middle East and North Africa: a systematic review

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Taha MAATOUG

B / 2 / 17

Poster P0696

Abstract 6308

Culprit or coloniser? To treat or ignore? Clinical relevance of nontuberculous mycobacteria (NTM) isolated in a tertiary care hospital in Western Rajasthan: time to go from bench side to bed side

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Nikhil JOHN

B / 2 / 18

Poster P0697

Abstract 6382

Exploring the link between psychosocial stress, mental health, and tuberculosis: a mixed methods study

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Sally HAYWARD

B / 2 / 19

Poster P0698

Abstract 6448

Adjunctive host-directed therapy to improve tuberculosis treatment outcomes: a systematic review

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Gemma SKELLERN

B / 2 / 20

Poster P0699

Abstract 6471

Mycobacterium kansasii in cancer patients: a 15-case series

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Patricia Rodrigues BONAZZI

B / 2 / 21

Poster P0700

Abstract 6502

Short course treatment strategy for the treatment of rifampicin resistant tuberculosis: comparison between a bedaquiline-based regimen and a bedaquiline-free regimen

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Joan MARTINEZ CAMPRECIOS

B / 2 / 22

Poster P0701

Abstract 6723

Comparative evaluation of sampling methods for detection of Mycobacterium leprae in suspected leprosy patients by RLEP-PCR

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Manjot KAUR

B / 2 / 23

Poster P0702

Abstract 6772

Rapid prediction of drug susceptibility using targeted NGS analysis of sputum from active TB patients in Japan

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Akiko TAKAKI

B / 2 / 24

Poster P0703

Abstract 6821

A novel, high-content imaging-based phenotypic screening assay to advance drug discovery for nontuberculous mycobacteria (NTM)

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Winston CHIU

B / 2 / 25

Poster P0704

Abstract 6856

1-day phenotypic drug susceptibility testing for Mycobacterium bovis BCG using single-cell imaging and a deep neural network

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Buu Minh TRAN

B / 2 / 26

Poster P0705

Abstract 6864

16S rRNA as a pathogen-directed biomarker of early treatment response in patients with susceptible tuberculosis

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Siphiwe MATUKANE

B / 2 / 27

Poster P0706

Abstract 6882

Rapid nanomotion-based phenotypic antibiotic susceptibility testing for the detection of bedaquiline resistance in MDR- and XDR-TB

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Anthony VOCAT

B / 2 / 28

Poster P0707

Abstract 6883

Quantiferon-TB Gold Plus in children: its role in discriminating latent from active Tuberculosis and monitoring LTB prophylaxis

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Francesco BISOGNIN

A / 3 / 1

Poster P0708

Abstract 6894

An individual-level pooled analysis of pyrazinamide toxicity and weight-based dosing in pulmonary tuberculosis in adults

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Navaneeth NARAYANAN

A / 3 / 2

Poster P0709

Abstract 6985

Development of tuberculosis in biological treated patients and evaluation of a screening strategy for latent tuberculosis infection based on QuantiFERON-TB Gold

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Sandra PÉREZ-RECIO

A / 3 / 3

Poster P0710

Abstract 7039

Epidemiology and drug susceptibility of nontuberculous mycobacteria (NTM) in the province of Pavia: an overview

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Mariangela SICILIANO

A / 3 / 4

Poster P0711

Abstract 7051

Integration of whole genome sequencing data for cluster analysis as part of the tuberculosis surveillance in Germany: results from three cities

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Teresa DOMASZEWSKA

A / 3 / 5

Poster P0712

Abstract 7056

New genome wide association study for tuberculosis meningitis and other extra-pulmonary clinical forms using different algorithms and statistical ranking

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Kevin LA

A / 3 / 6

Poster P0713

Abstract 7398

Analytical and clinical assessment of the PATHFAST TB LAM Ag assay for tuberculosis treatment monitoring

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Yassir Adam SHUAIB

A / 3 / 7

Poster P0714

Abstract 7667

The protection role and mechanism of intestinal Prevotella-induced differentiation of Th17 in latent tuberculosis infection

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Yuan HUANG

A / 3 / 8

Poster P0715

Abstract 7696

Implementation of the Bandim TBscore and routine testing of urine samples improves diagnostic efficacy amongst treatment naïve HIV patients

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Savannah DUUS

A / 3 / 9

Poster P0716

Abstract 7730

Mycobacterium abscessus genomic epidemiology in Northern Ireland, UK

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Zoe JOHNSTON

A / 3 / 10

Poster P0717

Abstract 7823

Efficacy and safety of a preventive strategy against tuberculosis in liver transplantation recipients including treatment of latent infection with moxifloxacin

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Marina FAYOS

A / 3 / 11

Poster P0718

Abstract 7900

Repeating the borderline interferon-gamma release assay (IGRA) test one month later in a general hospital: benefits and controversies

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Flor De María VALENZUELA MEDINA

A / 3 / 12

Poster P0719

Abstract 7978

Determining the effects on fitness of all mutations in the rifampicin resistance-determining region of mycobacteria

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Hui ZHAO

A / 3 / 13

Poster P0720

Abstract 7985

The correlation of phenotypic and genotipic methods, including the WGS, for detection of drug resistance of Mycobacterium tuberculosis

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Nelly CIOBANU

A / 3 / 14

Poster P0721

Abstract 8012

SIRT2 inhibition by AGK2 enhances mycobacteria-specific stem cell memory responses by modulating beta-catenin and glycolysis

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Ashima BHASKAR

A / 3 / 15

Poster P0722

Abstract 8056

Analysing decadal trends in nontuberculous mycobacteria prevalence and diversity in South Korea: insights from a large-scale clinical laboratory dataset

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Cho JINHEE

A / 3 / 16

Poster P0723

Abstract 8194

The diagnosis, management and outcome of bone and joint tuberculosis infections in UK adults

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Charlotte HALL

A / 3 / 17

Poster P0724

Abstract 8251

Tuberculous meningitis: a retrospective study in a Portuguese Hospital

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Francisco Neto NOVELA

A / 3 / 18

Poster P0725

Abstract 8429

Coinfections in patients with nontuberculous mycobacteria

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Pedro Ítalo OLIVEIRA GOMES

A / 3 / 19

Poster P0726

Abstract 8557

Ultrasound findings in patients with peritoneal tuberculosis: a proposal for improving a protocol of “point-of-care” ultrasound

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Alessia FRATER

A / 3 / 20

Poster P0727

Abstract 8573

First insights into the genetic composition of Mycobacterium tuberculosis strains circulating in Kosovo with Deeplex Myc-TB

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Rrezarta BAJRAMI HALILI

A / 3 / 21

Poster P0728

Abstract 8604

Mass spectrometry-based metabolite profiling to explain differential inhibitory effect of gallium levofloxacin and gallium linezolid combinations on drug-resistant Mycobacterium tuberculosis

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Olena RZHEPISHEVSKA

A / 3 / 22

Poster P0729

Abstract 8620

Spontaneous mutations conferring antibiotic resistance to new aroylhydrazones at a range of concentrations in Mycobacterium tuberculosis

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Simeon DIMITROV

A / 3 / 23

Poster P0730

Abstract 8683

Therapeutic drug monitoring of rifampin in a cohort of patients with pulmonary and extrapulmonary TB

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Bianca GRANOZZI

A / 3 / 24

Poster P0731

Abstract 8905

Performance evaluation of the FluoroType® MTBDR VER 2.0 with dual target detection of Mycobacterium tuberculosis complex from native sputum and culture

28/04 12:00

2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)

Vera ALLERHEILIGEN

A / 3 / 25

Poster P0732

Abstract 96

Characteristics of bloodstream infections in patients with liver cirrhosis in a general hospital

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sophie NGUYEN

A / 3 / 26

Poster P0733

Abstract 109

Patterns of lymphocyte count as a predictor of early mortality among adult patients with sepsis admitted at a tertiary hospital June 2020 - January 2022

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Stephannie Angel RICAFRENTE

A / 3 / 27

Poster P0734

Abstract 217

Mucositis-associated bloodstream infections in haematology patients with fever during neutropenia

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Nick DE JONGE

A / 3 / 28

Poster P0735

Abstract 271

Reliability of differential time to positivity technique in the diagnosis of catheter-related bloodstream infection: a retrospective analysis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Alvaro IRIGOYEN VON SIERAKOWSKI

B / 3 / 1

Poster P0736

Abstract 393

Follow-up, diagnosis, and outcomes of fever of unknown origin cases in which no diagnosis was established after initial evaluation: an international ID-IRI study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Oguz Resat SIPAHI

B / 3 / 2

Poster P0737

Abstract 433

Importance of source control in the subgroup of intra-abdominal infections for septic shock patients: analysis of 390 cases

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Ugur ÖNAL

B / 3 / 3

Poster P0738

Abstract 439

Prompt identification of etiologic microorganisms and their susceptibilities in bloodstream infections using a novel filtration concentration method

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Yung-Chieh FU

B / 3 / 4

Poster P0739

Abstract 466

Code sepsis: incidence, prognosis and risk factors of sepsis-associated mortality

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Maria Eugenia MARTINEZ-NUÑEZ

B / 3 / 5

Poster P0740

Abstract 476

A comparative study of ceftazidime/avibactam-based and fosfomycin plus meropenem-based regimens for managing infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Ugur ÖNAL

B / 3 / 6

Poster P0741

Abstract 484

Emergence of invasive group A streptococcal (iGAS) bloodstream infections (BSIs) in a French general hospital

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sophie NGUYEN

B / 3 / 7

Poster P0742

Abstract 494

Time to positivity is a risk factor for death among patients with bloodstream infections

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Kevin LAUPLAND

B / 3 / 8

Poster P0743

Abstract 499

Gram-negative bloodstream infections in hospitalised Australian children: epidemiology, antimicrobial resistance and clinical outcomes

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sophie Chien-Hui WEN

B / 3 / 9

Poster P0744

Abstract 3680

The effects of appropriate and inappropriate diagnosis and treatment of urinary tract tnfections on patient outcomes

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Rebecca OETTLE

B / 3 / 10

Poster P0745

Abstract 528

Blood culture contamination in a tertiary care hospital: a three-year study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Banan AIESH

B / 3 / 11

Poster P0746

Abstract 531

Contezolid, a novel oxazolidinone, is non-inferior and safer comparing with linezolid in treating Gram-positive sepsis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Chen DAYU

B / 3 / 12

Poster P0747

Abstract 538

Direct identification of microorganisms by MALDI-TOF MS from positive blood cultures and rapid antibiotic susceptibility testing

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Bilgehan ERGAN

B / 3 / 13

Poster P0748

Abstract 638

The effect of P2Y12 inhibitor in addition to anti-staphylococcal therapy on microbiologic clearance in patients with Staphylococcus aureus bacteremia

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Nobuaki MORI

B / 3 / 14

Poster P0749

Abstract 667

Multidrug-resistant pathogens and predictors of all-cause mortality in healthcare-associated bloodstream infections in intensive care unit at the University Hospital Center Zagreb over five-year period

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Dijana VARDA BRKIC

B / 3 / 15

Poster P0750

Abstract 803

Epidemiological and molecular insights into P. aeruginosa bloodstream infections: pre- and post-COVID comparison

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Yolanda SAENZ

B / 3 / 16

Poster P0751

Abstract 855

Neonatal early-onset sepsis bacterial etiology correlates with placental bacterial culture results

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Manon JABOYEDOFF

B / 3 / 17

Poster P0752

Abstract 880

Anaerobic growth as an independent prognostic factor of mortality in Pseudomonas aeruginosa blood stream infections

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Daniel Nicolás MARCO

B / 3 / 18

Poster P0753

Abstract 928

Risk factors for healthcare-associated Enterobacter spp. bacteremia: a case-case-control study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Shikai WU

B / 3 / 19

Poster P0754

Abstract 973

Follow-up blood cultures in Streptococcal and Enterococcal bacteremia, are they of any value?

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Romkje Sjoukje DE BOER

B / 3 / 20

Poster P0755

Abstract 978

Onset of nosocomial bloodstream infection in intestinal carriers of multidrung-resistant enterobacterales: a retrospective cohort study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Noureddine HENOUN LOUKILI

B / 3 / 21

Poster P0756

Abstract 983

Infective endocarditis and discovertebral infections in older adults: complications and functional decline

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Elise CASSAND

B / 3 / 22

Poster P0757

Abstract 1038

Low-risk Staphylococcus aureus bacteremia patients do not require routine diagnostic imaging: a multicentre retrospective cohort study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Marianne HENDRIKS

B / 3 / 23

Poster P0758

Abstract 1160

Feasibility study of hyperbaric oxygen treatment for left-sided infective endocarditis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Christian Johann LERCHE

B / 3 / 24

Poster P0759

Abstract 1850

A quantitative point-of-care device based on measurement of sTREM-1 levels for risk-stratification of febrile patients

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Barbara BARO SASTRE

B / 3 / 25

Poster P0760

Abstract 1222

Computational map of disease showed new aspects of severe systemic infections due to P. aeruginosa

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Francesco MESSINA

B / 3 / 26

Poster P0761

Abstract 1297

Community-acquired Staphylococcus aureus bacteraemia among people who inject drugs: a national cohort study in England, 2017-2020

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Emma MCGUIRE

B / 3 / 27

Poster P0762

Abstract 1339

Prevalence and molecular epidemiology of carbapenem-resistant Acinetobactor baumannii isolates from bloodstream infections: the first report of NDM-1 producing A. baumannii in Korea

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Young Ah KIM

B / 3 / 28

Poster P0763

Abstract 1349

Comprehensive analysis of myeloid nuclear differentiation antigen in urinary tract infection and urosepsis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Zhenglin CHANG

A / 4 / 1

Poster P0764

Abstract 1379

Obesity paradox does not apply to young adult patients with sepsis: analysis of the MIMIC-IV database

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Yongseop LEE

A / 4 / 2

Poster P0765

Abstract 1399

Benchmarking hospitals for comparing and understanding differences in antimicrobial resistance and hospital-acquired bloodstream infections

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Rishma AMARSY

A / 4 / 3

Poster P0766

Abstract 1407

Serum cytokine levels in early neonatal sepsis identify IL-27 as a predictive clinical biomarker

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Claudius MEYER

A / 4 / 4

Poster P0767

Abstract 1418

Nomenclature, definitions, and methodological approaches to estimate the impact of inappropriate antimicrobial treatment on drug-resistant bloodstream infection outcomes

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Nasreen HASSOUN-KHEIR

A / 4 / 5

Poster P0768

Abstract 1484

Exploring neutrophil migration dynamics in severe UTIs: Longitudinal analysis and clinical correlations

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Lena KARWATH

A / 4 / 6

Poster P0769

Abstract 1493

Ceftobiprole is safe and efficacious in treating renal impaired patients with complicated Staphylococcus aureus bacteraemia (SAB), including those on dialysis: results from the ERADICATE Phase 3 study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Marc ENGELHARDT

A / 4 / 7

Poster P0770

Abstract 1556

Does age matter? Risk factors, complications, and outcomes among patients with infective endocarditis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Caglayan Merve AYAZ

A / 4 / 8

Poster P0771

Abstract 1559

An analysis of baseline conditions or complications of S. aureus bacteraemia from a double-blind, randomised Phase 3 study (ERADICATE) comparing ceftobiprole vs daptomycin

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Thomas HOLLAND

A / 4 / 9

Poster P0772

Abstract 1563

An easy and cheap prognostic factor: does the hematocrit-corrected erythrocyte sedimentation rate to albumin ratio predict mortality in infective endocarditis patients

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Caglayan Merve AYAZ

A / 4 / 10

Poster P0773

Abstract 1568

Characteristics of urosepsis caused by ESBL producing Enterobacterales in Croatia

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Ana LONCAR

A / 4 / 11

Poster P0774

Abstract 1577

Comparison of ceftobiprole versus daptomycin for time to S. aureus bloodstream clearance in the recent double-blind randomised Phase 3 study (ERADICATE)

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Thomas HOLLAND

A / 4 / 12

Poster P0775

Abstract 1603

Rectal colonisation by carbapenem-resistant Gram-negative bacteria and subsequent occurrence of bloodstream infection

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Angeliki KASSOMENAKI

A / 4 / 13

Poster P0776

Abstract 1646

Exploring antibiotic combinations in the treatment of prosthetic valve endocarditis and prosthetic osteoarticular infections: prevalence and clinical impact of drug interactions

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Nikolaos FATSIS-KAVALOPOULOS

A / 4 / 14

Poster P0777

Abstract 1668

Characteristics and prognosis of patients following complete surgical removal of infected vascular graft

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Runza Buznego PAULA

A / 4 / 15

Poster P0778

Abstract 1685

Sepsis knowledge and management proficiency of nurses and physicians in tertiary care neonatal units of Switzerland

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sylvain MEYLAN

A / 4 / 16

Poster P0779

Abstract 1739

Epidemiology of bloodstream infections caused by extended-spectrum cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae in Switzerland, 2015-2022: secular trends and association with the COVID-19 pandemic

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Lauro DAMONTI

A / 4 / 17

Poster P0780

Abstract 1740

Different evolutions in incidence of invasive bacterial infections in Belgium

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Stefanie DESMET

A / 4 / 18

Poster P0781

Abstract 1751

E.faecium bloodstream infections and vancomycin resistance role: a five-year retrospective analysis in an Italian tertiary care hospital

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Lucia GRAZIANI

A / 4 / 19

Poster P0782

Abstract 1755

Real-world data on the use of intravenous (IV) fosfomycin for the treatment of critically ill patients: an update from a European, multicentre, non-interventional and prospective clinical study (FORTRESS)

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Klaus-Friedrich BODMANN

A / 4 / 20

Poster P0783

Abstract 1821

Risk factors for Aerococcus bloodstream infection: a nationwide observational case-control study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

John WALLES

A / 4 / 21

Poster P0784

Abstract 1823

Modelling the implementation of narrow versus broader spectrum antibiotics in the empiric treatment of E. coli bacteraemia

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Mark KHURANA

A / 4 / 22

Poster P0785

Abstract 1835

Electric field-mediated sample preparation for accelerated sepsis diagnosis: an innovative approach for blood cell lysis while keeping pathogens viable

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sandra REISCHL

A / 4 / 23

Poster P0786

Abstract 1852

Update of the leading causative organisms in community-acquired sepsis in a French paediatric emergency department

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Leon JAHDAUTI

A / 4 / 24

Poster P0787

Abstract 1862

Retrospective review of Streptococcus bovis-Streptococcus equinus complex bacteraemia over a 5-year period in Greater Glasgow and Clyde

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Samuel HARWOOD

A / 4 / 25

Poster P0788

Abstract 2040

Characteristics and outcomes of Stenotrophomonas maltophilia bacteremia: An 18-year study at two tertiary hospitals in South Korea

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sarah KIM

A / 4 / 26

Poster P0789

Abstract 2093

Evaluation of empirical treatment coverage in native valve endocarditis: are two antibiotics better than one?

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Oguzhan ACET

A / 4 / 27

Poster P0790

Abstract 2209

Prevalence of extracardiac vascular complications in Abiotrophia spp. and Granulaticatella spp. infective endocarditis: a single-centre experience and a systematic review of the literature

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Giacomo POZZA

A / 4 / 28

Poster P0791

Abstract 2224

Time to positivity as a mortality and source predictor in adults with Pseudomonas aeruginosa bloodstream infection

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Daniel Nicolás MARCO

B / 4 / 1

Poster P0792

Abstract 2303

A hidden factor to healthcare-associated bloodstream infections: collection and technique of blood culture sampling

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Guan-Jhou CHEN

B / 4 / 2

Poster P0793

Abstract 2314

Intensive care unit-onset bloodstream infections represent a distinct category of hospital-onset infections: a retrospective cohort study of bloodstream infections in ICU patients

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Kevin LAUPLAND

B / 4 / 3

Poster P0794

Abstract 2331

Two clades involved in a cluster of invasive group B streptococcal infection in non-pregnant adults in Hong Kong public hospitals in 2021 and 2023

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Carmen LI

B / 4 / 4

Poster P0795

Abstract 2350

Poly-microorganisms detected by droplet digital PCR and increased pathogen load a week after sepsis diagnosis were associated with poor prognosis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Zhang HAOCHENG

B / 4 / 5

Poster P0796

Abstract 2362

Risk factors and binary prediction models for bacteremia in patients with persistent neutropenic fever

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Kyung-Ran KIM

B / 4 / 6

Poster P0797

Abstract 2373

Impact of daptomycin dosing on mortality for vancomycin resistant enterococcal bloodstream infections in an Australian teaching hospital

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Kelly CAIRNS

B / 4 / 7

Poster P0798

Abstract 2398

How do experts classify sepsis cases for sepsis surveillance? Lessons learned from a behavioural artificial intelligence technology approach

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Renée TUINTE

B / 4 / 8

Poster P0799

Abstract 2424

High prevalence of hypogammaglobulinemia and B-cell malignancies in adults with invasive pneumococcal disease

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Karin BERGMAN

B / 4 / 9

Poster P0800

Abstract 2447

Tracking the evolution of antimicrobial resistance: whole genome sequencing for monitoring recurrent bacteremia caused by carbapenem-resistant Enterobacteriaceae

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Ahmed BAYOUMI

B / 4 / 10

Poster P0801

Abstract 2455

Predicting antimicrobial resistance in Gram-negative bacterial bloodstream infections through evaluation of dynamic host responses and deep learning

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Vasin VASIKASIN

B / 4 / 11

Poster P0802

Abstract 2559

SepsiSTAT: automated microbial extraction and enrichment for rapid BSI detection and AST, direct from blood

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Daniel LOCKHART

B / 4 / 12

Poster P0803

Abstract 2566

Epidemiology and outcomes of invasive group A Streptococcal bacteraemias 2017-2022: an increasing prevalence

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Jacinta NG

B / 4 / 13

Poster P0804

Abstract 2611

Early oral switch in endocarditis: an international cross-sectional survey by ESGBIES – results of the interim-analysis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Philipp MATHÉ

B / 4 / 14

Poster P0805

Abstract 2643

Identifying populations at increased risk of E. coli bloodstream infections

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Emma PRITCHARD

B / 4 / 15

Poster P0806

Abstract 2716

Follow-up blood cultures do not reduce mortality in hospitalised patients with Gram-negative bloodstream infection: a population-wide cohort study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sean Wei Xiang ONG

B / 4 / 16

Poster P0807

Abstract 2752

Implication of Staphylococcus aureus isolation from intravenous catheter tips in the absence of positive blood cultures

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Yoleidys Milagros MARTÍNEZ YSASIS

B / 4 / 17

Poster P0808

Abstract 2842

Understanding the burden of group A streptococcus bloodstream infections over an 8-year period in an Irish tertiary hospital

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Louise KELLY

B / 4 / 18

Poster P0809

Abstract 2908

Bacterial endocarditis: is the oral switch the optimal future strategy? A systematic review and meta-analysis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Beatrice BARDA

B / 4 / 19

Poster P0810

Abstract 2941

Inappropriate empirical antibiotic therapy does not adversely affect outcome for patients with bacteraemia caused by ESBL-producing Enterobacterales

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Daniel BREMELL

B / 4 / 20

Poster P0811

Abstract 2965

Piperacillin/tazobactam-resistant, ceftriaxone-susceptible E. coli bacteremia: a single centre experience

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Tommaso ALBANO

B / 4 / 21

Poster P0812

Abstract 2975

Ceftaroline vs vancomycin monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a matched cohort study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Roni BITTERMAN

B / 4 / 22

Poster P0813

Abstract 2996

Hypervirulent Klebsiella pneumoniae bacteremia

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Moufida HAMIDI

B / 4 / 23

Poster P0814

Abstract 3002

Epidemiology of infective endocarditis: data from a reference centre with cardiac surgery (2016-2022)

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Francisca ARTIGUES SERRA

B / 4 / 24

Poster P0815

Abstract 3027

Enterobacter invasive infections and their antimicrobial susceptibility patterns in children at a rural Kenyan hospital: a 10-year analysis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Jemima NYANDWARO

B / 4 / 25

Poster P0816

Abstract 3111

Impact of evidence-based quality-of-care processes from clinical trial (CAMERA2) participation on methicillin-resistant Staphylococcus aureus bacteraemia outcomes: an international, multicentre, retrospective study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Russel LEE

B / 4 / 26

Poster P0817

Abstract 3139

Defining clinical success in methicillin-resistant Staphylococcus aureus bacteremia patients treated with daptomycin and ceftaroline combination therapy

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Hanna SCHULTZ

B / 4 / 27

Poster P0818

Abstract 3158

Biofilm formation ability is not associated with worse outcome in Acinetobacter nosocomialis bacteremia

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Yi-Tzu LEE

B / 4 / 28

Poster P0819

Abstract 3272

Increase in bloodstream infections caused by MDR Staphylococcus haemolyticus during the COVID-19 pandemic

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

María BONILLA-MORENO

A / 5 / 1

Poster P0820

Abstract 3390

Approach to febrile neutropenia in Belgian hospitals

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Yuri VANBIERVLIET

A / 5 / 2

Poster P0821

Abstract 3428

Novel sequence types, carbapenem resistance, virulence, neonatal sepsis: the Acinetobacter non-baumannii story

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sulagna BASU

A / 5 / 3

Poster P0822

Abstract 3549

Multi-modal strategy reduces paediatric blood culture contamination rates and costs at a regional hospital in South Africa

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Kgaogelo MASEMOLA

A / 5 / 4

Poster P0823

Abstract 3571

Impact of a bundle intervention on clinical outcomes and adherence to quality of care indicators of Staphylococcus aureus bacteremia in non-referral community hospitals

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Francesc ESCRIHUELA-VIDAL

A / 5 / 5

Poster P0824

Abstract 3648

Impact of de-escalation in prognosis of patients with bloodstream infection by Enterobacterales presenting with sepsis or septic shock: a post-hoc analysis of a prospective multicentre cohort

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Francesc ESCRIHUELA-VIDAL

A / 5 / 6

Poster P0825

Abstract 3684

Emulating a target trial of early compared to late initiation of appropriate antibiotic therapy for hospital-acquired monobacterial Gram-negative bloodstream infections

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Abdullah Tarik ASLAN

A / 5 / 7

Poster P0826

Abstract 3697

Molecular evidence of Coxiella burnetii and Bartonella quintana endocarditis in Iran: a cross-sectional study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Saber ESMAEILI

A / 5 / 8

Poster P0827

Abstract 3711

Decrease in hospital-acquired bloodstream infection rates in very low birth weight infants: data from 14 years of country-wide surveillance in Germany

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Ferenc Darius RUETHER

A / 5 / 9

Poster P0828

Abstract 3717

Short duration for the treatment of carbapenemase-producing Enterobacterales bloodstream-infections: is an effective treatment?

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Celia SÁNCHEZ-MARTÍNEZ

A / 5 / 10

Poster P0829

Abstract 3748

Body mass index and waist circumference increase the incidence of infective endocarditis in patients with diabetes mellitus: nationwide cohort study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Jinnam KIM

A / 5 / 11

Poster P0830

Abstract 4073

The excess burden of antibiotic-resistant bloodstream infections among hospital patients: evidence from a retrospective cohort study in Chile, 2018-2022

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Kasim ALLEL

A / 5 / 12

Poster P0831

Abstract 4121

Clinical, microbiological and treatment features of infective endocarditis caused by Cardiobacterium spp. in a general hospital over 15 years

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Agustin ESTEVEZ

A / 5 / 13

Poster P0832

Abstract 4159

Epidemiology of ICU-acquired bloodstream infections in Italian intensive care units: data from the Italian network for the evaluation of ICU interventions

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Camilla GENOVESE

A / 5 / 14

Poster P0833

Abstract 4173

Adherence to 2022 IDSA guidance for the treatment of Stenotrophomonas malthophilia bloodstream infections: a multicentre cohort study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Renato PASCALE

A / 5 / 15

Poster P0834

Abstract 4180

Evaluation of outpatient parenteral antimicrobial therapy (OPAT) for infective endocarditis patients in a Belgian tertiary care centre

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Helena Cornelia VAN DEN HOUT

A / 5 / 16

Poster P0835

Abstract 4195

Severity of disease in Streptococcus dysgalactiae subspecies equisimilis bacteremia: a prospective 4-year study, Finland

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Viivi NEVANLINNA

A / 5 / 17

Poster P0836

Abstract 4203

The impact of risk factors for mortality in persistent Staphylococcus aureus bacteremia over time

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Annette WESTGEEST

A / 5 / 18

Poster P0837

Abstract 4289

Post-operative treatment regimens in patients with native valve endocarditis due to Staphylococcus aureus who undergo valve replacement or repair

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Silpita KATRAGADDA

A / 5 / 19

Poster P0838

Abstract 4295

Hypervirulent Klebsiella pneumoniae causing bloodstream infection in Hungary

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Fatma MOHAMED

A / 5 / 20

Poster P0839

Abstract 4316

Granulicatella adiacens penicillin-binding proteins (PBPs) ceftobiprole inhibition: time for double beta-lactam treatment in combination with ampicillin for infective endocarditis (IE)?

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Alberto PAGOTTO

A / 5 / 21

Poster P0840

Abstract 4339

Coagulase-negative Staphylococcus endocarditis: risk factors and outcome

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Milagros SUAREZ

A / 5 / 22

Poster P0841

Abstract 4358

Bacteremia in Denmark from 2010-2022: A population based nationwide cohort study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Ram B. DESSAU

A / 5 / 23

Poster P0842

Abstract 4374

Partnership with a commercial bloodstream infection service team significantly improves blood culture volumes in one Spanish hospital emergency department

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Lauren COOPER

A / 5 / 24

Poster P0843

Abstract 4376

An anti-infective immunotherapy against Klebsiella pneumoniae

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sweta PANDEY

A / 5 / 25

Poster P0844

Abstract 4388

Time to positivity re-evaluation and local epidemiology of blood cultures in Romagna, Italy

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Anna MARZUCCO

A / 5 / 26

Poster P0845

Abstract 4393

Septris2.0: an updated, free, mobile, online simulation game that improves sepsis recognition and management

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sylvain MEYLAN

A / 5 / 27

Poster P0846

Abstract 4416

Comparison of Qvella's Fast ID BSI with standard blood culture for the recovery of pathogens from blood of bacteremic patients

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Hossein SALIMNIA

A / 5 / 28

Poster P0847

Abstract 4423

Cut the contaminants: improving blood culture contamination rates in a tertiary centre emergency department

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sarah KENNY

B / 5 / 1

Poster P0848

Abstract 4425

Incidence risk of hospital-acquired infections due to carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa spp. in patients treated in intensive care units in Italy (INCREASE-IT Study)

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Matteo RINALDI

B / 5 / 2

Poster P0849

Abstract 4426

Transcatheter valve replacement as a salvage treatment for heart failure in infective endocarditis: a multicentre case series

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Miguel VILLAMARÍN MELIO

B / 5 / 3

Poster P0850

Abstract 4455

Prevalence of Escherichia coli resistant to piperacillin/tazobactam causing bloodstream infections in human adults after treatment with piperacillin/tazobactam: systematic review of literature and experience of a tertiary level hospital in Italy

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Rita MURRI

B / 5 / 4

Poster P0851

Abstract 4496

Investigation of the epidemiology, causative pathogens, complications and outcomes of infective endocarditis in cancer, transplantation and patients receiving immunosuppressive therapy.

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Özlem Kurt AZAP

B / 5 / 5

Poster P0852

Abstract 4517

Bacterial and fungal etiologies of bloodstream infections in children in a reference center in Yaounde, Cameroon

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Basilice Mireille MINKA OBAMA

B / 5 / 6

Poster P0853

Abstract 4596

Fusobacterium invasive infections: a ten-year overview of hospitalised patients in a tertiary healthcare centre

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Branimir GJURASIN

B / 5 / 7

Poster P0854

Abstract 4607

Emergence of carbapenemase-producing Enterobacterales and clinical characteristics of carbapenem-resistant invasive infections in Chile (2018-2023)

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Anne Sophie PETERS

B / 5 / 8

Poster P0855

Abstract 4616

Carbapenem combination therapy versus standard of care for persistent methicillin-susceptible Staphylococcus aureus bacteremia and endocarditis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sunish SHAH

B / 5 / 9

Poster P0856

Abstract 4627

Decision-support artificial intelligence models to predict the pattern of antimicrobial resistance in Gram-negative bloodstream infections

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Cecilia BONAZZETTI

B / 5 / 10

Poster P0857

Abstract 4709

The role of valve culture in the prognosis of patients with infective endocarditis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Pablo RUBINAN

B / 5 / 11

Poster P0858

Abstract 4735

Characteristics of infections due to subspecies of Streptococcus gallolyticus identified in two Romanian hospitals

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Endre-Csaba PÁL

B / 5 / 12

Poster P0859

Abstract 4786

Temporal trends in sepsis incidence and outcomes in Latvia (2015-2020): a retrospective administative data study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Laura PUCETA

B / 5 / 13

Poster P0860

Abstract 4811

Long-term outcomes and health care utilisation in sepsis survivors in Latvia: a retrospective observational study using nationwide administrative data

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Laura PUCETA

B / 5 / 14

Poster P0861

Abstract 4853

Activity of ceftobiprole alone versus ampicillin plus ceftriaxone against clinical Enterococcus faecalis blood isolates in 24-hour time-kill assays

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Jaclyn CUSUMANO

B / 5 / 15

Poster P0862

Abstract 4867

New β-lactam/β-lactamases inhibitor combinations can improve prognosis of KPC-producing Enterobacterales bloodstream infections

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Ana Cláudia CARVALHO

B / 5 / 16

Poster P0863

Abstract 4891

A systematic review of dalbavancin use as a sequential therapy for infective endocarditis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Gabriele Maria LEANZA

B / 5 / 17

Poster P0864

Abstract 4916

Factors associated with treatment failure of Stenotrophomonas maltophilia bloodstream infections from a single-centre study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sunish SHAH

B / 5 / 18

Poster P0865

Abstract 4930

EPIDEMIOLOGY OF BACTEREMIA AMONG ALLOGENEIC TRANSPLANTATION THROUGHOUT 12-YEAR PERIOD

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Rosa M PACHECO-GONZALEZ

B / 5 / 19

Poster P0866

Abstract 4935

Blood cultures contamination rate: overview of an Italian hospital

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Giulia RENISI

B / 5 / 20

Poster P0867

Abstract 4958

Comparison of ceftriaxone versus ceftaroline in combination with ampicillin or penicillin against Enterococcus faecalis bloodstream isolates

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Olivia FUNK

B / 5 / 21

Poster P0868

Abstract 4959

Early transition to oral antibiotics in uncomplicated Enterobacterales bloodstream infections: a retrospective cohort study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Aina MATEU SUBIRÀ

B / 5 / 22

Poster P0869

Abstract 4980

Burden and temporal trend of endocarditis in the Greater Antilles from 1990-2019

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Rafael CORTORREAL JAVIER

B / 5 / 23

Poster P0870

Abstract 4990

Staphylococcus aureus bacteremia: a monocentric, retrospective study comparing geriatric to non-geriatric patients

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sami SERRAJ

B / 5 / 24

Poster P0871

Abstract 4996

Bloodstream infections in patients with splenectomy

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Abiu SEMPERE

B / 5 / 25

Poster P0872

Abstract 5043

Predictors of bacteremia in patients with solid and hematologic neoplasms

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Julián Andres HOYOS PULGARIN

B / 5 / 26

Poster P0873

Abstract 5185

Clinical outcomes and bacterial characteristics of hospital-acquired bloodstream infections in Turkiye

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Abdullah Tarik ASLAN

B / 5 / 27

Poster P0874

Abstract 5282

The impact of rapid microbial identification report on the clinical and health economics of hospitalised patients with bloodstream infection

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Xinmin CHU

B / 5 / 28

Poster P0875

Abstract 5463

Gram-negative bacteremia in different types of immunocompromised patients: single centre observational study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Renato PASCALE

A / 6 / 1

Poster P0876

Abstract 5507

Trends in the epidemiology of infective endocarditis in Spain during the XXI century

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Jorge CALDERON PARRA

A / 6 / 2

Poster P0877

Abstract 5534

Comparison of bacteremia incidence in COVID-19 vs. non-COVID-19 wards, before and during the Omicron wave: a single-centre, retrospective, comparative study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Aikaterini GKOUFA

A / 6 / 3

Poster P0878

Abstract 5565

Evaluation of clinical utility of procalcitonin as a diagnostic marker in nonbacterial sepsis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Jaya GARG

A / 6 / 4

Poster P0879

Abstract 5614

Outstanding performance of XGBoost in predicting bloodstream infections

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Zhonghao WANG

A / 6 / 5

Poster P0880

Abstract 5640

Bacteriological and immunological characteristics of hospital-associated and community-associated methicillin-resistant Staphylococcus aureus

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Yeong Geon CHO

A / 6 / 6

Poster P0881

Abstract 5727

Nosocomial bacteremia in a cohort of 63 French neonatal wards, 2019-2023

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Nathalie VAN DER MEE-MARQUET

A / 6 / 7

Poster P0882

Abstract 5728

Does infectious disease consultation have any impact on patients with sepsis alert?

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Ana ÁLVAREZ-URÍA

A / 6 / 8

Poster P0883

Abstract 5736

Predictive factors for carbapenemase production and mortality in Enterobacteriaceae bacteremia

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Maximiliano Gabriel CASTRO

A / 6 / 9

Poster P0884

Abstract 5754

Higher effectiveness of new anti-pseudomonas cephalosporins versus piperacillin/tazobactam or carbapenems for the treatment of Pseudomonas aeruginosa bloodstream infections in intensive care unit: a multicentric retrospective propensity score adjusted study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Davide Fiore BAVARO

A / 6 / 10

Poster P0885

Abstract 5817

Rising resistance of invasive infant Group B Streptococcus in Western Australia over 15 years

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Lucy FURFARO

A / 6 / 11

Poster P0886

Abstract 5837

Patient outcomes of MBL-producing CRE infections: interim results from a retrospective observational study in two centres from the Kingdom of Saudi Arabia

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Bassem ALRADADI

A / 6 / 12

Poster P0887

Abstract 5925

Carbapenem-resistant Klebsiella pneumoniae emerging as the most prevalent MDR organism in bloodstream infections at the ICU: the experience of Saint George Hospital University Medical Center in Lebanon

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Eid AZAR

A / 6 / 13

Poster P0888

Abstract 5951

Non-fecalis enterococci should also be kept in mind as causative agents of infective endocarditis!

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Özlem Kurt AZAP

A / 6 / 14

Poster P0889

Abstract 5980

Impact of a multidisciplinary management team on clinical outcome in ICU patients affected by Gram-negative bloodstream infections: a pre-post quasi-experimental study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Matteo RINALDI

A / 6 / 15

Poster P0890

Abstract 6110

Think sepsis? Think diagnostics and source identification

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Frances GARRAGHAN

A / 6 / 16

Poster P0891

Abstract 6256

[18F]FDG-PET/CT utility in catheter-related Staphylococcus aureus bacteremia

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Miguel Ángel VERDEJO GÓMEZ

A / 6 / 17

Poster P0892

Abstract 6305

The potential predictive role of the neutrophil-to-lymphocyte ratio in patients with infective endocarditis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Lorenzo BERTOLINO

A / 6 / 18

Poster P0893

Abstract 6330

Prediction models on early identification of multidrug-resistant and carbapenems-resistant pseudomonas aeruginosa bloodstream infections in hematology patients prior to antimicrobial susceptibility testing: a multicentre cohort study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Xiaomeng FENG

A / 6 / 19

Poster P0894

Abstract 6335

Soluble immune receptors as severity markers in a multicentric group A Streptococcus pyogenes invasive disease paediatric cohort in Spain

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

José AVENDAÑO-ORTIZ

A / 6 / 20

Poster P0895

Abstract 6362

Bacteremia associated with Staphylococcus haemolyticus in a cohort of 24 French neonatal intensive care units, 2019-2023

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Nathalie VAN DER MEE-MARQUET

A / 6 / 21

Poster P0896

Abstract 6368

Combination antibiotic therapy in hematological patients with Pseudomonas aeruginosa bloodstream infections: friend or foe?

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Xiaomeng FENG

A / 6 / 22

Poster P0897

Abstract 6376

Early oral treatment of infective endocarditis in real-world settings: prospectively evaluated data from the German DERIVE network

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Johannes CAMP

A / 6 / 23

Poster P0898

Abstract 6495

Characterisation of hypervirulent Klebsiella pneumoniae strains causing blood stream infections or showing carbapenem resistance in Germany: a multicentre study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Jürgen HELD

A / 6 / 24

Poster P0899

Abstract 6535

The clinical and molecular characteristics of invasive Streptococcus agalactiae diseases in nonpregnant adults in Taiwan

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Ming Horng TSAI

A / 6 / 25

Poster P0900

Abstract 6536

Timing of extraction in patients with cardiac implantable electronic device infection: the sooner the better?

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Raffaella GALLO

A / 6 / 26

Poster P0901

Abstract 6708

Outcomes and factors associated with mortality for Enterococcus faecalis and Enterococcus faecium bloodstream infections: a prospective multicentre cohort study from the PROBAC project

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Fenna SCHARLOO

A / 6 / 27

Poster P0902

Abstract 6712

Reducing economic cost and carbon footprints through sequential antimicrobial therapy in bacterial infections

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Ana MARTÍNEZ-URREA FORTUÑO

A / 6 / 28

Poster P0903

Abstract 6721

Clinical characterisation of Bacteroides bloodstream infection: a 5-year multi-centre analysis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Cottom LAURA

B / 6 / 1

Poster P0904

Abstract 6735

Risk factors for mortality among elderly individuals hospitalised in the intensive care unit with hospital-acquired bloodstream infections: a multicenter cohort study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Tomer HOFFMAN

B / 6 / 2

Poster P0905

Abstract 6835

In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam-based therapies

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Paolo GAIBANI

B / 6 / 3

Poster P0906

Abstract 6857

Class 3 immune semaphorins: new biomarkers of sepsis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Lara SAMADAN MARKOVIC

B / 6 / 4

Poster P0907

Abstract 6858

Optimising diagnostic stewardship interventions: a 5-year multi-centre analysis of antimicrobial resistance and clinical outcome of Bacteroides blood stream infections

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Cottom LAURA

B / 6 / 5

Poster P0908

Abstract 6863

Pseudomonas aeruginosa bloodstream infections: is it time for combo-therapy?

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Nicholas GEREMIA

B / 6 / 7

Poster P0910

Abstract 6899

Impact of adequate empirical combination therapy on mortality in septic shock due to Pseudomonas aeruginosa bloodstream infections: a multicentre retrospective cohort study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Antonio VENA

B / 6 / 8

Poster P0911

Abstract 6912

Bacteremias due to NDM-1 and KPC-producing carbapenem-resistant Enterobacteriaceae in a high-prevalence area hospital: a comparative, single-centre, retrospective study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Nikolaos SIPSAS

B / 6 / 9

Poster P0912

Abstract 6930

Patients' experiences during hospitalization for Staphylococcus aureus bacteremia: a qualitative study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Marianne HENDRIKS

B / 6 / 10

Poster P0913

Abstract 6962

Mortality risk factors and antimicrobial resistance in E. coli bacteremia associated with urinary tract infections (UTI)

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Filip STEVANOVSKI

B / 6 / 11

Poster P0914

Abstract 7018

Epidemiology, clinical characteristics and outcome of Group B Streptococcal bacteraemia in non-pregnant adults in Denmark from 2007-2016: A population-based study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Thilde FABRICIUS

B / 6 / 12

Poster P0915

Abstract 7036

Clinical characteristics and outcomes of ST72 Staphylococcus aureus: comparison with S. aureus of other sequence types

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Jaijun HAN

B / 6 / 13

Poster P0916

Abstract 7042

Adequacy, escalation, and de-escalation of empirical therapy in patients with bacteremia

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Ljiljana LUKIC

B / 6 / 14

Poster P0917

Abstract 7066

Mortality impacts of inappropriate empirical antibiotic therapy in patients with bloodstream infections in Chile: a retrospective cohort study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Kasim ALLEL

B / 6 / 15

Poster P0918

Abstract 7094

Infective endocarditis: 13 years of experience in epidemiological and microbiological profile in a public cardiovascular tertiary centre, São Paulo, Brazil

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Cely ABBOUD

B / 6 / 16

Poster P0919

Abstract 7100

Focus on streptococcal endocarditis: a snapshot of ten years

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Özlem Kurt AZAP

B / 6 / 17

Poster P0920

Abstract 7230

Clinical utility of melatonin in the treatment of sepsis: a systematic review and meta-analysis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Alfonso J. RODRIGUEZ-MORALES

B / 6 / 18

Poster P0921

Abstract 7289

Community and hospital-acquired Gram-negative bloodstream infections in non-ICU patients

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Maria KYZIROGLOU

B / 6 / 19

Poster P0922

Abstract 7291

Culture-free rapid identification of bacterial pathogens in sepsis using RapidID, a novel real time multiplex, ribosomal RNA-based hybridization assay.

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Joseph M. BLONDEAU

B / 6 / 20

Poster P0923

Abstract 7305

Usability of procalcitonin to detect asymptomatic central line associated blood stream infections in children with chronic kidney disease

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sampath JAYAWEERA

B / 6 / 21

Poster P0924

Abstract 7316

Clinical outcomes, epidemiology and risk factors associated with peripherally inserted central venous catheter-associated bloodstream infection: a matched case-control study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Federico ROMANI

B / 6 / 22

Poster P0925

Abstract 7325

Bloodstream infections in allogeneic hematopoietic cell recipients: trends of incidence, susceptibility and risk factors for multidrug resistance

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sara SANTOS FERNANDES

B / 6 / 23

Poster P0926

Abstract 7339

Spatial distribution of hospitalisations and lethality with sepsis in San Paulo State, Brazil: a ten year-period population-based study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Carlos KIFFER

B / 6 / 24

Poster P0927

Abstract 7373

Comparison of trough vs point estimate area-under-curve vancomycin dosing for methicillin-resistant Staphylococcus aureus bacteremia in the midwest United States

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Christen ARENA

B / 6 / 25

Poster P0928

Abstract 7401

Risk factors and clinical outcomes associated with vancomycin-resistant vs vancomycin-susceptible Enterococcus faecium bloodstream infections: a five-year retrospective matched cohort study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Martina DEL MONTE

B / 6 / 27

Poster P0930

Abstract 7511

Mortality impact of microbiological factors in Escherichia coli bacteraemia presenting with sepsis/septic shock: a prospective cohort study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Natalia MALDONADO

B / 6 / 28

Poster P0931

Abstract 7563

Impact of baseline sociodemographic and drug use profile on short- and long-term outcomes in intravenous drug users following infective endocarditis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Inmaculada LÓPEZ MONTESINOS

A / 7 / 1

Poster P0932

Abstract 7570

Impact of lab automation and reorganisation on bloodstream infections management

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Maxime PALUCH

A / 7 / 2

Poster P0933

Abstract 7618

Clinical and microbiological risk factors for 30-day mortality associated with bloodstream infections caused by OXA-48-producing Klebsiella pneumoniae

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Javier FERNÁNDEZ

A / 7 / 3

Poster P0934

Abstract 7622

Microbiological characteristics of infectious endocarditis from heart valves with positive culture during the last ten years

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

María Paula VARGAS DURÁN

A / 7 / 4

Poster P0935

Abstract 7648

A bedside tool to predict the risk of mortality in internal medicine patients with Pseudomonas aeruginosa bloodstream infection

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Silvia CORCIONE

A / 7 / 5

Poster P0936

Abstract 7711

The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Niccolo BUETTI

A / 7 / 6

Poster P0937

Abstract 7715

Ampicillin-susceptible Enterococcus faecium bloodstream infections: a 5-year retrospective cohort study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Valentina MENOZZI

A / 7 / 7

Poster P0938

Abstract 7761

European antimicrobial resistance surveillance of Bacteroides fragilis from blood cultures 2022 (ReSuBacfrag)

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Michael BUHL

A / 7 / 8

Poster P0939

Abstract 7787

Does early appropriate empirical antibiotic therapy reduce 30-day mortality among hospitalised patients with Klebsiella spp. bacteremia? A retrospective study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Tanya BABICH

A / 7 / 9

Poster P0940

Abstract 7855

Standard deviation of the monocyte distribution width as a prognostic indicator of death in septic patients

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Dimitrios THEODORIDIS

A / 7 / 10

Poster P0941

Abstract 7885

Epidemiology of sepsis in trauma patients in Kharkiv, Ukraine

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Mariia MATVIEIENKO

A / 7 / 11

Poster P0942

Abstract 7912

Community acquired bacteremia due to multi-drug resistant organisms: risk factors and outcomes. A single centre prospective study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Pantazis-Michael VOUTSINAS

A / 7 / 12

Poster P0943

Abstract 7938

The skip phenomenon in Staphylococcus lugdunensis infective endocarditis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Luis GASCA

A / 7 / 13

Poster P0944

Abstract 7994

Short-course versus long-course antibiotic treatment in patients with uncomplicated Pseudomonas aeruginosa bacteremia: a systematic review and meta-analysis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Juan Pablo GARCIA MARMOLEJO

A / 7 / 14

Poster P0945

Abstract 8014

Hafnia alvei (HA) bacteremia is secondary to biliary infection in most cases

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Jacques TANKOVIC

A / 7 / 15

Poster P0946

Abstract 8017

Assessment of klotho as an early but non-invasive biomarker for septic acute kidney injury

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Xiaoyan WANG

A / 7 / 16

Poster P0947

Abstract 8030

Carbapenem resistant Gram-negative rods bloodstream infections in oncologic patients from Bogotá, Colombia, clinical characteristics and outcomes

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Maria Jose LOPEZ

A / 7 / 17

Poster P0948

Abstract 8045

Spatio-temporal evolution and mechanism of drug resistance and pathogenicity for carbapenem-resistant Klebsiella pneumoniae causing bloodstream infection

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Shen PING

A / 7 / 18

Poster P0949

Abstract 8062

Clinical impact of a rapid diagnostic bundle for the management of patients with suspected sepsis of urinary origin

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Ana ÁLVAREZ-URÍA

A / 7 / 19

Poster P0950

Abstract 8074

Vertebral osteomyelitis in patients with infective endocarditis: incidence, risk factors and mortality

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sabrine DOUIYEB

A / 7 / 20

Poster P0951

Abstract 8076

Staphylococcus aureus bacteraemia in the aged population in Australia: A retrospective cohort study reviewing outcomes and antimicrobial resistance

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Bryan TAN

A / 7 / 21

Poster P0952

Abstract 8154

Optimising echocardiogram requests: validating the VIRSTA score in a Spanish cohort of Staphylococcus aureus bacteremia

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Daniela MALANO BARLETTA

A / 7 / 22

Poster P0953

Abstract 8180

The risk of subsequent cardiovascular events among sepsis survivors in Sweden: a population-based matched cohort study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Hanna WETTERBERG

A / 7 / 23

Poster P0954

Abstract 8256

Impact of the COVID-19 pandemic on healthcare-associated bloodstream infections, between April 2017 to March 2023, in England

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sobia WASTI

A / 7 / 24

Poster P0955

Abstract 8331

Characteristics of infective endocarditis due to non-HACEK gram-negative bacilli in adults.

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Özlem Kurt AZAP

A / 7 / 25

Poster P0956

Abstract 8332

Epidemiology, risk factors and outcomes of bloodstream infections in critically-ill burn patients: an observational study from a burn referral center in Italy

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Niccolò RICCARDI

A / 7 / 26

Poster P0957

Abstract 8401

Invasive group A streptococcal infection: incidence, clinical presentation and outcomes, Catalonia 2022-2023

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Marta MARTORELL

A / 7 / 27

Poster P0958

Abstract 8403

Impact of delayed active targeted antibiotic treatment in bloodstream infections: a prospective, multicentre cohort (PROBAC).

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sandra DE LA ROSA RIESTRA

A / 7 / 28

Poster P0959

Abstract 8444

Prospective evaluation of the SeptiCyte® Rapid assay for the identification of systemic infectious diseases in patients with suspected sepsis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sören Leif BECKER

B / 7 / 1

Poster P0960

Abstract 8446

Fosfomicyn in urinary tract infections caused by multiresistant Escherichia coli bacteraemia: post hoc analysis applying DOOR methodology

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sandra DE LA ROSA RIESTRA

B / 7 / 2

Poster P0961

Abstract 8455

Next-generation sequencing in comparison to blood culture based diagnostic

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Marius HEGNER

B / 7 / 3

Poster P0962

Abstract 8470

Evaluation of the Film Array BCID2 system for the detection of pathogenic bacteria in bloodstream infections

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Konstantinia KONTOPOULOU

B / 7 / 4

Poster P0963

Abstract 8494

Clinical experience with ceftaroline fosamil in infective endocarditis due to methicillin-resistant Staphylococcus aureus

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Kaylee CANIFF

B / 7 / 5

Poster P0964

Abstract 8577

Impact of anti-enterococcal empirical therapy on survival of patients with enterococcal bloodstream infections: a retrospective multicentre cohort study

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Linda BUSSINI

B / 7 / 6

Poster P0965

Abstract 8578

Demographic data and follow-up of patients with infectious endocarditis (IE) by Enterococcus faecalis

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Rosa María BENITEZ DIAZ

B / 7 / 7

Poster P0966

Abstract 8634

Usefulness of the FilmArray blood culture identification two panel for pathogen detection in Limpopo South Africa

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Ivy RUKASHA

B / 7 / 8

Poster P0967

Abstract 8647

Linezolid or daptomycin as alternative to vancomycin for the treatment of vancomycin-susceptible Enterococcus faecium bloodstream infection

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Anne-Sophie BRUNEL

B / 7 / 9

Poster P0968

Abstract 8656

Clinico-microbiological analysis and molecular typing of Stenotrophomonas maltophilia isolated from bloodstream infections

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Sushree SARATHI

B / 7 / 10

Poster P0969

Abstract 8710

Increased incidence of methicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections in England

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Zahin AMIN-CHOWDHURY

B / 7 / 11

Poster P0970

Abstract 8813

Klebsiella spp. bacteraemia surveillance-collaborative strategies required to reduce the risk of infection

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Nabeela MUGHAL

B / 7 / 12

Poster P0971

Abstract 8835

Emergence of multidrug-resistant bloodstream infections in cancer patients: insights from a Bangladesh oncology center

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Ruksana RAIHAN

B / 7 / 13

Poster P0972

Abstract 8904

Early adequate antimicrobial regimen allows short-course treatment in Pseudomonas aeruginosa bloodstream infections

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Marco MERLI

B / 7 / 14

Poster P0973

Abstract 8929

Dilution of positive blood culture samples does not impact the microscopic examination

28/04 12:00

2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction)

Giulia GATTI

B / 7 / 15

Poster P0974

Abstract 228

Epidemiological analysis of Legionella pneumonia in Japan: a national inpatient database study

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Satoshi KUTSUNA

B / 7 / 16

Poster P0975

Abstract 230

Analysis of the effectiveness of combination antimicrobial therapy for Legionella pmeumonia: a nationwide inpatient database study

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Satoshi KUTSUNA

B / 7 / 17

Poster P0976

Abstract 234

Nasopharyngeal carriage of Streptococcus pneumoniae serotypes among healthy children and their cohabiting relatives: a cross-sectional study from LMIC

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Tushar SHAW

B / 7 / 19

Poster P0978

Abstract 1255

Factors associated with antibiotic prescription for lower respiratory tract infections in nursing homes in Switzerland

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Virginie PRENDKI

B / 7 / 20

Poster P0979

Abstract 1347

Nonalcoholic fatty liver disease increases the risk of lung abscess: insights from a nationwide cohort study

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Jungok KIM

B / 7 / 21

Poster P0980

Abstract 1375

Quality of life associated with pneumococcal disease: a targeted literature review

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Min HUANG

B / 7 / 22

Poster P0981

Abstract 1880

Effects of adjunctive corticosteroid treatment for adults with severe Mycoplasma pneumoniae pneumonia

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Karl HAGMAN

B / 7 / 23

Poster P0982

Abstract 2045

Current epidemiology of invasive bacterial diseases in Japan: investigation from the national surveillance data

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Hideharu HAGIYA

B / 7 / 24

Poster P0983

Abstract 2603

Invasive pneumococcal disease in children: a post COVID-19 increase

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Rebecca MCHUGH

B / 7 / 25

Poster P0984

Abstract 2717

Contribution of higher valency pneumococcal conjugate vaccines to reduce the burden of community-acquired pneumonia in adults by age group in Spain, 2016-2022: the CAPA study

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Rosario MENENDEZ VILLANUEVA

B / 7 / 26

Poster P0985

Abstract 2851

Idiopathic pulmonary fibrosis (IPF) exacerbations, microbiology and management

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Louise KELLY

B / 7 / 27

Poster P0986

Abstract 2891

Distribution of pneumococcal vaccines serotypes in adults with community-acquired pneumonia and chronic conditions in Spain, 2016-2022: the CAPA study

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Rosario MENENDEZ VILLANUEVA

B / 7 / 28

Poster P0987

Abstract 3030

Complicated community-acquired pneumonia before and after COVID-19 pandemic: the experience of a paediatric Italian tertiary care hospital

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Maia DE LUCA

A / 8 / 1

Poster P0988

Abstract 3219

Effect of exercise training on physical activity, functional ability, and body composition in community-acquired pneumonia

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Camilla RYRSØ

A / 8 / 2

Poster P0989

Abstract 3554

Gram-positive bacteria: the leading cause of pleural infections

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Ghariani ASMA

A / 8 / 3

Poster P0990

Abstract 3701

Malignant otitis externa: microbiology and implications on antimicrobial treatment

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Christen ARENA

A / 8 / 4

Poster P0991

Abstract 3792

Optimising ceftolozane/tazobactam therapy for respiratory-related infections caused by multidrug-resistant Gram-negative pathogens: insights from SPECTRA

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Emre YUCEL

A / 8 / 5

Poster P0992

Abstract 4168

Non-invasive pneumococcal disease in Portugal: serotype distribution and comparison with invasive pneumococcal disease (2019-2022)

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Catarina SILVA-COSTA

A / 8 / 6

Poster P0993

Abstract 4202

Dominance of serotypes 3 and 8 in adult invasive pneumococcal disease and the importance of non-PCV13 serotypes in antimicrobial resistance (Portugal 2019-2023)

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Catarina SILVA-COSTA

A / 8 / 7

Poster P0994

Abstract 4258

Community acquired pneumococcal pneumonia in adults: diagnostic sensitivity of pneumococcal urinary antigen and serotypes.

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Patricia GARCÍA GARCÍA

A / 8 / 8

Poster P0995

Abstract 4540

A 15-year review of children with pertussis shows the need for a multidisciplinary strategy to prevent this infection in Slovenia also

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Anna GORBUNOVA

A / 8 / 9

Poster P0996

Abstract 4636

Contact with school-aged children is a major risk factor for pneumococcal colonisation in older adults

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Anne WYLLIE

A / 8 / 10

Poster P0997

Abstract 4788

Patient discharge pathways for primary hospitalisation and readmission cases due to all-cause community-acquired pneumonia (CAP) in Canada

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Jelena VOJICIC

A / 8 / 11

Poster P0998

Abstract 5712

Video-assisted thoracoscopic surgery (VATS) for pleural empyema: evaluation of bacterial aetiology and prescribing practices at a thoracic surgery tertiary centre, London, UK

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Amy CARROLL

A / 8 / 12

Poster P0999

Abstract 6026

The decrease in pneumococcal carriage in Belgian children attending daycare centres contrasts to the stable carriage of other pathogens two years after the COVID-19 containment measures

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Esra EKINCI

A / 8 / 13

Poster P1000

Abstract 6104

Phenotypic and genotypic characterisation of Pseudomonas aeruginosa strains coming from non-cystic fibrosis bronchiectasis patients

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Irene CADENAS JIMÉNEZ

A / 8 / 14

Poster P1001

Abstract 6229

Fixed-dose combination of cephalexin extended release and clavulanate potassium in subset of patients with upper respiratory tract infection: a phase IV study

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Dipak PATIL

A / 8 / 15

Poster P1002

Abstract 6293

Treatment with elexacaftor/tezacaftor/ivacaftor leads to an increase in culture negativity of P. aeruginosa in cystic fibrosis sputum samples

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Maria PALS BENDIXEN

A / 8 / 16

Poster P1003

Abstract 6479

Aetiology of community-acquired pneumonia (CAP): impact of molecular techniques

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Concepción CAMPILLO MARTÍN

A / 8 / 17

Poster P1004

Abstract 6595

Enterobactin siderophore from Klebsiella pneumoniae manipulates inflammatory response during lung infection

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Julien VERLAGUET

A / 8 / 18

Poster P1005

Abstract 6625

Differential diagnoses of community-acquired pneumonia in the emergency department

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Susanne SIMON

B / 8 / 1

Poster P1006

Abstract 6806

Sequencing-based surveillance of circulating Bordetella pertussis strains in the Netherlands from 2015-2023

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Rob MARIMAN

B / 8 / 2

Poster P1007

Abstract 7049

Ceftobiprole treatment for pneumonia in internal medicine wards: a real-world single-centre study

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Silvia CORCIONE

B / 8 / 3

Poster P1008

Abstract 7201

Estimating the health and economic burden of pneumococcal diseases attributable to V116 vs PCV20 serotypes among adults in france

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Peter MUELLER

B / 8 / 4

Poster P1009

Abstract 7222

Molecular characterisation of non-invasive Haemophilus influenzae disease in Portugal: 2015-2022

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Maria Paula BAJANCA-LAVADO

B / 8 / 5

Poster P1010

Abstract 7550

Population structure, dynamics and spatial-temporal evolution of Bordetella pertussis producing pertussis in Spain, 1986-2020

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Alba MIR

B / 8 / 6

Poster P1011

Abstract 7572

Assessing the impact of COVID-19 pandemic on invasive pneumococcal disease in Catalonia (2017-2022)

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Sonia BRONER

B / 8 / 7

Poster P1012

Abstract 7627

Genomic characterisation and vaccine reactivity prediction to 4CMenB of Neisseria meningitidis collected from respiratory samples in Spain

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Josep ROCA-GRANDE

B / 8 / 8

Poster P1013

Abstract 7752

Adherence to antimicrobial guidelines for the treatment of Legionnaires' disease in Switzerland: data from the SwissLEGIO multicentre study

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Werner C. ALBRICH

B / 8 / 9

Poster P1014

Abstract 7921

Discerning regional Legionella test positivity rates: a study of increasing Legionnaires' disease trends in Denmark, 2014 – 2021

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Kelsie CASSELL

B / 8 / 10

Poster P1015

Abstract 8152

Persistent colonisation of Haemophilus influenzae in patients with non-cystic fibrosis bronchiectasis

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Paula CAMPS-MASSA

B / 8 / 11

Poster P1016

Abstract 8630

Peak incidence of atypical pneumonia in the paediatric population caused by Mycoplasma pneumoniae at Consorci Sanitari de Terrassa: accumulation of cases in November 2023

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Luis BRUSCA

B / 8 / 12

Poster P1017

Abstract 8763

Retrospective analysis of hospitalised pneumonia cases in Sicily from 2009 to 2021

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Domenico MARRALI

B / 8 / 13

Poster P1018

Abstract 8825

Pseudomonas aeruginosa and Aspergillus fumigatus infections in COPD patients at Bordeaux teaching Hospital

28/04 12:00

2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)

Sebastien IMBERT

B / 8 / 14

Poster P1019

Abstract 49

Whole genome sequencing of phenotypically detected quinolone and tetracycline co-resistant Campylobacter jejuni and Campylobacter coli and emergence of multidrug-resistant C. coli in the University Hospital of Split, Croatia

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Anita NOVAK

B / 8 / 15

Poster P1020

Abstract 249

Monitoring intestinal carriage in preterm newborns reveals intense acquisition of carbapenemase-producing Klebsiella pneumoniae co-harboring OXA-48, VIM, KPC, and NDM in a Moroccan neonatal intensive care unit

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Moussa BENBOUBKER

B / 8 / 16

Poster P1021

Abstract 309

Enteroaggregative Escherichia coli (EAEC) isolated from under-five children with diarrhoea in Ethiopia: genomic and phylogenetic analysis

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Tizazu ZELELIE

B / 8 / 17

Poster P1022

Abstract 486

Prevalence and characterisation of ESBL-producing Escherichia coli in healthy pregnant women and hospital environments in Benin: an approach based on Tricycle

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Kevin Mael Patrick Zinsou SINTONDJI

B / 8 / 18

Poster P1023

Abstract 687

Evidence gaps in the burden of complicated urinary tract infection (cUTI)

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Kristi KUPER

A / 9 / 1

Poster P1024

Abstract 818

Increase in the incidence of Campylobacter spp. isolates in stool cultures at a tertiary hospital

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Victoria CASTAÑO

A / 9 / 2

Poster P1025

Abstract 961

Temporal evolution of isolates and antibiotic susceptibility patterns in pediatric urine cultures from a university hospital over 13 years

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Felipe PÉREZ-GARCÍA

A / 9 / 3

Poster P1026

Abstract 1269

Estrogen alters the virulence of uropathogenic E. coli

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Carolina PETTERSSON

A / 9 / 4

Poster P1027

Abstract 1273

A novel functional food protein alleviates diarrheal symptoms in experimental cholera infection

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Marcus PETERSSON

A / 9 / 5

Poster P1028

Abstract 1332

Unraveling the tapestry: tracking sexually transmitted infections (STIs) in HIV pre-exposure prophylaxis (HIV PrEP) users, a journey from 2019 to 2023

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Jose Ignacio MATEO GONZALEZ

A / 9 / 6

Poster P1029

Abstract 1364

Clinical characteristics and antimicrobial resistance of uncomplicated acute pyelonephritis caused by Escherichia coli and Klebsiella pneumoniae

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Keon Young LEE

A / 9 / 7

Poster P1030

Abstract 1411

What is chronic urinary tract infection: a systematic review

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Janni HJELMAGER

A / 9 / 8

Poster P1031

Abstract 1532

Risk factors of infection cause by multidrug-resistant pathogens in kidney transplant pyelonephritis patients

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Sergey ANDREEV

A / 9 / 9

Poster P1032

Abstract 1578

Streptococcus agalactiae in pregnant women: prevalence, serotypes and in vitro antimicrobial resistance

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Stavroula BAKA

A / 9 / 10

Poster P1033

Abstract 1612

The relationship between antimicrobial consumption and resistance may be saturated in high antimicrobial consumption populations: implications for Doxy PEP studies

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Sheeba MANOHARAN-BASIL

A / 9 / 11

Poster P1034

Abstract 1701

Antimicrobial use and prescription for urinary tract infections by care physicians in Japanese general nursing homes

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Kumiko SUZUKI

A / 9 / 12

Poster P1035

Abstract 1753

Surveillance of typhoid fever following a typhoid conjugate vaccine trial in Nepal

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Suchita SHRESTHA

A / 9 / 13

Poster P1036

Abstract 1766

Increase in group A Streptococcus associated with vulvovaginitis in Spain (2011-2023)

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Eric LOPEZ

A / 9 / 14

Poster P1037

Abstract 1830

Patient characteristics associated with fluoroquinolone-resistant uropathogens: pooled results from two clinical trials of gepotidacin for the treatment of uncomplicated urinary tract infection

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Amanda SHEETS

A / 9 / 15

Poster P1038

Abstract 1857

Antibiotic treatment patterns in patients with evidence of oral antibiotic treatment failure (TF) for uncomplicated urinary tract infection (uUTI) in the United States

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Madison PREIB

A / 9 / 16

Poster P1039

Abstract 1876

Neisseria meningitidis prevalence in male urine by nucleic acid amplification testing in Northeast Ohio

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Hannah WANG

A / 9 / 17

Poster P1040

Abstract 1927

Clinical characteristics and risk factors for pyogenic liver abscess caused by multidrug-resistant organisms: a ten-year retrospective study

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Min HAO

A / 9 / 18

Poster P1041

Abstract 2008

Treatment of urinary tract infections in general practice and risk of recurrent urinary tract infection

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Katrine Hartung HANSEN

A / 9 / 19

Poster P1042

Abstract 2142

Asymptomatic bacteriuria and urological surgery: risk factor or not? Results from the national and multicentre TOCUS database

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Maxime VALLÉE

A / 9 / 20

Poster P1043

Abstract 2412

Risk factors and molecular epidemiology of intestinal colonisation by carbapenem-resistant Gram-negative bacteria in patients with haematological diseases: a multicentre case-controlled study

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Huangdu HU

B / 9 / 1

Poster P1044

Abstract 2428

Does the duration of antibiotic treatment of preoperative asymptomatic bacteriuria in urological surgery influence the occurrence of postoperative infectious complications? Results from the retrospective and multicentre TOCUS cohort

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Maxime VALLÉE

B / 9 / 2

Poster P1045

Abstract 2473

Mycoplasma genitalium: one year experience on macrolide and fluoroquinolone resistance

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Elena NICOLINI

B / 9 / 3

Poster P1046

Abstract 2515

High burden of syphilis and other sexually transmitted infections among international visitors practicing chemsex tested at Checkpoint BLN, Germany

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Lorenzo RABBI

B / 9 / 4

Poster P1047

Abstract 2630

A tree-year surveillance study in Split-Dalmatia County, Croatia: a new pattern in Salmonella species infections

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Merica CAREV

B / 9 / 5

Poster P1048

Abstract 2773

Syphilis patients undergoing HIV pre-exposure prophylaxis (PrEP) display a proportion of serofast comparable to that of HIV patients

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Miriam CAMPOS-RUIZ

B / 9 / 6

Poster P1049

Abstract 2792

The role of Mycoplasma genitalium infection in women diagnosed with pelvic inflammatory disease and/or tubo ovarial abcess

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Nikki ADRIAENS

B / 9 / 7

Poster P1050

Abstract 2857

Performance evaluation of an expanded PCR panel for uropathogen identification in urinary tract infections compared to standard urine culture

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Jelena FEENSTRA

B / 9 / 8

Poster P1051

Abstract 2936

Prognostic model for mortality assessment in patients with cirrhotic liver and infected ascites

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Silvia WÜRSTLE

B / 9 / 9

Poster P1052

Abstract 2940

Genetic relationship and mechanisms contributing to reduced gepotidacin susceptibility in isolates from EAGLE-2/EAGLE-3 clinical trials for uncomplicated urinary tract infections

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Rodrigo E. MENDES

B / 9 / 10

Poster P1053

Abstract 3005

Epidemiology of self-presenting users to a sexually transmitted infections clinic in Milan, Italy

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Lorenzo BIASIOLI

B / 9 / 11

Poster P1054

Abstract 3033

Molecular characterisation of fosfomycin-resistant uropathogens isolated from patients attended at 34 primary care units (PCUs)

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Silvia FIGUEIREDO COSTA

B / 9 / 12

Poster P1055

Abstract 3045

Mycoplasma genitalium: from neglected STI to worrying STD

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Mikel URRUTIKOETXEA-GUTIERREZ

B / 9 / 13

Poster P1056

Abstract 3054

Prevalence of antimicrobial-resistant Mycoplasma genitalium among men who have sex with men: a systematic review and meta-analysis

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Michael SCIAUDONE

B / 9 / 14

Poster P1057

Abstract 3226

Changing trends of microbiological characteristics and antimicrobial susceptibility of Klebsiella pneumoniae in community-acquired liver abscess of 2014-2015 and 2020-2021 in South Korea

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Keon Young LEE

B / 9 / 15

Poster P1058

Abstract 3253

Infectious causes of stillbirths: a descriptive aetiological study of 581 Ugandan women

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Lauren HOOKHAM

B / 9 / 16

Poster P1059

Abstract 3516

Prevalence, antibiotic resistance, virulence potential, and Enterobacterial repetitive intergenic consensus (ERIC)-PCR profiling of clinical and environmental Vibrio cholerae strains isolated in Qom, Iran

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Saeed SHAMS

B / 9 / 17

Poster P1060

Abstract 3616

No sustained decrease in chlamydia and gonorrhoea testing and notification trends during the COVID-19 pandemic, Finland, 2015-2022

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Wioleta KITOWSKA

B / 9 / 18

Poster P1061

Abstract 3679

Aeromonas-associated gastroenteritis in northern Israel: incidence and clinical-epidemiological characteristics

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Dana SAGAS

B / 9 / 19

Poster P1062

Abstract 3835

Comparison of serologic responses of early syphilis to treatment with single-dose ceftriaxone plus doxycycline versus single-dose benzathine penicillin G plus doxycycline among people with HIV: interim analysis

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Tzong Yow WU

B / 9 / 20

Poster P1063

Abstract 3842

Challenges in predicting ESBL intrabdominal infection in critically ill patients in Europe: a post-hoc analysis of the AbSeS cohort study

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Niccolo BUETTI

A / 10 / 1

Poster P1064

Abstract 4043

Efficacy of linezolid in enterococcal urinary tract infection: a multicentre study

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Kevin BOUILLER

A / 10 / 2

Poster P1065

Abstract 4084

Chlamydia trachomatis and lymphogranuloma venereum in HIV pre-exposure prophylaxis era: an inquiry into potential alterations

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Patricio FAVIER

A / 10 / 3

Poster P1066

Abstract 4306

Genital mycoplasma detection among pregnant women admitted to a university hospital with adverse pregnancy outcomes

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Cristina VEINTIMILLA

A / 10 / 4

Poster P1067

Abstract 4367

Clinical impact of antibiotic treatment of patients with acute pyelonephritis

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Joan ROIG SANCHIS

A / 10 / 5

Poster P1068

Abstract 4433

Impact of 2020 EUCAST criteria on antibiotic prescription for urinary tract infections due to Pseudomonas aeruginosa: a retrospective observational study

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Paolo MILANI

A / 10 / 6

Poster P1069

Abstract 4606

Unmasking colistin therapy for urinary tract infections due to multidrug-resistant bacteria: experience at a tertiary academic medical centre

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Atheer ALDAIREM

A / 10 / 7

Poster P1070

Abstract 4649

Factors associated with a severe form of acute obstructive pyelonephritis: preliminary results from the RAMP multicentre cohort

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Coline RICOLLEAU

A / 10 / 8

Poster P1071

Abstract 4718

Assessing the within-patient and within-household diversity of V. cholerae in a cholera endemic area

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Aline CUÉNOD

A / 10 / 9

Poster P1072

Abstract 4942

Pyogenic liver abscess in elderly patients: predictive factors of unfavorable outcome

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Ioannis BOURDALIS

A / 10 / 10

Poster P1073

Abstract 5210

Evolution of antimicrobial resistance in urinary tract infections, a nine-year analysis of a Mexican referral centre

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Aaron MOLINA JAIMES

A / 10 / 11

Poster P1074

Abstract 5394

Probiotic-based decolonisation of multidrug-resistant Klebsiella pneumoniae from the gut of diabetic mice

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Md Nannur RAHMAN

A / 10 / 12

Poster P1075

Abstract 5441

Prevalence estimation of Tropheryma whipplei in diarrheal stools and duodenal biopsy tissues of Koreans

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Mi-Kyung LEE

A / 10 / 13

Poster P1076

Abstract 5457

Epidemiology, antimicrobial resistance and outcomes of intra-abdominal infections in China (PRIME): protocol of a prospective observational study

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Sai TIAN

A / 10 / 14

Poster P1077

Abstract 5537

Impact of border closures on the molecular epidemiology of Neisseria gonorrhoeae during the COVID-19 pandemic in Western Australia

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Christopher MULLALLY

A / 10 / 15

Poster P1078

Abstract 5704

Efficacy and safety of antibiotics on asymptomatic bacteriuria in kidney transplant recipients: a systematic review and meta-analysis of randomised controlled trials

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Lokman Hekim TANRIVERDI

A / 10 / 16

Poster P1079

Abstract 5764

Epidemiology, characteristics and clinical predictors of Chlamydia trachomatis LGV and non-LGV serovars among men who have sex with men

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Alessia SIRIBELLI

A / 10 / 17

Poster P1080

Abstract 5851

Efficacy and safety of cefepime/enmetazobactam compared to novel antibiotics in patients with cUTI/AP: a Bayesian network meta analysis

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Verónica RICO CABALLERO

A / 10 / 18

Poster P1081

Abstract 6043

A Bayesian Network Meta Analysis of the efficacy for cefepime/enmetazobactam compared to established antibiotics in patients with complicated urinary tract infections including acute pyelonephritis

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Florian WAGENLEHNER

A / 10 / 19

Poster P1082

Abstract 6118

Urine sampling rates of general practice patients in England, 2015-2022

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Laura CIACCIO

A / 10 / 20

Poster P1083

Abstract 6144

Evaluation of the vivalytic one analyser for detecting uropathogenic bacteria and antimicrobial resistances in urines samples of urological patients

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Jessica HARTMANN

B / 10 / 1

Poster P1084

Abstract 6185

Gonorrhea on the rise in Denmark: distinct clones are driving the dramatic increase in heterosexual communities

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Thomas ROLAND PEDERSEN

B / 10 / 2

Poster P1085

Abstract 6339

STIs in a Portuguese university population: why testing is crucial

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Joana OLIVEIRA

B / 10 / 3

Poster P1086

Abstract 6678

Arcobacter spp: an emerging enteropathogen; clinical profile of patients, antibiotic susceptibility and genotypic characterisation in a referral microbiology laboratory in Spain

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Lidia GOTERRIS BONET

B / 10 / 4

Poster P1087

Abstract 6753

Investigating transmission patterns during an outbreak of necrotizing enterocolitis related to Clostridium butyricum using whole genome sequencing

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Youssra MIKRAT

B / 10 / 5

Poster P1088

Abstract 6763

Thomasclavelia ramosa is a specific signature of hepatocellular carcinoma among patients with alcohol-related liver disease: a culturomics and metagenomics case-control study

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Reham MAGDY WASFY

B / 10 / 6

Poster P1089

Abstract 6964

Revolutionising UTI diagnosis: lateral flow test demonstrates impressive performance across diverse patient profiles

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Emily ADAMS

B / 10 / 7

Poster P1090

Abstract 7300

Three-arm comparison of fidaxomicin monotherapy, fidaxomicin plus bezlotoxumab, and vancomycin plus bezlotoxumab on 90-day C. difficile clinical success

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Madison SALAM

B / 10 / 8

Poster P1091

Abstract 7343

Co-infection rate of sexually transmitted infections from a United States cohort

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Barbara VAN DER POL

B / 10 / 9

Poster P1092

Abstract 7350

Five years of spontaneous intra-abdominal infections: what are you doing here, Pseudomonas?

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Maria AMOROTO-BENGOETXEA

B / 10 / 10

Poster P1093

Abstract 7456

Vonoprazan-amoxicillin dual therapy vs bismuth-containing quadrable therapy for Helicobacter pylori eradication: a systematic review and meta-analysis of randomised controlled trials

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Omar ELKOUMI

B / 10 / 11

Poster P1094

Abstract 7478

Central and eastern Europe needs more attention and support for better management of sexually transmitted infections

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Merve MERT VAHABI

B / 10 / 12

Poster P1095

Abstract 7655

ChiA: a major player in the virulence of Crohn's disease-associated adherent and invasive Escherichia coli (AIEC)

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Margot FARGEAS

B / 10 / 13

Poster P1096

Abstract 7688

The 30-day in-hospital outcomes of patients with liver cirrhosis admitted with spontaneous bacterial peritonitis: a retrospective cohort study in a tertiary government hospital in the Philippines

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Jose Orlando NICOLAS

B / 10 / 14

Poster P1097

Abstract 7895

Evaluation of Ureaplasma spp. resistance status at a single-centre: are minocycline, josamycin and pristinamycin the new “sexys”?

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Ali Gökhan AKÇAY

B / 10 / 15

Poster P1098

Abstract 7989

Genomic insights into Klebsiella pneumoniae strains responsible for urinary tract infections in Indian isolates

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Akanksha HEGDE

B / 10 / 16

Poster P1099

Abstract 8113

Chlamydia trachomatis coinfection with multiple pathogens causing sexually transmitted infections: time course and epidemiological features

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Elisa GONZALEZ DE HERRERO MARTINEZ

B / 10 / 17

Poster P1100

Abstract 8365

The identification of inappropriate empiric antimicrobial therapy for urinary tract infection following an emergency department discharge: a computerised approach

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Greet VAN DE SIJPE

B / 10 / 18

Poster P1101

Abstract 8419

Lymphogranuloma venereum: an increasingly common anorectal infection among men who have sex, clinical and epidemiological characteristics

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Yolanda GARCÍA COLLADO

B / 10 / 19

Poster P1102

Abstract 8649

Non-typhi Salmonella urinary tract infection: review in a tertiary hospital

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Iris Sharon PÉREZ RAMOS

B / 10 / 20

Poster P1103

Abstract 8746

Revolutionising UTI treatment: machine learning models for predicting empirical antibiotic treatment failure and enhancing patient outcomes in the era of antimicrobial resistance

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Bhavika SHARMA

A / 11 / 1

Poster P1104

Abstract 8821

Evaluation of new and old drugs for the management of complicated urinary tract infection

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Nawal AL SHIZAWI

A / 11 / 2

Poster P1105

Abstract 8856

Isolation of Haemophilus parainfluenzae in urethral exudates from men with acute urethritis

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Konstantinia KONTOPOULOU

A / 11 / 3

Poster P1106

Abstract 8922

Cost and burden of recurrent urinary tract infection in patients with antibiotic treatment failure

28/04 12:00

2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention)

Madison PREIB

A / 11 / 4

Poster P1107

Abstract 180

Assessing the role of healthcare-seeking behaviours in the development of small-area health inequalities in EHR data using complex systems science methods

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Brittany MORGAN BUSTAMANTE

A / 11 / 5

Poster P1108

Abstract 192

Multicentre evaluation of clinical outcomes in patients with obesity using different ceftriaxone dosing strategies for serious infections

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Jack MCHUGH

A / 11 / 6

Poster P1109

Abstract 453

High risk of treatment failure in patients with vertebral osteomyelitis and an underlying malignancy

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Dorothee JOCHIMSEN

A / 11 / 7

Poster P1110

Abstract 581

Clinical and microbiological characteristics of purulent bacterial pericarditis in adults: experience in a tertiary care hospital in Thailand

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Rujipas SIRIJATUPHAT

A / 11 / 8

Poster P1111

Abstract 796

Psychiatric aspect of diabetic foot ulcers

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Oguzhan ACET

A / 11 / 9

Poster P1112

Abstract 1314

Infectious complications of the orthopedic injuries in earthquake survivors

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Imran HASANOGLU

A / 11 / 10

Poster P1113

Abstract 2154

Correlation of pathology, microbiology and virology of non-neoplastic vitrectomy specimens: a single-centre retrospective study

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Kristina SCHMAUDER

A / 11 / 11

Poster P1114

Abstract 2399

Virulence factors and genetic variability in Staphylococcus aureus colonising the skin microbiota of adult patients with severe atopic dermatitis

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Francesca SIVORI

A / 11 / 12

Poster P1115

Abstract 3126

Epidemiology and outcome trends for adult native joint septic arthritis in South Auckland, New Zealand

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Stephen MCBRIDE

A / 11 / 13

Poster P1116

Abstract 3138

Clinical characteristics and factors associated with treatment failure in non-Mycobacterial pyogenic vertebral osteomyelitis

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Runza Buznego PAULA

A / 11 / 14

Poster P1117

Abstract 3445

Regional assessment of paediatric bone and joint infection management in tertiary centres in North-West London, UK

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Rebecca FABER

A / 11 / 15

Poster P1118

Abstract 3745

Pediatric osteomyelitis: what are the predictors of sequelae?

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Francesca PIGNATELLI

A / 11 / 16

Poster P1119

Abstract 3847

Molecular epidemiology, antibiotic susceptibility and pathogenicity of Staphylococcus aureus from wound and soft tissue infection

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Huang HSIN-NI

A / 11 / 17

Poster P1120

Abstract 3893

Safety and efficacy of tedizolid phosphate versus comparators in patients <12 years of age with acute bacterial skin and skin structure infections (ABSSSI)

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Pamela SEARS

A / 11 / 18

Poster P1121

Abstract 4215

Assessment of outcomes and risk factors for Pseudomonas aeruginosa necrotizing soft tissue infections

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Anthony GERLACH

B / 11 / 1

Poster P1122

Abstract 4259

Changes in the bacterial epidemiology of paediatric mastoiditis over 10 years

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Vichita OK

B / 11 / 2

Poster P1123

Abstract 4292

Cohort cutaneous diphteriae in France

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Helene MASCITTI

B / 11 / 3

Poster P1124

Abstract 4303

The Atlantic route, an investigation of infections by Shewanella spp. in individuals who arrive irregularly by sea to the Canary Islands

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Laudy RIVERO RODRÍGUEZ

B / 11 / 4

Poster P1125

Abstract 4498

Is there an increasing number of infections by Group-A-Streptococcus in Tenerife, Spain?

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Berta PINO CALM

B / 11 / 5

Poster P1126

Abstract 4571

Thrice-weekly teicoplanin as outpatient parenteral antibiotic therapy (OPAT): experience at Infectious Disease Unit of Lecco Hospital (Italy)

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Valentina MORENA

B / 11 / 6

Poster P1127

Abstract 5216

Characteristics of resurgent invasive group A streptococcal infection post-pandemic in Toronto, Canada

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Halima DABAJA YOUNIS

B / 11 / 7

Poster P1128

Abstract 5220

Associations between types of skin and soft tissue infections and genotypes of MRSA isolated from these infections

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Hiroshi KANEKO

B / 11 / 8

Poster P1129

Abstract 5472

Clinical characteristics and management of vertebral osteomyelitis with known versus unknown aetiology: a single-centre retrospective study between 2017-2023

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Chiara MACI

B / 11 / 9

Poster P1130

Abstract 6025

Staphylococcus aureus the predominant pathogen in diabetes-related foot infections: a subtropical perspective

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Kate MORTON

B / 11 / 10

Poster P1131

Abstract 6645

In vitro evaluation of delafloxacin against Staphylococcus aureus in bone and joint infections

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Céline DUPIEUX-CHABERT

B / 11 / 11

Poster P1132

Abstract 6701

The changing face of septic bursitis

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Michal DEKEL

B / 11 / 12

Poster P1133

Abstract 7097

Demographic characteristics, clinical presentation and outcome of Gram-negative pyogenic vertebral osteomyelitis

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Susan OLAF LINDVIG

B / 11 / 13

Poster P1134

Abstract 7419

A year observation of hospital management of Native Vertebral Osteomyelitis/Discitis in Northumbria, United Kingdom

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Maria CALDERON CAHUA

B / 11 / 14

Poster P1135

Abstract 7658

Microbial analysis and fungi–bacteria correlation in chronic infectious wound

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Qingqing WANG

B / 11 / 15

Poster P1136

Abstract 7695

Fixed-dose combination of cephalexin extended release and clavulanate potassium in subset of patients with uncomplicated skin and soft tissue infection: a Phase 4 study

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Dipak PATIL

B / 11 / 17

Poster P1138

Abstract 7960

Burden and temporal trend of cellulitis in the United Kingdom from 1990-2019

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Michelle LUIS SIERRA

B / 11 / 18

Poster P1139

Abstract 8736

Vertebral osteomyelitis in adults: clinical, microbiology and outcome in 117 patients hospitalised in the province of Modena, Italy (2017-2022)

28/04 12:00

2e. Community acquired skin, soft tissue, bone & joint infections ((incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses)

Mariachiara PELLEGRINO

A / 12 / 1

Poster P1140

Abstract 156

Fluoroquinolone treatment failure higher in patients with BMI ≥ 30

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Brandon HAWKINS

A / 12 / 2

Poster P1141

Abstract 339

Brain abscess complicating bacterial meningitis: a prospective cohort study from the Netherlands

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Fabian D LIECHTI

A / 12 / 3

Poster P1142

Abstract 652

Functional prognosis of older adults with tetanus: a single-centre retrospective study

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Takeru YAMAMOTO

A / 12 / 4

Poster P1143

Abstract 754

Impact of SARS-CoV-2 pandemic on invasive pneumococcal disease in Navarra, Spain

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Irati ARREGUI GARCIA

A / 12 / 5

Poster P1144

Abstract 938

Neurofilament light chain levels as a diagnostic marker in European lyme neuroborreliosis

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Cédric HIRZEL

A / 12 / 6

Poster P1145

Abstract 953

Is additional treatment needed after completion of treatment for neurosyphilis? A retrospective bayesian analysis

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Shunkichi IKEGAKI

A / 12 / 7

Poster P1146

Abstract 1296

Streptococcus intermedius: a pathogen of increasing significance?

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Eliza GIL

A / 12 / 8

Poster P1147

Abstract 1687

Characteristics and prognostic factors of bacterial meningitis in the intensive care unit: a prospective nationwide cohort study

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Nora CHEKROUNI

A / 12 / 9

Poster P1148

Abstract 2151

Mind the switch: the use of oral antibiotics in deep-seated central nervous system (CNS) infections

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Alexander RICHARDS

A / 12 / 10

Poster P1149

Abstract 2215

Conservative vs neurosurgical treatment of brain abscess

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Emilie ERIKSEN

A / 12 / 11

Poster P1150

Abstract 2652

Clinical microbiology and management of brain abscess: a five-year retrospective study

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Piseth SENG

A / 12 / 12

Poster P1151

Abstract 3199

The trend of childhood bacterial meningitis in Vietnam

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Nam XUAN HA

A / 12 / 13

Poster P1152

Abstract 3675

Infective ring-enhancing brain lesions in a tertiary hospital in Singapore: a comparison of the clinical and radiological features between pyogenic and tuberculous brain abscesses

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Edwin SNG

A / 12 / 14

Poster P1153

Abstract 4347

Review of recurrent pneumococcal meningitis diagnosed in Gipuzkoa, Northern Spain

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Ayla MANZANAL PEREZ

A / 12 / 15

Poster P1154

Abstract 4639

Rising incidence of community-onset paediatric brain abscess and empyema post COVID-19 pandemic: a nine-year retrospective cohort study at a tertiary neurosurgical centre in Nottingham, UK

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Francesca HEARD

A / 12 / 16

Poster P1155

Abstract 5213

Nationwide population-based epidemiological study for maternal and neonatal risk factors of meningitis in infants in Taiwan

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Yu-Lung HSU

A / 12 / 17

Poster P1156

Abstract 6209

Efficacy and safety of intrathecal immunoglobulin administration in adult patients with tetanus – a systematic review

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Jao Jarro GARCIA

A / 12 / 18

Poster P1157

Abstract 6752

Non-compressive myelopathy complicating acute bacterial meningitis

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Evelien Hendrika Gerarda Maria DROST

A / 12 / 19

Poster P1158

Abstract 7059

Clinical and molecular characteristics of bacterial meningitis in children aged one to 59 months in Southern Vietnam (2012-2021): insights from hospital-based sentinel surveillance

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Hieu Cong TRUONG

A / 12 / 20

Poster P1159

Abstract 8077

Phylogenetic characterisation and analysis of virulence genes in invasive Listeria monocytogenes isolates

28/04 12:00

2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)

Petra KMETIC

A / 12 / 21

Poster P1160

Abstract 95

Listeria monocytogenes adenylosuccinate synthetase PurA is required for entry into eukaryotic cells

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Ângela ALVES

A / 12 / 22

Poster P1161

Abstract 272

Carbapenem-resistant Pseudomonas aeruginosa from patients, hospital environment, and water in Jakarta, Indonesia: distribution of antimicrobial resistance genes across domains

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Selvi Nafisa SHAHAB

A / 12 / 23

Poster P1162

Abstract 948

Potential pathogenicity of Enterococcus collected from surfaces of a veterinary biological isolation and containment unit

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Catarina GERALDES

A / 12 / 24

Poster P1163

Abstract 1098

Comprehensive meta-analysis of the global epidemiology of critically resistant Pseudomonas aeruginosa in livestock, wild and domestic animals

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Sirine MEJRI

A / 12 / 25

Poster P1164

Abstract 1110

Unravelling signals underlying Listeria monocytogenes cadC regulation

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Diana MEIRELES

A / 12 / 26

Poster P1165

Abstract 1118

Assessing the impact of erythromycin residues in food on the development of Streptococcus pneumoniae resistance: an in vivo investigation using wax moth larvae

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Sheeba MANOHARAN-BASIL

A / 12 / 27

Poster P1166

Abstract 1218

Burden of Lyme disease (BOLD) study: manifestations of clinically diagnosed Lyme borreliosis in six European countries

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Kate HALSBY

A / 12 / 28

Poster P1167

Abstract 1234

Frequency of occurrence of zoonotic tick-borne pathogens in ticks: Latvian 2023 year experience

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Beatrise ORLOVA

B / 12 / 1

Poster P1168

Abstract 1235

A One Health approach to the ocular surface microbiome of dogs and their owners

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Suzanne Bianca CLOUGHER

B / 12 / 2

Poster P1169

Abstract 1342

Epidemiology, management, and outcomes of Listeria monocytogenes infection: a tertiary centre experience in the Unites States

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Ayesha SAMREEN

B / 12 / 3

Poster P1170

Abstract 1373

Clinical and radiographic symptoms associated with spinal brucellosis

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Vigen ASOYAN

B / 12 / 4

Poster P1171

Abstract 1376

Diagnosis of scrub typhus by multiplex real-time PCR targeting groEL and 47kDa genes of Orientia tsutsugamushi and comparison with indirect immunofluorescence assay

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Moonsuk BAE

B / 12 / 5

Poster P1172

Abstract 1453

Leptospirosis and tularemia in a rural mountain valley in Switzerland and Italy: an underestimated burden?

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Flavio BRUNI

B / 12 / 6

Poster P1173

Abstract 1516

Streptococcus agalactiae ST283 bacteraemia dropped to zero in 2021, despite ongoing isolation from seafood samples

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Timothy BARKHAM

B / 12 / 7

Poster P1174

Abstract 1588

Refining the extraintestinal Escherichia coli foodborne zoonotic hypothesis: the ST117 lineage

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Andre BECKER SAIDENBERG

B / 12 / 8

Poster P1175

Abstract 1622

Prevalence of tick-borne pathogens in ticks collected from humans in the province of Verona during 2018-2022

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Lucia MORO

B / 12 / 9

Poster P1176

Abstract 1643

Molecular characterisation of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae among children and chicken in rural Korogwe, Tanzania

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Md Neyaz Ahmed KHAN

B / 12 / 10

Poster P1177

Abstract 1657

Unmasking the deadliest bite: exploring the upsurge disparity of female mortality in dengue virus in Bangladesh in 2023

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Supta SARKER

B / 12 / 11

Poster P1178

Abstract 2436

Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae among diarrhoea and non-diarrhoea children and farm animals in peri-rural Ghana

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Charity Wiafe AKENTEN

B / 12 / 12

Poster P1179

Abstract 2690

The microbiome and resistome of golden jackals in Israel

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Katherine WINNER

B / 12 / 13

Poster P1180

Abstract 2896

Leptospirosis at the modern stage in Georgia

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Tamar MEGRELISHVILI

B / 12 / 14

Poster P1181

Abstract 3135

One Health antimicrobial resistance surveillance system in an urban-rural complex integrating human, animal, environment and food sectors for comprehensive analysis

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Dokyun KIM

B / 12 / 15

Poster P1182

Abstract 3245

Usefulness of serology for the diagnosis of lyme borreliosis in an endemic area

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Zaira MOURE

B / 12 / 16

Poster P1183

Abstract 3269

Ruminants as potential reservoir for the emerging Shiga toxin-producing Escherichia coli O113:H4?

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Denis PIERARD

B / 12 / 17

Poster P1184

Abstract 3315

Predominance of the previously uncommon Clostridioides difficile PCR ribotype 695 (ST 11) in calves and cattle from Dutch dairy farms.

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Tryntsje CUPERUS

B / 12 / 18

Poster P1185

Abstract 5257

Comparison of Clostridium difficile isolated from human patients and companion animals in South Korea

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Su Min KWAK

B / 12 / 19

Poster P1186

Abstract 3393

Emergence of non-O1, non-O139 Vibrio cholerae infections in Hungary

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Judit HENCZKÓ

B / 12 / 20

Poster P1187

Abstract 3400

β-lactam, carbapenem, and colistin-resistant Klebsiella in healthy and diseased companion animals in northern Italy

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Andrea GRASSI

B / 12 / 21

Poster P1188

Abstract 3589

Salmonella Paratyphi B: Update on the two-faced Salmonella serovar from non-human sample surveillance in Germany

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Maria BOROWIAK

B / 12 / 22

Poster P1189

Abstract 3875

Comparison of prevalence and antimicrobial resistance of Salmonella isolated from raw chicken and duck meat in Korea

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Yeona KIM

B / 12 / 24

Poster P1191

Abstract 4522

Emergence of carbapenem-resistant Klebsiella pneumoniae in companion animals: unveiling a growing public health concern and the need for surveillance in veterinary medicine

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Laura FERNANDES

B / 12 / 25

Poster P1192

Abstract 4619

Clinical course and outcomes of severe leptospirosis treated in the intensive care unit: a retrospective cohort study

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Branimir GJURASIN

B / 12 / 26

Poster P1193

Abstract 4620

Human infections by Bordetella bronchiseptica in a university hospital in northern Spain

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Domingo FERNÁNDEZ VECILLA

B / 12 / 27

Poster P1194

Abstract 4641

Incidence of lyme carditis and lyme carditis as a cause of permanent pacemaker implantation: a registry-based study

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Sanna AVELLAN

B / 12 / 28

Poster P1195

Abstract 4701

Occurrence and characterization of Klebsiella aerogenes, Serratia marcescens, Enterobacter spp. and highly-susceptible Pseudomonas aeuroginosa and Acinetobacter baumannii from white storks foraged at two landfills in Spain

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Sandra A MARTÍNEZ ÁLVAREZ

A / 13 / 1

Poster P1196

Abstract 4857

Most patients referred to a british infectious disease clinic with possible Lyme disease have a different final diagnosis: no change in the last decade

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Fatimah SULIMAN

A / 13 / 2

Poster P1197

Abstract 4903

Mediterranean spotted fever: current status

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Najet MOUFFOK

A / 13 / 3

Poster P1198

Abstract 5042

11-year surveillance of clinical Listeria monocytogenes samples in Slovenia

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Tom KORITNIK

A / 13 / 4

Poster P1199

Abstract 5048

Whole genome sequencing reveals antibiotic resistance and genetic diversity of Listeria monocytogenes in food and related environments: implications for public health and food safety

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Adriana SILVA

A / 13 / 5

Poster P1200

Abstract 5089

Detection of IgM antibodies against Orientia tsutsugamushi for diagnosis of scrub typhus meningoencephalitis

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Bishal GUPTA

A / 13 / 6

Poster P1201

Abstract 5141

Surveillance of bovine tuberculosis in Taiwan, 2008-2023

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Hsin-Yi LIU

A / 13 / 7

Poster P1202

Abstract 5204

The role of One Health in understanding the transmission of Clostridioides difficile

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Su-Chen LIM

A / 13 / 8

Poster P1203

Abstract 5256

Carbapenem-Resistant Aeromonas hydrophila harboring blaCphA7 and ESBL-Producing E. coli isolated from seagulls in Nova Scotia, Canada

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Rym BEN SALLEM

A / 13 / 9

Poster P1204

Abstract 5284

Evaluation on acute, chronic and latent brucellosis based on brucellosis-specific ELISPOT assay through a large-scale epidemiological survey in northern China

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Hongyu WANG

A / 13 / 10

Poster P1205

Abstract 5300

Identifying key genes and pathways associated with acute brucellosis based on bioinformatics analysis of RNA-sequencing data

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Yuan GUANMIN

A / 13 / 11

Poster P1206

Abstract 5376

Clinical comparison between human granulocytic anaplasmosis and scrub typhus in Korea

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Da Young KIM

A / 13 / 14

Poster P1209

Abstract 5873

First report on pet food contamination by MR-CoNS presenting the MLS-B phenotype in South America

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Ikechukwu Benjamin MOSES

A / 13 / 15

Poster P1210

Abstract 5893

High-risk strains of CTX-M extended-spectrum β-lactamase-producing Escherichia coli: antibiotic resistance in rabbit farming

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Adriana SILVA

A / 13 / 16

Poster P1211

Abstract 5913

Prevalence and epidemiology of Rickettsia species in ticks of patients with tick bites in a tertiary-care hospital from Madrid, Spain

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Alfredo MALDONADO BARRUECO

A / 13 / 17

Poster P1212

Abstract 5948

Gut microbiome and resistome characterisation of pigs treated with commonly used post-weaning diarrhea treatments

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Judith GUITART-MATAS

A / 13 / 18

Poster P1213

Abstract 6005

In-depth characterisation and cluster analysis of Salmonella Muenchen isolates from non-human sources in Germany

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Jennie FISCHER

A / 13 / 19

Poster P1214

Abstract 6089

Whole genome sequencing-based microbiological investigation of a nationwide outbreak of Salmonella enteritidis linked to steak tartare

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Tjasa CERAR KISEK

A / 13 / 20

Poster P1215

Abstract 6213

Pathogenic leptospira in rats from Barcelona, Spain

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Aida PEIRO-MESTRES

A / 13 / 21

Poster P1216

Abstract 6257

Occurrence and characterisation of extended-spectrum beta-lactamase-producing Escherichia coli ST69 from free-living Dalmatian pelicans (Pelecanus crispus)

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Teresa CARDONA-CABRERA

A / 13 / 22

Poster P1217

Abstract 6289

Persistence of cefotaxime resistant Escherichia coli in semi-intensive broiler farms in Uganda during two consecutive production cycles

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Dickson NDOBOLI

A / 13 / 23

Poster P1218

Abstract 6306

The impact of misdiagnosis and inappropriate antimicrobial administration by healthcare providers on the prognosis of Japanese spotted fever

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Ryusuke KOIKE

A / 13 / 24

Poster P1219

Abstract 6437

High-priority resistant-Klebsiella pneumoniae in pets poses public health concerns: a systematic review and meta-analysis

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Ghada OCHI

A / 13 / 25

Poster P1220

Abstract 6609

Impact of Borrelia spirochetes on macrophages: unveiling gene expression amid oxidative stress in Lyme disease

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Ana ARMADA

A / 13 / 26

Poster P1221

Abstract 6789

A One Health approach to monitoring antimicrobial consumption in Belgium 2012-2021

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Lucy CATTEAU

A / 13 / 27

Poster P1222

Abstract 6949

Safety of traditional foods – detection and characterization of E. coli from Montenegrin artisanal salami and cheese

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Beatriz DAZA

A / 13 / 28

Poster P1223

Abstract 7065

Zoonotic Escherichia coli strains derived from food animals are linked to substantial E. coli bloodstream infections worldwide

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Lance PRICE

B / 13 / 1

Poster P1224

Abstract 7091

Looking systematically for Chlamydia psittaci: kill four birds with one stone?

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Elke VANLAERE

B / 13 / 2

Poster P1225

Abstract 7148

Characterization of virulence determinants of pathogenic Vibrio isolated from clinical samples in a hotspot in the South of Spain

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Sandra TAPIA-POZA

B / 13 / 3

Poster P1226

Abstract 7162

Revolutionising microbial monitoring: assessing the efficacy of an environmental kit in preserving and neutralising across diverse industrial settings

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Simone PAGHERA

B / 13 / 4

Poster P1227

Abstract 7200

Occurrence of the emerging pathogen Escherichia albertii in human clinical stools in Ghent, Belgium

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Klara DE RAUW

B / 13 / 5

Poster P1228

Abstract 7312

Streptococcus halichoeri: animal isolates of an emerging zoonosis

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Geoffrey FOSTER

B / 13 / 6

Poster P1229

Abstract 7488

Estimating the incidence of medically-attended Lyme borreliosis and its disseminated manifestations in Norway from 2015-2022

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Gordon BRESTRICH

B / 13 / 7

Poster P1230

Abstract 7516

Melioidosis in eastern Thailand: unraveling patient profiles, outcomes, and predictors of ICU admission

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Natthaphol CHAICHANASAK

B / 13 / 8

Poster P1231

Abstract 7543

Using genotyping to investigate transmission of Chlamydia psittaci between birds and humans

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Øystein ANGEN

B / 13 / 9

Poster P1232

Abstract 7685

Coxiella burnetii in ruminants from a Caribbean area, Colombia: a potential risk for public health

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Veronica CONTRERAS

B / 13 / 10

Poster P1233

Abstract 7722

Machine learning for forecasting daily Vibrio vulnificus cases in the US coasts

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Jordi Manuel CABRERA GUMBAU

B / 13 / 11

Poster P1234

Abstract 7748

Occurrence of Salmonella enterica in sewage from public toilets in Nigeria, and antimicrobial resistance and genetic relatedness of sewage isolates with strains associated with human infections in Africa

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Abdurrahman Hassan JIBRIL

B / 13 / 12

Poster P1235

Abstract 7813

Characteristics of 104 patients with confirmed human granulocytic anaplasmosis

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Tereza ROJKO

B / 13 / 13

Poster P1236

Abstract 7891

Genetic diversity of Bartonella rpoB haplotypes in domestic cats from Chile

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Patrick BUTAYE

B / 13 / 14

Poster P1237

Abstract 8204

First report of OXA-48 and OXA-244-producing Enterobacterales in captive wildlife and in sedentary/migrants Birds (Cinclus cinclus) and White Wagtail (Motacilla cinerea) in Algeria

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Imene MEHIDI

B / 13 / 15

Poster P1238

Abstract 8279

Genomic context of piperacillin-tazobactam resistance in clinical isolates from companion animals in an Italian University Veterinary Hospital

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Mario PULIDO-VADILLO

B / 13 / 16

Poster P1239

Abstract 8381

Revolutionising brucellosis defense: a combined recombinant subunit vaccine (CRSV) for enhanced safety and immunogenicity in pursuit of One Health excellence

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Qaiser AKRAM

B / 13 / 17

Poster P1240

Abstract 8404

Comparative analysis of single gene PCRs Vs STIC in scrub typhus diagnostics

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Kamlesh BISHT

B / 13 / 18

Poster P1241

Abstract 8676

Typing of clinical and environmental Legionella strains by Fourier transform infrared spectroscopy (FT-IR)

28/04 12:00

2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR)

Stefan ZIMMERMANN

B / 13 / 19

Poster P1242

Abstract 1050

Genomic insights into local scale evolution of ocular Chlamydia trachomatis strains within and between individuals in Gambian trachoma-endemic villages

28/04 12:00

2h. Other intracellular or rare bacteria

Ehsan GHASEMIAN

B / 13 / 20

Poster P1243

Abstract 1947

126 Lactobacillus delbrueckii strains identified as agents in urinary tract infections, and others 2,221 Lactobacillus isolates in Occitania (France) during 2021

28/04 12:00

2h. Other intracellular or rare bacteria

Matthieu BERNIER

B / 13 / 21

Poster P1244

Abstract 2084

Epidemiology, clinical manifestations, and outcomes of patients with Burkholderia pseudomallei bacteremia in eastern Thailand: a five-year single-centre retrospective cohort study

28/04 12:00

2h. Other intracellular or rare bacteria

Pichanon MINGCHAY

B / 13 / 22

Poster P1245

Abstract 2195

Nocardiosis and poor prognostic factors: retrospective observational study

28/04 12:00

2h. Other intracellular or rare bacteria

Carolina MONTEIRO

B / 13 / 23

Poster P1246

Abstract 2283

Origins of Bacillus subtilis strains isolated from blood cultures: insights from a single-centre retrospective study on traditional Japanese fermented soybeans Natto

28/04 12:00

2h. Other intracellular or rare bacteria

Sada RYUICHI MINODA

B / 13 / 25

Poster P1248

Abstract 3828

Description of four novel Anaerococcus spp., isolated from clinical human samples

28/04 12:00

2h. Other intracellular or rare bacteria

Kathleen BOITEN

B / 13 / 26

Poster P1249

Abstract 5393

Geospatial and genomic epidemiology of clinical Burkholderia pseudomallei isolates in Cambodia

28/04 12:00

2h. Other intracellular or rare bacteria

Yek CHRISTINA

A / 14 / 1

Poster P2259

Abstract 63

Enhancing NAM delivery with dendritic lipids

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Mariana GOMES

A / 14 / 2

Poster P2260

Abstract 126

Establishment of epidemiological cut-off values for etimicin sulfate, a new fourth-generation aminoglycoside, against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Luo ZHENGYU

A / 14 / 3

Poster P2261

Abstract 153

Potential susceptibility of OXA-48-producing Enterobacterales to flomoxef

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Victoria K. OWEN

A / 14 / 5

Poster P2263

Abstract 174

Internalisation of ethanol in porous silica nanoparticles as an aim to improve catheter lock therapy

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Marta DÍAZ-NAVARRO

A / 14 / 6

Poster P2264

Abstract 280

Bridge nucleic acid gapmers: changing the EGS technology paradigm

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Angel MAGANA

A / 14 / 7

Poster P2265

Abstract 302

A novel diarylquinoline, TBAJ-587, is active against Mycobacterium abscessus in vitro

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Junsheng FAN

A / 14 / 8

Poster P2266

Abstract 556

High level of performance of two anti-Staphylococcus aureus phages on clinical strains (PST CE-IVD)

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Rafael GOMES VON BOROWSKI

A / 14 / 9

Poster P2267

Abstract 578

A novel β-lactamase inhibitor, FL058, improves the in vitro efficacy of imipenem against Mycobacterium abscessus

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Zhili TAN

A / 14 / 10

Poster P2268

Abstract 606

Determination of the PK/PD driver for the LepB inhibitor, GDC-5780, a novel gram-negative antibiotic against Enterobacteriaceae infections

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Min XU

A / 14 / 11

Poster P2269

Abstract 626

Hospital multiresistant strains of Pseudomonas aeruginosa sensitivity to newly synthesised compounds based on diindolylmethane

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Svitlana MALANCHUK

A / 14 / 12

Poster P2270

Abstract 733

Synergistic effects of phage-antibiotic combinations against Enterococcus faecalis

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Minakshi SAHU

A / 14 / 13

Poster P2271

Abstract 935

Preclinical screening using zebrafish (Danio rerio) reveals the safety of microbisporicin (NAI-107) lantibiotic

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Sheeba MANOHARAN-BASIL

A / 14 / 14

Poster P2272

Abstract 985

Cefoxitin as definitive treatment for extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteraemia

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Tanguy DEQUIDT

A / 14 / 15

Poster P2273

Abstract 1042

Identification of candidate in vitro susceptibility test interpretive criteria (STIC) for oral cephalosporin antimicrobial agents against Escherichia coli and Staphylococcus aureus

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Sujata BHAVNANI

A / 14 / 16

Poster P2274

Abstract 1073

Enhancing phage delivery: exploring three-fluid nozzle spray-drying of PLGA microparticles for sustained release

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Chengxi LIU

A / 14 / 17

Poster P2275

Abstract 1092

Combining phages with antibiotics lowers minimal inhibitory concentrations for Klebsiella oxytoca

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Elisabed ZALDASTANISHVILI

A / 14 / 18

Poster P2276

Abstract 1170

Discovery of new antimicrobial thiophene derivatives with activity against colistin-resistant Gram-negative bacilli

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Irene MOLINA PANADERO

A / 14 / 19

Poster P2277

Abstract 1171

Use of tamoxifen derivatives in combination with colistin against colistin-resistant Acinetobacter baumannii

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Irene MOLINA PANADERO

A / 14 / 20

Poster P2278

Abstract 1214

Lysin exebacase demonstrates potent bactericidal activity against intraosteoblastic Staphylococcus aureus

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Frederic LAURENT

A / 14 / 21

Poster P2279

Abstract 1228

Comparing assays for clinical phage microbiology in Pseudomonas aeruginosa biofilm

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Ron BRAUNSTEIN

A / 14 / 22

Poster P2280

Abstract 1264

Evaluation of toxicity and efflux inhibitory activity of candidate drugs for repurposing against Neisseria gonorrhoeae

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Liliana RODRIGUES

A / 14 / 23

Poster P2281

Abstract 1272

Bacteriocins as a potential alternative to eradicate untreatable intracellular S. aureus

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Frédéric GOORMAGHTIGH

A / 14 / 24

Poster P2282

Abstract 1312

New antibacterial agent against nosocomial pathogens

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Elizaveta ROGACHEVA

A / 14 / 25

Poster P2283

Abstract 1389

A new peptIn with potent and broad-spectrum antimicrobial activity to combat ESKAPE pathogens

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Laleh KHODAPARAST

A / 14 / 26

Poster P2284

Abstract 1401

In vitro activity of lactone ketolide nafithromycin (WCK 4873) against Streptococcus pneumoniae isolates enriched with macrolide-resistance phenotype collected from mainland China

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Meng-Lan ZHOU

A / 14 / 27

Poster P2285

Abstract 1474

A novel cholesterol-conjugated antimicrobial peptide nucleic acid (PNA) against Mycoplasma genitalium

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Michael BEETON

A / 14 / 28

Poster P2286

Abstract 1539

Filamentous phages and its role in the phage defence in CF isolates of P. aeruginosa

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Olga PACIOS SANTAMARÍA

B / 14 / 1

Poster P2287

Abstract 1720

Aztreonam/avibactam effectiveness for aztreonam resistant Stenotrophomonas maltophilia strains

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Ozlem OYARDI

B / 14 / 2

Poster P2288

Abstract 1731

Venomous versatility: crafting a potent cationic peptide for wide-spectrum antimicrobial defense, rapid wound healing, and effective disinfection

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Samya SEN

B / 14 / 3

Poster P2289

Abstract 1744

APC148-avibactam restores meropenem susceptibility in multi-drug resistant Gram-negative bacteria in vitro

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Carina MATIAS

B / 14 / 4

Poster P2290

Abstract 1792

Factors influencing mortality in Staphylococcus aureus bacteremia and in vitro bacteriophage efficacy

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Fatma Irem YESILER

B / 14 / 5

Poster P2291

Abstract 1829

Relative inhibitory activities of the broad-spectrum ß-lactamase inhibitor xeruborbactam against metallo-ß-lactamases

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Christophe LE TERRIER

B / 14 / 6

Poster P2292

Abstract 1844

In vitro activity of newly-developed ß-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with broad-spectrum cephalosporins against AmpC overproducing clinical isolates of Pseudomonas aeruginosa

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Christophe LE TERRIER

B / 14 / 7

Poster P2293

Abstract 1847

Bacteriophages as innovative compounds against Pseudomonas aeruginosa infections in pets

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Eva CUNHA

B / 14 / 8

Poster P2294

Abstract 1854

In vitro activity of rifabutin combined with polymyxin B in Acinetobacter baumannii

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Christian KEMMER

B / 14 / 9

Poster P2295

Abstract 1996

In vivo efficacy of BV100 in combination with polymyxin B (POL) in neutropenic murine thigh infection models of Acinetobacter baumannii

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Glenn E DALE

B / 14 / 10

Poster P2296

Abstract 2065

An evolution approach for enhancing phage efficacy and minimising phage resistance

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Braira WAHID

B / 14 / 11

Poster P2297

Abstract 2171

In vitro activity of cefepime/zidebactam (WCK 5222) against a panel of MDR/XDR Pseudomonas aeruginosa isolates from India enriched with resistance to novel β-lactam/ β-lactamase inhibitor combinations

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Anouk Edwina MULLER

B / 14 / 12

Poster P2298

Abstract 2270

Antimicrobial activity of ceftriaxone 1 g twice versus 2 g once daily against Streptococcus pneumoniae in murine pneumonia model

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Hideo KATO

B / 14 / 13

Poster P2299

Abstract 2280

A novel dibenzodiazepine derivative reduces bacterial resistance to oxidative stress to inhibit intracellular Salmonella typhimurium

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Hao-Chieh CHIU

B / 14 / 14

Poster P2300

Abstract 2345

Bacteriophage-antibiotic combinations as an alternative treatment option for carbapenem-resistant Pseudomonas aeruginosa (CRPA)

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Andrea Lay Hoon KWA

B / 14 / 15

Poster P2301

Abstract 2351

Evaluating efficacy of bacteriophage-antibiotics combinations against clinical carbapenem-resistant Klebsiella pneumoniae (CRKP) isolates

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Andrea Lay Hoon KWA

B / 14 / 16

Poster P2302

Abstract 2414

Post-β-lactamase-inhibitor effect of nacubactam in combination with aztreonam and cefepime on ESBL, AmpC, KPC, or OXA-48-producing Enterobacterales

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Hayato OKADE

B / 14 / 17

Poster P2303

Abstract 2648

Evaluation of antibacterial properties of ionic liquids against Escherichia coli

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Jyothi EMBEKKAT KAVIYIL

B / 14 / 18

Poster P2304

Abstract 2678

Immunostimulatory effect of flagellin on multidrug-resistant Klebsiella pneumoniae infected human airway epithelial cells

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Christine VAN LINGE

B / 14 / 19

Poster P2305

Abstract 2696

Potential of an antimicrobial peptide and a polyurea pharmadendrimer for treating mild superficial diabetic foot infections by S. aureus and P. aeruginosa

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Manuela OLIVEIRA

B / 14 / 20

Poster P2306

Abstract 2743

Antimicrobial effect of antisense PNA conjugated with a CPP on different bacteria

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Joana SANTOS OLIVEIRA

B / 14 / 21

Poster P2307

Abstract 2757

A tomatidine derivative with significant bactericidal activity against methicillin-resistant Staphylococcus aureus and small colony variants

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Camélie MAILHOT

B / 14 / 22

Poster P2308

Abstract 2780

Identification of two new cecropin A/melittin hybrid peptides with wide-range antimicrobial activity against multidrug-resistant pathogens

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Mireia LÓPEZ-SILES

B / 14 / 23

Poster P2309

Abstract 2817

The use of metal ions and graphene-based compounds as novel antimicrobials against multidrug-resistant chlorhexidine adapted Klebsiella pneumoniae

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Nathalie KARAKY

B / 14 / 24

Poster P2310

Abstract 2890

Novel synthetic EGCG analogs potentiate intracellular killing of Staphylococcus aureus within liver-resident macrophages

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Riley GROSSO

B / 14 / 25

Poster P2311

Abstract 2899

Unlocking the role of neurosteroids in bacterial infection

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Daniela BRDOVA

B / 14 / 26

Poster P2312

Abstract 2953

Analysis of oritavancin in vitro activity against vancomycin-resistant Enterococcus faecium isolates

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Natalia BURILLO

B / 14 / 27

Poster P2313

Abstract 3130

In vitro potency of ceftibuten combinations with xeruborbactam, ledaborbactam or avibactam against recent European isolates of Enterobacterales

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Olga LOMOVSKAYA

B / 14 / 28

Poster P2314

Abstract 3146

Ciprofloxacin-aztreonam combination provides synergistic killing against Pseudomonas aeruginosa PAO1 and isogenic strains showing AmpC or MexAB-OprM hyperproduction

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Jessica TAIT

A / 15 / 1

Poster P2315

Abstract 3161

Determination of the PK/PD driver for the LepB inhibitor, GDC-0829, a novel broad-spectrum antibiotic against Gram-negative bacterial infections

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Min XU

A / 15 / 2

Poster P2316

Abstract 3162

Optimising a synergistic phage cocktail: development of a multiplex dPCR system

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Sue Chin NANG

A / 15 / 3

Poster P2317

Abstract 3198

Antimicrobial activity of biodegradation products of the magnesium-based alloy

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Dmytro KYRYK

A / 15 / 4

Poster P2318

Abstract 3210

Polymyxins differentially remodel human macrophage proteomic landscape in the presence and absence of bacterial infection

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Zhi Ying KHO

A / 15 / 6

Poster P2320

Abstract 3268

In vitro combination of phages with antibacterial agents against carbapenemase-producing K. pneumoniae clinical isolates

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Paschalis PARANOS

A / 15 / 7

Poster P2321

Abstract 3311

Optimisation of double-layer agar for phage quantification

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Paschalis PARANOS

A / 15 / 8

Poster P2322

Abstract 3352

A novel leucyl-tRNA synthetase inhibitor, MRX-5 is active against Mycobacterium abscessus

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Bing LI

A / 15 / 9

Poster P2323

Abstract 3420

A new phage-antibiotic strategy for restoring MDR Acinetobacter baumannii susceptibility

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Stefano STRACQUADANIO

A / 15 / 10

Poster P2324

Abstract 3457

Determination of the role of a novel synthetic cyclic peptide to revert resistance to tetracycline-like antimicrobials in Pseudomonas aeruginosa.

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Natalia ROSON-CALERO

A / 15 / 11

Poster P2325

Abstract 3485

A platform for screening of inhibitors of bacterial antibiotic resistance mechanisms

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Jitka VIKTOROVA

A / 15 / 12

Poster P2326

Abstract 3570

Enhancing the delivery efficiency of nucleic acid mimics into bacteria: influence of liposome composition/functionalisation

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

João Pedro FERREIRA DOS SANTOS

A / 15 / 13

Poster P2327

Abstract 3676

Antibacterial activity of ibezapolstat against antimicrobial resistant clinical strains of Clostridioides difficile

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Eugenie BASSERES

A / 15 / 14

Poster P2328

Abstract 3737

Prioritisation of potential drug targets using protein-protein interaction network analysis in uropathogenic Escherichia coli and insights for finding inhibitors through molecular docking studies

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Harpreet KAUR

A / 15 / 15

Poster P2329

Abstract 3933

A novel Klebsiella pneumoniae bacteriophage kpn17 with depolymerase activity: it's efficacy on biofilm formation

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Sezin UNLU

A / 15 / 16

Poster P2330

Abstract 3977

Overcoming intrinsic resistance of Enterobacterales with a novel molecule adjuvant (MD-124) by improving antibiotic activity through increased membrane permeability

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Jayden ROBERTS

A / 15 / 17

Poster P2331

Abstract 4119

Copper (II) compounds with enhanced photodynamic properties as antimicrobials for the treatment of wound infections

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Kaja TURZANSKA

A / 15 / 18

Poster P2332

Abstract 4193

Phage-mediated reduction of extensively drug-resistant (XDR) Klebsiella pneumoniae ST16 on hard surfaces for decontamination

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Michael Henrique LENZI

A / 15 / 19

Poster P2333

Abstract 4246

Study of the antimicrobial and biological properties of two cationic carbosilane dendrimers against extended-spectrum beta-lactamase-producing Escherichia coli

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Marcos HERNANDO GOZALO

A / 15 / 20

Poster P2334

Abstract 4372

Glyphosate sensibility screening on an extensive collection of microfungi and bacteria

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Hanane ZERROUKI

A / 15 / 21

Poster P2335

Abstract 4459

In vitro synergistic effect and mutant prevention concentration of eravacycline alone or in combination with various antibiotics against OXA-48 producing Enterobacterales

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Emel MATARACI-KARA

A / 15 / 22

Poster P2336

Abstract 4592

Low frequency of spontaneous resistance to LepB inhibitors, GDC-5780 and GDC-0829, in target Gram-negative bacterial species

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Hany GIRGIS

A / 15 / 23

Poster P2337

Abstract 4634

Subcutaneous administration of beta-lactams: a systematic review

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Beatrice LIGUORO

A / 15 / 24

Poster P2338

Abstract 4647

Using in vivo local chronic infection model to validate Pseudomonas aeruginosa clinical phage microbiology (cpm)

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Amit RIMON

A / 15 / 25

Poster P2339

Abstract 4706

In vivo evaluation of CZ-02188: PK and in vivo efficacy for a new class of antibacterial agent

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Chad TESTA

A / 15 / 26

Poster P2340

Abstract 4723

In vitro killing kinetics of GDC-5780, a novel Gram-negative antibiotic, against a panel of Enterobacteriaceae isolates

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Guennaelle DIEPPOIS

A / 15 / 27

Poster P2341

Abstract 4755

Antimicrobial photodynamic therapy of bacterial pneumonias and drug design to overcome the lung surfactant barrier

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Giulia KASSAB

A / 15 / 28

Poster P2342

Abstract 4814

High activity and specificity of bacteriophage cocktails against carbapenem-resistant Klebsiella pneumoniae belonging to high risk clones CG258 and ST307

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

J Natalia JIMENEZ

B / 15 / 1

Poster P2343

Abstract 4964

Assessing synergistic interactions of newly isolated phages in combination with antibacterial agents against MBL-producing P. aeruginosa clinical isolates

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Paschalis PARANOS

B / 15 / 2

Poster P2344

Abstract 4984

Combination of minocycline and ciprofloxacin enhances the inhibitory effect of TNF alpha production in LPS-stimulated THP-1 cells

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Ippei SAKAMAKI

B / 15 / 3

Poster P2345

Abstract 5019

Utilising non-antibiotic compounds to increase intracellular killing of Staphylococcus aureus through immunomodulation

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Riley GROSSO

B / 15 / 4

Poster P2346

Abstract 5051

Relebactam improves the efficacy of imipenem against Burkholderia cepacia complex in a neutropenic mouse lung infection model

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Katherine YOUNG

B / 15 / 5

Poster P2347

Abstract 5137

A novel antimicrobial peptide against multiple drug-resistant bacteria improves infection outcomes in mice

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

John VITUCCI

B / 15 / 6

Poster P2348

Abstract 5168

Evaluating the environmental stability of HtrA, a novel bacterial protease that protects mice from Clostridioides difficile disease

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Jill GREENLAW

B / 15 / 7

Poster P2349

Abstract 5188

Sulopenem: feasibility of an oral penem in tackling urinary Enterobacterale isolates in Indian population

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Sukriti YADAV

B / 15 / 8

Poster P2350

Abstract 5238

Phage-antibiotic synergistic effects on genetic and phenotypic changes in multidrug-resistant Pseudomonas aerguinosa (MDR-PA)

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Andrea Lay Hoon KWA

B / 15 / 9

Poster P2351

Abstract 5251

Characterisation of F. nucleatum FabK as a narrow-spectrum target for antibacterial chemotherapy?

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Kristiana AVAD

B / 15 / 10

Poster P2352

Abstract 5288

In silico selection and in vivo validation of new uropathogenic Escherichia coli inhibitors

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Harpreet KAUR

B / 15 / 11

Poster P2353

Abstract 5298

Optimising in vitro phage-ciprofloxacin combination formulation for respiratory therapy of multidrug-resistant Pseudomonas aeruginosa infections

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Qixuan HONG

B / 15 / 12

Poster P2354

Abstract 5331

Exploring the potential of thymoquinone-based organic nanoparticles in combating methicillin-resistant Staphylococcus aureus

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Nehal Aasem SAIF

B / 15 / 13

Poster P2355

Abstract 5338

Assessment of bacteriological profile and susceptibility pattern of multidrug-resistant Gram-negative bacteria to an innovative antibiotic combination: ceftriaxone-sulbactam plus EDTA

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Haritha MADIGUBBA

B / 15 / 14

Poster P2356

Abstract 5433

Optimised arylomycins GDC-5780 and GDC-0829 represent a promising novel class of antibiotics against Gram-negative pathogens

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Michael KOEHLER

B / 15 / 15

Poster P2357

Abstract 5445

Developing the arylomycins into novel antibiotics against Gram-negative bacteria

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Michael KOEHLER

B / 15 / 16

Poster P2358

Abstract 5495

Optimising buffer composition and salt concentration in a three-step workflow for bacteriophage purification in therapeutic applications

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Hadil ONALLAH

B / 15 / 17

Poster P2359

Abstract 5529

Evaluation of synergic activity between bacteriophage PSE1720 and meropenem against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Giulia TOCCACIELI

B / 15 / 18

Poster P2360

Abstract 5533

Assessment of zosurabalpin activity in combination with other antibiotics

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Isabelle ERBETTI

B / 15 / 19

Poster P2361

Abstract 5683

Evaluation of phage SAU 1593 activity combined with antibiotics against Staphylococcus aureus strains isolated from diabetic foot ulcers

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Giulia TOCCACIELI

B / 15 / 20

Poster P2362

Abstract 5689

In vitro evaluation of cefiderocol and the combination of ceftazidime/avibactam and aztreonam, against extensively drug-resistant Pseudomonas aeruginosa isolates producing serine and metallo-β-lactamases

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Maria Milagro MONTERO

B / 15 / 21

Poster P2363

Abstract 5739

MIC distributions and activity of the novel anti-Acinetobacter agent zosurabalpin (RG6006)

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Stephen HAWSER

B / 15 / 22

Poster P2364

Abstract 5815

Activity of cefepime/enmetazobactam against clinical isolates of carbapenem-resistant OXA-48-producing Enterobacterales

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Juan C. VAZQUEZ-UCHA

B / 15 / 23

Poster P2365

Abstract 5853

Development and in vitro bioevaluation of gentamicin-bacteriophage-loaded biodegradable dressing with antimicrobial prospects against Pseudomonas aeruginosa

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Lavanya KHULLAR

B / 15 / 24

Poster P2366

Abstract 5911

Antimicrobial activity of Staphylococcus isolates from free-living pelicans and potential role in microbiota modulation

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Carmen GONZÁLEZ-AZCONA

B / 15 / 25

Poster P2367

Abstract 5927

Microbiological characteristics of experimental long-term non-healing purulent wounds treated with silver nanoparticles and low-frequency ultrasound

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Petro MYRONOV

B / 15 / 26

Poster P2368

Abstract 5993

Prospects for the use of bacteriophages for the treatment of wound infection caused by MDR, XDR, PDR Klebsiella pneumoniae

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Vadym PONIATOVSKYI

B / 15 / 27

Poster P2369

Abstract 6143

Quinoline amphipaths: a promising frontier for enhancing beta-lactam efficacy against MRSA through synergistic potentiation

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Samya SEN

B / 15 / 28

Poster P2370

Abstract 6154

Exploring phage-antibiotic synergy: phage selection can restore antibiotic sensitivity to treat urinary tract infections in a preclinical study

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Naveen CHAUDHARY

A / 16 / 1

Poster P2371

Abstract 6217

Fluorinated selenoesters as novel inhibitors of bifunctional enzyme AAC/APH

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Michal DVORÁK

A / 16 / 2

Poster P2372

Abstract 6288

In vivo bacteriophage therapy in Pseudomonas aeruginosa burn wound infection

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Aylin USKUDAR-GUCLU

A / 16 / 3

Poster P2373

Abstract 6319

Rational in vitro design of a two-phage cocktail against a contemporary A. baumannii strain recovered from a burned patient at CHUV

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Hugues DE VILLIERS DE LA NOUE

A / 16 / 4

Poster P2374

Abstract 6400

Strain variability in pharmacodynamic responses to antibiotic-phage combination treatments in Pseudomonas aeruginosa

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Laura Rianne BAARS

A / 16 / 5

Poster P2375

Abstract 6564

In vitro effectiveness of new generation drugs on resistant Acinetobacter baumannii

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Yasemin BOLUKBASI

A / 16 / 6

Poster P2376

Abstract 6627

Novel β-lactamase inhibitors for combating OXA-48 carbapenemase-mediated resistance in Enterobacterales: a microbiological and biochemical evaluation

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Outeda MICHELLE

A / 16 / 7

Poster P2377

Abstract 6766

Cefepime/sulbactam versus multi drug resistant Gram-negative Enterobacterales infections

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Agata SOLTYSINSKA

A / 16 / 8

Poster P2378

Abstract 6780

Investigating potential of phage therapy to target Staphylococcus aureus orthopaedic infections

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Sheetal PATPATIA

A / 16 / 9

Poster P2379

Abstract 6807

Mechanism of in vitro resistance to zosurabalpin (RG6006) in Acinetobacter baumannii

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Andrej TRAUNER

A / 16 / 10

Poster P2380

Abstract 6875

Antibiotic susceptibility of Cutibacterium acnes in orthopedic patients and alternative treatments

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Alkmini ANGELOPOULOU

A / 16 / 11

Poster P2381

Abstract 7141

Blocking bacterial communication process with quorum sensing specific antibodies as a new therapeutic strategy to treat Pseudomonas aeruginosa infections

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Lluïsa VILAPLANA

A / 16 / 12

Poster P2382

Abstract 7145

Cyclometallated gold(III) dithiocarbamate complexes: searching for a clinical metalloantibiotic

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Sara Maria SOTO

A / 16 / 13

Poster P2383

Abstract 7170

Metformin's double duty: from antidiabetic hero to antibiotic dilemma

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Lina MAAROUF

A / 16 / 14

Poster P2384

Abstract 7243

Mechanisms of action of RW5, a Poly(Trp-Arg) peptide

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Ester FUSTE

A / 16 / 15

Poster P2385

Abstract 7292

Mechanisms of action of the Poly(Arg-Trp) peptide (RW2)

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Eric FERNANDEZ DE LA CRUZ

A / 16 / 16

Poster P2386

Abstract 7311

In vitro cefiderocol activity against multiple multidrug-resistant Gram-negative bacteria

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Rubén LOBATO CANO

A / 16 / 17

Poster P2387

Abstract 7377

SPR206: a novel polymyxin with broad-spectrum Gram-negative efficacy has potent synergy with macrolide and tetracycline antibiotics

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Ashelyn SIDDERS

A / 16 / 18

Poster P2388

Abstract 7498

Comparison of phage cocktail vs single phages against carbapenemase-producing K. pneumoniae clinical isolates

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Paschalis PARANOS

A / 16 / 19

Poster P2389

Abstract 7510

In vitro comparison of phage cocktail vs single phages against MBL-producing P. aeruginosa clinical isolates using growth curves

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Paschalis PARANOS

A / 16 / 20

Poster P2390

Abstract 7698

Let it flow: microfluidics to deliver antimicrobial nanoparticles for Helicobacter pylori management

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Diana FONSECA

A / 16 / 21

Poster P2391

Abstract 7713

New peptide-based constructs for wound healing

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Mariana FERREIRA

A / 16 / 22

Poster P2392

Abstract 7721

Synergistic bactericidal effect of phage therapy and pulsed blue light in planktonic and biofilm pseudomonas aeruginosa

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Amit RIMON

A / 16 / 23

Poster P2393

Abstract 7745

Virulent jumbo phage vB_Kpn_MSAZC, against carbapenemase-producing Klebsiella pneumoniae

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Bishoy ZAKI

A / 16 / 24

Poster P2394

Abstract 7861

Bacteriophage efficacy against Staphylococcus aureus in burn wounds, using an ex vivo human skin model

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Michele MOLENDIJK

A / 16 / 25

Poster P2395

Abstract 7982

Development of a novel class of ribosomal inhibitors with potent activity against MDR bacterial pathogens to treat wound infections

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Daniel ZURAWSKI

A / 16 / 26

Poster P2396

Abstract 7995

Antibiotic-loaded liposome armed on bacteriophage surface for combating methicillin-resistant Staphylococcus aureus infection by bio-orthogonal functionalisation strategy

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Lei WANG

A / 16 / 27

Poster P2397

Abstract 8299

Resistance reversing effect of azaindole and indole derivatives in bacteria

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Nikoletta SZEMERÉDI

A / 16 / 28

Poster P2398

Abstract 8353

Searching for antimicrobial-producing bacteria from soils and their potential as biocontrol agents

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Mario Sergio PINO HURTADO

B / 16 / 1

Poster P2399

Abstract 8359

MEndoB, a chimeric lysin featuring a novel domain architecture and superior activity for the treatment of staphylococcal infections

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Christian ROEHRIG

B / 16 / 2

Poster P2400

Abstract 8420

Host defence peptides as promising strategy against multidrug resistant bacteria

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Anna DE FILIPPIS

B / 16 / 3

Poster P2401

Abstract 8527

Synthesis of silver and gold nanoparticles using the leaf extract of M.esculenta and their antibacterial activity against pan-resistant clinical isolates of patients with urinary tract infections

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Diksha DIKSHA

B / 16 / 4

Poster P2402

Abstract 8638

Timely tactics: optimising bacteriophage and antimicrobial efficacy against daptomycin non-susceptible (DNS) and MRSA clinical isolates

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Callan BLEICK

B / 16 / 5

Poster P2403

Abstract 8642

A thoughtful combination of Tequatrovirus/Vectrevirus bacteriophages allows mice gut decolonisation of a multidrug-resistant ST131 Escherichia coli strain

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Floriane LAUMAY

B / 16 / 6

Poster P2404

Abstract 8693

Adaptation of a novel phage to enhance its lytic activity against multidrug-resistant Staphylococcus aureus

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Sara BOLOGNINI

B / 16 / 7

Poster P2405

Abstract 8709

Target identification and mode of action studies of zosurabalpin

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Claudia ZAMPALONI

B / 16 / 8

Poster P2406

Abstract 8718

Human serum lipids might affect Staphylococcus aureus sensitivity to phages

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Mariagrazia DI LUCA

B / 16 / 9

Poster P2407

Abstract 8735

Novel Klebsiella pneumoniae bacteriophages active against multi-drug resistant clinical strains for hospitalized patient decolonisation

28/04 12:00

5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Elisa FAUSTI

B / 16 / 11

Poster P2409

Abstract 206

Bayesian AUC-based dosing of vancomycin in pediatrics: a single centre experience

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Rachel MEYERS

B / 16 / 12

Poster P2410

Abstract 238

Tissue distribution of ceftazidime-avibactam in kidney tissue in healthy rats and pigs using a microdialysis technique.

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Maxime VALLÉE

B / 16 / 13

Poster P2411

Abstract 303

A systematic review of pulmonary pharmacokinetic/pharmacodynamic characteristics of beta-lactam antibiotics used to treat pneumonia caused by carbapenem-resistant Gram-negative bacteria

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Emanuele RANDO

B / 16 / 14

Poster P2412

Abstract 327

Development, validation and application of an LC-MS/MS method for the simultaneous quantitative determination of four triazole antifungal concentrations in human plasma

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Yun CAI

B / 16 / 15

Poster P2413

Abstract 425

Population pharmacokinetic model selection based on patient's characteristics improves the predictive performance of vancomycin individualised dosing

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Hanna Kadri LAAS

B / 16 / 16

Poster P2414

Abstract 631

Potential synergy of fluoxetine with antimicrobials

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Samar AHMED

B / 16 / 17

Poster P2415

Abstract 784

Therapeutic monitoring of dalbavancin concentrations in the long-term treatment of osteoarticular or periprosthetic joint infections: a single-centre experience

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Chiara MARIANI

B / 16 / 18

Poster P2416

Abstract 844

Dried blood spot analysis for the quantification of vancomycin and creatinine using liquid chromatography-tandem mass spectrometry: method development and validation

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Soma HERBERS BAHMANY

B / 16 / 19

Poster P2417

Abstract 857

Pharmacodynamics of fosfomycin in combination with meropenem: impact on the size of the fosfomycin pharmacodynamic index for Klebsiella pneumoniae

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Marie ATTWOOD

B / 16 / 20

Poster P2418

Abstract 936

Therapeutic drug monitoring of ceftazidime/avibactam supports continuous infusion administration: a retrospective analysis of pharmacological, microbiological, and clinical outcomes

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Sara FERIN

B / 16 / 21

Poster P2419

Abstract 1078

Pharmacokinetics and safety in ICU patients and healthy participants following single dose administration of zosurabalpin (RG6006), a novel pathogen-specific antibiotic for the treatment of serious Acinetobacter infections

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Emmanuelle COTTREEL

B / 16 / 22

Poster P2420

Abstract 1210

A six-year experience of therapeutic drug monitoring of linezolid: more evidence favouring the need to individualise dosage regimens

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Sonia LUQUE

B / 16 / 23

Poster P2421

Abstract 1275

Probability of target attainment analysis of orally administered amoxicillin using a physiology-based pharmacokinetic model

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Christopher DARLOW

B / 16 / 24

Poster P2422

Abstract 1398

Therapeutic drug monitoring of antibiotics in exhaled breath

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Sarah DRÄGER

B / 16 / 25

Poster P2423

Abstract 1421

Predictive performance of population pharmacokinetic models for model-informed precision dosing of meropenem in critically ill patients varied across different study settings

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Iris K MINICHMAYR

B / 16 / 26

Poster P2424

Abstract 1553

Pharmacokinetics of zoliflodacin in healthy participants in the presence of itraconazole suggest no clinically meaningful CYP3A4-mediated drug-drug interactions

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Alison LUCKEY

B / 16 / 27

Poster P2425

Abstract 1650

Influence of continuous infusion on the plasma exposure of novel betalactams: does it really reduce the interindividual pharmacokinetic variability in different populations?

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Sonia LUQUE

A / 17 / 1

Poster P2427

Abstract 1743

Short and extended infusion of beta-lactams: predicted impact on target attainment and risk for toxicity in intensive care patients

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Maria SWARTLING

A / 17 / 2

Poster P2428

Abstract 1786

Pharmacodynamic index driver of NOSO-502: conclusions from in vivo and in vitro studies

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Sanne VAN DEN BERG

A / 17 / 3

Poster P2429

Abstract 1819

Pharmacokinetics and safety of BV100 in subjects with mild and moderate hepatic impairment

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Glenn E DALE

A / 17 / 4

Poster P2430

Abstract 1831

In vivo efficacy of enmetazobactam combined with cefepime in a neutropenic murine OXA-48 Klebsiella pneumoniae pneumonia model

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Delphine CROISIER

A / 17 / 5

Poster P2431

Abstract 1993

BV100 displays potent efficacy against Acinetobacter baumannii in neutropenic murine thigh and lung infection models

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Michel PIEREN

A / 17 / 6

Poster P2432

Abstract 2034

Rapid design of combination antimicrobial therapy against Acinetobacter baumannii

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Brianna EALES

A / 17 / 7

Poster P2433

Abstract 2048

In vitro activity of gepotidacin and comparator agents against a collection of K. pneumoniae urine isolates collected from Europe during 2019-2022

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

S. J. Ryan ARENDS

A / 17 / 8

Poster P2434

Abstract 2073

Clinical efficacy of attaining aggressive PK/PD targets with beta-lactams in critically ill patients with Gram-negative infections: a systematic review and meta-analysis

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Milo GATTI

A / 17 / 9

Poster P2435

Abstract 2076

Population pharmacokinetics of flucloxacillin as intermittent bolus infusion in patients with Staphylococcus aureus bloodstream infection

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Sarah DRÄGER

A / 17 / 10

Poster P2436

Abstract 2081

A pre-post quasi-experimental study assessing the impact of a real-time TDM-guided expert clinical pharmacological advice programme for optimising continuous infusion beta-lactam PK/PD target attainment on clinical/microbiological outcome of documented Gram-negative infections among critical OLT recipients

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Milo GATTI

A / 17 / 11

Poster P2437

Abstract 2105

Classification of patients into subpopulations with different best-fitting population pharmacokinetic models to improve model-informed precision dosing

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Hiie SOEORG

A / 17 / 12

Poster P2438

Abstract 2145

The higher, the worse? Increasing antibiotic exposure is associated with mortality in critically ill patients: an unexpected finding in a secondary analysis of the DOLPHIN trial

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Sarah DRÄGER

A / 17 / 13

Poster P2439

Abstract 2238

Teicoplanin regimens for the treatment of osteoarticular infection: an observational study

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Alessandra Helen BEHRING

A / 17 / 14

Poster P2440

Abstract 2329

Simultaneous and fast UPLC-UV assay to quantify multiple triazole antifungal drugs for antifungal therapeutic drug monitoring (TDM)

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Tze-Peng LIM

A / 17 / 15

Poster P2441

Abstract 2332

Consideration of polymyxin B (PB) components matters when determining AUC values for accurate PB dose adjustments in patients with (extensively drug-resistant Gram-negative bacteria) XDR-GNB infections

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Tze-Peng LIM

A / 17 / 16

Poster P2442

Abstract 2343

Therapeutic drug monitoring of beta-lactams among hospitalised patients in Singapore: a prospective, single-centre, observational study (BLAST-2)

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Tze-Peng LIM

A / 17 / 17

Poster P2443

Abstract 2363

Development of an online tool for the management of drug-drug interactions with the novel anti-cytomegalovirus (CMV) agents letermovir and maribavir

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Laura NIJBOER

A / 17 / 18

Poster P2444

Abstract 2403

Pharmacokinetics of ethionamide and ethionamide sulfoxide in patients established on treatment for tuberculosis

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Michel PIEREN

A / 17 / 19

Poster P2445

Abstract 2423

Therapeutic drug monitoring of meropenem in critically ill patients during ECMO support: a single-centre prospective study

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Manuel SOSA

A / 17 / 20

Poster P2446

Abstract 2476

Pharmacokinetics of ceftazidime/avibactam in bile fluid: an in vivo study

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Lars PALMOWSKI

A / 17 / 21

Poster P2447

Abstract 2483

Impact of efflux transporters on fluoroquinolone accumulation in eukaryotic cells and activity against intracellular Staphylococcus aureus

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Gwenaëlle MAHIEU

A / 17 / 22

Poster P2448

Abstract 2503

Optimising dosing strategies of temocillin for systemic infections using pharmacokinetic-pharmacodynamic modelling and simulation

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Wisse VAN OS

A / 17 / 23

Poster P2449

Abstract 2547

Pharmacokinetic and pharmacodynamic properties of polymyxin B in Acinetobacter baumannii murine infection models

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Sanne VAN DEN BERG

A / 17 / 24

Poster P2450

Abstract 2563

The addition of polymyxin B to minocycline may increase the antibacterial activity against Klebsiella pneumoniae in a murine infection model

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Sanne VAN DEN BERG

A / 17 / 25

Poster P2451

Abstract 2607

Safety and pharmacokinetic results from the first-in-human study with intravenously administered OMN6, a novel antimicrobial peptide for Acinetobacter baumannii (AB), conducted in healthy volunteers

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Andrew SHORR

A / 17 / 26

Poster P2452

Abstract 2667

Preliminary zosurabalpin broth microdilution quality control ranges using Clinical and Laboratory Standards Institute M23 criteria

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Michael HUBAND

A / 17 / 27

Poster P2453

Abstract 2714

Lower temocillin doses are required in septic intensive care patients as compared to patients with mild urinary tract infections due to differences in protein binding

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Anouk Edwina MULLER

A / 17 / 28

Poster P2454

Abstract 2740

Anidulafungin exposure and population pharmacokinetics in critically ill patients with invasive candidiasis

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Omar ELKAYAL

B / 17 / 1

Poster P2455

Abstract 2755

Addition of urine NGAL to serum creatinine improves prediction of cefepime clearance in pediatric ICU patients at high risk of acute kidney injury

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Horace Rhodes HAMBRICK

B / 17 / 2

Poster P2456

Abstract 2875

A promising antimicrobial peptide against some virulence features of Acinetobacter baumannii clinical strains

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Irene PARIS

B / 17 / 3

Poster P2457

Abstract 3066

Mechanism-based mathematical modelling predicts the effects of ciprofloxacin and meropenem on Pseudomonas aeruginosa with different resistance mechanisms in cases where PK/PD indices cannot

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Alice TERRILL

B / 17 / 4

Poster P2458

Abstract 3097

Evaluation of the stability of ceftazidime/avibactam in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy utilising a national stability protocol framework

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Fekade SIME

B / 17 / 5

Poster P2459

Abstract 3143

High rates of augmented renal clearance identified in critically ill paediatric patients leads to poor attainment of antimicrobial PK/PD targets

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Suzanne PARKER

B / 17 / 6

Poster P2460

Abstract 3159

Pharmacokinetic/pharmacodynamics target attainment rate of β-lactam antibiotic in low body weight patients

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Chien Chih WU

B / 17 / 7

Poster P2461

Abstract 3200

In vivo efficacy of humanized pulmonary exposures of WCK 5222 (cefepime/zidebactam) in neutropenic murine lung infection caused by carbapenemase-producing Klebsiella pneumoniae (KP) and Acinetobacter baumannii (AB) with WCK 5222 MICs of 16/16 to 64/64 mg/L

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Anouk Edwina MULLER

B / 17 / 8

Poster P2462

Abstract 3223

Exploring antibacterial potential of Withania coagulans: GC-MS profiling, molecular docking and in vitro studies

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Aqeela ASHRAF

B / 17 / 9

Poster P2463

Abstract 3279

Plasma and prostatic tissue pharmacokinetics of gepotidacin in patients undergoing prostatectomy: an ex vivo microdialysis study

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Valentin AL JALALI

B / 17 / 10

Poster P2464

Abstract 3282

Pharmacokinetics of ceftazidime-avibactam in critically ill patients undergoing continuous venovenous hemodiafiltration

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Amaury O'JEANSON

B / 17 / 11

Poster P2465

Abstract 3305

Different therapeutic schemes influence PK/PD target attainment in patients administered with cefiderocol

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Jacopo MULA

B / 17 / 12

Poster P2466

Abstract 3439

Continuous versus intermittent piperacillin-tazobactam infusion against low and high inoculum of ESBL-producing Escherichia coli infections

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Marion GIRY

B / 17 / 13

Poster P2467

Abstract 3476

Pharmacodynamics of minocycline combined with rifampicin against Staphylococcus aureus and Acinetobacter baumannii in a neutropenic murine lung infection model

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Anouk Edwina MULLER

B / 17 / 14

Poster P2468

Abstract 3541

Key factors influencing phage pharmacokinetics in healthy rodents through a model-based approach

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Yu-Wei LIN

B / 17 / 15

Poster P2469

Abstract 3567

Exploring drug-exposure and therapeutic drug monitoring (TDM) in an outpatient antimicrobial therapy (OPAT) service

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Richard WILSON

B / 17 / 16

Poster P2470

Abstract 3779

Meropenem and linezolid plasma and subcutaneous tissue pharmacokinetics in septic patients

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Maria SANZ CODINA

B / 17 / 17

Poster P2471

Abstract 3794

Fosfomycin and amikacin show a highly synergistic interaction against resistant Escherichia coli: a promising antibiotic combination therapy

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Nicole ZIMMERMANN

B / 17 / 18

Poster P2472

Abstract 3807

A pooled population pharmacokinetic study of oral and intravenous clavulanic acid in neonates and infants: too many ratios?

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Stef SCHOUWENBURG

B / 17 / 19

Poster P2473

Abstract 3966

The instantaneous minimum inhibitory concentration as promising pharmacodynamic metric to optimise dosing strategies of piperacillin/tazobactam

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Malin ANDERSSON

B / 17 / 20

Poster P2474

Abstract 4062

Determination of the pharmacodynamic driver of efficacy of a novel type-3 secretion system inhibitor MBX-5452 against Pseudomonas aeruginosa

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Alexander LEPAK

B / 17 / 21

Poster P2475

Abstract 4183

High target attainment for B-lactam antibiotics in patients with Gram-negative blood stream infections when actual minimum inhibitory concentrations are applied

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Ilja ARESKOG LEJBMAN

B / 17 / 22

Poster P2476

Abstract 4190

The pharmacokinetics of cloxacillin in the intensive care unit depend on the glomerular filtration rate and the plasma protein concentration

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Sophie PERINEL RAGEY

B / 17 / 23

Poster P2477

Abstract 4284

TDM-guided thrice weekly versus once daily administrations to optimise teicoplanin use in real-life settings

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Martina GERBI

B / 17 / 24

Poster P2478

Abstract 4676

Analysis of ceftazidime-avibactam concentrations in critically ill patients under extracorporeal membrane oxigenation support: a prospective single-centre observational study

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Manuel SOSA

B / 17 / 25

Poster P2479

Abstract 4707

Activity of gepotidacin against molecularly characterized Klebsiella pneumoniae isolates from patients with urinary tract infections in Europe and adjacent regions (2019-2022)

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Rodrigo E. MENDES

B / 17 / 26

Poster P2480

Abstract 4749

Spine-tastic revolutions: tailoring dalbavancin treatment for infectious spondylodiscitis with a therapeutic drug monitoring (TDM) twist

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Fabiana DELLAI

B / 17 / 27

Poster P2481

Abstract 4849

Subcutaneous and intravenous ceftriaxone show similar PK/PD in older patients

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Sylvain GOUTELLE

B / 17 / 28

Poster P2482

Abstract 4859

Effect of fosfomycin minimal inhibitory concentration determined by agar dilution on outcomes of ceftazidime/avibactam plus fosfomycin combination for the treatment of KPC-producing K. pneumoniae bloodstream infections

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Alessandra OLIVA

A / 18 / 1

Poster P2483

Abstract 5054

Pharmacokinetic/pharmacodynamic characteristics of the new monobactam AIC499 in murine thigh and lung infection models against Gram-negative pathogens

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Panagiota-Christina GEORGIOU

A / 18 / 2

Poster P2484

Abstract 5101

Pharmacodynamics of the new monobactam AIC499 in combination with tazobactam against Gram-negative pathogens in an experimental thigh infection murine model

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Panagiota-Christina GEORGIOU

A / 18 / 3

Poster P2485

Abstract 5339

Antimicrobial dosing in augmented renal clearance: a scoping review

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Aysel PEHLI?VANLI

A / 18 / 4

Poster P2486

Abstract 5579

Time-dependent amoxicillin concentrations in infected tissue of deep-seated musculoskeletal infections

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Joana ERDMANN

A / 18 / 5

Poster P2487

Abstract 5612

Serial nitrite measurement to evaluate antimicrobial pharmacodynamics (PD) in urinary tract infections (UTIs): a proof-of-concept for precision antimicrobial therapy

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Ellen STADLER

A / 18 / 6

Poster P2488

Abstract 5615

Pharmacokinetics/pharmacodynamics and safety of EVER206, a novel polymyxin antimicrobial, in healthy Chinese subjects

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Size LI

A / 18 / 7

Poster P2489

Abstract 5672

Interspecies variability in protein binding of antibiotics as basis for translational PK/PD studies: a case study using cefazolin and clindamycin

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Hifza AHMED

A / 18 / 8

Poster P2490

Abstract 5678

Spotting method as a high throughput alternative to the conventional spread plating method for bacterial time-kill experiments

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Vincent ARANZANA-CLIMENT

A / 18 / 9

Poster P2491

Abstract 5747

A six-year study examining the correlation between daptomycin exposure, clinical outcomes, and toxicity

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Luisa SORLÍ

A / 18 / 10

Poster P2492

Abstract 5785

Development and validation of a PBPK model of gepotidacin in rats to predict exposure in human prostate

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Vincent ARANZANA-CLIMENT

A / 18 / 11

Poster P2493

Abstract 5800

Exposure to rifampicin and its metabolite 25-deacetylrifampicin rapidly decreases during tuberculosis therapy

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Sylvain GOUTELLE

A / 18 / 12

Poster P2494

Abstract 5824

Pulmonary penetration of high doses ceftobiprole administered by continuous infusion in critically ill patients with community-acquired pneumonia

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Claire ROGER

A / 18 / 13

Poster P2495

Abstract 5936

Optimising linezolid therapy in critical care: combining therapeutic drug monitoring and model-based approaches enhances target attainment

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Johannes STARP

A / 18 / 14

Poster P2496

Abstract 5955

Enhanced ceftolozane-tazobactam exposure improved eradication of resistant bacteria: implications for revised S, I, and R classification

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Alina NUSSBAUMER-PRÖLL

A / 18 / 15

Poster P2497

Abstract 5973

Model-informed drug development for antimicrobials: translational pharmacokinetic-pharmacodynamic modelling of apramycin to facilitate prediction of efficacious dose in complicated urinary tract infections

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Irene HERNANDEZ-LOZANO

A / 18 / 16

Poster P2498

Abstract 6342

Loading dose of ceftazidime need to be increased in critically ill patients

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Manon LAUNAY

A / 18 / 17

Poster P2499

Abstract 6454

Comparative assessment of renal function estimating equations as surrogates for amoxicillin clearance in geriatric inpatients

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Arnaud DE CLERCQ

A / 18 / 18

Poster P2500

Abstract 6475

Bayesian LeiCNS PBPK modeling for acyclovir dose optimisation for central nervous system viral infection

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Sun MING

A / 18 / 19

Poster P2501

Abstract 6510

Population pharmacokinetics and model-informed precision dosing of unbound teicoplanin in intensive care and hematology patients

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Jaap MOUTON

A / 18 / 20

Poster P2502

Abstract 6516

Cotrimoxazole pharmacokinetics in critically-ill patients with impaired or augmented renal function

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Sophie PERINEL RAGEY

A / 18 / 21

Poster P2503

Abstract 6613

Near real-time dose adjustment of benzylpenicillin: a proof-of-concept for closed-loop control in healthy volunteers

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Ryan ARMIGER

A / 18 / 22

Poster P2504

Abstract 6634

Pharmacokinetics of amoxicillin/clavulanate in pediatric patients with severe community acquired pneumonia: a preliminary analysis from the PediCAP trial

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Jennie VAN DYK

A / 18 / 23

Poster P2505

Abstract 6702

Therapeutic drug monitoring and model-informed precision dosing are highly effective for optimising duration of dalbavancin exposure in long-term treatment of staphylococcal infections

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Pier Giorgio COJUTTI

A / 18 / 24

Poster P2506

Abstract 6756

Pharmacokinetic/pharmacodynamic target attainment of beta-lactam antibiotics in geriatric inpatients using standard-of-care dosing regimens

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Arnaud DE CLERCQ

A / 18 / 25

Poster P2507

Abstract 7165

In vitro activity of cefepime/enmetazobactam,and comparators, against OXA carbapenemase-positive Acinetobacter baumannii

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Nathalie DUNKEL

A / 18 / 26

Poster P2508

Abstract 7205

A small step in target site concentrations analysis, a big leap for prosthetic joint infection patients

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Gerbert Coen DE WAARD

A / 18 / 27

Poster P2509

Abstract 7318

What clindamycin dose for which administration route in case of combination with rifampicin?

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Vincent JULLIEN

A / 18 / 28

Poster P2510

Abstract 7379

Pharmacokinetics, safety, and tolerability of funobactam alone or in combination with imipenem/cilastati in healthy subjects

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Jianguo LI

B / 18 / 1

Poster P2511

Abstract 7529

Probability of target attainment and neurotoxic concentration of broad spectrum β-lactams in critically ill patients receiving continuous kidney replacement therapy

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Chihhsun TAI

B / 18 / 2

Poster P2512

Abstract 7590

Comparison of two different methods for measuring unbound concentrations of daptomycin in patients with proven or suspected gram-positive bacterial infections

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Sonia LUQUE

B / 18 / 3

Poster P2513

Abstract 7863

Cefepime/enmetazobactam dose adjustments for renal function in patients using population pharmacokinetic simulations

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Anne SANTERRE HENRIKSEN

B / 18 / 4

Poster P2514

Abstract 7947

Global standardisation of the preclinical translational murine pneumonia model: influence of starting inoculum on viability and reproducibility of Klebsiella pneumoniae in vivo growth

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Fratoni ANDREW

B / 18 / 5

Poster P2515

Abstract 7948

Humanised plasma profiles in a standardised preclinical murine infection model miss the mark on replicating pulmonary epithelial lining fluid (ELF) concentrations

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Fratoni ANDREW

B / 18 / 6

Poster P2516

Abstract 8198

Systematic review of antimicrobial pharmacokinetic/pharmacodynamic indices in murine thigh and hollow fibre infection models

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Najla ALABDULKARIM

B / 18 / 7

Poster P2517

Abstract 8412

Low early vancomycin target attainment: failing implementation or failing dosing recommendation?

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Dorian VANNESTE

B / 18 / 8

Poster P2518

Abstract 8680

In vitro evaluation of the inoculum effect of various β-lactamase-producing Klebsiella pneumoniae isolates on ceftazidime-avibactam

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Alexia CHAUZY

B / 18 / 9

Poster P2519

Abstract 8720

Impact of model-informed precision dosing in adults receiving vancomycin via continuous infusion: interim analysis of a randomised, controlled clinical trial

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Pieter DE COCK

B / 18 / 10

Poster P2520

Abstract 8902

Isavuconazole pharmacokinetics in critically ill patients on extracorporeal membrane oxygenation

28/04 12:00

5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)

Manuel SOSA

B / 18 / 11

Poster P2521

Abstract 222

Cefiderocol either in monotherapy or combination vs best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Lorenzo ONORATO

B / 18 / 12

Poster P2522

Abstract 887

Outcomes at test of cure by baseline pathogen and cefepime-taniborbactam or meropenem MIC in the Phase 3 CERTAIN-1 study of patients with complicated urinary tract infection (cUTI)

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Greg MOECK

B / 18 / 13

Poster P2523

Abstract 1497

Real-world effectiveness and safety of cefiderocol in patients with Gram-negative bacterial infections in the early access programme in Spain: results of the PERSEUS study

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Sarda JESSICA

B / 18 / 14

Poster P2524

Abstract 1499

Real-world effectiveness and safety of long-term (>28 days) cefiderocol treatment in patients with Gram-negative bacterial infections in the PERSEUS study in Spain

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Sarda JESSICA

B / 18 / 15

Poster P2525

Abstract 1501

Effectiveness of cefiderocol in patients with intra-abdominal infections caused by Gram-negative bacteria in the PERSEUS study in Spain

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Sarda JESSICA

B / 18 / 16

Poster P2526

Abstract 1631

Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of ANT3310, a novel serine beta-lactamase inhibitor, in healthy volunteers

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Christian ZWINGELSTEIN

B / 18 / 17

Poster P2527

Abstract 1634

Antimicrobial susceptibility of baseline Neisseria gonorrhoeae isolates from participants recruited in the global zoliflodacin Phase 3 randomised controlled trial

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Esther BETTIOL

B / 18 / 18

Poster P2528

Abstract 1761

Early symptom response in patients with uncomplicated urinary tract infection treated with gepotidacin or nitrofurantoin: pooled data from two pivotal Phase 3 studies

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Keith KAYE

B / 18 / 19

Poster P2529

Abstract 1767

Ceftazidime/avibactam versus other antimicrobial agents for treatment of multidrug-resistant Pseudomonas aeruginosa: a systematic review and meta-analysis

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Chhavi GUPTA

B / 18 / 20

Poster P2530

Abstract 2495

Efficacy of gepotidacin vs nitrofurantoin for uncomplicated urinary tract infections: outcomes in EUCAST-based analysis populations from two Phase 3 noninferiority trials

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Amanda SHEETS

B / 18 / 21

Poster P2531

Abstract 2650

Gepotidacin and nitrofurantoin efficacy by baseline uropathogen phenotypes and genotypes recovered from EAGLE-2/EAGLE-3 clinical trials for uncomplicated urinary tract infections

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Nicole SCANGARELLA-OMAN

B / 18 / 22

Poster P2532

Abstract 2674

In vitro activity of gepotidacin against baseline uropathogenic phenotypes and genotypes recovered from EAGLE-2/EAGLE-3 clinical trials for uncomplicated urinary tract infections

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Nicole SCANGARELLA-OMAN

B / 18 / 23

Poster P2533

Abstract 2705

Colistin/meropenem: the impact of synergy on outcomes in the OVERCOME trial

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Mariya HURALSKA

B / 18 / 24

Poster P2534

Abstract 3164

A randomised trial evaluating a novel individualised treatment strategy for carbapenem-resistant Gram-negative infections

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Jocelyn TEO

B / 18 / 25

Poster P2535

Abstract 3563

Normobaric oxygen therapy augments killing of slow growing Pseudomonas aeruginosa by quinolones

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Mette KOLPEN

B / 18 / 26

Poster P2536

Abstract 3830

Efficacy of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the United States (CACTUS) among immunocompromised patients

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Ryan SHIELDS

B / 18 / 27

Poster P2537

Abstract 4185

Pivmecillinam for oral transition therapy in Gram-negative bacteraemia

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Neil STEVENSON

B / 18 / 28

Poster P2538

Abstract 4254

Efficacy of cefiderocol for the treatment of Stenotrophomonas maltophilia infections: a case series from the SUSANA cohort

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Marco FOIS

A / 19 / 1

Poster P2539

Abstract 4605

Dalbavancin in the treatment of osteoarticular infections: real-world data from the Italian cohort SUSANA

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Luca MEZZADRI

A / 19 / 2

Poster P2540

Abstract 4675

Dalbavancin as consolidation therapy of enterococcal infective endocarditis: preliminary results of Spanish-French cohort

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Svetlana SADYRBAEVA-DOLGOVA

A / 19 / 3

Poster P2541

Abstract 4846

Real-world use of dalbavancin in the Italian SUSANA cohort (SUrveillance of SAfety and outcome of New Antibiotics)

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Sara TORDI

A / 19 / 4

Poster P2542

Abstract 5017

Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multi-drug resistant Pseudomonas aeruginosa

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Lodise THOMAS

A / 19 / 5

Poster P2543

Abstract 5227

Establishment and application of evaluation criteria for the clinical use of ceftazidime-avibactam

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Tianping CHEN

A / 19 / 6

Poster P2544

Abstract 5464

IPTC standardised phage matching, treatment, and monitoring protocol for compassionate bacteriophage use in non-resolving infections

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Hadil ONALLAH

A / 19 / 7

Poster P2545

Abstract 6081

Effectiveness of fifth-generation-cephalosporins plus daptomycin compared to other-antimicrobial-regimens for methicillin-resistant Staphylococcus aureus bacteraemia: a multicentre retrospective cohort study (Staphy-DOOR)

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Alessandra BELATI

A / 19 / 8

Poster P2546

Abstract 6148

Chronic Pseudomonas aeruginosa pulmonary infection treated with a nebulised phage cocktail in patients with cystic fibrosis: a phase 1b/2a randomised, double-blind, placebo-controlled, multicentre study

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Urania RAPPO

A / 19 / 10

Poster P2548

Abstract 6644

Nano boost: enhancing antibacterial efficacy of ceftriaxone with magnesium oxide nanoparticles to tackle antimicrobial resistance

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Qaiser AKRAM

A / 19 / 11

Poster P2549

Abstract 6813

Cefiderocol for the treatment of resistant Gram-negative infections: preliminary results from the Italian multicentre CEFI-BAC study

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Benedetta VARISCO

A / 19 / 12

Poster P2550

Abstract 7413

A Phase 1 study of the safety, tolerability, and pharmacokinetics of the beta-lactamase inhibitor xeruborbactam (XER) administered as the isobutyryloxymethyl oral prodrug to healthy adult subjects

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Jason ROBERTS

A / 19 / 13

Poster P2551

Abstract 7549

An interim analysis of fovocip: a multicentre randomised trial of fosfomycin vs ciprofloxacin for febrile neutropenia prevention in haematological patients

28/04 12:00

5c. New or repurposed antibacterial agents: clinical studies and randomised trials

Javier FERNÁNDEZ

A / 19 / 14

Poster P2552

Abstract 90

Antimicrobial dosing optimisation during continuous renal replacement therapy: a comparison of clinical decision support systems

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Helin SAHINTURK

A / 19 / 15

Poster P2553

Abstract 200

De-escalation of antibiotics in critically-ill patients with negative clinical cultures

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Sruthi MENON

A / 19 / 16

Poster P2554

Abstract 299

Stronger together? Potential of combining AMR industry datasets and comparison with WHO GLASS

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Quentin LECLERC

A / 19 / 17

Poster P2555

Abstract 402

Successful intervention in intensive care unit (ICU) of a private hospital in Rio de Janeiro: decreasing MDR bugs and keeping the patient´s safety

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Wania FREITAS

A / 19 / 18

Poster P2556

Abstract 417

Hospital-based antimicrobial stewardship in Denmark, Greenland, and the Faroe Islands: current landscape and barriers

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Christian KRAEF

A / 19 / 19

Poster P2557

Abstract 482

Adherence to the recommendations of the antimicrobial stewardship program audits in a university hospital: what can we do better?

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Alvaro IRIGOYEN VON SIERAKOWSKI

A / 19 / 20

Poster P2558

Abstract 533

Improving appropriate empiric antibiotic treatment through the use of antibiotic standardised treatment packages

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Kristina ÖBRINK-HANSEN

A / 19 / 21

Poster P2559

Abstract 539

Mixed-method approach to determine additional off-label indications for specific antimicrobials: an example with ceftaroline

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Hester STOORVOGEL

A / 19 / 22

Poster P2560

Abstract 541

Opportunities for self-administered outpatient parenteral antimicrobial therapy: a systematic literature review

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Hester STOORVOGEL

A / 19 / 23

Poster P2561

Abstract 579

Need for proactive antimicrobial stewardship and effective infection control measures to address the escalating threat of antimicrobial resistance in Pakistan: A five-year analysis of carbapenem-resistant Gram-negative bacterial infections

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Sadia ISHAQUE

A / 19 / 24

Poster P2562

Abstract 660

National colistin prescribing practices in neonates and children in South Africa: clinician survey

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Vindana CHIBABHAI

A / 19 / 25

Poster P2563

Abstract 677

Impact of antibiotic stewardship program on hospital antibiotic consumption in an Italian hospital: an observational study

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Giacomo STROFFOLINI

A / 19 / 26

Poster P2564

Abstract 737

Successful implementation of an antimicrobial stewardship program in an oncology center in Lima, Peru

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Carlos SEAS

A / 19 / 27

Poster P2565

Abstract 749

Prospective pharmacist-led interventional study with multidisciplinary antimicrobial stewardship (AMS) programs among neonatal intensive care units (NICU) in South Africa

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Debbie GOFF

A / 19 / 28

Poster P2566

Abstract 895

Study of prescribing patterns and effectiveness of ceftolozane/tazobactam real-world analysis (SPECTRA): results on Australian utilisation and outcomes

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Emre YUCEL

B / 19 / 1

Poster P2567

Abstract 965

Implementation of a tailored made multimodal strategy to reduce health care associated infections (HAI) in ten hospitals from two Latin-American countries: a challenge to overcome inequities

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Wanda CORNISTEIN

B / 19 / 2

Poster P2568

Abstract 967

Designing theory-driven behaviour change interventions to reduce unnecessary antibiotic prescribing in primary care in Vietnam: a systematic approach using the theoretical domains framework and behaviour change wheel

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Minh Duy VU

B / 19 / 3

Poster P2569

Abstract 1010

Optimising antibiotic via direct antibiotic susceptibility testing and stewardship among bacteraemic critically ill

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Chee Lan LAU

B / 19 / 4

Poster P2570

Abstract 1049

Impact of multiplexed upper respiratory panels on antimicrobial stewardship

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Mesut YILMAZ

B / 19 / 5

Poster P2571

Abstract 1055

Impact of implementing repeated clinical audits and feedback on outpatient antibiotic prescribing in the paediatric emergency department at Nancy University Hospital, France

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Mariem BEN YAGHLANE

B / 19 / 6

Poster P2572

Abstract 1159

A multi-centre quantitative and qualitative evaluation following removal of a linezolid formulary restriction

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Thomas LIU

B / 19 / 7

Poster P2573

Abstract 1308

Oral doxycycline for bacterial cystitis: an underutilised tool for antimicrobial stewardship programs

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Emily ONEILL

B / 19 / 8

Poster P2574

Abstract 1321

Assessment of a rapid diagnostic assay and antimicrobial stewardship intervention on treatment of Gram-negative bacteremia

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Julian VENTRES

B / 19 / 9

Poster P2575

Abstract 1360

Reporting the results of qualitative assessment of antibiotics prescribed in urinary tract infections improves appropriate antibiotic use

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Yoon Soo PARK

B / 19 / 10

Poster P2576

Abstract 1466

Antimicrobial prescription rate in Japan reduced significantly following the implementation of the national action plan on antimicrobial resistance

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Hideki HASHIMOTO

B / 19 / 11

Poster P2577

Abstract 1558

Implementing antimicrobial stewardship and infectious diseases specialist activities in non-university hospitals in Germany: the multicentre, clustered, two-arm interventional ID ROLL-OUT study

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Siegbert RIEG

B / 19 / 12

Poster P2578

Abstract 1644

Targeted Clostridioides difficile infection antimicrobial stewardship ward round improves patient care: an Irish experience

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Sadhbh GASH

B / 19 / 13

Poster P2579

Abstract 1712

Building a roadmap for antimicrobial stewardship by assessment of prevailing practices in India: SWOT analysis from 40 hospitals

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Kashish CHHOTARIA

B / 19 / 14

Poster P2580

Abstract 1832

Excessive duration of antibiotic therapy in patients with common infections in Tergooi MC

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Sharon VAN DEN EIJNDE

B / 19 / 15

Poster P2581

Abstract 1841

Factors associated with antibiotic use in long-term care facilities: a systematic review of quantitative studies

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Aurélie BOCQUIER

B / 19 / 16

Poster P2582

Abstract 1879

Achievement of an optimal vancomycin plasma concentration according to different loading dose regimens, a prospective observational multicentre cohort study, VANCOCINEMA

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Adrien GALY

B / 19 / 17

Poster P2583

Abstract 1915

Patterns of outpatient antibiotic prescribing in older adults by social determinants of healthcare access before and during the COVID-19 pandemic: a population-based cohort study

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Mia SAPIN

B / 19 / 18

Poster P2584

Abstract 1926

Antimicrobial stewardship outcomes improve after infectious disease pharmacist integration with infectious disease consultation teams

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Jacqueline BORK

B / 19 / 19

Poster P2585

Abstract 2010

Impact of proactive antimicrobial stewardship (AS) intervention with a computerised microbiological alert system in patients with bloodstream infections (BSI): a pre-post intervention study

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Arianna DI MARCELLO

B / 19 / 20

Poster P2586

Abstract 2036

Engaging health workers and the public to take action to tackle AMR: the antibiotic guardian campaign

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Diane ASHIRU-OREDOPE

B / 19 / 21

Poster P2587

Abstract 2047

Jabs to tabs goes global: point-prevalence of doses of intravenous antibiotic administered as a function of daily census

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Abi JENKINS

B / 19 / 22

Poster P2588

Abstract 2074

Impact of an antimicrobial stewardship programme on empiric colistin usage in a paediatric ICU in a tertiary care hospital

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Divya NANDAKUMAR

B / 19 / 23

Poster P2589

Abstract 2120

Prospective audit of piperacillin-tazobactam prescriptions in a university hospital

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Christelle MEURIS

B / 19 / 24

Poster P2590

Abstract 2268

Fungicap: knowledge, attitudes, and practices survey on prescribing antifungals by physicians in Colombia

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Laura Cristina NOCUA BAEZ

B / 19 / 25

Poster P2591

Abstract 2284

Antibiotic prescribing patterns and associated factors in hospitals across three Asian countries: results from a point prevalence survey and focus group discussions with prescribers

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Yen DUONG

B / 19 / 26

Poster P2592

Abstract 3287

Effect of oral fosfomycin compared to the intravenous beta lactam/beta-lactamase inhibitor or carbapenem in step-down treatment of patients with complicated urinary tract infection due to extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae: a multicentre, open-label, randomised controlled, non-inferiority trial

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Jun-Won SEO

B / 19 / 27

Poster P2593

Abstract 2482

Implementation of pathogen independent, model informed AUC-based dosing of vancomycin at university hospital Würzburg (UKW)

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Laura GUNDLACH

B / 19 / 28

Poster P2594

Abstract 2496

Quantifying the carbon cost of intravenous antibiotics

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Phillip REAY

A / 20 / 1

Poster P2595

Abstract 2556

Antibiotic management programme in a tertiary intensive care unit: investigation of the effects of a carbapenem-restricted period

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Rahmet GÜNER

A / 20 / 2

Poster P2596

Abstract 2591

Appropriateness of antibiotic use: an antimicrobial stewardship implementation project in a regional hospital in north Denmark

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Shakil A. SHAKAR

A / 20 / 3

Poster P2597

Abstract 2595

National surveillance of antibiotic use among dentists in Japan from 2015 to 2021 using the national database of health insurance claims and specific health checkups of Japan

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Masahiro ISHIKANE

A / 20 / 4

Poster P2598

Abstract 2762

The evolution of a beta-lactam resistance: a holistic narrative

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Tom ASHFIELD

A / 20 / 5

Poster P2599

Abstract 2905

Study of prescribing patterns and effectiveness of ceftolozane/tazobactam (C/T) real-world analysis (SPECTRA): clinical outcomes and treatment patterns from Italy

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Emre YUCEL

A / 20 / 6

Poster P2600

Abstract 2911

Pharmacist-led optimisation of discharge antibiotic therapy duration in the emergency department

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Joel ZAPATA

A / 20 / 7

Poster P2601

Abstract 2919

Study of prescribing patterns and effectiveness of ceftolozane/tazobactam (C/T) real-world analysis (SPECTRA): clinical outcomes and treatment patterns from Spain

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Emre YUCEL

A / 20 / 8

Poster P2602

Abstract 3007

Promoting real-world evidence use in antimicrobial stewardship in Latin America

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Maria Virginia VILLEGAS

A / 20 / 9

Poster P2603

Abstract 3025

Effect of an antibiotic stewardship intervention on provider prescribing behavior for acute respiratory infections

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Larissa MAY

A / 20 / 10

Poster P2604

Abstract 3080

Study of prescribing patterns and effectiveness of ceftolozane/tazobactam (C/T) real-world analysis (SPECTRA): clinical outcomes and treatment patterns from UK

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Emre YUCEL

A / 20 / 11

Poster P2605

Abstract 3088

Study of prescribing patterns and effectiveness of ceftolozane/tazobactam (C/T) real-world analysis (SPECTRA): clinical outcomes and treatment patterns from Austria and Germany

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Emre YUCEL

A / 20 / 12

Poster P2606

Abstract 3145

Impact of enhanced antimicrobial stewardship and environmental cleaning on carbapenem-resistant Enterobacterales incidence in a hospital setting

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Toshibumi TANIGUCHI

A / 20 / 13

Poster P2607

Abstract 3147

Data for action: results of the 2022 Australian hospital national antimicrobial prescribing survey

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Zohal RASHIDZADA

A / 20 / 14

Poster P2608

Abstract 3193

Community antibiotic consumption in Cyprus 2015-2022

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Eirini MITSOURA

A / 20 / 15

Poster P2609

Abstract 3202

Outcomes of antimicrobial de-escalation with emphasis on antimicrobial utilisation in a tertiary care hospital at south India

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Jasper Victoria Leelarani MARTINRAJ

A / 20 / 16

Poster P2610

Abstract 3262

The GraNBASS (Gram-negative bacteraemia antimicrobial spectrum score): a new score to evaluate antibiotic treatment spectrum in uncomplicated Gram-negative bacteraemia

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Marco BONGIOVANNI

A / 20 / 17

Poster P2611

Abstract 3329

Improving antibiotic prescribing quality: impact of AMS measures and infectious diseases specialist services in non-university hospitals in Germany

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Gesche FÖRST

A / 20 / 18

Poster P2612

Abstract 3364

Surveillance of antibiotic prescriptions in primary care in the Netherlands: indication-linked antibiotic prescribing quality indicator outcomes collected from routine care data

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Lieke WIELDERS

B / 20 / 1

Poster P2613

Abstract 3366

Reduction in piperacillin/tazobactam empiric use by antimicrobial stewardship implementation

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Jon HOLLER GITZ

B / 20 / 2

Poster P2614

Abstract 3376

Clinical outcomes of hospitalised patients with chronic pulmonary diseases treated with ceftolozane/tazobactam: results from SPECTRA

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Emre YUCEL

B / 20 / 3

Poster P2615

Abstract 3395

Identifying excessive length of antibiotic treatment duration for hospital-acquired infections: a semi-automated approach to enhance antimicrobial stewardship

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Suzanne KUIJPERS

B / 20 / 4

Poster P2616

Abstract 3429

Driving antimicrobial stewardship practice change: analysis of ten years of data from a national antimicrobial prescribing auditing platform in Australian hospitals

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Zohal RASHIDZADA

B / 20 / 5

Poster P2617

Abstract 3448

Impact of new EUCAST criteria on the treatment of Pseudomonas aeruginosa respiratory tract infections

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Anna MURGADELLA-SANCHO

B / 20 / 6

Poster P2618

Abstract 3449

The first audit of antifungal prescribing quality in Australia

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Anna KHANINA

B / 20 / 7

Poster P2619

Abstract 3452

Improving patient outcomes by addressing access disparities to develop quality antimicrobial stewardship programmes

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Mark GILCHRIST

B / 20 / 8

Poster P2620

Abstract 3497

Carbapenem or new β-lactam-β-lactamase inhibitors for empiric therapy? An Italian survey supported by SITA, SIMIT and SIAARTI to identify the factors affecting empiric antimicrobial therapy choice in real-life clinical practice

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Marta COLANERI

B / 20 / 9

Poster P2621

Abstract 3510

Is shortened surgical antimicrobial prophylaxis the new norm? Surgeons' perspective

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Saied ALI

B / 20 / 10

Poster P2622

Abstract 3544

Antibiotic utilisation for residents with suspected infections in nursing homes

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Carl LLOR

B / 20 / 11

Poster P2623

Abstract 3556

Antimicrobial prescribing in emergency wards in Belgium, Brazil, Canada, Georgia and the United Kingdom: first results from the outpatient Global Point Prevalence Survey of Antimicrobial Consumption and Resistance

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Annelies BOVEN

B / 20 / 12

Poster P2624

Abstract 3594

A scoping review of implementation of infection prevention and control programmes & antimicrobial stewardship in Sub-Saharan African hospitals: Facilitators and barriers

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Natasha BERTULIS

B / 20 / 13

Poster P2625

Abstract 3600

Antibiotic prescription appropriateness in directing stewardship interventions and benchmarking

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Liliana DIAS

B / 20 / 14

Poster P2626

Abstract 3739

A quality improvement initiative to improve compliance with timely antimicrobial review

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Sabina BASHIR

B / 20 / 15

Poster P2627

Abstract 3800

Implementation of a regional antibiotic stewardship program (ASP) in a high-income, low multidrug-resistant organisms setting

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Susanna DEUTCH

B / 20 / 16

Poster P2628

Abstract 3813

Antimicrobial stewardship program value driven outcomes

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Geraldine FOO

B / 20 / 17

Poster P2629

Abstract 3902

Measuring the impact of improved diagnostics on antimicrobial stewardship in respiratory tract infection (MIDAS-RTI Study)

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Alexandria CHUNG

B / 20 / 18

Poster P2630

Abstract 3903

Improved usage of standard treatment packages for community-acquired pneumonia in the emergency department

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Susanna DEUTCH

A / 21 / 1

Poster P2631

Abstract 3915

Improving inpatient antimicrobial stewardship through single dose oral amoxicillin challenge among penicillin allergic veterans

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

A / 21 / 2

Poster P2632

Abstract 3922

How much can we SAVE? A cost-effectiveness analysis of an antibiotic stewardship intervention in the intensive care setting

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Anna ERBOGASTO

A / 21 / 3

Poster P2633

Abstract 3957

Preliminary findings on antimicrobial stewardship in Brazilian primary care

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Marcelo CARNEIRO

A / 21 / 4

Poster P2634

Abstract 4023

A comparison of antimicrobial prescription between a Belgian and Rwandan tertiary care hospital using the Global Point Prevalence Survey (Global-PPS) tool

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Caroline THEUNISSEN

A / 21 / 5

Poster P2635

Abstract 4046

Antimicrobial stewardship in Brazilian intensive care units: second round

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Marcelo CARNEIRO

A / 21 / 6

Poster P2636

Abstract 4136

Long term benefits of an AMS intervention to improve blood culture diagnostics in the emergency department

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Jette JUNG

A / 21 / 7

Poster P2637

Abstract 4296

Mapping and characterisation of antimicrobial stewardship tools for nursing homes in France

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Nicolas JACQUET

A / 21 / 8

Poster P2638

Abstract 4329

Clinical impact of extended spectrum β-lactamases (ESBL)-producing Escherichia coli and antimicrobial stewardship in a cohort study of bacteremic urinary tract infections

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Silvia GÓMEZ-ZORRILLA

A / 21 / 9

Poster P2639

Abstract 4407

Switzerland on its way to the WHO target of 60% access group antibiotics: a two decades analysis of outpatient antibiotic consumption

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Catherine PLUESS-SUARD

A / 21 / 10

Poster P2640

Abstract 4439

EU targets for 2030 from the European action plan to combat antimicrobial resistance: where does Germany stand in the outpatient sector? Prescriptions of antibiotics for systemic use vary by patient age, prescribing specialty and geographical region, Germany 2019-2022

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Susanne Barbara SCHINK

A / 21 / 11

Poster P2641

Abstract 4483

Knowledge gap in urine diagnostics

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Anna SCHWABE

A / 21 / 12

Poster P2642

Abstract 4521

A need for better communication between clinicians and microbiology laboratories in human and animal health care

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Oana JOEAN

A / 21 / 13

Poster P2643

Abstract 4567

Impact of changes in antibiotic susceptibility reporting on meropenem prescriptions for Pseudomonas aeruginosa bacteraemia

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Yvon RUCH

A / 21 / 14

Poster P2644

Abstract 4776

Geriatric ward perspectives on antibiotic use in palliative care: need for specific antibiotic policies

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Matteo MORRA

A / 21 / 15

Poster P2645

Abstract 4823

Trends in antibiotics prescription during the implementation of antibiotic stewardship in high antimicrobial resistance settings

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Konstantinos THOMAS

A / 21 / 16

Poster P2646

Abstract 4886

Lack of agreement of 80 national standard treatment guidelines with WHO AWaRe antibiotic book recommendations

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Giovanni AUTORE

A / 21 / 17

Poster P2647

Abstract 4914

Mycology stewardship tool (MyST): reviewing antifungal prescribing practice to improve patient care

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Bee NG

A / 21 / 18

Poster P2648

Abstract 4923

Implementation of antimicrobial stewardship (AMS) ward round at University Hospital of Birmingham, Queen Elizabeth Hospital (QE), United Kingdom

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Nirlep AGRAVEDI

B / 21 / 1

Poster P2649

Abstract 4973

Leveraging partnerships to strengthen antimicrobial stewardship in Zambian public hospitals using a hub-and-spoke model

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

David BANDA

B / 21 / 2

Poster P2650

Abstract 4988

Switching the script: nurses perceptions of IV-to-oral switch in acute care

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Shahzad RAZAQ

B / 21 / 3

Poster P2651

Abstract 5020

Real-life use of recently introduced antibiotics against multidrug-resistant Gram-negative bacteria at Swedish university hospitals

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Lisa FAXÉN

B / 21 / 4

Poster P2652

Abstract 5027

Mapping methods and metrics for assessing antibiotic use in primary care

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Martina ESCHER

B / 21 / 5

Poster P2653

Abstract 5078

Piperacillin-tazobactam and carbapenem use for ESBL-producing Enterobacteriaceae in urinary tract infections

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Catarina MELITA

B / 21 / 6

Poster P2654

Abstract 5111

Antibiotic consumption in inpatient CF medicine

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Johannes Till OTHMER

B / 21 / 7

Poster P2655

Abstract 5154

Are cephalosporins without beta-lactamase inhibitors an option for treating OXA-48 carbapenemase-producing Enterobacterales bloodstream infections?

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Alejandro BLANCO ARÉVALO

B / 21 / 8

Poster P2656

Abstract 5187

Reduction of antimicrobial resistance after the implementation of an antimicrobial stewardship program in a Mexican reference hospital

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Aaron MOLINA JAIMES

B / 21 / 9

Poster P2657

Abstract 5208

Nationwide assessment of hospital antibiotic stewardship programme implementation in Indonesia

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Robert SINTO

B / 21 / 11

Poster P2659

Abstract 5311

Long-term and sustained effect of a multifaceted intervention to improve antibiotic management in patients with penicillin allergy at a university hospital in Florida, USA

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Jose Guillermo CASTRO DANOS

B / 21 / 12

Poster P2660

Abstract 5501

Retrospective multicentre cohort of critically ill burn patients treated with cefiderocol for infections caused by multidrug-resistant non-fermenting Gram-negative bacteria

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Sarah SOUEGES

B / 21 / 13

Poster P2661

Abstract 5613

WHO reserved antibiotic utilisation patterns: audit from a tertiary care hospital in India

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Ratheesh RAJAKUMAR

B / 21 / 14

Poster P2662

Abstract 5695

Pharmacist-led stewardship of echinocandins at a private hospital in South Africa

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Cahlia NAESTED

B / 21 / 15

Poster P2663

Abstract 5896

Antimicrobial stewardship (AMS) practices in intensive care units (ICU): which elements should be implemented?

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Roberta BUSSOLINO

B / 21 / 16

Poster P2664

Abstract 6051

Development and evaluation of a novel antibiotic point prevalence survey method in primary care (APC-PPS)

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Aislinn COOK

B / 21 / 17

Poster P2665

Abstract 6053

Implementation of a national workshop on antimicrobial resistance in Lao PDR

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Christelle ELIAS

B / 21 / 18

Poster P2666

Abstract 6121

Determinants and opportunities of antimicrobial stewardship implementation in hospitals in low- and middle- income countries: a qualitative study

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Ines PAUWELS

A / 22 / 1

Poster P2667

Abstract 6145

Utilising pharmacist-led antimicrobial stewardship (AMS) rounds as a means to stop and reduce antibacterial use: a quality improvement approach

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Priti KUKADIA

A / 22 / 2

Poster P2668

Abstract 6183

Point prevalence survey on antibiotic use in a tertiary care hospital in Lao PDR

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Christelle ELIAS

A / 22 / 3

Poster P2669

Abstract 6304

Optimising vancomycin management in paediatric ICU: impact of a dosing package on severe AKI

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Michael STOKES

A / 22 / 4

Poster P2670

Abstract 6371

Co-design of a visual ICU nurse handover tool to optimise infection care in a low-resource setting: a nurse led collaboration

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Candice BONACONSA

A / 22 / 5

Poster P2671

Abstract 6420

Global Antimicrobial Consumption System (GLASS-AMC): 2023 highlights

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Martina ESCHER

A / 22 / 6

Poster P2672

Abstract 6424

Exploring antibiotic prescription patterns in a low-income country: the TSARA project in Madagascar

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Christelle ELIAS

A / 22 / 7

Poster P2673

Abstract 6473

Implementing antimicrobial stewardship in a Philippine tertiary care hospital: a five-year analysis of repeated point prevalence surveys for monitoring and quality improvement

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Mari Rose DELOS REYES

A / 22 / 8

Poster P2674

Abstract 6474

Impact of an antimicrobial stewardship intervention in patients with negative blood cultures in days of treatment: the NO-BACT clinical trial

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

José Antonio GIRÓN ORTEGA

A / 22 / 9

Poster P2675

Abstract 6523

Process evaluation of an effective antibiotic stewardship intervention in hospitalised patients with community-acquired pneumonia

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Sharon VAN DEN EIJNDE

A / 22 / 10

Poster P2676

Abstract 6555

The global point prevalence survey of antimicrobial consumption and resistance (Global-PPS): October 2023 results of antimicrobial prescribing in Calabar, Nigeria

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Akaninyene OTU

A / 22 / 11

Poster P2677

Abstract 6562

Impact of a bundle of interventions on quality-of-care indicators for Staphylococcus aures bacteraemia: preliminary results of a quasi-experimental study

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Giacomo CASALINI

A / 22 / 12

Poster P2678

Abstract 6598

Antimicrobial susceptibility and time of hospitalisation: when is the empiric initiation of broad-spectrum antibiotics necessary?

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Andrea MORENO ARAYA

A / 22 / 13

Poster P2679

Abstract 6653

Audit of penicillin-allergy incidence in BMT patients and its effect on meropenem usage

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Philip BAKER

A / 22 / 14

Poster P2680

Abstract 6709

Consumption of reserve-antibiotics in German acute care hospitals: before, during and after the COVID-19 pandemic

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Birgitta SCHWEICKERT

A / 22 / 15

Poster P2681

Abstract 6718

Antimicrobial prescribing in three public hospitals of rural South-Africa in 2023: results from the global point prevalence survey

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Joanna GALLAY

A / 22 / 16

Poster P2682

Abstract 6768

Multidisciplinary perspectives on training for non-allergy specialists new to penicillin allergy de-labelling

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Bee Yean NG

A / 22 / 17

Poster P2683

Abstract 6778

Implementation of clinical decision rules in Dutch hospitals to improve the quality of antibiotic prescribing

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

P.D. VAN DER LINDEN

A / 22 / 18

Poster P2684

Abstract 6817

Trends in antibacterial consumption in Belgian hospitals 2017-2021: assessing the impact of the COVID-19 pandemic

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Lucy CATTEAU

A / 22 / 19

Poster P2685

Abstract 6917

A systematic review of patient and public knowledge and understanding of antimicrobial resistance and antimicrobial stewardship

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Benson JACOB

A / 22 / 20

Poster P2686

Abstract 6939

Assessing the differences in outpatient antibiotic consumption between reimbursement and sales data in Belgium, 2012-2022

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Lucy CATTEAU

A / 22 / 21

Poster P2687

Abstract 6943

Evaluation and expansion of a pharmacy-led therapeutic drug monitoring advisory service as part of an antimicrobial stewardship programme

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Pieter DE COCK

A / 22 / 22

Poster P2688

Abstract 7089

Patient-focused training in outpatient parenteral antimicrobial therapy (OPAT) results in significant increases in self-administration

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Imogen KEMP

A / 22 / 23

Poster P2689

Abstract 7122

Structuring and implementation of an antimicrobial stewardship program in a public oncological hospital: challenges and achievements

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Odeli Nicole ENCINAS SEJAS

A / 22 / 24

Poster P2690

Abstract 7160

Improving primary care antibiotic prescribing to reduce antibiotic-resistant urine infections (IPAP-UTI): methods for selecting integrated care boards

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Susan HOPKINS

A / 22 / 25

Poster P2691

Abstract 7203

Transforming prescribing culture: the impact of a restrictive intervention on empirical antimicrobial prescribing at a third-level hospital in Costa Rica

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Luis David GARRO ZAMORA

A / 22 / 26

Poster P2692

Abstract 7263

A multifaceted antimicrobial stewardship intervention in the urology department

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Giacomo STROFFOLINI

A / 22 / 27

Poster P2693

Abstract 7371

Impact of the EUCAST rapid antimicrobial susceptibility testing (RAST) in patients with bacteremia on outcomes and antimicrobial stewardship: a real-life study

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Antonella SANTORO

A / 22 / 28

Poster P2694

Abstract 7383

Check of appropriateness of antimicrobial therapy in nursing homes (CAPTAIN) study: a point prevalence study in Belgium

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Charlotte QUINTENS

B / 22 / 1

Poster P2695

Abstract 7404

Impact on the pharmacoeconomics of a public oncological hospital through the implementation of an antimicrobial stewardship program

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Odeli Nicole ENCINAS SEJAS

B / 22 / 2

Poster P2696

Abstract 7468

Stealth prescribing of antibiotics after the implementation of a urinary tract infection e-prescribing protocol

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Elpida MASTROGIANNI

B / 22 / 3

Poster P2697

Abstract 7539

Engaging the patients and prescribers of tomorrow to address antimicrobial resistance

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Christopher LITTLE

B / 22 / 4

Poster P2698

Abstract 7556

Reducing empirical ceftriaxone use for CAP: a behavioral intervention tutored within the 2022-2024 ESCMID AMS Certificate

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Francisco ALMEIDA

B / 22 / 5

Poster P2699

Abstract 7672

Antibiotic consumption and prescription patterns over seven years in a tertiary care hospital in Karachi, Pakistan

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Nosheen NASIR

B / 22 / 6

Poster P2700

Abstract 7674

Point-of-care tests for acute respiratory infections need comprehensive implementation packages to support use in primary care

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Sibyl ANTHIERENS

B / 22 / 7

Poster P2701

Abstract 7677

The global point revalence survey (Global-PPS): surgical antimicrobial prophylaxis in the Philippines from 2017-2022

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Jemelyn GARCIA

B / 22 / 8

Poster P2702

Abstract 7788

Impact of respiratory PCR testing on antimicrobial prescription in a infectious diseases department

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Lotfi DAHMANE

B / 22 / 9

Poster P2703

Abstract 7798

Adherence of quality indicators for appropriate antibiotic use in the emergency department (ED)

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Garreta Fontelles GEMMA

B / 22 / 10

Poster P2704

Abstract 7889

The clinimetric profile of 11 generic quality indicators for appropriate antibiotic use in Hospitalised patients in Indonesia

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Rahajeng N. TUNJUNGPUTRI

B / 22 / 11

Poster P2705

Abstract 7919

Mortality predictors in patients with negative blood cultures after a specific antimicrobial stewardship intervention: a post hoc analysis of NO-BACT clinical trial

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Pilar RETAMAR GENTIL

B / 22 / 12

Poster P2706

Abstract 7962

Implementation of a pharmacist driven nasal MRSA PCR screening protocol and evaluation on impact of vancomycin utilisation and antibiotic susceptibility at a community hospital in Miami

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Renata BOATWRIGHT

B / 22 / 13

Poster P2707

Abstract 8029

Antibiotic usage shifts in a northeast Mexico COVID-19 care facility: a retrospective analysis

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Gloria Mayela AGUIRRE-GARCÍA

B / 22 / 14

Poster P2708

Abstract 8080

A carbapenem focussed stewardship ward round (CSW), reduces duration of carbapenem prescribing in a tertiary hospital

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Jacob BROLLY

B / 22 / 15

Poster P2709

Abstract 8097

Uptake of OpenWHO massive open online courses on antimicrobial stewardship

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Deborah TONG

B / 22 / 16

Poster P2710

Abstract 8218

Point prevalence vs period prevalence: the best timing to collect antibiotic prescription data in a hospital setting using AWARE classification

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Giulia BRIGADOI

B / 22 / 17

Poster P2711

Abstract 8230

Surveillance non-directed bronchial lavage allows early targeted antibiotic therapy in ventilator associated pneumonia

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Joseph THOMPSON

B / 22 / 18

Poster P2712

Abstract 8524

Intervention programme for optimisation of antimicrobials in an haematology service

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Maria Del Mar ARENAS MIRAS

B / 22 / 19

Poster P2713

Abstract 8541

When the solution becomes the problem: particulate formation in piperacillin/tazobactam continuous infusion

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Charlotte QUINTENS

B / 22 / 20

Poster P2714

Abstract 8556

The experience of an antimicrobial stewardship programme and resistance trends during the COVID-19 pandemic at a tertiary care center in a low- and middle-income country

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Remie EL HELOU

B / 22 / 21

Poster P2715

Abstract 8591

Age and sex-specific differences in inpatient antibiotic utilisation at a tertiary care centre in a low-middle-income country

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Nosheen NASIR

B / 22 / 22

Poster P2716

Abstract 8635

Facilitating safer fluoroquinolone prescribing using formalised risk-assessment

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Sandra LAUHOFF

B / 22 / 23

Poster P2717

Abstract 8657

Role of clinical pharmacists (CP)in the conduct of auditing antibiotic IP prescriptions in resource-limited countries

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Anusha ROHIT

B / 22 / 24

Poster P2718

Abstract 8659

Multidisciplinary visit of the antimicrobial stewardship programme as a strategy for optimising antimicrobial use in the intensive care units of a private hospital with an open medical staff

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Odeli Nicole ENCINAS SEJAS

B / 22 / 25

Poster P2719

Abstract 8661

Point prevalence survey in community pharmacies identifies targets for quality improvement in antimicrobial stewardship in community pharmacies in Lagos Nigeria

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Philip OSHUN

B / 22 / 26

Poster P2720

Abstract 8723

Antibiotic dispensing per type of healthcare provider in rural Burkina Faso: a healthcare visit exit survey

28/04 12:00

5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects)

Daniel VALIA

B / 22 / 27

Poster P2721

Abstract 668

Risk factors for the development of acute kidney injury in patients treated with polymyxin B in a tertiary medical centre: a prospective cohort study

28/04 12:00

5e. Safety, hypersensitivity and adverse effects of treatment

Joseph Louie VICENCIO

B / 22 / 28

Poster P2722

Abstract 976

Outpatient parenteral antibiotic therapy (OPAT) through elastomeric continuous infusion pumps in a real-life observational study: characteristics, safety, and efficacy analysis

28/04 12:00

5e. Safety, hypersensitivity and adverse effects of treatment

Gabriele GIULIANO

A / 23 / 1

Poster P2723

Abstract 1590

RETRACE: a retrospective chart review to evaluate the safety profile of ceftobiprole in patients with impaired hepatic, renal or immune function

28/04 12:00

5e. Safety, hypersensitivity and adverse effects of treatment

Emanuele DURANTE-MANGONI

A / 23 / 2

Poster P2724

Abstract 1633

Safety profile of oral zoliflodacin for uncomplicated gonorrhoea in a Phase 3 trial

28/04 12:00

5e. Safety, hypersensitivity and adverse effects of treatment

Gabrielle KORNMANN

A / 23 / 3

Poster P2725

Abstract 1732

Five years of quality control of therapeutic phage APIs in Belgium: lessons learned

28/04 12:00

5e. Safety, hypersensitivity and adverse effects of treatment

Pieter-Jan CEYSSENS

A / 23 / 4

Poster P2726

Abstract 1818

Penicillin allergy delabeling in Germany: current challenges and novel clinical pathways

28/04 12:00

5e. Safety, hypersensitivity and adverse effects of treatment

Till KOCH

A / 23 / 5

Poster P2727

Abstract 3127

Search for nephroprotectants to eliminate polymyxin nephrotoxicity

28/04 12:00

5e. Safety, hypersensitivity and adverse effects of treatment

Ilya KLEYN

A / 23 / 6

Poster P2728

Abstract 3740

Implementation of UK regulator advice on risk of deafness with aminoglycosides

28/04 12:00

5e. Safety, hypersensitivity and adverse effects of treatment

Philip HOWARD

A / 23 / 7

Poster P2729

Abstract 3962

Evaluating the safety of a novel bacterial protease for the treatment of Clostridioides difficile infection in a murine model

28/04 12:00

5e. Safety, hypersensitivity and adverse effects of treatment

Hannah M WOOD

A / 23 / 8

Poster P2730

Abstract 4201

Investigation of polypharmacy, antimicrobial related potential drug-drug interactions in patients with hematological malignities

28/04 12:00

5e. Safety, hypersensitivity and adverse effects of treatment

Rahmet GÜNER

A / 23 / 9

Poster P2731

Abstract 4835

Incidence of serotonin syndrome caused by tedizolid and concomitant serotonergic agents

28/04 12:00

5e. Safety, hypersensitivity and adverse effects of treatment

Sunish SHAH

A / 23 / 10

Poster P2732

Abstract 5014

Intravenous push vs intermittent infusion beta-lactams in paediatrics: safety and time to administration

28/04 12:00

5e. Safety, hypersensitivity and adverse effects of treatment

Kassandra MARSH

A / 23 / 11

Poster P2733

Abstract 5068

Spatially resolved transcriptomic analysis of polymyxin-induced nephrotoxicity in mice

28/04 12:00

5e. Safety, hypersensitivity and adverse effects of treatment

Jinxin ZHAO

A / 23 / 12

Poster P2734

Abstract 5279

The strategy of preventing colistin induced nephrotoxicity on murine thigh model

28/04 12:00

5e. Safety, hypersensitivity and adverse effects of treatment

Kook MINSOO

A / 23 / 13

Poster P2735

Abstract 6153

How should we start implementing aminoglycoside pharmacogenetic testing to prevent ototoxicity? Considerations for future practice

28/04 12:00

5e. Safety, hypersensitivity and adverse effects of treatment

Veronica CHORRO-MARI

A / 23 / 14

Poster P2736

Abstract 8586

Allergy to liposomal amphotericin B: how does it compare with other antimicrobials and what are the risks associated with use?

28/04 12:00

5e. Safety, hypersensitivity and adverse effects of treatment

Sophie ROBERTS

A / 23 / 15

Poster P2737

Abstract 1262

Budget impact evaluation of fidaxomicin vs vancomycin in treating Clostridioides difficile infections: a retrospective analysis of reimbursement data of a German tertiary hospital

28/04 12:00

5f. Pharmacoepidemiology / pharmacoeconomics (incl cost-effectiveness, modelling, data tools)

Ann-Cathrine SIEFEN

A / 23 / 16

Poster P2738

Abstract 1998

Essential antibiotics experience an 87% price variation, impacting affordability in India: a study over a decade

28/04 12:00

5f. Pharmacoepidemiology / pharmacoeconomics (incl cost-effectiveness, modelling, data tools)

Sriram RADHAKRISHNAN

A / 23 / 17

Poster P2739

Abstract 3743

Antibiotic prescribing for common infections and association with patient outcomes: analysis using electronic prescription data in Vietnam primary care centres

28/04 12:00

5f. Pharmacoepidemiology / pharmacoeconomics (incl cost-effectiveness, modelling, data tools)

Vinh Nam NGUYEN

A / 23 / 18

Poster P2740

Abstract 4099

Antimicrobial subscription pilot model: thirteen months experience in England

28/04 12:00

5f. Pharmacoepidemiology / pharmacoeconomics (incl cost-effectiveness, modelling, data tools)

Philip HOWARD

A / 1 / 1

Poster P1250

Abstract 152

Resistome diversity in coagulase-negative staphylococci from nostrils of healthy humans in La Rioja (Spain): genomic analysis of MDR-S. epidermidis and S. haemolyticus strains

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Idris Nasir ABDULLAHI

A / 1 / 2

Poster P1251

Abstract 281

Unveiling the potency of combined fosfomycin and meropenem against methicillin-resistant Staphylococcus aureus (MRSA) using the hollow-fiber infection model

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Tetsuo YAMAGUCHI

A / 1 / 3

Poster P1252

Abstract 777

Molecular characterisation of vanA genotype-VanB phenotype vancomycin- resistant Enterococcus faecium isolates from Taiwan

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Tzu-Ching HUNG

A / 1 / 4

Poster P1253

Abstract 909

Disease pattern, serotype distribution and risk factors of antimicrobial resistance in patients with pneumococcal infection in Hong Kong – a population-based study

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Sze Ling Celine CHUI

A / 1 / 5

Poster P1254

Abstract 1074

Characteristics of Staphylococcus aureus sterilisation with various aminoglycoside antibiotics used by the continuous local antibiotic perfusion (CLAP) therapy

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Takumi SATO

A / 1 / 6

Poster P1255

Abstract 1326

Shedding light on the population structure of vancomycin-susceptible and -resistant Enterococcus faecium (VSE/VRE) from German hospital patients, 2010-2019

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Jennifer BENDER

A / 1 / 7

Poster P1256

Abstract 1340

Emergence of multidrug-resistant penicillin non-susceptible Streptococcus agalactiae via community and nosocomial transmission in Korea

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Bosung PARK

A / 1 / 8

Poster P1257

Abstract 1358

Changes in Staphylococcus aureus antimicrobial susceptibility during the COVID-19 pandemic

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Tomonori TAKANO

A / 1 / 9

Poster P1258

Abstract 1482

Insights into S. pneumoniae serotypes dynamics and antimicrobial resistance in Argentine adults: 2018-2022 perspective

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Jonathan ZINTGRAFF

A / 1 / 10

Poster P1259

Abstract 1486

Dynamic trends in serotypes and antimicrobial resistance of S. pneumoniae in Argentine paediatrics: insights from 2018 to 2022

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Jonathan ZINTGRAFF

A / 1 / 11

Poster P1260

Abstract 1562

Whole-genome sequencing analysis of Listeria monocytogenes case clusters in maternity hospital, Kuwait

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Ola MOGHNIA

A / 1 / 12

Poster P1261

Abstract 1760

Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae clinical isolates in Greek adults between 2017 and 2022

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Dimitra STAFYLAKI

A / 1 / 13

Poster P1262

Abstract 1775

Population structure of Czech vancomycin-resistant and susceptible enterococci, a multicentric surveillance study, 2022

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Marie BRAJEROVÁ

A / 1 / 14

Poster P1263

Abstract 1962

Emergence of linezolid resistance in Staphylococcus epidermidis in Occitania (France): a growing concern in healthcare settings

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Matthieu BERNIER

A / 1 / 15

Poster P1264

Abstract 2129

Antibiotic resistance and clonal composition of methicillin-susceptible Staphylococcus aureus in Kuwait hospitals

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Edet Ekpenyong UDO

A / 1 / 16

Poster P1265

Abstract 2157

Resistome and phylogenetic characterization of Streptococcus pyogenes clinical isolates from adult patients in Riga East University Hospital

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Girts SKENDERS

A / 1 / 17

Poster P1266

Abstract 2211

Streptococcus pyogenes infections, clinical presentation and trends in resistance across the COVID-19 pandemic?

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

José CANELA GOMÀ

A / 1 / 18

Poster P1267

Abstract 2264

MRSA from bloodstream and skin and soft tissue infections in Polish hospitals, 2022

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Monika ORCZYKOWSKA-KOTYNA

A / 1 / 19

Poster P1268

Abstract 2334

Molecular epidemiology of methicillin resistant Staphylococcus aureus: emerging trends from the United Arab Emirates

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Syrine Nouara BOUCHERABINE

A / 1 / 20

Poster P1269

Abstract 2337

Streptococcus pneumoniae surveillance in the United Arab Emirates: a comparative analysis of trends before and during the COVID-19 pandemic

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Abiola SENOK

A / 1 / 21

Poster P1270

Abstract 2396

Incidence of Staphylococcus argenteus and methicillin-resistant S. argenteus based on the Dutch national surveillance system of antimicrobial resistance (ISIS-AR)

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Feline VELTHUIS

A / 1 / 22

Poster P1271

Abstract 2552

Unveiling the status of antiseptic resistance in Staphylococcus aureus from South America

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Jesús Eduardo VIELMA VALLENILLA

A / 1 / 23

Poster P1272

Abstract 2560

In vitro effectiveness of ceftobiprole alone and in combination on methicillin-resistant Staphylococcus aureus isolates isolated from clinical samples

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Lutfiye OKSUZ

A / 1 / 24

Poster P1273

Abstract 2572

In vitro efficacy of ceftaroline alone and in combinations against methicillin-resistant Staphylococcus aureus isolates

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Lutfiye OKSUZ

B / 1 / 1

Poster P1274

Abstract 2748

Surveillance of vancomycin-resistant enterococci in Denmark between 2015 and 2022 reveals a shift in dominating resistance genes and core genome clusters from vanA Enterococcus faecium to vanB E. faecium clusters

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Kasper THYSTRUP KARSTENSEN

B / 1 / 2

Poster P1275

Abstract 2767

Trends in the prevalence of virulence and antimicrobial resistant genes among USA300 MRSA from 2004-2020 in Chicago, IL

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Timileyin ADEDIRAN

B / 1 / 3

Poster P1276

Abstract 2775

Dynamics of antibiotic resistance in Staphylococcus aureus during persistent airway infection in people with cystic fibrosis

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Barbara C. KAHL

B / 1 / 4

Poster P1277

Abstract 2951

Emergence of optrA/cfr(D)-positive Enterococcus spp. resistant to linezolid and vancomycin in tertiary hospital

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Vyacheslav PLESHKOV

B / 1 / 5

Poster P1278

Abstract 3213

Prevalence of methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative staphylococci in nasal cavity of healthy individuals in Japan

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Sayaka ANDO

B / 1 / 6

Poster P1279

Abstract 3399

Prevalence and time of infection with vancomycin-resistant or -susceptible Enterococcus faecium following a rectal swab positive for vancomycin-resistant E. faecium

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Julia NILSSON GRAM

B / 1 / 7

Poster P1280

Abstract 3480

Study on Streptococcus pyogenes strains isolated from university hospital in Sofia, Bulgaria during pharyngitis/scarlet fever outbreak 2023

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Georgi TODOROV

B / 1 / 8

Poster P1281

Abstract 3488

Eravacycline susceptibility against Gram-positive pathogens, collected in Europe during 2022

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Stephen HAWSER

B / 1 / 9

Poster P1282

Abstract 3494

Antimicrobial susceptibilities of toxin producing Corynebacterium diphtheriae and Corynebacterium ulcerans in Belgium

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Zan JANSSEN

B / 1 / 10

Poster P1283

Abstract 3552

Increasing trend of community-associated methicillin-resistant Staphylococcus aureus infections among patients of a tertiary care hospital

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Jan TKADLEC

B / 1 / 11

Poster P1284

Abstract 3569

The increased occurrence and virulence of Streptococcus pyogenes in the Czech Republic: genomic futures of epidemic lineages

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Marek STEFAN

B / 1 / 12

Poster P1285

Abstract 3597

S. epidermidis from blood cultures of newborn infants in Sweden: a four-decade genome-based retrospective study

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Mia Aarris NIELSEN

B / 1 / 13

Poster P1286

Abstract 3601

The true burden of group A streptococcus in South East Ireland

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Meadhbh COLLISON

B / 1 / 14

Poster P1287

Abstract 3686

Split k-mer analysis of the vancomycin-resistant Enterococcus faecium CT71 endemic clone from Germany

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Kyriaki XANTHOPOULOU

B / 1 / 15

Poster P1288

Abstract 3753

Increasing macrolide resistance among pharyngeal Streptococcus pyogenes in a Portuguese hospital due to emm2-ST55 lineage carrying mef(A)-msr(D)

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Ana FRIÃES

B / 1 / 16

Poster P1289

Abstract 3776

Antibiotics' synergistic activity in a Granulicatella adiacens strain: could double beta-lactam be an option for treatment?

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Francesca PRATAVIERA

B / 1 / 17

Poster P1290

Abstract 3822

Antimicrobial selective pressure and the expression of oxacillin resistance in Staphylococcus aureus

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Helvécio CARDOSO CORRÊA PÓVOA

B / 1 / 18

Poster P1291

Abstract 3884

Antimicrobial resistant Corynebacterium diphtheriae: what, when, where, how and why?

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Sylvain BRISSE

B / 1 / 19

Poster P1292

Abstract 3928

Genomic epidemiology of vancomycin-resistant Enterococcus faecium in Stockholm, Sweden 2018-2022

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Hong FANG

B / 1 / 20

Poster P1293

Abstract 3988

Beyond Antimicrobial Resistance: Competitive interactions and bacteriocin diversity in Enterococcus faecium and E. lactis

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Ana ALMEIDA SANTOS

B / 1 / 21

Poster P1294

Abstract 4210

Population snapshot of vancomycin-resistant enterococci in central Europe.

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Wulf SCHNEIDER

B / 1 / 22

Poster P1295

Abstract 4238

Impact of conjugate vaccines in penicillin and cefotaxime resistance of Streptococcus pneumoniae causing meningitis in Gipuzkoa, Spain, 1993-2023.

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Ayla MANZANAL PEREZ

B / 1 / 23

Poster P1296

Abstract 4242

Vancomycin-variable Enterococcus faecium (VVE) in human clinical and commensal samples: a challenge in antibiotic stewardship

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Ana ALMEIDA SANTOS

B / 1 / 24

Poster P1297

Abstract 4244

Macrolide-resistant Mycoplasma pneumoniae in paediatric population in a low income setting - an emerging threat

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Sajitha VENKATESAN

A / 2 / 1

Poster P1298

Abstract 4331

Streptococcus pneumoniae antibiotic susceptibility among isolates from hospitalised adults with invasive pneumococcal disease in Portugal - the SPHERE study

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Filipe FROES

A / 2 / 2

Poster P1299

Abstract 4469

Antimicrobial resistance and multiple resistance in Listeria monocytogenes human strains isolated from invasive listeriosis cases

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Maria GORI

A / 2 / 3

Poster P1300

Abstract 4518

Post-pandemic acquisition of vanA gene cluster into vanB harbouring vancomycin-resistant Enterococcus faecium isolates from invasive infections in Chile

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Jose R. W. MARTINEZ

A / 2 / 4

Poster P1301

Abstract 4526

South american CC398: primary clone associated with erythromycin and clindamycin resistance in MSSA bacteremia, featuring the genetic element carrying ermT

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Jesús Eduardo VIELMA VALLENILLA

A / 2 / 5

Poster P1302

Abstract 4566

Nasal carriage of (mecA-carrying) Staphylococcus aureus among health sciences students: intermittent colonisation and lifestyle factors

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Ana Raquel FREITAS

A / 2 / 6

Poster P1303

Abstract 4624

Emergence of invasive isolates of vancomycin- and penicillin-resistant Enterococcus faecalis exhibiting unusually high MICs to ß-lactam antibiotics in Chile

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Lorena DIAZ

A / 2 / 7

Poster P1304

Abstract 4822

Correlation between resistance pheno- and genotypes of Enterococcus spp. collected in a tertiary hospital in Denmark

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Karen Leth NIELSEN

A / 2 / 8

Poster P1305

Abstract 4977

Risk factors of vancomycin reduced susceptibility in clinical Clostridioides difficile isolates

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Taryn EUBANK

A / 2 / 9

Poster P1306

Abstract 5125

Prevalence of Streptococcus pneumoniae resistance to antibiotics in Brazilian patients with bacteremic pneumococcal pneumonia in Rio de Janeiro

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Paulo Vieira DAMASCO

A / 2 / 10

Poster P1307

Abstract 5314

Molecular nature of Staphylococcus aureus causing infections in hospitals in Lagos, Nigeria

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Adesola OLALEKAN

A / 2 / 11

Poster P1308

Abstract 5361

Genomic characterisation of linezolid-resistant Enterococcus faecalis isolated in Western Australia, 2016-2021

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Shakeel MOWLABOCCUS

A / 2 / 12

Poster P1309

Abstract 5417

Antimicrobial resistance genomics of Enterococcus faecium causing bloodstream infections across Australia in 2022

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Shakeel MOWLABOCCUS

A / 2 / 13

Poster P1310

Abstract 5454

Linezolid-resistant Enterococcus clinical isolates from Pakistan: a genomic analysis

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Syed Mohammad ZEESHAN

A / 2 / 14

Poster P1311

Abstract 5576

Genomic surveillance of invasive Staphylococcus isolates in Germany, 2021-2023

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Franziska LAYER-NICOLAOU

A / 2 / 15

Poster P1312

Abstract 5610

AMR trends in Streptococcus pyogenes in the Netherlands

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Rony Elisabeth ZOETIGHEID

A / 2 / 16

Poster P1313

Abstract 5660

Proportion of vancomycin MIC other than 1 mg/L in MRSA and its potential implication in therapeutic drug monitoring

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Beom Joon KIM

A / 2 / 17

Poster P1314

Abstract 5758

Correlation of GAS emm-types and invasiveness: a retrospective cohort study, Germany, 2023

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Joerg STEINMANN

A / 2 / 18

Poster P1315

Abstract 5776

Virulome of vancomycin-resistant enterococci in bloodstream infection and carriage

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Christian Wilhelm BÖING

A / 2 / 19

Poster P1316

Abstract 5917

Assessing the molecular bases of fusidic acid resistance Staphylococcus aureus methicillin susceptible clinical strains

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Emanuele NICITRA

A / 2 / 20

Poster P1317

Abstract 5969

Performance of chromogenic selective agar for identifying linezolid resistant enterococci and staphylococci using a genetically defined set of challenge isolates

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Sarah BUUR BENDIXEN

A / 2 / 21

Poster P1318

Abstract 6012

Linezolid-resistant Enterococcus faecium and Enterococcus faecalis from Polish hospitals: diversity of resistance determinants and clonal types

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Dorota ZABICKA

A / 2 / 22

Poster P1319

Abstract 6052

Antibiotic resistance and epidemiological evolution of Streptococcus pneumoniae in 2020-2022 at Hospital Universitari de Bellvitge, Barcelona

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Rocío ESPAÑA BONILLA

A / 2 / 23

Poster P1320

Abstract 6107

Linezolid-resistant Enterococcus faecium bloodstream isolates from Germany: molecular epidemiology and resistance mechanisms

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

David TOBYS

A / 2 / 24

Poster P1321

Abstract 6189

VanB Enterococcus faecium and Enterococcus faecalis isolated from blood in 2022 in Poland

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Malgorzata GRZEGORCZYK

A / 2 / 25

Poster P1322

Abstract 6301

Frequency of MRSA-CC398 among tetracycline resistant MRSA isolates. A multicentre study in 2023

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Allelen CAMPAÑA-BURGUET

A / 2 / 26

Poster P1323

Abstract 6332

Detection of MRSA and MSSA CC398 isolates in osteoarticular infections in a multicenter study, Spain.

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Paula EGUIZÁBAL

A / 2 / 27

Poster P1324

Abstract 6602

Livestock-associated methicillin-resistant S. aureus causing bacteremia in a region with high pig-farming-density

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Saray MORMENEO

A / 2 / 28

Poster P1325

Abstract 6722

Temporal trends of Enterococcal and vancomycin-resistant E. faecium Bloodstream infections in the Northern Dutch-German cross-border region: a ten-year multi-centre analysis (2013-2022)

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Cansu CIMEN VAN DIJCK

B / 2 / 1

Poster P1326

Abstract 7015

Increasing macrolide and lincosamide resistance among Streptococcus dysgalactiae subsp. equisimilis invasive isolates (Portugal, 2019-2022)

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Marcos Daniel PINHO

B / 2 / 2

Poster P1327

Abstract 7019

An increase of the emerging methicillin-resistant Staphylococcus aureus t4549 lineage in Denmark: an investigation of demographics and risk factors

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Johanna YOUNG

B / 2 / 3

Poster P1328

Abstract 7231

Evaluation of oritavancin susceptibility in vancomycin-resistant Enterococcus faecium isolates

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Carcione DAVIDE

B / 2 / 4

Poster P1329

Abstract 7357

A multicentre study: penicillin is still susceptible, macrolide resistance and biofilm production is low in Streptococccus pyogenes isolates

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Özgen ESER

B / 2 / 5

Poster P1330

Abstract 7717

Detection of poxtA- and optrA-positive enterococci and lactobacilli from rectal swabs from hospitalized patients in Tuscany, Italy

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Nicla GIOVACCHINI

B / 2 / 6

Poster P1331

Abstract 7763

Increase in methicillin-resistant Staphylococcus spp. colonisation among pregnant women in Brazil, during the COVID-19 pandemic

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Tatiana PINTO

B / 2 / 7

Poster P1332

Abstract 8071

Genomic insights into community-associated methicillin resistant Staphylococcus aureus: an Egyptian perspective

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Nehal Aasem SAIF

B / 2 / 8

Poster P1333

Abstract 8089

Increase of invasive group A streptococcal (GAS) disease in adult patients in Barcelona 2018-2023

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Dàmaris BERBEL PALAU

B / 2 / 9

Poster P1334

Abstract 8142

Unveiling pediatric challenges: Serotype dynamics, sequence types and multidrug resistance of Streptococcus pneumoniae isolates – insights from a comprehensive Indian study???

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Gk HARSHITHA

B / 2 / 10

Poster P1335

Abstract 8614

Decoding diversity of Streptococcus pneumoniae isolated from Indian adults: genomic insights into lineages, population dynamics, and resistance patterns

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Varun SHAMANNA

B / 2 / 11

Poster P1336

Abstract 8907

Epidemiology of bacterial resistance at the Grand Magal of Touba in Senegal.

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Ouaddane IHSSANE

B / 2 / 12

Poster P1337

Abstract 8910

Correlation between the incidence of invasive Streptococcus pyogenes and influenza virus infection in the paediatric age: a retrospective population-based study in Catalonia

29/04 12:00

3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

Victoria RELLO

B / 2 / 13

Poster P1338

Abstract 29

In vitro and in vivo activity of cefiderocol against Elizabethkingia spp. and its resistance mechanisms

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Shu-Chen KUO

B / 2 / 14

Poster P1339

Abstract 58

In vitro activity of cefiderocol against clinical Gram-negative bacteria in Taiwan

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Shu-Chen KUO

B / 2 / 15

Poster P1340

Abstract 173

A retrospective single centre study to access risk factors for colistin-resistant Acinetobacter baumannii (CoR-AB) infection among patients in tertiary care hospital in Thailand

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Sureerat WATCHARASUWANSEREE

B / 2 / 16

Poster P1341

Abstract 216

The molecular epidemiology and characterisation carbapenem-resistant Klebsiella pneumoniae among hospitalised patients in Cape Town, South Africa

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Clinton MOODLEY

B / 2 / 17

Poster P1342

Abstract 260

Elucidating the underlying genetic mechanism of amoxicillin-clavulanate resistance in Escherichia coli isolated from a highly anthropogenic urban river

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Nambram SOMENDRO SINGH

B / 2 / 18

Poster P1343

Abstract 265

In vitro activity of ceftazidime-avibactam against ceftazidime-non-susceptible Gram-negative pathogens recovered from hospitalised patients from Germany, Austria and Switzerland, 2019-2020

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Esther WOHLFARTH

B / 2 / 19

Poster P1344

Abstract 289

Diversity of carbapenemase gene localised across different plasmid incompatibility groups among Gram-negative clinical bacteria and antibiotic combinations to combat them

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Sangram Singh PATEL

B / 2 / 20

Poster P1345

Abstract 298

Multidrug-resistant invasive nontypeable Haemophilus influenzae in Taiwan: molecular epidemiology, antimicrobial resistance mechanisms

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Tsai-Wen WAN

B / 2 / 21

Poster P1346

Abstract 312

Distribution of ß-lactamase genes among multidrug-resistant and extended-spectrum ß-lactamase-producing diarrheagenic Escherichia coli from under-five children in Ethiopia

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Tizazu ZELELIE

B / 2 / 22

Poster P1347

Abstract 380

Superinfection with carbapenemase-producing organisms in a patient who received treatment in Indonesia

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Satoshi NISHIDA

B / 2 / 23

Poster P1348

Abstract 395

Frequency of carbapenem resistant Providencia stuartii isolation from clinical samples in relation to colistin consumption in the ICU of a tertiary hospital before and during the pandemic (2019-2022)

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Charalampos ZARRAS

B / 2 / 24

Poster P1349

Abstract 406

Clonal diversity and antimicrobial resistance of Escherichia coli from a tertiary care hospital in Nepal

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Suchitra THAPA

B / 2 / 25

Poster P1350

Abstract 682

Longitudinal analysis of in vitro activities of aztreonam-avibactam and comparator agents against metallo-β-lactamase-producing Enterobacterales: ATLAS global surveillance program, 2018-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mark ESTABROOK

B / 2 / 26

Poster P1351

Abstract 689

In vitro activity of aztreonam-avibactam and comparator agents against clinical Enterobacterales isolates collected worldwide, stratified by global region as a part of ATLAS global surveillance program, 2018-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mark ESTABROOK

B / 2 / 27

Poster P1352

Abstract 694

In vitro activity of aztreonam-avibactam and comparator agents against Enterobacterales isolates collected from patients in ICU compared to other wards, ATLAS global surveillance program, 2018-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mark ESTABROOK

B / 2 / 28

Poster P1353

Abstract 696

In vitro activity of aztreonam-avibactam and comparator agents against carbapenemase-producing Enterobacterales collected as part of the ATLAS surveillance program: 2018-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mark WISE

A / 3 / 1

Poster P1354

Abstract 697

Longitudinal analysis of the in vitro activity of aztreonam-avibactam and comparator agents against Enterobacterales collected globally for the ATLAS surveillance program, 2018-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mark ESTABROOK

A / 3 / 2

Poster P1355

Abstract 801

Activity of the novel combination therapies aztreonam/nacubactam and cefepime/nacubactam against 3,694 clinical isolates of Enterobacterales collected worldwide during 2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Stephen HAWSER

A / 3 / 3

Poster P1356

Abstract 941

Characteristics of E. coli and K. pneumoniae infections in international travellers: a GeoSentinel analysis

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Giacomo STROFFOLINI

A / 3 / 4

Poster P1357

Abstract 942

Antimicrobial activity of aztreonam-avibactam and comparator agents against a large collection of Stenotrophomonas maltophilia isolates collected in Europe, Asia and Latin America (2018-2023)

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Helio SADER

A / 3 / 5

Poster P1358

Abstract 964

Clonal diversity and mechanisms of antimicrobial resistance in clinical Pseudomonas aeruginosa strains from northern-western Nigeria

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Yahaya USMAN

A / 3 / 6

Poster P1359

Abstract 966

Characteristics of patients with carbapenem-resistant Enterobacterales infections demonstrating heteroresistance to novel antibiotic combinations

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Christina LIN

A / 3 / 7

Poster P1360

Abstract 1066

Activity of cefiderocol and comparator agents against Difficult-to-Treat Resistant (DTR) Pseudomonas aeruginosa collected during 2020-2022 as part of the SENTRY antimicrobial surveillance program

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Boudewijn DEJONGE

A / 3 / 8

Poster P1361

Abstract 1068

Activity of cefiderocol and comparator agents against difficult-to-treat resistant (DTR) Acinetobacter baumannii-calcoaceticus species complex isolates collected during 2020-2022 as part of the SENTRY antimicrobial surveillance programme

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Boudewijn DEJONGE

A / 3 / 9

Poster P1362

Abstract 1077

Results of nationwide enhanced surveillance on antimicrobial resistance (AMR) in Ukraine: data for July–September of 2023

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Arkadii VODIANYK

A / 3 / 10

Poster P1363

Abstract 1091

High prevalence of faecal carriage of extended-spectrum beta-lactamase-producing Enterobacterales among patients with urinary tract infections in rural Tanzania: preliminary findings

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Magreth MACHA

A / 3 / 11

Poster P1364

Abstract 1164

In vitro activity of aztreonam-avibactam (ATM-AVI) and comparators against Enterobacterales collected worldwide stratified by infection source: ATLAS global surveillance program, 2018-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mark WISE

A / 3 / 12

Poster P1365

Abstract 1165

In vitro activity of ceftazidime-avibactam and comparator agents against KPC-producing Enterobacterales collected globally as a part of the ATLAS global surveillance program from 2018-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mark ESTABROOK

A / 3 / 13

Poster P1366

Abstract 1169

In vitro activity of ceftaroline and comparator agents against bacterial pathogens frequently isolated from patients with respiratory tract, skin and soft tissue, and bloodstream infections collected during the ATLAS global surveillance program in 2018-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Meredith HACKEL

A / 3 / 14

Poster P1367

Abstract 1254

In vitro activity of cefiderocol in bloodstream infection isolates from North American and European hospitals: SENTRY 2020-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Sean NGUYEN

A / 3 / 15

Poster P1368

Abstract 1315

Occurrence and molecular characterisation of ceftazidime-avibactam resistant Pseudomonas aeruginosa in a hospital in Lisbon, Portugal

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Samanta FREIRE

A / 3 / 16

Poster P1369

Abstract 1320

Genomics of a surge in VIM-carbapenemase-producing Enterobacterales in a London hospital network

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Elita JAUNEIKAITE

A / 3 / 17

Poster P1370

Abstract 1348

Surveillance of cefiderocol activity against carbapenem-resistant Gram-negative clinical isolates in a tertiary care hospital

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Sreekanthreddy BASIREDDY

A / 3 / 18

Poster P1371

Abstract 1384

Genomic study of high-risk clones of Enterobacter hormaechei collected from tertiary hospitals in United Arab Emirates

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Akela Ahmed GHAZAWI

A / 3 / 19

Poster P1372

Abstract 1410

Activity of a combination of ceftolozane and tazobactam in vitro against ESBL-producing Enterobacterales in China: SMART 2016 – 2019

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Qiwen YANG

A / 3 / 20

Poster P1373

Abstract 1461

Epidemiology and clinical characteristics of patients with carbapenem-resistant enterobacterales infections: experience from a large tertiary care centre in a developing country

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Banan AIESH

A / 3 / 21

Poster P1374

Abstract 1600

The activity of cefiderocol and comparator agents against uncommon Gram-negative isolates collected during 2020-2022 as part of the SENTRY antimicrobial surveillance programme

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Christopher LONGSHAW

A / 3 / 22

Poster P1375

Abstract 1607

Spontaneous frequency of resistance to meropenem/ANT3310 in carbapenem-resistant Enterobacterales and Acinetobacter baumannii

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Agustina LLANOS

A / 3 / 23

Poster P1376

Abstract 1659

Epidemiologic and trend changes in antimicrobial resistance in Pseudomonas aeruginosa: a regional five-year time-lapse study

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Lucía HENRÍQUEZ MEDEROS

A / 3 / 24

Poster P1377

Abstract 1670

Molecular features of carbapenem-producing Enterobacteriaceae strains: a regional multicenter genomic surveillance study

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Lucía HENRÍQUEZ MEDEROS

A / 3 / 25

Poster P1378

Abstract 1737

In vitro activity of aztreonam-avibactam against MBL-producing Enterobacterales isolates across Germany

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Esther WOHLFARTH

A / 3 / 26

Poster P1379

Abstract 1782

E. coli-ST131-blaCTX-M-15 and K. pneumoniae-ST1- blaNDM-1 strains in Tunisia: a report of genetic surveillance of Enterobacteriaceae from diabetic foot infections

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Klibi NAOUEL

A / 3 / 27

Poster P1380

Abstract 1822

Carbapenem and colistin resistant Acinetobacter spp. cultured from hospital sanitary ware

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Shannon CARTER

A / 3 / 28

Poster P1381

Abstract 1843

Epidemiology of Citrobacter infections among hospitalised patients: a systematic review and meta-analysis

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Pérince FONTON

B / 3 / 1

Poster P1382

Abstract 1884

Gut Escherichia coli of healthy humans and animals are reservoirs of critical antimicrobial resistance genes: a meta-analysis

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Islem TRABELSI

B / 3 / 2

Poster P1383

Abstract 1910

Heteroresistance to piperacillin-tazobactam in Klebsiella pneumoniae is mediated by amplification of multiple beta-lactamase genes

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Ahmed BABIKER

B / 3 / 3

Poster P1384

Abstract 2058

Genomic features of carbapenem-resistant Klebsiella pneumoniae isolated in French Polynesia and novel transposon responsible for blaNDM-1 dissemination

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Huynh Ngoc Tram VO

B / 3 / 4

Poster P1385

Abstract 2072

Culture positivity and antimicrobial susceptibility profile of Helicobacter pylori isolates from 2009-2023 in Vancouver, Canada.

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Hasan HAMZE

B / 3 / 5

Poster P1386

Abstract 2112

Epidemiology of carbapenemases in carbapenemase producing Klebsiella spp., and Pseudomonas spp. strains isolated from a tertiary hospital in Athens, Greece during 2020-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Eleni VOUDANTA

B / 3 / 6

Poster P1387

Abstract 2305

The impact of peri-COVID-19 antibiotic prescribing on downstream antimicrobial resistance: a population-based cohort study ?

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Derek MACFADDEN

B / 3 / 7

Poster P1388

Abstract 2335

Prevalence and characteristics of carbapenem-resistant Enterobacterales in 23 hospitals in Nara City, Japan from 2018 to 2020: predominance of IMP-6 carbapenemase

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Ryuichi NAKANO

B / 3 / 8

Poster P1389

Abstract 2339

Surveillance report (ATLAS) on antimicrobial activity of aztreonam-avibactam and comparator agents tested against metallo-β-lactamase (MBL)-positive carbapenem-resistant E. coli and Klebsiella spp. isolated from India (2020-2021)

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Akshata MANE

B / 3 / 9

Poster P1390

Abstract 2347

Epidemiology of carbapenem-resistant Klebsiella pneumoniae reveals a crisis of the resistance and virulence convergence in China

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Qiucheng SHI

B / 3 / 10

Poster P1391

Abstract 2354

Coexistence of seven different carbapenemase producers in one patient upon hospital admission confirmed by whole-genome sequencing

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Frieder FUCHS

B / 3 / 11

Poster P1392

Abstract 2384

Antimicrobial resistance profile of Helicobacter pylori in a large tertiary hospital in Singapore from 2004 to 2023

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Azhar HAMDAN

B / 3 / 12

Poster P1393

Abstract 2405

Unlocking the iron gate: cefiderocol's efficacy against Acinetobacter baumannii biofilms

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Ilaria CAVALLO

B / 3 / 13

Poster P1394

Abstract 2445

Antimicrobial susceptibility trends of multidrug-resistant Pseudomonas aeruginosa in Africa

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Yogandree RAMSAMY

B / 3 / 14

Poster P1395

Abstract 2500

Impacts and management of carbapenem-resistant and hypervirulent Klebsiella pneumoniae infection on gut health

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Hongyuhang NI

B / 3 / 15

Poster P1396

Abstract 2523

Clinical relevance, mechanisms and evolution of polymyxin B heteroresistance carbapenem-resistant Klebsiella pneumoniae: a genomic, retrospective cohort study

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Qixia LUO

B / 3 / 16

Poster P1397

Abstract 2587

Trends in Klebsiella pneumoniae antimicrobial susceptibility in Africa: phenotypic and genotypic regional analyses, 2005-2021

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Trusha NANA

B / 3 / 17

Poster P1398

Abstract 2619

In vitro activity of aztreonam-avibactam and cefiderocol against metallo-β-lactamase-producing Enterobacterales

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Anna DUDAKOVA

B / 3 / 18

Poster P1399

Abstract 2647

In vitro activity of ceftibuten/avibactam and comparator agents against Enterobacterales collected globally as part of the ATLAS surveillance programme, 2022 by β-lactamase carriage

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mark ESTABROOK

B / 3 / 19

Poster P1400

Abstract 2671

In vitro activity of ceftibuten-avibactam and comparator agents against Enterobacterales collected globally as part of the ATLAS Surveillance Program, 2022 by length of stay

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Meredith HACKEL

B / 3 / 20

Poster P1401

Abstract 2724

In vitro activity of aztreonam/avibactam and comparator agents against multidrug-resistant Enterobacterales collected globally as part of the ATLAS Surveillance Program, 2018-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Meredith HACKEL

B / 3 / 21

Poster P1402

Abstract 2735

Molecular epidemiology and genomic comparison of ST191/195/208 and other types of Acinetobacter baumannii in eastern China

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Yonghong XIAO

B / 3 / 22

Poster P1403

Abstract 2776

Activity of aztreonam/avibactam against a panel of multi-drug resistant Klebsiella pneumoniae

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Jamie MURPHY

B / 3 / 23

Poster P1404

Abstract 2860

Screening sites for detection of carbapenemase-producers: a retrospective cohort study

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Isabelle VOCK

B / 3 / 24

Poster P1405

Abstract 2901

Co-existence of extended-spectrum β-lactamases and carbapenemases in neonatal Klebsiella pneumoniae isolates from a children's specialized hospital in Cairo, Egypt

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Marwa ABOU-GALIEL

B / 3 / 25

Poster P1406

Abstract 2902

Activity of cefiderocol against carbapenem non-susceptible Enterobacterales, including molecularly characterised clinical isolates causing infection in hospitals in European and adjacent regions (2020–2022)

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Rodrigo E. MENDES

B / 3 / 26

Poster P1407

Abstract 2937

Molecular characterisation of carbapenem-resistant Enterobacteriaceae isolated from military Ukrainian patients in a tertiary hospital in Zaragoza, Spain

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Miriam LATORRE-MILLÁN

B / 3 / 27

Poster P1408

Abstract 3001

Surveillance of carbapenemase-producing Enterobacterales in six medical centres in Germany between 2015 and 2021: results from the DIOGENES study

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Janko SATTLER

B / 3 / 28

Poster P1409

Abstract 3050

Double beta-lactam therapy in ESBL+CPE+E. Coli isolates - what is the relationship between synergy, penicillin-binding protein activity, and in vitro susceptibility?

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Joseph SUICH

A / 4 / 1

Poster P1410

Abstract 3085

Prevalence and characteristics of third-generation cephalosporin-resistant Escherichia coli isolated from deer at a tourist area in Japan

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Akiyo NAKANO

A / 4 / 2

Poster P1411

Abstract 3101

Molecular epidemiology of carbapenem-resistant Gram-negative isolates obtained from clinical samples at Jimma Medical Center, Ethiopia

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mulatu Gashaw ADBARU

A / 4 / 3

Poster P1412

Abstract 3205

Characterisation of carbapenem-resistant Klebsiella pneumoniae and Escherichia coli isolates from bloodstream infections in a tertiary care hospital in south India and their susceptibility to ceftazidime-avibactam

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Anna KURIAN

A / 4 / 4

Poster P1413

Abstract 3314

Genomic analysis of blaOXA-48 plasmids in a single hospital in Singapore over ten years

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Dennis LOY

A / 4 / 5

Poster P1414

Abstract 3377

Decoding genetics of AMR genes in human pathogens for rapid diagnostic test development

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Tanshi MEHROTRA

A / 4 / 6

Poster P1415

Abstract 3421

60 years of evolution in Bacteroides fragilis antimicrobial resistance

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Flemming Damgaard NIELSEN

A / 4 / 7

Poster P1416

Abstract 3427

Emerging resistance against new antibiotics in carbapenem resistant Pseudomonas aeruginosa infections

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Fatihan PINARLIK

A / 4 / 8

Poster P1417

Abstract 3447

Clinical profile and outcome of nosocomial Stenotrophomonas maltophilia infection among adult patients in a tertiary hospital: a five-year retrospective study

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Ralph Bryan HERNANDEZ

A / 4 / 9

Poster P1418

Abstract 3464

Molecular analysis of metallo-beta-lactamase-producing Pseudomonas aeruginosa in Switzerland 2022-2023

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Jacqueline FINDLAY

A / 4 / 10

Poster P1419

Abstract 3477

Use of antipseudomonal antibiotics and prevalence of multiple drug resistance (MDR) in Pseudomonas aeruginosa (PA): a time series analysis in hospitalised patients

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

José Antonio MARTÍNEZ

A / 4 / 11

Poster P1420

Abstract 3489

In vitro activity of cefiderocol against carbapenem-resistant Pseudomonas aeruginosa (CRPA) clinical isolates from countries with high CRPA incidence, 2019-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Renata DA COSTA

A / 4 / 12

Poster P1421

Abstract 3538

In vitro activity of eravacycline against Enterobacterales and non-fermenter clinical isolates, including resistant isolates, collected in Europe during 2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Stephen HAWSER

A / 4 / 13

Poster P1422

Abstract 3545

Fosfomycin resistance in E. coli ST131: an emerging Italian threat

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Vittoria MATTIONI MARCHETTI

A / 4 / 14

Poster P1423

Abstract 3658

In-depth genomic analysis of two Acinetobacter baumannii isolates from the same patient

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Linda Alexandra CASSELMANN

A / 4 / 15

Poster P1424

Abstract 3683

Characterising a cluster of NDM-5-positive Escherichia coli clinical isolates

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Rocío ARAZO DEL PINO

A / 4 / 16

Poster P1425

Abstract 3698

Carbapenem-resistant Pseudomonas aeruginosa prevailing among the hospitals in Czech Republic: the evolution of a regional menace

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Tsolaire SOURENIAN

A / 4 / 17

Poster P1426

Abstract 3702

Genotypes of ESBL-producing Escherichia coli isolated from lower respiratory tract samples before and during the COVID-19 pandemic (2017–2022)

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Katja HROVAT

A / 4 / 18

Poster P1427

Abstract 3708

In vitro activity of cefiderocol against carbapenemases-OXA-type producing Acinetobacter baumannii clinical strains: a report of six Italian laboratories

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mariagrazia PERILLI

A / 4 / 19

Poster P1428

Abstract 3724

Frequent high-level rifaximin resistance in Escherichia coli associated with long-term treatment of patients with hepatic cirrhosis – a prospective, controlled study

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Johannes CAMP

A / 4 / 20

Poster P1429

Abstract 3729

Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against a Spanish nationwide collection of double carbapenemase-producing Enterobacterales

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Tania BLANCO MARTÍN

A / 4 / 21

Poster P1430

Abstract 3772

Acquisition and loss of carriage of antimicrobial resistant Enterobacterales among vulnerable children Africa and Asia

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Caroline TIGOI

A / 4 / 22

Poster P1431

Abstract 3799

Effect of glyphosate and antibiotic combinations on ESKAPEE Gram-negative bacteria

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Hanane ZERROUKI

A / 4 / 23

Poster P1432

Abstract 3845

Antimicrobial resistance and genomic insights into Campylobacter spp. isolated from Australian meat chickens

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Sam ABRAHAM

A / 4 / 24

Poster P1433

Abstract 3868

Emergence of Klebsiella pneumoniae ST307 colistin resistant and co-producing NDM-5 and CTX-M-15 in Uruguay

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Carmen MAGALLANES

A / 4 / 25

Poster P1434

Abstract 4103

In vitro activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates from countries with high CRAB incidence, 2019-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Renata DA COSTA

A / 4 / 26

Poster P1435

Abstract 4111

Emerging cefiderocol resistance in carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Jale BORAL

A / 4 / 27

Poster P1436

Abstract 4158

TROJAN-BMR: in vitro activity of cefiderocol and its comparators on multidrug-resistant Enterobacterales and Pseudomonas aeruginosa strains in South of France, performance of available testing methods

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Massinissa BENYAHIA

A / 4 / 28

Poster P1437

Abstract 4171

Exploring multidrug resistance patterns in community acquired E. coli urinary tract infections with machine learning

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Elise HODBERT

B / 4 / 1

Poster P1438

Abstract 4178

Activity of new β-lactamases inhibitors/antibiotic combination and cefiderocol against carbapenems resistant Pseudomonas aeruginosa strains

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Elena ADDIS

B / 4 / 2

Poster P1439

Abstract 4216

Activity of aztreonam-avibactam and comparator agents against a global collection of MBL-producing Enterobacterales

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mariana CASTANHEIRA

B / 4 / 3

Poster P1440

Abstract 4247

High frequency of CTX-M-115 and OXA-72 in ST78 Acinetobacter baumannii

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Paul G HIGGINS

B / 4 / 4

Poster P1441

Abstract 4262

Activity of gepotidacin against Klebsiella pneumoniae, including molecularly characterised fluoroquinolone not susceptible subsets causing urinary tract infections in Europe and adjacent regions (2019-2022)

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Rodrigo E. MENDES

B / 4 / 5

Poster P1442

Abstract 4264

Activity of aztreonam-avibactam and comparator agents against Enterobacterales collected from patients with presumed hospital- and community-acquired infections: ATLAS Global Surveillance Program, 2018-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mark WISE

B / 4 / 6

Poster P1443

Abstract 4300

In vitro activity of ceftazidime-avibactam and comparator agents against Enterobacterales and Pseudomonas aeruginosa stratified by infection source and patient age: ATLAS Global Surveillance Program, 2018-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mark WISE

B / 4 / 7

Poster P1444

Abstract 4302

Prevalence and genetic background of trimethoprim-sulfamethoxazole and levofloxacin resistance in Stenotrophomonas maltophilia

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Céline SAKR

B / 4 / 8

Poster P1445

Abstract 4304

Activity of sulbactam/durlobactam against a panel of multi-drug resistant Acinetobacter baumannii

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Zhayne HACKETT

B / 4 / 9

Poster P1446

Abstract 4348

In vitro activity of cefiderocol against carbapenem-resistant Enterobacterales (CREs) clinical isolates from countries with high CRE incidence, 2019-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Renata DA COSTA

B / 4 / 10

Poster P1447

Abstract 4369

Antimicrobial resistance in Helicobacter pylori: a ten-year perspective from the national gastrointestinal bacteria reference unit, UK Health Security Agency, United Kingdom

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Vanessa WONG

B / 4 / 11

Poster P1448

Abstract 4387

Activity of cefiderocol and comparator agents against isolates from paediatric patients collected during 2020-2022 as part of the SENTRY antimicrobial surveillance program

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Sean NGUYEN

B / 4 / 12

Poster P1449

Abstract 4392

Aztreonam-avibactam resistance is lower than cefiderocol resistance in recent carbapenemase-positive Enterobacterales from the German National Reference Centre (NRC) for multidrug-resistant Gram-negative bacteria

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Agnes ANDERS

B / 4 / 13

Poster P1450

Abstract 4400

Antimicrobial activity of cefepime in combination with taniborbactam against resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Europe, 2018-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Meredith HACKEL

B / 4 / 14

Poster P1451

Abstract 4453

Activity of cefepime-taniborbactam and comparators against Enterobacterales and Pseudomonas aeruginosa with defined β-lactamase carriage collected in Europe, 2018-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mark WISE

B / 4 / 15

Poster P1452

Abstract 4473

Is imipenem a good option for treatment of erythromycin-resistant Campylobacter coli infections?

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Laura PÉREZ FERNÁNDEZ

B / 4 / 16

Poster P1453

Abstract 4500

Rising prevalence of ST15-KL19 carbapenemase-producing Klebsiella pneumoniae in post-COVID-19 in Portugal

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

B / 4 / 17

Poster P1454

Abstract 4637

Genomics of a global collection of Klebsiella pneumoniae reveals multiple routes for the emergence of convergent lineages

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Anjali SAPRE

B / 4 / 18

Poster P1455

Abstract 4705

Susceptibility of ESBL-producing, carbapenemase-negative clinical Enterobacterales isolates from eastern Europe to ceftolozane/tazobactam and comparator antibiotics: SMART 2018-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mark WISE

B / 4 / 19

Poster P1456

Abstract 4731

Activity of ceftolozane/tazobactam and comparators against ESBL-producing, carbapenemase-negative clinical Enterobacterales isolates from the Middle East/Africa region: SMART 2018-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mark WISE

B / 4 / 20

Poster P1457

Abstract 4736

A new problem for the Romanian healthcare system: the emergence of Stenotrophomonas maltophilia

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Alin-Stefan VIZITIU

B / 4 / 21

Poster P1458

Abstract 4758

Rising of ArmA and OXA-23 co-occurrence in Acinetobacter baumannii ST2: an increasingly challenging scenario for antibiotic resistance management in Europe

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Paula GUIJARRO

B / 4 / 22

Poster P1459

Abstract 4769

Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from hospitalised patients in South Africa: SMART 2018-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mark WISE

B / 4 / 23

Poster P1460

Abstract 4796

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Pseudomonas aeruginosa from hospitalised patients in Israel: SMART 2018-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mark WISE

B / 4 / 24

Poster P1461

Abstract 4815

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Pseudomonas aeruginosa from latin America: SMART 2020-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mark WISE

B / 4 / 25

Poster P1462

Abstract 4892

Unraveling cefiderocol resistance in Acinetobacter baumannii: a genomic perspective on in vivo adaptations

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Sara CARLONI

B / 4 / 26

Poster P1463

Abstract 4895

Extensively drug-resistant Acineto­bacter baumannii in an intensive care burn center unit in Uruguay: molecular epidemiology and synergy in colistin resistant strains.

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Matilde OUTEDA

B / 4 / 27

Poster P1464

Abstract 4919

Antibiotic susceptibility and molecular resistance mechanisms in Escherichia coli and Klebsiella pneumoniae isolates from Peruvian hospitals: a focus on cefiderocol

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Joaquin RUIZ BLAZQUEZ

B / 4 / 28

Poster P1465

Abstract 4934

Relebactam enhances the activity of imipenem against Burkholderia cepacia complex isolates SMART 2020-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Katherine YOUNG

A / 5 / 1

Poster P1466

Abstract 4956

Antimicrobial susceptibility of Stenotrophomonas maltophilia clinical isolates and genotypic analysis of cotrimoxazole resistance

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Patricia Luisa GÓMEZ SASTRE

A / 5 / 2

Poster P1467

Abstract 4991

NDM-5-producing Klebsiella pneumoniae ST258 in a university hospital in Argentina

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Laura DABOS

A / 5 / 3

Poster P1468

Abstract 5046

Multidrug-resistant, extensively drug-resistant and pan drug resistance Gram-negative orthopedic implant-associated infections: role of carbapenemase production

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mariana NERI LUCAS KURIHARA

A / 5 / 4

Poster P1469

Abstract 5180

Phenotypic and genotypic characterization of ertapenem-mono-resistant carbapenem-resistant Enterobacterales

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Yinping WANG

A / 5 / 5

Poster P1470

Abstract 5218

Epidemiologic, clinical profile and antibiotic sensitivity and resistance pattern of melioidosis at Southern Isabela Medical Centre, Santiago City, Philippines

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Maria Jonelyn MENDOZA-COLOBONG

A / 5 / 6

Poster P1471

Abstract 5271

Multi-institute analysis of carbapenem-resistant Enterobacterales reveals rapid changes in resistance mechanisms over time

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Nicoletta COMMINS

A / 5 / 7

Poster P1472

Abstract 5278

Molecular genetic analysis of extended-spectrum β-lactamase(ESBL)-producing Escherichia coli isolated from outpatients at a tertiary care emergency centre

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Yasumitsu NOMURA

A / 5 / 8

Poster P1473

Abstract 5285

Epidemiology of Klebsiella pneumoniae and their plasmids through the last decade in the United States

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Ting LUO

A / 5 / 9

Poster P1474

Abstract 5316

Susceptibility levels to cefiderocol in carbapenem-resistant Acinetobacter baumannii (CRAB) from Peruvian hospitals

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Rosario Del Pilar HUERTO HUÁNUCO

A / 5 / 10

Poster P1475

Abstract 5431

In vitro evaluation of antibiotic combinations against Acinetobacter baumannii isolated from bloodstream infections in Indian intensive care units

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Manasa Chandrashekar TANTRY

A / 5 / 11

Poster P1476

Abstract 5434

Antibiotic resistance patterns of Pseudomonas aeruginosa in a community-based hospital in Korea: the role of ceftazidime-avibactam

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Hyo-Jin LEE

A / 5 / 12

Poster P1477

Abstract 5508

Antimicrobial use and combination of resistance phenotypes in bacteraemic Escherichia coli in primary care: a study based on Japanese national data

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Yumiko HOSAKA

A / 5 / 13

Poster P1478

Abstract 5519

Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol in carbapenem-resistant Pseudomonas aeruginosa

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Ecem BUYUKYANBOLU

A / 5 / 14

Poster P1479

Abstract 5572

High prevalence of hypervirulence-associated genes in carbapenemase-producing Klebsiella pneumoniae isolates in Hungary

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Akos TOTH

A / 5 / 15

Poster P1480

Abstract 5677

Unnoticeable resistant pathogen Stenotrophomonas maltophilia: antimicrobial resistance, virulence and biofilm production

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Seyma Aybüke ÖZYAR KURTÇU

A / 5 / 16

Poster P1481

Abstract 5703

Phenotypic characteristics of multidrug-resistant bacteria from five Ukrainian war-trauma patients

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Diana Isabela STRACHINARU

A / 5 / 17

Poster P1482

Abstract 5713

In vitro activity of cefepime-enmetazobactam against OXA-48-like carbapenemase producing Enterobacterales collected in France

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Laurent DORTET

A / 5 / 18

Poster P1483

Abstract 5720

Antimicrobial resistance of Shigella spp. in south Australia and its detection using whole genome sequencing

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Helena TORPY

A / 5 / 19

Poster P1484

Abstract 5731

Distribution of resistance determinants among the most prevalent clones of Campylobacter jejuni according to cgMLST scheme

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Pablo FERNÁNDEZ PALACIOS

A / 5 / 20

Poster P1485

Abstract 5796

Epidemiology of IMI-type-carbapenemase-producing E. cloacae complex in France from 2012 to 2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Cécile EMERAUD

A / 5 / 21

Poster P1486

Abstract 5858

High levels of antimicrobial resistance among common bacterial pathogens in Indonesia: a systematic review

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Raph HAMERS

A / 5 / 22

Poster P1487

Abstract 5890

Characterisation of carbapenemase-producing Klebsiella pneumoniae isolates in a hospital in Madrid (Spain) before and during COVID-19 pandemic

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Marta NIETO TORRES

A / 5 / 23

Poster P1488

Abstract 5908

Plasmid-driven epidemiology: unravelling carbapenem resistance transmission in hospital setting

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Dominique S. BLANC

A / 5 / 24

Poster P1489

Abstract 6010

A five-year trend analysis of epidemiology and susceptibility of Salmonella species in a tertiary care centre, South India

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Jaya PRASANTHI

A / 5 / 25

Poster P1490

Abstract 6018

Russian-Ukraine war raised antibiotic resistance and Gram-negative infections of wounds in Ukraine

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Kateryna RUDNIEVA

A / 5 / 26

Poster P1491

Abstract 6024

The global burden of infections caused by metallo-β-lactamase- producing carbapenem-resistant Enterobacterales: results of a targeted literature review

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Maria GHEORGHE

A / 5 / 27

Poster P1492

Abstract 6082

Identification of regional, interregional, and international dissemination events of Klebsiella pneumoniae clones from Portugal

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Rita ELIAS

A / 5 / 28

Poster P1493

Abstract 6084

Clonal dissemination of a trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia harbouring the carbapenemase gene blaIMP in a clinical setting

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Esther ALMAZÁN GÁRATE

B / 5 / 1

Poster P1494

Abstract 6093

A melanin-producing Acinetobacter baumannii outbreak: the first report in EU area

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Alessandro LEONILDI

B / 5 / 2

Poster P1495

Abstract 6111

Clinical characteristics of patients with reported acquired carbapenemase-producing Gram-negative bacteria in England, October 2020 – April 2023

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Emily MASON

B / 5 / 3

Poster P1496

Abstract 6122

Phenotypic and genotypic characterisation of colistin-resistant Escherichia coli isolates from poultry farms in Uganda

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Ulrike BINSKER

B / 5 / 4

Poster P1497

Abstract 6131

Within-host chromosomal diversity of extended-spectrum beta-lactamase-producing Escherichia coli during long-term carriage

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Karlijn HOUKES

B / 5 / 5

Poster P1498

Abstract 6218

Colonisation rates of hospitalised patients with carbapenem resistant pathogens in a Greek hospital: a single centre, point prevalence study

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Nikolaos SIPSAS

B / 5 / 6

Poster P1499

Abstract 6222

Azithromycin mitigates PDR phenotype and improves sensitivity to meropenem in PDR Klebsiella pneumoniae biofilms

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Olena MOSHYNETS

B / 5 / 7

Poster P1500

Abstract 6263

Emergence of extensively drug-resistant hypervirulent Acinetobacter baumannii ST2 in Taiwan, a 16-year study

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Pek Kee CHEN

B / 5 / 8

Poster P1501

Abstract 6414

Epidemiological profile and antimicrobial resistance of non typhoidal Salmonella isolates in children in Tunis 2000-2022

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Eya ANANE

B / 5 / 9

Poster P1502

Abstract 6428

Evolution of betalactam susceptibility and penA polymorphism in invasive meningococcal disease in a Tunisian pediatric population (2009-2019)

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Dhouha KARRAY

B / 5 / 10

Poster P1503

Abstract 6436

Bacteriological profile of carbapenem-resistant organism colonisation and infections among inpatients at a national spinal injuries unit: a five-year retrospective study

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Melanie ETTI

B / 5 / 11

Poster P1504

Abstract 6442

Carbapenem-resistant Acinetobacter baumannii causing healthcare-associated bloodstream infections in Hungary in 2018-2019 and in 2020-2021: epidemiological and genomic epidemiological aspects

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Adrienn HANCZVIKKEL

B / 5 / 12

Poster P1505

Abstract 6458

Road to success in a quality improvement activity for the detection of carbapenemase producing Enterobacterales in a tertiary care hospital in the United Kingdom

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Gammanpila I. ATHUKORALA

B / 5 / 13

Poster P1506

Abstract 6500

Characterisation of beta-lactam resistance among H. influenzae in Switzerland

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Dominique HILTI

B / 5 / 14

Poster P1507

Abstract 6505

National surveillance of carbapenemase-producing Pseudomonas aeruginosa and Acinetobacter baumannii circulating in Belgian hospitals, 2023

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Denis OLIVIER

B / 5 / 15

Poster P1508

Abstract 6546

In vitro antibiotic susceptibility of Vibrio parahaemolyticus strains isolated in Southern Spain

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Sandra TAPIA-POZA

B / 5 / 16

Poster P1509

Abstract 6578

Prevalence of carbapenem-resistant Enterobacteriaceae (CRE) among various specimen received at Kwazulu-Natal Academic Hospital, South Africa: a retrospective study

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Afsana KAJEE

B / 5 / 17

Poster P1510

Abstract 6656

Carbapenemases in Germany in 2023: report of the German national reference centre for multidrug-resistant Gram-negative bacteria

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Niels PFENNIGWERTH

B / 5 / 18

Poster P1511

Abstract 6738

Carbapenem-resistant Escherichia coli: the results of 1-year WGS surveillance in a northern Italy hospital

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Aurora PIAZZA

B / 5 / 19

Poster P1512

Abstract 6779

In vitro activity of newly-developed ß-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with aztreonam against metallo-ß-lactamase producing Escherichia coli clinical isolates

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Clement VIGUIER

B / 5 / 20

Poster P1513

Abstract 6781

In vitro evaluation of incremental avibactam concentrations on ceftazidime activity against ceftazidime/avibactam susceptible and resistant KPC-producing Klebsiella pneumoniae clinical isolates

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Paolo GAIBANI

B / 5 / 21

Poster P1514

Abstract 6898

Efficacy in the use of beta-lactamase inhibitors compared to other antimicrobials in carbapenem-resistant Acinetobacter baumannii infections

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Maria LIMA

B / 5 / 22

Poster P1515

Abstract 6947

Genomic epidemiology of Klebsiella pneumoniae in the Comunitat Valenciana, Spain (2017-2019)

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Fernando GONZALEZ-CANDELAS

B / 5 / 23

Poster P1516

Abstract 7115

Unraveling the impact of COVID-19: a comprehensive study on Pseudomonas aeruginosa and carbapenem-resistant strains in Italian ICUs

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Giovanni SCAGLIONE

B / 5 / 24

Poster P1517

Abstract 7172

Comparison of resistance profiles of extended-spectrum β-lactamase-producing Escherichia coli from two poultry production systems in Uganda

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Ulrike BINSKER

B / 5 / 25

Poster P1518

Abstract 7319

Clinical and microbiological characterisation of infections by Stenotrophomonas maltophilia in a university hospital in Chile in 2021

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Patricio ROSS

B / 5 / 26

Poster P1519

Abstract 7355

Polymyxin and meropenem resistance in clinical Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii isolates and respective outcomes in patients treated at a tertiary hospital

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Carlos KIFFER

B / 5 / 27

Poster P1520

Abstract 7406

In vitro activity of funobactam (XNW4107) combined with imipenem against Gram-negative isolates collected in 2021

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Jianguo LI

B / 5 / 28

Poster P1521

Abstract 7445

Epidemiological and clinical characteristics of infected and colonised patients with carbapenem-resistant Enterobacterales in a university hospital of Colombia: are coproductions relevant?

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Sandra Milena GUALTERO TRUJILLO

A / 6 / 1

Poster P1522

Abstract 1718

In vitro activity of gepotidacin against urine isolates of Escherichia coli from outpatient departments in Germany, 2022/23

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Esther WOHLFARTH

A / 6 / 2

Poster P1523

Abstract 7592

Antimicrobial resistance surveillance of Pseudomonas aeruginosa invasive isolates in Catalonia (Spain) in the 2016-2022 period

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Pilar CIRUELA

A / 6 / 3

Poster P1524

Abstract 7703

Molecular epidemiology and genomic insights into cefiderocol-resistant carbapenemase-producing Citrobacter spp. isolates obtained in Barcelona

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Guillem PUIGSECH BOIXEDA

A / 6 / 4

Poster P1525

Abstract 7911

Epidemiology and antimicrobial susceptibility pattern of Klebsiella pneumoniae isolated from clinical samples in Poland

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Elzbieta LITERACKA

A / 6 / 5

Poster P1526

Abstract 7924

Prevalence of carbapenemase-producing enterobacteriaceae in kidney transplant patients

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Ariane BAPTISTA MONTEIRO

A / 6 / 6

Poster P1527

Abstract 7997

Presence of multidrug-resistant Acinetobacter kanungonis with blaIMP-16, blaGES-1 and blaOXA-143 in the Aurá river, Amazon, Brazil

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

A / 6 / 7

Poster P1528

Abstract 8018

Faecal carriage of carbapenemase-producing Enterobacteriaceae among patients admitted to tertiary hospital in Havana, Cuba

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Dianelys QUINONES PEREZ

A / 6 / 8

Poster P1529

Abstract 8022

CORE-MDR study: contact isolation removal evaluation on multidrug-resistant bacterial infections in India

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Sureshkumar DORAIRAJAN

A / 6 / 9

Poster P1530

Abstract 8061

Integrating genetic and epidemiological data supported the investigation of spatiotemporally dispersed genetic clusters and a local outbreak of NDM-1 producing Klebsiella pneumoniae in Germany, 2022-2023

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mirco SANDFORT

A / 6 / 10

Poster P1531

Abstract 8068

Emerging metallo-β-lactamase producing Klebsiella oxytoca complex in Taiwan: a decade-long analysis

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Chou CHIAHUA

A / 6 / 11

Poster P1532

Abstract 8081

Comparison of gene-by-gene and SNPs analysis for typing of K. pneumoniae ST512/KPC-3 genomes from southern Spain

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Mercedes DELGADO VALVERDE

A / 6 / 12

Poster P1533

Abstract 8167

Recurrence rate carbapenemase-producing Enterobacterales (CPE) after clearance

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Ji Hye PARK

A / 6 / 13

Poster P1534

Abstract 8244

Are ceftolozane/tazobactam and imipenem/relebactam potential options to overcome the threat of Gram-negative bacterial infections in Portugal? SMART 2018-21

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Hugo CRUZ

A / 6 / 14

Poster P1535

Abstract 8252

Colonisation by multidrug-resistant Gram-negative bacteria in acute graft-versus-host disease

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Aleksandr SINIAEV

A / 6 / 15

Poster P1536

Abstract 8261

AMRnet: unlocking pathogen genomics data for AMR surveillance

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Megan Elizabeth CAREY

A / 6 / 16

Poster P1537

Abstract 8339

Antimicrobial susceptibility rates and carbapenemase types of carbapenem-resistant Klebsiella pneumoniae isolated over a six-year period

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Selin Gamze KILIC SINCI

A / 6 / 17

Poster P1538

Abstract 8385

Genetic analysis of carbapenem resistant Acinetobacter baumannii isolates associated with the war in Ukraine

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Jessica EISFELD

A / 6 / 18

Poster P1539

Abstract 8386

Multidrug-resistance Enterobacteriaceae isolated from meats marketed in El Tarf, Algeria

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Zineb BELBEL

A / 6 / 19

Poster P1540

Abstract 8394

Genomics of clinical extensively drug-resistant Enterobacteriaceae strains isolated in Dakar, Senegal

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Komla Mawunyo DOSSOUVI

A / 6 / 20

Poster P1541

Abstract 8472

Prevalence of plasmid-mediated AmpC in Enterobacterales clinical isolates

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Patricia Luisa GÓMEZ SASTRE

A / 6 / 21

Poster P1542

Abstract 8477

Co-existence of two blaNDM-5 and blaOXA-181 on distinct plasmids in carbapenem-resistant Klebsiella pneumoniae isolates a tertiary hospital, Tanzania

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Joel MANYAHI

A / 6 / 22

Poster P1543

Abstract 8480

The changing epidemiology of carbapenem-resistant Klebsiella pneumoniae in Serbia: the expansion of the high-risk clone ST147/blaNDM-1

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Ina GAJIC

A / 6 / 23

Poster P1544

Abstract 8567

One year surveillance of carbapenem-resistant Enterobacterales: the impact of WGS

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Cristina MERLA

A / 6 / 24

Poster P1545

Abstract 8601

Comparative analysis of the multidrug-resistant Acinetobacter baumannii ST492 Romanian isolates in a global context

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Marius SURLEAC

A / 6 / 25

Poster P1546

Abstract 8726

Evaluation of new and old drugs for the management of complicated urinary tract infection in the era of MDR and XDR Gram-negative Bacilli in Oman

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Nawal AL SHIZAWI

A / 6 / 26

Poster P1547

Abstract 8824

Multidrug-resistant carbapenemase-producing Acinetobacter species in hospitals from Brazilian Amazon region during the COVID-19 pandemic

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Danielle BRASILIENSE SELIGMANN

A / 6 / 27

Poster P1548

Abstract 8908

Genomic characterisation of colistin-resistant clinical isolates of Klebsiella pneumoniae from Tahiti (French Polynesia)

29/04 12:00

3b. Resistance surveillance & epidemiology: Gram-negatives

Nadia AMRAOUI

A / 6 / 28

Poster P1549

Abstract 67

Multivariable evaluation of in vitro erformance of ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam & cefiderocol on difficult-to-treat Pseudomonas aeruginosa isolated from clinical samples

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Jose ALEXANDER

B / 6 / 1

Poster P1550

Abstract 186

Dual E-test overlay method to screen multi-drug resistant Gram-negative bacteria for synergy with meropenem-vaborbactam and aztreonam

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Oliver FLETCHER

B / 6 / 2

Poster P1551

Abstract 269

Multicentre interlaboratory study of routine systems for the susceptibility testing of temocillin using a challenge panel of multidrug-resistant strains

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Corentin DECKERS

B / 6 / 3

Poster P1552

Abstract 436

Sub-MIC antibiotic pre-exposure increased the single-cell MIC and promoted hetero-resistance in bacteria

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Shakeel AHMAD

B / 6 / 4

Poster P1553

Abstract 535

Rapid antimicrobial susceptibility testing using automated broth microdilution: performance evaluation of a four-hours bacterial cultivation from positive blood cultures

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Barbara KÖRBER-IRRGANG

B / 6 / 5

Poster P1554

Abstract 753

Comparison of two commercial broth microdilution panels for AST of multidrug-resistant Gram-negative bacteria

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Antoine AUPAIX

B / 6 / 6

Poster P1555

Abstract 763

Performance of a commercial assay for the detection and classification of OXA-48 producing-Escherichia coli isolates that do not co-produce ESBL/pAmpC

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Fátima GALÁN-SÁNCHEZ

B / 6 / 7

Poster P1556

Abstract 805

Evaluation of gradient strip diffusion for measuring the minimum inhibitory concentration of aztreonam/avibactam in metallo-beta-lactamase producing Enterobacterales

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Jamie LEMON

B / 6 / 8

Poster P1557

Abstract 893

Development and evaluation of gradient strip-based synergy testing methods to determine susceptibility of carbapenem-resistant Gram-negative organisms to the aztreonam (ATM) and ceftazidime-avibactam (CZA) combination

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Carmila MANUEL

B / 6 / 9

Poster P1558

Abstract 1103

Rapid antimicrobial susceptibility testing by SdFFF directly from positive blood cultures

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Linda TLILI

B / 6 / 10

Poster P1559

Abstract 1183

Identification of in vitro susceptibility test interpretive criteria (STIC) for sulfamethoxazole (SMX)-trimethoprim (TMP) against Escherichia coli and Klebsiella pneumoniae

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Brian VANSCOY

B / 6 / 11

Poster P1560

Abstract 1318

Evaluation of a new gradient MIC test for aztreonam/avibactam (AZA) susceptibility testing of Enterobacterales

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Maxime BOUVIER

B / 6 / 12

Poster P1561

Abstract 1476

Adaptation of the updated CA-SFM 2022 algorithm for screening of carbapenemase-producing Enterobacterales on automated antibiotic susceptibility test instrument

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Charles GIBERT

B / 6 / 13

Poster P1562

Abstract 1487

Rapid antimicrobial susceptibility testing of urinary tract infection bacteria using an innovative technology: scattered light integrated collector

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Hellen ONYANGO

B / 6 / 14

Poster P1563

Abstract 1492

Minimal inhibitory concentrations (MICs) of tigecycline correlate strongly with those of omadacycline

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Vinicius CALADO

B / 6 / 15

Poster P1564

Abstract 1495

Validation of aztreonam-avibactam MIC antimicrobial susceptibility test for MicroScan dried Gram-negative MIC panels from a multicenter assessment of Enterobacterales, Pseudomonas species, and Stenotrophomonas maltophilia

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Christine HASTEY

B / 6 / 16

Poster P1565

Abstract 1551

Evaluation of a rapid antibiotic susceptibility testing system on multidrug-resistant Gram-negative bacteria responsible for non-bloodstream infections: preliminary data

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Paolo BOTTINO

B / 6 / 17

Poster P1566

Abstract 1575

A comparative study of the specific REVEAL vs the VITEK2 system in susceptibility testing of NDM-producing Enterobacterales directly from positive blood cultures

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Amos ADLER

B / 6 / 18

Poster P1567

Abstract 1610

Evaluation of the equivalency of the oxoid aztreonam/avibactam (30/20 μg) antimicrobial susceptibility testing disc to the CLSI M07 broth microdilution frozen reference method

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

James BOVILL

B / 6 / 19

Poster P1568

Abstract 1664

Performance of a novel holographic imaging system for rapid susceptibility testing directly from Gram-negative positive blood cultures

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Dulini GAMAGE

B / 6 / 20

Poster P1569

Abstract 1806

VITEK reveal, a new fast, phenotypical antimicrobial susceptibility testing from positive blood culture: a real-life experience in a tertiary care hospital from Spain

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Josué PENDONES ULERIO

B / 6 / 21

Poster P1570

Abstract 1810

Comparison of three MIC gradient tests with the disk diffusion method for cefiderocol susceptibility testing on carbapenem-resistant Enterobacterales

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Andrea ZAPPAVIGNA

B / 6 / 22

Poster P1571

Abstract 1826

Rapid AST directly from blood culture bottles is now possible on lab automation: a performance study

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Matteo LUCCHINI

B / 6 / 23

Poster P1572

Abstract 1858

Disc diffusion test is reliable in detecting penicillin susceptibility in Staphylococcus aureus bacteraemia

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Pernilla KIHLBERG

B / 6 / 24

Poster P1573

Abstract 2018

Can EUCAST rapid antibiotic susceptibility testing be considered for Salmonella enterica? A pilot study

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Gunnar KAHLMETER

B / 6 / 25

Poster P1574

Abstract 2258

New insights in therapeutic options against difficult-to-threat Pseudomonas aeruginosa (DTR-PA): in vitro activity of aztreonam in combination with avibactam, relebactam and in double β-lactams combinations with ceftazidime/avibactam and imipenem/relebactam

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Fernando PASTERAN

B / 6 / 26

Poster P1575

Abstract 2349

Multicentre evaluation of a newly developed rapid antibiotic susceptibility testing automated system with three-hours MIC results using commonly encountered Gram-negative organisms in Chinese clinical microbiology laboratories

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Ming YANG

B / 6 / 27

Poster P1576

Abstract 2372

Susceptibility testing for Enterococcus species other than E. faecalis and E. faecium using EUCAST methodology and breakpoints

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Jenny AHMAN

B / 6 / 28

Poster P1577

Abstract 2391

Multicentre evaluation of a newly developed rapid antibiotic susceptibility testing automated system with 3-hours MIC results using commonly encountered gram-negative organisms in Chinese clinical microbiology laboratories

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Enhua SUN

A / 7 / 1

Poster P1578

Abstract 2394

Increasing pH of the test medium suppresses trailing phenomenon in cefiderocol MIC determinations for Acinetobacter baumannii

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Naoki ISHIBASHI

A / 7 / 2

Poster P1579

Abstract 2524

Comparison of different disk diffusion and MIC test strips brands with reference broth microdilution for imipenem/relebactam susceptibility testing of Pseudomonas aeruginosa

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Ana CANDELA

A / 7 / 3

Poster P1580

Abstract 2545

Performance of the EUCAST disk diffusion method for linezolid susceptibility testing in enterococci: a nordic multicentre study

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Björg C. HALDORSEN

A / 7 / 4

Poster P1581

Abstract 2549

How accurate is direct antibiotic sensitivity testing of Enterobacterales from positive blood cultures? Don't get caught out!

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Gemma VANSTONE

A / 7 / 5

Poster P1582

Abstract 2570

Detection by automated antimicrobial susceptibility testing method of trimethoprim/sulfamethoxazole heteroresistance in Staphylococcus aureus not detected by reference methods

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Geraldine DURAND

A / 7 / 6

Poster P1583

Abstract 2597

In vitro assessment of the novel antibiotic combination meropenem/ANT3310 against Gram-negative bacteria: CLSI Tier 1 study examining effects of varying MIC parameters and equivalency between agar dilution and broth microdilution methodologies

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Stephen HAWSER

A / 7 / 7

Poster P1584

Abstract 2637

Effect of miniaturisation of EUCAST broth microdilution

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Sarah NEEDS

A / 7 / 8

Poster P1585

Abstract 2754

A comparison of cefiderocol broth microdilution and disk diffusion against a panel of carbapenem-resistant Pseudomonas aeruginosa

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Katherine LANE

A / 7 / 9

Poster P1586

Abstract 2763

Diagnostic pathways for a rapid, culture based antibiotic susceptibility testing for urinary tract infections

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Stephen KIDD

A / 7 / 10

Poster P1587

Abstract 2855

Environmental context influences antimicrobial susceptibility testing

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Caroline BLACK

A / 7 / 11

Poster P1588

Abstract 2934

Evaluation of in vitro antibiotic susceptibility of Haemophilus influenzae strains isolated from clinical samples according to the EUCAST and CLSI criteria and molecular analysis of beta-lactam resistance

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Aylin Irem OCAKLI

A / 7 / 12

Poster P1589

Abstract 3148

Measuring reactive oxygen species (ROS) to determine minimal inhibitory concentrations (MIC) for Enterobacterales using flow cytometry (FCM)

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Andrea Lay Hoon KWA

A / 7 / 13

Poster P1590

Abstract 3201

Third generation cephalosporin antimicrobial susceptibility testing assay using scanning electron microscopy: a pilot investigation

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Omar ZMERLI

A / 7 / 14

Poster P1591

Abstract 3203

Comparative analysis of a commercially avaialble antibiotic susceptibility testing with microbial suspensions prepared with an automated specimen workup instrument

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Nicole SCHEPIS

A / 7 / 15

Poster P1592

Abstract 3250

Performance evaluation of meropenem-vaborbactam on clinical isolates in a fully automated rapid AST system

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Jenny GÖRANSSON

A / 7 / 16

Poster P1593

Abstract 3264

Interim results of a clinical and economic evaluation of a rapid AST system – the LIFETIMES study

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Gian Maria ROSSOLINI

A / 7 / 17

Poster P1594

Abstract 3496

Comparison of testing methods assessing the in vitro efficacy of the combination of aztreonam with avibactam on multidrug-resistant Gram-negative bacilli

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Te-Din Daniel HUANG

A / 7 / 18

Poster P1595

Abstract 3520

Deduction of dalbavancin susceptibility from vancomycin susceptibility in staphylococci

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Céline DUPIEUX-CHABERT

A / 7 / 19

Poster P1596

Abstract 3529

Analytical and clinical performance of a rapid AST system directly from positive blood cultures: results of a real-life diagnostic clinical trial in Madrid, Spain

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Ana Verónica HALPERIN

A / 7 / 20

Poster P1597

Abstract 3583

Phenotypic antibiotic susceptibility testing for last-resort antibiotics based on bacterial nanomotions provides results in two hours

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Alexander STURM

A / 7 / 21

Poster P1598

Abstract 3636

Multicentre comparison of different commercial antimicrobial susceptibility testing methods compared to broth microdilution for beta-lactam susceptibility testing of Streptococcus pneumoniae

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Steven MARTENS

A / 7 / 22

Poster P1599

Abstract 3647

Assessment of aztreonam-avibactam (ATM-AVI) CLSI 30/20 μg disk content against carbapenemase-producing Enterobacterales (CPEs)

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Paulina MARCHETTI

A / 7 / 23

Poster P1600

Abstract 3657

Detection of colistin susceptibility in multidrug resistant Acinetobacter baumannii isolates by different methods, determination of colistin resistance by molecular and rapid methods

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Fatih Mehmet AKILLI

A / 7 / 24

Poster P1601

Abstract 3673

How to properly determine fosfomycin susceptibility: comparison of three susceptibility methods

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Gabriela KRONEISLOVÁ

A / 7 / 25

Poster P1602

Abstract 3730

Performance of a novel microfluidic rapid AST assay for Gram-negative bloodstream infections in low and high resistance settings

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Christer MALMBERG

A / 7 / 26

Poster P1603

Abstract 3803

Developing a microfluidic-platform to support in vitro assessment of dynamic exposure-response relationships: towards individualised susceptibility testing

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Jennifer LAWRENCE

A / 7 / 27

Poster P1604

Abstract 3880

A cost-effective AST directly from positive blood culture bottles: preliminary data for Enterobacterales and staphylococci using two automatized methods

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Marco PERADOTTO

A / 7 / 28

Poster P1605

Abstract 3894

Preliminary performance of a new gradient MIC test strip for aztreonam/avibactam susceptibility testing of Enterobacterales

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Edwige PILLON

B / 7 / 1

Poster P1606

Abstract 4083

Ability of two rapid phenotypic AST methods to detect carbapenem-resistance in Gram-negative bacteria directly from positive blood cultures

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Nicole DEGEL-BROßMANN

B / 7 / 2

Poster P1607

Abstract 4206

Automated screening of carbapenemase classes by an antimicrobial susceptibility testing system

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Gilles ZAMBARDI

B / 7 / 3

Poster P1608

Abstract 4341

CLSI M23 tier 2 study to establish broth microdilution quality control ranges for meropenem-ANT3310

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Dana DRESSEL

B / 7 / 4

Poster P1609

Abstract 4378

Evaluation of the QuickMIC rapid antibiotic susceptibility testing assay with carbapenem resistant Escherichia coli and Klebsiella pneumoniae isolates

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Meszéna RÉKA

B / 7 / 5

Poster P1610

Abstract 4717

Comparison of Enterococcus faecalis penicillin susceptibility via commercial direct MIC test vs broth microdilution

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Olivia FUNK

B / 7 / 7

Poster P1612

Abstract 4965

AST comparison for Pseudomonas aeruginosa and other nonfermenting Gram-negative bacilli: disk diffusion and automated microdilution vs broth microdilution

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Samy MZOUGUI

B / 7 / 8

Poster P1613

Abstract 4992

Testing efficacy of a novel diagnostic antimicrobial susceptibility testing platform on patient bacterial isolates from a large Scottish teaching hospital

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Stuart REID

B / 7 / 9

Poster P1614

Abstract 5155

Evaluation of disk diffusion breakpoints for Aerococcus spp. using CLSI methods

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Richard MAYNARD

B / 7 / 10

Poster P1615

Abstract 5241

Fine tuning polymyxin B combinations: tackling the growing threat of pan-drug resistant Klebsiella pneumoniae

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Jan Naseer KAUR

B / 7 / 11

Poster P1616

Abstract 5444

mATM/CZA: a new rapid and inexpensive methodology for evaluating the combination in vitro of ceftazidime-avibactam plus aztreonam among Enterobacterales

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Juliana CAIERÃO

B / 7 / 12

Poster P1617

Abstract 5453

Validation of commercial automated bacterial suspension preparation and plate streaking for antibiotic disk diffusion susceptibility testing

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Robin VANSTOKSTRAETEN

B / 7 / 13

Poster P1618

Abstract 5542

Evaluation of EUCAST breakpoints and methods for antimicrobial susceptibility testing of cefiderocol

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Erika MATUSCHEK

B / 7 / 14

Poster P1619

Abstract 5549

Quality assessment of antimicrobial susceptibility testing among Level 2 and 3 medical laboratories in Zambia

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Lungowe Inonge MUKUBUTA

B / 7 / 15

Poster P1620

Abstract 5767

Prospects for using MICs assessed under clinically relevant conditions to predict the development of antibiotic resistance: a study with meropenem and Klebsiella pneumoniae

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Stephen H. ZINNER

B / 7 / 16

Poster P1621

Abstract 5783

Direct identification and antibiotic susceptibility testing in Bacteroides fragilis isolates from positive blood cultures

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Mervenur DEMIR

B / 7 / 17

Poster P1622

Abstract 5814

Cefiderocol MIC against cefiderocol-resistant Acinetobacter baumannii can be affected by starting inoculum size

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Hidenori YAMASHIRO

B / 7 / 18

Poster P1623

Abstract 5816

New approach to evaluate the bactericidal activity of different antiseptic ophthalmic preparations used as surgical prophylaxis

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Sara CALDRER

B / 7 / 19

Poster P1624

Abstract 5830

Evaluation of methods for aztreonam-avibactam MIC determination

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Laurent DORTET

B / 7 / 20

Poster P1625

Abstract 5954

Evaluation of antibiogram and microbial identification in terms of accuracy and time when applied with the RAST technique

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Huseyin GUDUCUOGLU

B / 7 / 21

Poster P1626

Abstract 6037

Evaluation of the oxoid imipenem/relebactam (10/25 µg) antimicrobial susceptibility testing (AST) disc against the predicate AST disc

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

James BOVILL

B / 7 / 22

Poster P1627

Abstract 6105

A novel fast and easy test for determination of tigecycline and colistin susceptibility

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Seyma Aybüke ÖZYAR KURTÇU

B / 7 / 23

Poster P1628

Abstract 6159

Two-dimensional checkerboard screening of ceftazidime-avibactam and fosfomycin against carbapenemase-producing E. coli, K. oxytoca, E. cloacae and K. pneumoniae clinical isolates

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Miklas MARTENS

B / 7 / 24

Poster P1629

Abstract 6203

FASTinov ultrarapid AST directly from positive blood cultures: performance validation study in 6 Portuguese hospitals

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Luís ROSETA

B / 7 / 25

Poster P1630

Abstract 6230

Inoculum effect of meropenem and meropenem/avibactam with Klebsiella pneumoniae: can MIC at high inoculum predict MPC?

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Stephen H. ZINNER

B / 7 / 26

Poster P1631

Abstract 6239

Comparison of commercial methods for evaluating susceptibility to cefiderocol

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Edoardo CARRETTO

B / 7 / 27

Poster P1632

Abstract 6270

QMAC dRAST for rapid AST on colonies yielded from respiratory specimens in ICU

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Emmanuelle GALLOIS

B / 7 / 28

Poster P1633

Abstract 6416

Investigation of carbapenem heteroresistance in Acinetobacter baumannii and Pseudomonas aeruginosa blood isolates

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Ekin KIRBAS

A / 8 / 1

Poster P1634

Abstract 6455

Is counting of Colony-Forming Units a reliable method to evaluate antibiotic activity against intracellular bacteria?

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Audrey COMEIN

A / 8 / 2

Poster P1635

Abstract 6480

Rapid antibiotic susceptibility testing in patients with bloodstream infection in a low resistance environment

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Jan Egil AFSET

A / 8 / 3

Poster P1636

Abstract 6541

Evaluation of a novel system for rapid antimicrobial susceptibility testing of Gram-negative pathogens from positive blood cultures

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Fabio MORECCHIATO

A / 8 / 4

Poster P1637

Abstract 6549

Evaluation of a new system for rapid antimicrobial susceptibility of Gram-negative bacteria directly from positive blood cultures

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Livia TARTAGLIONE

A / 8 / 5

Poster P1638

Abstract 6799

Evaluation of an automated antimicrobial susceptibility testing system performance for colistin susceptibility in multi drug resistant Acinetobacter baumannii isolates

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Arzu ILKI

A / 8 / 6

Poster P1639

Abstract 6811

Optimising ESBL confirmation: evaluating routine EUCAST cephalosporin disks in double disk synergy test

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Eysan ÖZGÜR YARKICI

A / 8 / 7

Poster P1640

Abstract 6825

Reducing turn around time by rapid identification and antimicrobial susceptibility testing directly from urine combining conventional with automated technology advancing integrated stewardship

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Maitrayee NARAYAN

A / 8 / 8

Poster P1641

Abstract 6973

In vitro susceptibility test to cefiderocol of NDM-producing K. pneumoniae from bloodstream isolates: a comparison of commercial methods and the reference method

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Alessandro LEONILDI

A / 8 / 9

Poster P1642

Abstract 6987

Optimising access to ceftazidime-avibactam-aztreonam combination therapy and in-house susceptibility testing

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Emily WOODHOUSE

A / 8 / 10

Poster P1643

Abstract 7025

Evaluation of pH-dependent effect on finafloxacin activity against Pseudomonas aeruginosa isolates

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Alba RUIZ-GAITÁN

A / 8 / 11

Poster P1644

Abstract 7027

Evaluation of media for MIC susceptibility testing of N. gonorrhoeae.

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Leanne DAVIES

A / 8 / 12

Poster P1645

Abstract 7113

Metronidazole MIC testing and anaerobic bacteria: comparison of the two agar dilution reference method EUCAST and CLSI. Impact on a commercial device

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Martelin ROLAND

A / 8 / 13

Poster P1646

Abstract 7281

Study of two susceptibility testing methods with gradient strips for aztreonam and ceftazidime/avibactam combination in bacteria producing metallo-β-lactamases

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Violeta ARTAL

A / 8 / 14

Poster P1647

Abstract 7416

A new rapid antimicrobial susceptibility testing assay evaluated with positive blood cultures for antimicrobial-resistant bacterial pathogens

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Giulia MENCHINELLI

A / 8 / 15

Poster P1648

Abstract 7531

Susceptibility testing of carbapenemase-producing bacteria: comparison of two MIC panels

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Petra HILKENS

A / 8 / 16

Poster P1649

Abstract 7535

Determination of aztreonam/avibactam MIC and two simple methods for detection of combined in-vitro activity of aztreonam and ceftazidim/avibactam against metallobetalactamase-producing Enterobacterales

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Julija GERM

A / 8 / 17

Poster P1650

Abstract 8184

First hospital trials of a new antimicrobial susceptibility test (AST) demonstrate accurate, cost-effective results from positive blood cultures in three hours

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Toby KING

A / 8 / 18

Poster P1651

Abstract 8324

Investigation of the synergistic effect of ceftazidime-avibactam and aztreonam combination in multidrug-resistant Stenotrophomonas maltophilia clinical isolates using checkerboard and double disk synergy methods

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Ekin KIRBAS

B / 8 / 1

Poster P1652

Abstract 8486

Performance of two different colistin susceptibility tests on carbapenemase producing Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Stenotrophomonas maltophilia

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Doga ILKI

B / 8 / 2

Poster P1653

Abstract 8549

Utilisation of the breakpoints from the clinical and laboratory standards institute and the European committee on antimicrobial susceptibility testing at the quality control programme of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Enrique RUIZ DE GOPEGUI BORDES

B / 8 / 3

Poster P1654

Abstract 8933

Rapid antimicrobial susceptibility testing directly from urine

29/04 12:00

3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)

Emelie JANSSON

B / 8 / 4

Poster P1655

Abstract 8

Lipid remodelling in Gram-negative bacteria does not affect octenidine's activity

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Nermina MALANOVIC

B / 8 / 5

Poster P1656

Abstract 114

Divergent genetic landscapes drive lower levels of AmpC induction and stable de-repression in Serratia marcescens compared to Enterobacter cloacae

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Lazarus JACOB

B / 8 / 7

Poster P1658

Abstract 602

Changing trend of Enterobacterales carrying blaNDM and the emergence of multidrug-resistant E. coli ST8346 with multiple carbapenemases in southern Taiwan, 2016-2022

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Tu-Hsuan CHANG

B / 8 / 8

Poster P1659

Abstract 672

Integrative and conjugative elements in invasive Haemophilus influenzae in Scandinavia

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Helene Johannessen WEFRING

B / 8 / 9

Poster P1660

Abstract 674

Association between MLST and the PmrCAB operon with colistin resistance and biofilm-related gene expression in Acinetobacter nosocomialis strains

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Jun-Ren SUN

B / 8 / 10

Poster P1661

Abstract 933

Emergence of a transferrable daptomycin resistance mechanism in Gram-positive bacteria: a novel membrane-associated ABC transporter confers high-level daptomycin resistance in Staphylococci

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Tessa MARCINIAK

B / 8 / 11

Poster P1662

Abstract 1241

Highly active blaDHA-1 harbouring transposon in E. coli from German food production chain

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Alexandra IRRGANG

B / 8 / 12

Poster P1663

Abstract 1286

NDM-1-mediated resistance to cefiderocol (FDC): mechanistic insights

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Alejandro Jose VILA

B / 8 / 13

Poster P1664

Abstract 1294

Evolutionary advantage of taniborbactam-resistant NDM-9

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Alejandro Jose VILA

B / 8 / 14

Poster P1665

Abstract 1378

Mobile integrons carry phage defence cassettes

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Nicolas KIEFFER

B / 8 / 15

Poster P1666

Abstract 1430

Genomic and metabolic characteristics in laboratory-induced colistin-resistance Acinetobacter baumannii

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Huang XIAOLAN

B / 8 / 16

Poster P1667

Abstract 1533

Phenotypic and genotypic characterization of a carbapenem-resistant Acinetobacter baumannii clinical isolate harboring the carbapenemase IMP-8

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Xu QINGYE

B / 8 / 17

Poster P1668

Abstract 1682

Carvacrol: a natural defense against Staphylococcus aureus and its aminoglycoside resistance

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Cristina GAN ORIA

B / 8 / 18

Poster P1669

Abstract 1992

Clonal lineage profiling of colistin resistance gene mcr-1 in clinical, veterinary and environmental bacterial isolates and antibiotics effective in them

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Chinmoy SAHU

A / 9 / 1

Poster P1670

Abstract 2053

Mechanisms of acquisition of vanA operon among vancomycin-resistant Staphylococcus aureus genomes: the tip of the iceberg?

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Huynh Ngoc Tram VO

A / 9 / 2

Poster P1671

Abstract 2346

In vivo evolution of a novel KPC-144 variant conferring ceftazidime/avibactam resistance in ST11 carbapenem-resistant Klebsiella pneumoniae

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Ping YANG

A / 9 / 3

Poster P1672

Abstract 2348

Two-component sensor factor envZ influence antibiotic resistance and virulence in the evolutionary dynamics of multidrug-resistant Salmonella enteritidis causing multisite invasive infections

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Lifei YU

A / 9 / 4

Poster P1673

Abstract 2357

Chromosomal integration and plasmid fusion induce the transmission, resistance, fitness differences in carbapenem-resistant Klebsiella pneumoniae isolates co-harboring blaNDM-1 and blaIMP-4

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Qiucheng SHI

A / 9 / 5

Poster P1674

Abstract 2522

Antimicrobial treatment failure: persistence and toxin/antitoxin systems in carbapenem-resistant Acinetobacter baumannii evolving in colistin-resistant strains

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Eleonora CHINES

A / 9 / 6

Poster P1675

Abstract 2702

The transcriptional regulator SpoVG strongly impacts the zinc tolerance of Staphylococcus aureus via regulation of multiple cellular pathways

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Jacqueline SCHÜRMANN

A / 9 / 7

Poster P1676

Abstract 2729

Spontaneous resistance against novel β-lactamase inhibitors

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Ling ZHUOREN

A / 9 / 8

Poster P1677

Abstract 2741

Suppression of fumarases and adaptive response in combination with the SOS response enhances antimicrobial susceptibility in Escherichia coli

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Marina MURILLO TORRES

A / 9 / 9

Poster P1678

Abstract 2782

Host-specific evolution of NDM carbapenemases

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Lisandro Javier GONZÁLEZ

A / 9 / 10

Poster P1679

Abstract 2789

Phenotypic and genetic characteristics of blaIMP-6 harbouring Enterobacteriaceae: emergence of novel plasmid variants coding blaIMP-6

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Koichi YAMAGUCHI

A / 9 / 11

Poster P1680

Abstract 2904

Dynamics of antimicrobial resistance plasmids in OXA-48-producing K. pneumoniae

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Fátima GALÁN-SÁNCHEZ

A / 9 / 12

Poster P1681

Abstract 3023

Conditional evolution and novel mechanism of biocide tolerance in two nosocomial Gram-positive pathogens

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Maria SOLSONA GAYA

A / 9 / 13

Poster P1682

Abstract 3134

Genomic variability and resistance mechanisms of Salmonella isolates recovered at hospitals in Peru

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Fiorella KRAPP LOPEZ

A / 9 / 14

Poster P1683

Abstract 3172

Identification of the novel fosfomycin resistance gene fosSC in Staphylococcus capitis

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Yueqin HONG

A / 9 / 15

Poster P1684

Abstract 3251

Impact of transferable β-lactamases and intrinsic AmpC amino acid substitutions on the activity of cefiderocol against wild-type and iron uptake deficient mutants of Pseudomonas aeruginosa

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Gonzalez LUCIA

A / 9 / 16

Poster P1685

Abstract 3252

Interplay between DNA repair systems and antimicrobial heteroresistance in Escherichia coli

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Sara DIAZ-DIAZ

A / 9 / 17

Poster P1686

Abstract 3278

Prevalence and distribution of mobile genetic elements in ESBL and/or carbapenemase-producing Klebsiella pneumoniae isolates belonging or not to high-risk clones

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Manuel ALCALDE-RICO

A / 9 / 18

Poster P1687

Abstract 3337

Triclosan-selected de novo mutations in carbapenemase-producing Klebsiella pneumoniae clinical isolates

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Patricia PEREZ PALACIOS

A / 9 / 19

Poster P1688

Abstract 3509

Characterisation of a high-risk Klebsiella pneumoniae clone with normal and small colony variant phenotypes in the form of a phenotypic “hyper-splitting” phenomenon

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Eyüp DOGAN

A / 9 / 20

Poster P1689

Abstract 3537

FosA gene is not responsible of the different in vitro response to fosfomycin in carbapenem-resistant K. pneumoniae clinical strains

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Stefano STRACQUADANIO

B / 9 / 1

Poster P1690

Abstract 3540

ATP-binding cassette transporter mediates and regulates metronidazole resistance in Clostridioides difficile

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Xu TENG

B / 9 / 2

Poster P1691

Abstract 3553

Cefepime/enmetazobactam is an innovative ?-lactam/?-lactam-derived ?-lactamase inhibitor combination with increased in vitro potency against KPC Ω-loop variants involved in ceftazidime/avibactam resistance

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Martín PAMPÍN GARCÍA

B / 9 / 3

Poster P1692

Abstract 3669

Chromosomally encoded OXA-23 transferred by recombination in Acinetobacter baumannii

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Kyriaki XANTHOPOULOU

B / 9 / 4

Poster P1693

Abstract 3709

Evaluation of cefiderocol stability against clinically relevant serine- and metallo-β-lactamases

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Alessandra PICCIRILLI

B / 9 / 5

Poster P1694

Abstract 3774

High-level plazomicin exposure selects for mutations in fusA, ratA, and a novel two-component system in Morganella morganii

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Mariana CASTANHEIRA

B / 9 / 6

Poster P1695

Abstract 3775

Investigation of the β-lactam/β-lactamase combination resistance mechanisms of Bacteroides species

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Danhui HEO

B / 9 / 7

Poster P1696

Abstract 3885

Heteroresistance to piperacillin-tazobactam in Klebsiella pneumoniae is mediated by increased copy number of multiple beta-lactamase genes

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Ahmed BABIKER

B / 9 / 8

Poster P1697

Abstract 3980

Co-selection of IncC plasmids carrying blaVIM-1 and IncFII plasmids carrying the mercury resistance operon (merRTPCADE) in Escherichia coli in presence of mercury.

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Patricia PEREZ PALACIOS

B / 9 / 9

Poster P1698

Abstract 4370

Impact of two missense mutations (p.I515M and p.A606D) in the pbp2 gene of an MRSA strain on the development of resistance to dalbavancin and cell wall thickness

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Heimo LAGLER

B / 9 / 10

Poster P1699

Abstract 4514

First report of resistance to aztreonam/avibactam and to cefiderocol in NDM-5 producers E.coli in Algeria

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Mohamed Azzedine BACHTARZI

B / 9 / 11

Poster P1700

Abstract 4539

Changes in resistance phenotype in consecutive isolates of KPC-8-producing Klebsiella pneumoniae from a long-term colonised patient

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Fátima GALÁN-SÁNCHEZ

B / 9 / 12

Poster P1701

Abstract 4591

Presence of OXA-1 gene not predictive of Piperacillin-Tazobactam resistance among ESBL Enterobacteriales

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Melissa GITMAN

B / 9 / 13

Poster P1702

Abstract 4618

Differences in oxazolidinone resistance mechanisms and small colony variants emergence of Staphylococcus aureus induced in an in vitro resistance development model

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Heimo LAGLER

B / 9 / 14

Poster P1703

Abstract 4794

Molecular mechanisms of cefiderocol resistance in Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa isolates from Peru

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Luciano Augusto PALOMINO KOBAYASHI

B / 9 / 15

Poster P1704

Abstract 4901

Environmental reservoir of carbapenemase-producing Klebsiella pneumoniae ST35 and molecular characterisation of incF plasmids

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Liliana Marcela PESARESI

B / 9 / 16

Poster P1705

Abstract 4993

Presence of diverse metal resistance determinants amongst antibiotic-resistant bacteria from Peru

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Luciano Augusto PALOMINO KOBAYASHI

B / 9 / 17

Poster P1706

Abstract 5003

Increased efficiency or periplasm stability? That is the question, in the evolution of KPC-2

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Laura DABOS

B / 9 / 18

Poster P1707

Abstract 5099

Conformational changes in Acinetobacter-derived cephalosporinase (ADC) variants lead to enhanced cephalosporinase activity in Acinetobacter baumannii; two mechanisms of deacylation

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Brad WALLAR

B / 9 / 19

Poster P1708

Abstract 5118

Assessing genetic diversity and similarity of carbapenemases-encoding plasmids in Gram-negative bacteria isolated from cases of bacteremia of Ecuador

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Gabriela SEVILLANO

B / 9 / 20

Poster P1709

Abstract 5649

Trade-off between beta-lactam resistance and stability in Gram-positive class B1 penicillin binding proteins

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Mélanie ROCH

A / 10 / 1

Poster P1710

Abstract 5745

Delaying the emergence of cefiderocol resistance in NDM-producing Enterobacter cloacae complex using the combination cefiderocol-aztreonam in vitro

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Dennis NURJADI

A / 10 / 2

Poster P1711

Abstract 5759

Cross regulation of IMI carbapenemase and intrinsic cephalosporinase AmpC in Enterobacter cloacae complex

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Cécile EMERAUD

A / 10 / 3

Poster P1712

Abstract 5829

Mutations of surA and pcoS increase carbapenem resistance in Klebsiella pneumoniae with blaOXA-48

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Martina CREMANNS

A / 10 / 4

Poster P1713

Abstract 5854

In-human reversion from methicillin-resistant to methicillin-susceptible Staphylococcus aureus leads to potential fitness benefit at the site of infection

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Aya IIZUKA

A / 10 / 5

Poster P1714

Abstract 5960

The analysis of cell wall morphological changes induced by betalactams in Haemophilus influenzae

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Lucia MALISOVA

A / 10 / 6

Poster P1715

Abstract 6113

Three major plasmid groups mobilize the most frequent third-generation cephalosporin resistance genes among E. coli isolated from poultry and human clinical samples in Switzerland

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Javier Eduardo FERNANDEZ

A / 10 / 7

Poster P1716

Abstract 6267

Comparative genomic analysis reveals the emergence of ST-2096 Klebsiella pneumoniae strains associated with the high transmissibility of blaOXA-232 in Oman

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Alrujaibi ARWA

A / 10 / 8

Poster P1717

Abstract 6285

In vitro development of aztreonam-avibactam resistance in clinical isolates of NDM-1-producing Klebsiella pneumoniae

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Stephanie WILSON

A / 10 / 9

Poster P1718

Abstract 6769

A delayed resistance evolution under combination treatment strategy in carbapenem-resistant Klebsiella pneumoniae

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Ruobing WANG

A / 10 / 10

Poster P1719

Abstract 6838

A single point mutation in the promoter region of the mgrB gene induces colistin resistance in Salmonella enterica

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Judith GUITART-MATAS

A / 10 / 11

Poster P1720

Abstract 6963

Purification and enzyme kinetics of newly discovered metallo-beta-lactamase NWM-1

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Lisa-Marie HÖFKEN

A / 10 / 12

Poster P1721

Abstract 6970

Molecular characterisation of resistance mechanisms in cefiderocol-resistant Enterobacterales

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Pia TUROWSKI

A / 10 / 13

Poster P1722

Abstract 7005

Molecular and biochemical characterization of a putative Pseudomonas prolyl-4-hydroxylase involved in the resistance to siderophore conjugated antibiotics

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Faisal ALSHREF

A / 10 / 14

Poster P1723

Abstract 7021

Mutation in mepM confers salt tolerance in Escherichia coli

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Priya NAGPAL

A / 10 / 15

Poster P1724

Abstract 7375

Absence of LiaF increases daptomycin activity against E. faecalis in a rat model of infective endocarditis

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Cesar ARIAS

A / 10 / 16

Poster P1725

Abstract 7384

ACM-like enzymes, new subclass B3 metallo-ß-lactamases identified in Acinetobacter spp.

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Clement VIGUIER

A / 10 / 17

Poster P1726

Abstract 7399

Transmission of mcr-3-carrying IncHI2 plasmids at high temperature through formation a hybrid plasmid

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Mei LI

A / 10 / 18

Poster P1727

Abstract 7558

In vivo development of cefiderocol resistance in carbapenem-resistant Acinetobacter baumannii associated with the downregulation of a TonB-dependent siderophore receptor, PiuA

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Jacqueline FINDLAY

A / 10 / 19

Poster P1728

Abstract 7565

Molecular characterisation of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Emilia CERCENADO

A / 10 / 20

Poster P1729

Abstract 7741

A strain of Serratia marcescens exhibiting high-level tolerance to meropenem

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Xiaobing CHU

B / 10 / 1

Poster P1730

Abstract 7961

Mutation in piuA promoter mediated reduced cefiderocol susceptibility in Acinetobacter baomannii

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Xiaochen LIU

B / 10 / 2

Poster P1731

Abstract 8084

Analysis of two class A β-lactamases from Nocardia brasiliensis (BRA-1 and BRA-2) and associated β-lactam resistance

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Hervé JACQUIER

B / 10 / 3

Poster P1732

Abstract 8186

Tolerance detection among Enterococcus gallinarum bloodstream isolates

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Jacob STRAHILEVITZ

B / 10 / 4

Poster P1733

Abstract 8283

The cooperative interaction of penicillin-binding proteins (PBPs) in Enterococcus faecalis promotes resistance to beta-lactams

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Paola CONTI

B / 10 / 5

Poster P1734

Abstract 8344

Genomic framework of Klebsiella pneumoniae high-risk clone sequence type 101 and the CZA resistance evolution by the novel KPC-111 variant

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Riccardo POLANI

B / 10 / 6

Poster P1735

Abstract 8361

Carbapenem resistance determinants in integrons and related mobilisable elements in KAPEc isolates from Peru

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Luciano Augusto PALOMINO KOBAYASHI

B / 10 / 7

Poster P1736

Abstract 8366

In vitro selected V562L substitution outside the PBP3 transpeptidase region in Haemophilus influenzae results in increased MIC of cefuroxime

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Vladislav JAKUBU

B / 10 / 8

Poster P1737

Abstract 8376

Fosfomycin resistance associated with chromosomic fosA gene overexpression in Klebsiella pneumoniae clinical isolates

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Ághata RIBEIRO

B / 10 / 9

Poster P1738

Abstract 8618

Evolution of viscosity due to the wzc mutation in Klebsiella pneumoniae isolates producing KPC-31 carbapenemase variant from a single patient

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Valerio CAPITANI

B / 10 / 10

Poster P1739

Abstract 8700

Population analysis, mutant prevention concentrations and characterisation of resistance mutations to novel β-lactams in wild-type, mutator, and high-risk clones of Pseudomonas aeruginosa

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Miquel Àngel SASTRE FEMENIA

B / 10 / 11

Poster P1740

Abstract 8780

The role of tpiA: a key metabolic enzyme in regulating drug-resistance and virulence in Klebsiella pneumoniae

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Anru ZHANG

B / 10 / 12

Poster P1741

Abstract 8784

LiaF has an activator role in the LiaR-mediated response against daptomycin (DAP) in Enterococcus faecalis (Efs)

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Cesar ARIAS

B / 10 / 13

Poster P1742

Abstract 8863

ST39 K. pneumoniae harboring an IncM1-plasmid promotes clonal and plasmid-mediated OXA-48 transmission in a Swiss institution

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Diego ANDREY

B / 10 / 14

Poster P1743

Abstract 8875

Molecular analysis of the carbapenem resistance mechanism of a Phocaeicola vulgatus strain

29/04 12:00

3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)

Bakhtiyar MAHMOOD

B / 10 / 15

Poster P1744

Abstract 759

Adaptation of an antibiotic disc-based assay for improved detection of carbapenemases in Enterobacterales

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Meg JAGO

B / 10 / 16

Poster P1745

Abstract 794

Comparative analysis of prediction values for antimicrobial resistance of Staphylococcus aureus using MALDI-TOF mass spectra and various machine learning programs

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Wei-Yao WANG

B / 10 / 17

Poster P1746

Abstract 831

High accuracy and prediction values for mecA+ methicillin-resistant (MRSA) and phenotypic oxacillin-resistant Staphylococcus aureus (ORSA) on the basis of MALDI-TOF MS by using machine learning approach

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Wei-Yao WANG

B / 10 / 18

Poster P1747

Abstract 899

Evaluation of blood culture identification and antimicrobial resistance instrumentation for detection of antimicrobial resistance markers

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Richard MAYNARD

B / 10 / 19

Poster P1748

Abstract 1046

Evaluation of an immunochromatographic test for rapid detection of patients colonised with carbapenemase-producing organisms from broth-enriched rectal swabs

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Maristela P FREIRE

B / 10 / 20

Poster P1749

Abstract 1270

Evaluation of an immunochromatographic method (NG-TEST CARBA-5) for detection of different allelic variants of KPC, NDM, IMP and VIM carbapenemases in Enterobacterales (ETB) and Pseudomonas aeruginosa (PAE) isolates

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Fernando PASTERAN

A / 11 / 1

Poster P1750

Abstract 1524

Epidemiology of carbapenemase-producing Enterobacterales (CPE) and a proposed adequate phenotypic methods for carbapenemase detection

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Yiel-Hea SEO

A / 11 / 2

Poster P1751

Abstract 1635

MultiRapid NP test for detecting concomitantly susceptibility and resistance of last resort novel antibiotics available to treat multidrug-resistant Enterobacterales infections

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Otavio RARO

A / 11 / 3

Poster P1752

Abstract 1836

Evaluation of the ability of the Gene Xpert Carba-R system to detect KPC and IMP carbapenemases variants

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Alejandra CORSO

A / 11 / 4

Poster P1753

Abstract 1860

Detection of lipid A by MALDI-TOF for colistin heteroresistant strains

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Nadine PERROT

A / 11 / 5

Poster P1754

Abstract 1869

Cefiderocol resistance genes identified using functional metagenomics

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Rémi GSCHWIND

A / 11 / 6

Poster P1755

Abstract 1870

Genetic determinants against therapeutically relevant antibiotics in 26,557 publicly available genome sequences from Clostridioides difficile isolates

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Baban Sanjay KOLTE

A / 11 / 7

Poster P1756

Abstract 2082

Rapid detection of third-generation cephalosporin resistance in Enterobacterales directly from positive blood cultures by an electrochemical test

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Philipp THELEN

A / 11 / 8

Poster P1757

Abstract 2478

CRISPR-Cas12a-based GES carbapenemase detection assay: a pilot study

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Samuel GARCÍA GARCÍA

A / 11 / 9

Poster P1758

Abstract 2531

Rapid detection of aztreonam/avibactam susceptibility by MALDI-TOF MS in a collection of β-lactamase producing Enterobacterales

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Ana CANDELA

A / 11 / 10

Poster P1759

Abstract 2614

Tracking clonal and plasmid transmissions in colistin and carbapenem resistant Klebsiella pneumoniae

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Sandra REUTER

A / 11 / 11

Poster P1760

Abstract 2684

Standardisation of an agglutination test for detection of clinical isolates producing carbapenemases

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Valêncio Siqueira ANDRÉ

A / 11 / 12

Poster P1761

Abstract 2870

Carbapenemases screening of high-risk patients with a commercial test: a 4-year follow-up study

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Frederic JANVIER

A / 11 / 13

Poster P1762

Abstract 2881

A pooling strategy for detecting carbapenem resistance genes by a commercial test in rectal swab specimens

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Frederic JANVIER

A / 11 / 14

Poster P1763

Abstract 2947

Uncovering genetic markers of antimicrobial resistance in Bacillus anthracis using comparative genomic analysis

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Tucker MAXSON

A / 11 / 15

Poster P1764

Abstract 2994

Lateral flow assay phenotypically detects bacterial growth for antibiotic susceptibility testing

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Emily MELZER

A / 11 / 16

Poster P1765

Abstract 2995

XDR nosocomial Pseudomonas putida driving a plasmid-blaVIM-1 gene

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Lidia RUIZ-ROLDÁN

A / 11 / 17

Poster P1766

Abstract 3308

Occurrence of β-lactone synthesis among OXA-48-like carbapenemase-producing bacteria collected in the Czech Republic and the implication for MALDI-TOF MS-based carbapenemase detection

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Vendula HERINGOVÁ

A / 11 / 18

Poster P1767

Abstract 3353

Evaluation of a modified carbapenem inactivation method for detection of carbapenemases in Enterobacterales: results of a multi-centre surveillance study in Turkey

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Elif Seren TANRIVERDI

B / 11 / 1

Poster P1768

Abstract 3580

Iridium oxide-based biosensors towards the quantification of ESBL production

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Jennifer LAWRENCE

B / 11 / 2

Poster P1769

Abstract 3865

Chip-based molecular detection of beta-lactam resistance in pathogen-positive blood cultures

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Vittorio IVAGNES

B / 11 / 3

Poster P1770

Abstract 3960

Including structural information complements antibiotic susceptibility prediction methods in M. tuberculosis and E. coli

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Viktoria BRUNNER

B / 11 / 4

Poster P1771

Abstract 4005

From phenotype to genotype: mapping the epidemiology of carbapenemase-producing Enterobacteriaceae using whole genome sequencing

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Pedro SUAREZ URQUIZA

B / 11 / 5

Poster P1772

Abstract 4115

Polymerase chain reaction blood sample genotype results accurately predict blood culture resistance phenotypes and aid in optimal antimicrobial selection

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Jill ARGOTSINGER

B / 11 / 6

Poster P1773

Abstract 4267

Refined algorithm for detection of OXA-48-like carbapenemase producing Enterobacterales

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Peter Michael KELLER

B / 11 / 7

Poster P1774

Abstract 4558

Indeterminate CPE testing – what are the chances?

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Julie-Anne HOULIHAN

B / 11 / 8

Poster P1775

Abstract 4654

Carbapenemase detection by flow cytometry: a rapid and promising technology

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Blanca PÉREZ VISO

B / 11 / 9

Poster P1776

Abstract 4733

Resistome description of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa isolated from Ukrainian military patients

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Miriam LATORRE-MILLÁN

B / 11 / 10

Poster P1777

Abstract 4983

The rapid detection of carbapenem resistance by using fluorescence flow cytometry analyser

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Seyma Aybüke ÖZYAR KURTÇU

B / 11 / 11

Poster P1778

Abstract 5012

Evaluation of the DNA microarray, sepsis flow chip assay for the rapid detection of microorganisms and resistance genes directly from positive blood cultures

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Prakaithip THONGKOOM

B / 11 / 12

Poster P1779

Abstract 5040

Genomic analysis of Klebsiella pneumoniae clinical isolates from greek hospitals resistant to β-lactams/β-lactamase inhibitor combinations

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Olga KOUTSOPETRA

B / 11 / 13

Poster P1780

Abstract 5105

Reducing rectal carriage of carbapenemase-producing bacteria in general wards: the impact of implementing a modified Blue-Carba test to guide infection control

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Fernando PASTERAN

B / 11 / 14

Poster P1781

Abstract 5506

Evaluation of a molecular test for H. pylori & Clarithromycin resistance from stool reveals a highly efficient non-invasive diagnostic tool

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Yael MALI

B / 11 / 15

Poster P1782

Abstract 5546

Early life factors influencing the gut resistome and mobilome: meta-analysis

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Ahmed BARGHEET

B / 11 / 16

Poster P1783

Abstract 5584

Investigation of the presence of tolerance in Esherichia coli isolates isolated from urine cultures

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Ecem BUYUKYANBOLU

B / 11 / 17

Poster P1784

Abstract 5598

Comparison of modified hodge test and carbapenem inactivation method in carbapenemase producing Klebsiella pneumoniae isolates

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Fatih Mehmet AKILLI

B / 11 / 18

Poster P1785

Abstract 5641

Effect of rapid carbapenemases detection-guided antibiotic therapy on clinical response in patients with intra-abdominal infections (RAPID): protocol for a randomised controlled trial

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Jiajie WANG

A / 12 / 1

Poster P1786

Abstract 5710

Mycoplasma genitalium, drug resistance, nucleic acid detection; introducing a new external quality assessment scheme

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Kati LUIRO

A / 12 / 2

Poster P1787

Abstract 5724

Analytic and clinical validation of a lab-developed multiplex-PCR assay for fully-automated high-throughput detection of seven carbapenemase genes for isolate characterization and primary patient screening.

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Dominik Sebastian NOERZ

A / 12 / 3

Poster P1788

Abstract 5772

Evaluation of the novel French disc diffusion-based algorithm for the phenotypic screening of carbapenemase-producing Enterobacterales

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Laurent DORTET

A / 12 / 4

Poster P1789

Abstract 5778

Deciphering the molecular basis of colistin-resistant Escherichia marmotae

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Ulrike BINSKER

A / 12 / 5

Poster P1790

Abstract 6324

Resistome and plasmid content of ceftazidime/avibactam Resistant Klebsiella pneumoniae strains isolated in a transplant and highly specialised therapies centre

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Alessia MIRABILE

A / 12 / 6

Poster P1791

Abstract 6477

Comprehensive whole exome sequencing correlates with antimicrobial resistance genes acquired by two Indian clinical isolates of Klebsiella pneumoniae: first report

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Deepali DESAI

A / 12 / 7

Poster P1792

Abstract 6717

Rapid Combo ESBL/Carba NP test for rapid detection of expanded-spectrum ß-lactamase and carbapenemase producers in Enterobacterales

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Clement VIGUIER

A / 12 / 8

Poster P1793

Abstract 6765

Indirect detection of blaKPC in Klebsiella pneumoniae and Escherichia coli by MALDI-TOF mass spectrometry: a single centre experience

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Marines DALLA VALLE MARTINO

A / 12 / 9

Poster P1794

Abstract 7007

Performance of an automated method for screening carbapenem-resistant Enterobacterales (CRE) compared to a reference method

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Marines DALLA VALLE MARTINO

A / 12 / 10

Poster P1795

Abstract 7070

KPC enzymes with new mutations: the new challenge of clinical microbiology laboratory

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Annarita MAZZARIOL

A / 12 / 11

Poster P1796

Abstract 7266

Evaluation of the comercial test for the rapid detection of third-generation cephalosporins resistance in Enterobacterales on early culture of positive blood cultures

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Mehdi BONNET

A / 12 / 12

Poster P1797

Abstract 7347

Decipherin the evolution of the infant intestinal resistome

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

A / 12 / 13

Poster P1798

Abstract 7420

Deciphering the genome of a Acinetobacter seifertii (Asf) strain showing co-resistance to carbapenems and polymyxin B in Brazil

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Alessandro RODRIGUES

A / 12 / 14

Poster P1799

Abstract 7716

Performance of MBT Lipid Kit for rapid screening of colistin resistance in Klebsiella pneumoniae

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Sam LOCKWOOD

A / 12 / 15

Poster P1800

Abstract 7785

Rapid temocillin resistance detection by a colorimetric test

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

José Luis RODRÍGUEZ OCHOA

A / 12 / 16

Poster P1801

Abstract 7834

Economic impact of rapid molecular diagnostic testing in management of carbapenem-resistant Enterobacteriaceae in high risk patients in the UK

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Isaac ODEYEMI

A / 12 / 17

Poster P1802

Abstract 8260

Evaluation of whole genome sequencing to predict quinolones susceptibilityphenotypes in non-typhoidal Salmonella enterica.????

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Manuel A. RODRÍGUEZ-IGLESIAS

A / 12 / 18

Poster P1803

Abstract 8267

Landscape of open-access antimicrobial resistance gene catalogues

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Chad CENTNER

A / 12 / 19

Poster P1804

Abstract 8397

Genomic diversity and resistome of Acinetobacter baumannii from a hospital in Paraguay

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Elena BELLO-LOPEZ

A / 12 / 20

Poster P1805

Abstract 8800

New protocol for rapid detection and differentiation of carbapenemases in rectal swabs by laser nephelometry, mass spectrometry and lateral flow assay

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Diego JOSA

A / 12 / 21

Poster P1806

Abstract 8819

Rapid characterisation of antimicrobial resistance genes by PCR and reverse hybridisation in rectal swab samples from colonised patients

29/04 12:00

3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

Diego JOSA

A / 12 / 22

Poster P1807

Abstract 197

Comparison of the clinical outcomes of patients with carbapenem-resistant and susceptible Pseudomonas aeruginosa in Japan

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Sho SAITO

A / 12 / 23

Poster P1808

Abstract 457

Comparison of clinical outcomes and molecular epidemiology between fluoroquinolone-susceptible and resistant carbapenem-resistant Enterobacterales: a multicentre study from multi-drug resistant organisms clinical research network (MDRnet)

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Kubo TAKETO

A / 12 / 24

Poster P1809

Abstract 642

Blaz betalactamase impacts treatment outcomes in infective endocarditis due to methicillin-sensitive Staphylococcus aureus

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Baptiste JEAN

A / 12 / 25

Poster P1810

Abstract 680

Carbapenem-based antibiotic regimen in the treatment of carbapenemase-producing Enterobacterales infections: a retrospective cohort study

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Baptiste HOELLINGER

A / 12 / 26

Poster P1811

Abstract 952

Risk factors and outcomes of linezolid- and vancomycin-resistant E. faecium infections: a case-control study

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Flavio SANGIORGI

A / 12 / 27

Poster P1812

Abstract 1488

Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas (POP) study

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Lee GOTTESDIENER

A / 12 / 28

Poster P1813

Abstract 2161

Mortality and morbidity attributable to infections caused by carbapenem-resistant Enterobacterales – initial results from a matched cohort study in Vietnam

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Hoa NGUYEN THI

B / 12 / 1

Poster P1814

Abstract 2183

Effect of antimicrobial stewardship actions on broad-spectrum antibiotic usage and resistance patterns of Gram-negative isolates at a district general hospital

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Eleanor SENIOR

B / 12 / 2

Poster P1815

Abstract 2275

The changing epidemiology and long-term outcomes of patients with CRE infections

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Ryan SHIELDS

B / 12 / 3

Poster P1816

Abstract 2715

In vitro activity of sulbactam/durlobactam in combination with cefepime against Gram-negative bacterial isolates from a recent Phase 3 clinical trial

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Sarah MCLEOD

B / 12 / 4

Poster P1817

Abstract 2876

Cefiderocol for the treatment of infections by VIM-type-producing Gram-negative bacteria

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Cristina KIRKEGAARD BIOSCA

B / 12 / 5

Poster P1818

Abstract 2886

The emergence of difficult to treat Klebsiella pneumoniae in COVID-19 patients in a Vietnamese tertiary hospital

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Thi Quynh Ngan LE

B / 12 / 6

Poster P1819

Abstract 3047

Reappraisal of mortality risk associated with cefiderocol based therapy for treatment of carbapenem resistant Acinetobacter baumannii infections: a real-world comparative effectiveness study from 201 US hospitals

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Morgan WALKER

B / 12 / 7

Poster P1820

Abstract 3078

Use of novel ß-lactam-ß-lactamase-inhibitors in adult cystic fibrosis medicine: a 5-year monocentric retrospective analysis

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Johannes Till OTHMER

B / 12 / 8

Poster P1821

Abstract 3218

A real-world study on efficacy, safety, and cost-effectiveness of ceftazidime-avibactam and polymyxin B for the treatment of CRE infections

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Chen DAYU

B / 12 / 9

Poster P1822

Abstract 3333

Multidrug-resistant organism bloodstream infections in solid organ transplant recipients and impact on mortality: a systematic review

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Alice LIU

B / 12 / 10

Poster P1823

Abstract 3613

A recursive partitioning approach to identify prognostic factors associated with mortality at time of infection in patients with carbapenem-resistant Enterobacterales infection

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Yiying CAI

B / 12 / 11

Poster P1824

Abstract 3906

β-lactam resistance mechanisms in baseline Enterobacterales from the REVIST and ASSEMBLE aztreonam-avibactam Phase 3 clinical trials

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Rodrigo E. MENDES

B / 12 / 12

Poster P1825

Abstract 3917

Resistance Optimised Antibiotic Dosing (The ROAD Study): is beta-lactam dosing optimised to prevent the emergence of antibiotic resistance safe and feasible in the ICU?

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Jason ROBERTS

B / 12 / 13

Poster P1826

Abstract 3947

Impact of colistin MIC on outcomes: results from the OVERCOME trial comparing colistin monotherapy and colistin + meropenem combination therapy

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Jason POGUE

B / 12 / 14

Poster P1827

Abstract 4188

Ceftazidime/avibactam alone or in combination to treat infections caused by Pseudomonas aeruginosa: preliminary reports from a retrospective observational multi-centre cohort study

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Pietro VALSECCHI

B / 12 / 15

Poster P1828

Abstract 4499

The production of OXA-2/10 ß-lactamases is a risk factor for resistance development to ceftolozane/tazobactam and ceftazidime/avibactam during the treatment of Pseudomonas aeruginosa infections

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Inmaculada LÓPEZ MONTESINOS

B / 12 / 16

Poster P1829

Abstract 4625

Black females hospitalised in the United States have worse outcomes after carbapenem-resistant Enterobacterales (CRE) bloodstream infection (BSI)

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Felicia RUFFIN

B / 12 / 17

Poster P1830

Abstract 4680

Resistance to third generation cephalosporins is associated with increased all-cause mortality at 1 year among patients with Enterobacterales clinical isolates

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Heather HENDERSON

B / 12 / 18

Poster P1831

Abstract 5063

Comparison of piperacillin-tazobactam and carbapenem strategies in ESBL-producing Enterobacteriaceae urinary tract infections

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Leonor NEVES

B / 12 / 19

Poster P1832

Abstract 5156

Outcomes of adult patients with multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) treated with monotherapy versus combination therapy in a tertiary hospital

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Leisa Jeanne Kaye YEE

B / 12 / 20

Poster P1833

Abstract 5174

Characteristics and outcomes of resistant Gram-negative infections treated with cefiderocol in a multi-centre institution

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Olivia FUNK

B / 12 / 21

Poster P1834

Abstract 5229

Outcomes of intermittent versus extended infusion of common beta-lactams in Pseudomonas aeruginosa infections where minimum inhibitory concentration is at the susceptibility breakpoint

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Megan KLATT

B / 12 / 22

Poster P1835

Abstract 5373

Analysis of clearance and infection rates according to the genotype in patients with carbapenemase-producing Enterobacterales co-colonization

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Lee JIYOUNG

B / 12 / 23

Poster P1836

Abstract 5846

Excess mortality due to antimicrobial resistance in bacteraemias among cancer patients in Oxford and Oslo, 2008-2018

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Anders SKYRUD DANIELSEN

B / 12 / 24

Poster P1837

Abstract 6294

Use of cefiderocol to treat carbapenem resistant Acinetobacter baumanii NDM-producing strains

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Giovanna TRAVI

B / 12 / 25

Poster P1838

Abstract 6445

Risk factors for carbapenem-resistant Acinetobacter baumannii (CRAB) ventilator-associated pneumonia (VAP) in critically ill patients with respiratory CRAB colonisation

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Sara COVINO

B / 12 / 26

Poster P1839

Abstract 6518

MIC increase in Clostridioides difficile isolates from patients with recurrence: results from a retrospective single-centre cohort study

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Pietro VALSECCHI

B / 12 / 27

Poster P1840

Abstract 6776

HAI mortality in acute hospitals in Spain 2022-2023

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Lina Marcela PARRA

B / 12 / 28

Poster P1841

Abstract 7207

Risk factors and clinical outcomes associated with the acquisition of New Delhi metallo-beta-lactamase (NDM) in Enterobacterales: a single-center study

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Raissa ARONICA

A / 13 / 1

Poster P1842

Abstract 7359

A single hospital-based study on the profile and outcomes of patients treated with Polymyxin B: the difficulties for controlled clinical trials

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Carlos KIFFER

A / 13 / 2

Poster P1843

Abstract 7382

Prevalence of antimicrobial resistance in patients with cancer in the outpatient setting: a multicentre analysis

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Diane FLAYHART

A / 13 / 3

Poster P1844

Abstract 7738

Use of ceftaroline for treatment of bacteremia in Colombian paediatric patients: a descriptive study of 34 patients

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Natalia GONZÁLEZ-LEAL

A / 13 / 4

Poster P1845

Abstract 7774

Real world data for novel β-lactam/β-lactamase inhibitors: a prospective single-institution study

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Pantazis-Michael VOUTSINAS

A / 13 / 5

Poster P1846

Abstract 7875

Management of febrile neutropenia in hematologic patients colonized by OXA-48-producing Enterobacter cloacae: experience from a tertiary-level hospital

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Miguel RODRÍGUEZ FERNÁNDEZ

A / 13 / 6

Poster P1847

Abstract 8402

Is cefepime safe to treat infections caused by Escherichia coli or Klebsiella pneumoniae that display an ESBL phenotype? Results from a systematic review and meta-analysis of clinical studies

29/04 12:00

3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs)

Giulia MENCHINELLI

A / 13 / 7

Poster P1848

Abstract 467

Characterising the loss and acquisition of Tn2-like transposon in Klebsiella pneumoniae: implications for carbapemase gene dissemination

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Xiao YU

A / 13 / 8

Poster P1849

Abstract 944

Antimicrobial resistance prevalence varies by age and sex in bloodstream infection in European hospitals

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Gwen KNIGHT

A / 13 / 9

Poster P1850

Abstract 1549

First report of colistin-resistant Escherichia coli carrying mcr-1 IncI2(delta) and IncX4 plasmids from camels (Camelus dromedarius) in the Gulf region

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Akela Ahmed GHAZAWI

A / 13 / 10

Poster P1851

Abstract 1787

Antibiotic resistance profiles of Escherichia coli from wastewater treatment plants in the full water cycle in Barcelona, Spain

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Laura MONDÉJAR TRAVERIA

A / 13 / 11

Poster P1852

Abstract 2128

Exploring the dynamics of Staphylococcus spp. in wild bat populations: insights into antibiotic resistance and microbial adaptation

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Vanessa SILVA

A / 13 / 12

Poster P1853

Abstract 2204

Profile of bacterial infections in COVID-19 time in a health area

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Maria Jesús GUTIÉRREZ FERNÁNDEZ

A / 13 / 13

Poster P1854

Abstract 2307

Comparison of antibiotic resistance in Aeromonas spp. between clinical isolates and food animals in Hong Kong

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Christopher Koon Chi LAI

A / 13 / 14

Poster P1855

Abstract 2377

Spread of plasmidic blaOXA-58, blaNDM-1 and blaIMP-14 among three different Acinetobacter spp.

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Pierre BOGAERTS

A / 13 / 15

Poster P1856

Abstract 2392

The potential for antimicrobial resistance in highly transferable strains of Haemophilus influenzae

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Takeaki WAJIMA

A / 13 / 16

Poster P1857

Abstract 2468

Pseudomonas aeruginosa carriage and associated risk factors in patients and healthy individuals

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Anneloes VAN VEEN

A / 13 / 17

Poster P1858

Abstract 2631

How to measure bacterial genome plasticity? New insights and implications for pathogens

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Stefano GAIARSA

A / 13 / 18

Poster P1859

Abstract 2653

Global colistin-resistance mcr-1 plasmid epidemiology: mystooking the part for the whole, or how Asia does not mean the whole world

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Biel GARCIAS

A / 13 / 19

Poster P1860

Abstract 2666

Characterisation of bacterial isolates throughout the entire water cycle in Barcelona, Spain.

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Victoria Del Pilar BALLÉN TORRES

A / 13 / 20

Poster P1861

Abstract 2772

Increased abundance of ESBL producing Enterobacterales in municipal wastewater receiving hospital effluent during and after the COVID-19 pandemic

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Lisandra AGUILAR BULTET

A / 13 / 21

Poster P1862

Abstract 2958

AVIAR, arthropods as vectors of infection and antimicrobial resistance: a global study update

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Edward A R PORTAL

A / 13 / 22

Poster P1863

Abstract 3029

Identifying risk factors for carbapenem-resistant Acinetobacter baumannii carriage upon admission: a case-case control study

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Debby BEN-DAVID

A / 13 / 23

Poster P1864

Abstract 3039

The overlooked pandemic in the shadow of COVID-19: antimicrobial use and resistance data, a Romanian single-centre study

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Agnes CSISZER

A / 13 / 24

Poster P1865

Abstract 3254

Black-headed gulls as a reservoir for multidrug-resistant high-risk clonal Enterobacterales

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Jana BRENDECKE

A / 13 / 25

Poster P1866

Abstract 3469

Extended co-colonisation of IncX3-type plasmid harbouring blaNDM-5 among non-clonal Escherichia coli in a dog

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Juliana MENEZES

A / 13 / 26

Poster P1867

Abstract 3482

Nasopharyngeal bacterial carriage and antibiotic resistance in children with sickle cell disease: DREPANOBACT a French multicentric prospective study

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Luu-Ly PHAM

A / 13 / 27

Poster P1868

Abstract 3542

Paws and pathogens: co-carriage of ESBL-producing Enterobacterales strains between companion animals and owners

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Juliana MENEZES

A / 13 / 28

Poster P1869

Abstract 3626

Spreading colistin resistant Klebsiella pneumoniaein Rabta Tunisian hospital

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Meriam ZRIBI

B / 13 / 1

Poster P1870

Abstract 3871

Potential for widespread dissemination of blaOXA-370 in a new genetic context within IncN2 Plasmids of Klebsiella pneumoniae ST6326 – KL151

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Ághata RIBEIRO

B / 13 / 2

Poster P1871

Abstract 3890

Penicillin allergy is associated with increased resistance in Streptococcus pneumoniae

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Shadia AHMED

B / 13 / 4

Poster P1873

Abstract 4301

Impact of sub-inhibitory concentrations of chlorhexidine on in vitro horizontal transfer of vancomycin and linezolid resistance genes in Enterococcus faecium

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Carla NOVAIS

B / 13 / 5

Poster P1874

Abstract 4513

Local circulation of ESBL genes: what is behind the scenes?

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Bálint TIMMER

B / 13 / 6

Poster P1875

Abstract 4531

Analysis of plasmid-mediated ESBL production and colistin resistance in Escherichia coli from pig nostrils: a new reservoir of concern?

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Sandra A MARTÍNEZ ÁLVAREZ

B / 13 / 7

Poster P1876

Abstract 4939

Inter-species transmission of a blaVIM-2 carrying plasmid during an hospital outbreak of VIM-producing Pseudomonas spp.

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Laurence ARMAND-LEFEVRE

B / 13 / 8

Poster P1877

Abstract 5100

Recurring import of an endemic pstS-null ST-1421 vancomycin-resistant Enterococcus faecium from Australia to the United States

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Brendan JONES

B / 13 / 9

Poster P1878

Abstract 5106

Genomics analysis of methicillin-resistant Staphylococcus aureus: detection of the clonal lineage ST398 in wild birds from Brazil

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Jussara Kasuko PALMEIRO

B / 13 / 10

Poster P1879

Abstract 5126

Monitoring clinically important antimicrobial-resistant bacteria in wastewater and clinical samples from children's hospital

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Hiroaki BABA

B / 13 / 11

Poster P1880

Abstract 5130

Antibiotics and the gut microbiome: potential roles in persistent gut colonization with ESBL-producing Enterobacterales among Peruvian children

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Maya NADIMPALLI

B / 13 / 12

Poster P1881

Abstract 5158

Presence of pharmaceutical contaminants and antibiotic-resistant bacteria across diverse environmental matrices within a Brazilian lagoon ecosystem

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Jussara Kasuko PALMEIRO

B / 13 / 13

Poster P1882

Abstract 5587

Microcosmic matters: assessing micropollutants and evaluating removal efficiency in urban wastewater treatment plants

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Poonam SHARMA

B / 13 / 14

Poster P1883

Abstract 5637

Sinks as a reservoir of ceftazidime-avibactam resistant ST307 K. pneumoniae high-risk clone harbouring novel blaKPC variants in a hospital in Spain

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Marta HERNÁNDEZ-GARCÍA

B / 13 / 15

Poster P1884

Abstract 5779

Variability of multidrug-resistant Enterobacterales prevalence carriage and interfacilities connections across a large nursing homes network

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Cécile FERRIOT

B / 13 / 16

Poster P1885

Abstract 5909

e-DNA approach to assess the antimicrobial resistance genes in the coastal sediments of India

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Pradip GAWANDE

B / 13 / 17

Poster P1886

Abstract 5970

Bacterial diversity in choanal swabs from free-living pelicans in Greece. High frequency of methicillin-susceptible S. aureus

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Teresa CARDONA-CABRERA

B / 13 / 18

Poster P1887

Abstract 6116

Plasmid sharing between cephalosporin-resistant commensal bacteria and enteropathogens in Vietnamese community

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Phuong PHAM

B / 13 / 19

Poster P1888

Abstract 6259

Antibiotic resistance in Italian urban wastewater: exploring of antibiotic-resistant bacteria (ARBs), antibiotic resistance genes (ARGs), and microbial communities

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Giusy BONANNO FERRARO

B / 13 / 20

Poster P1889

Abstract 6391

Diversity and dynamics of Pseudomonas spp. in ICU sinks with long-term persistent clones carrying blaGES and blaVIM far beyond outbreaks

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Bárbara CATALÁ-SÁNCHEZ

B / 13 / 21

Poster P1890

Abstract 6606

NDM-producing clone of Klebsiella pneumoniae ST6668 (CC147) keeps spreading in the Pavia area, Italy

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Irene MILETO

B / 13 / 22

Poster P1891

Abstract 6691

High household co-carriage of extended-spectrum beta-lactamases in Hong Kong

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Kin On KWOK

B / 13 / 23

Poster P1892

Abstract 7047

That sinking feeling: destructive u-bend sampling reveals common OXA-48 plasmids among Enterobacterales in an environmental reservoir

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Aoife KEARNEY

B / 13 / 24

Poster P1893

Abstract 7253

Effect of various strategies of antibiotic de-escalation and continuous ciprofloxacin on the intestinal microbiota and its colonization by multidrug resistant E. coli in a murine experimental model

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Quentin LE BASTARD

B / 13 / 25

Poster P1894

Abstract 7284

Unexpected cefiderocol resistance in Stenotrophomonas maltophilia associated to the genogroup 4 genetic background

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Céline SAKR

B / 13 / 26

Poster P1895

Abstract 7436

Inter- and intraspecies spread of mcr-1 between twenty-nine distinct Enterobacteriaceae isolates from one patient

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Beiwen ZHENG

B / 13 / 27

Poster P1896

Abstract 7452

The veterinary hospital as a cross-infection hub of multidrug resistant bacteria

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Tal ZILBERMAN DANIELS

B / 13 / 28

Poster P1897

Abstract 7568

Large DNA fragment transposition during natural transformation allows interspecies dissemination of antimicrobial resistance genes

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Tiago LIMA

A / 14 / 1

Poster P1898

Abstract 7575

Urban and rural free-ranging hedgehogs as sentinels of environmental extended-spectrum beta-lactamase producing enterobacterales

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Tal ZILBERMAN DANIELS

A / 14 / 2

Poster P1899

Abstract 7692

Long persistence of Citrobacter freundii carrying blaVIM-1 encoding plasmids in water systems in an intensive care unit

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Natalia GUERRA PINTO

A / 14 / 3

Poster P1900

Abstract 7701

Klebsiella pneumoniae ST307 and its multidrug-resistant plasmids in the environmental water reservoir of an intensive care unit.

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Natalia GUERRA PINTO

A / 14 / 4

Poster P1901

Abstract 8221

Host distribution, dissemination and mobile genetic context of the NpmA gene in Clostridioides difficile populations

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Carlos SERNA

A / 14 / 5

Poster P1902

Abstract 8516

Resistance to critically important antibiotics in meat sold for consumption

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Jordan SEALEY

A / 14 / 6

Poster P1903

Abstract 2220

Plasmid location of carbapenemase encoding genes in Enterobacterales co-harbouring two carbapenemases

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Marta HERNÁNDEZ-GARCÍA

A / 14 / 7

Poster P1904

Abstract 8674

Antimicrobial resistance of Mammaliicoccus species and staphylococci other than Staphylococcus aureus isolated from retail beef in KwaZulu Natal, South Africa

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Thembeka THWALA

A / 14 / 8

Poster P1905

Abstract 8840

A few days of parenteral colistin therapy markedly selects colistin-resistant Enterobacteriaceae in the gut flora of critically ill Indian patients

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Jayeeta BHOWMICK

A / 14 / 9

Poster P1906

Abstract 8850

Vancomycin-resistant Enterococcus faecium in black-headed Gulls (Chroicocephalus ridibundus): nosocomial clonal complex 17 detected in wild birds

29/04 12:00

3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission)

Balázs KOLESZÁR

A / 14 / 10

Poster P1907

Abstract 1412

Expert consensus on antimicrobial resistance research priorities to guide antibacterial vaccines and monoclonal antibodies development and implementation

29/04 12:00

3h. Policy aspects of AMR (incl societal impact, economics, mitigation)

Nasreen HASSOUN-KHEIR

A / 14 / 11

Poster P1908

Abstract 1845

Evidence-based policy for mitigating AMR in Lao PDR: an intervention-implementation research approach

29/04 12:00

3h. Policy aspects of AMR (incl societal impact, economics, mitigation)

Somphou SAYASONE

A / 14 / 12

Poster P1909

Abstract 2479

Global costing of key AWaRe antibiotics

29/04 12:00

3h. Policy aspects of AMR (incl societal impact, economics, mitigation)

Filip DJUKIC

A / 14 / 13

Poster P1910

Abstract 2760

Meri-no or meri-yes: that is the question! Healthcare professional preferences in managing piperacillin/tazobactam-susceptible ESBL-producing Gram-negative bacilli bacteremia at an university hospital in Spain

29/04 12:00

3h. Policy aspects of AMR (incl societal impact, economics, mitigation)

Patricio FAVIER

A / 14 / 14

Poster P1911

Abstract 2885

Local antimicrobial resistance surveillance in nursing homes using lot quality assurance sampling

29/04 12:00

3h. Policy aspects of AMR (incl societal impact, economics, mitigation)

Sacha KUIL

A / 14 / 15

Poster P1912

Abstract 3690

Globally antimicrobial stewardship programs are lagging behind: an example of the need for a people-centred comprehensive approach to address antimicrobial resistance

29/04 12:00

3h. Policy aspects of AMR (incl societal impact, economics, mitigation)

Zlatina DOBREVA

A / 14 / 16

Poster P1913

Abstract 5072

Current global total and AWaRe global antibiotic use are inversely related to infectious disease burden and not equitable.

29/04 12:00

3h. Policy aspects of AMR (incl societal impact, economics, mitigation)

Aislinn COOK

A / 14 / 17

Poster P1914

Abstract 5889

Estimation of the annual burden of infections caused by multidrug-resistant bacteria in hospitalised patients in Spain: the SEIMC_BMR-2023 study

29/04 12:00

3h. Policy aspects of AMR (incl societal impact, economics, mitigation)

José Miguel CISNEROS

A / 14 / 18

Poster P1915

Abstract 5940

Economic costs associated to antimicrobial resistance among newborns with bloodstream infection in a maternity hospital in Peru

29/04 12:00

3h. Policy aspects of AMR (incl societal impact, economics, mitigation)

Maria J. PONS

A / 14 / 19

Poster P1916

Abstract 6187

Antibiotic resistance watch: Gaza's post-war preparedness

29/04 12:00

3h. Policy aspects of AMR (incl societal impact, economics, mitigation)

Anna FARRA

A / 14 / 20

Poster P1917

Abstract 6329

Minimum inhibitory concentration distributions of worldwide clinical bacterial isolates vary by patient age and other key variables

29/04 12:00

3h. Policy aspects of AMR (incl societal impact, economics, mitigation)

Jacob WILDFIRE

A / 14 / 21

Poster P1918

Abstract 7002

Evidence on the intersection of the social determinants of health and antibiotic resistant (ABR) infections: a systematic review

29/04 12:00

3h. Policy aspects of AMR (incl societal impact, economics, mitigation)

Alison SHUTT

A / 14 / 22

Poster P1919

Abstract 7249

Globally there has been a fragmented approach to AMR national action plan implementation – results of trend analysis of the one health and human health indicators in the tracking AMR country self-assessment survey (TrACSS)

29/04 12:00

3h. Policy aspects of AMR (incl societal impact, economics, mitigation)

Ponnu PADIYARA

A / 14 / 23

Poster P1920

Abstract 7878

Cost impact of implementing carbapenemase-producing Enterobacterales (CPE) screening guidelines in France

29/04 12:00

3h. Policy aspects of AMR (incl societal impact, economics, mitigation)

Isaac ODEYEMI

A / 14 / 24

Poster P1921

Abstract 8727

High levels of antibiotic resistance: latest insights from WHO's GLASS surveillance system

29/04 12:00

3h. Policy aspects of AMR (incl societal impact, economics, mitigation)

Olga TOSAS AUGUET

A / 14 / 25

Poster P1922

Abstract 8867

Practices and drivers for antibiotic use in cattle production systems in Kenya

29/04 12:00

3h. Policy aspects of AMR (incl societal impact, economics, mitigation)

Lydiah KISOO

A / 14 / 26

Poster P1923

Abstract 8870

Differences in patient access to antimicrobial medicines in Europe

29/04 12:00

3h. Policy aspects of AMR (incl societal impact, economics, mitigation)

Elina BACHEVA

A / 15 / 1

Poster P2741

Abstract 184

Manifestations and risk of cryptococcosis in liver transplant candidiates

29/04 12:00

6a. Fungal disease epidemiology

Wan-Ting TSAI

A / 15 / 2

Poster P2742

Abstract 540

The Cologne ECMM Excellence Center: a comprehensive evaluation of its external consultation service for invasive fungal infections over two years

29/04 12:00

6a. Fungal disease epidemiology

Jon SALMANTON-GARCIA

A / 15 / 3

Poster P2743

Abstract 546

Assessing diagnostic capabilities and treatment accessibility for invasive fungal infections in the Balkan Region

29/04 12:00

6a. Fungal disease epidemiology

Jon SALMANTON-GARCIA

A / 15 / 4

Poster P2744

Abstract 548

Exploring invasive fungal infection diagnosis and treatment: a cross-continental comparison between Brazil and Europe

29/04 12:00

6a. Fungal disease epidemiology

Jon SALMANTON-GARCIA

A / 15 / 5

Poster P2745

Abstract 566

A review of coccidioidomycosis occurrence in Europe

29/04 12:00

6a. Fungal disease epidemiology

Priya SHASTRI

A / 15 / 6

Poster P2746

Abstract 817

Otomycosis: the foremost etiological agent causing otitis externa and the antifungal susceptibility pattern in Iran

29/04 12:00

6a. Fungal disease epidemiology

Mahmoud KHANSARI

A / 15 / 7

Poster P2747

Abstract 877

The tale of two seas: the Black and the Mediterranean regarding clinically relevant fungi

29/04 12:00

6a. Fungal disease epidemiology

Mihai MARES

A / 15 / 8

Poster P2748

Abstract 1071

Whole genome sequencing of Candida glabrata isolates in Korea: unveiling nosocomial transmission and antifungal resistance mechanisms

29/04 12:00

6a. Fungal disease epidemiology

Jong Hee SHIN

A / 15 / 9

Poster P2749

Abstract 1126

Clinical outcomes of Candida auris fungemia at an academic medical centre

29/04 12:00

6a. Fungal disease epidemiology

Yifan WANG

A / 15 / 10

Poster P2750

Abstract 1377

Attributable mortality of candidaemia: results from the ECMM Candida III multinational European observational cohort study

29/04 12:00

6a. Fungal disease epidemiology

Jon SALMANTON-GARCIA

A / 15 / 11

Poster P2751

Abstract 1473

Higher Blastomyces dermatitidis initial antigen levels associated with disseminated disease, use of amphotericin B, and mortality

29/04 12:00

6a. Fungal disease epidemiology

Caroline EWING

A / 15 / 12

Poster P2752

Abstract 1511

High rates of azole resistant Aspergillus fumigatus in Asia: results from a systematic review

29/04 12:00

6a. Fungal disease epidemiology

Souradeep CHOWDHURY

A / 15 / 13

Poster P2753

Abstract 1557

Clinical characteristics of hospitalised adults with invasive pulmonary aspergillosis: a single-institution retrospective study (2013-2022)

29/04 12:00

6a. Fungal disease epidemiology

Sara ARAÚJO

A / 15 / 14

Poster P2754

Abstract 1580

Invasive fungal infections in solid organ transplant recipients

29/04 12:00

6a. Fungal disease epidemiology

Caglayan Merve AYAZ

A / 15 / 15

Poster P2755

Abstract 1594

Risk of Candida auris infection following positive surveillance screening

29/04 12:00

6a. Fungal disease epidemiology

Emily DRWIEGA

A / 15 / 16

Poster P2756

Abstract 1672

Mandatory notification of human cases of cat-transmitted sporotrichosis (CTS) caused by Sporothrix brasiliensis in Southern Brazil indicates expressive raising of zoonosis in the State

29/04 12:00

6a. Fungal disease epidemiology

Francelise BRIDI CAVASSIN

A / 15 / 17

Poster P2757

Abstract 1676

Epidemiology, clinical manifestations, and outcome of mucormycosis in solid organ transplant recipients: a systematic review of reported cases

29/04 12:00

6a. Fungal disease epidemiology

Emanuele PALOMBA

A / 15 / 18

Poster P2758

Abstract 2012

Epidemiology and clinical outcomes of histoplasmosis among kidney transplant recipients

29/04 12:00

6a. Fungal disease epidemiology

Caroline AGNELLI

A / 15 / 19

Poster P2759

Abstract 2019

Culture-positive sporotrichosis: the ten-year Mayo Clinic experience

29/04 12:00

6a. Fungal disease epidemiology

Rita IGWILO-ALANEME

A / 15 / 20

Poster P2760

Abstract 2022

Mycological trends (1999-2019) in patients treated for postoperative peritonitis

29/04 12:00

6a. Fungal disease epidemiology

Philippe MONTRAVERS

A / 15 / 21

Poster P2761

Abstract 2237

Impact of lactate dehydrogenase, bacterial and cytomegalovirus co-infections on mortality in non-HIV-infected patients with Pneumocystis jirovecii pneumonia

29/04 12:00

6a. Fungal disease epidemiology

Berk MIZRAK

A / 15 / 22

Poster P2762

Abstract 2409

Point prevalence study of Candida auris in a tertiary hospital in Crete, Greece

29/04 12:00

6a. Fungal disease epidemiology

Petros IOANNOU

A / 15 / 23

Poster P2763

Abstract 2457

Incidence of invasive pulmonary aspergillosis according to basal thoracic computed tomography findings in patients with newly diagnosed acute myeloid leukaemia

29/04 12:00

6a. Fungal disease epidemiology

Buket ERTURK SENGEL

A / 15 / 24

Poster P2764

Abstract 2529

A retrospective study on profile of Pneumocystis jirovecii pneumonia among cancer patients of a tertiary care cancer centre in eastern India

29/04 12:00

6a. Fungal disease epidemiology

Soumyadip CHATTERJI

A / 15 / 25

Poster P2765

Abstract 2540

Emergence of fluconazole-resistant Candida parapsilosis in a population of burn patients

29/04 12:00

6a. Fungal disease epidemiology

Gianpiero TEBANO

A / 15 / 26

Poster P2766

Abstract 2873

Aspergillosis in patients with lymphoproliferative malignancies: new population at risk?

29/04 12:00

6a. Fungal disease epidemiology

Anna FALCÓ ROGET

A / 15 / 27

Poster P2767

Abstract 2884

The state of laboratory mycology in France in 2023: a survey from the European Confederation of Medical Mycology (ECMM), International Society for Human and Animal Mycology (ISHAM) and French Society of Medical Mycology (SFMM)

29/04 12:00

6a. Fungal disease epidemiology

Francoise BOTTEREL

A / 15 / 28

Poster P2768

Abstract 2964

Positivity of galactomannan and fungal culture in bronchoalveolar lavage early after lung transplantation as risk factors for invasive aspergillosis and chronic lung allograft dysfunction

29/04 12:00

6a. Fungal disease epidemiology

Roni BITTERMAN

B / 15 / 1

Poster P2769

Abstract 3018

Audit of paediatric candidaemia using the European Confederation of Medical Mycology (ECMM) Quality (EQUAL) of clinical candidaemia management score

29/04 12:00

6a. Fungal disease epidemiology

Collette MCCARRON

B / 15 / 2

Poster P2770

Abstract 3120

Mucormycosis in Colombia: the relevance of Cunninghamella spp. in the epidemological landscape

29/04 12:00

6a. Fungal disease epidemiology

Isabel RAMIREZ

B / 15 / 3

Poster P2771

Abstract 3125

Invasive fusariosis in patients with haematological malignancies: a single-centre experience in Colombia

29/04 12:00

6a. Fungal disease epidemiology

Isabel RAMIREZ

B / 15 / 4

Poster P2772

Abstract 3128

Epidemiologic investigation of a potential Candida auris hospital outbreak in Rio de Janeiro, Brazil

29/04 12:00

6a. Fungal disease epidemiology

Matheus OLIVEIRA BASTOS

B / 15 / 5

Poster P2773

Abstract 3277

Clinical characteristics of endemic mycoses in HIV and non-HIV individuals: a 23-year retrospective study in a university hospital in Thailand

29/04 12:00

6a. Fungal disease epidemiology

Yanapat TAECHASANSIRI

B / 15 / 6

Poster P2774

Abstract 3283

Skin colonisation by Candida auris and the associated risk of bloodstream infection

29/04 12:00

6a. Fungal disease epidemiology

Spyros POURNARAS

B / 15 / 7

Poster P2775

Abstract 3410

Anti-GM-CSF autoantibodies predict outcome of cryptococcal meningitis in patients not infected with HIV: a cohort study

29/04 12:00

6a. Fungal disease epidemiology

Ying-Kui JIANG

B / 15 / 8

Poster P2776

Abstract 3568

Invasive fungal infections (IFIs) and survival of acute myeloid leukemia (AML) patients at 12 months after AML diagnosis

29/04 12:00

6a. Fungal disease epidemiology

Alessandra MICOZZI

B / 15 / 9

Poster P2777

Abstract 3579

The virulence potential of Prototheca microalgae as assessed by histopathological and microbiological studies in a murine model

29/04 12:00

6a. Fungal disease epidemiology

Angelika PROSKURNICKA

B / 15 / 10

Poster P2778

Abstract 3632

Epidemiology of candidaemia in Czech Republic in 2023

29/04 12:00

6a. Fungal disease epidemiology

Pavlina LYSKOVA

B / 15 / 11

Poster P2779

Abstract 3831

Real-world epidemiology and risk factors of invasive fungal infections in haematologic patients in the era of new oncologic therapies and antifungal prophylaxis

29/04 12:00

6a. Fungal disease epidemiology

Patricia MONZO GALLO

B / 15 / 12

Poster P2780

Abstract 3856

Clavispora lusitaniae invasive infection in two immunocompromised patients

29/04 12:00

6a. Fungal disease epidemiology

Francesca PRATAVIERA

B / 15 / 13

Poster P2781

Abstract 3940

Clinical characteristics and outcomes of invasive mucormycosis following allogeneic haematopoietic stem cell transplantation

29/04 12:00

6a. Fungal disease epidemiology

Yuqian SUN

B / 15 / 14

Poster P2782

Abstract 3978

A laboratory experience on infection control after Candida auris isolation in neurology ICU

29/04 12:00

6a. Fungal disease epidemiology

Baran IRMAK

B / 15 / 15

Poster P2783

Abstract 4134

A retrospective study of candidaemia and Candida auris colonisation in a tertiary hospital

29/04 12:00

6a. Fungal disease epidemiology

Spyridon KAMARIOTIS

B / 15 / 16

Poster P2784

Abstract 4181

Epidemiology of candiduria in hospitalised patients: evolution and predictive value for candidaemia

29/04 12:00

6a. Fungal disease epidemiology

Pedro SUAREZ URQUIZA

B / 15 / 17

Poster P2785

Abstract 4233

Impact of breakthrough status on mortality in patients with haematological malignancies (HM) and invasive pulmonary aspergillosis (IPA): a propensity score-matched analysis

29/04 12:00

6a. Fungal disease epidemiology

Sung-Yeon CHO

B / 15 / 18

Poster P2786

Abstract 4263

Preliminary results of the epidemiology of invasive fungal infections in patients with haematological malignancies in the greater Paris area between 2017 and 2022

29/04 12:00

6a. Fungal disease epidemiology

Emmanuelle GRAS

B / 15 / 19

Poster P2787

Abstract 4294

CANDINEG Registry: is it worth performing a fundoscopy examination in all patients affected by candidaemia?

29/04 12:00

6a. Fungal disease epidemiology

Melody PÉREZ LÓPEZ

B / 15 / 20

Poster P2788

Abstract 4354

Fusariosis in patients with acute leukaemia: a 26-case series

29/04 12:00

6a. Fungal disease epidemiology

Raquel Keiko DE LUCA ITO

B / 15 / 21

Poster P2789

Abstract 4419

Baseline IgG Aspergillus and SGRQ at 3 months can predict the occurrence of chronic pulmonary aspergillosis at end-of-therapy in newly diagnosed pulmonary tuberculosis patients

29/04 12:00

6a. Fungal disease epidemiology

Animesh RAY

B / 15 / 22

Poster P2790

Abstract 4486

Association between allergic bronchopulmonary aspergillosis and tuberculosis: a systematic review of 397 cases in literature

29/04 12:00

6a. Fungal disease epidemiology

Anuj AJAYABABU

B / 15 / 23

Poster P2791

Abstract 4593

Contribution of Aspergillus fumigatus and A. flavus to invasive aspergillosis and azole resistance: results from a national surveillance programme in Israel

29/04 12:00

6a. Fungal disease epidemiology

Ronen BEN-AMI

B / 15 / 24

Poster P2792

Abstract 4615

Changes in species distribution, antifungal resistance, and outcomes of candidemia at two south korean tertiary hospitals: a 9-year retrospective study

29/04 12:00

6a. Fungal disease epidemiology

Ahrang LEE

B / 15 / 25

Poster P2793

Abstract 4667

Epidemiology of Candida auris asymptomatic colonisation in a Greek intensive care unit

29/04 12:00

6a. Fungal disease epidemiology

Spyros POURNARAS

B / 15 / 26

Poster P2794

Abstract 4679

How paediatric epidemiology and outcome of yeast fungemia differ from adults

29/04 12:00

6a. Fungal disease epidemiology

Fanny ALBY-LAURENT

B / 15 / 27

Poster P2795

Abstract 4689

Update on the antifungal susceptibility pattern of Trichophyton isolates in Greece: alarming rise in terbinafine-resistant T. indotineae

29/04 12:00

6a. Fungal disease epidemiology

Maria SIOPI

B / 15 / 28

Poster P2796

Abstract 4724

Association between allergic bronchopulmonary aspergillosis, aspergillus sensitisation and chronic obstructive pulmonary disease: a systematic review of 369 cases in literature

29/04 12:00

6a. Fungal disease epidemiology

Anuj AJAYABABU

A / 16 / 1

Poster P2797

Abstract 4791

Underdiagnosis of invasive fungal infections amongst inpatients in Ireland: a national retrospective study of discharge diagnoses

29/04 12:00

6a. Fungal disease epidemiology

Josephine HEBERT

A / 16 / 2

Poster P2798

Abstract 4828

Update on the Iranian Candida auris isolates, a retrospective analysis

29/04 12:00

6a. Fungal disease epidemiology

Hamid BADALI

A / 16 / 3

Poster P2799

Abstract 4926

Candida osteoarticular infections: a case series of cancer patients from an oncological tertiary centre since 2018

29/04 12:00

6a. Fungal disease epidemiology

Adriana MAGRI

A / 16 / 4

Poster P2800

Abstract 4941

Risk factors, complications and mortality associated to intravascular Candida infection: CANDINEG database results

29/04 12:00

6a. Fungal disease epidemiology

Cristobal RAMÍREZ

A / 16 / 5

Poster P2801

Abstract 4952

Invasive pulmonary aspergillosis in heart transplant recipients: contemporary incidence, characteristics and outcomes

29/04 12:00

6a. Fungal disease epidemiology

Marina MACHADO

A / 16 / 6

Poster P2802

Abstract 4962

Epidemiology of superficial mycoses in Tenerife Island

29/04 12:00

6a. Fungal disease epidemiology

Ana MARTÍN

A / 16 / 7

Poster P2803

Abstract 5075

Invasive aspergillosis in patients with liver disease: a comprehensive analysis of characteristics, risk factors, and outcomes

29/04 12:00

6a. Fungal disease epidemiology

Alessandro GIACINTA

A / 16 / 8

Poster P2804

Abstract 5151

Infection prevention, antimicrobial stewardship and genome sequencing interventions to control an outbreak of Candida auris in adult and paediatric intensive care units

29/04 12:00

6a. Fungal disease epidemiology

Rossana ROSA

A / 16 / 9

Poster P2805

Abstract 5191

Changing trends in the sources and volumes of clinical cultures with Candida auris at an integrated health system in Miami, Florida, 2019-2023

29/04 12:00

6a. Fungal disease epidemiology

Rossana ROSA

A / 16 / 10

Poster P2806

Abstract 5212

Development of a diagnostic score for disseminated histoplasmosis in a cohort of HIV patients

29/04 12:00

6a. Fungal disease epidemiology

Julián Andres HOYOS PULGARIN

A / 16 / 11

Poster P2807

Abstract 5443

Evaluation of pulmonary aspergillosis in COVID-19 patients admitted to intensive care unit

29/04 12:00

6a. Fungal disease epidemiology

Afsane VAEZI

A / 16 / 12

Poster P2808

Abstract 5456

Characteristics and outcomes of Pneumocystis pneumonia in different immunocompromised populations

29/04 12:00

6a. Fungal disease epidemiology

Javier Tomás SOLERA RALLO

A / 16 / 13

Poster P2809

Abstract 5521

Prospective evaluation of septic shock patients with culture-proven Candida spp in a tertiary care educational university hospital: a series of 103 cases

29/04 12:00

6a. Fungal disease epidemiology

Gamze SANLIDAG ISBILEN

A / 16 / 14

Poster P2810

Abstract 5568

Exploring the dynamics of the epidemic C. parapsilosis bloodstream infections in a tertiary university hospital in Greece

29/04 12:00

6a. Fungal disease epidemiology

Joseph MELETIADIS

A / 16 / 15

Poster P2811

Abstract 5622

Colonising Candida in the ICU: the impact of antifungal exposure on epidemiology and resistance

29/04 12:00

6a. Fungal disease epidemiology

Phoebe ALLEBONE-SALT

A / 16 / 16

Poster P2812

Abstract 5843

Risk factors and outcome associated with fungal infections in patients with severe burn injury: 10-year retrospective IFI-BURN study

29/04 12:00

6a. Fungal disease epidemiology

Sarah DELLIERE

A / 16 / 17

Poster P2813

Abstract 5928

Mycophenolic acid selects specific strains responsible for Pneumocystis pneumonia (PCP) in organ transplant recipients: probable implication in PCP outbreaks

29/04 12:00

6a. Fungal disease epidemiology

Gilles NEVEZ

A / 16 / 18

Poster P2814

Abstract 6008

Epidemiology and risk factors for mortality in a large cohort of patients diagnosed with proven/probable invasive aspergillosis

29/04 12:00

6a. Fungal disease epidemiology

Matteo RINALDI

A / 16 / 19

Poster P2815

Abstract 6021

The prevalence of Cryptococcus positive samples from hospitals in KwaZulu-Natal (KZN), South Africa

29/04 12:00

6a. Fungal disease epidemiology

Brilliant ZANDILE

A / 16 / 20

Poster P2816

Abstract 6062

Distribution and antifungal susceptibility pattern of Candida spp. in a Belgian Walloon university hospital between January 2017 and October 2023

29/04 12:00

6a. Fungal disease epidemiology

Sarah CUGNATA

A / 16 / 21

Poster P2817

Abstract 6179

CNS sporotrichosis (clinical features, diagnosis, and treatment): a systematic review and meta-analysis

29/04 12:00

6a. Fungal disease epidemiology

Vítor FALCÃO DE OLIVEIRA

A / 16 / 22

Poster P2818

Abstract 6232

Non-Aspergillus mould infections in adult liver transplant recipients, a French national retrospective cohort from 2007 to 2021

29/04 12:00

6a. Fungal disease epidemiology

Cléa MELENOTTE

A / 16 / 23

Poster P2819

Abstract 6651

Candida spp. workload: the burden and cost of a yeast in a microbiology department

29/04 12:00

6a. Fungal disease epidemiology

Ana SORIANO-MARTÍN

A / 16 / 24

Poster P2820

Abstract 6652

Sporothrix brasiliensis spread is largely driven by single clonal clade

29/04 12:00

6a. Fungal disease epidemiology

Eelco F.J. MEIJER

A / 16 / 25

Poster P2821

Abstract 6887

Candida auris candidemia in colonised patients: antifungal susceptibility and outcome

29/04 12:00

6a. Fungal disease epidemiology

Aikaterini MICHELAKI

A / 16 / 26

Poster P2822

Abstract 6915

Emergence of invasive infections due to the rare yeast Trichosporon austroamericanum sp. nov. (formerly T. inkin sensu lato) in patients undergoing cardio-vascular surgery in three European countries

29/04 12:00

6a. Fungal disease epidemiology

Arnaud FEKKAR

A / 16 / 27

Poster P2823

Abstract 7016

Characteristics and prognosis factors of Pneumocystis jirovecii pneumonia according to underlying disease: a retrospective multicentre study

29/04 12:00

6a. Fungal disease epidemiology

Romain LECUYER

A / 16 / 28

Poster P2824

Abstract 7131

Should we reconsider Pneumocystis pneumonia presentation and treatment according to its underlying disease? An unsupervised cluster analysis of a retrospective multicentre study

29/04 12:00

6a. Fungal disease epidemiology

Benjamin GABORIT

B / 16 / 1

Poster P2825

Abstract 7306

Prevalence and clinic-radiological features of allergic bronchopulmonary aspergillosis and chronic pulmonary aspergillosis in patients with post tubercular lung disease

29/04 12:00

6a. Fungal disease epidemiology

Anuj AJAYABABU

B / 16 / 2

Poster P2826

Abstract 7380

Investigation of breakthrough invasive fungal infection risk factors in patients with haematological malignancy

29/04 12:00

6a. Fungal disease epidemiology

Dondu CELIK

B / 16 / 3

Poster P2827

Abstract 7576

Epidemiological trends and genotypic analysis of Candida parapsilosis candidaemia: a 13-year retrospective study in a tertiary care hospital in Madrid, Spain

29/04 12:00

6a. Fungal disease epidemiology

Ana SORIANO-MARTÍN

B / 16 / 4

Poster P2828

Abstract 7615

Clinical significance of mucor in airway culture of immunocompetent patients with chronic lung disease

29/04 12:00

6a. Fungal disease epidemiology

Michal MEIR

B / 16 / 5

Poster P2829

Abstract 7740

Distribution of fluconazole-resistant Candida parapsilosis in a university hospital: the transformation of an epidemic event?

29/04 12:00

6a. Fungal disease epidemiology

Luigi RONGA

B / 16 / 6

Poster P2830

Abstract 7743

Prevalence of vaginal Candida infections among females under screening to high risk human papillomavirus infection

29/04 12:00

6a. Fungal disease epidemiology

Elahe NASRI

B / 16 / 7

Poster P2831

Abstract 7836

Immune profile in Covid-19 associated pulmonary aspergillosis: The CYTOCAPA Study

29/04 12:00

6a. Fungal disease epidemiology

Olivier MASCLE

B / 16 / 8

Poster P2832

Abstract 7846

The alarming prevalence of Trichophyton indotineae as the causal agent of skin dermatophytosis in Iran

29/04 12:00

6a. Fungal disease epidemiology

Hossein MIRHENDI

B / 16 / 9

Poster P2833

Abstract 7892

Pneumonia by Pneumocystis jirovecii in elderly patients: new clinical and microbiological data

29/04 12:00

6a. Fungal disease epidemiology

Sara FUEYO

B / 16 / 10

Poster P2834

Abstract 7894

Invasive aspergillosis in non-haematological patients

29/04 12:00

6a. Fungal disease epidemiology

Vasilyeva NATALYA

B / 16 / 11

Poster P2835

Abstract 8047

Pulmonary mucormycosis is a complex infection: ten-year experience in Mexico

29/04 12:00

6a. Fungal disease epidemiology

Paulina CARREÑO PÉREZ

B / 16 / 12

Poster P2836

Abstract 8083

Four-year retrospective case-control study on the bacteremia concomitant with candidemia: clinical, risk factors and impact on the survival at an Italian tertiary-care hospital.

29/04 12:00

6a. Fungal disease epidemiology

Andrea BEDINI

B / 16 / 13

Poster P2837

Abstract 8155

Global emergence of Candida auris: first outbreaks in Germany

29/04 12:00

6a. Fungal disease epidemiology

Alexander Maxmilian ALDEJOHANN

B / 16 / 14

Poster P2838

Abstract 8305

Clinical and mycological implications of cryptococcal meningitis in Iran with emphasis on immunocompetent patients

29/04 12:00

6a. Fungal disease epidemiology

Sadegh KHODAVAISY

B / 16 / 15

Poster P2839

Abstract 8336

Prevalence assessment of Candida auris colonisation in hospitalised patients: implications for transmission control

29/04 12:00

6a. Fungal disease epidemiology

Shivaprakash SHASHIKALA

B / 16 / 16

Poster P2840

Abstract 8407

Gastrointestinal mucormycosis: an analysis of 339 adults from the FungiScope registry and literature

29/04 12:00

6a. Fungal disease epidemiology

Ertan SAL

B / 16 / 17

Poster P2841

Abstract 8571

Population genomic analyses reveal high diversity, recombination, and nosocomial transmission among Candida glabrata isolates causing invasive infections

29/04 12:00

6a. Fungal disease epidemiology

Clement TSUI

B / 16 / 18

Poster P2842

Abstract 8632

Outcomes associated with mucor infections at a tertiary care hospital over a ten year period

29/04 12:00

6a. Fungal disease epidemiology

Gautam KALYATANDA

B / 16 / 19

Poster P2843

Abstract 8664

Epidemiologic surveillance of Candida auris: a comparative study of pre and post-COVID periods in the ICU at IRCCS Ospedale Policlinico San Martino, Liguria, Italy

29/04 12:00

6a. Fungal disease epidemiology

Elisa GIRIBALDI

B / 16 / 20

Poster P2844

Abstract 8673

Changing epidemiology of candidaemia: data from a referral tertiar university hospital

29/04 12:00

6a. Fungal disease epidemiology

Michela PAGNUCCO

B / 16 / 21

Poster P2845

Abstract 8742

Epidemiological trends of human aspergillosis in the region of Sousse, Tunisia, from 1982-2021

29/04 12:00

6a. Fungal disease epidemiology

Rania MRASSI

B / 16 / 22

Poster P2846

Abstract 8900

Candida auris: data from the national surveillance system for mandatory notification (SURVNET) 2021-2023

29/04 12:00

6a. Fungal disease epidemiology

Jane HECHT

B / 16 / 23

Poster P2847

Abstract 213

Rapid identification of Candia auris from screen samples

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Merav STRAUSS

B / 16 / 24

Poster P2848

Abstract 326

Clinical evaluation of commercial candida panel for the rapid diagnosis of candidemia

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Kuenyoul PARK

B / 16 / 25

Poster P2849

Abstract 451

Comparison of 1,3 β-D-glucan values for Candida auris to other Candida species

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Trusha NANA

B / 16 / 26

Poster P2850

Abstract 577

Comparative analysis of abnormalities detected in chest radiography vs chest computed tomography for pulmonary coccidioidomycosis

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Sandhya NAGARAKANTI

B / 16 / 27

Poster P2851

Abstract 584

Usefulness of the fungus (1-3)-β-D-glucan assay (chemiluminescence) as a diagnostic tool of invasive fungal disease

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Zhou ZEQI

B / 16 / 28

Poster P2852

Abstract 809

Pneumocystis jirovecii pneumonia: quantitative PCR clinical impact and differences with qualitative PCR

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Riccardo PAGGI

A / 17 / 1

Poster P2853

Abstract 903

Prospective evaluation of Aspergillus-specific IgG assay using a new chemiluminescence method for diagnosis of chronic pulmonary aspergillosis

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Zhou ZEQI

A / 17 / 2

Poster P2854

Abstract 1040

Diagnosis of invasive fungal infection using a cell-free DNA assay coupled with giant magnetoresistance lab-on-a-chip technology

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Paschalis VERGIDIS

A / 17 / 3

Poster P2855

Abstract 1069

Point-of-care testing for peritoneal and serum 1.3 beta-D-glucan to rule out intra-abdominal candidiasis in critically ill patients

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Emmanuel NOVY

A / 17 / 4

Poster P2856

Abstract 1120

Comparative evaluation between two real-time PCR for the detection of Pneumocystis jirovecii and the ability to differentiate colonisation and clinical infection

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Tsz Yung HUI

A / 17 / 5

Poster P2857

Abstract 1156

Digital diagnostics in medical mycology

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Volkan ÖZENCI

A / 17 / 6

Poster P2858

Abstract 1188

Assessing new approaches for establishing the fast identification process of filamentous fungi

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Chou CHIAHUA

A / 17 / 7

Poster P2859

Abstract 1261

Evaluation of the Aspergillus Galactomannan enzyme immunoassay for the diagnosis of invasive pulmonary aspergillosis in bronchoalveolar lavage fluid

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Sarah SEDIK

A / 17 / 8

Poster P2860

Abstract 1263

Validation and implementation of a real-time PCR assay for the direct detection of Candida auris from surveillance samples in the context of a C. auris outbreak

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Esther FRANCO

A / 17 / 9

Poster P2861

Abstract 1268

Rapid identification and antifungal susceptibility testing of Candida spp. from blood culture bottles

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Volkan ÖZENCI

A / 17 / 10

Poster P2862

Abstract 1310

A novel T cell assay for monitoring scedosporiosis treatment

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Rosanne SPRUTE

A / 17 / 11

Poster P2863

Abstract 1512

The combination of multiplex Aspergillus PCR assay and Aspergillus galactomannan lateral flow assay for the rapid diagnosis of invasive aspergillosis

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

He WANG

A / 17 / 12

Poster P2864

Abstract 1523

A novel chemiluminescent immunoassay detection of Aspergillus galactomannan antigen

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Zhou ZEQI

A / 17 / 13

Poster P2865

Abstract 1906

MALDI biotyping of fungal siderophores: how far we are?

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Vladimir HAVLICEK

A / 17 / 14

Poster P2866

Abstract 2232

PCR on respiratory tract specimens of immunocompromised patients to diagnose Pneumocystis Pneumonia (PcP): a systematic review and meta-analysis

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Lottie BROWN

A / 17 / 15

Poster P2867

Abstract 2279

Evaluation of a rapid and high throughput automated Candida auris PCR assay for screening samples

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Terrence KUNG

A / 17 / 16

Poster P2868

Abstract 2437

Chronic respiratory diseases: bacterial or fungal?

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Mohit CHOWDHURY

A / 17 / 17

Poster P2869

Abstract 2530

Enhancing fungal DNA detection in liquid biopsies of paediatric cancer patients at risk of invasive pulmonary aspergillosis: a comprehensive computational and sequencing approach

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Emmy WESDORP

A / 17 / 18

Poster P2870

Abstract 2799

Opening the DOOR to candidaemia diagnostics: a desirability of outcomes ranking analysis of a commerical assay vs blood culture in critically ill patients

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Kaylee CANIFF

A / 17 / 19

Poster P2871

Abstract 2816

Enhancing mycological investigations: insights from a pilot study on inter-laboratory consistency and molecular identification

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Sara ALHOSANI

A / 17 / 20

Poster P2872

Abstract 2836

Does the highly migratory Trichophyton indotineae finally knock the UAE?: “does the buck stop here?”

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Hari VANAM

A / 17 / 21

Poster P2873

Abstract 2986

Advancing mold identification in the routine laboratory: performance of smartphone-based imaging and a newly developed convolutional neural network

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Lukas WEBER

A / 17 / 22

Poster P2874

Abstract 2998

Verification, analytical sensitivity, cost-effectiveness, and comparison of four Candida auris screening methods

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Xena LI

A / 17 / 23

Poster P2875

Abstract 3124

Multicentre prospective clinical validation of the novel Mp1p enzyme immunoassay as a screening tool for talaromycosis

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Khanh DANG HOANG

A / 17 / 24

Poster P2876

Abstract 3209

Aspergillus IgG antibodies in diagnosing pulmonary aspergillosis

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Tingting WANG

A / 17 / 25

Poster P2877

Abstract 3225

Fungal species identification: a comparative analysis of nanopore-based 18S sequencing and Sanger sequencing of the large subunit (LSU)

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Silje HOEGH

A / 17 / 26

Poster P2878

Abstract 3797

Enhancing dermatomycosis sample collection and transport performance for molecular detection approaches

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Chiara SENTI

A / 17 / 27

Poster P2879

Abstract 3905

In-vitro performance of a novel broth media for selection and enrichment of Candida auris strain

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Chiara SENTI

A / 17 / 28

Poster P2880

Abstract 4128

Current microbiological testing and diagnostic yield for fungal infections in hospitalised haematological patients: a call for diagnostic stewardship

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Patricia MONZO GALLO

B / 17 / 1

Poster P2881

Abstract 4209

Sensitivity of urine antigen for diagnosis of blastomycosis in solid organ transplant recipients

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Vaisak NAIR

B / 17 / 2

Poster P2882

Abstract 4211

Evaluation of a commercial real-time PCR assay on pulmonary and extra-pulmonary aamples for mucormycosis diagnosis: assessing diagnostic performance

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Kruthi MALUR

B / 17 / 3

Poster P2883

Abstract 4412

Candida PCR optimise the diagnosis of intra-abdominal candidiasis?

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Cristian CASTELLÓ-ABIETAR

B / 17 / 4

Poster P2884

Abstract 4417

Microbial cell-free DNA sequencing from plasma and BAL in patients with a suspected invasive fungal infection: a retrospective multicentre study

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Sammy HUYGENS

B / 17 / 5

Poster P2885

Abstract 5090

How can a Candida real-time PCR complement culture-based diagnostics of invasive candidiasis?

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Elizabeth Nagy Roshdy ISKANDAR

B / 17 / 6

Poster P2886

Abstract 5222

Accuracy of galactomannan in tracheal aspirate for diagnosing invasive pulmonary aspergillosis in non-neutropaenic patients

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Graciela HERNANDEZ SILVA

B / 17 / 7

Poster P2887

Abstract 5293

Laboratory diagnosis of invasive aspergillosis among haematological patients with use of 1,3-β-D glucan in combination with galactomannan and molecular detection of Aspergillus DNA: routine laboratory data collection 2019-2023

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Georgia VRIONI

B / 17 / 8

Poster P2888

Abstract 5326

Development of multiplex real-time PCR assay for the simultaneous detection of two pathogens causing fungal pneumonia

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Younghyun BAEK

B / 17 / 9

Poster P2889

Abstract 5479

Screening for Candida auris in critically ill patients: a two-year analysis from a Greek tertiary-care hospital, during COVID-19 waves

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Vasiliki MAMALI

B / 17 / 10

Poster P2890

Abstract 5894

Comparison of culture and molecular detection of infections in nails and skin samples

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Radovan BRIGITA

B / 17 / 11

Poster P2891

Abstract 6432

Single enrichment approach: evaluating thiol broth for comprehensive detection of bacteria and fungi in human bone fragments

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Livia TARTAGLIONE

B / 17 / 12

Poster P2892

Abstract 6574

Diagnostic performance of different Candida antigens and anti-Candida antibody assays for the diagnosis of invasive candidiasis in ICU patients: an analysis of the CandiSep randomized clinical trial

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Jürgen HELD

B / 17 / 13

Poster P2893

Abstract 6886

Longitudinal study reviewing the performance of Candida molecular diagnostic workflows from 2019 to 2023

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Dorothy MONTGOMERY

B / 17 / 14

Poster P2894

Abstract 6977

MALDI-TOF MS in the identification of filamentous fungi, directly from the colony

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Eva MOLNAR

B / 17 / 15

Poster P2895

Abstract 7041

Suboptimal sensitivity of a commercial panel for candidaemia: a Bayesian latent class meta-analysis of diagnostic test accuracy

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Alberto Enrico MARAOLO

B / 17 / 16

Poster P2896

Abstract 7168

Infection vs colonisation: low-level detection of Pneumocystis jirovecii by PCR is uncommon in asymptomatic community patients

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Vicki FLEMING

B / 17 / 17

Poster P2897

Abstract 7185

Development and performance of a new commercial urine diagnostic test for aspergillosis

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Kieren MARR

B / 17 / 18

Poster P2898

Abstract 7296

Pentraxin 3 in onco-haematological patients: a potential biomarker for invasive fusariosis and aspergillosis

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Elaine Cristina FRANCISCO

B / 17 / 19

Poster P2899

Abstract 7582

Analytical and clinical performance of a Candida auris IVD real-time PCR kit

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Julie GREEN

B / 17 / 20

Poster P2900

Abstract 7723

Acute infection or colonisation? A comparative analysis of four molecular assays for the detection of Pneumocystis jirovecii

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Rosalind TUCKER

B / 17 / 21

Poster P2901

Abstract 7750

Identification of fungi from histopathology positive formalin fixed paraffin embedded tissue by panfungal PCR

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Rija ZEHRA

B / 17 / 22

Poster P2902

Abstract 7805

Can bronchoalveolar lavage galactomannan levels predict patient outcomes

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Elif ATES

B / 17 / 23

Poster P2903

Abstract 7972

Performance of the Aspergillus galactomannan lateral flow assay with a digital reader for the diagnosis of invasive aspergillosis: A multicenter study

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Guo JIAN

B / 17 / 24

Poster P2904

Abstract 8117

Development and validation of a molecular assay for the rapid diagnosis of fungal pneumonia

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Margherita CACACI

B / 17 / 25

Poster P2905

Abstract 8145

Real-time assessment of dermatomycosis using a PCR/microarray-based diagnostic system

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Vittorio IVAGNES

B / 17 / 26

Poster P2906

Abstract 8294

Optimisation of two commercial real-time PCR assays for rapid diagnosis of mucormycosis; analysis of 120 clinical specimens from COVID-19 patients

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Sajedeh SOLTANI

B / 17 / 27

Poster P2907

Abstract 8317

Study of Candida spp. colonisation in patients admitted to an ICU

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Konstantinia KONTOPOULOU

B / 17 / 28

Poster P2908

Abstract 8457

Mucor germinans, a novel dimorphic species mimicking Paracoccidioides in a pulmonary sample

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Seyed Mojtaba SEYED MOUSAVI TASIEH

A / 18 / 1

Poster P2909

Abstract 8491

Label-free surface-enhanced Raman scattering (SERS) spectroscopy as a diagnostic tool for invasive aspergillosis: a pilot study

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Maria SIOPI

A / 18 / 2

Poster P2910

Abstract 8648

Real-world applicability of EUROArray DNA systems for molecular diagnosis of dermatophytoses

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Claudelle TACUGUE

A / 18 / 3

Poster P2911

Abstract 8786

Detection Mucorales DNA in sera specimens of both COVID-19 and non-COVID-19 associated mucormycosis using probe-based Mucorales-specific real-time PCR

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Kazem AHMADIKIA

A / 18 / 4

Poster P2912

Abstract 3756

Evaluation of the metabolomic changes of fluconazole-resistant C.parapsilosis under fluconazole exposure

29/04 12:00

6b. Diagnostic mycology (incl traditional, molecular and other methods)

Ozlem DOGAN

A / 18 / 4

Poster P2912

Abstract 804

A novel mechanism drives amphotericin B resistance in Candida auris

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Phan-Canh TRINH

A / 18 / 5

Poster P2913

Abstract 1146

Antifungal susceptibility profile and local epidemiological cut-off values of Yarrowia (Candida) lipolytica: an emergent and rare opportunistic yeast

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Jinhan YU

A / 18 / 6

Poster P2914

Abstract 1451

The seven year itch: how T. indotineae is driving the dermatophytosis epidemic in India

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Vaishnavi VERMA

A / 18 / 8

Poster P2916

Abstract 1536

Whole genome sequencing of fluconazole non-susceptible bloodstream Candida parapsilosis isolates in South Korea

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Jong Hee SHIN

A / 18 / 9

Poster P2917

Abstract 1783

Nationwide surveillance of azole resistance in clinical Aspergillus fumigatus (ARAf) 2018-2022

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Karen ASTVAD

A / 18 / 10

Poster P2918

Abstract 1811

Molecular identification and antifungal susceptibility of clinical isolates of Fusarium spp: a single centre study

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Aleksandra GÓRZYNSKA

A / 18 / 11

Poster P2919

Abstract 2583

Analysis of resistance in antifungals (ARIA): surveillance of Aspergillus isolates collected globally from 2020-2022

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Stephen HAWSER

A / 18 / 12

Poster P2920

Abstract 2895

SCY-247, a novel second-generation IV/oral triterpenoid antifungal, demonstrates in vitro activity against fungal pathogens, including azole-resistant strains of Candida and Aspergillus

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Nathan WIEDERHOLD

A / 18 / 13

Poster P2921

Abstract 3306

Aneuploidy is associated with azole cross-resistance in Trichosporon asahii evolved to voriconazole

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Lina GUO

A / 18 / 14

Poster P2922

Abstract 3694

A service evaluation of the management of candidaemia in a UK tertiary healthcare centre

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Vanessa WONG

A / 18 / 15

Poster P2923

Abstract 3771

In vitro activity of olorofim against the agents of the endemic mycoses

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Corinne PINDER

A / 18 / 16

Poster P2924

Abstract 3786

In vitro activity of olorofim against Scedosporium species, Lomentospora prolificans and Scopulariopsis species

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Corinne PINDER

A / 18 / 17

Poster P2925

Abstract 3934

Life in plastic is (not so) fantastic: a single-centre study on antifungal susceptibility of Candida parapsilosis

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Denise D'ELIA

A / 18 / 18

Poster P2926

Abstract 3944

Survey on azole resistance in clinical Aspergillus spp collected in 2023 in hospitals located in central Iberian Peninsula (ASPEIN III)

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Jesus GUINEA

A / 18 / 19

Poster P2927

Abstract 4085

Olorofim showed potent in vitro activity against Aspergillus spp clinical isolates collected in a national survey on azole resistance conducted in Spain in 2022 (ASPEIN II)

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Julia SERRANO-LOBO

A / 18 / 20

Poster P2928

Abstract 4174

Biocide and antifungal susceptibility of Candida auris isolates

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Bedia DINC

A / 18 / 21

Poster P2929

Abstract 4232

Synergistic interaction of milbemycin oxime with fluconazole against Candida auris

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Lola AUBRY

A / 18 / 22

Poster P2930

Abstract 4243

Use of voriconazole to predict susceptibility and resistance to isavuconazole for Aspergillus fumigatus by using the CLSI methods and interpretive criteria

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Mariana CASTANHEIRA

A / 18 / 23

Poster P2931

Abstract 4346

Unveiling azole-resistant Aspergillus fumigatus in ambient air: genotypic relationship between clinical and environmental isolates

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Laura ALGUACIL CUÉLLAR

A / 18 / 24

Poster P2932

Abstract 4386

Characterisation of fluconazole non susceptible (FNS) Candida parapsilosis strains isolated from Hospitals from Spain

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Oscar ZARAGOZA

A / 18 / 25

Poster P2933

Abstract 4454

Clinical impact of azole-resistant A. fumigatus (AFAR) complex isolates in a tertiary centre

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Anna FALCÓ ROGET

A / 18 / 26

Poster P2934

Abstract 4657

Gradient diffusion plastic strip for detection of azole resistance in Aspergillus fumigatus sensu stricto: inoculum preparation might not require prior filtration and adjustment

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Julia SERRANO-LOBO

A / 18 / 27

Poster P2935

Abstract 4746

Effect of SCY-247, a second-generation triterpenoid antifungal, on growth kinetics and ultrastructure of Candida auris

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Mahmoud A. GHANNOUM

A / 18 / 28

Poster P2936

Abstract 4773

Comparative evaluation of gradient concentration strip and reference CLSI methods for antifungal susceptibility testing of Candida auris using a representative international panel of isolates

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Maria SIOPI

B / 18 / 1

Poster P2937

Abstract 4789

Azole-resistant aspergillus species in poultry feed in Kabale, South West, Uganda

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Adeyinka ODEBODE

B / 18 / 2

Poster P2938

Abstract 4888

Species-specific mortality and antifungal susceptibilityof the Candida spp. isolated in a north-eastern italian region between 2018 and 2022

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Fabiana DELLAI

B / 18 / 3

Poster P2939

Abstract 4889

Inoculum density has an impact on SF001 fungicidal activity against Candida albicans

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

David HUFNAGEL

B / 18 / 4

Poster P2940

Abstract 5329

In vitro activities of polyene, azole, and echinocandins against Candida auris isolates under both planktonic and biofilm-growing conditions

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Hamid BADALI

B / 18 / 5

Poster P2941

Abstract 5336

Surveillance study of triazole-resistant Aspergillus fumigatus isolates in Iran

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Hamid BADALI

B / 18 / 6

Poster P2942

Abstract 5368

Minimum inhibitory concentrations of antifungals against invasive isolates of Cryptococcus species worldwide: antimicrobial testing leadership and surveillance programme, 2010–2020

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Po-Ren HSUEH

B / 18 / 7

Poster P2943

Abstract 5380

Candida guilliermondii fungemia: 10-year retrospective clinical analysis and antimicrobial susceptibility profiles from a reference laboratory

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Jack MCHUGH

B / 18 / 8

Poster P2944

Abstract 5462

Distribution and antifungal susceptibility of yeast species causing invasive fungal diseases in China: a 12.5 years' review from the CHIF-NET study

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Meng XIAO

B / 18 / 9

Poster P2945

Abstract 5525

Multicentre evaluation of a EUCAST-based agar-screening method for terbinafine and itraconazole susceptibility of Trichophyton spp.

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Joseph MELETIADIS

B / 18 / 10

Poster P2946

Abstract 5705

Mechanistic investigations to understand the complex metabolism of voriconazole by cross-linking in silico and in vitro methods

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Amrei-Pauline KONRAD

B / 18 / 11

Poster P2947

Abstract 6015

Current antifungal resistance in invasive aspergillosis

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Andrea GUTIÉRREZ VILLANUEVA

B / 18 / 12

Poster P2948

Abstract 6030

Status of surveillance of antifungal resistance in candidaemia to inform antifungal stewardship in European countries

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Liliana GALIA

B / 18 / 13

Poster P2949

Abstract 6139

Q-PHAST: simple, large-scale quantitative phenotyping and antimicrobial susceptibility testing

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

B / 18 / 14

Poster P2950

Abstract 6225

In vitro antifungal susceptibility testing of Cladophialophora bantiana clinical isolates in France

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Dea GARCIA-HERMOSO

B / 18 / 15

Poster P2951

Abstract 6227

Copy number variants of ERG11 gene: an uncharacterised mechanism of azole resistance in Candida parapsilosis

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Ning YATING

B / 18 / 16

Poster P2952

Abstract 6528

Worldwide genomic convergent evolution in clinical fungi: an emerging azole-resistance mechanism

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Rong-Chen DAI

B / 18 / 17

Poster P2953

Abstract 7069

Amino-acid substitutions in CYP51A protein from Purpureocillium lilacinum likely to be associated with itraconazole resistance

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Lorra MONPIERRE

B / 18 / 18

Poster P2954

Abstract 7107

Whole genome sequence analysis of terbinafine resistant and susceptible Trichophyton isolates from human and animal origin

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Sheetal THAKUR

B / 18 / 19

Poster P2955

Abstract 7128

Mutations of the ERG11 gene in fluconazole-resistant Candida albicans isolates in Ivory Coast

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Kouassi Francis KOUADJO

B / 18 / 20

Poster P2956

Abstract 7297

Delineation of the direct contribution of clinically observed FKS1 mutations to echinocandin resistance in Candida auris

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Katherine BARKER

B / 18 / 21

Poster P2957

Abstract 7442

Antifungal resistance and breakthrough candidaemia among paediatric cancer patients: an emerging threat

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Youssef MADNEY

B / 18 / 22

Poster P2958

Abstract 7545

In vitro antifungal susceptibility profile and genotypic characterisation of clinical Aspergillus isolates in eastern China on behalf of eastern China invasive fungi infection group

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Wenjuan WU

B / 18 / 23

Poster P2959

Abstract 7781

Antifungal susceptibility profiles of dermatophyte isolates in Iran

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Shima ABOUTALEBIAN

B / 18 / 24

Poster P2960

Abstract 7829

In vitro long-term exposure to chlorhexidine or triclosan is associated with cross-resistance against azoles in Nakaseomyces glabratus

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Kathrin SPETTEL

B / 18 / 25

Poster P2961

Abstract 8063

Antifungal susceptibility and clinical outcomes of Candida parapsilosis bloodstream infections: a multicentre observational study of the Turkish fungal infections study group

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Suda TEKIN

B / 18 / 26

Poster P2962

Abstract 8335

Comparing the in vitro activity of seven antifungal drug with chlorhexidine against the most important causative agents of fungal keratitis

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Sadegh KHODAVAISY

B / 18 / 27

Poster P2963

Abstract 8430

Unraveling the genotypic diversity and molecular mechanisms of fluconazole resistance in Candida parapsilosis clinical isolates in a tertiary care hospital from North India

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Vrinda SHARMA

B / 18 / 28

Poster P2964

Abstract 8481

Synergistic interaction between amphotericin B and azoles against Candida guilliermondii using pharmacodynamics-modelling approach.

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Adrien BAILLOD

A / 19 / 1

Poster P2965

Abstract 8860

ERG11 copy number variations in the human fungal pathogen Yarrowia lipolytica

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Jinhan YU

A / 19 / 2

Poster P2966

Abstract 8898

In vitro activity of the novel antifungal olorofim against multiresistant Fusarium in China

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Yinggai SONG

A / 19 / 3

Poster P2967

Abstract 8909

Categorisation of Candida auris isolates for second generation triazoles based on fluconazole susceptibility

29/04 12:00

6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)

Paschalis PARANOS

A / 19 / 4

Poster P2968

Abstract 360

Post-infectious inflammatory response syndrome (PIIRS) in HIV-negative patients with cryptococcal meningitis in Vietnam

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Dang Trung Nghia HO

A / 19 / 5

Poster P2969

Abstract 589

Real-world evaluation of isavuconazole as prophylaxis and therapy for invasive fungal infections in paediatric patients with cancer

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Janine NIJHUIS

A / 19 / 6

Poster P2970

Abstract 593

Inadequate isavuconazole plasma concentrations in haemato-oncological non-ICU patients: need for routine therapeutic drug monitoring?

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Till KLEIN

A / 19 / 7

Poster P2971

Abstract 911

Evaluation of posaconazole serum concentrations achieved with delayed-release tablets and oral suspension in patients undergoing intensive chemotherapy for acute myeloid leukemia and myelodysplastic syndrome

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Cédric HIRZEL

A / 19 / 8

Poster P2972

Abstract 1060

Efficacy and safety of ibrexafungerp in the treatment of vulvovaginal candidiasis: a systematic review and meta–analysis

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Thiago NETTO

A / 19 / 9

Poster P2973

Abstract 1285

Front-loaded exposures increase the fungicidal effect of SF001: a basis for infrequent dosing regimens

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Brian VANSCOY

A / 19 / 10

Poster P2974

Abstract 1334

Opening the DOOR for clinical mycology: preliminary results of a Delphi process

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Jose PORTUGAL GONZALES

A / 19 / 11

Poster P2975

Abstract 1546

In vitro interactions between 1,3,4-thiadiazole derivative and selected antifungal drugs

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Dominika KUBERA

A / 19 / 12

Poster P2976

Abstract 1571

The evaluation of risk factors and prognostic impact of glucocorticoid therapy among non-HIV patients with Pneumocystis jirovecii pneumonia (PCP)

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Jun LI

A / 19 / 13

Poster P2977

Abstract 1777

Treatment outcomes with rezafungin and caspofungin in adults with invasive candidiasis and/or candidaemia who had received no prior antifungal therapy: ReSTORE trial subgroup analysis

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

George R THOMPSON

A / 19 / 14

Poster P2978

Abstract 1828

Personalised antifungal therapy through model-informed precision dosing of posaconazole

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Anouk JANSEN

A / 19 / 15

Poster P2979

Abstract 1875

Daily intravenous liposomal Amphotericin B as antifungal prophylaxis in haematological patients: a clinical experience

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Ana María BADÍA-TEJERO

A / 19 / 16

Poster P2980

Abstract 2102

Breakthrough invasive mould infections among high-risk haematologic patients

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Jorge BOÁN

A / 19 / 17

Poster P2981

Abstract 2218

Timing of antifungal therapy for candida bloodstream infection

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Alaa ATAMNA

A / 19 / 18

Poster P2982

Abstract 2341

Fluconazole target attainment during mechanical circulatory support device insertion

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Kelly CAIRNS

A / 19 / 19

Poster P2983

Abstract 2438

Toward individualised antifungal therapy: mechanism-based pharmacokinetic/pharmacodynamic model of voriconazole to predict the clinical outcomes of adult patients with invasive aspergillosis

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Vasin VASIKASIN

A / 19 / 20

Poster P2984

Abstract 2615

Efficacy and safety of L-AmB-containing treatment on paediatric IFD patients previously exposed to broad spectrum antifungal agents

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Beiqun CHEN

A / 19 / 21

Poster P2985

Abstract 2623

An analysis of the use of posaconazole alone or in combination with any form of amphotericin B during a pandemic disaster in a low resource setting for COVID-19 associated mucormycosis (CAM)

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Pugazhenthan THANGARAJU

A / 19 / 22

Poster P2986

Abstract 2925

Olorofim demonstrates potent in vitro activity against Coccidioides species including against isolates with reduced fluconazole susceptibility

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Nathan WIEDERHOLD

A / 19 / 23

Poster P2987

Abstract 3048

Novel liposomal formulations of amphotericin B (LFAMB) were effective in murine models of experimental mycotic keratitis caused by Candida albicans (CA), Aspergillus fumigatus (AF), and Fusarium solani complex (FS)

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Ruta PETRAITIENE

A / 19 / 24

Poster P2988

Abstract 3560

Voriconazole as secondary invasive fungal infection prophyalxis during allogeneic haematopoietic stem cell transplantation

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Yuwen WANG

A / 19 / 25

Poster P2989

Abstract 3936

Revisiting amphotericin B prophylaxis in patients with haematology malignancies

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Gajaani KUGANARUL

A / 19 / 26

Poster P2990

Abstract 4864

SF001, a novel micellar polyene, demonstrates a prolonged post-antifungal effect in vitro against yeast

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

David HUFNAGEL

A / 19 / 27

Poster P2991

Abstract 5035

Using real-world data: can CYP2C19 genotype predict poor response to voriconazole?

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Sophie STOCKER

A / 19 / 28

Poster P2992

Abstract 5129

PK/PD target attainment with contemporary dosing of antifungal drugs. Outcomes from an international, multicentre pharmacokinetic study for screening antifungal exposure in intensive care units: The SAFE-ICU study

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Jason ROBERTS

B / 19 / 1

Poster P2993

Abstract 5719

Role of isavuconazole therapeutic drug monitor (TDM) in real life: is it possible and sure to reduce isavuconazole dosage in patients with overdose?

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Elena GHIDONI

B / 19 / 2

Poster P2994

Abstract 5866

The echipof study: predictors of treatment failure to echinocandins for Candida bloodstream infection: a multicentre retrospective cohort study

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Lucia DIELLA

B / 19 / 3

Poster P2995

Abstract 6197

Retrospective cost analysis model of treating candidaemia with rezafungin based on real-world data from a German tertiary hospital

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Melina Sophie KURTE

B / 19 / 4

Poster P2996

Abstract 6392

Efficacy of extended-interval micafungin dosing against Candida albicans and Candida parapsilosis isolates using an in vitro pharmacokinetic/pharmacodynamic model

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Maria-Ioanna BEREDAKI

B / 19 / 5

Poster P2997

Abstract 6465

Posaconazole TDM and pharmacogenetic as a tool for antifungal stewardship in haematological patients with acute myeloid leukaemia

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Silvia CORCIONE

B / 19 / 6

Poster P2998

Abstract 6511

Evaluation of real-world isavuconazole therapeutic drug monitoring: where to go from here?

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Beatrijs MERTENS

B / 19 / 7

Poster P2999

Abstract 3638

Model-informed identification of a weight-based fluconazole dosing strategy aiming for improved target attainment in critically ill patients

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Luong VUONG

B / 19 / 7

Poster P2999

Abstract 7818

Evaluation of clinical outcomes for anidulafungin standard dosing in hospitalised critically ill obese patients with candidaemia: a retrospective cohort study

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Yazed ALSOWAIDA

B / 19 / 8

Poster P3000

Abstract 7974

Isavuconazole therapeutic drug monitoring may be advocated in Asian patients with invasive mould infections based on their pharmacogenomic profiling

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Fu Zi Yvonne CHAN

B / 19 / 9

Poster P3001

Abstract 8220

Voriconazole or isavuconazole in the treatment of aspergillosis in elderly patients?

29/04 12:00

6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials)

Julieth CABALLERO

B / 19 / 10

Poster P3002

Abstract 684

A multidrug delivery platform based on azole-loaded mucosomes as promising strategy to counteract infections caused by Candida albicans

29/04 12:00

6e. Basic mycology (incl in vitro and in vivo studies, pathogenesis, virulence, mycobiome)

Giuliana BANCHE

B / 19 / 11

Poster P3003

Abstract 1178

In vivo effectiveness of fluconazole and posaconazole in a murine model of Coccidioides meningitis caused by fluconazole-resistant isolates

29/04 12:00

6e. Basic mycology (incl in vitro and in vivo studies, pathogenesis, virulence, mycobiome)

Laura NAJVAR

B / 19 / 12

Poster P3004

Abstract 1277

Anti-fungal and anti-biofilm activities of polycaprolactone blended with calcium phosphates and silver against Candida albicans and C. auris for bone tissue regeneration applications

29/04 12:00

6e. Basic mycology (incl in vitro and in vivo studies, pathogenesis, virulence, mycobiome)

Valeria ALLIZOND

B / 19 / 13

Poster P3005

Abstract 1561

IL-15 secretion enhances the potential of Af-CAR-NK92 cells for off-the-shelf treatment of invasive pulmonary aspergillosis

29/04 12:00

6e. Basic mycology (incl in vitro and in vivo studies, pathogenesis, virulence, mycobiome)

Beeke TAPPE

B / 19 / 14

Poster P3006

Abstract 1713

The impact of melanisation on hyphal formation in pathogenic fungi

29/04 12:00

6e. Basic mycology (incl in vitro and in vivo studies, pathogenesis, virulence, mycobiome)

Hamide ZOQI

B / 19 / 15

Poster P3007

Abstract 1871

Development of a combat-relevant murine model of wound mucormycosis as a platform for rapid screening and validation of novel treatments

29/04 12:00

6e. Basic mycology (incl in vitro and in vivo studies, pathogenesis, virulence, mycobiome)

Alexander BOBROV

B / 19 / 16

Poster P3008

Abstract 2417

The intravenous challenge mouse model for experimental infections with Yarrowia lipolytica

29/04 12:00

6e. Basic mycology (incl in vitro and in vivo studies, pathogenesis, virulence, mycobiome)

Jinhan YU

B / 19 / 17

Poster P3009

Abstract 2441

Detection and prevalence of moulds and aflatoxins in food and feed for animal and human consumption

29/04 12:00

6e. Basic mycology (incl in vitro and in vivo studies, pathogenesis, virulence, mycobiome)

Emina IDRIZOVIC

B / 19 / 18

Poster P3010

Abstract 3577

Bacterial-mucorales interactions and antimicrobial resistance during mucormycosis: literature search and in vitro observations

29/04 12:00

6e. Basic mycology (incl in vitro and in vivo studies, pathogenesis, virulence, mycobiome)

Dora Edith CORZO LEON

B / 19 / 19

Poster P3011

Abstract 3886

Isavuconazole and micafungin elicit synergistic antifungal activity against azole-resistant Aspergillus fumigatus and stimulate hyphal inactivation by mononuclear phagocytes

29/04 12:00

6e. Basic mycology (incl in vitro and in vivo studies, pathogenesis, virulence, mycobiome)

Sebastian WURSTER

B / 19 / 20

Poster P3012

Abstract 6988

N-chlorotaurine is effective in Aspergillus fumigatus pneumonia in the mouse model

29/04 12:00

6e. Basic mycology (incl in vitro and in vivo studies, pathogenesis, virulence, mycobiome)

Markus NAGL

B / 19 / 21

Poster P3013

Abstract 7636

Whole genome sequencing endorses microsatellite-defined Candida parapsilosis genotypes even though they involve isolates from unrelated patients

29/04 12:00

6e. Basic mycology (incl in vitro and in vivo studies, pathogenesis, virulence, mycobiome)

Aina Catalina MESQUIDA MARCOS

B / 19 / 22

Poster P3014

Abstract 8751

Fungal pathogens exposed – genomic and phenotypic insights into Candida auris and its relatives of the Candida haemulonii species complex

29/04 12:00

6e. Basic mycology (incl in vitro and in vivo studies, pathogenesis, virulence, mycobiome)

Auke DE JONG

B / 19 / 23

Poster P3015

Abstract 8775

Fungal BET protein Bdf1 shows promise as a potential antifungal drug target in Candida spp.

29/04 12:00

6e. Basic mycology (incl in vitro and in vivo studies, pathogenesis, virulence, mycobiome)

Carlo PETOSA

A / 20 / 1

Poster P3016

Abstract 33

Rodent-adapted Cryptosporidium infections in humans: seven new cases and review of the literature

29/04 12:00

7a. Parasitic disease epidemiology

Christen Rune STENSVOLD

A / 20 / 2

Poster P3017

Abstract 472

Canine and sand fly aspects to the Leishmania donovani transmission in endemic villages of Bihar, India

29/04 12:00

7a. Parasitic disease epidemiology

Anurag KUSHWAHA

A / 20 / 3

Poster P3018

Abstract 1085

Investigation of the Visceral Leishmaniasis outbreak in the endemic region of India

29/04 12:00

7a. Parasitic disease epidemiology

Aziza NEYAZ

A / 20 / 4

Poster P3019

Abstract 1443

Can the use of larviciding with biological compounds contribute in increasing Anopheles gambiae s.l. susceptibility to pyrethroid in a population expressing high resistance intensity?

29/04 12:00

7a. Parasitic disease epidemiology

Diane Leslie NKAHE

A / 20 / 5

Poster P3020

Abstract 1807

Toxoplasmosis surveillance in a tertiary hospital in Barcelona, Spain

29/04 12:00

7a. Parasitic disease epidemiology

Celso BATISTA

A / 20 / 6

Poster P3021

Abstract 2057

Oxyuriasis is a risk factor for Dientamoeba fragilis infection: a case-control study

29/04 12:00

7a. Parasitic disease epidemiology

Felipe PÉREZ-GARCÍA

A / 20 / 7

Poster P3022

Abstract 2516

Leishmaniasis: looking back to face the future. A retrospective study of an endemic area in the south of Madrid

29/04 12:00

7a. Parasitic disease epidemiology

Víctor ANTÓN BERENGUER

A / 20 / 8

Poster P3023

Abstract 2518

Odyssean malaria outbreak investigations in South Africa, 2014-2022

29/04 12:00

7a. Parasitic disease epidemiology

Lucille BLUMBERG

A / 20 / 9

Poster P3024

Abstract 2794

Factors associated with severe Plasmodium vivax infection in Thailand was different from the WHO criteria

29/04 12:00

7a. Parasitic disease epidemiology

Pattaratida SINGHASENEE

A / 20 / 10

Poster P3025

Abstract 2838

TB-TROPIcare: Prevalence study of schistosomiasis and strongyloidiasis in a multicultural TB clinic

29/04 12:00

7a. Parasitic disease epidemiology

Camilla GENOVESE

A / 20 / 11

Poster P3026

Abstract 3187

Zoonotic Echinococcus granulosus sensu lato genotypes circulating in small ruminants of north India: a comprehensive appraisal based on mtDNA signatures

29/04 12:00

7a. Parasitic disease epidemiology

Pallavi MOUDGIL

A / 20 / 12

Poster P3027

Abstract 3677

Toxoplasmosis in the Netherlands: seroprevalence and risk factors

29/04 12:00

7a. Parasitic disease epidemiology

Titia M. KORTBEEK

A / 20 / 13

Poster P3028

Abstract 4574

Prevalence and associated factors of pediculosis capitis (Phthiraptera: Pediculidae) among primary schoolchildren in rural and urban areas in Monastir, Tunisia

29/04 12:00

7a. Parasitic disease epidemiology

Dhekra FARJALLAH

A / 20 / 14

Poster P3029

Abstract 5134

Declining seroprevalence of toxoplasmosis in the female population and changing ethnic distributions in Singapore over the last 2 decades

29/04 12:00

7a. Parasitic disease epidemiology

Cecilia Cheng Lai NGAN

A / 20 / 15

Poster P3030

Abstract 5223

Chagas disease causing heart failure in Central America: burden and trend analysis between 1990 and 2019.

29/04 12:00

7a. Parasitic disease epidemiology

Rafael CORTORREAL JAVIER

A / 20 / 16

Poster P3031

Abstract 5276

First report of seroprevalence and risk factors of human fascioliasis in communities in North Vietnam

29/04 12:00

7a. Parasitic disease epidemiology

Thi Bich Thao NGUYEN

A / 20 / 17

Poster P3032

Abstract 5986

Unusual increase of Cryptosporidium spp. cases in Madrid, Spain

29/04 12:00

7a. Parasitic disease epidemiology

Claudia SANZ-GONZÁLEZ

A / 20 / 18

Poster P3033

Abstract 6014

Visceral leishmaniasis resurgence after COVID-19 pandemic. Data from Regional Surveillance System of the Lazio Region (Italy)

29/04 12:00

7a. Parasitic disease epidemiology

Martina SPAZIANTE

B / 20 / 1

Poster P3034

Abstract 6219

Shifting sands: Exploring the clinical and genomic dynamics of leishmaniasis in Turkey's changing landscape

29/04 12:00

7a. Parasitic disease epidemiology

Varol TUNALI

B / 20 / 2

Poster P3035

Abstract 6363

Sequencing and Phylogenetic Analysis of Enterobius Vermicularis Isolates from Bulgaria - First Genetic Study

29/04 12:00

7a. Parasitic disease epidemiology

Reneta DIMITROVA

B / 20 / 3

Poster P3036

Abstract 6427

Overview of clinical, microbiological and epidemiological characteristics of patients with malaria in Slovenia

29/04 12:00

7a. Parasitic disease epidemiology

Jasna CERNOSA

B / 20 / 4

Poster P3037

Abstract 6972

DNA sequencing of Plasmodium falciparum apical membrane antigen-1 identified genetic sub-structure and novel nsSNPs modulating functional motifs

29/04 12:00

7a. Parasitic disease epidemiology

Sahib GUL

B / 20 / 5

Poster P3038

Abstract 7557

Reactivation of Trypanosoma cruzi infection in immunosuppressed patients: a systematic review and meta-analysis

29/04 12:00

7a. Parasitic disease epidemiology

Alba ANTEQUERA MARTIN

B / 20 / 6

Poster P3039

Abstract 8542

Cystic echinococcosis among adults in Tunisia: a burden of a disease

29/04 12:00

7a. Parasitic disease epidemiology

Sana ROUIS

B / 20 / 7

Poster P3040

Abstract 210

Confirmation of Ancylostoma and Strongyloides nematodes through molecular analysis in human and canine populations of Bangladesh

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Tilak Chandra NATH

B / 20 / 8

Poster P3041

Abstract 242

Congenital malaria in a non-endemic setting: a literature review and update on diagnosis and management

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Charlotte PATTERSON

B / 20 / 9

Poster P3042

Abstract 628

Increased detection of strongyloidiasis in Gipuzkoa, northern Spain, after a change in diagnostics algorithm and introduction of a multiplex PCR

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Inigo ANSA ISASA

B / 20 / 10

Poster P3043

Abstract 1094

Comparative evaluation of microscopy, conventional PCR and real-time PCR for detection of soil-transmitted helminths

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Sumeeta KHURANA

B / 20 / 11

Poster P3044

Abstract 1619

Comparison between a molecular and a standard staining technique to detect Cryptosporidium sp in stool samples: evaluation in an outbreak situtation

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Jordi IGLESIES TORRENT

B / 20 / 12

Poster P3045

Abstract 1681

Evaluation of Lb6H recombinant protein produced in Brazil to diagnose American tegumentary leishmaniasis

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Ruth Tamara VALENCIA PORTILLO

B / 20 / 13

Poster P3046

Abstract 1954

Utilizing a real-time PCR platform to identify Strongyloides stercoralis infection.

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Chao-Chi CHEN

B / 20 / 14

Poster P3047

Abstract 2259

High proportion of sexually transmitted infections in Trichomonas vaginalis positive patients using syndromic PCR: a French monocentric study on 199 patients

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Jean-Pierre GANGNEUX

B / 20 / 15

Poster P3048

Abstract 3028

Comparison of prototype ELISAs for serodiagnosis of visceral leishmaniasis

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Babett MENGE

B / 20 / 16

Poster P3049

Abstract 3343

Diagnostic performance of qPCR for detecting cell-free DNA (cf DNA) in urine and serum of amoebic liver abscess patients before & after treatment

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Priya DATTA

B / 20 / 17

Poster P3050

Abstract 3650

Performance and impact of introducing real-time PCR for detection of Acanthamoeba spp in corneal scrapings

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Stefanie VAN KLEEF VAN KOEVERINGE

B / 20 / 18

Poster P3051

Abstract 4139

Usefulness of real-time PCR for malaria diagnosis and identification of Plasmodium species in febrile patients in Cubal, Angola

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Alejandro MEDIAVILLA PÉREZ

A / 21 / 1

Poster P3052

Abstract 4275

Taenia asiatica: mitochondrial signatures based analysis of an emerging global health threat

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Aman Dev MOUDGIL

A / 21 / 2

Poster P3053

Abstract 4317

A novel syndromic approach for the diagnosis of gastrointestinal parasites

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Maria Sofia MONTANARI

A / 21 / 3

Poster P3054

Abstract 4598

Genetic variation of metabolic enzymes of Leishmania spp. parasites isolated from different clinical types of cutaneous leishmaniasis patients

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Mansoure HOSSEINI

A / 21 / 4

Poster P3055

Abstract 5643

Accuracy of the new immunocromatography black version as a novel sensitive tool for both screening and diagnosis of schistosomiasis among Sub-Saharan immigrants in health care settings in non endemic countries

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Alaa H. A. HEGAZY

A / 21 / 5

Poster P3056

Abstract 5748

Detection of new genotype of Echinococcus multilocularis raising health concerns in Canada

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Kinga KOWALEWSKA-GROCHOWSKA

A / 21 / 6

Poster P3057

Abstract 5923

Evaluation of a western blot associated with a line blot assay for the serodiagnosis of alveolar and cystic echinococcosis

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Sabrina EGREK

A / 21 / 7

Poster P3058

Abstract 6309

Molecular screening of Malaria and other neglected parasitic diseases in the Peruvian Amazon by Multiplex qPCR

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Víctor ANTÓN BERENGUER

A / 21 / 8

Poster P3059

Abstract 6385

Behind the veil: Exploring the hidden dynamics of asymptomatic cutaneous leishmaniasis

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Varol TUNALI

A / 21 / 9

Poster P3060

Abstract 6576

Intestinal protozoa diagnosis in a low prevalence setting: evaluation of the impact of formalin-free fixative and the number of specimens/episode using a commercial single-vial in a referral laboratory

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Lidia GOTERRIS BONET

A / 21 / 10

Poster P3061

Abstract 6633

The emergence of a hypertransmissible Cryptosporidium hominis subtype in Spain

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

María DUCÓNS

A / 21 / 11

Poster P3062

Abstract 7229

Investigation of Leishmania RNA viruses (LRV 1, LRV 2) in L.tropica isolated from CL patients in Sanliurfa, Turkiye where CL is highly endemic

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Fadile YILDIZ ZEYREK

A / 21 / 12

Poster P3063

Abstract 7251

The correlation between procalcitonin levels and the possibility of bacteremia in the setting of malaria infection

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Shahad ABASAEED ELHAG

A / 21 / 13

Poster P3064

Abstract 7356

Heterogeneity primer spacers (staggering) improve the performance of amplicon sequencing of V3-V4 region of 16S rDNA as well as 18S region for Blastocystis subtyping

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Ondrej CINEK

A / 21 / 14

Poster P3065

Abstract 7670

Molecular detection of cell-free DNA in human plasma with cystic echinococcosis as a diagnosis method

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Mahboubeh HADIPOUR

A / 21 / 15

Poster P3066

Abstract 8171

Detection of Treponema pallidum in non-lesional specimens

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Roberto ALONSO

A / 21 / 16

Poster P3067

Abstract 8456

Evaluation of a commercial kit for detection of T. cruzi-specific antibodies

29/04 12:00

7b. Diagnostic parasitology (incl traditional, molecular and other methods)

Aroa SILGADO

A / 21 / 17

Poster P3068

Abstract 1889

Evolving trends of molecular subtyping and macrolide resistance of Treponema pallidum in British Columbia, Canada: a ten years review

29/04 12:00

7c. Antiparasitic susceptibility & drug resistance (incl surveillance, mechasnism)

Muhammad MORSHED

A / 21 / 18

Poster P3069

Abstract 2089

In silico analysis of tryparedoxin peroxidase in Leishmania major

29/04 12:00

7c. Antiparasitic susceptibility & drug resistance (incl surveillance, mechasnism)

Sahel HAMZEHPOUR

B / 21 / 1

Poster P3070

Abstract 8915

Frequencies of molecular markers of plasmodium falciparum antimalarial drug resistance in a context of seasonal malaria chemoprevention (smc) with two different treatment regimens in koulikoro health district, mali

29/04 12:00

7c. Antiparasitic susceptibility & drug resistance (incl surveillance, mechasnism)

Kane FOUSSEYNI

B / 21 / 2

Poster P3071

Abstract 27

Pyocyanin displays amoebicidal activity against Naegleria fowleri, a brain-eating amoeba, through inducing reactive oxygen species accumulation

29/04 12:00

7d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials)

Pichet RUENCHIT

B / 21 / 3

Poster P3072

Abstract 718

Targeting sterol 14α-demethylase (CYP51) in Leishmania major: towards effective broad-spectrum treatment and overcoming drug resistance

29/04 12:00

7d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials)

Chandra Kanta BHUSAL

B / 21 / 4

Poster P3073

Abstract 782

Acanthamoeba castellanii prefers lipids as food, offering new possibilities for treatment

29/04 12:00

7d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials)

Maarten SARINK

B / 21 / 5

Poster P3074

Abstract 2132

Visceral leishmaniasis by L. infantum in immunosupressed patients

29/04 12:00

7d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials)

Juan Victor SAN MARTIN

B / 21 / 6

Poster P3075

Abstract 2160

Analysis of clinical characteristics and results of patients with Plasmodium vivax infection in South Korean military hospital, 2012-2021

29/04 12:00

7d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials)

Hong Sang OH

B / 21 / 7

Poster P3076

Abstract 2365

Novel artemisinin hunt: investigation of the in vivo antimalarial efficacy of Cotinus coggygria

29/04 12:00

7d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials)

Ahmet YILDIRIM

B / 21 / 8

Poster P3077

Abstract 2375

Antileishmanial activity of thymol on Leishmania tropica isolated from Turkey: in vitro and ex vivo study

29/04 12:00

7d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials)

Tülay AKSOY

B / 21 / 9

Poster P3078

Abstract 2672

Efficacy of adjunctive topical liposomal clarithromycin on systemic glucantime in old world cutaneous leishmaniasis: a pilot clinical study

29/04 12:00

7d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials)

Atousa HAKAMIFARD

B / 21 / 10

Poster P3079

Abstract 3367

Longitudinal changes in iron homeostasis in human experimental and clinical malaria

29/04 12:00

7d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials)

Stephen WOOLLEY

B / 21 / 11

Poster P3080

Abstract 3462

Recurrence of pleural echinococcosis: a surgical challenge

29/04 12:00

7d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials)

Raffaella LISSANDRIN

B / 21 / 12

Poster P3081

Abstract 3662

Evaluation of BCG training effects on lesion size and parasite load caused by Leishmania major in BALB/c mice

29/04 12:00

7d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials)

Askarypour ZOHREH

B / 21 / 13

Poster P3082

Abstract 4477

A national multidisciplinary team meeting for leishmaniasis in the United Kingdom: experience at two years

29/04 12:00

7d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials)

Owain DONNELLY

B / 21 / 14

Poster P3083

Abstract 7342

Use of extracellular vesicles of Giardia lamblia as a promising vaccine candidate

29/04 12:00

7d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials)

Bárbara FERREIRA

B / 21 / 15

Poster P3084

Abstract 7951

Tolerance and safety of benznidazol in adults patients with chagas disease: experience in four public medical center of Buenos Aires, Argentina

29/04 12:00

7d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials)

Alvaro OTRERAS

B / 21 / 16

Poster P3085

Abstract 8405

Biodiversity study of endophytes fungi from Alstonia boonei De Wild and assessment of the antiplasmodial effects of their ethyl acetate extracts against Plasmodium falciparum strains

29/04 12:00

7d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials)

Paola Cynthia DEMENI EMOH

B / 21 / 17

Poster P3086

Abstract 8415

Cellular effects of fosfomycin on Wolbachia spp.

29/04 12:00

7d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials)

Lara BEHRMANN

A / 22 / 1

Poster P3088

Abstract 256

Documentation of initial health assessments for people seeking asylum presenting to an infectious disease clinic in a tertiary infectious diseases centre

29/04 12:00

7e. Travel medicine, migrant and refugee health

Ioan Dafydd WARDHAUGH

A / 22 / 2

Poster P3089

Abstract 468

Seroprevalence of Schistosoma and Strongyloides in migrants from sub-Saharan Africa screened in Sweden

29/04 12:00

7e. Travel medicine, migrant and refugee health

Caroline RÖNNBERG

A / 22 / 3

Poster P3090

Abstract 2042

Imported Plasmodium vivax cases among newly arrived migrants in New York City

29/04 12:00

7e. Travel medicine, migrant and refugee health

Maria Alyssa POLICARPIO

A / 22 / 4

Poster P3091

Abstract 2155

Risk factors for Strongyloides stercoralis infection in immigrant populations: case-control study

29/04 12:00

7e. Travel medicine, migrant and refugee health

Azucena RODRIGUEZ-GUARDADO

A / 22 / 5

Poster P3092

Abstract 2207

Burden of infectious diseases in pregnant and postpartum migrant women and newborn babies and barriers to health services: a systematic review in MENA region and qualitative study in Tunisia

29/04 12:00

7e. Travel medicine, migrant and refugee health

Anissa OUAHCHI

A / 22 / 6

Poster P3093

Abstract 2228

Results of a screening programme for schistosomiasis in an immigrant population

29/04 12:00

7e. Travel medicine, migrant and refugee health

Azucena RODRIGUEZ-GUARDADO

A / 22 / 7

Poster P3094

Abstract 2390

Epidemiological characteristics of respiratory illnesses among Thai repatriates from armed conflict areas in Myanmar, November 2023

29/04 12:00

7e. Travel medicine, migrant and refugee health

Bhanasut HUNSAJARUPAN

A / 22 / 8

Poster P3095

Abstract 2945

Improving malaria care in a non-endemic setting with high malaria caseloads but without a specialist infection unit: a targeted approach

29/04 12:00

7e. Travel medicine, migrant and refugee health

Marc WOODMAN

A / 22 / 9

Poster P3096

Abstract 3348

Diagnostic landscape of eosinophilia in immigrants

29/04 12:00

7e. Travel medicine, migrant and refugee health

Laura Noelly NIÑO PUERTO

A / 22 / 10

Poster P3097

Abstract 4000

Imported schistosomiasis in travelers: experience from a referral tropical medicine unit in Barcelona, Spain

29/04 12:00

7e. Travel medicine, migrant and refugee health

Fernando SALVADOR

A / 22 / 11

Poster P3098

Abstract 4836

Asymptomatic malaria infection can affect the lipid profile of patients: cause or consequence?

29/04 12:00

7e. Travel medicine, migrant and refugee health

Diego GAYOSO CANTERO

A / 22 / 12

Poster P3099

Abstract 4884

S. stercoralis infections in a Tropical Medicine Clinic - a 5 year retrospective review

29/04 12:00

7e. Travel medicine, migrant and refugee health

Maria Alyssa POLICARPIO

A / 22 / 13

Poster P3100

Abstract 5831

Sexual and reproductive health of female asylum seekers seen by RESPOND, a UK integrated refugee health screening programme

29/04 12:00

7e. Travel medicine, migrant and refugee health

Rebecca RYAN

A / 22 / 14

Poster P3101

Abstract 5844

Traveller's adherence to atovaquone/proguanil malaria chemoprophylaxis after return from endemic areas

29/04 12:00

7e. Travel medicine, migrant and refugee health

Jenny Lea SCHNYDER

A / 22 / 15

Poster P3102

Abstract 6127

Missed opportunities for Chagas screening in in a UK tertiary-level hospital

29/04 12:00

7e. Travel medicine, migrant and refugee health

Harriet DAVIDSON

A / 22 / 16

Poster P3103

Abstract 6198

Clinical findings in sub-Saharan migrants with asymptomatic Plasmodium infections screened in Sweden

29/04 12:00

7e. Travel medicine, migrant and refugee health

Isabelle ELIASSON

A / 22 / 17

Poster P3104

Abstract 6679

Severe Plasmodium falciparum Malaria: Epidemiological Shifts and Clinical Challenges in the Czech Republic

29/04 12:00

7e. Travel medicine, migrant and refugee health

Vyacheslav GREBENYUK

A / 22 / 18

Poster P3105

Abstract 7394

The malaria mantra mislaid: new insights from a retrospective analysis of malaria cases at a UK south coast centre

29/04 12:00

7e. Travel medicine, migrant and refugee health

Daisy WOOLHAM

A / 22 / 19

Poster P3106

Abstract 7458

Health screening for returning Hajj pilgrims across international airports in Thailand, July 2023

29/04 12:00

7e. Travel medicine, migrant and refugee health

Suttiporn PRAPASO

A / 22 / 20

Poster P3107

Abstract 8124

Views and experiences of catch-up vaccination among adult migrants in the UK: an in-depth interview study

29/04 12:00

7e. Travel medicine, migrant and refugee health

Anna DEAL

A / 22 / 21

Poster P3108

Abstract 8285

Experience from a diagnosis approach algorithm for travelers diarrhoea in a specialised international health unit, Barcelona, Spain

29/04 12:00

7e. Travel medicine, migrant and refugee health

Saul LEVY BLITCHTEIN

A / 22 / 22

Poster P3109

Abstract 8773

A closer look into imported malaria diagnosis delay: medical skills need a push forward

29/04 12:00

7e. Travel medicine, migrant and refugee health

Joaquín SALAS-CORONAS

A / 22 / 23

Poster P3110

Abstract 121

Insecticide susceptibility of the sand fly leishmaniasis vector Phlebotomus argentipes in Bihar, India

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Ashish SHUKLA

A / 22 / 24

Poster P3111

Abstract 1423

Salmonella enterica in farm environments in the Ashanti region of Ghana

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Dennis FOSU

A / 22 / 25

Poster P3112

Abstract 1654

Tick-borne encephalitis seroprevalence in Northern Italy: a cross-sectional study on a randomly selected population

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Silvia NOZZA

A / 22 / 26

Poster P3113

Abstract 1711

Genomic characteristics of carbapenemase-producing non-Enterobacterale Gram-negative isolates from wastewater in Japan

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Hiroaki BABA

A / 22 / 27

Poster P3114

Abstract 2894

Assessment of antimicrobial resistance in Gram-negative bacteria from rivers supplying drinking water: insights for water quality management

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Patricia ANTUNES

A / 22 / 28

Poster P3115

Abstract 3635

Persistence of viable but nonculturable Legionella pneumophila state in hospital water systems

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Laura GAVALDÀ-MESTRE

B / 22 / 1

Poster P3116

Abstract 3759

Nationwide surveillance, antibiogram, and genotypic characteristic of pathogenic Escherichia coli isolated from pork production chain in Korea

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Hyeonwoo CHO

B / 22 / 3

Poster P3118

Abstract 4669

Vulnerability to infectious diseases among people exposed to climate disasters in Mozambique: a cross-sectional study

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Elda DE VITA

B / 22 / 4

Poster P3119

Abstract 5461

Epidemiological study on prevalence of Toxoplasma gondii from pigs, cats, water, soil and vegetables in North India: One health integrative research

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Divya RATTAN

B / 22 / 5

Poster P3120

Abstract 6160

Predicting the age of field Anopheles mosquitoes using mass spectrometry and deep learning

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Pauline NAUDION

B / 22 / 6

Poster P3121

Abstract 6452

Antimicrobial resistant enterococci in semi-intensive and free-range broiler farms in Uganda

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Linnet ATIENO OCHIENG

B / 22 / 7

Poster P3122

Abstract 6674

Application of Culturomics and Whole Genome Sequencing for the detection of antibiotic resistance genes in novel bacteria isolated from Wastewater Treatment sites.

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Eleni OURANOU

B / 22 / 8

Poster P3123

Abstract 6794

Occurrence and persistence of multi-drug resistant Enterobacterales isolated from urban, industrial and surface water in Monastir, Tunisia

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Wejdene MANSOUR

B / 22 / 9

Poster P3124

Abstract 6830

Carbapenem-resistant P. aeruginosa from environmental origin: spread of GES-5 producing ST235 strains.

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Klibi NAOUEL

B / 22 / 10

Poster P3125

Abstract 6831

Detection of Salmonella in stream environment and its association with clinical strains

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Jeong Hwan SHIN

B / 22 / 11

Poster P3126

Abstract 6872

Therapeutic alternative to the use of antibiotics in chicken farming: about detection of ESBL Escherichia coli?

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Wejdene MANSOUR

B / 22 / 12

Poster P3127

Abstract 6937

Ticks on French Riviera (France): Diversity, seasonality and associated bacteria

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Christelle POMARES

B / 22 / 13

Poster P3128

Abstract 7282

Resistant-Enterococcus species in wild boar (Sus scrofa) from Portugal

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Josman PALMEIRA

B / 22 / 14

Poster P3129

Abstract 8210

Seeking the molecular identity of blood meals in mosquitoes of medical importance, collected within a five-year period (2017-2022) in urban and rural areas of Greece

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Nikolaos TEGOS

B / 22 / 15

Poster P3130

Abstract 8239

Metagenomic approach to aquatic matrices in the South American metropolitan region: pathways for maintenance and dissemination of antimicrobial resistance genes (ARGs)

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Fernanda FERNANDES SANTOS

B / 22 / 16

Poster P3131

Abstract 8565

BIM-1 (Belém-Imipenemase) in multidrug-resistant Pseudomonas spp in rivers and hospital sewage in the Brazilian Amazon

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Marcia NAZARE MIRANDA BAHIA

B / 22 / 17

Poster P3132

Abstract 8699

Residual Bacillus cereus contamination of processed laundry supplied to health and social care providers: more questions than answers

29/04 12:00

7f. Food & water safety, environmental health, vector epidemiology

Christopher JONES

B / 22 / 18

Poster P3133

Abstract 550

Assessing pandemic risks: expert ranking of infectious diseases in WHO's blueprint for action to prevent epidemics

29/04 12:00

7g. Global and public health &health security (incl policy-making, climate change, biosafety/biosecurity)

Jon SALMANTON-GARCIA

B / 22 / 19

Poster P3134

Abstract 932

Increase of Legionella positive environmental sources and its correlation with climate change

29/04 12:00

7g. Global and public health &health security (incl policy-making, climate change, biosafety/biosecurity)

Elisenda ARQUÉ PÉREZ

B / 22 / 20

Poster P3135

Abstract 3414

Lessons to be learned: challenges and solutions to implementation of clinical research responses to high priority diseases of epidemic/pandemic potential: a scoping review

29/04 12:00

7g. Global and public health &health security (incl policy-making, climate change, biosafety/biosecurity)

Shanthi LEVANITA

B / 22 / 21

Poster P3136

Abstract 5193

Knowledge about sexually transmitted infections according to the biopsychosocial characteristics of Brazilian undergraduates

29/04 12:00

7g. Global and public health &health security (incl policy-making, climate change, biosafety/biosecurity)

Felipe Santos De CARVALHO

B / 22 / 22

Poster P3137

Abstract 5949

A rapid evaluation of the New Variant Assessment Platform: promoting programme sustainability

29/04 12:00

7g. Global and public health &health security (incl policy-making, climate change, biosafety/biosecurity)

Koren JONES

B / 22 / 23

Poster P3138

Abstract 6355

Modelling the interplay between patients' socioeconomic characteristics, health insurance, contextual factors and antibiotic misuse behaviour in Tanzania: a Bayesian Belief Network approach

29/04 12:00

7g. Global and public health &health security (incl policy-making, climate change, biosafety/biosecurity)

Madeleine CLARKSON

B / 22 / 24

Poster P3139

Abstract 6537

Charting the landscape: understanding the full scope of the burden of bacterial antimicrobial resistance in the WHO Eastern Mediterranean Region

29/04 12:00

7g. Global and public health &health security (incl policy-making, climate change, biosafety/biosecurity)

Tomislav MESTROVIC

B / 22 / 25

Poster P3140

Abstract 6903

A cutaneous anthrax outbreak in the rural region of Kars, Turkey

29/04 12:00

7g. Global and public health &health security (incl policy-making, climate change, biosafety/biosecurity)

Hazal ERDEM

B / 22 / 26

Poster P3141

Abstract 7756

Climate change negatively impacts AMR

29/04 12:00

7g. Global and public health &health security (incl policy-making, climate change, biosafety/biosecurity)

Srishti GOEL

B / 22 / 27

Poster P3142

Abstract 7931

The Italian registry of fever of unknown origin

29/04 12:00

7g. Global and public health &health security (incl policy-making, climate change, biosafety/biosecurity)

Verena ZERBATO

B / 22 / 28

Poster P3143

Abstract 611

Factors that affect the timely diagnosis and treatment of neutropenic fever in Ugandan patients with cancer and HIV: A process mapping study

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Elizabeth GULLEEN

A / 23 / 1

Poster P3144

Abstract 647

Expansion of cytotoxic immune cells in the lesion border skin of PKDL and Leprosy

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Shashi KUMAR

A / 23 / 2

Poster P3145

Abstract 960

The experience of genital ulcer disease, barriers to treatment and acceptability of sexually transmitted infection diagnostics in Harare, Zimbabwe

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Catrin THOMAS

A / 23 / 4

Poster P3147

Abstract 1820

Findings of a low-cost nurse-led mental health screening approach: underdiagnosis and undertreatment of mental health disorders among people living with HIV in Rwanda

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Laura OMANN

A / 23 / 5

Poster P3148

Abstract 2071

High rates of ciproflaxicin and doxycline resistance in Neisseria gonorrhoeae infection in Lesotho

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Liteboho MADUNA

A / 23 / 6

Poster P3149

Abstract 2404

The burden and clinical outcomes for neglected tropical diseases in migrant populations in the Middle East and North Africa: a systematic review

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Eman ELAFEF

A / 23 / 7

Poster P3150

Abstract 2707

Assessment on the rational use of antimalaria drugs in health facilities of Ethiopia: cross sectional study

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Natnael Solomon HASSEN

A / 23 / 8

Poster P3151

Abstract 3718

Systemic engineering initiative for patient safety model helped categorize barriers and facilitators for surgical site infection prevention at King Faisal Hospital Rwanda

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Buddhi HATHARALIYADDA

A / 23 / 9

Poster P3152

Abstract 3819

Human African trypanosomiasis: preliminary retrospective analysis of cases treated in Lui Hospital, Western Equatoria, South Sudan

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Francesca MARIOTTI

A / 23 / 10

Poster P3153

Abstract 4075

Anal self-sampling is suitable for anal cancer screening among men who have sex with men in Togo

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Valentine Marie FERRÉ

A / 23 / 11

Poster P3154

Abstract 4738

Infectious disease profile in the Embera Dóbida, indigenous tribe of Colombian Pacific Coast: descriptive cross-sectional study

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Santiago RAMIREZ

A / 23 / 12

Poster P3155

Abstract 4850

Impact of diabetes and metabolic syndrome on malaria severity in two hospital settings in Cameroon

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Katja WYSS

A / 23 / 13

Poster P3156

Abstract 5559

High prevalence of antimicrobial resistance in bacterial isolates from clinical specimens in Timor-Leste

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Tessa OAKLEY

A / 23 / 14

Poster P3157

Abstract 5571

Serotype distribution of invasive pneumococcal disease in Vietnam in the pre-vaccination era: a retrospective study 2011-2023

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Thomas KESTEMAN

A / 23 / 15

Poster P3158

Abstract 7164

Malaria in the indigenous peoples of the Colombian Pacific coast: ancestral knowledge and practices

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Maria Jose GARCIA TIRADO

A / 23 / 16

Poster P3159

Abstract 7257

Achieving threshold coverage in mass drug administration campaigns; mixed methods approach Bijagos Archipelago, Guinea-Bissau

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Ellen SUGRUE

A / 23 / 17

Poster P3160

Abstract 7304

Carrier Mediated Delivery of Amphotericin-B Through Mannosylated Liposomes for Effective Management of Leishmaniasis

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Mani BHARGAVA

A / 23 / 18

Poster P3161

Abstract 7485

Chagas disease: treatments with nifurtimox and benznidazole in indigenous communities in Colombia

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Simone KANN

A / 23 / 19

Poster P3162

Abstract 7825

Developing a clinical prediction model to modify empirical antibiotics for non-typhoidal Salmonella bloodstream infection in children under-five in DR Congo

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Bieke TACK

A / 23 / 20

Poster P3163

Abstract 7847

World Health Organization's clinical criteria orienting hospital referral and diagnosis of serious bacterial infections in children under-five perform poorly

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Bieke TACK

A / 23 / 21

Poster P3164

Abstract 8580

A multi-component pragmatic intervention to improve diagnosis and early hospital management of patients with suspected acute brain infections in Brazil, India and Malawi: the Brain Infections Global Intervention Study

29/04 12:00

7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations)

Bhagteshwar SINGH

A / 21 / 1

Poster LB001

Abstract 9660

Immune response to MPXV wanes rapidly after intradermal vaccination with MVA-BN (Jynneos)

30/04 12:00

21. New drugs and vaccines

Klara SONDÉN

A / 21 / 2

Poster LB002

Abstract 9625

In vitro activity of two aztreonam-based combinations, aztreonam/avibactam and aztreonam/nacubactam against molecularly characterised carbapenemase expressing Enterobacterales collected in India

30/04 12:00

21. New drugs and vaccines

Yamuna Devi BAKTHAVATCHALAM

A / 21 / 3

Poster LB003

Abstract 9614

SLAMF1 weaken colonization resistance of gut microbiome against carbapenem-resistant Klebsiella pneumoniae

30/04 12:00

21. New drugs and vaccines

Tian GUO-BAO

A / 21 / 4

Poster LB004

Abstract 9317

Toll-like receptor ligand as a potent adjuvant for extracellular vesicle-based vaccines

30/04 12:00

21. New drugs and vaccines

Young Rong KIM

A / 21 / 5

Poster LB005

Abstract 9596

Targeted-Antibacterial-Plasmid (TAPs) delivered by RP4 conjugation system specifically kill E.coli ST131 resistant strains carrying blaCTX-M-15 in vitro

30/04 12:00

21. New drugs and vaccines

Elisabeth DEROLLEZ

A / 21 / 6

Poster LB006

Abstract 9580

Flavone acetic acid can inhibit SARSCoV2 variants and mimicry of human respiratory pacemaker proteins

30/04 12:00

21. New drugs and vaccines

Manish KUMAR

A / 21 / 7

Poster LB007

Abstract 9517

A novel compound library screen identifies antibiotics that can be combined with LpxC inhibitors for treatment of Acinetobacter baumannii

30/04 12:00

21. New drugs and vaccines

Beatriz CANO CASTAÑO

A / 21 / 8

Poster LB008

Abstract 9450

A cocktail of two heavy chain-only antibodies targeting three epitopes spread across the spike protein S1 and S2 subunits that neutralises all SARS-CoV-2 variants tested so far with exceptional potency

30/04 12:00

21. New drugs and vaccines

Viki BOCKSTAL

A / 21 / 10

Poster LB010

Abstract 9539

High specificity of bacteriophages and cocktails against methicillin sensitive and resistant S. aureus (MSSA-MRSA) belonging to clonal complex 8 (CC8)

30/04 12:00

21. New drugs and vaccines

Lorena SALAZAR OSPINA

A / 21 / 11

Poster LB011

Abstract 9519

An in vitro approach for anti-microbial peptide library screening on a high-throughput droplet-based microfluidic platform

30/04 12:00

21. New drugs and vaccines

Eunhee CHO

A / 21 / 12

Poster LB012

Abstract 9473

Drug repurposing for treatment of Prototheca infections

30/04 12:00

21. New drugs and vaccines

Amir ALIRAMEZANI

A / 21 / 13

Poster LB013

Abstract 9123

Serotype coverage of invasive pneumococcal disease with V116 and other vaccines among adults in Canada

30/04 12:00

21. New drugs and vaccines

Marie Claude MEILLEUR

A / 21 / 14

Poster LB014

Abstract 9380

Triple synergistic action of a novel small molecule adjuvant with gentamicin and daptomycin against MRSA persisters

30/04 12:00

21. New drugs and vaccines

Wooseong KIM

A / 21 / 15

Poster LB015

Abstract 9337

Preclinical efficacy and safety of AIC468: a first-in class antiviral antisense oligonucleotide for the treatment of BKV infection in kidney transplant recipients

30/04 12:00

21. New drugs and vaccines

Peter LISCHKA

A / 21 / 16

Poster LB016

Abstract 9331

Preclinical development and proteomic and immunogenic analysis of a cytomegalovirus vaccine based on dense bodies produced by epithelial cells

30/04 12:00

21. New drugs and vaccines

Clara MARTÍN MARTÍN

A / 21 / 17

Poster LB017

Abstract 9329

Characterisation of immune response to recombinant varicella-zoster vaccine in people with multiple sclerosis under disease-modifying therapies

30/04 12:00

21. New drugs and vaccines

Federica DOMINELLI

A / 21 / 18

Poster LB018

Abstract 9316

Inhibition of the outer membrane protein OprF: a novel target to counteract carbapenem resistance in Pseudomonas aeruginosa

30/04 12:00

21. New drugs and vaccines

Nicolas HELSENS

B / 21 / 1

Poster LB019

Abstract 9278

Novel antibiotics: the promise of small molecule iron-inhibitors against multidrug-resistant Gram-negative superbugs

30/04 12:00

21. New drugs and vaccines

Emmanuel Chima EZE

B / 21 / 2

Poster LB020

Abstract 9226

Unveiling the mechanism of action and resistance of novel quaternary phosphonium compound effective against highly drug-resistant Pseudomonas aeruginosa isolates

30/04 12:00

21. New drugs and vaccines

German VARGAS-CUEBAS

B / 21 / 3

Poster LB021

Abstract 9249

Superior immunogenicity of self-amplifying mRNA vs standard mRNA COVID-19 vaccine

30/04 12:00

21. New drugs and vaccines

Yukihiro YAGI

B / 21 / 4

Poster LB022

Abstract 9015

COSAN boosts colistin's bactericidal power against Gram-negative nosocomial pathogens

30/04 12:00

21. New drugs and vaccines

Andromeda Celeste GOMEZ CAMACHO

B / 21 / 5

Poster LB023

Abstract 9666

B cell depletion therapy in people with multiple sclerosis impacts on antibody response to COVID-19 mRNA vaccines

30/04 12:00

22. Clinical trials

Marianne SHAWE-TAYLOR

B / 21 / 6

Poster LB024

Abstract 9612

Exploring the efficacy of plasma exchange therapy in post-COVID-19 condition: a pilot randomised double-blind trial

30/04 12:00

22. Clinical trials

Sergio ESPAÑA-CUETO

B / 21 / 7

Poster LB026

Abstract 9323

Pharmacokinetics and safety of the SARS-CoV-2 monoclonal antibody AZD3152 are consistent with those of tixagevimab/cilgavimab

30/04 12:00

22. Clinical trials

Taylor S. COHEN

B / 21 / 8

Poster LB027

Abstract 9303

Tocilizumab in COVID-19 with significant hypoxia and inflammation does not improve clinical outcomes

30/04 12:00

22. Clinical trials

Eoin FEENEY

B / 21 / 9

Poster LB028

Abstract 9649

Impact of ceftriaxone+ sulbactam+ EDTA combination in treatment of metallo beta-lactamase producing Enterobacterales causing complicated urinary tract infections: an open label randomised controlled trial

30/04 12:00

22. Clinical trials

Subhashree SAMANTARAY

B / 21 / 10

Poster LB029

Abstract 9645

Divergent performance of bivalent BA.5 and monovalent XBB.1.5 COVID-19 vaccines given as annual booster

30/04 12:00

22. Clinical trials

Marianne SHAWE-TAYLOR

B / 21 / 11

Poster LB030

Abstract 9428

Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea: results of a randomised, multicentre Phase 3 trial (EAGLE-1)

30/04 12:00

22. Clinical trials

Jonathan ROSS

B / 21 / 12

Poster LB031

Abstract 9245

Early treatment with pyronaridine-artesunate reduced time to sustained symptom resolution in patients with mild-to-moderate COVID-19 not requiring supplemental oxygen

30/04 12:00

22. Clinical trials

Joon Young SONG

B / 21 / 13

Poster LB032

Abstract 9500

Oral sulopenem/probenecid for uncomplicated urinary tract infections (uUTI): results from the REASSURE trial

30/04 12:00

22. Clinical trials

Kalpana GUPTA

B / 21 / 14

Poster LB033

Abstract 9569

Repurposing Clofazimine as a part of first line anti-TB regimen in order to shorten the overall duration of treatment in patients with drug susceptible pulmonary TB - CORTAIL Study

30/04 12:00

22. Clinical trials

Nusrat SHAFIQ

B / 21 / 15

Poster LB034

Abstract 9513

A nationwide randomised trial to confirm effectiveness of electronically delivered nudges in increasing influenza vaccination uptake among older adults: the NUDGE-FLU-2 trial

30/04 12:00

22. Clinical trials

Niklas Dyrby JOHANSEN

B / 21 / 16

Poster LB035

Abstract 9521

Electronic nudges to increase influenza vaccination uptake: a prespecified participant-level pooled analysis of NUDGE-FLU, NUDGE-FLU-2, and NUDGE-FLU-CHRONIC

30/04 12:00

22. Clinical trials

Niklas Dyrby JOHANSEN

B / 21 / 17

Poster LB036

Abstract 9220

Open-label study to evaluate the safety and immunogenicity of an XBB.1.5 (Omicron subvariant) CoV-2 rS vaccine booster in previously mRNA COVID-19 vaccinated participants

30/04 12:00

22. Clinical trials

Vivek SHINDE

B / 21 / 18

Poster LB037

Abstract 9431

Cytomegalovirus (CMV) immunoguided prevention clinical trial in CMV-seropositive lung transplant recipients

30/04 12:00

22. Clinical trials

Elisa RUIZ ARABÍ

A / 22 / 1

Poster LB038

Abstract 9439

Effectiveness of one dose of MVA-BN vaccine against mpox: a multicountry target trial emulation study

30/04 12:00

22. Clinical trials

Clara SUÑER

A / 22 / 2

Poster LB039

Abstract 9426

A novel human co-infection model of Streptococcus pneumoniae and respiratory syncytial virus: initial safety results of the RESPECCT study

30/04 12:00

22. Clinical trials

Sanjita BRITO MUTUNAYAGAM

A / 22 / 3

Poster LB040

Abstract 9423

Mid-season 2023-2024 influenza vaccine effectiveness in children and elderly: a register-based cohort analysis, Finland

30/04 12:00

22. Clinical trials

Hanna M. NOHYNEK

A / 22 / 4

Poster LB041

Abstract 9410

Short-course aminoglycosides as adjunctive treatment in adults with sepsis: a cluster randomised trial

30/04 12:00

22. Clinical trials

Eva KOEKENBIER

A / 22 / 5

Poster LB042

Abstract 9379

Intravenous brincidofovir rapidly clears adenoviremia in immunocompromised patients: interim results from Phase 2a ATHENA study

30/04 12:00

22. Clinical trials

Genovefa PAPANICOLAOU

A / 22 / 6

Poster LB043

Abstract 9194

Clinical impact of laboratory stewardship intervention for plasma metagenomic next-generation sequencing infectious disease testing in a multi-centre paediatric hospital system

30/04 12:00

22. Clinical trials

Denver NILES

A / 22 / 7

Poster LB044

Abstract 9269

Self-replicating RNA vaccine: significantly improved de novo immune protection, safety against rabies in healthy volunteers

30/04 12:00

22. Clinical trials

Zelanna GOLDBERG

A / 22 / 8

Poster LB045

Abstract 9236

Effect of a community-based behavioural intervention bundle to improve antibiotic use, quality of primary care, and household infection prevention/control in rural Burkina Faso and DR Congo: preliminary analysis of a cluster controlled trial

30/04 12:00

22. Clinical trials

Brecht INGELBEEN

A / 22 / 9

Poster LB046

Abstract 9121

Immunogenicity and reactogenicity of fractional vs full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, Phase 4 clinical trial in Brazil

30/04 12:00

22. Clinical trials

Julio CRODA

A / 22 / 10

Poster LB047

Abstract 9105

Continuation vs temporary interruption of immunomodulatory agents during infections: preliminary results of a randomised controlled trial in patients with inflammatory rheumatic diseases

30/04 12:00

22. Clinical trials

Merel Antoinette Aloisius OPDAM

A / 22 / 11

Poster LB048

Abstract 9183

ADVANCED trial: a clinical trial on dried blood spot samples and venepuncture plasma samples for monitoring vancomycin and creatinine simultaneously in trauma and orthopedic adult patients

30/04 12:00

22. Clinical trials

Moska HASSANZAI

A / 22 / 12

Poster LB049

Abstract 9029

Olgotrelvir as a standalone treatment for non-hospitalised COVID-19 patients: a Phase 3, double-blind, randomised, placebo-controlled trial

30/04 12:00

22. Clinical trials

Xiao XU

A / 22 / 13

Poster LB050

Abstract 9154

Adjuvanted recombinant zoster vaccine (RZV) is the first vaccine to provide durable protection against herpes zoster (HZ) in all age ranges ≥50 years: final analysis of efficacy and safety after 11 years (Y) of follow-up

30/04 12:00

22. Clinical trials

Ana STREZOVA

A / 22 / 14

Poster LB051

Abstract 9076

Boosted antibody responses after sequential vaccination with PCV13 and PPSV23 in patients with moderate to severe plaque psoriasis under immunosuppressive therapy: a prospective trail

30/04 12:00

22. Clinical trials

Lukas VAN DE SAND

A / 22 / 15

Poster LB052

Abstract 9072

Prolonged awake prone positioning vs usual care for non-intubated patients with COVID-19-related acute respiratory failure: a multicentre, randomised controlled trial

30/04 12:00

22. Clinical trials

Ling LIU

A / 22 / 16

Poster LB053

Abstract 9055

Modelling the impact of the Autumn 2022 and Spring 2023 COVID-19 booster vaccine campaigns in the UK

30/04 12:00

22. Clinical trials

Cale HARRISON

A / 22 / 17

Poster LB054

Abstract 9034

Ivermectin therapy for young children aged <5 years with scabies infection

30/04 12:00

22. Clinical trials

Amanda GWEE

A / 22 / 18

Poster LB055

Abstract 9027

IgG subclass switch in volunteers repeatedly immunised with the full-length Plasmodium falciparum merozoite surface protein 1 (MSP1)

30/04 12:00

22. Clinical trials

Veronika RATHAY

A / 22 / 19

Poster LB056

Abstract 9440

Identification of two new species of the family Silvanigrellaceae and study of virulence characteristics of clinical isolates

30/04 12:00

23. New and emerging pathogens

Peijuan TANG

A / 22 / 20

Poster LB057

Abstract 9694

Genomic characterisation of a blaOXA-244-producing Escherichia coli ST648 outbreak in Irish hospitals 2023-2024

30/04 12:00

24. Outbreaks and public health emergencies

Liam BURKE

A / 22 / 21

Poster LB058

Abstract 9689

Contribution of laboratories during a measles epidemic among vaccinated adolescents

30/04 12:00

24. Outbreaks and public health emergencies

Julia DINA

A / 22 / 22

Poster LB059

Abstract 9673

The prevalence of antimicrobial resistance among the wounded in Ukraine makes it impossible to prescribe effective empiric antibiotic therapy

30/04 12:00

24. Outbreaks and public health emergencies

Mariia PANASIUK

A / 22 / 23

Poster LB060

Abstract 9657

Ongoing low-intensity outbreak of hepatitis A virus among men who have sex with men in Italy with molecular links to sub-genotype 1B epidemic strain in 2022 in Hungary

30/04 12:00

24. Outbreaks and public health emergencies

Sara CAUCCI

A / 22 / 24

Poster LB061

Abstract 9532

Emergence of a Klebsiella pneumoniae ST307 clone carrying an IncFBI plasmid with blaCTX-M-15 and blaOXA-1: a One Health concern

30/04 12:00

24. Outbreaks and public health emergencies

Ana GALES

A / 22 / 25

Poster LB062

Abstract 9139

Protective effect of influenza vaccination among children in Hong Kong, 2022-23 season

30/04 12:00

24. Outbreaks and public health emergencies

Chun Wai Jerome LEUNG

A / 22 / 26

Poster LB063

Abstract 9529

Genomic surveillance of an outbreak of Legionella pneumophila in Galicia, 2023

30/04 12:00

24. Outbreaks and public health emergencies

Sonia PEREZ-CASTRO

A / 22 / 27

Poster LB064

Abstract 9639

First Austrian mpox breakthrough infection after full vaccination course

30/04 12:00

24. Outbreaks and public health emergencies

Julia PONGRACZ

A / 22 / 28

Poster LB065

Abstract 9621

Wastewater surveillance detects echovirus 11 lineage 1 introduction in Sicily

30/04 12:00

24. Outbreaks and public health emergencies

Chiara FILIZZOLO

B / 22 / 1

Poster LB066

Abstract 9405

Clonal dissemination of methicillin-resistant Staphylococcus saprophyticus and Staphylococcus haemolyticus among different sheep farms: an emerging threat to animal and public health

30/04 12:00

24. Outbreaks and public health emergencies

Chahrazed BELHOUT

B / 22 / 2

Poster LB067

Abstract 9590

Measles strikes back: up-to-the-minute updates from surveillance activities

30/04 12:00

24. Outbreaks and public health emergencies

Silvia BIANCHI

B / 22 / 3

Poster LB068

Abstract 9567

Multi-country outbreak of multi-drug resistant Campylobacter coli ST-10042 strain (2018-2023)

30/04 12:00

24. Outbreaks and public health emergencies

Mónica OLEASTRO

B / 22 / 4

Poster LB069

Abstract 9566

First genomic description of pig-to-pig transmission of an emerging and extensively drug-resistant Staphylococcus borealis in Spain

30/04 12:00

24. Outbreaks and public health emergencies

Idris Nasir ABDULLAHI

B / 22 / 5

Poster LB070

Abstract 9552

Indirect interhuman transmission of Mycobacterium abscessus subsp. massiliense among non-cystic fibrosis patients at a pediatric hospital in Japan

30/04 12:00

24. Outbreaks and public health emergencies

Shiomi YOSHIDA

B / 22 / 6

Poster LB071

Abstract 9436

Pertussis epidemic in 2023-2024, region of Vallès (Catalonia, Spain)

30/04 12:00

24. Outbreaks and public health emergencies

Eva BORRÀS LOPEZ

B / 22 / 7

Poster LB072

Abstract 9546

Feasibility of point-of-care multiplex RT-PCR testing at airport for acute respiratory tract infection among Thai repatriate workers from Israel, Thailand, October – December 2023

30/04 12:00

24. Outbreaks and public health emergencies

Anongnat MANOPIROM

B / 22 / 8

Poster LB073

Abstract 9482

Epidemiological aspects of current measles outbreak in Romania

30/04 12:00

24. Outbreaks and public health emergencies

David MANGALOIU

B / 22 / 9

Poster LB074

Abstract 9395

Point of entry screening for cutaneous leishmaniasis among Thai repatriate workers from Israel, Thailand, October – December 2023

30/04 12:00

24. Outbreaks and public health emergencies

Ladda WONGKAEW

B / 22 / 10

Poster LB075

Abstract 9392

Tracking two-way human-mink transmission during an outbreak of severe acute respiratory syndrome coronavirus 2 on a farm in Bulgaria

30/04 12:00

24. Outbreaks and public health emergencies

Ivelina TRIFONOVA

B / 22 / 11

Poster LB076

Abstract 9357

Aircraft lavatory wastewater surveillance for SARS-CoV-2 and other coronaviruses by using family-wide PCR, Thailand, October – November 2023

30/04 12:00

24. Outbreaks and public health emergencies

Rome BUATHONG

B / 22 / 12

Poster LB077

Abstract 9075

A large outbreak of acute hemorrhagic conjunctivitis in Hainan, China in 2023

30/04 12:00

24. Outbreaks and public health emergencies

Dongmei YAN

B / 22 / 13

Poster LB078

Abstract 9020

Development of a small animal model for aerosolised Ebola virus

30/04 12:00

24. Outbreaks and public health emergencies

Aysegul NALCA

A / 1 / 1

Poster P3165

Abstract 700

Antibiotic lock therapy versus catheter removal: evaluating the optimal approach for management of central vascular catheter infection

30/04 12:00

8a. Intravascular catheter-related infections (incl epidemiology, prevention)

Nischal RANGANATH

A / 1 / 2

Poster P3166

Abstract 2149

The impact of early infectious disease consultation for central line associated bloodstream infection: a retrospective cohort study

30/04 12:00

8a. Intravascular catheter-related infections (incl epidemiology, prevention)

Jeong-Han KIM

A / 1 / 3

Poster P3167

Abstract 2385

Touch the zero in central line-associated bloodstream infection in the medical intensive care unit at Rambam medical campus, Israel

30/04 12:00

8a. Intravascular catheter-related infections (incl epidemiology, prevention)

Jalal TARABEIA

A / 1 / 4

Poster P3168

Abstract 2971

Tackling rising numbers of hospital acquired Staphylococcus aureus blood stream infections (HASABSI): failures in peripheral venous access device (PVAD) care in Tallaght University Hospital (TUH)

30/04 12:00

8a. Intravascular catheter-related infections (incl epidemiology, prevention)

Zachary RAMSAMAROO

A / 1 / 5

Poster P3169

Abstract 3154

Hospital outcomes of hemodialysis patients with central line associated bloodstream infection admitted in a tertiary government hospital

30/04 12:00

8a. Intravascular catheter-related infections (incl epidemiology, prevention)

Edson FUENTES

A / 1 / 6

Poster P3170

Abstract 3598

The risk of bloodstream infections in patients with central venous access port in non-ICUs in Germany

30/04 12:00

8a. Intravascular catheter-related infections (incl epidemiology, prevention)

Beate WEIKERT

A / 1 / 7

Poster P3171

Abstract 4824

Central venous catheter fungal infection: incidence and predictive factors

30/04 12:00

8a. Intravascular catheter-related infections (incl epidemiology, prevention)

Aida ZAGHDOUDI

A / 1 / 8

Poster P3172

Abstract 4999

Utility of tip cultures in the diagnosis of catheter-related bloodstream infections

30/04 12:00

8a. Intravascular catheter-related infections (incl epidemiology, prevention)

Vaisak NAIR

A / 1 / 9

Poster P3173

Abstract 6312

Impact of the COVID-19 pandemic on incidence and epidemiology of catheter-related bloodstream infection two years later

30/04 12:00

8a. Intravascular catheter-related infections (incl epidemiology, prevention)

Maria Jesus PEREZ-GRANDA

A / 1 / 10

Poster P3174

Abstract 6426

Impact of sterile gloving during proximal manipulation of a central venous catheter: the multicentre study CleanHandPROX

30/04 12:00

8a. Intravascular catheter-related infections (incl epidemiology, prevention)

Anne-Sophie VALENTIN

A / 1 / 11

Poster P3175

Abstract 6637

Central line-associated bloodstream infection incidence in Belgium's general hospitals: comparison between before and after the start of the COVID-19 pandemic (2013-2019 vs 2020-2022)

30/04 12:00

8a. Intravascular catheter-related infections (incl epidemiology, prevention)

Nathalie SHODU

A / 1 / 12

Poster P3176

Abstract 7209

The potential role of Presepsin(sCD14) in device-associated ventriculitis/meningitis

30/04 12:00

8a. Intravascular catheter-related infections (incl epidemiology, prevention)

Veena Kumari HARADARA BAHUBALI

A / 1 / 13

Poster P3177

Abstract 8778

The impact of a newly established intravenous care team on peripheral venous catheter bloodstream infections in an acute hospital in Ireland

30/04 12:00

8a. Intravascular catheter-related infections (incl epidemiology, prevention)

Margaret CARROLL

A / 1 / 14

Poster P3178

Abstract 442

Worrying rates of MDR organisms causing PJI; A retrospective study from India

30/04 12:00

8b. Other foreign-body and implant-associated infections (incl PJI)

Souradeep CHOWDHURY

A / 1 / 15

Poster P3179

Abstract 621

Fungal periprosthetic joint infection: uncommon but complex condition

30/04 12:00

8b. Other foreign-body and implant-associated infections (incl PJI)

Helmi ERNANDES

A / 1 / 16

Poster P3180

Abstract 1133

Dalbavancin as suppressive treatment in a tertiary hospital

30/04 12:00

8b. Other foreign-body and implant-associated infections (incl PJI)

Loeches Yague MARÍA BELEN

A / 1 / 17

Poster P3181

Abstract 1279

Highly tunable release of antimicrobial peptide SAAP-148 to prevent implant-associated-infections using drop-on-demand printing technology

30/04 12:00

8b. Other foreign-body and implant-associated infections (incl PJI)

Clara GUARCH PÉREZ

A / 1 / 18

Poster P3182

Abstract 1795

Quantification of sonicated implants from patients with osteoarticular implant infections

30/04 12:00

8b. Other foreign-body and implant-associated infections (incl PJI)

Llanos SALAR VIDAL

A / 1 / 19

Poster P3183

Abstract 2133

Bioinspired antibacterial nanostructured surfaces based on oriented calcium phosphate nanocrystals arrays against carbapenems-resistant P.aeruginosa and methicillin-resistant S.aureus

30/04 12:00

8b. Other foreign-body and implant-associated infections (incl PJI)

Damiano SQUITIERI

A / 1 / 20

Poster P3184

Abstract 2250

Sonication fluid culture shows little benefit compared with optimised periprosthetic tissue sample culture for diagnosis of periprosthetic hip infections

30/04 12:00

8b. Other foreign-body and implant-associated infections (incl PJI)

Reinhard HOFFMANN

A / 1 / 21

Poster P3185

Abstract 2360

Real-world experience of cefiderocol in bone and joint infections from the PROVE (retrospective cefiderocol chart review) study

30/04 12:00

8b. Other foreign-body and implant-associated infections (incl PJI)

Anne SANTERRE HENRIKSEN

A / 1 / 22

Poster P3186

Abstract 3099

Suppressive antimicrobial therapy for prosthetic joint infection

30/04 12:00

8b. Other foreign-body and implant-associated infections (incl PJI)

Craig ABOLTINS

A / 1 / 23

Poster P3187

Abstract 3539

Using the WHO multimodal strategy in an improvement project to minimize surgical site infections in total knee and hip prosthesis

30/04 12:00

8b. Other foreign-body and implant-associated infections (incl PJI)

Ellen VAN GEERTSOM

A / 1 / 24

Poster P3188

Abstract 3666

Suppressive antibiotic treatment for orthopaedic implant infections: how to dose and when to stop?

30/04 12:00

8b. Other foreign-body and implant-associated infections (incl PJI)

Jaap Leonardus Jacobus HANSSEN

B / 1 / 1

Poster P3189

Abstract 4492

Activity of standard surgical antimicrobial prophylaxis regimens against pathogens causing postoperative prosthetic joint infections: a multinational study

30/04 12:00

8b. Other foreign-body and implant-associated infections (incl PJI)

Natividad BENITO

B / 1 / 2

Poster P3190

Abstract 4697

What's the fate of prosthetic joint infection-associated Cutibacterium acnes after the interaction with neutrophils?

30/04 12:00

8b. Other foreign-body and implant-associated infections (incl PJI)

Fany REFFUVEILLE

B / 1 / 3

Poster P3191

Abstract 4953

Clinical experience with intravenous (IV) fosfomycin for treatment of complex bone and implant-associated infections: prospective cohort

30/04 12:00

8b. Other foreign-body and implant-associated infections (incl PJI)

Svetlana KARBYSHEVA

B / 1 / 4

Poster P3192

Abstract 5786

High rates of polymicrobial and multidrug-resistant bacterial infections of modular megaprostheses: a retrospective cohort study

30/04 12:00

8b. Other foreign-body and implant-associated infections (incl PJI)

Giulia MICHELI

B / 1 / 5

Poster P3193

Abstract 6231

A retrospective study of sonicate fluid cultures for the diagnosis of orthopedic implant infections

30/04 12:00

8b. Other foreign-body and implant-associated infections (incl PJI)

Spyridon KAMARIOTIS

B / 1 / 6

Poster P3194

Abstract 7812

Proof-of-concept for intraoperative electric field application as prophylaxis against prosthetic joint infections: in vivo validation

30/04 12:00

8b. Other foreign-body and implant-associated infections (incl PJI)

Francisco CARMONA-TORRE

B / 1 / 7

Poster P3195

Abstract 8264

Cutibacterium species in orthopaedic patients: pathogenic or contaminating role? A five-year retrospective study in a tertiary-care hospital

30/04 12:00

8b. Other foreign-body and implant-associated infections (incl PJI)

Andrea BEDINI

B / 1 / 8

Poster P3196

Abstract 8622

Panton-valentine leucocidin-producing Staphylococcus aureus strains are associated with treatment failure of implant-associated infections

30/04 12:00

8b. Other foreign-body and implant-associated infections (incl PJI)

Martina MARITATI

B / 1 / 9

Poster P3197

Abstract 73

Surgical antibiotic prophylaxis: acompliance improving practices

30/04 12:00

8c. Surgical site infections

Tugba YANIK YALÇIN

B / 1 / 10

Poster P3198

Abstract 470

Semiautomated surveillance of deep surgical site infections: algorithms for colon surgery, vascular surgery and orthopaedics

30/04 12:00

8c. Surgical site infections

Jannie ROMME

B / 1 / 11

Poster P3199

Abstract 726

Administration of cephalosporine surgical antimicrobial prophylaxis in low-risk cholecystectomy and its association with surgical site infections

30/04 12:00

8c. Surgical site infections

Rami SOMMERSTEIN

B / 1 / 12

Poster P3200

Abstract 740

Automated trend monitoring of surgical site infection incidence

30/04 12:00

8c. Surgical site infections

Mark TINGA

B / 1 / 13

Poster P3201

Abstract 871

Post operative spinal infection; a review of epidemiology, microbiology, management and outcomes over a 15 month period at a tertiary UK hospital

30/04 12:00

8c. Surgical site infections

Peter DAVIS

B / 1 / 14

Poster P3202

Abstract 1513

Optimising prophylactic antibiotic use among surgery patients in Ethiopian hospitals

30/04 12:00

8c. Surgical site infections

Niranjan KONDURI

B / 1 / 15

Poster P3203

Abstract 1696

Adherence to antimicrobial prophylaxis guidelines for elective surgeries in a tertiary hospital: ADEQUAP study

30/04 12:00

8c. Surgical site infections

Marco PISCAGLIA

B / 1 / 16

Poster P3204

Abstract 2049

Complications of cesarean sections in Brazil: a population-based study

30/04 12:00

8c. Surgical site infections

Jonas MARSCHALL

B / 1 / 17

Poster P3205

Abstract 2194

Surgical site infection surveillance in knee and hip arthroplasty: an algorithm to detect high risk patients based on electronic health records

30/04 12:00

8c. Surgical site infections

Mariana GUEDES

B / 1 / 18

Poster P3206

Abstract 2294

To what extent can colorectal surgical site infections be prevented? An individual-based modelling study

30/04 12:00

8c. Surgical site infections

Jonas MARSCHALL

B / 1 / 19

Poster P3207

Abstract 2872

Antimicrobial resistance in post transrectal ultrasound-guided biopsy infections – the case for transperineal biopsies

30/04 12:00

8c. Surgical site infections

James DONNELLY

B / 1 / 20

Poster P3208

Abstract 3052

Performance of an algorithm for semi-automated surveillance of surgical site infections after cardiac valve replacement: preliminary results

30/04 12:00

8c. Surgical site infections

Mireia PUIG-ASENSIO

B / 1 / 21

Poster P3209

Abstract 4725

Impact of VRE active perioperative prophylaxis in liver transplant patients colonised by Vancomycin-resistant Enterococci

30/04 12:00

8c. Surgical site infections

Giulia Jole BURASTERO

B / 1 / 22

Poster P3210

Abstract 5606

Surgical antibiotic prophylaxis adherence in cardiothoracic and vascular surgeries: a four-year report from the developing world

30/04 12:00

8c. Surgical site infections

G PAVITHRA

B / 1 / 23

Poster P3211

Abstract 5919

Optimising antibiotic selection in Fournier's gangrene: a rationalised approach in the South East of Scotland

30/04 12:00

8c. Surgical site infections

Simon DEWAR

B / 1 / 24

Poster P3212

Abstract 6961

Surveillance of surgical site infections: a prospective study in a tertiary care hospital in Bangladesh

30/04 12:00

8c. Surgical site infections

Saifur RAHMAN

A / 2 / 1

Poster P3213

Abstract 7143

Origin of pathogens: surgery-dependent S. epidermidis strains in endophthalmitis

30/04 12:00

8c. Surgical site infections

Leandro Andrés ESCOBAR-HERRERA

A / 2 / 2

Poster P3214

Abstract 7465

A prospective study on implementing the ideal time to administer pre - operative antibiotics for cesarean delivery in a south indian secondary care hospital

30/04 12:00

8c. Surgical site infections

Sanju Menaka SIVAKUMAR

A / 2 / 3

Poster P3215

Abstract 7506

Postsurgical mediastinis after major heart surgery: a retrospective study of the last 11 years at a tertiary care institution

30/04 12:00

8c. Surgical site infections

Maria Jesus PEREZ-GRANDA

A / 2 / 4

Poster P3216

Abstract 7578

A multi-faceted, surgically led quality improvement initiative produces positive change in surgical antibiotic prophylaxis practices

30/04 12:00

8c. Surgical site infections

Katie GIBLIN

A / 2 / 5

Poster P3217

Abstract 70

Single-drug versus combination antimicrobial therapy in critically ill patients with hospital-acquired pneumonia and ventilator-associated pneumonia due to Gram-negative pathogens: a multicentre cohort study

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

François BARBIER

A / 2 / 6

Poster P3218

Abstract 492

Protocol for the Hospital Acquired Pneumonia PrEveNtion (The HAPPEN study): a multi-centre randomised control trial exploring the effectiveness of improving the frequency and quality of oral care, in reducing the incidence of pneumonia

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Brett MITCHELL

A / 2 / 7

Poster P3219

Abstract 683

Combined therapy with phages and ceftolozane/tazobactam against P. aeruginosa endotracheal tube biofilms

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Laia FERNÁNDEZ-BARAT

A / 2 / 8

Poster P3220

Abstract 815

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with bacterial pneumonia in western and eastern Europe (SENTRY Program; 2021-2022)

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Helio SADER

A / 2 / 9

Poster P3221

Abstract 915

Prognosis and etiology of hospital-acquired pneumonia and ventilator-associated pneumonia in patients with active lung or lower neck cancer: the PEPP-C study

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Sebastian WINGEN-HEIMANN

A / 2 / 10

Poster P3222

Abstract 955

Hospital acquired Burkholderia cepacia complex carrying blaNDM-1 and blaNDM-5 in ventilator-associated pneumonia patients and contaminated ventilator tubing

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Muhammad SAEED

A / 2 / 11

Poster P3223

Abstract 1076

Risk factors on multiple drug-resistant organisms infection in patients with nosocomial pneumonia and their prognosis assessment: a nationwide multi-centre, large population, retrospective nested case-control study

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Zhenchao WU

A / 2 / 12

Poster P3224

Abstract 1291

Piperacillin is an effective de-escalation treatment for ventilator associated pneumonia caused by Pseudomonas aeruginosa

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Sirine SMAOUI

A / 2 / 13

Poster P3225

Abstract 1564

The Ecraid perpetual observational study on ventilator-associated pneumonia: a solid operational backbone ready for embedding clinical studies

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Holly JACKSON

A / 2 / 14

Poster P3226

Abstract 1827

Ventilator-associated lower respiratory tract infections in intensive care unit patients at a tertiary care centre after implementation of a multifaceted intervention: a before-after study

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Nando BLOCH

A / 2 / 15

Poster P3227

Abstract 1863

Identifying patients at risk for S. aureus ICU pneumonia: the added predictive value of immunological biomarkers

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Claudia RECANATINI

A / 2 / 16

Poster P3228

Abstract 2376

Real-world experience of cefiderocol in France from the PROVE (retrospective cefiderocol chart Rreview) study

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Anne SANTERRE HENRIKSEN

A / 2 / 17

Poster P3229

Abstract 3301

Clinical epidemiology of ventilator-associated pneumonia caused by Acinetobacter baumannii in Vietnam

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Hidetoshi NOMOTO

A / 2 / 18

Poster P3230

Abstract 3783

Survival impact of initial adequate antimicrobial therapy in critically ill patients with nosocomial pneumonia due to Gram-negative pathogens: a multicenter cohort study

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

François BARBIER

A / 2 / 19

Poster P3231

Abstract 3942

Comparing inhaled colistin with inhaled fosfomycin/tobramycin as an adjunctive treatment for ventilator-associated pneumonia: An open-label randomized controlled trial

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Atousa HAKAMIFARD

A / 2 / 20

Poster P3232

Abstract 4364

Role of microbiological confirmation in ventilator-associated pneumonia diagnosis: data from PULMIVAP, an Italian prospective multicentre study

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Anna TONIZZO

A / 2 / 21

Poster P3233

Abstract 5426

The clinical characteristics and bacterial genomics of HAP caused by Acinetobacter baumannii

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Zhenchao WU

A / 2 / 22

Poster P3234

Abstract 5782

Incidence and lethality of hospitalised pneumonia among people over 50 years in Catalonia in the pre-COVID-19 era: a population-based study

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Cinta DE DIEGO-CABANES

A / 2 / 23

Poster P3235

Abstract 5849

Hospital acquired pneumonia has a significant attributable mortality and triples hospital length of stay

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Dan WOOTTON

A / 2 / 24

Poster P3236

Abstract 5990

Wide variations in the incidence risk of hospital acquired pneumonia in England

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Dan WOOTTON

A / 2 / 25

Poster P3237

Abstract 6071

A multistate model for clinical outcomes in nosocomial pneumonia patients

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Diego VERA-YUNCA

A / 2 / 26

Poster P3238

Abstract 6501

Post-antibiotic risk for recurrent lower respiratory tract infection during prolonged hospitalisation

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Brendan KELLY

A / 2 / 27

Poster P3239

Abstract 7225

Persistent higher antimicrobial resistance in mechanically ventilated ICU patients: a before-and-after analysis of the COVID-19 surge

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Fernando BOZZA

A / 2 / 28

Poster P3240

Abstract 8229

Adjunctive nebulised colistin along with intravenous polymyxin B versus intravenous polymyxin B alone for the treatment of nosocomial pneumonia caused by multi-drug resistant gram-negative (MDR) bacteria: A retrospective study

30/04 12:00

8d. Healthcare-associated pneumonia (incl VAP)

Viplov VAIDYA

B / 2 / 1

Poster P3241

Abstract 555

Rapid detection of carbapenem non-susceptible bacteria isolated from patients for public policy strategies to control hospital-acquired infections

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Maria NOVELLA

B / 2 / 2

Poster P3242

Abstract 571

How long do nosocomial pathogens persist on inanimate surfaces: a scoping review

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Philip RUSSO

B / 2 / 3

Poster P3243

Abstract 583

Nosocomial and household transmission of carbapenemase-producing organisms (CPO) through direct patient contact: interim analysis of a multicentre prospective cohort study

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Stephanie SUTJIPTO

B / 2 / 5

Poster P3245

Abstract 1053

Loaned endoscopes: how safe are they?

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Taeyang CHIN

B / 2 / 6

Poster P3246

Abstract 1260

Whole genome sequencing reveals a cluster of Enterobacter cloacae ST198, blaVIM-1 positive in pediatric haematologic ward

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Sergio Maria Ivano MALANDRIN

B / 2 / 7

Poster P3247

Abstract 1343

Pathogenic microbial contamination of handwashing sinks changes over time following installation

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Itaru NAKAMURA

B / 2 / 8

Poster P3248

Abstract 1350

A comparison of an algorithm and coding data to traditional surveillance to identify surgical site infections: an Australian retrospective multicentred cohort study

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Philip RUSSO

B / 2 / 9

Poster P3249

Abstract 1530

Factors impacting hospital-associated microbial communities composition and stability

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Iván LINARES AMBOHADES

B / 2 / 11

Poster P3251

Abstract 1614

Predictors of vancomycin-resistant Enterococcus acquisition among acute care roommate exposures

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Victoria WILLIAMS

B / 2 / 12

Poster P3252

Abstract 1651

Impact of the COVID-19 pandemic on antibiotic resistance spread among hospitalised patients in France

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Maylis LAYAN

B / 2 / 13

Poster P3253

Abstract 1855

Epidemiology of multi-resistant S. haemolyticus in French neonatal intense care units: spread of two multidrug-resistant lineages

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Camille KOLENDA

B / 2 / 14

Poster P3254

Abstract 1868

Community-onset impetigo: emergence of a multi-resistant clone in France

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Anne TRISTAN

B / 2 / 15

Poster P3255

Abstract 2421

Carbapenem-resistant non-aeruginosa Pseudomonas species in the wet hospital environment

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Anneloes VAN VEEN

B / 2 / 16

Poster P3256

Abstract 2491

Simplified hospital acquired infection prevalence method with high sensitivity

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Anna Maria KAISER

B / 2 / 17

Poster P3257

Abstract 2508

Rapid MRSA/MSSA surveillance: insights from a six-years dual molecular-cultural approach

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Valeria CENTO

B / 2 / 18

Poster P3258

Abstract 2561

Screening of haematology patients on admission for P. aeruginosa (PA) showed acquisition from the hospital environment, particularly drains, is more likely than from endogenous flora

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Özge YETIS

B / 2 / 19

Poster P3259

Abstract 2576

Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii isolated in intensive care unit

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Tingting XIAO

B / 2 / 20

Poster P3260

Abstract 2585

Investigating linezolid resistant Staphylococcus epidermidis (LRSE) at a tertiary hospital

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Katrine Snorradottir GUDMUNDSSON

B / 2 / 21

Poster P3261

Abstract 3115

Comparison of sink sites carbapenemase-producing organisms (CPOs) colonisation in a tertiary hospital in Singapore

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Xiaowei HUAN

B / 2 / 22

Poster P3262

Abstract 3166

Genomic characterisation of ST23 K1 Serotype ESBL Klebsiella pneumoniae ST23 strains in University Hospital Brno, Czech Republic

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Matej BEZDÍCEK

B / 2 / 23

Poster P3263

Abstract 3255

Impact of medical waste bin on contamination of patient's environment

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Minkyeong LEE

B / 2 / 24

Poster P3264

Abstract 3291

Transmission patterns of ESBL-producing Enterobacterales in a non-critical care setting

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Minh NGUYEN NGOC

B / 2 / 25

Poster P3265

Abstract 3312

Decreasing Staphylococcus aureus colonisation rates in a Greek neonatal intensive care unit during the COVID-19 pandemic

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Spyros POURNARAS

B / 2 / 26

Poster P3266

Abstract 3391

Trends in healthcare associated infections and medical device use in hospitals, based on point prevalence studies in the Netherlands from 2014-2023

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Sarah Juanita VALK

B / 2 / 28

Poster P3268

Abstract 3426

Epidemiology of intestinal colonisation with carbapenem-resistant organisms (MDROs) in a Greek Intensive care Unit

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

George BAZIOTIS

A / 3 / 1

Poster P3269

Abstract 3582

Investigation of a cluster of carbapenemase-producing Klebsiella pneumoniae identifies a persistent two-year cluster with multiple routes of transmission among patients attending hospital ward X in England

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Kate WILSON

A / 3 / 2

Poster P3270

Abstract 3612

Implementation of semi-automated surveillance of surgical site infections after hip or knee replacement: a pilot study

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Manon BREKELMANS

A / 3 / 3

Poster P3271

Abstract 3699

Conception of a score to predict the result of extensively drug-resistant bacteria screening in known carriers

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Florence STORDEUR

A / 3 / 4

Poster P3272

Abstract 3727

Comparison of clinical outcomes of patients with serial negative surveillance cultures according to a subsequent PCR test for carbapenemase-producing Enterobacterales

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Hyeonji SEO

A / 3 / 5

Poster P3273

Abstract 3785

An active follow-up strategy for carbapenemase-producing Enterobacterales carriers: do carbapenemase genes and patient characteristics matter?

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Jade Leigh VAN RHEENEN

A / 3 / 6

Poster P3274

Abstract 3867

Genetic insights into carbapenem-resistant and carbapenemase-producing Enterobacterales

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Suhanya Veronica PRASAD

A / 3 / 7

Poster P3275

Abstract 4007

Risk factors in endoscopes reprocessing: microbiological surveillance to support the device engineering

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Luna GIROLAMINI

A / 3 / 8

Poster P3276

Abstract 4057

One year of genomic surveillance of healthcare-associated bloodstream infections at a university hospital

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Thomas VOGNBJERG SYDENHAM

A / 3 / 9

Poster P3277

Abstract 4086

Implementation of a system for early detection of bacterial clusters in a tertiary care university hospital using laboratory routine data

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Mélanie COLOMB-COTINAT

A / 3 / 10

Poster P3278

Abstract 4208

Deciphering the temporal short-term dynamics of Acinetobacter baumannii: impact of colonisation pressure on infection in an endemic Indian intensive care unit

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

A / 3 / 11

Poster P3279

Abstract 4218

NDM dissemination within ICU patients associated with an epidemic clone and putative horizontal transfer to other Enterobacterales

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Cristina PITART FERRE

A / 3 / 12

Poster P3280

Abstract 4399

Implementation of cohorting to reduce transmission of carbapenemase-producing Klebsiella pneumoniae in a Greek ICU

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Elisavet KOUSOULI

A / 3 / 13

Poster P3281

Abstract 4413

Transmission of multidrug-resistant organisms during physical and occupational therapy appointments at three VA CLCs

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Kristen PANSON (GIBSON)

A / 3 / 14

Poster P3282

Abstract 4479

Follow-up of digestive Klebsiella pneumoniae species complex in ICUs patients

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Bénédicte LANGLOIS

A / 3 / 15

Poster P3283

Abstract 4504

Multidrug-resistant organism transmission during out-of-room visits in post-acute care: a multicentre study

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Lona MODY

A / 3 / 16

Poster P3284

Abstract 4589

No evidence for transmission of carbapenem-resistant pathogens from war injured Ukrainian patients (2014-2019) to other inpatients: a retrospective molecular study from a Military hospital

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Frieder FUCHS

A / 3 / 17

Poster P3285

Abstract 4787

A machine learning approach to predict healthcare-associated infections in an intensive care unit patients in Tunisia

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Asma MHIRI

A / 3 / 18

Poster P3286

Abstract 4832

Routine genomic surveillance of third generation cephalosporins resistant Enterobacterales in a Neonatology Unit

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

François GRAVEY

A / 3 / 19

Poster P3287

Abstract 5005

Investigation of the environmental presence of Pseudomonas aeruginosa to facilitate sequence analysis and determine a possible cause of bloodstream infection

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Katherine DEVER

A / 3 / 21

Poster P3289

Abstract 5287

Prevalence of Stenotrophomonas maltophilia colonization among patients receiving mechanical ventilation in long-term care facilities in the state of Maryland, United States

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Green ALEXIS

A / 3 / 22

Poster P3290

Abstract 5476

The use of whole genome and metagenomic sequencing for environmental surveillance of blaOXA48 antimicrobial resistance transmission in a hospital setting

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Linzy ELTON

A / 3 / 23

Poster P3291

Abstract 5492

Study of hospital-acquired infections, a multidrug-resistant organism in tertiary hospital, Malaysia

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Noor Zaitulakma MD ZAIN

A / 3 / 24

Poster P3292

Abstract 5661

Unit-level antibiotic resistant bacterial colonisation pressure in 14 neonatal units across Europe

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Aislinn COOK

A / 3 / 25

Poster P3293

Abstract 5741

AMR surveillance in wastewater and clinical isolates from a tertiary hospital: preliminary results

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Carlos FRANCÉS CUESTA

A / 3 / 26

Poster P3294

Abstract 5780

Nanopore long-reads sequencing is suitable for epidemiological surveillance of Klebsiella pneumoniae using cgMLST

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Dominique S. BLANC

A / 3 / 27

Poster P3295

Abstract 5822

Unveiling microbial dynamics in neonatal intensive care: applications from long-read sequencing

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Stefany AYALA MONTAÑO

A / 3 / 28

Poster P3296

Abstract 5996

Exploring the environment's role in hospitals as a reservoir for carbapenemase-producing Enterobacteriaceae

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Lena SLEIMAN

B / 3 / 1

Poster P3297

Abstract 6003

Recall of 5,000 patients related to no-conformity sterilization practices of dental instrumentation.

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Juliette DESSEMON

B / 3 / 2

Poster P3298

Abstract 6234

Genomic surveillance and computational modeling of the transmission of multi-drug resistant isolates in hospital settings during the SARS-CoV-2 pandemic

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Judit BURGAYA

B / 3 / 3

Poster P3299

Abstract 6384

Assessment of using linked electronic surveillance data to replace mandatory reporting of healthcare-associated infections in England

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Ann Sarah WALKER

B / 3 / 4

Poster P3300

Abstract 6395

E.coli bacteraemia surveillance: bridging the data and clinical gap to improve outcomes

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Harin NAVALAN

B / 3 / 5

Poster P3301

Abstract 6411

Nosocomial transmission of NDM-producing Klebsiella pneumoniae ST147 in a Dutch paediatric cancer centre associated with patients from Ukraine

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Wouter SMIT

B / 3 / 6

Poster P3302

Abstract 6517

Seek and you shall find: the practical infection control implications of culture-negative results when introducing molecular-based screening for Carbapenemase-producing Enterobacterales (CPE)

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Mairead SKALLY

B / 3 / 7

Poster P3303

Abstract 6587

Longitudinal carriage of antimicrobial resistant microorganisms in preterm neonates gastrointestinal tract

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Anna MCCORMICK

B / 3 / 8

Poster P3304

Abstract 6683

Prevalence of healthcare-associated infections and antimicrobial use in Spanish long-term care hospitals (2022-2023)

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Lina Marcela PARRA

B / 3 / 9

Poster P3305

Abstract 6726

Molecular epidemiology of bacteria infecting war wounds at tertiary care hospitals in Ukraine

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Patrick MC GANN

B / 3 / 10

Poster P3306

Abstract 6870

Unnecessary contact precaution for MRSA in a low-endemicity area

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Euclimeire NEVES

B / 3 / 11

Poster P3307

Abstract 6885

Time-saving water monitoring -qPCR-based detection of up to 15 Legionella cells per mL within 4 hours

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Peter Michael KELLER

B / 3 / 12

Poster P3308

Abstract 6995

Environmental air and surface sampling for mpox virus in contaminated settings

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Ginny MOORE

B / 3 / 13

Poster P3309

Abstract 7044

The data when tortured, speaks: the FUO's whispering

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Alessandra SCAGLIARINI

B / 3 / 14

Poster P3310

Abstract 7106

Hospital-acquired bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacterales: 20 years of surveillance in a French tertiary hospital

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Antoine VILLA

B / 3 / 15

Poster P3311

Abstract 7126

Longitudinal genomic analysis of clinical and environmental Pseudomonas aeruginosa links sink drains to nosocomial transmission in intensive care units

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Katelyn BARTLETT

B / 3 / 16

Poster P3312

Abstract 7224

Can hospitals derive clinically useful surveillance data from their wastewater using currently available collection methods and next-generation sequencing data?

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Aoife KEARNEY

B / 3 / 17

Poster P3313

Abstract 7245

The environmental microbiome of hospital areas with and without patient areas reveals the influence of human activity in the dynamics of multidrug-resistant organisms

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Natalia GUERRA PINTO

B / 3 / 18

Poster P3314

Abstract 7345

Antimicrobial resistance in clinically important anaerobes at a tertiary university hospital in Greece

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Eleni KALOGEROPOULOU

B / 3 / 19

Poster P3315

Abstract 7501

Nine-year epidemiology of group A streptococci and whole-genome sequencing of invasive strains isolated in an Italian hospital

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Angela KUKA

B / 3 / 20

Poster P3316

Abstract 7507

Impact of whole genome sequencing to investigate transmission of Serratia marcescens in a neonatal intensive care unit

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Marina RAMUS

B / 3 / 21

Poster P3317

Abstract 7734

CPE screening in a tertiary care hospital in Portugal: burden of colonisation and impact on subsequent infection

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Margarida TORRES

B / 3 / 22

Poster P3318

Abstract 8096

Vancomycin resistant enterococci (VRE) surveillance using hospital wastewater during an outbreak with VRE

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Djamayl ENGELEN

B / 3 / 23

Poster P3319

Abstract 8149

Pseudomonas aeruginosa as relevant cause of healthcare-associated infections in neonatal intensive care: a molecular epidemiology investigation

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Giancarlo RIPABELLI

B / 3 / 24

Poster P3320

Abstract 8298

Genomic Epidemiology insights reveals pivotal role of plasmids in blaNDM mediated antimicrobial resistance - Need for urgent global action

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Nagaraj GEETHA

B / 3 / 25

Poster P3321

Abstract 8530

Transmission dynamics of carbapenemase-producing microorganisms in a high endemicity critical care unit from a public hospital in Bogota, Colombia

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Gerardo Antonio MUÑETON LOPEZ

B / 3 / 26

Poster P3322

Abstract 8596

Long-read sequencing characterises multi-modal transmission of ESBL genes amongst Klebsiella pneumoniae and Escherichia coli in a neonatal unit

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Melody PARKER

B / 3 / 27

Poster P3323

Abstract 8645

Excess length of stay due to healthcare-associated infections in acute care hospitals in Spain

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Lina Marcela PARRA

B / 3 / 28

Poster P3324

Abstract 8719

Years of life lost atributables to healthcare-associated infections in Spain

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Lina Marcela PARRA

A / 4 / 1

Poster P3325

Abstract 8808

Recent emergence of the multidrug-resistant epidemic variant in Acinetobacter baumannii revealed by hierarchical genotype

30/04 12:00

8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment)

Shengkai LI

A / 4 / 2

Poster P3326

Abstract 69

Secondary prophylaxis for Clostridioides difficile infection for patients on non-Clostridioides difficile antibiotics: a retrospective cohort study

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Ronza NAJJAR-DEBBINY

A / 4 / 3

Poster P3327

Abstract 125

The first established microsatellite markers to distinguish Candida orthopsilosis isolates and detection of a nosocomial outbreak in China

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Luo ZHENGYU

A / 4 / 4

Poster P3328

Abstract 218

Selective, isosteric growth inhibitors of Clostridioides difficile

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

William FRASER

A / 4 / 5

Poster P3329

Abstract 443

Electric floor scrubbers, centralised kitchens and an outbreak of carbapenemase producing Enterobacterales

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Aled BENBOW

A / 4 / 6

Poster P3330

Abstract 532

Melioidosis outbreak traced to a single hospital ward in Singapore

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Hwang Ching CHAN

A / 4 / 7

Poster P3331

Abstract 570

Quinolone-resistant Acinetobacter baumannii international clone II outbreak with shower trolleys as reservoir

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Hideki KAWAMURA

A / 4 / 8

Poster P3332

Abstract 761

Significant and sustained decline in catheter-associated urinary tract infections rate following implementation of a multifaceted interdisciplinary infection prevention programme

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Avish NAGPAL

A / 4 / 9

Poster P3333

Abstract 847

Phenotypic characterisation of Clostridioides difficile PCR ribotype 046, involved in an outbreak, presents high toxin production and multidrug-resistance

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Cecilia MAGNUSSON

A / 4 / 10

Poster P3334

Abstract 916

Clinical and pharmacoeconomic evaluation of fidaxomicin in risk patients with recurrent or refractory Clostridioides difficile infection

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Sina Marie HOPFF

A / 4 / 11

Poster P3335

Abstract 1102

Interrogation of Clostridioides difficile (CD) Ribotype 078 genomes from Irish pigs and human cases of CD Infection (CDI) to determine epidemiological relationships.

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Aoife DOYLE

A / 4 / 12

Poster P3336

Abstract 1417

Antimicrobial susceptibility pattern of Clostridioides difficile in a Spanish university hospital

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Luciana URBINA

A / 4 / 13

Poster P3337

Abstract 1504

Identification of the first nosocomial outbreak of clade ? Candida auris in Korea: a nationwide surveillance study

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Yong Jun KWON

A / 4 / 14

Poster P3338

Abstract 1698

Core genome multi-locus sequence typing (cgMLST) reveals a long-term silent outbreak with the rare MRSA ST4110 in outpatient wound care

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Danielle VUICHARD-GYSIN

A / 4 / 15

Poster P3339

Abstract 1742

Whole-genome sequencing revealed multiple undetected SARS-CoV-2 outbreaks in a university hospital in Norway

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Kirsten GRAVNINGEN

A / 4 / 16

Poster P3340

Abstract 1803

Multicentre outbreak of blaOXA-72 Acinetobacter baumannii: a comprehensive whole genome sequencing analysis

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Tomasz KASPERSKI

A / 4 / 17

Poster P3341

Abstract 1838

Effectiveness and safety of bezlotoxumab in combination with standard-of-care therapy in patients with Clostridioides difficile infection: a single-centre real-life experience

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Judith POBLET

A / 4 / 18

Poster P3342

Abstract 1848

First report of outbreaks of Clostridioides difficile caused by ribotype 955: a highly transmissible and pathogenic strain

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Eftihia YIANNAKIS

A / 4 / 19

Poster P3343

Abstract 1912

Risk factors and outcomes of bloodstream infections following Clostridioides difficile infection in the time of increased use of fidaxomicin

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Vera MAURO

A / 4 / 20

Poster P3344

Abstract 2062

Characteristics of dual carbapenemase-producing Klebsiella pneumoniae ST147 strains from an outbreak in Tenerife

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Cristian MATEO LEÓN

A / 4 / 21

Poster P3345

Abstract 2117

The burden of Clostridioides difficile infection in the COVID-19 era in the second largest Slovak hospital

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Daniela JAVORSKÁ

A / 4 / 22

Poster P3346

Abstract 2188

Increasing incidence of Clostridium difficile (CDI) infection in admitted patients in the post covid era: epidemiological data

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Dimitrios KOUROUPIS

A / 4 / 23

Poster P3347

Abstract 2190

PopPIPE accurately clusters vancomycin resistant Enterococcus faecium in nosocomial outbreaks

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Martin MCHUGH

A / 4 / 24

Poster P3348

Abstract 2201

Outcome of Clostridium difficile infection (CDI) in admitted patients; association with epidemiological and clinical parameters

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Dimitrios KOUROUPIS

A / 4 / 25

Poster P3349

Abstract 2309

Real-world data on epidemiology and tests of Clostridioides difficile infection in Korea: the need for nationwide diagnostic stewardship

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Jae Hyeon PARK

A / 4 / 26

Poster P3350

Abstract 2431

Plasmid content and composition in vancomycin-resistant Enterococci from suspected hospital outbreaks in Berlin, Germany

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Friederike MAECHLER

A / 4 / 27

Poster P3351

Abstract 2448

Outbreak of carbapenem-resistant Enterobacteriaceae in a kidney transplant unit, how to manage?

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Charlotte MOREAU

A / 4 / 28

Poster P3352

Abstract 2512

Successful control of an outbreak of vancomycin-resistant Enterococcus faecium in a low-prevalence setting

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Jordi CÀMARA

B / 4 / 1

Poster P3353

Abstract 2514

A linezolid resistant coagulase-negative Staphylococci outbreak in an intensive care unit in Gipuzkoa, northern Spain

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Inigo ANSA ISASA

B / 4 / 2

Poster P3354

Abstract 2837

Current perspectives on ventriculitis: clinical insights, microbial trends, and the impact of the COVID-19 pandemic

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Alejandro DÍEZ VIDAL

B / 4 / 4

Poster P3356

Abstract 2932

Efficacy of polyclonal intravenous immunoglobulin for refractory Clostridioides difficile infection: time for a re-think?

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Shanika Anne-Marie CRUSZ

B / 4 / 5

Poster P3357

Abstract 3004

Clostrioides difficile infection at County Durham and Darlington NHS Foundation Trust (CDDFT) 2022/23: review of antimicrobial stewardship and treatment outcomes

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Matthew CHRISTIE

B / 4 / 6

Poster P3358

Abstract 3012

Clostridioides difficile infection epidemiology during COVID-19 pandemic in Greece

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Anna NIKOPOULOU

B / 4 / 7

Poster P3359

Abstract 3152

Exploring the mode of transmission of community-acquired C.difficile from the concept of One Health

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Sadako YOSHIZAWA

B / 4 / 8

Poster P3360

Abstract 3409

Prospective surveillance of health-care associated infections in long-term care facilities in Graz, Austria from 2018 to 2022

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Ines ZOLLNER-SCHWETZ

B / 4 / 9

Poster P3361

Abstract 3417

Accumulation of antimicrobial resistance in Czech and Slovak Clostridioides difficile isolates

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Jaroslava ZÍKOVÁ

B / 4 / 10

Poster P3362

Abstract 3592

Long lasting outbreak of VIM-producing Pseudomonas aeruginosa in a surgical intensive care unit

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Sarah JOLIVET

B / 4 / 11

Poster P3363

Abstract 3639

Cost-effectiveness analysis in the treatment of Clostridioides difficile infection in the Brazilian healthcare system and faecal transplant microbiote

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Leticia DANTAS

B / 4 / 12

Poster P3364

Abstract 3664

Identification of the first large French Candida auris outbreak using qPCR

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Sarah JOLIVET

B / 4 / 13

Poster P3365

Abstract 3700

Berberine alleviates the severity of recurrent Clostridioides difficile infection by enhancing intestinal epithelial barrier and modulating gut microbiota

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Haihui HUANG

B / 4 / 14

Poster P3366

Abstract 3747

Healthcare-associated infections following kidney or kidney-pancreas transplantations

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Elodie MARION

B / 4 / 15

Poster P3367

Abstract 3965

Whole genome sequencing is superior to high molecular weight typing by MALDI-ToF in clarifying Clostridioides difficile transmission

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Sara MERNELIUS

B / 4 / 16

Poster P3368

Abstract 4040

A hospital outbreak with methicillin-resistant Staphylococcus argenteus in the Netherlands, June 2023

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Serena SLAVENBURG

B / 4 / 17

Poster P3369

Abstract 4080

Is older age a risk factor for recurrent Clostridioides difficile infection (r-CDI) in the era of new C. difficile treatments?

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Cecilia SUÁREZ CARANTOÑA

B / 4 / 18

Poster P3370

Abstract 4314

A real-world analysis of Clostridioides difficile infection epidemiology using the TriNetX global health research network

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Kelsey STREY

B / 4 / 19

Poster P3371

Abstract 4336

Outbreak of a linezolid resistant clone of ST18 Enterococcus faecium bearing the G2576T 23S rDNA mutation and its control

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Aleksandra MAREK

B / 4 / 20

Poster P3372

Abstract 4435

Study of antibacterial susceptibility and the hypervirulent strains of Clostridioides difficile in a Spanish hospital

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Carlos RESCALVO CASAS

B / 4 / 21

Poster P3373

Abstract 4443

Outbreak caused by NDM-producing Pseudomonas aeruginosa in a Greek hospital: just visiting or here to stay?

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Christina LOUKA

B / 4 / 22

Poster P3374

Abstract 4444

Prolonged regional outbreak of clinically virulent, highly resistant Klebsiella pneumoniae NDM-14 (ST-147) in Corsica, France, 2022-2023

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Arthur MAKA

B / 4 / 23

Poster P3375

Abstract 4452

Empiric treatment of healthcare-associated central nervous system infections in Denmark: do we need carbapenems?

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Christian KRAEF

B / 4 / 24

Poster P3376

Abstract 4827

Prolonged VIM-producing Pseudomonas aeruginosa outbreak at a Belgian intensive care department, an outbreak investigation report 2019-2023

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Marco MORETTI

B / 4 / 25

Poster P3377

Abstract 4869

Use of bezlotoxumab for the prevention of Clostridioides difficile infections within the German health care system: an observational post-authorization study (BODEGA Study)

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Katharina GIESBRECHT

B / 4 / 26

Poster P3378

Abstract 4937

From the shadows to the spotlight: emergence of vancomycin-resistant Enterococcus faecium ST1299-vanA in upper Austria

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Adriana CABAL ROSEL

B / 4 / 27

Poster P3379

Abstract 4951

Basis of fidaxomicin resistance in Clostridioides difficile: a systematic review and meta-analysis

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Thanh LE

B / 4 / 28

Poster P3380

Abstract 5131

A study on the microbiological differences of Clostridioides difficile strains isolated from community onset Clostridioides difficile infection (CDI) patients and healthcare-associated CDI patients in South Korea

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Jieun KIM

A / 5 / 1

Poster P3381

Abstract 5203

Clostridium difficile contamination of Australian retail vegetables and households

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Deirdre COLLINS

A / 5 / 2

Poster P3382

Abstract 5294

The use of whole genome sequence to uncover undetected healthcare outbreak and transmission of extensively drug-resistant Pseudomonas aeruginosa across four hospitals

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Edwin KAMAU

A / 5 / 3

Poster P3383

Abstract 5432

Relationship between high-risk antibiotic consumption and incidence of nosocomial Clostridiodes difficile infection in tertiary care hospitals in Costa Rica during COVID-19 pandemic

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Cristina FERNANDEZ-BARRANTES

A / 5 / 4

Poster P3384

Abstract 5564

High risk of recurrent Clostridioides difficile infection after previous episodes, regardless of treatment or number of recurrences

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Måns STEFANSSON

A / 5 / 5

Poster P3385

Abstract 5699

Recurrent outbreak of carbapenemase-producing Pseudomonas aeruginosa (IMIP) in kidney transplant recipients: the role of prolonged carriers

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Maristela P FREIRE

A / 5 / 6

Poster P3386

Abstract 5717

Successful control of a cluster of OXA-48 producing Klebsiella pneumoniae sequence type 147 in a tertiary care spinal unit

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Abhijit BAL

A / 5 / 7

Poster P3387

Abstract 5756

Uncovering the alarming spike of VRE CC17 at a Belgian hospital in 2022: a comprehensive genome sequencing investigation

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Katrien VAN DEN PLAS

A / 5 / 8

Poster P3388

Abstract 5972

Genomically-supported redefinition of an outbreak in a paediatric unit caused by blaVIM-harboring Klebsiella michiganensis

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Elena LÓPEZ CAMACHO

A / 5 / 9

Poster P3389

Abstract 6006

Genomic analysis of a nosocomial outbreak of Candida auris in the Comunitat Valenciana (Spain)

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Fernando GONZALEZ-CANDELAS

A / 5 / 10

Poster P3390

Abstract 6207

Toilet drain water as a potential reservoir for NDM1-producing Klebsiella pneumoniae: an outbreak report from a German university hospital including an effective eradication strategy

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Giovanni-Battista FUCINI

A / 5 / 11

Poster P3391

Abstract 6327

Are cycle threshold (CT) values useful for predicting specific attributes of Clostridioides difficile infection?

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Mairead SKALLY

A / 5 / 12

Poster P3392

Abstract 6383

The added value of a regional, prospective whole genome sequencing (WGS) based surveillance for methicillin-resistant Staphylococcus aureus (MRSA) outbreak detection in five hospitals in the Netherlands

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Veronica WETERINGS

A / 5 / 13

Poster P3393

Abstract 6434

Increase in antimicrobial consumption and C. difficile infection after the SARS-CoV-2 pandemic

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Michail SAMARKOS

A / 5 / 14

Poster P3394

Abstract 6522

Prevalence of healthcare-associated infections in Greek long-term care facilities, HALT-4 2023: a fleeting glance for a promising future

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Lida POLITI

A / 5 / 15

Poster P3395

Abstract 6646

Correlation between toxin-producing Clostridiodes difficile infection and multidrug-resistant bacteria in pre- and COVID-19 periods

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Luisa TORRINI

A / 5 / 16

Poster P3396

Abstract 6707

Implementing nanopore whole-genome sequencing in C. difficile surveillance and outbreak investigation

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Anita BLOMFELDT

A / 5 / 17

Poster P3397

Abstract 6890

WGS confirmed the non-inferiority of the rapid and simple McRAPD typing in comparison with MLST in a Klebsiella pneumoniae outbreak

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Rakesh Rao GERGAL NAGABHUSHANA RAO

A / 5 / 18

Poster P3398

Abstract 7004

Tip of the iceberg: how severe is ‘severe' C. difficile?

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Niamh REIDY

A / 5 / 19

Poster P3399

Abstract 7026

Outbreak of gastrointestinal symptoms in professionals related to water consumption in hospital

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Euclimeire NEVES

A / 5 / 20

Poster P3400

Abstract 7178

Clostridioides difficile-associated infections: a gap in the Swiss surveillance of hospital-acquired infections

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Andreas F. WIDMER

A / 5 / 21

Poster P3401

Abstract 7204

Acquisition of blaCTX-M-15 throughout a Pseudomonas aeruginosa nosocomial outbreak

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Katelyn BARTLETT

A / 5 / 22

Poster P3402

Abstract 7235

Two years of an active carbapenem-resistant Acinetobacter baumannii outbreak in a burn intensive care unit

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Nagham Léa KHANAFER

A / 5 / 23

Poster P3403

Abstract 7244

Early developability assessment of a single-domain antibody construct for gastrointestinal neutralisation of Clostridium difficile toxins

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Everardo RODRIGUEZ RODRIGUEZ

A / 5 / 24

Poster P3404

Abstract 7484

Efficient outbreak investigation of post-surgical intraocular Staphylococcus epidermidis infections by rapid whole genome sequencing and sharing data between hospitals.

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Michael KEMP

A / 5 / 25

Poster P3405

Abstract 7537

Genomic insight into suspected outbreak of methicillin-susceptible Staphylococcus aureus surgical site infections in orthopaedic surgery

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Chloé MAGNAN

A / 5 / 26

Poster P3406

Abstract 7540

Outbreak of Burkholderia contaminans in Intensive Care Units of a Tertiary Hospital

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Marcos BELSOL

A / 5 / 27

Poster P3407

Abstract 7544

Chlorhexadine linked Burkholderia-like outbreak in a tertiary care hospital: unique challenges in LMICs

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Syed Faisal MAHMOOD

A / 5 / 28

Poster P3408

Abstract 7571

Investigation of an outbreak due to Achromobacter xylosoxidans

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Konstantinia KONTOPOULOU

B / 5 / 2

Poster P3410

Abstract 7767

Adjunctive eravacycline as treatment in severe and fulminant Clostridioides difficile infections?

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Christen ARENA

B / 5 / 3

Poster P3411

Abstract 7794

Outbreak of NDM-1, OXA-48 and CTXM co-producing Klebsiella pneumoniae in a tertiary hospital in Spain

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Patricia Luisa GÓMEZ SASTRE

B / 5 / 4

Poster P3412

Abstract 7909

Outbreak of Burkholderia cepacia in a hospital in southern Spain

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Ana LÓPEZ GONZÁLEZ-SALIDO

B / 5 / 5

Poster P3413

Abstract 7952

Assessment of institutional management and control of Clostridioides difficile in public and private hospitals in Brazil

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Silvia FIGUEIREDO COSTA

B / 5 / 6

Poster P3414

Abstract 7958

Impact of the COVID-19 pandemic on Clostridioides difficile infection in Brazilian hospitals

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Luiza ARCAS GONÇALVES

B / 5 / 7

Poster P3415

Abstract 8258

Increased incidence of CDI over time as an indirect consequence of COVID-19 pandemic?

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Evdoxia DOUMOULIAKA

B / 5 / 8

Poster P3416

Abstract 8354

Epidemiology and antimicrobial resistance pattern of Clostridioides difficile at a tertiary university hospital in Greece

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Eleni KALOGEROPOULOU

B / 5 / 9

Poster P3417

Abstract 8370

Healthcare-associated spondilodiscitis: worse outcome in patients on hemodialysis

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Özlem AZAP

B / 5 / 10

Poster P3418

Abstract 8517

Clostridioides difficile Infections in England: switch to sustained increasing trends

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Rimsha QURESHI

B / 5 / 11

Poster P3419

Abstract 8570

Core genome predictors of CDI severity

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

S GABER

B / 5 / 12

Poster P3420

Abstract 8654

A novel sequence-based typing scheme for Candida parapsilosis can be used to track outbreaks

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Phillip BRASSINGTON

B / 5 / 13

Poster P3421

Abstract 8923

Practices to reduce the risk of transmission of Clostridioides difficile in France: national survey

30/04 12:00

8f. Other healthcare associated infections (incl CDI, hospital outbreaks)

Nagham Léa KHANAFER

B / 5 / 14

Poster P3422

Abstract 1150

Direct molecular detection of pathogens in stool sample donors for fecal microbiota transplantation: five years experience

30/04 12:00

8g. Infection control interventions and trials (incl. microbiota transplantation)

Gianluca QUARANTA

B / 5 / 15

Poster P3423

Abstract 1589

Contaminated duodenoscopes in endoscopic retrograde cholangiopancreatopgraphy: assessing risk and culture sensitivity

30/04 12:00

8g. Infection control interventions and trials (incl. microbiota transplantation)

Koen VAN DER PLOEG

B / 5 / 17

Poster P3425

Abstract 1729

The impact of universal contact precautions and chlorhexidine bathing on the acquisition of carbapenem resistant Enterobacterales in the intensive care unit

30/04 12:00

8g. Infection control interventions and trials (incl. microbiota transplantation)

Jung JONGTAK

B / 5 / 18

Poster P3426

Abstract 1990

Faecal microbiota transplantation with lyophilized oral capsules in patients with Clostridioides difficile infection: a five-year experience in a university hospital

30/04 12:00

8g. Infection control interventions and trials (incl. microbiota transplantation)

Sofia DE LA VILLA MARTINEZ

B / 5 / 19

Poster P3427

Abstract 2415

Prolonged use of breathing systems used in anaesthesia for up to seven days instead of 24 hours

30/04 12:00

8g. Infection control interventions and trials (incl. microbiota transplantation)

Cynthia Paola HAANAPPEL

B / 5 / 20

Poster P3428

Abstract 2711

Efficacy and safety of antiseptic cleansing in reducing bacterial vertical transmission: NeoVTAMR

30/04 12:00

8g. Infection control interventions and trials (incl. microbiota transplantation)

Emily BEALES

B / 5 / 21

Poster P3429

Abstract 2869

Faecal microbiota transplantation excluding C. difficile French experience from 2019 to 2022, indication and efficacy analysis

30/04 12:00

8g. Infection control interventions and trials (incl. microbiota transplantation)

Alexandre BLEIBTREU

B / 5 / 22

Poster P3430

Abstract 3169

Decolonization: the beginning of the end of carbapenemases?

30/04 12:00

8g. Infection control interventions and trials (incl. microbiota transplantation)

Ana ALBEROLA ROMANO

B / 5 / 23

Poster P3431

Abstract 5205

Nanoparticle-impregnated textiles as a promising tool to reduce incidence of healthcare-associated infections in the intensive care unit: an interrupted time-series study

30/04 12:00

8g. Infection control interventions and trials (incl. microbiota transplantation)

Diego Rodrigues FALCI

B / 5 / 24

Poster P3432

Abstract 5967

Safe and effective administration of subcutaneous antimicrobials: an observational retrospective cohort-study in 136 patients

30/04 12:00

8g. Infection control interventions and trials (incl. microbiota transplantation)

Marie JUMPERTZ

B / 5 / 25

Poster P3433

Abstract 8039

Results of an antibiotic stewardship programme in an oncologic institution from Bogota, Colombia

30/04 12:00

8g. Infection control interventions and trials (incl. microbiota transplantation)

Maria Jose LOPEZ

B / 5 / 26

Poster P3434

Abstract 8106

Semi-continuous disinfection of sinks with UVC on a haematology-oncology department for prevention of nosocomial infection

30/04 12:00

8g. Infection control interventions and trials (incl. microbiota transplantation)

Wil VAN DER ZWET

B / 5 / 27

Poster P3435

Abstract 8265

Faecal microbiota transplantation: bacterial viability throughout the procedure of capsule preparation

30/04 12:00

8g. Infection control interventions and trials (incl. microbiota transplantation)

Lucía SAIZ ESCOBEDO

B / 5 / 28

Poster P3436

Abstract 8333

Whole genome sequencing in clinical microbiology laboratory as a tool for infection control

30/04 12:00

8g. Infection control interventions and trials (incl. microbiota transplantation)

Maria RIESGO MAGAÑA

A / 6 / 1

Poster P3437

Abstract 8411

Impact of in loco training to reduce cases of Clostridioides difficile infection in onco-hematology patients and hematopoietic stem cell transplantation

30/04 12:00

8g. Infection control interventions and trials (incl. microbiota transplantation)

Odeli Nicole ENCINAS SEJAS

A / 6 / 2

Poster P3438

Abstract 8628

Intestinal microbiota transplantation for patients colonised with multidrug-resistant organisms have an improvement in clinical outcomes associated with a significant increase in alpha-diversity metrics of the gastrointestinal microbiota

30/04 12:00

8g. Infection control interventions and trials (incl. microbiota transplantation)

Rohma GHANI

A / 6 / 3

Poster P3439

Abstract 799

Unraveling the complex interplay of biocide resistance, efflux pump mechanisms, and sequence typing in carbapenem-resistant Acinetobacter baumannii: a comprehensive multicentre investigation

30/04 12:00

8h. Disinfection & biocides

Muhammd Usman QAMAR

A / 6 / 5

Poster P3441

Abstract 2469

Antiseptics, biocides, disinfectants: a common practice under the aegis of complex regulations

30/04 12:00

8h. Disinfection & biocides

Charlotte MOREAU

A / 6 / 6

Poster P3442

Abstract 2858

Exploring tolerance to quaternary ammonium compounds in Klebsiella pneumoniae with a focus on the food chain: phenotypic and genomic insights

30/04 12:00

8h. Disinfection & biocides

Patricia ANTUNES

A / 6 / 7

Poster P3443

Abstract 3072

Portable UV-C device decontaminator: an in vitro microbiological analysis

30/04 12:00

8h. Disinfection & biocides

Natalia IORIO

A / 6 / 8

Poster P3444

Abstract 3216

Persistence and bactericidal effect of various disinfectants for clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii

30/04 12:00

8h. Disinfection & biocides

Masato KAWAMURA

A / 6 / 9

Poster P3445

Abstract 3418

Alcohol-based hand rubs meet EN 1500 requirements in 15 seconds

30/04 12:00

8h. Disinfection & biocides

Christoph SENGES

A / 6 / 10

Poster P3446

Abstract 3536

Biocide resistance among Enterobacteriaceae from fecal samples of children living in urban polluted areas

30/04 12:00

8h. Disinfection & biocides

Carolina LÓPEZ LÓPEZ

A / 6 / 11

Poster P3447

Abstract 4608

Bactericidal activities of ceragenins and N-chlorotaurine against Staphylococcus aureus and Pseudomonas aeruginosa clinical strains

30/04 12:00

8h. Disinfection & biocides

Mayram HACIOGLU

A / 6 / 12

Poster P3448

Abstract 6176

Biocides susceptibility among high-risk clones of multidrug-resistant Pseudomonas aeruginosa in Southern France

30/04 12:00

8h. Disinfection & biocides

Maëliss CONSTANT

A / 6 / 13

Poster P3449

Abstract 6456

Fading solutions: are 2-in-1 oxidising disinfectants too good to be true?

30/04 12:00

8h. Disinfection & biocides

Lauren BROWN

A / 6 / 14

Poster P3450

Abstract 8433

Label-free flow cytometry for fast evaluation of surface disinfectants bactericidal efficacy

30/04 12:00

8h. Disinfection & biocides

Andreea Maria PÎNDARU

A / 6 / 15

Poster P3451

Abstract 178

Hand hygiene practice compliance among health care workers and associated factors during and after COVID-19 pandemic

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Haythem AYACHI

A / 6 / 16

Poster P3452

Abstract 245

Frequency and distribution of carriers of pathogenic bacteria during regular sanitary examinations in throat and nose swabs of employees in the surgical departments of the University Clinical Center Tuzla, Bosnia and Herzegovina: overview of the period 2020-2022

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Dijana HASIC

A / 6 / 17

Poster P3453

Abstract 1134

Reliability of healthcare worker self-reported COVID-19 vaccination status

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Liam TOWNSEND

A / 6 / 18

Poster P3454

Abstract 1283

Employing Delphi survey methods to identify indicators and targets for the World Health Organization (WHO) infection prevention and control (IPC) global action plan

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Giovanni SATTA

A / 6 / 19

Poster P3455

Abstract 1629

Does gel nail polish really have a negative impact on the quality of hand hygiene (HH) with alcohol rub?

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Paula ARREBA

A / 6 / 20

Poster P3456

Abstract 1747

Enhancing feedback and implementation of infection risk scan (IRIS) findings among healthcare workers in nursing homes

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Yvonne HENDRIKS

A / 6 / 21

Poster P3457

Abstract 2179

Radiant protection: confidence in appropriate use of personal protective equipment improved following ultraviolet dye simulation training in a pilot study

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Alexander RICHARDS

A / 6 / 22

Poster P3458

Abstract 2214

Assessment of a novel isolation care tent in Uganda during the 2022 Sudan ebolavirus outbreak showed potential impact and feasibility

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Mara Jana BROADHURST

A / 6 / 23

Poster P3459

Abstract 2308

Hand hygiene compliance rates and the interventions to increase hand hygiene compliance among healthcare workers in a tertiary care educational hemato-oncology hospital

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Oguz Resat SIPAHI

A / 6 / 24

Poster P3460

Abstract 2317

Isolation precautions compliance rates among healthcare workers in a tertiary care educational hemato-oncology hospital

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Oguz Resat SIPAHI

A / 6 / 25

Poster P3461

Abstract 2420

Proper glove use: a multicentre before-after regional de-implementation study

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Anne VOOR IN T HOLT

A / 6 / 26

Poster P3462

Abstract 2481

Immune status of healthcare workers to the measles virus in an infectious disease tertiary medical center in Croatia

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Oktavija DAKOVIC RODE

A / 6 / 27

Poster P3463

Abstract 2487

Preliminary insights into the applicability of a gamification strategy to improve hand hygiene and IPC

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Nicolas REINOSO SCHILLER

A / 6 / 28

Poster P3464

Abstract 3077

Factors influencing healthcare workers' compliance with infection prevention and control measures in acute care settings during the COVID-19 pandemic in Canada

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Nicole ROBERTSON

B / 6 / 1

Poster P3465

Abstract 3515

Healthcare workers known to be colonised with livestock-associated methicillin-resistant Staphylococcus aureus did not cause nosocomial transmission

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Thera HABBEN JANSEN

B / 6 / 2

Poster P3466

Abstract 3581

Electronic hand hygiene monitoring tools for implementation of optimal hand sanitising adherence in neonatal intensive care

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Chiara MINOTTI

B / 6 / 3

Poster P3467

Abstract 3769

A multimodal approach to high consequence infectious disease training

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Cecilia TUUDAH

B / 6 / 4

Poster P3468

Abstract 4175

Results of electronic monitoring of hand hygiene performance in Dutch primary care

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Nataliya HILT

B / 6 / 5

Poster P3469

Abstract 4503

Assessing the Hawthorne effect: implications and solutions

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Syed Faisal MAHMOOD

B / 6 / 6

Poster P3470

Abstract 5164

Adherence to hand hygiene in the five moments in an intensive care unit of a reference hospital for infectious diseases in the state of San Paulo, Brazil

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Raquel Keiko DE LUCA ITO

B / 6 / 7

Poster P3471

Abstract 5429

Occupational HIV exposures and post-exposure prophylaxis practices in Indian healthcare organisations: a survey

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Jasper Victoria Leelarani MARTINRAJ

B / 6 / 8

Poster P3472

Abstract 6244

Evaluation of the infection prevention and control education program for all medical master students at Radboud university medical centre, the Netherlands

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Olga COENEN

B / 6 / 10

Poster P3474

Abstract 6745

Preparing first-line health care workers in the Flemish health care system for 'Virus X' (FiLi-Vi-X)

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Annelies MONDELAERS

B / 6 / 11

Poster P3475

Abstract 6876

A decade of high-level isolation unit activities at Antwerp university hospital: lessons learned and future challenges (2014-2023)

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Annelies MONDELAERS

B / 6 / 12

Poster P3476

Abstract 6880

Infection prevention and control and water, sanitation and hygiene training for strengthening national outbreak capacity in the eastern mediterranean region

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

April BALLER

B / 6 / 13

Poster P3477

Abstract 7554

Assessing infection control readiness in LMIC hospitals through mystery patient drills

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Syed Faisal MAHMOOD

B / 6 / 14

Poster P3478

Abstract 8308

Evaluation of the knowledge of doctors in training at the Mohamed VI university hospital of Marrakech regarding blood exposure accidents

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Fatima IHBIBANE

B / 6 / 15

Poster P3479

Abstract 8853

Evaluation of infection prevention and control practices at a tertiary care hospital in southwest Ethiopia

30/04 12:00

8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices)

Mulualem Tadesse JANO

A / 7 / 1

Poster P3480

Abstract 772

Clostridioides difficile toxin B suppresses the migration ability in human neutrophils

30/04 12:00

9a. Microbial pathogenesis & virulence

Yoshitaka KIMURA

A / 7 / 2

Poster P3481

Abstract 1005

Decoding Acinetobacter pittii: unveiling phenotypic and genotypic traits in seven isolates

30/04 12:00

9a. Microbial pathogenesis & virulence

Nadya RAKOVITSKY

A / 7 / 3

Poster P3482

Abstract 1143

Testosterone alters the virulence traits of uropathogenic Escherichia coli

30/04 12:00

9a. Microbial pathogenesis & virulence

Rongrong WU

A / 7 / 4

Poster P3483

Abstract 1191

ST218 Klebsiella pneumoniae became a high-risk clone for multidrug resistance and hypervirulence

30/04 12:00

9a. Microbial pathogenesis & virulence

Ping YANG

A / 7 / 5

Poster P3484

Abstract 1645

Alpha-1-antitrypsin as novel target of Staphylococcus aureus' Spl proteases

30/04 12:00

9a. Microbial pathogenesis & virulence

Franziska SCHERR

A / 7 / 6

Poster P3485

Abstract 1872

Polymicrobial interactions: implications for virulence in chronic lung disease

30/04 12:00

9a. Microbial pathogenesis & virulence

Natasha SARWAR

A / 7 / 8

Poster P3487

Abstract 2584

Virulence factors among carbapenem-resistant Klebsiella pneumoniae in Portugal: a multicentre study

30/04 12:00

9a. Microbial pathogenesis & virulence

Gabriel MENDES

A / 7 / 9

Poster P3488

Abstract 2662

Molecular and phenotypic approaches to characterise virulence determinants among clinical Staphylococcus lugdunensis isolates

30/04 12:00

9a. Microbial pathogenesis & virulence

Christophe ISNARD

A / 7 / 10

Poster P3489

Abstract 2695

Virulence Factor Profiles of carbapenem-resistant Acinetobacter baumannii harbouring blaOXA-24/40 involved in two outbreaks in a Tertiary Hospital in northern Spain

30/04 12:00

9a. Microbial pathogenesis & virulence

Maitane ARANZAMENDI

A / 7 / 11

Poster P3490

Abstract 2840

Roles of mltB1-rlpA-dacC operon in bacterial morphology and β-lactam susceptibility in Stenotrophomonas maltophilia

30/04 12:00

9a. Microbial pathogenesis & virulence

Cheng-Mu WU

A / 7 / 12

Poster P3491

Abstract 2850

Virulence mechanism changes in colistin tolerant K.pneumoniae, A.baumannii, and P.aeruginosa cells at the transcriptomic level

30/04 12:00

9a. Microbial pathogenesis & virulence

Cansel VATANSEVER

A / 7 / 13

Poster P3492

Abstract 2962

Microbiological features and clinical impact of the T6SS in Pseudomonas aeruginosa isolates

30/04 12:00

9a. Microbial pathogenesis & virulence

Telma Susana LOPES DE SOUSA

A / 7 / 14

Poster P3493

Abstract 3170

Testing physiologically relevant oxygen concentrations on antibiotic susceptibility and virulence of classical multidrug-resistant, hypervirulent and convergent Klebsiella pneumoniae lineages

30/04 12:00

9a. Microbial pathogenesis & virulence

Amal AL-BAKRI

A / 7 / 15

Poster P3494

Abstract 3722

Disappearance and recovery of ompW protein in cellular membrane of Acinetobacter baumannii in relation with colistin resistance

30/04 12:00

9a. Microbial pathogenesis & virulence

Jale BORAL

A / 7 / 16

Poster P3495

Abstract 3777

The roles of Wzc variants on hypermucoviscosity (HMV) and capsular polysaccharide (CPS) production in Klebsiella pneumoniae

30/04 12:00

9a. Microbial pathogenesis & virulence

Wenxing ZHAO

A / 7 / 17

Poster P3496

Abstract 3790

Cyclophilin AIL09810.1 from Stenotrophomonas maltophilia has a PPIase activity and could potentially be inhibited by non-peptide small-molecule cyclophilin inhibitors

30/04 12:00

9a. Microbial pathogenesis & virulence

Francoise BOTTEREL

A / 7 / 18

Poster P3497

Abstract 3851

Evolution of triclosan resistance modulates bacterial permissiveness to multidrug resistance plasmids and phages

30/04 12:00

9a. Microbial pathogenesis & virulence

Qiu YANG

A / 7 / 19

Poster P3498

Abstract 3910

Inter-species interactions alter antimicrobial susceptibility in polymicrobial infection scenarios

30/04 12:00

9a. Microbial pathogenesis & virulence

Eva BENYEI

A / 7 / 20

Poster P3499

Abstract 3919

Impact of genomic adaptation on stress response and virulence of sequential urinary isolates of Pseudomonas aeruginosa

30/04 12:00

9a. Microbial pathogenesis & virulence

Caroline MARTIN-DUVAL

A / 7 / 21

Poster P3500

Abstract 4199

Characterisation of the outer membrane vesicles of Pseudomonas aeruginosa exhibiting growth inhibition against Acinetobacter baumannii

30/04 12:00

9a. Microbial pathogenesis & virulence

Jinwoong SUH

A / 7 / 22

Poster P3501

Abstract 4743

Comparative genomic markers of Staphylococcus epidermidis strains causing bone and joint infection with skin colonisers

30/04 12:00

9a. Microbial pathogenesis & virulence

Mauro SALLES

A / 7 / 23

Poster P3502

Abstract 5002

Pig farms in crisis: Reveals imminent threats of antibiotic resistance, biofilm formation and high-risk clonal lineages

30/04 12:00

9a. Microbial pathogenesis & virulence

Adriana SILVA

A / 7 / 24

Poster P3503

Abstract 5958

Hypervirulent Klebsiella pneumoniae isolates from the Western Cape of South Africa

30/04 12:00

9a. Microbial pathogenesis & virulence

Amike DE VILLIERS

A / 7 / 25

Poster P3504

Abstract 6095

The FhaB/C two partner secretion system plays an important role in the pathogenesis of Klebsiella pneumoniae ST15

30/04 12:00

9a. Microbial pathogenesis & virulence

Ana TAJUELO MORENO-PALANCAS

A / 7 / 26

Poster P3505

Abstract 6192

Altered virulence patterns in the ST235 high-risk clone of carbapenem-resistant Pseudomonas aeruginosa

30/04 12:00

9a. Microbial pathogenesis & virulence

Cansel VATANSEVER

A / 7 / 27

Poster P3506

Abstract 6345

Implication of colanic acid in the pathogenicity of adherent-invasive Escherichia coli

30/04 12:00

9a. Microbial pathogenesis & virulence

Queralt BONET-ROSSINYOL

A / 7 / 28

Poster P3507

Abstract 6557

Phylogenic and genomic comparative studies of Pseudomonas aeruginosa strains without the type III secretion system

30/04 12:00

9a. Microbial pathogenesis & virulence

Yolanda SAENZ

B / 7 / 1

Poster P3508

Abstract 6833

Pilus expression and gene copy number dynamics in Neisseria meningitidis causing invasive disease vs carriage

30/04 12:00

9a. Microbial pathogenesis & virulence

Sara THULIN HEDBERG

B / 7 / 2

Poster P3509

Abstract 7731

Streptococcus sanguinis strains isolated from patients with infective endocarditis show immune system evasion mechanisms

30/04 12:00

9a. Microbial pathogenesis & virulence

Livia ARAUJO ALVES

B / 7 / 3

Poster P3510

Abstract 7746

Clinical GBS strains display membrane damaging activity which is glucose dependent

30/04 12:00

9a. Microbial pathogenesis & virulence

Emelie ALSHEIM

B / 7 / 4

Poster P3511

Abstract 7893

Exploring microbial interaction in polymicrobial biofilms: impact on biomass and antibiotic susceptibility

30/04 12:00

9a. Microbial pathogenesis & virulence

Tiago LIMA

B / 7 / 5

Poster P3512

Abstract 8255

Corema album activity against biofilm formation and adhesion in Streptococcus pyogenes

30/04 12:00

9a. Microbial pathogenesis & virulence

Nádia OSÓRIO

B / 7 / 6

Poster P3513

Abstract 8883

Unusual hypermucoid KPC-producing Klebsiella pneumoniae Sequence Type 101

30/04 12:00

9a. Microbial pathogenesis & virulence

Alice DE FRANCESCO

B / 7 / 7

Poster P3514

Abstract 220

The impacts of the crosstalk between bacterial vaginosis associated bacteria and Trichomonas vaginalis on the pathogenesis and host immune responses

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Shu-Fang CHIU

B / 7 / 7

Poster P3514

Abstract 1764

Gut microbiome characterisation of inflammatory bowel disease, Clostridioides difficille infection and co-infection

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Silvia Noemi VAZQUEZ CUESTA

B / 7 / 8

Poster P3515

Abstract 320

In vivo mapping of key bacterial species reveals Enterococcus faecalis and Escherichia coli as promising biomarkers of postmortem interval estimation

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Ana Raquel FREITAS

B / 7 / 9

Poster P3516

Abstract 403

Ex vivo modeling of pneumonia-associated bacterial infections using hamster precision-cut lung tissue slices

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Hsung-Yu CHEN

B / 7 / 10

Poster P3517

Abstract 517

Impact of achieving bone sterilisation on bone architecture and bone marrow, in an experimental rabbit model of osteomyelitis caused by carbapenemase-producing Enterobacterales

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Benjamin DAVIDO

B / 7 / 11

Poster P3518

Abstract 520

Synchrony or divergence? Exploring the vaginal and endometrial microbiome

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Courtney POVEY

B / 7 / 12

Poster P3519

Abstract 929

Ciprofloxacin residues in food can induce resistance to ciprofloxacin in Klebsiella pneumoniae in Galleria mellonella

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Chris KENYON

B / 7 / 13

Poster P3520

Abstract 1011

Establishing Zophobas morio larvae as a model for the study of Klebsiella pneumoniae virulence and therapeutics

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Nadya RAKOVITSKY

B / 7 / 14

Poster P3521

Abstract 1096

Impact of gestation, maternal diet and low body mass index (BMI) on breastmilk microbiome of Indian mothers delivering preterm

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Anwesha CHAKRABORTY

B / 7 / 15

Poster P3522

Abstract 1139

Associations between the gut microbiome, inflammation and cardiovascular profiles in People with HIV (PWH)

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Rachel MAC CANN

B / 7 / 16

Poster P3523

Abstract 1544

Analgesia with buprenorphine influences clinical relevant outcome parameters in experimental pneumococcal meningitis

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Denis GRANDGIRARD

B / 7 / 17

Poster P3524

Abstract 1626

High-frequency apoptosis upon human splenic macrophages after phagocytosis of blood borne pathogens

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Marco Rinaldo OGGIONI

B / 7 / 18

Poster P3525

Abstract 1900

THP-1 infection model for characterization of clinical Mycobacterium abscessus strains from Cystic Fibrosis patients: a multicenter study.

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Alba RUEDAS LÓPEZ

B / 7 / 19

Poster P3526

Abstract 1952

Alterations in gut microbiome-immune interface in multiple sclerosis

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Simeon NTHUKU

B / 7 / 20

Poster P3527

Abstract 2087

Urinary tract microbiological diversity of healthy young men in Poland

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Filip BIELEC

B / 7 / 21

Poster P3528

Abstract 2116

Cefiderocol and inoculum effect: discordant results between in vitro and murine model of peritonitis

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Agnès LEFORT

B / 7 / 22

Poster P3529

Abstract 2229

Delving into the oral-gut axis: within-host evolution and dynamics of oral and intestinal streptococci

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Mohamed M. H. ABDELBARY

B / 7 / 23

Poster P3530

Abstract 2241

A four-member defined microbial community and its soluble products protect mice from Clostridioides difficile infection

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Katya DOUCHANT

B / 7 / 24

Poster P3531

Abstract 2381

Deepness of dormancy of intracellular persisters of Escherichia coli selected by ciprofloxacin depends on host cell oxidative stress

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Gang WANG

B / 7 / 25

Poster P3532

Abstract 2397

Staphylococcus epidermidis has low internalization capacity in periprosthetic nonprofessional phagocytic cells

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Anne-Lise MAUCOTEL

B / 7 / 26

Poster P3533

Abstract 2484

Salmonella type 1 fimbriae induce interferon-β expression via Toll-like receptor in macrophages

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Uchiya KEI-ICHI

B / 7 / 27

Poster P3534

Abstract 2510

Ultraviolet A light, a novel approach to combat ventilator-associated pneumonia caused by Pseudomonas aeruginosa: an animal study

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Blanca LLONCH BERTRAND

B / 7 / 28

Poster P3535

Abstract 2525

Clinical isolates of P. aeruginosa cause different virulence biomarker signatures in the course of a chronic lung infection model

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Katharina ROX

A / 8 / 1

Poster P3536

Abstract 2703

Nasal microbiota influence clinical response in chronic rhinosinusitis with nasal polyps in surgery and monoclonal treatments

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Gaia VERTILLO ALUISIO

A / 8 / 2

Poster P3537

Abstract 2852

Urinary tract microbiome of asymptomatic individuals with spinal cord injury

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Ezra VALIDO

A / 8 / 3

Poster P3538

Abstract 2897

HOCl-producing electrochemical bandages for treating MRSA and polymicrobial murine wound infections

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Derek FLEMING

A / 8 / 4

Poster P3539

Abstract 2914

The immune modulator role of the peg344 gene among Hypervirulent Klebsiella pneumoniae (hvKp)

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Güz EKINCI

A / 8 / 5

Poster P3540

Abstract 3466

Multi-kingdom oral microbiome analysis identifies biomarkers of early-onset cryptogenic ischemic stroke

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Muhammed MANZOOR

A / 8 / 6

Poster P3541

Abstract 3474

Glatiramer acetate used for the treatment of multiple sclerosis stimulates phagocytosis and intracellular killing of Escherichia coli by peritoneal macrophages and microglia

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Roland NAU

A / 8 / 7

Poster P3542

Abstract 4240

A pilot study to investigate the competence of the eye-seeking fly Musca sorbens as a vector for ocular strains of Chlamydia trachomatis

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Eyob Addise WORKNEH

A / 8 / 8

Poster P3543

Abstract 4251

Different phylotypes of Cutibacterium acnes strains were able to infect an in vivo model of Galleria mellonella

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Mariana NERI LUCAS KURIHARA

A / 8 / 9

Poster P3544

Abstract 4468

Duration of cefazolin prophylaxis did not impact periprosthetic joint infection (PJI) risk in a murine model of total joint arthroplasty

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Melissa KARAU

A / 8 / 10

Poster P3545

Abstract 4478

Characterising the synovial microbiome: a role for nanopore sequencing?

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Chuo CHER BING

A / 8 / 11

Poster P3546

Abstract 4765

Humanised serum concentrations of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam against carbapenem-resistant Enterobacter cloacae

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Thomas LAVOIE

A / 8 / 12

Poster P3547

Abstract 4883

In vivo evolution of antimicrobial resistance in a biofilm model of Pseudomonas aeruginosa chronic lung infection

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Doaa HIGAZY

A / 8 / 13

Poster P3548

Abstract 4950

Neutrophil-mediated molecular immune response to bacterial CNS infection

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Dominika LUPTÁKOVÁ

A / 8 / 14

Poster P3549

Abstract 5065

Impact of antibiotic substance class and duration on intestinal microbiome alterations and presence of fungi

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Lena BIEHL

A / 8 / 15

Poster P3550

Abstract 5178

Quantitative assessment of pneumococcal urinary antigen reflects the severity of pneumonia and the effect of antibiotics treatment in pneumococcal pneumonia mouse model

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Shota KIKUCHI

A / 8 / 16

Poster P3551

Abstract 5267

Inhibition of high-priority respiratory pathogens is a general feature of the fastidious nasal commensal Dolosigranulum pigrum

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Nathan WEBER

A / 8 / 17

Poster P3552

Abstract 5418

Melatonin induces antiviral effect in human intestinal organoids via type III IFN pathway

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Milda SESKUTE

A / 8 / 18

Poster P3553

Abstract 5504

Gut Muribaculaceae determines susceptibility to sepsis by modulating the systemic immune response

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Hwi Won SEO

B / 8 / 1

Poster P3554

Abstract 6060

Characterization of Escherichia coli present in maternal-infant environment

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Manuel BERNABEU

B / 8 / 2

Poster P3555

Abstract 6152

Giardia infection is associated with altered Commensal Microbial Diversity of the Murine Gut

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Sucheta GULERIA

B / 8 / 3

Poster P3556

Abstract 6166

Human papillomavirus infection and cervico-vaginal microbiome in women in the sub-Himalayan population of India

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Shailesh Kumar GUPTA

B / 8 / 4

Poster P3557

Abstract 6279

Probing the Antimicrobial Arsenal: Characterization and Evaluation of a Proteus Phage isolated from Human Pus against Predefined Multidrug-Resistant Host-Range

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Sreska SHRESTHA

B / 8 / 5

Poster P3558

Abstract 6298

Interaction between IgA and Methanobrevibacter smithii in early onset of Multiple Sclerosis

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Tea SONICKI

B / 8 / 6

Poster P3559

Abstract 6328

Differential phagocytosis and cytokine response to Mycobacterium massiliense and Mycobacterium abscessus in human keratinocytes

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Un In WU

B / 8 / 7

Poster P3560

Abstract 6389

Microbiome analysis of non-healing diabetic foot ulcers reveal distinct patient specific microbiomes containing fungi that are minimally impacted by antibiotic therapy

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Craig WILLIAMS

B / 8 / 8

Poster P3561

Abstract 6531

Dietary consumption of antibiotics can favour the colonization of antibiotic resistant Gram-negative pathogens (ARGNs) in an ex-vivo model of the human gut microbiome

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Didier HOCQUET

B / 8 / 9

Poster P3562

Abstract 6976

Characterization of Enterococcus faecalis-platelet interactions: insights into infective endocarditis mechanisms

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Mustapha Abdeljalil BRAI

B / 8 / 10

Poster P3563

Abstract 6989

Effect of metabolites produced by pathogenic microbes on wound healing

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Chandni SACHDEVA

B / 8 / 11

Poster P3564

Abstract 7105

Faecal microbiota transplantation alleviates alcohol preference in vulnerable stressed rats

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Sedreh NASSIRNIA

B / 8 / 12

Poster P3565

Abstract 7237

Characterisation of Enterococcus faecalis, platelet interactions: insights into infective endocarditis

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Mustapha Abdeljalil BRAI

B / 8 / 13

Poster P3566

Abstract 7279

Antagonistic interactions among clinical isolates of Staphylococcus aureus and Pseudomonas aeruginosa in ex vivo donor cornea model of polymicrobial infections

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Sanchita MITRA

B / 8 / 14

Poster P3567

Abstract 7547

Location and profile of commensal bacteria in human milk

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Ambika SHARMA

B / 8 / 15

Poster P3568

Abstract 7601

A porcine model of pyelonephritis with uropathogenic Escherichia coli

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Kristian STÆRK

B / 8 / 16

Poster P3569

Abstract 7718

Investigating bacterial infections in Galleria mellonella larvae: insights into pathogen dissemination and behavior

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Admella Pedrico JOANA

B / 8 / 17

Poster P3570

Abstract 7749

The taxonomic structure of lung-associated microbiota can modulate tumor microenvironment

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Emerenziana OTTAVIANO

B / 8 / 18

Poster P3571

Abstract 7853

Enriched polyphenol cultures of Lactobacillus helveticus and Lactobacillus rhamnosus inhibit Candida albicans growth and modulate pro-inflammatory signaling

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Silvia RIZZO

A / 9 / 1

Poster P3572

Abstract 8003

Skin microbiome of healthcare workers who utilised individual protective masks during and after the SARS-CoV-2 pandemic

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Joyce Vanessa Da Silva FONSECA

A / 9 / 2

Poster P3573

Abstract 8041

The pro-inflammatory signature of gut microbiota in CDKL5 disorder

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Elisa BORGHI

A / 9 / 3

Poster P3574

Abstract 8100

Strong homology between colonising and bloodstream carbapenem-resistant Acinetobacter spp.: implications for empiric antibiotic therapy in haematological patients

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Jia LI

A / 9 / 4

Poster P3575

Abstract 8479

Evaluation of gastric microbiota and gastric cancer association in patients infected with Helicobacter pylori

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Dogukan OZBEY

A / 9 / 5

Poster P3576

Abstract 8546

Gut microbiota composition and Clostridioides difficile infection: the potential protective role of Faecalibacterium prausnitzii

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Nadim CASSIR

A / 9 / 6

Poster P3577

Abstract 8575

Role of the T4aP pilus of P. aeruginosa in recognition by the innate immune system

30/04 12:00

9b. Host-pathogen interaction (incl basic microbiome studies, animal models)

Youssouf SEREME

A / 9 / 7

Poster P3578

Abstract 61

Oral biofilm engineering: in vitro oral biofilm model for mimicking biofilm development under in vivo conditions on Ti6Al4V and Y-TZP specimens

30/04 12:00

9c. Pre-clinical biofilm studies

Romualdus Nugraha Catur UTOMO

A / 9 / 8

Poster P3579

Abstract 151

Anti-biofilm characterisation of PEEK coated with antiseptics

30/04 12:00

9c. Pre-clinical biofilm studies

Marta DÍAZ-NAVARRO

A / 9 / 9

Poster P3580

Abstract 255

Under the hypercapnic challenge: how macrophages react to pneumonia-causing bacteria

30/04 12:00

9c. Pre-clinical biofilm studies

Elena CAMPAÑA-DUEL

A / 9 / 10

Poster P3581

Abstract 381

Development of inhaled dry powder fluconazole and investigation of the effectiveness in the eradication of Candida albicans biofilms

30/04 12:00

9c. Pre-clinical biofilm studies

Reham ALJALAMDEH

A / 9 / 11

Poster P3582

Abstract 547

Clone-specific effect of ibuprofen, paracetamol and acetylsalicylic acid on growth and biofilm formation of methicillin-resistant Staphylococcus aureus

30/04 12:00

9c. Pre-clinical biofilm studies

Adéla ROZSYPÁLKOVÁ

A / 9 / 12

Poster P3583

Abstract 812

Staphylococcus aureus biofilm attachment strength correlated to zeta-potential charge

30/04 12:00

9c. Pre-clinical biofilm studies

Thomas LAVOIE

A / 9 / 13

Poster P3584

Abstract 981

Determination of multidrug-resistant Proteus mirabilis biofilm formation ability of urinary infection in pregnant women

30/04 12:00

9c. Pre-clinical biofilm studies

Maryna MISHYNA

A / 9 / 14

Poster P3585

Abstract 1070

Oral ciprofloxacin biofilm activity in a catheter-associated urinary tract infection model

30/04 12:00

9c. Pre-clinical biofilm studies

Iain ABBOTT

A / 9 / 15

Poster P3586

Abstract 1117

Optimising biofilm management: thymol's synergistic partnership with antibiotics

30/04 12:00

9c. Pre-clinical biofilm studies

María Rosa PINO OTÍN

A / 9 / 16

Poster P3587

Abstract 1155

SdiA regulates biofilm maturation of Klebsiella pneumoniae in response to C6-HSL

30/04 12:00

9c. Pre-clinical biofilm studies

Sergio SILVA BEA

A / 9 / 17

Poster P3588

Abstract 1212

Glucosazone as an inhibitor of quorum sensing in biofilm-forming P. aeruginos, an in silico and in vitro study

30/04 12:00

9c. Pre-clinical biofilm studies

Prasanna Kumar Reddy GAYAM

A / 9 / 18

Poster P3589

Abstract 1409

The antifungal luliconazole is efficient against Aspergillus fumigatus biofilm formation in human-like models

30/04 12:00

9c. Pre-clinical biofilm studies

Dan-Tiberiu FURNICA

A / 9 / 19

Poster P3590

Abstract 1779

Quantification and comparison of different biofilm components from methicillin-susceptible Staphylococcus aureus treated with tranexamic acid using an in vitro model

30/04 12:00

9c. Pre-clinical biofilm studies

Marta DÍAZ-NAVARRO

A / 9 / 20

Poster P3591

Abstract 1904

Tiered approach to predict in vitro antibiofilm activity of plant extracts against cystic fibrosis isolates for drug discovery and development

30/04 12:00

9c. Pre-clinical biofilm studies

Eduarda SILVA

B / 9 / 1

Poster P3592

Abstract 2233

Activity of phage alone and with vancomycin against periprosthetic joint infection-associated Staphylococcus aureus, Staphylococcus epidermidis and Staphylococcus lugdunensis on orthopedic Kirschner wires: an in vitro study

30/04 12:00

9c. Pre-clinical biofilm studies

Judith ALVAREZ OTERO

B / 9 / 2

Poster P3593

Abstract 2426

Biofilm formation and antibiotic tolerance in Staphylococcus aureus from spinal cord stimulation device-related infections

30/04 12:00

9c. Pre-clinical biofilm studies

Francesca SIVORI

B / 9 / 3

Poster P3594

Abstract 2460

Antimicrobial and antibiofilm activities of an electrolytic sodium hypochlorite solution against ESKAPE pathogens and Candida albicans from patients with infected pressure ulcers

30/04 12:00

9c. Pre-clinical biofilm studies

Giorgia FABRIZIO

B / 9 / 4

Poster P3595

Abstract 2467

Synergistic activity of amphotericin B with voriconazole against Trichosporon asahii biofilms: is it worth combining?

30/04 12:00

9c. Pre-clinical biofilm studies

Konstantinos ZARRAS

B / 9 / 5

Poster P3596

Abstract 2573

Genotypic and phenotypic characterisation of biofilm-forming Borrelia burgdorferi s.l. strains isolated from patients with erythema migrans

30/04 12:00

9c. Pre-clinical biofilm studies

Giorgia FABRIZIO

B / 9 / 6

Poster P3597

Abstract 2601

Pseudomonas mendocina isolated from Anopheles midguts generates thick biofilms: a potential new malaria transmission blocking tool

30/04 12:00

9c. Pre-clinical biofilm studies

Sofia Santos COSTA

B / 9 / 7

Poster P3598

Abstract 2645

Effectiveness of clindamycin in treatment strategies for staphylococcal mature biofilm-associated infections?

30/04 12:00

9c. Pre-clinical biofilm studies

Sven VAN DUN

B / 9 / 8

Poster P3599

Abstract 2988

Synergistic effect of N-acetyl-L-cysteine and propolis dry extract combination on bacterial biofilms of upper respiratory tract pathogens

30/04 12:00

9c. Pre-clinical biofilm studies

Dragana BOZIC

B / 9 / 10

Poster P3601

Abstract 3618

Biofilm development of enteropathogenic bacteria according to growth temperature

30/04 12:00

9c. Pre-clinical biofilm studies

Marina MEDEL PLAZA

B / 9 / 11

Poster P3602

Abstract 3652

Induction thermal disinfection: in vitro and in vivo control of mature biofilms on prosthetic metal components

30/04 12:00

9c. Pre-clinical biofilm studies

Marina MEDEL PLAZA

B / 9 / 12

Poster P3603

Abstract 3798

Are quaternary ammonium compounds effective against carbapenemase-producing microorganisms?

30/04 12:00

9c. Pre-clinical biofilm studies

Elisabeth PRESTERL

B / 9 / 13

Poster P3604

Abstract 3969

Biofilm formation and multidrug resistance in strains isolated from medical device-associated infection

30/04 12:00

9c. Pre-clinical biofilm studies

Alba SANCHEZ MORILLO

B / 9 / 14

Poster P3605

Abstract 4213

Anti-biofilm activity of virulent Acinetobacter baumannii phages encoding depolymerases

30/04 12:00

9c. Pre-clinical biofilm studies

Sezin UNLU

B / 9 / 15

Poster P3606

Abstract 4253

Characterization of biofilm matrix of Staphylococcus lugdunensis reveals key differences according to strain and iron availability

30/04 12:00

9c. Pre-clinical biofilm studies

Laurie DESTRUEL

B / 9 / 16

Poster P3607

Abstract 5081

Breast Implant Topography Influences S. epidermidis Biofilm: A Comparative In Vivo Study.

30/04 12:00

9c. Pre-clinical biofilm studies

Francisco CARMONA-TORRE

B / 9 / 18

Poster P3609

Abstract 5707

Pharmacodynamic modeling of colistin and imipenem against in vitro P. aeruginosa biofilms

30/04 12:00

9c. Pre-clinical biofilm studies

Yuchen GUO

B / 9 / 19

Poster P3610

Abstract 5807

Activities of CSA-44 and CSA-131 against Staphylococcus aureus and Pseudomonas aeruginosa biofilms in collagen wound biofilm and Caenorhabditis elegans model systems

30/04 12:00

9c. Pre-clinical biofilm studies

Fatima Nur YILMAZ

B / 9 / 20

Poster P3611

Abstract 6300

Antibiofilm activity of a broad-spectrum novel antimicrobial hydrogel in an ex vivo porcine wound infection model

30/04 12:00

9c. Pre-clinical biofilm studies

Hawraa SHAHROUR

A / 10 / 1

Poster P3612

Abstract 6316

Novel compounds with an isocyanide pharmacophore show antimicrobial and antibiofilm activity against multidrug-resistant staphylococci

30/04 12:00

9c. Pre-clinical biofilm studies

Chiara CERESA

A / 10 / 2

Poster P3613

Abstract 6341

Selenocompounds as efflux pump and biofilm inhibitors on Staphylococcus aureus strains

30/04 12:00

9c. Pre-clinical biofilm studies

Gabriella SPENGLER

A / 10 / 3

Poster P3614

Abstract 6354

Evolution of invasive Salmonella typhimurium towards decreased biofilm formation

30/04 12:00

9c. Pre-clinical biofilm studies

Enya ARCONADA NUIN

A / 10 / 4

Poster P3615

Abstract 6358

Psoralen plus UVA (PUVA) treatment as an effective intervention to prevent biofilm formation of Staphylococcus aureus in patients' wounds

30/04 12:00

9c. Pre-clinical biofilm studies

Mohammad POOYA

A / 10 / 5

Poster P3616

Abstract 6558

Evasion of host immune system by Acinetobacter baumannii biofilm

30/04 12:00

9c. Pre-clinical biofilm studies

Deepak KUMAR

A / 10 / 6

Poster P3617

Abstract 6650

3D printed melt electrowritten drug eluting fibre for prevention of device-associated infections: a pilot study

30/04 12:00

9c. Pre-clinical biofilm studies

Joana MARTINS

A / 10 / 7

Poster P3618

Abstract 6907

Evaluation of Direct and Alternating Electrical Current against Staphylococcus aureus Biofilms

30/04 12:00

9c. Pre-clinical biofilm studies

Rima FANAEI PIRLAR

A / 10 / 8

Poster P3619

Abstract 7111

Combination of sonication with dithiothreitol treatment does not improve bacterial dislodging from biofilm in an in vitro model

30/04 12:00

9c. Pre-clinical biofilm studies

Elena DE VECCHI

A / 10 / 9

Poster P3620

Abstract 7135

Biofilm formation and mucosal barrier disruption by mycobacteria on airway epithelial cells

30/04 12:00

9c. Pre-clinical biofilm studies

Amy BARCLAY

A / 10 / 10

Poster P3621

Abstract 7519

Acetylation of xenogenetic silencer H-NS regulates biofilm developmemt through the nitrogen homeostasis regulator in Shewanella

30/04 12:00

9c. Pre-clinical biofilm studies

Xiaoxiao LIU

A / 10 / 11

Poster P3622

Abstract 7525

Iminosugar PDIA as potential novel antibiofilm compound that shows in vivo activity against staphylococcal skin wound infection in mice

30/04 12:00

9c. Pre-clinical biofilm studies

Edyta GOLINSKA

A / 10 / 12

Poster P3623

Abstract 7652

Degradation of preformed Gram-positive and Gram-negative bacteria biofilms using disintegrated and intact phages

30/04 12:00

9c. Pre-clinical biofilm studies

Abdulkerim KARAYNIR

A / 10 / 13

Poster P3624

Abstract 7689

Phage-encoded novel DP21 enzyme, a polysaccharide depolymerase, prevents and destruct biofilms of various species

30/04 12:00

9c. Pre-clinical biofilm studies

Salih Dogan HANIFE

A / 10 / 14

Poster P3625

Abstract 7762

Periprosthetic hip and knee joint infection: biofilm and c-di-GMP production

30/04 12:00

9c. Pre-clinical biofilm studies

Andrea LIBERATORE

A / 10 / 15

Poster P3626

Abstract 8005

Antibacterial and Antibiofilm potential of green synthesised nanoparticles by optimising its reaction parameters against multidrug-resistant clinical isolates of nosocomial infections

30/04 12:00

9c. Pre-clinical biofilm studies

Diksha DIKSHA

A / 10 / 16

Poster P3627

Abstract 8007

Does biofilm forming capacity responsible for antifungal resistance among the Trichophyton mentagrophytes/interdigitale complex isolates without mutation in squalene gene (F397L)?

30/04 12:00

9c. Pre-clinical biofilm studies

Dipika SHAW

A / 10 / 17

Poster P3628

Abstract 8753

Mucin drives fitness trade-offs between phage resistance and biofilm formation in Yersinia enterocolitica serotype O:8

30/04 12:00

9c. Pre-clinical biofilm studies

Sophie GHOLADZE

A / 10 / 18

Poster P3629

Abstract 8919

In vitro biofilm formation by methicillin-resistant S. aureus in skin, blood, and bone/joint infections

30/04 12:00

9c. Pre-clinical biofilm studies

Kevin BOUILLER

A / 10 / 19

Poster P3630

Abstract 47

CRISPRi-seq identifies genes enhancing phage lysin Cpl-1 susceptibility in S. pneumoniae

30/04 12:00

9d. Experimental and cellular microbiology

Hugues DE VILLIERS DE LA NOUE

A / 10 / 20

Poster P3631

Abstract 544

Mutations triggered by antiseptic and antibiotic selective pressure on clinical Pseudomonas aeruginosa isolates

30/04 12:00

9d. Experimental and cellular microbiology

Laurent POIREL

B / 10 / 1

Poster P3632

Abstract 585

Bactericidal effect and the mechanism by the high-speed water nanodroplet generation technology as a new sterilisation method

30/04 12:00

9d. Experimental and cellular microbiology

Yurina TAMURA

B / 10 / 2

Poster P3633

Abstract 659

HemU (Smlt3895) is the inner membrane transporter responsible for hemin acquisition in Stenotrophomonas maltophilia

30/04 12:00

9d. Experimental and cellular microbiology

Tsuey-Ching YANG

B / 10 / 3

Poster P3634

Abstract 711

Comparison between brand-name and generic drugs about meropenem-induced endotoxin release in Pseudomonas aeruginosa

30/04 12:00

9d. Experimental and cellular microbiology

Masato KAWAMURA

B / 10 / 4

Poster P3635

Abstract 736

FepA, FciA, and SbaA are the TonB-dependent transporters responsible for ferri-stenobactin uptake in Stenotrophomonas maltophilia KJ

30/04 12:00

9d. Experimental and cellular microbiology

Li-Hua LI

B / 10 / 5

Poster P3636

Abstract 808

Diversity in infection capacity of epidemic and sporadic vancomycin-variable and resistant Enterococcus faecium isolates studied in an in vitro intestinal flow model

30/04 12:00

9d. Experimental and cellular microbiology

Ditte RASK TORNBY

B / 10 / 6

Poster P3637

Abstract 901

Influencing the paedatric oral resistome: host genetics, environment or mother?

30/04 12:00

9d. Experimental and cellular microbiology

Elena MARTINEZ

B / 10 / 7

Poster P3638

Abstract 947

Induction of antibiotic resistance in Klebsiella pneumoniae: a study on the effects of sub-MIC ciprofloxacin exposure

30/04 12:00

9d. Experimental and cellular microbiology

Zina GESTELS

B / 10 / 8

Poster P3639

Abstract 1573

Development of an antibacterial plus bacteriophage combination assays

30/04 12:00

9d. Experimental and cellular microbiology

Marie ATTWOOD

B / 10 / 9

Poster P3640

Abstract 2358

Staphylococcal occupancy within the human nasal microbiota

30/04 12:00

9d. Experimental and cellular microbiology

Marc STEGGER

B / 10 / 10

Poster P3641

Abstract 2548

Effect of essential oils on microbial cultures tracked by Raman spectroscopy

30/04 12:00

9d. Experimental and cellular microbiology

Katarína REBROSOVÁ

B / 10 / 11

Poster P3642

Abstract 2634

Meropenem or ceftazidime/avibactam first in ESBL-harbouring Enterobacterales?

30/04 12:00

9d. Experimental and cellular microbiology

Doris ZOLLINGER

B / 10 / 12

Poster P3643

Abstract 2992

Graphene quantum dots as promising nanomaterials against Mycobacterium tuberculosis infection

30/04 12:00

9d. Experimental and cellular microbiology

Giulia SANTARELLI

B / 10 / 13

Poster P3644

Abstract 3037

A systematic characterization of the highly conserved Proteus mirabilis urease promoter

30/04 12:00

9d. Experimental and cellular microbiology

Madison FITZGERALD

B / 10 / 14

Poster P3645

Abstract 3098

Structural analysis and chemical mapping of individual bacteriophage using infrared nanospectroscopy

30/04 12:00

9d. Experimental and cellular microbiology

Yue CAO

B / 10 / 15

Poster P3646

Abstract 3117

Microbial growth enhancers and their influence on multi-drug resistance strains

30/04 12:00

9d. Experimental and cellular microbiology

Ilya KLEYN

B / 10 / 16

Poster P3647

Abstract 3153

Assessing mastoparan in eradicating persisters-manifested clinical isolates alone or in-combination with antibiotics and/or immune cells in-vitro

30/04 12:00

9d. Experimental and cellular microbiology

Andrea Lay Hoon KWA

B / 10 / 17

Poster P3648

Abstract 3321

Lactic acid as a factor preventing the development of urinary tract infections caused by Proteus mirabilis

30/04 12:00

9d. Experimental and cellular microbiology

Dominika SZCZERBIEC

B / 10 / 18

Poster P3649

Abstract 3419

Streptococcus pneumoniae serotype 8: to be or not to be mucoid

30/04 12:00

9d. Experimental and cellular microbiology

Joana GOMES-SILVA

B / 10 / 19

Poster P3650

Abstract 3535

A zeta potential study to measure S. aureus adhesion on human bone osteosarcoma cells

30/04 12:00

9d. Experimental and cellular microbiology

Paolo Giuseppe BONACCI

B / 10 / 20

Poster P3651

Abstract 4170

Understanding of quorum sensing profile in Staphylococcus aureus infections

30/04 12:00

9d. Experimental and cellular microbiology

Nerea CASTRO AGIRRE

A / 11 / 1

Poster P3652

Abstract 4936

Biosynthesis of titanium oxide nanoparticles using Olea europaea and evaluation of its antibiofilm potential against Pseudomonas aeruginosa isolates from cystic fibrosis patients

30/04 12:00

9d. Experimental and cellular microbiology

Hafez AL-MONMAI

A / 11 / 2

Poster P3653

Abstract 5244

Exploring the Vaginal Ecosystem in the Rhesus Macaques: A lesson from HIV prevention strategies

30/04 12:00

9d. Experimental and cellular microbiology

Kyla TOZER

A / 11 / 3

Poster P3654

Abstract 5593

Antibacterial, resistance modulation, anti-biofilm, and efflux pump inhibition properties of Loeseneriella africana (Willd.) N. Halle (Celastraceae) stem extract and its constituents

30/04 12:00

9d. Experimental and cellular microbiology

Jonathan ASANTE

A / 11 / 4

Poster P3655

Abstract 5874

Evaluation of the synergy, mutant prevention concentrations and resistance mechanisms to minocycline combinations with a novel cyclic peptide in Pseudomonas aeruginosa

30/04 12:00

9d. Experimental and cellular microbiology

Maria Antonia GOMIS FONT

A / 11 / 5

Poster P3656

Abstract 5888

In vitro activity in urine-mimicking acidic conditions and in vitro selection of resistant mutants for levofloxacin, moxifloxacin and delafloxacin against Enterococcus faecalis isolates responsible for male urinary tract infections

30/04 12:00

9d. Experimental and cellular microbiology

Vincent CATTOIR

A / 11 / 6

Poster P3657

Abstract 6164

Epistasis and antimicrobial resistance in the carbapenemase KPC-2

30/04 12:00

9d. Experimental and cellular microbiology

Zahia Inssaf NEDJARI

A / 11 / 7

Poster P3658

Abstract 6282

Natural loss of LPS biogenesis genes in Serratia spp.: lipid A analysis in bacteraemia isolates

30/04 12:00

9d. Experimental and cellular microbiology

Blanca PÉREZ VISO

A / 11 / 8

Poster P3659

Abstract 6453

Clinical E. coli isolates varies in persistence and antibiotic tolerance when exposed to β-lactams

30/04 12:00

9d. Experimental and cellular microbiology

Nicolai Riff ALEXANDERSEN

A / 11 / 9

Poster P3660

Abstract 6544

Developing a rapid phenotypic assessment of phage susceptibility using a nanomotion technology platform

30/04 12:00

9d. Experimental and cellular microbiology

Amanda LURASCHI-EGGEMANN

A / 11 / 10

Poster P3661

Abstract 6685

Enhanced supply of beneficial microbiota from maternal milk for preterm newborns through a milk personalisation process

30/04 12:00

9d. Experimental and cellular microbiology

Thaís SINCERO

A / 11 / 11

Poster P3662

Abstract 6782

Transmission mechanism of blaCTX-M-1 gene mediated by certain IncI1 plasmids in Salmonella isolates from non-human origin in Germany

30/04 12:00

9d. Experimental and cellular microbiology

Aitor ATXAERANDIO-LANDA

A / 11 / 12

Poster P3663

Abstract 6785

Polyphasic approach to detect, to isolate and to characterise candidate phyla radiation in human saliva

30/04 12:00

9d. Experimental and cellular microbiology

Fatma BENSEDDIK

A / 11 / 13

Poster P3664

Abstract 7013

Anti-toxin B neutralizing mAb AZD5148 provides protection in a Clostridioides difficile gnotobiotic piglet model

30/04 12:00

9d. Experimental and cellular microbiology

Christine TKACZYK

A / 11 / 14

Poster P3665

Abstract 7063

Bypassing proline auxotrophy in Escherichia coli

30/04 12:00

9d. Experimental and cellular microbiology

Diarmaid HUGHES

A / 11 / 15

Poster P3666

Abstract 7467

Role of Burkholderia pseudomallei quorum molecules causes apoposis in A549 cell lines

30/04 12:00

9d. Experimental and cellular microbiology

Vishnu AGARWAL

A / 11 / 17

Poster P3668

Abstract 7946

Classical Klebsiella pneumoniae and hypervirulent Klebsiella pneumoniae have different clinical outcomes and biological characteristics

30/04 12:00

9d. Experimental and cellular microbiology

Xianxia ZHUO

B / 11 / 1

Poster P3670

Abstract 8189

Assessment of Staphylococcus aureus phenotypic heterogeneity mediated by small colony variant formation

30/04 12:00

9d. Experimental and cellular microbiology

Dalida BIVONA

B / 11 / 2

Poster P3671

Abstract 8522

The release of cations from the clinical CoCrMo alloy has a direct impact on staphylococcal adherence

30/04 12:00

9d. Experimental and cellular microbiology

Marta MARTIN GARCIA

B / 11 / 3

Poster P3672

Abstract 150

Determination of the virulence profile of Klebsiella pneumoniae strains by an in vivo model of Galleria mellonella

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Marta DÍAZ-NAVARRO

B / 11 / 4

Poster P3673

Abstract 456

Proteomic investigation of distinct P. aeruginosa strains with reduced motility evolved in the presence of S. aureus and K. pneumoniae supernatants

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Yanrong PAN

B / 11 / 5

Poster P3674

Abstract 469

Specific genes deletion promotes virulence plasmid mobilising into CRKP evolved to CR-HvKP with enhanced antioxidant capacity and survival ability in macrophage

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Xinmiao JIA

B / 11 / 6

Poster P3675

Abstract 534

Construction of a core genome multi-locus sequence typing schemes for population structure analyses of five Nocardia species

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Amos ADLER

B / 11 / 7

Poster P3676

Abstract 811

Unveiling the emergence of hypermucoviscosity during drug adaptive evolution in carbapenem-resistant Klebsiella pneumoniae

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Qi DING

B / 11 / 8

Poster P3677

Abstract 1030

Bacteria and host transcriptome and phenotype revealed the role of a novel plasmid pvirhs1 in hypervirulent carbapenem-resistant Klebsiella pneumoniae

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Yi ZHANG

B / 11 / 9

Poster P3678

Abstract 1390

Mapping co-translation protein aggregation in E coli by inclusion body RNA sequencing and nascent chain profiling

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Khodaparast LADAN

B / 11 / 10

Poster P3679

Abstract 1391

Genomic identification of capsular type and other virulence factors of multi-drug resistant Acinetobacter baumannii clinical isolates recovered from Alexandria, Egypt

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Sandra SÁNCHEZ-URTAZA

B / 11 / 11

Poster P3680

Abstract 1450

Genomic and phenotypic characterization of Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients from two Mexican CF-attention centers

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Luis Ángel NUÑEZ-GARCÍA

B / 11 / 12

Poster P3681

Abstract 1464

Whole genome analysis revels differences in the type VI secretion system among serogroups of neonatal meningitis Escherichia coli

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Julia IENES-LIMA

B / 11 / 13

Poster P3682

Abstract 1567

Gut microbiome characterisation of patients with localised and metastatic colorectal cancer

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Silvia Noemi VAZQUEZ CUESTA

B / 11 / 14

Poster P3683

Abstract 1717

Metabolomic perturbations dictate bacterial growth in the human bloodstream

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Lovnish THAKUR

B / 11 / 15

Poster P3684

Abstract 2416

Insight into Acinetobacter baumannii's phenotypic and genotypic traits in oncological patients

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Ilaria CAVALLO

B / 11 / 16

Poster P3685

Abstract 2658

Bacterial transcriptomics in staphylococcal bone and joint infections: translational experiments from exponential in vitro culture to in vivo infection

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Frederic LAURENT

B / 11 / 17

Poster P3686

Abstract 2693

Presence of microorganisms inside healthy human internal organs, challenging the sterility of human tissues

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Anargyros SKOULAKIS

B / 11 / 18

Poster P3687

Abstract 2709

Anthrax-associated virulence genes in whole genome sequences of archival and contemporary Bacillus cereus group isolates

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Susanna J. SABIN

A / 12 / 1

Poster P3688

Abstract 2892

Staphylococcus epidermidis genome remodelling during adaptation to hospital environment

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Maria MIRAGAIA

A / 12 / 2

Poster P3689

Abstract 3212

The quinone oxidoreductase gene qorA contributes to host adaptation in MRSA ST59 lineage

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Fengning CHEN

A / 12 / 3

Poster P3690

Abstract 3382

Different subtypes of post-stroke pain syndrome: features of the gut microbiota

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Igor STOMA

A / 12 / 4

Poster P3691

Abstract 3645

Whole genome sequences revealed a novel phage-plasmid infecting Klebsiella pneumoniae

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Aylin USKUDAR-GUCLU

A / 12 / 5

Poster P3692

Abstract 4385

Integrative -omic analysis reveals trans-translation pathway small protein B (smpB) as a novel drug target against multi-drug resistant E.coli

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Neelja SINGHAL

A / 12 / 6

Poster P3693

Abstract 4523

Global transcriptomic study of a K.variicola clinical strain mutated in ramR

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Bénédicte LANGLOIS

A / 12 / 7

Poster P3694

Abstract 4660

Comparative genomic analysis of in vitro phenotypically distinct multidrug-resistant Klebsiella pneumoniae recovered from a single patient

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Natalia BURILLO

A / 12 / 8

Poster P3695

Abstract 4799

Accessory genome of difficult to treat K. pneumoniae and P. aeruginosa and its association with inpatient colonization status

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Laura Eva FRANCO FOBE

A / 12 / 9

Poster P3696

Abstract 5818

Alteration of Gut Virome in Primary Antibody Deficiencies

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Lejla IMAMOVIC

A / 12 / 10

Poster P3697

Abstract 5941

Probing Spatial Host-Pathogen Gene Expression: Unveiling Bacterial Pathogenesis and Regulatory Mechanisms of Virulence Factors in Tissues

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Federico DI MARCO

A / 12 / 11

Poster P3698

Abstract 5976

Comparison of direct cDNA and PCR-cDNA Nanopore sequencing to evaluate gene expression in Escherichia coli isolates

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Gillian RODGER

A / 12 / 12

Poster P3699

Abstract 6373

Lipooligosaccharide deficiency does not result in antigen loss in Acinetobacter baumannii membrane vesicles.

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Beatriz CANO CASTAÑO

A / 12 / 13

Poster P3700

Abstract 6419

Unveiling ppGpp's role in Adherent-Invasive Escherichia coli through a transcriptomic analysis

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Llorenç FERNÁNDEZ-COLL

A / 12 / 15

Poster P3702

Abstract 6565

Chromosomal hybrids derived from clinical strains

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Talia BERRUGA FERNANDEZ

A / 12 / 16

Poster P3703

Abstract 6623

High diversity of biosynthetic gene clusters and bacteriocins in staphylococci

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Søren IVERSEN

A / 12 / 17

Poster P3704

Abstract 6700

The Influence of Stress on the Gynecological Health of Minority Women

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Carl YEOMAN

A / 12 / 18

Poster P3705

Abstract 6705

Human milk metabolites association with infant gut microbiome and metabolome development

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Heidi ISOKÄÄNTÄ

A / 12 / 19

Poster P3706

Abstract 6730

Pre-analytic procedures including stabilisation for nucleic acid analysis from stool

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Helena BLOCK

A / 12 / 20

Poster P3707

Abstract 6946

Gardnerella Genomic and Phenotypic Insights into Female Urogenital Health Complexity

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Filipa GROSSO

A / 12 / 21

Poster P3708

Abstract 7602

Comparative transcriptomics disclose differences in gene expression that may be involved in the pathogenicity of adherent-invasive Escherichia coli

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Queralt BONET-ROSSINYOL

A / 12 / 22

Poster P3709

Abstract 7608

Staphylococcus aureus-expressed acetolactate synthase enhances the biosynthesis of branched-chain amino acids and is linked to blood glucose in type 2 diabetes

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Tingting LIANG

A / 12 / 23

Poster P3710

Abstract 7614

Whole genome virulence trait screening of colistin-resistant and colistin-susceptible Acinetobacter baumannii

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Jale BORAL

A / 12 / 24

Poster P3711

Abstract 7769

Genomic profile of Staphylococcus aureus from atopic dermatitis collected worldwide

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Maria MIRAGAIA

A / 12 / 25

Poster P3712

Abstract 7854

Vaginal microbiome and phageome associated with bacterial vaginosis (BV)

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Rumeysa Gulsu OZKAN

A / 12 / 26

Poster P3713

Abstract 8070

Identification and characterisation of coding and non-coding RNAs (cncRNAs) in hepatitis B virus

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Sneha SNEHA

A / 12 / 27

Poster P3714

Abstract 8414

A dual function for the messenger RNA encoding the major pneumococcal virulence factor PspA

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Jens Sivkær PETTERSEN

A / 12 / 28

Poster P3715

Abstract 8679

Whole-transcriptome sequencing identifies key differentially expressed mRNAs, miRNAs, lncRNAs, and circRNAs associated with gastric cancer

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Xiaoli ZHOU

B / 12 / 1

Poster P3716

Abstract 8930

Whole genome sequencing analysis of C. albicans and C. parapsilosis blood-cultured serial isolates collected at different time points: intra-patient analysis of 11 patients with candidaemia

30/04 12:00

9e. Basic science studies using Omics (in vitro and in vivo)

Aina Catalina MESQUIDA MARCOS

A / 19 / 1

Poster P3898

Abstract 2608

Graduate to scientist in UK microbiology: choosing the right path

30/04 12:00

11a. Professional affairs and career development

Ashleigh HALE

A / 19 / 2

Poster P3899

Abstract 4327

Perceptions from pharmacists attending ECCMID conference: a cross-sectional survey of 25 pharmacists from eight countries that attended the 2023 ECCMID conference

30/04 12:00

11a. Professional affairs and career development

Diane ASHIRU-OREDOPE

A / 19 / 3

Poster P3900

Abstract 2187

Sharing and re-use of anonymised individual data for infectious diseases research: challenges and solutions from PrIMAVeRa project

30/04 12:00

11b. Publishing, ethics, other academic affairs

Mariana GUEDES

A / 19 / 4

Poster P3901

Abstract 4462

Full open access in infectious diseases and clinical microbiology is associated with lower article processing charges but lower academic impact

30/04 12:00

11b. Publishing, ethics, other academic affairs

Dafna YAHAV

A / 19 / 5

Poster P3902

Abstract 8691

What do we know about different stakeholders' attitudes towards sharing participant-level biomedical data during and outside of pandemics? A measurement systematic review

30/04 12:00

11b. Publishing, ethics, other academic affairs

Lauren MAXWELL

A / 19 / 6

Poster P3903

Abstract 1154

Lessons learned: vaccination knowledge, opinions and practices of future healthcare providers

30/04 12:00

11c. Medical education for CM/ID

Nelia AFONSO

A / 19 / 7

Poster P3904

Abstract 1730

Identification and evaluation of quality indicators in infectious diseases consultation reports by a Delphi-based online survey: evaluation of first survey responses

30/04 12:00

11c. Medical education for CM/ID

Daniel HORNUSS

A / 19 / 8

Poster P3905

Abstract 1959

A scope of the new OPAT virtual ward service using nurse-filled flucloxacillin elastomeric pumps for orthopaedic infections with respect to cost-effectiveness and its limitation in secondary care

30/04 12:00

11c. Medical education for CM/ID

Alice LIU

A / 19 / 9

Poster P3906

Abstract 2247

Physicians' knowledge, attitude, and practice towards blood culture sampling

30/04 12:00

11c. Medical education for CM/ID

Helmi ERNANDES

A / 19 / 10

Poster P3907

Abstract 2501

Evaluation of multidisciplinary tutorials sessions about antibiotics in the third year of pharmacy studies, school of pharmacy, Angers, France

30/04 12:00

11c. Medical education for CM/ID

Audrey TAISNE

A / 19 / 11

Poster P3908

Abstract 2701

Tricks and treat! Gamification of learning concepts in infectious diseases through escape room case solving

30/04 12:00

11c. Medical education for CM/ID

Romina KARDASHI

A / 19 / 12

Poster P3909

Abstract 2950

­Knowledge, attitudes and practices on the climate crisis and the changing burden of infectious diseases among young Italian doctors and medical students: a national survey

30/04 12:00

11c. Medical education for CM/ID

Francesco Vladimiro SEGALA

A / 19 / 13

Poster P3910

Abstract 3194

Challenges in obtaining adequate blood culture volumes: education required

30/04 12:00

11c. Medical education for CM/ID

Lauren HOOKHAM

A / 19 / 14

Poster P3911

Abstract 3907

Medical online independent education significantly improves physician competence regarding the first line management of Clostridioides difficile infection

30/04 12:00

11c. Medical education for CM/ID

Julia DUFFEY

A / 19 / 15

Poster P3912

Abstract 3927

Parasitological and microbiological assessment of contact lens storage cases: a survey on asymptomatic lens student wearers in Monastir, Tunisia

30/04 12:00

11c. Medical education for CM/ID

Sameh BELGACEM

A / 19 / 16

Poster P3913

Abstract 4744

Medical microbiology in Europe: developments in training and scope of practice

30/04 12:00

11c. Medical education for CM/ID

Maeve DOYLE

A / 19 / 17

Poster P3914

Abstract 4826

E-learning and mentoring to fight against antimicrobial resistance: feedback on a unique and impactful experience with Médecins Sans Frontières

30/04 12:00

11c. Medical education for CM/ID

Marie POUPARD

A / 19 / 18

Poster P3915

Abstract 5036

Taking a travel history is not explicitly mapped to undergraduate curricula across the UK

30/04 12:00

11c. Medical education for CM/ID

Francesca LIUZZI

A / 19 / 19

Poster P3916

Abstract 5450

Lessons learned from final year medical students and curriculum analysis on antibiotic stewardship in Africa

30/04 12:00

11c. Medical education for CM/ID

Muhammad Augie BASHAR

A / 19 / 20

Poster P3917

Abstract 5752

Revision of third year medical student microbiology syllabus using serious games: proof of concept

30/04 12:00

11c. Medical education for CM/ID

Sarah DELLIERE

A / 19 / 21

Poster P3918

Abstract 7984

Mini lessons, maximum impact: empowering medical resident's approach to antimicrobial stewardship with microlearning teaching-learning modules

30/04 12:00

11c. Medical education for CM/ID

Raksha KOCHI

A / 19 / 22

Poster P3919

Abstract 8320

Which antimicrobial are you? A personality quiz to create AMR awareness in Belgian healthcare professionals

30/04 12:00

11c. Medical education for CM/ID

Phebe DE NOCKER

A / 19 / 23

Poster P3920

Abstract 8422

Clinicians' confidence in recognising and managing high consequence infectious diseases in the UK: a cross-sectional survey

30/04 12:00

11c. Medical education for CM/ID

Ali ALAM

A / 19 / 24

Poster P3921

Abstract 8427

Educational tool for antimicrobial stewardship (AMS): teaching and learning through self-assessment and feedback

30/04 12:00

11c. Medical education for CM/ID

Susan LAPTHORNE

A / 19 / 25

Poster P3922

Abstract 91

How does ChatGPT respond to questions pertaining to vaccine hesitancy from the general public?

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Matthew Chung Yi KOH

A / 19 / 26

Poster P3923

Abstract 94

ChatGPT as a tool to improve knowledge on sexually transmitted infections

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Matthew Chung Yi KOH

A / 19 / 27

Poster P3924

Abstract 559

High accuracy of convolutional neural network algorithm in Helicobacter pylori detection based on endoscopic imaging: a meta-analysis

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Mochamad AFIFUDIN

A / 19 / 28

Poster P3925

Abstract 560

First steps in establishing EU/EEA level surveillance of bloodstream infections from electronic health records

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Alexis SENTIS

B / 19 / 1

Poster P3926

Abstract 702

Developing an AI-enabled leprosy knowledge base chatbot for healthcare professionals in Malaysia

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Norana ABDUL RAHMAN

B / 19 / 2

Poster P3927

Abstract 841

Clinicians' perceptions of electronic clinical decision support tools to manage patients with lower respiratory tract infections in Sri Lanka

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Warsha DE ZOYSA

B / 19 / 3

Poster P3928

Abstract 848

Co-design of a digital application to remotely monitor long COVID symptoms: results from the UpcomingVoice study

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Aurélie FISCHER

B / 19 / 4

Poster P3929

Abstract 1002

Artificial intelligence in urinary tract infection: can machine learning models accurately predict antimicrobial susceptibility in urine culture bacterial isolates?

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Alfred Lok Hang LEE

B / 19 / 5

Poster P3930

Abstract 1346

Predicting COVID-19 severity level using an attention-based long short-term memory model utilising clinical data

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Inuk JUNG

B / 19 / 6

Poster P3931

Abstract 1361

β-LacFamPred: an online tool for prediction and classi?cation of β-lactamase class, subclass, and family

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Deeksha PANDEY

B / 19 / 7

Poster P3932

Abstract 1397

Health Catch-UP!: process evaluation and co-development of an implementation strategy for a migrant multi-disease screening and vaccination tool

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Jessica CARTER

B / 19 / 8

Poster P3933

Abstract 1692

Machine learning for antibiotic optimisation in multi-morbid patients

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

William BOLTON

B / 19 / 9

Poster P3934

Abstract 1699

Machine learning based individualised intravenous-to-oral antibiotic switch decision support

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

William BOLTON

B / 19 / 10

Poster P3935

Abstract 1969

Optimisation of AI for swift outpatient management of urinary tract infections

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Yannick ROUQUET

B / 19 / 11

Poster P3936

Abstract 2050

Assessing the performance of artificial intelligence vs human experts in answering clinical practice guideline questions related to periprosthetic joint infections

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Thomas SCHMIDT

B / 19 / 12

Poster P3937

Abstract 2310

Evaluation of blood culture outcome prediction machine learning model on prospectively collected emergency department dataset: results, lessons, and opportunities

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Benjamin MCFADDEN

B / 19 / 13

Poster P3938

Abstract 2327

A multicentre federated learning study to identify patients at high risk for 30-day mortality among vaccinated Omicron-infected patients

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Chien-Chang LEE

B / 19 / 14

Poster P3939

Abstract 2513

Insights from artificial intelligence, COVID-19 pandemic impact on vaccination hesitancy in Algerian population

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Baya BOULILA

B / 19 / 15

Poster P3940

Abstract 2567

Epidemiology of the national clinical infectious disease response service in Japan during 2014−2023

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Masahiro ISHIKANE

B / 19 / 16

Poster P3941

Abstract 2733

The use of UZA@home as an online contact tracing tool in the follow up of 12 students after contact with Lassa fever cases

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Yvan SOMERS

B / 19 / 17

Poster P3942

Abstract 3022

Development and validation of an easy-to-use electronic data capture system for HIV-STIs data collection and management to support cohort studies in a pandemic scenario

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Alessia SAVOLDI

B / 19 / 18

Poster P3943

Abstract 3103

Antimicrobial resistance and virulence gene diversity in Escherichia coli and their classification by genomic context

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Takahiro SEKINE

B / 19 / 19

Poster P3944

Abstract 3157

A new approach for establishing multilocus sequence typing scheme: Staphylococcus capitis as an example

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Zhengan WANG

B / 19 / 20

Poster P3945

Abstract 3503

Deep-learning model for discrimination of different pneumonia from chest CT scans

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Wenting JIN

B / 19 / 21

Poster P3946

Abstract 3659

Development and evaluation of an artificial intelligence tool to keep standard operating procedures up to date with guidelines: a test case on hospital infection control

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Thera HABBEN JANSEN

B / 19 / 22

Poster P3947

Abstract 3764

Artificial intelligence for infectious diseases: a systematic review of diagnostics, surveillance, and treatment

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Gijs DANOE

B / 19 / 23

Poster P3948

Abstract 4066

Extracting symptoms from free-text responses using ChatGPT among COVID-19 cases in Hong Kong

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Wan In WEI

B / 19 / 24

Poster P3949

Abstract 4320

Automating routine clinical data extraction to characterise acute infectious presentations in real-time

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Robbie HAMMOND

B / 19 / 25

Poster P3950

Abstract 4463

Daily monitoring of isolation-demanding patients: a programme based on electronic LIMS and automated mails

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Steen Christian RASMUSSEN

B / 19 / 26

Poster P3951

Abstract 4519

Assessing ChatGPT's theoretical knowledge and prescriptive accuracy in bacterial infections: a comparative study with residents and specialists

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Andrea DE VITO

B / 19 / 27

Poster P3952

Abstract 4661

Performance, efficiency and medical value of artificial intelligence software for MDRO screening

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Olivier DAUWALDER

B / 19 / 28

Poster P3953

Abstract 4875

Public perception of the FDA approval of a long-acting injectable for HIV prevention: natural language processing study

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Tsz Ho KWAN

A / 20 / 1

Poster P3954

Abstract 4917

Evaluation of removal of an electronic health record alert on cephalosporin usage in patients with penicillin allergies

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Scott FERREN

A / 20 / 2

Poster P3955

Abstract 5061

ReferenceSurfer: a bibliometric algorithm to identify underpinning original research in literature review and its application in reviewing beta-lactam pharmacodynamic targets

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Nada REZA

A / 20 / 3

Poster P3956

Abstract 5066

Rapid multiplex antigen testing and self-declared symptom checkers as a tool to detect and manage respiratory disease on a university campus

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Clo O'RIORDAN

A / 20 / 4

Poster P3957

Abstract 5209

Antibiotic dispensing without a prescription among community pharmacies in the post COVID-19 era: a simulated client approach

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Hoa Quoc NGUYEN

A / 20 / 5

Poster P3958

Abstract 5269

Randomised experiment of recruitment letter strategies to maximise clinical trial enrollment: insights from the DANFLU-2 trial

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Niklas Dyrby JOHANSEN

A / 20 / 6

Poster P3959

Abstract 5309

Comparative genome analysis reveals insights into agr gene defects in Staphylococcus aureus

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Furqan AWAN

A / 20 / 7

Poster P3960

Abstract 5436

COVID-19 vaccine introduction amplified negative sentiments on social media

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Guillermo RODRIGUEZ-NAVA

A / 20 / 8

Poster P3961

Abstract 6415

Artificial intelligence/machine-learning tool for post-market surveillance of in vitro diagnostic assays

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Joanna RENIEWICZ

A / 20 / 9

Poster P3962

Abstract 6444

Plasmid annotation confounding not a leading cause for taxonomic misclassification

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Iris GOLD RODAL

A / 20 / 10

Poster P3963

Abstract 6482

Evaluation of travelers surveillance management information system (TSMIS) for points of entry in Pakistan, 2023

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Zeba NASIR

A / 20 / 11

Poster P3964

Abstract 6496

IMMORTOOL: a web based application for quantifying the potential impact of immortal time bias in observational studies seeking to estimate treatment effects

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Tom A. YATES

A / 20 / 12

Poster P3965

Abstract 6774

Impact of intervention using Kaizen method in blood culture workflow and turn around time in Roberto del Rio Children's Hospital microbiology laboratory, experience before and after

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Dona BENADOF

A / 20 / 13

Poster P3966

Abstract 6815

Artificial Intelligence applications in parasitology diagnosis

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Matin SOTOUDEH NEJAD

A / 20 / 14

Poster P3967

Abstract 6895

Imputation of missing antibiotic susceptibility values in Pseudomonas aeruginosa using machine learning

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Elsa DENAKPO

A / 20 / 15

Poster P3968

Abstract 6968

mHealth for point-of-care testing and self-reporting of an infectious disease: a systems developer perspective

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Ciara HEAVIN

A / 20 / 16

Poster P3969

Abstract 7064

GENTRAIN: genome-based infection chain analysis to increase digitalisation level in the public health sector

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Markus TRÖGER

A / 20 / 17

Poster P3970

Abstract 7409

Enhancing cybersecurity resilience in healthcare: a qualitative exploration of ransomware threats and educational interventions

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Jelili MUSTAPHA

A / 20 / 18

Poster P3971

Abstract 7628

Application of the artificial intelligence to identification of the different bacteria in multi-species mixtures from the Gram stained microscopic preparations

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Monika BRZYCHCZY-WLOCH

B / 20 / 1

Poster P3972

Abstract 7656

Clinical decision support of meropenem continuity in PICU using machine learning

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Jaber ABDULLAH

B / 20 / 2

Poster P3973

Abstract 7744

Recent updates on Bakta - a rapid & standardized software tool for the comprehensive annotation of bacterial genomes

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Oliver SCHWENGERS

B / 20 / 3

Poster P3974

Abstract 7864

Off-label indications and outcomes for watch and reserve antibiotics according to the WHO AWaRe classification: a real-time interactive computer-assisted one-year survey in a large tertiary care hospital in northern Italy

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Livia MARLETTA

B / 20 / 4

Poster P3975

Abstract 8582

Impact of electronic auditable pharmaceutical transaction and service (eAPTS) system implementation for supply chain, proper use of medicines, and delivering health services in Ethiopia

30/04 12:00

11d. Digital health and infection (incl AI, data mining, informatics)

Natnael Solomon HASSEN

B / 20 / 5

Poster P3976

Abstract 325

The Colombo dengue study: a successful collaboration between two countries for more inclusive research

30/04 12:00

11e. Diversity and equality

Chathuraka RODRIGO

B / 20 / 6

Poster P3977

Abstract 4319

Evaluating social determinants of health (SDOH) in a diverse cohort initiating long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in NYC

30/04 12:00

11e. Diversity and equality

Patricia PAGÁN PIRALLO

B / 20 / 7

Poster P3978

Abstract 4798

An equitable strategy to recruit underserved populations into LAI-PrEP Care in NYC

30/04 12:00

11e. Diversity and equality

Ofole MGBAKO

B / 20 / 8

Poster P3979

Abstract 8583

Addressing HIV testing gaps amongst migrant communities in Europe

30/04 12:00

11e. Diversity and equality

Denis ONYANGO

B / 20 / 9

Poster P3980

Abstract 8234

Unravelling vaccine hesitancy: insights from an indigenous perspective in Meghalaya, India

30/04 12:00

11f. Advocacy and role of patients

Shanthosh Priyan SUNDARAM

B / 20 / 10

Poster P3981

Abstract 8755

Enhancing World Antimicrobial Resistance Awareness Week: a patient-engaged paediatric hospital initiative to illuminate research questions

30/04 12:00

11f. Advocacy and role of patients

Neha VORALIA

A / 13 / 1

Poster P3982

Abstract 620

Successful use of prolonged oral nirmatrelvir/ritonavir in an immunocompromised host with persistent SARS-CoV-2 viraemia and severe pneumonitis

30/04 12:00

12a. Viral infections

Jessica TAYLOR

A / 13 / 2

Poster P3983

Abstract 1031

Tropical spastic paraparesis or multiple sclerosis? A diagnostic challenge from a non-endemic area

30/04 12:00

12a. Viral infections

Samuele GAGGIOLI

A / 13 / 3

Poster P3984

Abstract 1231

Dumb rabies a close mimicker of Guillain-Barre syndrome

30/04 12:00

12a. Viral infections

Sayan MAHARATNA

A / 13 / 4

Poster P3985

Abstract 1449

Asymptomatic transmission of human mpox

30/04 12:00

12a. Viral infections

Vitor DUQUE

A / 13 / 5

Poster P3986

Abstract 1914

Severe chronic mpox in HIV/AIDS: implications on diagnosis and management

30/04 12:00

12a. Viral infections

Ia Marie Donna CRUZ

A / 13 / 6

Poster P3987

Abstract 2321

Hemophagocytic lymphohistiocytosis in an undiagnosed HIV patient with SARS-CoV-2 co-infection after initiating antiretroviral therapy

30/04 12:00

12a. Viral infections

Szu Yu LIU

A / 13 / 7

Poster P3988

Abstract 2463

Chronic Enterovirus infection following disseminated disease occurred during obinutuzumab treatment

30/04 12:00

12a. Viral infections

Elena STAFFILANO

A / 13 / 8

Poster P3989

Abstract 2726

Hepatitis B virus reactivation in a cancer patient with seronegative occult hepatitis B infection

30/04 12:00

12a. Viral infections

Torres HARRYS

A / 13 / 9

Poster P3990

Abstract 2809

The diagnostic value of HSV antibody index in a post-transplant patient with refractory status epilepticus

30/04 12:00

12a. Viral infections

Asimenia HALIOTI

A / 13 / 10

Poster P3991

Abstract 3076

The utilisation of microbial cell-free DNA next-generation sequencing for the detection of human herpesvirus-8 in a quaternary care centre

30/04 12:00

12a. Viral infections

Rebecca BERGER

A / 13 / 11

Poster P3992

Abstract 3323

Don't trust the appearances: how Epstein-Barr virus infection can mask a diagnosis of lymphoma

30/04 12:00

12a. Viral infections

Silvia RODA

A / 13 / 12

Poster P3993

Abstract 3575

Herpes simplex virus 1 (HSV) pneumonia in post solid organ transplant setting: a case series

30/04 12:00

12a. Viral infections

Polati VISHNU RAO

A / 13 / 13

Poster P3994

Abstract 4230

Emergence of a unique immune evasive SARS-CoV-2 variant during a persistent infection for 613 days in an immunocompromised patient

30/04 12:00

12a. Viral infections

Magda VERGOUWE

A / 13 / 14

Poster P3995

Abstract 4298

Human herpesvirus 6 reactivation in immunocompetent patients with psychiatric disorders

30/04 12:00

12a. Viral infections

Elena STAFFILANO

A / 13 / 15

Poster P3996

Abstract 4360

Early immunoglobulins in disseminated varicella: a worthy thought

30/04 12:00

12a. Viral infections

Netto George MUNDADAN

A / 13 / 16

Poster P3997

Abstract 4555

Dengue-induced haemophagocytic lymphohistiocytosis

30/04 12:00

12a. Viral infections

Irene ODEA

A / 13 / 17

Poster P3998

Abstract 4685

Primary HSV-2 infection complicated by radiculomyelitis in a young immunocompetent female patient with inherited chromosomally integrated HHV-6

30/04 12:00

12a. Viral infections

Marie Therese NGO NSOGA

A / 13 / 18

Poster P3999

Abstract 4778

A clinical case of haemorrhagic fever with renal syndrome in Lviv oblast: difficulties of diagnostics

30/04 12:00

12a. Viral infections

Olena ZUBACH

A / 13 / 19

Poster P4000

Abstract 4829

HTLV-1-associated syndromes: 2 case reports

30/04 12:00

12a. Viral infections

Cristina BAYO

A / 13 / 20

Poster P4001

Abstract 5243

Orthopoxvirus' infection with interpersonal transmission in humans

30/04 12:00

12a. Viral infections

Gabriel RAMALHO DE JESUS

A / 13 / 21

Poster P4002

Abstract 5469

Acquired immunodeficiency syndrome masquerading as anti-neutrophil cytoplasmic antibody-associated vasculitis

30/04 12:00

12a. Viral infections

Ellani Louise HUILAR

A / 13 / 22

Poster P4003

Abstract 5478

A case of leukocytoclastic vasculitis related to acute parvovirus B19 infection

30/04 12:00

12a. Viral infections

Eren ÖZTÜRK

A / 13 / 23

Poster P4004

Abstract 5484

Hemophagocytic lymphohistiocytosis: the hidden sniper unmasked

30/04 12:00

12a. Viral infections

Anupama KURUP

A / 13 / 24

Poster P4005

Abstract 5488

Combination antiviral therapy for persistent SARS-CoV-2 infection in immunocompromised patients: a case series

30/04 12:00

12a. Viral infections

Aikaterini GKOUFA

A / 13 / 25

Poster P4006

Abstract 6450

Dengue or not? A rare case of seronegative dengue haemorrhagic encephalitis in an adult

30/04 12:00

12a. Viral infections

Shekhar ANGIREKULA

A / 13 / 26

Poster P4007

Abstract 6499

Three cases of haemorrhagic fever with renal sydrome

30/04 12:00

12a. Viral infections

Dimitar KOMITOV

A / 13 / 27

Poster P4008

Abstract 6945

Diagnostic dilemma: a case series unraveling disseminated HSV-1 infection in patients with liver disease in a tertiary care liver centre

30/04 12:00

12a. Viral infections

Malika GROVER

A / 13 / 28

Poster P4009

Abstract 7061

Role of early detection of pericholecystic fluid as a predictive marker for dengue fever leaking stage: experience from a low-resource centre

30/04 12:00

12a. Viral infections

Shirom Rajeev SIRIWARDANA

B / 13 / 1

Poster P4010

Abstract 7112

Occupational transmission of measles in the COVID-19 era

30/04 12:00

12a. Viral infections

Gabriella DE CARLI

B / 13 / 2

Poster P4011

Abstract 7121

First documented case of meningoencephalitis by herpes simplex type 2 and human herpesvirus type 6 coinfection in an immunocompetent patient

30/04 12:00

12a. Viral infections

Armando BARRAGÁN-REYES

B / 13 / 3

Poster P4012

Abstract 7238

Herpes simplex virus 2 lymphadenitis in a patient with chronic lymphocytic leukaemia under ibrutinib

30/04 12:00

12a. Viral infections

João Carlos SILVA MATOS

B / 13 / 4

Poster P4013

Abstract 7315

Human rabies and COVID-19 coinfection diagnosed by minimally invasive autopsy: lessons from a development country

30/04 12:00

12a. Viral infections

Luís Arthur Brasil GADELHA FARIAS

B / 13 / 5

Poster P4014

Abstract 7340

Autochthonous dengue outbreak in the Paris region, October 2023

30/04 12:00

12a. Viral infections

Marta ZATTA

B / 13 / 6

Poster P4015

Abstract 7793

Maribavir for resistant CMV disseminated disease in a kidney transplant recipient: what goes around comes around

30/04 12:00

12a. Viral infections

Davide VITA

B / 13 / 7

Poster P4016

Abstract 7918

A case of fatal bocavirus pulmonary infection in an adult autologous haematopoietic stem cell transplant recipient

30/04 12:00

12a. Viral infections

Pantazis-Michael VOUTSINAS

B / 13 / 8

Poster P4017

Abstract 8160

Fever with breathing crisis: a rare case of diffuse alveolar haemorrhage in dengue

30/04 12:00

12a. Viral infections

Naresh Kumar MIDHA

B / 13 / 9

Poster P4018

Abstract 8302

Severe adenovirus pneumonia in immunocompetent patients presenting as typical bacterial pneumonia

30/04 12:00

12a. Viral infections

Matthew KENNEDY

B / 13 / 10

Poster P4019

Abstract 8342

P323L mutation in a case with prolonged SARS-CoV-2 PCR positivity

30/04 12:00

12a. Viral infections

Yücebag EBRU

B / 13 / 11

Poster P4020

Abstract 8347

Cytomegalovirus colitis mimicking ulcerative colitis

30/04 12:00

12a. Viral infections

Monika CHAUDHARY

B / 13 / 12

Poster P4021

Abstract 8490

Progressive multifocal leukoencephalopathy: old acquaintance, new perspective

30/04 12:00

12a. Viral infections

Carmen HIDALGO TENORIO

B / 13 / 13

Poster P4022

Abstract 8538

Unravelling subacute sclerosis panencephalitis in a young patient with seizures and a measles Complexity: a rare encounter

30/04 12:00

12a. Viral infections

Aditya KALE

B / 13 / 14

Poster P4023

Abstract 8662

Persistent replication of the human herpesvirus type 6A in two immunosuppressed patients

30/04 12:00

12a. Viral infections

Virginia RODRÍGUEZ

B / 13 / 15

Poster P4024

Abstract 8682

Varicella pneumonia, in an immunocompetent patient

30/04 12:00

12a. Viral infections

Samet ACAR

B / 13 / 16

Poster P4025

Abstract 8782

Delayed viral clearance during respiratory infections in children with combined immunodeficiency

30/04 12:00

12a. Viral infections

Siwar FRIGUI

B / 13 / 17

Poster P4026

Abstract 24

The devastating triad: a rare case of Austrian syndrome following COVID-19 infection

30/04 12:00

12b. Bacterial infections

Adrian ESTEPA

B / 13 / 18

Poster P4027

Abstract 54

Community-acquired Acinetobacter baumannii meningitis in Guinea: has the threat extended beyond the healthcare facilities?

30/04 12:00

12b. Bacterial infections

Meriam ROMDHANI

B / 13 / 19

Poster P4028

Abstract 115

Dynamic evolution of Achromobacter xylosoxidans during antibiotic treatment in a single patient

30/04 12:00

12b. Bacterial infections

Maria Soledad RAMIREZ

B / 13 / 20

Poster P4029

Abstract 129

Infective endocarditis coexisting with acute bacterial meningitis caused by Streptococcus suis

30/04 12:00

12b. Bacterial infections

Sireethorn NIMITVILAI

B / 13 / 21

Poster P4030

Abstract 170

Old ways won't open new doors

30/04 12:00

12b. Bacterial infections

Teja VASIREDDY

B / 13 / 22

Poster P4031

Abstract 195

Nocardia brain abscesses due to anti-GM-CSF autoantibodies treated with IFN-γ supplementation

30/04 12:00

12b. Bacterial infections

Rob ARTS

B / 13 / 23

Poster P4032

Abstract 229

Clinical characteristics of Desulfovibrio spp. bacteremia in a Japanese tertiary hospital

30/04 12:00

12b. Bacterial infections

Hiroki KITAGAWA

B / 13 / 24

Poster P4033

Abstract 283

Leclercia adecarboxylata necrotising soft tissue infection in an immunocompetent adult

30/04 12:00

12b. Bacterial infections

Lordieliza MELENDREZ

B / 13 / 25

Poster P4034

Abstract 323

Emergence of Neisseria meningitidis isolates with reduced susceptibility to third generation cephalosporins: report of the first two cases in Costa Rica, Latin America

30/04 12:00

12b. Bacterial infections

Manuel Antonio VILLALOBOS ZÚÑIGA

B / 13 / 26

Poster P4035

Abstract 355

Uncommon neonatal pyoderma associated with coagulase-negative Staphylococcus infection

30/04 12:00

12b. Bacterial infections

Meri TER-STEPANYAN

B / 13 / 27

Poster P4036

Abstract 358

Tetanus in a patient with fungating breast cancer

30/04 12:00

12b. Bacterial infections

Lordieliza MELENDREZ

B / 13 / 28

Poster P4037

Abstract 367

Disseminated tuberculosis presenting as Evans syndrome: successful treatment with guideline-directed antituberculosis regimen and eltrombopag

30/04 12:00

12b. Bacterial infections

Vienne PINLAC

A / 14 / 1

Poster P4038

Abstract 460

Bacillary angiomatosis-associated immune reconstitution inflammatory syndrome

30/04 12:00

12b. Bacterial infections

Caryl DURANTE

A / 14 / 2

Poster P4039

Abstract 506

Unmasking multifocal tubercular pyomyositis: a challenging diagnostic journey

30/04 12:00

12b. Bacterial infections

Abhishek G P

A / 14 / 3

Poster P4040

Abstract 637

Primary acute toxogenic Clostridium difficle megaprosthetic joint infection

30/04 12:00

12b. Bacterial infections

Sophie TAN

A / 14 / 4

Poster P4041

Abstract 639

First report of cefiderocol resistance in Croatia

30/04 12:00

12b. Bacterial infections

Branka BEDENIC

A / 14 / 5

Poster P4042

Abstract 648

Hepatobiliary and pancreatic tuberculosis: exceptional association

30/04 12:00

12b. Bacterial infections

Helmi ERNANDES

A / 14 / 6

Poster P4043

Abstract 662

Leptospirosis in Liverpool: another “great imitator”?

30/04 12:00

12b. Bacterial infections

Hugh ADLER

A / 14 / 7

Poster P4044

Abstract 755

Purulent Klebsiella pneumoniae meningitis complicated by thrombosis of the left internal carotid artery, cerebral abscesses and hydrocephalus

30/04 12:00

12b. Bacterial infections

Dady HASSAN

A / 14 / 8

Poster P4045

Abstract 836

Bacteriophage therapy of chronic non-healing wounds: a case series

30/04 12:00

12b. Bacterial infections

Subhash Lal KARN

A / 14 / 9

Poster P4046

Abstract 891

Lyme neuroborreliosis: Tunisian pediatric series

30/04 12:00

12b. Bacterial infections

Nada MISSAOUI

A / 14 / 10

Poster P4047

Abstract 968

A complex case of Brucella endocarditis of cardiac implantable device

30/04 12:00

12b. Bacterial infections

Junais KOLERI

A / 14 / 11

Poster P4048

Abstract 998

Urine brilliance: urine TB LAM's role in challenging AIDS cases from LMIC's perspective

30/04 12:00

12b. Bacterial infections

Ummu Afeera ZAINULABID

A / 14 / 12

Poster P4049

Abstract 1035

A unique case of Listeria monocytogenes superinfection of tuberculous lymphadenitis

30/04 12:00

12b. Bacterial infections

Flavio SANGIORGI

A / 14 / 13

Poster P4050

Abstract 1114

Lactobacillus: an unlikely invader

30/04 12:00

12b. Bacterial infections

Candice DATNOW

A / 14 / 14

Poster P4051

Abstract 1179

Granulicatella adiacens periprosthetic knee joint infection

30/04 12:00

12b. Bacterial infections

Ishani DE SILVA

A / 14 / 15

Poster P4052

Abstract 1250

Unravelling the diagnostic and therapeutic challenges of atypical salmonella infections: insights from three cases

30/04 12:00

12b. Bacterial infections

Harish MANOHARAN

A / 14 / 16

Poster P4053

Abstract 1282

Orthopaedic infections associated with Nocardia species: a case series

30/04 12:00

12b. Bacterial infections

Khodadadi RYAN

A / 14 / 17

Poster P4054

Abstract 1322

Tuberculosis: an enigma for clinicians and an uncertainty in diagnosis

30/04 12:00

12b. Bacterial infections

Akhilesh KUMAR P H

A / 14 / 18

Poster P4055

Abstract 1355

First case of bacterial meningitis caused by Bacteroides pyogenes

30/04 12:00

12b. Bacterial infections

Tomonori TAKANO

A / 14 / 19

Poster P4056

Abstract 1537

A case report of oral condyloma lata with mucous patches mimicking mucosal papilloma

30/04 12:00

12b. Bacterial infections

Kantaphop PATTAMASIRIKUN

A / 14 / 20

Poster P4057

Abstract 1574

Pulmonary actynomicosis following a dog bite

30/04 12:00

12b. Bacterial infections

Sara ARAÚJO

A / 14 / 21

Poster P4058

Abstract 1605

A case series of fatal Streptococcus pyogenes cases in Europe and Turkey: ESGFOR experience

30/04 12:00

12b. Bacterial infections

Amparo FERNÁNDEZ-RODRÍGUEZ

A / 14 / 22

Poster P4059

Abstract 1615

Delamanid use in children aged 0-2 years with MDR/preXDR-TB: case series report

30/04 12:00

12b. Bacterial infections

Vladislav PRIVOLNEV

A / 14 / 23

Poster P4060

Abstract 1725

Unravelling the enigma: a rare case of tuberculosis aortitis in a young adult

30/04 12:00

12b. Bacterial infections

Hamdan ALAWADHI

A / 14 / 24

Poster P4061

Abstract 1799

A case of Listeria rhombencephalitis

30/04 12:00

12b. Bacterial infections

Juan José FERNÁNDEZ DÍAZ

A / 14 / 25

Poster P4062

Abstract 1840

Delayed diagnosis of cutaneous diphtheria within an inpatient setting, leading to a large infection control incident

30/04 12:00

12b. Bacterial infections

Nishchay KAKKAR

A / 14 / 26

Poster P4063

Abstract 1925

Recurrent pulmonary nocardiosis in a patient with underlying idiopathic CD4 lymphocytopenia: a case report

30/04 12:00

12b. Bacterial infections

Durga Shankar MEENA

A / 14 / 27

Poster P4064

Abstract 1951

Mysterious rods: an unusual heart valve infection

30/04 12:00

12b. Bacterial infections

Thivandika JAYASUNDERA

A / 14 / 28

Poster P4065

Abstract 2023

An interesting case of lepra reaction presenting as fever of unknown origin in a tertiary care centre in India

30/04 12:00

12b. Bacterial infections

Jayasree SUBRAMANIAN

B / 14 / 1

Poster P4066

Abstract 2033

A series of leptospirosis cases in industrial city

30/04 12:00

12b. Bacterial infections

Oksana ISHCHENKO

B / 14 / 2

Poster P4067

Abstract 2069

Striking a chord: Fusobacterium nucleatum's symphony in the intricacies of biliary sepsis

30/04 12:00

12b. Bacterial infections

Ummu Afeera ZAINULABID

B / 14 / 3

Poster P4068

Abstract 2070

Pulmonary disease due to Nocardia cyriacigeorgica in an immunomodulated inflammatory bowel disease patient

30/04 12:00

12b. Bacterial infections

Natalí URIBE PULIDO

B / 14 / 4

Poster P4069

Abstract 2108

Conquering the pink invader: a triumph over Roseomonas mucosa bacteraemia in an elderly patient

30/04 12:00

12b. Bacterial infections

Ummu Afeera ZAINULABID

B / 14 / 5

Poster P4070

Abstract 2138

Paws, probes, and PCR: unraveling the clinical jigsaw puzzle of Bartonella henselae infection

30/04 12:00

12b. Bacterial infections

Ummu Afeera ZAINULABID

B / 14 / 6

Poster P4071

Abstract 2269

Difficult-to-treat urethritis and orchiepididymitis due to Mycoplasma hominis in immunocompetent man

30/04 12:00

12b. Bacterial infections

Victor PASSARELLI

B / 14 / 7

Poster P4072

Abstract 2277

The first case of acute cholangitis with bacteremia caused by Weissella viridescens

30/04 12:00

12b. Bacterial infections

Jiwoo LEE

B / 14 / 8

Poster P4073

Abstract 2323

From drowning to stenotrophomonas maltophilia meningitis

30/04 12:00

12b. Bacterial infections

Fatima Halima BOUHALLOUFA

B / 14 / 9

Poster P4074

Abstract 2364

Contamination of an advanced organ support (ADVOS) system with Ralstonia pickettii as potential source of pyrexia in critically ill patients

30/04 12:00

12b. Bacterial infections

Stefanie KAMPMEIER

B / 14 / 10

Poster P4075

Abstract 2474

Cryptic tularaemia infection: a multi-agency investigation of the first case presumed to be acquired in the United Kingdom

30/04 12:00

12b. Bacterial infections

Ameeka THOMPSON

B / 14 / 11

Poster P4076

Abstract 2575

Multiple metastatic primary multidrug-resistant tubercular abscesses in an immunocompetent individual

30/04 12:00

12b. Bacterial infections

Megha PRIYADARSHI

B / 14 / 12

Poster P4077

Abstract 2657

Rapid AST expedites antimicrobial therapy optimisation in BSI patients: clinical cases from the LIFETIMES HEOR study

30/04 12:00

12b. Bacterial infections

Gian Maria ROSSOLINI

B / 14 / 13

Poster P4078

Abstract 2659

Recurrent at intervals of 3 months or more: three cases of recurrent bacteraemic cholangitis caused by Aeromonas caviae

30/04 12:00

12b. Bacterial infections

Yuji HIRAI

B / 14 / 14

Poster P4079

Abstract 2691

Non-typhoidal Salmonella breast implant infection and bacteraemia in an HIV patient: a case report

30/04 12:00

12b. Bacterial infections

Yober Mateo RODRIGUEZ VELASCO

B / 14 / 15

Poster P4080

Abstract 2744

Non-cholera Vibrio spp. invasive infections in the summer following May 2023 flood disaster in Romagna, Italy: a case series

30/04 12:00

12b. Bacterial infections

Irene ZAGHI

B / 14 / 16

Poster P4081

Abstract 2787

Panton-Valentine leukocidin: from diagnostic suspicion to detection in skin and soft tissue pediatric patients infections

30/04 12:00

12b. Bacterial infections

Gabriella PARISI

B / 14 / 17

Poster P4082

Abstract 2790

Community-acquired meningitis due to Pseudomonas aeruginosa (PA) in an immunocompetent patient: case report and literature review

30/04 12:00

12b. Bacterial infections

Alina-Ioana POPA

B / 14 / 18

Poster P4083

Abstract 2956

Bacteriophage therapy plus fecal microbiota transplantation to treat recurrent urinary tract infection (rUTI): a case series

30/04 12:00

12b. Bacterial infections

Shawna MCCALLIN

B / 14 / 19

Poster P4084

Abstract 3008

Navigating the complexity: disseminated Mycobacterium chelonae (M.chelonae) in an immunocompromised host

30/04 12:00

12b. Bacterial infections

Lee Xin TING

B / 14 / 20

Poster P4085

Abstract 3180

A novel bacterium of the family Silvanigrellaceae isolated from blood cultures of a drowned patient

30/04 12:00

12b. Bacterial infections

Xu QINGYE

B / 14 / 21

Poster P4086

Abstract 3296

Shewanella algae: the first reported case of infection in Ireland

30/04 12:00

12b. Bacterial infections

Jane O'CONNOR

B / 14 / 22

Poster P4087

Abstract 3432

Long term prosthetic joint infection caused by an ESBL producing Klebsiella pneumoniae: genomic evolution and clinical microbiology lesson

30/04 12:00

12b. Bacterial infections

Damasie MALANDAIN

B / 14 / 23

Poster P4088

Abstract 3451

My soft kitty: not as innocent as it sounds

30/04 12:00

12b. Bacterial infections

Mar RIVERO RODRÍGUEZ

B / 14 / 24

Poster P4089

Abstract 3484

Campylobacter fetus: a rare cause of cellulitis

30/04 12:00

12b. Bacterial infections

Adrián DOMÍNGUEZ LAGO

B / 14 / 25

Poster P4090

Abstract 3491

Neisseria meningitidis: a cause of anogenital infections in six patients in a tertiary hospital over one-year period

30/04 12:00

12b. Bacterial infections

Llanos SALAR VIDAL

B / 14 / 26

Poster P4091

Abstract 3507

Cefepime/zidebactam as a salvage therapy for lung empyema caused by multidrug-resistant (MDR) Pseudomonas Aeruginosa (PSA) under compassionate use

30/04 12:00

12b. Bacterial infections

Polati VISHNU RAO

B / 14 / 27

Poster P4092

Abstract 3691

A rare encounter of penicillin-resistant Listeria monocytogenes brain abscess

30/04 12:00

12b. Bacterial infections

Santosh GATTU

B / 14 / 28

Poster P4093

Abstract 3696

Dalbavancin paediatric therapeutic drug monitoring: real-life experience of complicated pneumonia treatment in an immunocompromised patient

30/04 12:00

12b. Bacterial infections

Marcello MARIANI

A / 15 / 1

Poster P4094

Abstract 3812

Native valve endocarditis caused by Neisseria gonorrhoeae: a case report

30/04 12:00

12b. Bacterial infections

Manel TUELLS MORALES

A / 15 / 2

Poster P4095

Abstract 3839

Nothing is as it seems in solid organ transplant recipients: the importance of pursuing etiological diagnosis in cutaneous lesions

30/04 12:00

12b. Bacterial infections

Flavia D' ANDREA

A / 15 / 3

Poster P4096

Abstract 4105

Bacteremia due to Weissella confusa in a patient with acute myelogenous leukaemia at the Uganda Cancer Institute

30/04 12:00

12b. Bacterial infections

Margaret LUBWAMA

A / 15 / 4

Poster P4097

Abstract 4110

A case of bacteraemic pneumonia caused by hypervirulent Klebsiella pneumoniae

30/04 12:00

12b. Bacterial infections

Martina Laura COLOMBO

A / 15 / 5

Poster P4098

Abstract 4138

Urogenital infection by Neisseria meningitidis

30/04 12:00

12b. Bacterial infections

Laura ANDRÉS ESLAVA

A / 15 / 6

Poster P4099

Abstract 4353

Beware the rods in Rodney Bay

30/04 12:00

12b. Bacterial infections

Olivia BIRD

A / 15 / 7

Poster P4100

Abstract 4355

Rare case of Lawsonella clevelandensis postoperative infection

30/04 12:00

12b. Bacterial infections

Toni DOSENOVIC

A / 15 / 8

Poster P4101

Abstract 4487

Successful microbiological treatment of extensively drug-resistant Pseudomonas aeruginosa endocarditis with imipenem/cilastatin/relebactam and fosfomycin

30/04 12:00

12b. Bacterial infections

Federica SALVATI

A / 15 / 9

Poster P4102

Abstract 4494

Lung abscess and pleural empyema due to Lawsonella clevelandensis: a first report

30/04 12:00

12b. Bacterial infections

Matthias VON ROTZ

A / 15 / 10

Poster P4103

Abstract 4575

Not a grade B pathogen: two cases of Streptococcus agalactiae meningitis in adults, molecular diagnosis is essential

30/04 12:00

12b. Bacterial infections

Dominic HEINING

A / 15 / 11

Poster P4104

Abstract 4628

Phage therapy in recurrent Pseudomonas septicemia in a patient with an arterial stent

30/04 12:00

12b. Bacterial infections

Ulla OTAVA

A / 15 / 12

Poster P4105

Abstract 4645

Non-O1/non-O139 Vibrio cholerae bacteraemia and cholangitis: an unusual case in an oncological patient in Lecco hospital, Italy

30/04 12:00

12b. Bacterial infections

Nicole GEMIGNANI

A / 15 / 13

Poster P4106

Abstract 4691

A complex case of encephalitis and ventriculitis caused by Bacillus Calmette Guerin (BCG)

30/04 12:00

12b. Bacterial infections

Maddalena ALBERTINI

A / 15 / 14

Poster P4107

Abstract 4761

Roseomonas mucosa an uncommon pathogen responsible for invasive infection with discrepancies among antimicrobial susceptibility testing methods

30/04 12:00

12b. Bacterial infections

Camille COTET

A / 15 / 15

Poster P4108

Abstract 4782

Multivisceral brucellosis: unveiling the great mimicker

30/04 12:00

12b. Bacterial infections

Olfa SMAOUI

A / 15 / 16

Poster P4109

Abstract 4905

Neurobrucellosis: report of 8 cases

30/04 12:00

12b. Bacterial infections

Meryem DJEMA

A / 15 / 17

Poster P4110

Abstract 4944

Tigecycline-based regimens for complicated urinary tract infections caused by carbapenem-resistant Gram-negative bacteria: case series

30/04 12:00

12b. Bacterial infections

Maria-Evelina GOREA

A / 15 / 18

Poster P4111

Abstract 5028

Kingella kingae: a pathogen with profound potential

30/04 12:00

12b. Bacterial infections

Julie-Anne HOULIHAN

A / 15 / 19

Poster P4112

Abstract 5114

Click the right diagnosis of the patient: choose the right sample at the right time

30/04 12:00

12b. Bacterial infections

Bishal GUPTA

A / 15 / 20

Poster P4113

Abstract 5186

Stenotrophomonas maltophilia bloodstream infections successfully treated with ceftazidime/avibactam and aztreonam

30/04 12:00

12b. Bacterial infections

Patricio ROSS

A / 15 / 21

Poster P4114

Abstract 5200

Mycobacterium abscessus complex pneumonia in two immunocompetent patients

30/04 12:00

12b. Bacterial infections

Ana Raquel FERNÁNDEZ

A / 15 / 22

Poster P4115

Abstract 5308

Reason for consult: we need you to evaluate this patient for liver transplantation

30/04 12:00

12b. Bacterial infections

Maria Alejandra MENDOZA

A / 15 / 23

Poster P4116

Abstract 5341

Successful treatment of XDR/ST2 Acinetobacter baumannii ventriculitis with intrathecal tigecycline in 8-month-old infant

30/04 12:00

12b. Bacterial infections

Victor PASSARELLI

A / 15 / 24

Poster P4117

Abstract 5520

Spirochaetastrophe

30/04 12:00

12b. Bacterial infections

Syed Noman ATTA

A / 15 / 25

Poster P4118

Abstract 5553

Unusual syphilis chronicles: unveiling skeletal involvement in two cases at an Italian STI clinic

30/04 12:00

12b. Bacterial infections

Lorenzo Brando LUNDGREN

A / 15 / 26

Poster P4119

Abstract 5595

Fatal necrotising fasciitis caused by hypervirulent Klebsiella pneumoniae serotype K2 ST 380

30/04 12:00

12b. Bacterial infections

Moufida HAMIDI

A / 15 / 27

Poster P4120

Abstract 5654

Bullous chronic type 2 leprosy reaction: a case report

30/04 12:00

12b. Bacterial infections

Deanna Jill BALAGASAY

A / 15 / 28

Poster P4121

Abstract 5762

The first case of bacteremia caused by Chryseobacterium haifensis: identification of C. haifensis with multiple names in 16S rRNA databases

30/04 12:00

12b. Bacterial infections

Woo Jin SHIN

B / 15 / 1

Poster P4122

Abstract 5876

Therapeutic challenges in managing genitourinary infection caused by multidrug-resistant Mycobacterium abscessus strain FLAC013 in a young adult male

30/04 12:00

12b. Bacterial infections

Yash KHATOD

B / 15 / 2

Poster P4123

Abstract 5937

Personalised bacteriophage therapy to treat multidrug-resistant biliary tract Pseudomonas aeruginosa infection

30/04 12:00

12b. Bacterial infections

Na LI

B / 15 / 3

Poster P4124

Abstract 5981

Human infections caused by Shewanella algae producing natural carbapenemase OXA-964: a 4 cases series

30/04 12:00

12b. Bacterial infections

Laurent DORTET

B / 15 / 4

Poster P4125

Abstract 6101

A mysterious chest pain

30/04 12:00

12b. Bacterial infections

Enrico PATRESE

B / 15 / 5

Poster P4126

Abstract 6123

Eggerthella lenta causing bacteraemia in a university hospital of Spain

30/04 12:00

12b. Bacterial infections

Domingo FERNÁNDEZ VECILLA

B / 15 / 6

Poster P4127

Abstract 6161

Mediastinal melioid lymphadenitis: a diagnostic challenge

30/04 12:00

12b. Bacterial infections

Matthew HOWES

B / 15 / 7

Poster P4128

Abstract 6182

The alternative low-cost approach to combating PDR Gram-negative infections of war injuries in Ukraine using a combination of azithromycin-meropenem

30/04 12:00

12b. Bacterial infections

Olena MOSHYNETS

B / 15 / 8

Poster P4129

Abstract 6236

Musculoskeletal involvement in leprosy misdiagnosed as rheumatoid arthritis

30/04 12:00

12b. Bacterial infections

Monika CHAUDHARY

B / 15 / 9

Poster P4130

Abstract 6248

Clinical dilemma: to treat or not to treat the mother in a case of early onset neonatal invasive Neisseria meningitidis serogroup Y infection

30/04 12:00

12b. Bacterial infections

Conor MULROONEY

B / 15 / 10

Poster P4131

Abstract 6314

Surviving a deadly prick: a case of tetanus infection treated successfully in a resource-limited institution

30/04 12:00

12b. Bacterial infections

Ervin ESPINOSA

B / 15 / 11

Poster P4132

Abstract 6503

Escherichia coli plasmidic AmpC production: "I just can't get enough"

30/04 12:00

12b. Bacterial infections

Tosca SEMENZIN

B / 15 / 12

Poster P4133

Abstract 6504

Subcutaneuous antibiotic: "I've got you under my skin"

30/04 12:00

12b. Bacterial infections

Luca MONTANARI

B / 15 / 13

Poster P4134

Abstract 6506

Escherichia coli and plasmidic AmpC production: "I Just Can't Get Enough"

30/04 12:00

12b. Bacterial infections

Tosca SEMENZIN

B / 15 / 14

Poster P4135

Abstract 6728

Neonatal pericardial effusion due to Escherichia coli sepsis

30/04 12:00

12b. Bacterial infections

Nada MISSAOUI

B / 15 / 15

Poster P4136

Abstract 6783

Rifampicin, ciprofloxacin, and carbapenem combination therapy for hypervirulent Klebsiella pneumoniae: induced liver abscess with metastatic infection

30/04 12:00

12b. Bacterial infections

Vishal SHANBHAG

B / 15 / 16

Poster P4137

Abstract 6820

Pulmonary nocardiosis masquerading as a lung mass

30/04 12:00

12b. Bacterial infections

Noor-Mohammad ABDUL-HAQU

B / 15 / 17

Poster P4138

Abstract 6852

Extragenital infection by Neisseria gonorrhoeae

30/04 12:00

12b. Bacterial infections

Lucía TEJEDOR CANTERO

B / 15 / 18

Poster P4139

Abstract 6920

A challenging case of leprosy complicated by severe type 1 immune reaction.

30/04 12:00

12b. Bacterial infections

Ahmed AL MESSABI

B / 15 / 19

Poster P4140

Abstract 6953

The return of forgotten diseases

30/04 12:00

12b. Bacterial infections

Crt LOBODA

B / 15 / 20

Poster P4141

Abstract 6965

Extensively drug-resistant Haemophilus parainfluenzae in a patient from preexposure prophylaxis program

30/04 12:00

12b. Bacterial infections

Marc GARRETA ESTEBAN

B / 15 / 21

Poster P4142

Abstract 6992

Uncommon presentation of cellulitis: a case report of Klebsiella pneumoniae-induced thoracic anterior wall infection

30/04 12:00

12b. Bacterial infections

Ana Patrícia BRITO

B / 15 / 22

Poster P4143

Abstract 7022

Fatal infection caused by cutaneous toxigenic Corynebacterium ulcerans with extensive soft tissue involvement and late-onset toxic myocarditis

30/04 12:00

12b. Bacterial infections

Peter Michael KELLER

B / 15 / 23

Poster P4144

Abstract 7161

Challenges in Pseudomonas aeruginosa infective endocarditis: insights from case series on resistance, clinical manifestations, and treatment outcomes

30/04 12:00

12b. Bacterial infections

Akshatha RAVINDRA

B / 15 / 24

Poster P4145

Abstract 7189

Severe pneumonia caused by Legionella longbeachae: an underdiagnosed infection leading to critical care admission

30/04 12:00

12b. Bacterial infections

Vicki FLEMING

B / 15 / 25

Poster P4146

Abstract 7285

An illustrative case series of complex and challenging left ventricular assist device infections

30/04 12:00

12b. Bacterial infections

Nim WICKRAMASINGHE

B / 15 / 26

Poster P4147

Abstract 7338

Invasive Streptococcus infection: a diagnostic dilemma

30/04 12:00

12b. Bacterial infections

Shahad ABASAEED ELHAG

B / 15 / 27

Poster P4148

Abstract 7346

A rare encounter: Listeria monocytogenes and brain abscess

30/04 12:00

12b. Bacterial infections

Iffat KHANUM

B / 15 / 28

Poster P4149

Abstract 7430

Successful clinical and microbiological resolution of carbapenem-resistant Acinetobacter baumannii in a central nervous system infection in an oncological patient

30/04 12:00

12b. Bacterial infections

Odeli Nicole ENCINAS SEJAS

A / 16 / 1

Poster P4150

Abstract 7552

Tracheobronchitis caused by Mycoplasma hominis in a polytraumatised patient, a finding with clinical repercussions

30/04 12:00

12b. Bacterial infections

Lais SIMONATO ALTOE

A / 16 / 2

Poster P4151

Abstract 7594

Corneal abscess due to Mycobacterium abscessus

30/04 12:00

12b. Bacterial infections

Maria Angeles ASENCIO

A / 16 / 3

Poster P4152

Abstract 7604

Hemophagocytic lymph histiocytosis: a fatal complication of rickettsial infection

30/04 12:00

12b. Bacterial infections

Kamlesh BISHT

A / 16 / 4

Poster P4153

Abstract 7645

Streptococcus equi sp. zooepidemicus meningoencephalitis: an emerging microorganism in northeastern Brazil

30/04 12:00

12b. Bacterial infections

Luís Arthur Brasil GADELHA FARIAS

A / 16 / 5

Poster P4154

Abstract 7668

Whipple disease posing as ear-nose-throat malignancy: a diagnostic challenge

30/04 12:00

12b. Bacterial infections

Andreea STANCIU

A / 16 / 6

Poster P4155

Abstract 7727

Intrigue in the isles: investigating the first presumed indigenous case of tularaemia in the United Kingdom

30/04 12:00

12b. Bacterial infections

Isra HALIM

A / 16 / 7

Poster P4156

Abstract 7837

A case of brain abscess due to Capnocytophaga Sputigena

30/04 12:00

12b. Bacterial infections

Özcan SARBAT

A / 16 / 8

Poster P4157

Abstract 7843

Disseminated Mycobacterium abscessus infection

30/04 12:00

12b. Bacterial infections

Hajir ABID

A / 16 / 9

Poster P4158

Abstract 7910

Disseminated Coccidioidomycosis in a patient with HIV

30/04 12:00

12b. Bacterial infections

Maria Luisa GURRUCHAGA YANES

A / 16 / 10

Poster P4159

Abstract 8043

Primary pyogenic ventriculitis caused by Neisseria meningitidis Serogroup Y

30/04 12:00

12b. Bacterial infections

Gavin Francis KELLY

A / 16 / 11

Poster P4160

Abstract 8054

Precision therapy at its the best: Escherichia coli empyema successfully treated with bacteriophage therapy

30/04 12:00

12b. Bacterial infections

Holly SINCLAIR

A / 16 / 12

Poster P4161

Abstract 8098

From scalp to spine: an interesting case of cutaneous actinomycoses leading to brain invasion

30/04 12:00

12b. Bacterial infections

Naman LODHA

A / 16 / 13

Poster P4162

Abstract 8102

Mycoplasma hominis and two severe clinical presentations

30/04 12:00

12b. Bacterial infections

Laura HUYVENEERS

A / 16 / 14

Poster P4163

Abstract 8121

Acute myocarditis following Campylobacter jejuni enterocolitis: a rare but potentially severe sequelae

30/04 12:00

12b. Bacterial infections

Amrei VON BRAUN

A / 16 / 15

Poster P4164

Abstract 8197

Bacteriophage therapy for extensively drug-resistant Klebsiella aerogenes infection due to necrotising pancreatitis demonstrating in vivo bacterial and phage coevolution and phage resistance.

30/04 12:00

12b. Bacterial infections

Holly A SINCLAIR

A / 16 / 16

Poster P4165

Abstract 8209

Meningococcal pneumonia: diagnosis by blood culture

30/04 12:00

12b. Bacterial infections

Natalia GONZÁLEZ ESPINOSA

A / 16 / 17

Poster P4166

Abstract 8309

Vancomycin variable Enterococci (VVE) responsible for two cases of severe bloodstream infections in immunocompromised patients colonised with vancomycin resistance Enterococcus faecium (VRE)

30/04 12:00

12b. Bacterial infections

Andrea DESSILANI

A / 16 / 18

Poster P4167

Abstract 8349

Native valve endocarditis caused by coagulase negative Staphylococcus kloosii

30/04 12:00

12b. Bacterial infections

Anne-Marie DOLAN

A / 16 / 19

Poster P4168

Abstract 8474

Ceftazidime-related neurotoxicity: what is the ceiling?

30/04 12:00

12b. Bacterial infections

Dorian VANNESTE

A / 16 / 20

Poster P4169

Abstract 8701

Hypervirulent Klebsiella pneumoniae (HvKp) strains in a teaching hospital

30/04 12:00

12b. Bacterial infections

Domingo FERNÁNDEZ VECILLA

A / 16 / 21

Poster P4170

Abstract 8711

A fatal case of septic shock caused by Vibrio cholerae non-O1/O139 in patient with diffuse lymphoma B cells in Italy

30/04 12:00

12b. Bacterial infections

Federica GUIDA MARASCIA

A / 16 / 22

Poster P4171

Abstract 8713

A fatal case of Catabacter hongkongensis

30/04 12:00

12b. Bacterial infections

Nouf ALMAGHLOUTH

A / 16 / 23

Poster P4172

Abstract 8760

An outbreak of Streptococcus equi infection in Italy: clinical features

30/04 12:00

12b. Bacterial infections

Simona COLADONATO

A / 16 / 24

Poster P4173

Abstract 8827

Mom, my knee hurts! Lyme disease arthritis

30/04 12:00

12b. Bacterial infections

Maria Luisa GURRUCHAGA YANES

A / 16 / 25

Poster P4174

Abstract 8858

Melioidosis in northern Luzon, Philippines: a case series

30/04 12:00

12b. Bacterial infections

Keren Joy COMPELIO

A / 16 / 26

Poster P4175

Abstract 8864

Uncommon presentation of cutaneous botryomycosis in an immunocompetent patient

30/04 12:00

12b. Bacterial infections

Sagarika NANDA

A / 16 / 27

Poster P4176

Abstract 8892

The valve was the key: the importance of microbiology techniques

30/04 12:00

12b. Bacterial infections

Maria Del Mar ARENAS MIRAS

A / 16 / 28

Poster P4177

Abstract 8945

Murine typhus triggering haemophagocytic lymphohistiocytosis in an immunocompromised host

30/04 12:00

12b. Bacterial infections

Nicholas POWER

B / 16 / 1

Poster P4178

Abstract 8950

Multifocal actinomycosis in a penicillin-allergic patient

30/04 12:00

12b. Bacterial infections

Rebecca RYAN

B / 16 / 2

Poster P4179

Abstract 8989

Undifferenciated fever: a diagnostic odyssey

30/04 12:00

12b. Bacterial infections

Cristina MARCELO CALVO

B / 16 / 3

Poster P4180

Abstract 8990

Crossing the diagnostic gap

30/04 12:00

12b. Bacterial infections

Abusalem LANA

B / 16 / 4

Poster P4181

Abstract 8998

Ureaplasma spp. peritonitis resulting in hyperammonemia and coma in a heart transplant patient following intrauterine device removal: a case report

30/04 12:00

12b. Bacterial infections

Matthew DRIEDGER

B / 16 / 5

Poster P4182

Abstract 44

Central line-associated Cyberlindnera fabianii fungemia: an emerging fungal pathogen

30/04 12:00

12c. Fungal infections

Gawahir A. ALI

B / 16 / 6

Poster P4183

Abstract 76

Aspergillus endocarditis in an immunocompetent host

30/04 12:00

12c. Fungal infections

Wenjie HUANG

B / 16 / 7

Poster P4184

Abstract 82

Disseminated sporotrichosis in a healthy elderly

30/04 12:00

12c. Fungal infections

Parissada ANUGOOLGARN

B / 16 / 8

Poster P4185

Abstract 187

COVID-19 pneumonitis and reactivation of an endemic mycoses

30/04 12:00

12c. Fungal infections

Catherine JONES

B / 16 / 9

Poster P4186

Abstract 273

Navigating the maze: A 52-year-old man with brain abscess

30/04 12:00

12c. Fungal infections

Sandhya NAGARAKANTI

B / 16 / 10

Poster P4187

Abstract 314

Clinical presentation and management of concurrent infection with Talaromyces marneffei, Cryptococcus neoformans, and nocardiosis in AIDS patient

30/04 12:00

12c. Fungal infections

Laddarat SRIKHAM

B / 16 / 11

Poster P4188

Abstract 384

Diffuse fibrosing mediastinitis with predominant cardiac involvement due to Aspergillus in an immunocompetent patient

30/04 12:00

12c. Fungal infections

Sreethish SASI

B / 16 / 12

Poster P4189

Abstract 444

Lips don't lie: a curious case of facial swelling in a child

30/04 12:00

12c. Fungal infections

Souradeep CHOWDHURY

B / 16 / 13

Poster P4190

Abstract 500

Paracoccidioidomycosis with dramatic skin manifestations

30/04 12:00

12c. Fungal infections

Aliya REHMAN

B / 16 / 14

Poster P4191

Abstract 832

Scedosporium apiospermum peritonitis in patient with continuous ambulatory peritoneal dialysis: a first case report in Thailand

30/04 12:00

12c. Fungal infections

Nattapat NITINAI

B / 16 / 15

Poster P4192

Abstract 881

Successful treatment of severe pulmonary mucormycosis presenting with left lung consolidation and endobronchial obstruction

30/04 12:00

12c. Fungal infections

Cunliang CAI

B / 16 / 16

Poster P4193

Abstract 1197

Cryptococcal myelitis in an immunocompetent patient

30/04 12:00

12c. Fungal infections

Queency Joy BATUCAN

B / 16 / 17

Poster P4194

Abstract 1357

Severe musculoskeletal manifestations of lower extremity coccidioidomycosis: a case series

30/04 12:00

12c. Fungal infections

William ESTES

B / 16 / 18

Poster P4195

Abstract 1429

Candida meningitis and sepsis in an immunocompromised patient with a complication of cerebral sinus venous thrombosis

30/04 12:00

12c. Fungal infections

Marius OGENSKAS

B / 16 / 19

Poster P4196

Abstract 1608

Gastrointestinal basidiobolomycosis, a rare fungal infection: challenging to diagnose yet treatable

30/04 12:00

12c. Fungal infections

Hasti KAMALI SARVESTANI

B / 16 / 20

Poster P4197

Abstract 1709

Human skin infection from Trichophyton verrucosum: a case report presentation

30/04 12:00

12c. Fungal infections

Georgia VRIONI

B / 16 / 21

Poster P4198

Abstract 1895

Uncommon Neosartorya hiratsukae fungus as a causative agent of endophthalmitis

30/04 12:00

12c. Fungal infections

Cristian MATEO LEÓN

B / 16 / 22

Poster P4199

Abstract 1964

Two case reports of disseminated cryptococcosis in patients with anti-granulocyte-macrophage colony-stimulating factor autoantibodies

30/04 12:00

12c. Fungal infections

Sureerat WATCHARASUWANSEREE

B / 16 / 23

Poster P4200

Abstract 2005

Aspergillus endocarditis in a patient with chronic lymphocytic leukemia

30/04 12:00

12c. Fungal infections

Luca MEZZADRI

B / 16 / 24

Poster P4201

Abstract 2007

FDG WBC scan as a diagnostic method in a patient with an equivocal recurrence of pulmonary aspergillosis: a case report

30/04 12:00

12c. Fungal infections

Mohammadreza SALEHI

B / 16 / 25

Poster P4202

Abstract 2166

Enhancing patient care through molecular fungal diagnostics: two clinical cases in the UAE

30/04 12:00

12c. Fungal infections

Akela Ahmed GHAZAWI

B / 16 / 26

Poster P4203

Abstract 2485

Tinea corporis caused by a rare, dysgonic strain of Microsporum canis: a case report

30/04 12:00

12c. Fungal infections

Athanasia SERGOUNIOTI

B / 16 / 27

Poster P4204

Abstract 2599

Meningitis as a complication of progressive disseminated histoplasmosis

30/04 12:00

12c. Fungal infections

Omayra CHINCHA

B / 16 / 28

Poster P4205

Abstract 2868

Safety of prolonged use of rezafungin in two difficult-to-treat azole-resistant Candida tropicalis infections in Lecco hospital, Italy

30/04 12:00

12c. Fungal infections

Valentina MORENA

A / 17 / 1

Poster P4206

Abstract 3106

Mixed sinus and subcutaneous phaeohyphomycosis in a lung transplant recipient

30/04 12:00

12c. Fungal infections

Isabel RAMIREZ

A / 17 / 2

Poster P4207

Abstract 3276

Mixed invasive pulmonary aspergillosis and mucormycosis in prospective format in (non)neutropaenic patients: two cases of early diagnosis with non-invasive sampling

30/04 12:00

12c. Fungal infections

Radim DOBIAS

A / 17 / 3

Poster P4208

Abstract 3896

Chorioamnionitis by Candida spp:a decade of cases in a tertiary hospital

30/04 12:00

12c. Fungal infections

Pedro SUAREZ URQUIZA

A / 17 / 4

Poster P4209

Abstract 3914

Subcutaneous zygomycosis in an immunocompetent child

30/04 12:00

12c. Fungal infections

Divya NANDAKUMAR

A / 17 / 5

Poster P4210

Abstract 4071

Report of the first case of disseminated lomentosporiosis in Singapore

30/04 12:00

12c. Fungal infections

Geraldine GOH

A / 17 / 6

Poster P4211

Abstract 4089

Rapidly progressive fungal infection in a seemingly immunocompetent patient, a diagnostic conundrum

30/04 12:00

12c. Fungal infections

Sagarika NANDA

A / 17 / 7

Poster P4212

Abstract 4112

Treatment of chronic pulmonary aspergillosis with isavuconazole: an indication to perform routine TDM?

30/04 12:00

12c. Fungal infections

Deborah LUSETTI

A / 17 / 8

Poster P4213

Abstract 4205

TDM-guided isavuconazole treatment for cerebro-pulmonary aspergillosis in severe liver impairment

30/04 12:00

12c. Fungal infections

Riccardo UNGARO

A / 17 / 9

Poster P4214

Abstract 4629

Early confirmation of a severe candidaemia caused by Candida albicans in a critical ill patient due to next-generation sequencing results

30/04 12:00

12c. Fungal infections

Sebastian DECKER

A / 17 / 10

Poster P4215

Abstract 4659

Disseminated cryptococcal infection by Cryptococcus gattii in an imunocompetent host presenting with a pulmonary mass and headache

30/04 12:00

12c. Fungal infections

Thiago NETTO

A / 17 / 11

Poster P4216

Abstract 4948

Aspergillus sydowii endocarditis in a patient with a history of drug abuse: a case report

30/04 12:00

12c. Fungal infections

Agnese GIACCONE

A / 17 / 12

Poster P4217

Abstract 5296

Failure of Vitek2 equipment in the identification of Hanseniaspora, a rare yeast of doubtful pathogenicity: report of two cases

30/04 12:00

12c. Fungal infections

Alexander JIMBO ZAPATA

A / 17 / 13

Poster P4218

Abstract 5480

Cryptococcal meningitis in Timor-Leste: a case series

30/04 12:00

12c. Fungal infections

Lucia Florenciana TOTO

A / 17 / 14

Poster P4219

Abstract 5574

Aspergillus endocarditis: a rare presentation of invasive aspergillosis

30/04 12:00

12c. Fungal infections

Faiza MUHAMMAD ILYAS

A / 17 / 15

Poster P4220

Abstract 5722

Interdisciplinary and multimodal seamless cooperation successfully cured one case of hemoptysis pulmonary mucormycosis

30/04 12:00

12c. Fungal infections

Yanfen LIU

A / 17 / 16

Poster P4221

Abstract 5842

Subcutaneous phaeohyphomycosis caused by an emerging fungus Parathyridaria percutanea in an immunocompetent host: a first case from central India

30/04 12:00

12c. Fungal infections

Girish PATIL

A / 17 / 17

Poster P4222

Abstract 6258

Uncommon presentation of cutaneous Basidiobolomycosis: a mimicry of Mucormycosis

30/04 12:00

12c. Fungal infections

Tejasvi KANAGIRI

A / 17 / 18

Poster P4223

Abstract 6377

Aspergillus fumigatus: a rare postoperative peritonitis case report

30/04 12:00

12c. Fungal infections

Marie-Alice BOVY

A / 17 / 19

Poster P4224

Abstract 6642

A case of PUO in immunocompetent person-time to consider commonly missed uncommon agent

30/04 12:00

12c. Fungal infections

Hardik PATEL

A / 17 / 20

Poster P4225

Abstract 6693

Cryptococcal meningoencephalitis in a multiple sclerosis patient receiving fingolimod

30/04 12:00

12c. Fungal infections

Noor-Mohammad ABDUL-HAQU

A / 17 / 21

Poster P4226

Abstract 6770

Clival canal defect causing recurrent meningitis and Aspergillus fumigatus brainstem abscess in an immunocompetent child

30/04 12:00

12c. Fungal infections

James HATCHER

A / 17 / 22

Poster P4227

Abstract 6800

Cryptococcal osteomyelitis manifesting in a leprosy patient: an incidental detection

30/04 12:00

12c. Fungal infections

Sushree SARATHI

A / 17 / 23

Poster P4228

Abstract 7274

Mucorales PCR in blood for early and non-invasive diagnosis of mucormycosis: a confronting case-series

30/04 12:00

12c. Fungal infections

Robina AERTS

A / 17 / 24

Poster P4229

Abstract 7324

Trichophyton rubrum-induced majocchi's granuloma in an immunocompetent individual mimicking fish tank granulomatous disease

30/04 12:00

12c. Fungal infections

Mauricio ARIAS

A / 17 / 25

Poster P4230

Abstract 7451

A difficult diagnosis: concomitant antisynthetase syndrome and coccidioidomycosis infection

30/04 12:00

12c. Fungal infections

Diego ERDMENGER

A / 17 / 26

Poster P4231

Abstract 7942

An atypical case of cutaneous mucormycosis caused by Saksenaea sp. in an immunocompetent patient

30/04 12:00

12c. Fungal infections

David Adolfo SUAREZ SILVA

A / 17 / 27

Poster P4232

Abstract 8052

Successful management of chronic pulmonary mucormycosis with multi-facet diagnosis and non-surgical therapy: a case series

30/04 12:00

12c. Fungal infections

Yiyi QIAN

A / 17 / 28

Poster P4233

Abstract 8391

A cryptic conundrum

30/04 12:00

12c. Fungal infections

Kruthi MALUR

B / 17 / 1

Poster P4234

Abstract 8545

Direct identification of Cladophialophora bantiana by sequencing from a cerebral biopsy specimen

30/04 12:00

12c. Fungal infections

Jacques SEVESTRE

B / 17 / 2

Poster P4235

Abstract 8613

Metagenomic next-generation sequencing promotes the diagnosis of Rhizomucor pusillus infection

30/04 12:00

12c. Fungal infections

Xiaoli ZHOU

B / 17 / 3

Poster P4236

Abstract 8666

Osteomyelitis of the skull caused by Apophysomyces variabilis in an immunocompetent patient after a road-traffic accident in Ghana

30/04 12:00

12c. Fungal infections

Maria Alejandra REHNFELDT

B / 17 / 4

Poster P4237

Abstract 8857

Pneumocystis pneumonia and pulmonary tuberculosis coinfection in an HIV-seronegative older patient

30/04 12:00

12c. Fungal infections

Battikh RIADH

B / 17 / 5

Poster P4238

Abstract 16

Refractory inflammatory bowel disease: Entamoeba histolytica, the forgotten suspect

30/04 12:00

12d. Parasitic infections

Catherine DOMINIC

B / 17 / 6

Poster P4239

Abstract 525

Challenges in screening for Strongyloides: a case of delayed detection

30/04 12:00

12d. Parasitic infections

Caitlin TROTTIER

B / 17 / 7

Poster P4240

Abstract 729

Multiple episodes of Plasmodium malariae despite antimalarial treatment: “quartana te teneat”?

30/04 12:00

12d. Parasitic infections

Federica SALARI

B / 17 / 8

Poster P4241

Abstract 824

Unusual presentation of fever and gastrointestinal symptoms in a traveller returning from Nigeria: A case report

30/04 12:00

12d. Parasitic infections

Anna BOTÉ CASAMITJANA

B / 17 / 9

Poster P4242

Abstract 837

Chronic diarrhoea and failure of oral therapy: treatment of strongyloides hyperinfection with subcutaneous ivermectin in an immunocompromised patient

30/04 12:00

12d. Parasitic infections

Peter CONLON

B / 17 / 10

Poster P4243

Abstract 923

Non-surgical exceptional management of inoperable vertebral hydatidosis with radiotherapy and nitazoxanide

30/04 12:00

12d. Parasitic infections

Maria F RAMIREZ HIDALGO

B / 17 / 11

Poster P4244

Abstract 990

Concomitant parenchymal, subarachnoid, and ventricular neurocysticercosis: a case report with a three-year follow-up

30/04 12:00

12d. Parasitic infections

Maria Letizia GIANCOLA

B / 17 / 12

Poster P4245

Abstract 1217

Swimming with buffaloes: a case of recurrent nasal polyps

30/04 12:00

12d. Parasitic infections

Yuan Yi Constance CHEN

B / 17 / 13

Poster P4246

Abstract 1309

Strongyloides hyperinfection associated with Escherichia coli bacteremia, purulent meningitis and ventriculitis

30/04 12:00

12d. Parasitic infections

Luca CECCARELLI

B / 17 / 14

Poster P4247

Abstract 1802

Leishmania induced hemophagocytic lymphohistiocytosis (HLH) syndrome in a patient with systemic lupus erythematosus (SLE)

30/04 12:00

12d. Parasitic infections

Sunit SIKDAR

B / 17 / 15

Poster P4248

Abstract 1842

Challenging rapid diagnostic test in a rare Plasmodium malariae infection considered as a prozone-like phenomenon

30/04 12:00

12d. Parasitic infections

Frieder FUCHS

B / 17 / 16

Poster P4249

Abstract 1986

Hepatitis C virus (HCV) antibody false positive due to tapeworm infection: a potential new public health concern in HCV diagnosis, a case report

30/04 12:00

12d. Parasitic infections

Yusuke AINODA

B / 17 / 17

Poster P4250

Abstract 2196

An unexpected case: relapsing laryngeal leishmaniasis in an asthmatic woman in Northern Italy

30/04 12:00

12d. Parasitic infections

Serena REATO

B / 17 / 18

Poster P4251

Abstract 3436

Myocardial and mediastinal hydatid cysts

30/04 12:00

12d. Parasitic infections

Raffaella LISSANDRIN

B / 17 / 19

Poster P4252

Abstract 4415

A case of neurocysticercosis thought to be glial tumor

30/04 12:00

12d. Parasitic infections

Elif ATES

B / 17 / 20

Poster P4253

Abstract 4653

The crucial role of early diagnosis in disseminated toxoplasmosis: urging vigilance in the high-risk allogenic-haematologic-stem-cells (allo-HSCT) population

30/04 12:00

12d. Parasitic infections

Fabiana DELLAI

B / 17 / 21

Poster P4254

Abstract 4722

Recurrence of visceral leishmaniasis in immunocompromised patients: experience of long-term treatment with miltefosine at Careggi University Hospital

30/04 12:00

12d. Parasitic infections

Flavia CHECHI

B / 17 / 23

Poster P4256

Abstract 5138

A case of Echinococcus multilocularis acquired in Ontario

30/04 12:00

12d. Parasitic infections

Rahel ZEWUDE

B / 17 / 24

Poster P4257

Abstract 5214

A tale of two lungs, overcoming challenges in managing a complicated pulmonary hydatid cyst with rupture

30/04 12:00

12d. Parasitic infections

Sagarika NANDA

B / 17 / 25

Poster P4258

Abstract 5551

Case series of difficult to treat Giardia intestinalis infections in the immnuocompromised patients seen at the Hospital for Tropical Diseases, London

30/04 12:00

12d. Parasitic infections

Gauri GODBOLE

B / 17 / 26

Poster P4259

Abstract 5805

Primary amoebic meningoencephalitis in a solid-organ transplant recipient

30/04 12:00

12d. Parasitic infections

Adrian Anthony ALEXANDER

B / 17 / 27

Poster P4260

Abstract 5848

Amoebic brain abscess in a tertiary hospital in the Philippines: a case report

30/04 12:00

12d. Parasitic infections

Margie Angelica SIGUE

B / 17 / 28

Poster P4261

Abstract 5891

Is artesunate related to pancreatitis? Description of a case report and review of literature and pharmacovigilance databases

30/04 12:00

12d. Parasitic infections

Alex ALMUEDO-RIERA

A / 18 / 1

Poster P4262

Abstract 6214

A special cause of acute scrotum

30/04 12:00

12d. Parasitic infections

Szofia HAJÓSI-KALCAKOSZ

A / 18 / 2

Poster P4263

Abstract 6247

Mucocutaneous leishmaniasis caused by Leishmania infantum in Europe

30/04 12:00

12d. Parasitic infections

Marie-Therese LEIBENGUTH

A / 18 / 3

Poster P4264

Abstract 6497

Unmasking of visceral leishmaniasis in a patient with a haemophagocytic lymphohistiocytosis (HLH) syndrome in an endemic setting

30/04 12:00

12d. Parasitic infections

Aida MARY VARGHESE

A / 18 / 4

Poster P4265

Abstract 6573

Autochthonous myiasis in infected ulcers: A case report

30/04 12:00

12d. Parasitic infections

Lucía TEJEDOR CANTERO

A / 18 / 5

Poster P4266

Abstract 6617

Hydatidosis in a university hospital in northern Spain over a 5-year period

30/04 12:00

12d. Parasitic infections

Domingo FERNÁNDEZ VECILLA

A / 18 / 6

Poster P4267

Abstract 7045

NGS-characterised infection with Dibothriocephalus latus after consumption of supermarket sushi, France

30/04 12:00

12d. Parasitic infections

Marie Gladys ROBERT

A / 18 / 7

Poster P4268

Abstract 7262

Cutaneous leishmaniasis in Brazil diagnosed by a metagenomic approach

30/04 12:00

12d. Parasitic infections

Andre DOI

A / 18 / 8

Poster P4269

Abstract 7272

Löffler's syndrome due to toxocariasis in male patient

30/04 12:00

12d. Parasitic infections

Giorgio GIANNETTA

A / 18 / 10

Poster P4271

Abstract 8296

Strictures are forever: a case of delayed diagnosis of urogenital schistosomiasis in a patient with obstructive uropathy in a non-endemic setting

30/04 12:00

12d. Parasitic infections

Evdoxia DOUMOULIAKA

A / 18 / 11

Poster P4272

Abstract 8355

Severe non-falciparum malaria with atypical pulmonary involvement

30/04 12:00

12d. Parasitic infections

Ana María GUTIÉRREZ BAENA

A / 18 / 12

Poster P4273

Abstract 8488

An uncommon case of a fleeting rash from Western Rajasthan

30/04 12:00

12d. Parasitic infections

Vibhor TAK

A / 18 / 13

Poster P4274

Abstract 8518

Schistosomiasis unveiled: navigating clinical challenges in non-endemic regions

30/04 12:00

12d. Parasitic infections

Clara CARRERAS-ABAD

A / 18 / 14

Poster P4275

Abstract 8540

One thing is certain on Bamako: everything is uncertain

30/04 12:00

12d. Parasitic infections

Éva Lívia NAGY

A / 18 / 15

Poster P4276

Abstract 8888

Case of Fasciola infection with fever and hepatitis in a chronic lymphocytic leukaemia patient under remission

30/04 12:00

12d. Parasitic infections

Simge SEKIN

A / 18 / 16

Poster P4277

Abstract 57

Disseminated macrolide-resistant Mycobacterium intracellulare infection in a non-HIV paediatric patient: a case report

30/04 12:00

12e. Other unusual clinical situations

Sophida BOONSATHORN

A / 18 / 17

Poster P4278

Abstract 68

Use of next-generation sequencing for assessing and precisely modulating the vaginal microbiome with Lactobacillus crispatus

30/04 12:00

12e. Other unusual clinical situations

Jose ALEXANDER

A / 18 / 18

Poster P4279

Abstract 305

"Silent" infective endocarditis (SIE): a new entity, a poor clinical evaluation or an incidental finding?

30/04 12:00

12e. Other unusual clinical situations

Luis Martin MOLTRASIO

A / 18 / 19

Poster P4280

Abstract 1658

CMV meningitis and Rhodotorula coinfection in a term infant

30/04 12:00

12e. Other unusual clinical situations

Chhavi GUPTA

A / 18 / 20

Poster P4281

Abstract 1987

Delayed diagnosis of chronic necrotising granulomatous skin lesions due to TAP2 deficiency

30/04 12:00

12e. Other unusual clinical situations

Ilad ALAVI DARAZAM

A / 18 / 21

Poster P4282

Abstract 2020

Severe falciparum malaria requiring exchange transfusion in a returned traveler

30/04 12:00

12e. Other unusual clinical situations

Ravi Teja KANDIKUPPA

A / 18 / 22

Poster P4283

Abstract 3060

Rituximab immunosoppression leading to fulminant enteroviruses hepatitis and capsulated bacteria meningitis

30/04 12:00

12e. Other unusual clinical situations

Marcello MAFFEZZONI

A / 18 / 23

Poster P4284

Abstract 3204

An enigmatic case of unmasking nocardiosis immune reconstitution inflammatory syndrome (IRIS) in AIDS, unveiled after anti-retroviral therapy (HAART) initiation

30/04 12:00

12e. Other unusual clinical situations

Rohit KUMAR

A / 18 / 24

Poster P4285

Abstract 3320

Relapsing melioidosis: the hunt for an unusual sanctuary site

30/04 12:00

12e. Other unusual clinical situations

Stephen WOOLLEY

A / 18 / 25

Poster P4286

Abstract 3605

Eosinophilic meningoencephalitis successfully treated with glucocorticoids and intravenous immunoglobulin

30/04 12:00

12e. Other unusual clinical situations

Soo Hyun AHN

A / 18 / 26

Poster P4287

Abstract 4002

Drug-induced aseptic meningitis: unveiling the role of levamisole

30/04 12:00

12e. Other unusual clinical situations

Mikita SALAVEI

A / 18 / 27

Poster P4288

Abstract 4396

Successful treatment of pneumonia due to Mycobacterium goodii in a young, severely underweight 45-year-old woman

30/04 12:00

12e. Other unusual clinical situations

Francesca CATANIA

B / 18 / 1

Poster P4290

Abstract 5648

Tuberculosis immune reconstitution syndrome (TB-IRIS) recurring eight years after the original diagnosis

30/04 12:00

12e. Other unusual clinical situations

Ole SKOUVIG PEDERSEN

B / 18 / 2

Poster P4291

Abstract 6999

A storm of HHV-8: simultaneous multicentric Castleman's disease and visceral Kaposi sarcoma in a HIV-1 infected patient.

30/04 12:00

12e. Other unusual clinical situations

Pedro LEAL

B / 18 / 3

Poster P4292

Abstract 7990

A case of alpha-gal syndrome: focus on the diagnosis and management of an emergent tick-borne disease

30/04 12:00

12e. Other unusual clinical situations

Michelle ABBOTT

B / 18 / 4

Poster P4293

Abstract 8119

Haemophagocytic lymphohistiocytosis driven by hepato-splenic tuberculosis

30/04 12:00

12e. Other unusual clinical situations

Ali ALAM

B / 18 / 5

Poster P4294

Abstract 8199

Acute generalised exanthematous pustulosis caused by meropenem: an uncommon reaction to a common drug

30/04 12:00

12e. Other unusual clinical situations

Sagar CHANDRAKAR

B / 18 / 6

Poster P4295

Abstract 8322

An atypical and rare case of primary facial palsy caused by Mycoplasma pneumoniae and literature review

30/04 12:00

12e. Other unusual clinical situations

Anusha RATHI

B / 18 / 7

Poster P4296

Abstract 8544

Cutaneous tuberculosis presenting as isolated para-articular swellings

30/04 12:00

12e. Other unusual clinical situations

Sudharshan JAGENNATH

B / 18 / 8

Poster P4297

Abstract 8717

Management of a patient with multi-resistant HIV infectionstrain undergoingin allogeneic stem cell transplant

30/04 12:00

12e. Other unusual clinical situations

Zeno PASQUINI

B / 18 / 10

Poster P4299

Abstract 8964

Cerebral toxoplasmosis and persistent Enterovirus encephalitis in a woman with thymoma-associated Good's syndrome

30/04 12:00

12e. Other unusual clinical situations

Frederike WALDECK

B / 18 / 11

Poster P4300

Abstract 8978

Surviving the unseen battle: pulmonary mucormycosis and bacterial Infections in post-renal transplant Patient

30/04 12:00

12e. Other unusual clinical situations

Radhika SARDA

No more content to display